0001493152-24-004069.txt : 20240129 0001493152-24-004069.hdr.sgml : 20240129 20240129083832 ACCESSION NUMBER: 0001493152-24-004069 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 74 FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BullFrog AI Holdings, Inc. CENTRAL INDEX KEY: 0001829247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 844786155 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-276740 FILM NUMBER: 24570542 BUSINESS ADDRESS: STREET 1: 325 ELLINGTON BLVD. STREET 2: UNIT 317 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 3013672055 MAIL ADDRESS: STREET 1: 325 ELLINGTON BLVD. STREET 2: UNIT 317 CITY: GAITHERSBURG STATE: MD ZIP: 20878 S-1 1 forms-1.htm
false 0001829247 0001829247 2023-01-01 2023-09-30 0001829247 dei:BusinessContactMember 2023-01-01 2023-09-30 0001829247 2022-12-31 0001829247 2021-12-31 0001829247 us-gaap:NonrelatedPartyMember 2022-12-31 0001829247 us-gaap:NonrelatedPartyMember 2021-12-31 0001829247 us-gaap:RelatedPartyMember 2022-12-31 0001829247 us-gaap:RelatedPartyMember 2021-12-31 0001829247 2023-09-30 0001829247 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2023-09-30 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2022-12-31 0001829247 2022-01-01 2022-12-31 0001829247 2021-01-01 2021-12-31 0001829247 2023-07-01 2023-09-30 0001829247 2022-07-01 2022-09-30 0001829247 2022-01-01 2022-09-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001829247 us-gaap:CommonStockMember 2020-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2020-12-31 0001829247 us-gaap:RetainedEarningsMember 2020-12-31 0001829247 2020-12-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001829247 us-gaap:CommonStockMember 2021-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2021-12-31 0001829247 us-gaap:RetainedEarningsMember 2021-12-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001829247 us-gaap:CommonStockMember 2022-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001829247 us-gaap:RetainedEarningsMember 2022-12-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-03-31 0001829247 us-gaap:CommonStockMember 2023-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001829247 us-gaap:RetainedEarningsMember 2023-03-31 0001829247 2023-03-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001829247 us-gaap:CommonStockMember 2023-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001829247 us-gaap:RetainedEarningsMember 2023-06-30 0001829247 2023-06-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001829247 us-gaap:CommonStockMember 2022-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001829247 us-gaap:RetainedEarningsMember 2022-03-31 0001829247 2022-03-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001829247 us-gaap:CommonStockMember 2022-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001829247 us-gaap:RetainedEarningsMember 2022-06-30 0001829247 2022-06-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001829247 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2021-01-01 2021-12-31 0001829247 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2022-01-01 2022-12-31 0001829247 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001829247 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001829247 2023-01-01 2023-03-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-06-30 0001829247 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001829247 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001829247 2023-04-01 2023-06-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-07-01 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001829247 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001829247 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001829247 2022-01-01 2022-03-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-04-01 2022-06-30 0001829247 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001829247 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001829247 2022-04-01 2022-06-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-07-01 2022-09-30 0001829247 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001829247 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001829247 us-gaap:ReceivablesFromStockholderMember 2022-12-31 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001829247 us-gaap:RetainedEarningsMember 2023-09-30 0001829247 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-09-30 0001829247 us-gaap:CommonStockMember 2022-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001829247 us-gaap:RetainedEarningsMember 2022-09-30 0001829247 2022-09-30 0001829247 us-gaap:IPOMember 2023-02-13 2023-02-13 0001829247 BFRG:SBAPPPLoanMember 2020-05-05 0001829247 us-gaap:ShortTermDebtMember 2023-01-31 0001829247 us-gaap:ShortTermDebtMember 2023-02-28 0001829247 us-gaap:ShortTermDebtMember 2023-02-01 2023-02-28 0001829247 us-gaap:ShortTermDebtMember 2023-09-30 0001829247 2021-06-15 0001829247 2021-06-14 2021-06-15 0001829247 2021-11-19 0001829247 2021-11-18 2021-11-19 0001829247 2021-12-13 0001829247 2021-12-12 2021-12-13 0001829247 2021-12-01 2021-12-31 0001829247 BFRG:MarylandTechnologyDevelopmentCorporationMember BFRG:ConvertibleLoanAgreementMember 2020-03-27 0001829247 BFRG:MarylandTechnologyDevelopmentCorporationMember BFRG:ConvertibleLoanAgreementMember 2020-03-27 2020-03-27 0001829247 BFRG:MarylandTechnologyDevelopmentCorporationMember BFRG:ConvertibleLoanAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-09 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-09 2021-08-09 0001829247 BFRG:ConvertibleLoanAgreementMember 2022-12-31 0001829247 BFRG:NewAgreementMember 2022-05-31 0001829247 BFRG:NewAgreementMember 2022-12-31 0001829247 BFRG:NewAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:LoanAgreementMember 2021-12-20 0001829247 BFRG:LoanAgreementMember 2021-12-20 2021-12-20 0001829247 BFRG:LoanAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:LoanAgreementMember 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-12-20 0001829247 BFRG:LoanAgreementMember 2022-04-01 2022-04-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-04-28 2022-04-28 0001829247 BFRG:WallachBethMember 2022-04-28 2022-04-28 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-09-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-09-01 2022-09-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember 2022-09-01 2022-09-30 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-30 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-01 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-01-01 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:AugustTwentyTwentyOneNoteMember 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2022-05-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-12-20 2021-12-20 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-10-01 2022-12-31 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember 2023-02-28 2023-02-28 0001829247 BFRG:ConvertibleDebtOneMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtOneMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtTwoMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtTwoMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtThreeMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtThreeMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtFourMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtFourMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtFiveMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtFiveMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtSixMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtSixMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtSevenMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtSevenMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtEightMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtEightMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtNineMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtNineMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtTenMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtTenMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 us-gaap:ConvertibleDebtMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2021-07-08 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2022-12-31 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-19 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-18 2021-08-19 0001829247 BFRG:NewLoanAgreementMember 2022-05-31 0001829247 BFRG:NewLoanAgreementMember 2022-12-31 0001829247 BFRG:NewLoanAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:SimpleAgreementForFutureEquityMember us-gaap:RelatedPartyMember 2021-07-08 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2023-02-28 2023-02-28 0001829247 BFRG:ConvertibleLoanAgreementMember 2023-02-28 2023-02-28 0001829247 BFRG:ConvertibleLoanAgreementMember 2023-02-28 0001829247 srt:ChiefFinancialOfficerMember 2021-01-01 2021-12-31 0001829247 srt:ChiefFinancialOfficerMember 2023-01-01 2023-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001829247 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001829247 us-gaap:CommonStockMember BFRG:ExchangeAgreementMember us-gaap:InvestorMember 2022-10-04 2022-10-05 0001829247 BFRG:SeriesAConvertiblePreferredStockMember BFRG:ExchangeAgreementMember us-gaap:InvestorMember 2022-10-04 2022-10-05 0001829247 us-gaap:SeriesAPreferredStockMember 2022-10-05 0001829247 2020-06-01 2020-06-30 0001829247 BFRG:NoteHolderMember 2022-01-01 2022-12-31 0001829247 us-gaap:CommonStockMember BFRG:LicenseAgreementMember 2022-01-01 2022-12-31 0001829247 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001829247 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001829247 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2022-12-31 0001829247 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 us-gaap:WarrantMember BFRG:AdvisorsMember 2021-01-01 2021-12-31 0001829247 us-gaap:WarrantMember BFRG:AdvisorsMember 2021-12-31 0001829247 us-gaap:WarrantMember 2022-06-01 2022-06-30 0001829247 us-gaap:WarrantMember 2021-12-31 0001829247 us-gaap:WarrantMember BFRG:ConvertibleBridgeDebtAgreementsMember 2021-12-31 0001829247 us-gaap:WarrantMember 2022-06-30 0001829247 us-gaap:WarrantMember 2022-05-31 0001829247 us-gaap:WarrantMember BFRG:NewAgreementsMember 2022-05-31 0001829247 BFRG:WarrantOneMember 2022-05-31 0001829247 BFRG:WarrantOneMember BFRG:NewAgreementsMember 2022-05-31 0001829247 2022-10-05 0001829247 us-gaap:SeriesAPreferredStockMember BFRG:ExchangeAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:PriorAgreementsAndNewAgreementsMember 2022-01-01 2022-12-31 0001829247 us-gaap:IPOMember 2023-02-01 2023-02-28 0001829247 us-gaap:IPOMember 2023-02-28 0001829247 BFRG:TradeableWarrantsMember 2023-02-01 2023-02-28 0001829247 BFRG:TradeableWarrantsMember 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember 2023-02-01 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember 2023-02-28 0001829247 us-gaap:IPOMember us-gaap:CommonStockMember 2023-02-01 2023-02-28 0001829247 2023-02-01 2023-02-28 0001829247 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001829247 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001829247 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2022-11-01 2022-11-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2022-11-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2023-09-30 0001829247 us-gaap:IPOMember us-gaap:WarrantMember 2023-02-28 2023-02-28 0001829247 us-gaap:IPOMember us-gaap:WarrantMember 2023-02-28 0001829247 BFRG:UnderwritersMember us-gaap:WarrantMember 2023-02-28 2023-02-28 0001829247 BFRG:UnderwritersMember us-gaap:WarrantMember 2023-02-28 0001829247 us-gaap:IPOMember BFRG:TradableWarrantMember 2023-02-28 2023-02-28 0001829247 us-gaap:IPOMember BFRG:TradableWarrantMember 2023-02-28 0001829247 us-gaap:IPOMember BFRG:NonTradableWarrantMember 2023-02-28 2023-02-28 0001829247 us-gaap:IPOMember BFRG:NonTradableWarrantMember 2023-02-28 0001829247 us-gaap:OverAllotmentOptionMember BFRG:TradableWarrantMember 2023-02-28 2023-02-28 0001829247 us-gaap:OverAllotmentOptionMember BFRG:TradableWarrantMember 2023-02-28 0001829247 us-gaap:OverAllotmentOptionMember BFRG:NonTradableWarrantMember 2023-02-28 2023-02-28 0001829247 us-gaap:OverAllotmentOptionMember BFRG:NonTradableWarrantMember 2023-02-28 0001829247 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001829247 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001829247 BFRG:UnvestedWarrantsMember 2023-01-01 2023-09-30 0001829247 srt:MinimumMember 2022-01-01 2022-12-31 0001829247 srt:MaximumMember 2022-01-01 2022-12-31 0001829247 srt:MinimumMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 srt:MaximumMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 srt:MinimumMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember 2023-01-01 2023-09-30 0001829247 us-gaap:WarrantMember 2020-12-31 0001829247 BFRG:ExercisePriceMember 2023-09-30 0001829247 BFRG:ExercisePriceMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceOneMember srt:MinimumMember 2023-09-30 0001829247 BFRG:ExercisePriceOneMember srt:MaximumMember 2023-09-30 0001829247 BFRG:ExercisePriceOneMember srt:MinimumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceOneMember srt:MaximumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceOneMember 2023-09-30 0001829247 BFRG:ExercisePriceTwoMember srt:MinimumMember 2023-09-30 0001829247 BFRG:ExercisePriceTwoMember srt:MaximumMember 2023-09-30 0001829247 BFRG:ExercisePriceTwoMember srt:MinimumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceTwoMember srt:MaximumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceTwoMember 2023-09-30 0001829247 BFRG:ExercisePriceThreeMember srt:MinimumMember 2023-09-30 0001829247 BFRG:ExercisePriceThreeMember srt:MaximumMember 2023-09-30 0001829247 BFRG:ExercisePriceThreeMember srt:MinimumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceThreeMember srt:MaximumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceThreeMember 2023-09-30 0001829247 BFRG:ExercisePriceFourMember 2023-09-30 0001829247 BFRG:ExercisePriceFourMember srt:MinimumMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceFourMember srt:MaximumMember 2023-01-01 2023-09-30 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2018-02-05 2018-02-07 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember BFRG:YearTwentyTwentyTwoMember 2021-10-01 2021-10-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember BFRG:YearTwentyTwentyThreeMember 2021-10-01 2021-10-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember BFRG:YearTwentyTwentyFourMember 2021-10-01 2021-10-31 0001829247 BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember BFRG:OtherPartiesMember 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember BFRG:InternallyDevelopmentDrugProjectsMember 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember srt:MaximumMember 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember srt:MinimumMember 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyTwoMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyThreeMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyFourMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember 2022-12-31 0001829247 BFRG:GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember 2022-01-14 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember BFRG:YearTwentyTwentyThreeMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember BFRG:YearTwentyTwentyFourMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember BFRG:YearTwentyTwentyFiveMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember BFRG:YearTwentyTwentySixMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember BFRG:YearTwentyTwentySevenMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-12-31 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember BFRG:YearTwentyTwentySevenMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember BFRG:YearTwentyTwentyEightMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember BFRG:YearTwentyTwentyNineMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember BFRG:YearTwentyThirtyMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember BFRG:YearTwentyThirtyOneMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:LicenseAgreementMember 2022-12-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:YearTwentyTwentyThreeMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyThreeMember 2023-05-30 2023-05-31 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyFiveMember 2023-05-30 2023-05-31 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentySixMember 2023-05-30 2023-05-31 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentySevenMember 2023-05-30 2023-05-31 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyTwoMember 2023-05-30 2023-05-31 0001829247 BFRG:NewLicenseAgreementMember BFRG:YearTwentyTwentyThreeMember 2023-09-30 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2023-02-28 2023-02-28 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2023-09-30 0001829247 BFRG:LicenseAgreementMember 2023-09-30 0001829247 us-gaap:SubsequentEventMember us-gaap:IPOMember 2023-02-14 2023-02-14 0001829247 us-gaap:SubsequentEventMember us-gaap:IPOMember 2023-02-14 0001829247 us-gaap:SubsequentEventMember BFRG:TradeableWarrantsMember 2023-02-14 2023-02-14 0001829247 us-gaap:SubsequentEventMember BFRG:TradeableWarrantsMember 2023-02-14 0001829247 us-gaap:SubsequentEventMember BFRG:NonTradeableWarrantsMember 2023-02-14 2023-02-14 0001829247 us-gaap:SubsequentEventMember BFRG:NonTradeableWarrantsMember 2023-02-14 0001829247 us-gaap:IPOMember 2022-11-30 2022-11-30 0001829247 us-gaap:IPOMember 2022-11-30 0001829247 us-gaap:SubsequentEventMember 2023-04-13 0001829247 us-gaap:SubsequentEventMember 2023-04-05 2023-04-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

As filed with the Securities Exchange Commission on January 29, 2024

 

Registration No. 333-____________

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-1

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

BULLFROG AI HOLDINGS, INC.

(Exact Name of Registrant as specified in its charter)

 

Nevada   7374   84-4786155

(State or other Jurisdiction of

Incorporation or Organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification No.)

 

325 Ellington Blvd., Unit 317

Gaithersburg, MD 20878

Tel: (240) 658-6710

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Vininder Singh

Chief Executive Officer

Bullfrog AI Holdings, Inc.

325 Ellington Blvd., Unit 317

Gaithersburg, MD 20878

Tel: (240) 658-6710

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

With copies to:

 

Arthur S. Marcus, Esq.   Richard A. Friedman, Esq.
Sichenzia Ross Ference Carmel LLP   Sheppard, Mullin, Richter & Hampton, LLP
1185 Avenue of the Americas, 31 Fl. New York, NY 10036   30 Rockefeller Plaza New York, NY 10112
Telephone: (212) 930-9700   Telephone: (212) 653-8700
Facsimile: (212) 930-9725   Facsimile: (212) 653-8701

 

Approximate date of commencement of proposed sale to the public:

As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-Accelerated Filer Smaller Reporting Company
  Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B)

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 

 

 

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED JANUARY 29, 2024

 

Up to 786,938 shares of Common Stock

Warrants to Purchase up to 786,938 shares of Common Stock

786,938 shares underlying the Warrants

Pre-Funded Warrants to Purchase up to 786,938 shares of Common Stock

786,938 shares underlying the Pre-Funded Warrants

 

BULLFROG AI HOLDINGS, INC.

 

 

 

This is a firm commitment offering (“Offering”) of shares of common stock, par value $0.00001 per share (“common stock”) of Bullfrog AI Holdings, Inc. (the “Company”, “we”, “us”, “our”). Of the total shares being offered under this prospectus, the Company is offering 786,938 shares of common stock (the “Company Shares”) and accompanying warrants (the “Company Warrants”) to purchase up to 786,938 shares of common stock (the “Company Warrant Shares”). The assumed combined public offering price for each Company Share and accompanying Company Warrant is $6.63, which represents the last reported sale price of our common stock as reported on the Nasdaq Capital Market on January 25, 2024. As part of the compensation, the Company is also issuing 47,216 warrants to the Representative of the underwriters (the “Underwriter’s Warrants,” together with the Company Warrants and Pre-Funded Warrants, “Warrants”) to purchase 47,216 shares of common stock (the “Underwriter Warrant Shares,” together with the Company Warrant Shares and Pre-Funded Warrant Shares, the “Warrant Shares”).

 

We are also offering to those purchasers, if any, whose purchase of Company Shares in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this Offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants (each a “Pre-Funded Warrant”) in lieu of Company Shares that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. The holder of each Pre-funded Warrant has the right to purchase one share of common stock (each, a “Pre-Funded Warrant Share”) at an exercise price of $0.001 per share. The Pre-funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The combined purchase price of each Pre-Funded Warrant and Company Warrant is equal to the combined price per Company Share and Company Warrant being sold to the public in this Offering, minus $0.001. Therefore, we are offering the Pre-Funded Warrants and the Company Warrants at an assumed combined public offering price of $6.629.

 

For each Pre-Funded Warrant we sell, the number of Company Shares we are offering will be decreased on a one-for-one basis. The Company Shares or Pre-Funded Warrants, as the case may be, and the Company Warrants, can only be purchased together in this Offering, but these securities are immediately separable and will be issued separately.

 

The underwriter has the option to purchase additional securities, solely to cover over-allotments, if any, at the public offering price less the underwriting discount. The over-allotment option may be used to purchase (i) additional Company Shares from us, representing 15% of the number of Company Shares and/or Pre-funded Warrants initially sold in this Offering and/or (ii) additional warrants from us, representing 15% of the Company Warrants initially sold in this Offering. The over-allotment option is exercisable for 45 days from the date we initially sell securities in this Offering.

 

Our common stock and tradeable warrants are quoted on The Nasdaq Capital Market LLC (“Nasdaq”) under the symbols “BFRG” and “BFRGW,” respectively. We have not applied, and do not intend to apply, to list the Pre-Funded Warrants or the Company Warrants on Nasdaq. As of January 25, 2024, the last reported sales price of our common stock on Nasdaq was $6.63 per share. On January 25, 2024, we had 6,094,644 shares of common stock outstanding.

 

We are an emerging growth company under the Jumpstart our Business Startups Act of 2012, or JOBS Act, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings. Investing in our common stock involves a high degree of risk.

 

Investing in our common stock is highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 7 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

   Per Company Share and
Company
Warrant
   Per Pre-Funded Warrant and Company Warrant   Offering without
Exercise of
Over-Allotment
Option (4) (5)
   Offering with
Full Exercise of
Over-Allotment
Option (4)
 
Public offering price  $            $                  $                   $                     
Underwriting discount and commissions (8.0%) (1)(2)  $    $    $    $  
Proceeds to Company (before expenses)(3)  $    $    $    $  

 

  (1) See “Underwriting” for a description of compensation payable to the underwriters.
     
  (2) Does not include a non-accountable expense allowance equal to 1% of the public offering price payable to WallachBeth Capital LLC (the “Representative”), the representative of the underwriters or the reimbursement of certain expenses of the underwriters. See “Underwriting” for a description of compensation payable to the underwriters.
     
  (3) Does not include estimated offering expenses including, without limitation, legal, accounting, auditing, escrow agent, transfer agent, other professional, printing, advertising, travel, marketing, blue-sky compliance and other expenses of this Offering. We estimate the total expenses of this Offering, excluding the underwriter’s discount and expenses, will be approximately $258,000.
     
  (4) Assumes no exercise of the Company Warrants.
     
  (5) Assumes no Pre-Funded Warrants are sold.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

 

The underwriters expect to deliver our shares to purchasers in the offering on or about , 2024.

 

Sole Book-Running Manager

 

WALLACHBETH CAPITAL LLC

 

The date of this prospectus is , 2024

 

 

 

 

TABLE OF CONTENTS

 

PROSPECTUS SUMMARY 1
THE OFFERING 5
RISK FACTORS 7
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS 21
USE OF PROCEEDS 22
DIVIDEND POLICY 22
CAPITALIZATION 22
DILUTION 23
DESCRIPTION OF CAPITAL STOCK 25
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29
DESCRIPTION OF BUSINESS 35
MANAGEMENT 53
EXECUTIVE COMPENSATION 55
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 57
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 58
SHARES ELIGIBLE FOR FUTURE SALE 59
UNDERWRITING 60
DETERMINATION OF OFFERING PRICE 62
EXPERTS 64
LEGAL MATTERS 64
WHERE YOU CAN FIND ADDITIONAL INFORMATION 65
INDEX TO FINANCIAL STATEMENTS F-1

 

You should rely only on information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with additional information or information different from that contained in this prospectus. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful or in any state or other jurisdiction where the offer is not permitted.

 

For investors outside the United States: Neither we nor the underwriters have taken any action that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities covered hereby and the distribution of this prospectus outside of the United States.

 

The information in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since those dates.

 

No person is authorized in connection with this prospectus to give any information or to make any representations about us, the securities offered hereby or any matter discussed in this prospectus, other than the information and representations contained in this prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us.

 

Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. You are required to inform yourself about, and to observe any restrictions relating to, this offering and the distribution of this prospectus.

 

i

 

 

PROSPECTUS SUMMARY

 

This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our securities. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth under the sections “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes thereto, in each case included in this prospectus. Some of the statements in this prospectus constitute forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements.” Except as otherwise indicated, references to “we”, “us”, “our”, and the “Company” refer to Bullfrog AI Holdings, Inc. and its wholly-owned subsidiaries.

 

Business Overview

 

Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.

 

We use artificial intelligence and machine learning to advance medicines for both internal and external projects. We are committed to increasing the probability of success and decreasing the time and cost involved in developing therapeutics. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™, is an analytical AI/ML platform derived from technology developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL), which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise3, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

 

The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a prior hypothesis. Supervised machine learning uses labeled input and output data, while an unsupervised learning algorithm does not. In supervised learning, the algorithm “learns” from the training dataset by iteratively making predictions on the data and adjusting for the correct answer. Unsupervised learning, also known as unsupervised machine learning, uses machine learning algorithms to analyze and cluster unlabeled datasets. These algorithms discover hidden patterns or data groupings without the need for human intervention. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.

 

Together with our strategic partners and collaborators, our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development. Our primary business model is improving the success and efficiency of drug development which is accomplished either through acquisition of drugs or partnerships and collaborations with companies that are developing drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially derived from technology developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. In November 2021, we amended the agreement with JHU-APL to include additional advanced AI technology. On July 8, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The July 8, 2022 JHU-APL license provides the Company with new intellectual property and also encompasses most of the intellectual property from the February 2018 license.

 

We believe bfLEAP™ will inform/enable decision making throughout the development cycle:

 

1. Discovery Phase – Analyze and categorize discovery phase data to better define highest-value leads from groups of candidates, for advancement to preclinical phase of development. Integrate data from high-throughput screening, pharmacodynamics assays, pharmacokinetics assays, and other key data sets to create the most accurate profile of a pool of therapeutic candidates. There is often a high degree of similarity among closely related therapeutics in a candidate pool – bfLEAP™ is able to harmonize disparate data streams for a more nuanced understanding of each candidate’s characteristics/potency.

 

 

3In an August 2021 publication in DeepAI.org (https://deepai.org/publication/random-subspace-mixture-models-for-interpretable-anomaly-detection), the algorithms used in bfLEAP were compared to 10 of the most popular clustering algorithms in the world using 12 data sets. The end result showed that the algorithms used in bfLEAP had the highest average score when measuring speed and accuracy of prediction. The bfLEAP platform currently has more advanced versions of these algorithms and is applying them in multiple data analytics projects.

 

1
 

 

2. Pre-Clinical Data - Large-scale/multivariate analysis of pre-clinical and/or early-stage clinical data sets. In these settings, bfLEAP could be used to find novel drug targets, elucidate mechanism of action (MOA), predict potential off-target effects/side effects, uncover specific genetic/phenotypic background(s) with highest correlation to therapeutic response, etc. These insights from bfLEAP™ analysis can be used to inform decision making/study design at the subsequent step(s) of therapeutic/diagnostic development, including first-inhuman/Phase I RCTs.

 

3. Clinical Development - Advanced/multivariate analysis of PhI and/or PhII clinical trials data, to find niche populations of highly responsive patients and/or inform patient selection for later-stage CT(s). This can be used to decrease overall study risk for larger clinical trials - including Phase II trials, and any Phase III Registration Clinical Trials. The bfLEAP™ platform analysis can also be used to more precisely understand complex correlations between therapeutic treatment and adverse events, side effects, and other undesirable responses which could jeopardize clinical trial success.

 

Our platform is agnostic to the disease indication or treatment modality and therefore we believe that it is of value in the development of biologics or small molecules.

 

The process for our drug asset enhancement program is to:

 

  acquire the rights to a drug from a biopharmaceutical industry company or academia;
  use the proprietary bfLEAP™ AI/ML platform to determine a multi-factorial profile for a patient that would best respond to the drug;
  rapidly conduct a clinical trial to validate the drug’s use for the defined “high-responder” population; and
  divest/sell the rescued drug asset with the new information back to a large player in the pharma industry, following positive results of the clinical trial.

 

As part of our strategy, we will continue evolving our intellectual property, analytical platform and technologies, build a large portfolio of drug candidates, and implement a model that reduces risk and increases the frequency of cash flow from rescued drugs. This strategy will include strategic partnerships, collaborations, and relationships along the entire drug development value chain, as well as acquisitions of the rights to developing failed drugs and possibly the underlying companies.

 

To date, we have not conducted clinical trials on any pharmaceutical drugs and our platform has not been used to identify a drug candidate that has received regulatory approval for commercialization. However, we currently have a strategic relationship with a leading rare disease non-profit organization for AI/ML analysis of late stage clinical data. We have also positioned the Company to acquire the rights to a series of preclinical and early clinical drug assets from universities, as well as a strategic collaboration with a world renowned research institution to create a HSV1 viral therapeutic platform to engineer immunotherapies for a variety of diseases. In addition, we have signed exclusive world-wide license agreements with Johns Hopkins University for a cancer drug that targets glioblastoma (brain cancer), pancreatic cancer, and other cancers. We have also signed an exclusive worldwide license with George Washington University for another cancer drug that targets hepatoceullar carcinoma (liver cancer), and other liver diseases.

 

Our platform was originally developed by the JHU-APL. JHU-APL uses the same technology for applications related to national defense. Over several years, the software and algorithms have been used to identify relationship, patterns, and anomalies, and make predictions that otherwise may not be found. These discoveries and insights provide an advantage when predicting a target of interest, regardless of industry or sector. We have applied the technology to various clinical data sets and have identified novel relationships that may provide new intellectual property, new drug targets, and other valuable information that may help with patient stratification for a clinical trial thereby improving the odds for success. The platform has not yet aided in the development of a drug that has reached commercialization. However, we own one drug candidate that has completed a phase 1 trial and a second candidate that is in the preclinical stages. Our aim is to use our technology on current and future available data to help us better determine the optimal path for development.

 

While we have not generated significant revenues from our AI/ML operations, we anticipate generating revenue in the future from the following three sources:

 

Contract Services

 

Our fee for service partnership offering model is designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. We provide the customer with an analysis of large complex data sets using our proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. Our service model involves a cash fee plus the potential for rights to new intellectual property generated from the analysis, which can be performed at the discovery, preclinical, or clinical stages of drug development.

 

Collaborative Arrangements

 

We plan to enter into collaborative arrangements with biotechnology and pharmaceutical companies who have drugs that are in development or have failed late Phase 2 or Phase 3 trials. The collaborations may also be at the discovery or preclinical stages of drug development. Our revenue will be a combination of fee for service cash payments and success fees based on achieving certain milestones as determined by each specific arrangement. There may also be fees or legal rights associated with the development of new intellectual property.

 

2
 

 

Acquisition of Rights to Certain Drugs

 

We may acquire the rights to drugs that have failed late Phase 2 or Phase 3 trials and generate revenues by using our platform to accurately determine the profile of patients that would respond to the drugs, conduct a clinical trial to test our findings either independently or with a clinical partner, and finally sell the drug back to pharmaceutical companies. We have and may continue acquiring the rights to drugs that have not yet failed any trials. We will use our technology to improve the chances for success, conduct a trial, and divest the asset. When divesting assets, the transaction may involve a combination of upfront payments, milestone payments based on clinical success, and royalties on sales of the product.

 

Our bfLEAP™ Analytics Platform

 

We are able to pursue our drug rescue business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) derived from technology developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL). The bfLEAP™ platform is based on an exclusive, world-wide license granted by Johns Hopkins University Applied Physics Laboratory. The license covers three (3) issued patents, as well as a new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, which also includes modifications and improvements. On July 8, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. Under the terms of the new License Agreement, JHU will be entitled to eight (8%) percent of net sales for the services provided by the Company to other parties and 3% for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues.

 

We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The input data for bfLEAP™ can include raw data (preclinical and/or clinical readouts), categorical data, sociodemographic data of patients, and various other inputs. Thus, the bfLEAP™ platform is capable of capturing the particular genetic and physical characteristics of patients in an unbiased manner, and contextualizing it against other disparate data sources from patients (e.g. molecular data, physiological data, etc.) for less biased and more meaningful conclusions. It is also uniquely scalable – the bfLEAP™ platform is able to perform analysis on large, high-volume data sets (i.e. ‘big data’) and also able to analyze highly disparate “short and wide” data as well. In terms of visualization, bfLEAP™ is able to integrate with most commonly used visualization tools for graph analytics.

 

We believe that the combination of a) scalable analytics (i.e., large data or short/wide data), b) state-of-the-art proprietary algorithms, c) unsupervised machine learning, and d) streamlined data ingestion/visualization makes bfLEAP™ one of the most flexible and powerful new platforms available on the market.

 

The Company will continue to evolve and improve bfLEAP™, and some of the proceeds from this offering may be used toward that effort either in-house or with development partners like The Johns Hopkins University Applied Physics Lab.

 

Summary Risk Factors

 

Our business is subject to numerous risks as described in the section entitled “Risk Factors” and elsewhere in this prospectus. You should carefully consider these risks before making an investment. Some of these risks include:

 

  We have a limited operating history upon which you can evaluate our performance, and accordingly, our prospects must be considered in light of the risks that any new company encounters.
  In order for the Company to compete and grow, it must attract, recruit, retain and develop the necessary personnel who have the needed experience.
  The development and commercialization of our technology, products, and services is highly competitive.
  The Company’s success depends on the experience and skill of the board of directors, its executive officers and key employees.
  We rely on various intellectual property rights, including patents and licenses in order to operate our business.
  From time to time, third parties may claim that one or more of our products or services infringe their intellectual property rights.
  New product development involves a lengthy, expensive and complex process.
  We may not be able to conduct clinical trials necessary to commercialize and sell our proposed products and formulations.
  Our long-term viability and growth will depend upon successful clinical trials.
  We face significant competition from other biotechnology and pharmaceutical companies.
  Our research and development efforts may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.
  Even if we are able to obtain regulatory approvals for new pharmaceutical products, generic or branded, the success of those products is dependent upon acceptance of such products, particularly by the pharmaceutical industry.

 

3
 

 

  We extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house.
  We may not be able to acquire the rights to any failed drugs or we may not be able to rescue failed drugs through analysis due to our technology or the lack of clinical data.
  We have no current specific plan for a significant portion of the offering proceeds and it is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for you.

 

Implications of Being an Emerging Growth Company

 

As a company with less than $1.235 billion in revenue during our last completed fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are otherwise applicable generally to public companies. These reduced reporting requirements include:

 

  an exemption from compliance with the auditor attestation requirement on the effectiveness of our internal control over financial reporting;
     
  an exemption from compliance with any requirement that the Public Company Accounting Oversight Board may adopt regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
     
  an exemption from the requirements to obtain a non-binding advisory vote on executive compensation or a stockholder approval of any golden parachute arrangements;
     
  extended transition periods for complying with new or revised accounting standards;
     
  being permitted to present only two years of audited financial statements and only two years of related “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, in addition to any required unaudited interim financial statements in this prospectus; and
     
  reduced disclosures regarding executive compensation in our periodic reports, proxy statements and registration statements, including in this prospectus.

 

We will remain an emerging growth company until the earliest to occur of: (i) the end of the first fiscal year in which our annual gross revenue is $1.235 billion or more; (ii) the end of the first fiscal year in which we are deemed to be a “large accelerated filer,” as defined in the Securities Exchange Act of 1934, as amended, (the “Exchange Act”); (iii) the date on which we have, during the previous three-year period, issued more than $1.00 billion in non-convertible debt securities; and (iv) the end of the fiscal year during which the fifth anniversary of this offering occurs. We may choose to take advantage of some, but not all, of the available benefits under the JOBS Act. We currently intend to take advantage of the exemptions discussed above. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.

 

We are also a “smaller reporting company,” as defined under SEC Regulation S-K. As such, we also are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and also are subject to less extensive disclosure requirements regarding executive compensation in our periodic reports and proxy statements. We will continue to be deemed a smaller reporting company until our public float exceeds $75 million on the last day of our second fiscal quarter in the preceding fiscal year.

 

4
 

 

Corporate Information

 

Bullfrog AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc. The Company’s principal business address is 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878. Our website address is www.bullfrogai.com. The references to our website in this prospectus are inactive textual references only. The information on our website is neither incorporated by reference into this prospectus nor intended to be used in connection with this offering. All of our operations are currently conducted through BullFrog AI, Inc.

 

Going Concern

 

The Company intends to overcome the circumstances that impact its ability to remain a going concern through a combination of expanding its revenues and additional equity and debt financing. The Company anticipates raising additional funds through public or private financing, strategic relationships or other arrangements in the near future to support its business operations; however, the Company may not have commitments from third parties for a sufficient amount of additional capital. The Company cannot be certain that any such financing will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations. The Company’s ability to obtain additional funding will determine its ability to continue as a going concern. Failure to secure additional financing in a timely manner and on favorable terms would have a material adverse effect on the Company’s financial performance, results of operations and stock price and may require it to curtail or cease operations, sell off its assets, seek protection from its creditors through bankruptcy proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of the Company’s common stock, and debt financing, if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require that the Company relinquish valuable rights. Please see note 1, in our financial statements, for further information. The Company believes that, following this offering, it will have sufficient capital to sustain its operations for at least the next 15 months, however, there can be no assurance that sufficient funds required during the subsequent year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources.

 

THE OFFERING

 

The following summary of the offering contains basic information about the offering and the common stock and is not intended to be complete. It does not contain all the information that is important to you. For a more complete understanding of the common stock, please refer to the section of this prospectus entitled “Description of Capital Stock.”

 

Securities offered by us   We are offering (i) up to 786,938 shares (the “Company Shares”) of our common stock, par value $0.00001 per share, assuming the underwriter does not exercise its over-allotment option, or 904,978 shares of common stock, assuming the underwriter exercise its over-allotment option in full, (ii) pre-funded warrants to purchase up to 786,938 shares of common stock (“Pre-funded Warrants”), and/or (iii) warrants to purchase up to 786,938 shares of common stock (“Company Warrants”), assuming the underwriter does not exercise its over-allotment option, or warrants to purchase up to 904,978 shares of common stock, assuming the underwriter exercise its over-allotment option in full.
     
Company Warrants   Warrants to purchase up to 786,938 shares of common stock (or 904,978 shares of common stock if the underwriter exercises its over-allotment option in full). The warrants will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date and have an initial exercise price equal to $7.29. Please see “Description of Capital Stock - Company Warrants” for a description of these warrants.
     
Pre-Funded Warrants   Warrants to purchase up to 786,938 shares of common stock. Each Pre-Funded Warrant and Company Warrant is being offered for an assumed combined price of $6.629, equal to the assumed combined price per Company Share and Company Warrant being sold to the public in this Offering, minus $0.001. The Pre-Funded Warrants will be exercisable immediately upon issuance, may be exercised at any time until all of the Pre-Funded Warrants are exercised in full, and have an initial exercise price equal to $0.001. Please see “Description of Capital Stock - Pre-Funded Warrants” for a description of these warrants.
     
Assumed combined public offering price per Company Share/Pre-Funded Warrant, and Company Warrant   $6.63 per Company Share and accompanying Company Warrant, or $6.629 per Pre-Funded Warrant and accompanying Company Warrant (the combined purchase price of each Pre-funded Warrant and Company Warrant is equal to the combined price per Company Share and Company Warrant being sold to the public in this Offering, minus $0.001)
     
Nasdaq Listing   Our common stock and tradeable warrants currently trade on the Nasdaq Capital Market under the symbol “BFRG” and “BFRGW,” respectively.
     
Number of shares of common stock outstanding before the Offering:   6,094,644 shares
     
Number of shares of common stock outstanding after the Offering:   6,881,582 shares (assuming none of the Warrants issued in this Offering are exercised and the Representative does not exercise its over-allotment option)
     
Over-allotment option   We have granted the underwriters an option, exercisable within 45-days after the closing of this Offering to purchase (i) an additional 118,040 Company Shares from us, representing 15% of the number of Company Shares (and/or Pre-Funded Warrants issued in lieu of Company Shares) initially sold in this Offering and/or (ii) an additional 118,040 warrants from us, representing 15% of the Company Warrants initially sold in this Offering.

 

5
 

 

Underwriter   WallachBeth Capital LLC
     
Underwriter’s Warrants   Upon closing of this Offering, we have agreed to issue to the Representative of the underwriters warrants (“Underwriter’s Warrants”) to purchase that number of shares of our common stock equal to six percent (6%) of the aggregate number of shares sold in the Offering. The Underwriter’s Warrants will be exercisable at any time, and from time to time, in whole or in part, during the period commencing 180 days following the effective date of this Offering and expiring on the fifth anniversary thereof at an exercise price per share of $7.29 (110% of the combined public offering price of each Company Share and Company Warrant) assuming a combined public offering price of $6.63 per Company Share and Company Warrant. See “Underwriting - Underwriter’s Warrants”. The registration statement of which this prospectus is apart also covers the Underwriter’s Warrants and the shares of our common stock issuable upon exercise of the Underwriter’s Warrants.
     
Use of proceeds:  

We expect to receive approximately $4,546,007 in net proceeds from the sale of our securities offered by us in this Offering (approximately $5,257,399 if the underwriters exercise their over-allotment option in full), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds received from this offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology, the repayment of debt and for working capital and general corporate purposes.

 

See “Use of Proceeds” on page 22 for a description of the intended use of proceeds from this Offering.

     
Risk Factors:   Investing in our securities is highly speculative and involves a high degree of risk. You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors” section beginning on page 7 of this prospectus before deciding whether or not to invest in our securities.
     
Lock-ups   We and our directors, officers and holders of ten percent (10%) or more of our outstanding securities have agreed with the underwriters, subject to certain exceptions, not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock for a period of ninety (90) days after the completion of this Offering. See “Underwriting” on page 60.

 

Unless otherwise indicated in this prospectus, the information in this prospectus assumes:

 

  an assumed public offering price of $6.63 per Company Share and accompanying Company Warrant;
     
  no sale of Pre-Funded Warrants in this Offering, no exercise of the Company Warrants being offered in this Offering, no exercise of the underwriters’ over-allotment option, and no exercise of the Underwriter’s Warrants; and
     
  786,938 Company Shares sold in this Offering.

 

6
 

 

RISK FACTORS

 

An investment in our securities is highly speculative and involves a high degree of risk. In determining whether to purchase the Company’s securities, an investor should carefully consider all of the material risks described below, together with the other information contained in this prospectus. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.

 

Risks Related to Liquidity, the Company’s Business and Industry

 

We have a limited operating history upon which you can evaluate our performance, and accordingly, our prospects must be considered in light of the risks that any new company encounters.

 

We were incorporated under the laws of Nevada on February 26, 2020. Accordingly, we have no significant history upon which an evaluation of our prospects and future performance can be made. Our proposed operations are subject to all of the business risks associated with a new enterprise. The likelihood of our creation of a viable business must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the inception of a business, operation in a competitive industry, and the continued development of our technology and the results of our clinical data. We anticipate that our operating expenses will increase for the near future. There can be no assurances that we will ever operate profitably. You should consider the Company’s business, operations and prospects in light of the risks, expenses and challenges faced as an early-stage company.

 

If we are unable to attract and retain key management, scientific personnel and advisors, we may not achieve our business objectives.

 

Our success depends on the availability and contributions of members of our senior management team. The loss of services of any of these individuals could delay, reduce or prevent our drug development and other business objectives. Furthermore, recruiting and retaining qualified scientific personnel to perform drug development work will be critical to our success. We face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other public and private research institutions. We may be unable to attract and retain these individuals, and our failure to do so could materially adversely affect our business and financial condition.

 

7
 

 

The development of our technology, products, and services is highly competitive.

 

We face competition with respect to any products that we may seek to develop or commercialize in the future. Our competitors include major companies worldwide. Many of our competitors have significantly greater financial, technical and human resources than we have and superior expertise in research and development and marketing approved products/services and thus may be better equipped than us to develop and commercialize products/services. These competitors also compete with us in recruiting and retaining qualified personnel and acquiring technologies. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Accordingly, our competitors may commercialize products more rapidly or effectively than we are able to, which would adversely affect our competitive position, the likelihood that our products/services will achieve initial market acceptance and our ability to generate meaningful additional revenues from our products.

 

From time to time, third parties may claim that one or more of our products or services infringe their intellectual property rights.

 

Any dispute or litigation regarding patents or other intellectual property could be costly and time consuming due to the uncertainty of intellectual property litigation and could divert our management and key personnel from our business operations. A claim of intellectual property infringement could force us to enter into a costly or restrictive license agreement, which might not be available under acceptable terms or at all, could require us to redesign our products, which would be costly and time-consuming, and/or could subject us to an injunction against development and sale of certain of our products or services. We may have to pay substantial damages, including damages for past infringement if it is ultimately determined that our products infringe on a third party’s proprietary rights. Even if these claims are without merit, defending a lawsuit takes significant time, may be expensive and may divert management’s attention from other business concerns. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our business to be harmed. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response to a claim of intellectual property infringement. In certain of our businesses we rely on third party intellectual property licenses and we cannot ensure that these licenses will be available to us in the future on favorable terms or at all.

 

Although dependent on certain key personnel, the Company does not have any key man life insurance policies on any such people.

 

The Company is dependent on Vininder Singh in order to conduct its operations and execute its business plan and the loss of Vininder Singh or any member of the board of directors or executive officer could harm the Company’s business, financial condition, cash flow and results of operations; however, the Company has not purchased any insurance policies with respect to those individuals in the event of their death or disability. Therefore, if Vininder Singh or any member of the board of directors or an executive officer dies or become disabled, the Company will not receive any compensation to assist with such person’s absence. The loss of such person could negatively affect the Company and its operations.

 

8
 

 

New product development involves a lengthy, expensive and complex process.

 

We may be unable to develop or commercialize any product candidates. Moreover, even if we develop such candidates, they may be subject to significant regulatory review, approval and other government regulations. There can be no assurance that our technologies will be capable of developing and commercializing products at all. New product development involves a lengthy, expensive and complex process and we currently have no fully validated diagnostic candidates. In addition, before we can commercialize any new product candidates, we will need to:

 

  conduct substantial research and development;
  conduct validation studies;
  expend significant funds;
  develop and scale-up our laboratory processes; and
  obtain regulatory approval and acceptance of our product candidates.

 

This process involves a high degree of risk and takes several years. Our product development efforts may fail for many reasons, including:

 

  failure of the product at the research or development stage; and
  lack of clinical validation data to support the effectiveness of the product.

 

Few research and development projects result in commercial products, and perceived viability in early clinical trials often is not replicated in later studies. At any point, we may abandon development of a product candidate or we may be required to expend considerable resources repeating clinical trials, which would adversely impact the timing for generating potential revenues from those product candidates. In addition, as we develop product candidates, we will have to make significant investments in product development, marketing and sales resources.

 

We may not be able to conduct clinical trials necessary to increase the value of our proposed products and formulations.

 

In order to conduct clinical trials that are necessary to obtain approval of a product by the FDA, it is necessary to receive clearance from the FDA to conduct such clinical trials. The FDA can halt clinical trials at any time for safety reasons or because we or our clinical investigators do not follow the FDA’s requirements for conducting clinical trials. If we are unable to receive clearance to conduct clinical trials or the trials are halted by the FDA, the likelihood of our ability to sell or license our products would be greatly reduced as it is the FDA approval which will enhance the value of our products.

 

Our ability to resell and/or license our products will depend upon successful clinical trials.

 

Only a small number of research and development programs result in the development of a product that obtains FDA approval. Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete our clinical trials in a timely fashion depends in large part on a number of key factors including protocol design, regulatory and institutional review board approval, the rate of patient enrollment in clinical trials, and compliance with extensive current Good Clinical Practices. If we fail to adequately manage the design, execution and regulatory aspects of our clinical trials, our studies and ultimately our regulatory approvals may be delayed, or we may fail to gain approval for our product candidates. Clinical trials may indicate that our product candidates have harmful side effects or raise other safety concerns that may significantly reduce the likelihood of regulatory approval, result in significant restrictions on use and safety warnings in any approved label, adversely affect placement within the treatment paradigm, or otherwise significantly diminish the commercial potential of the product candidate. Also, positive results in a registrational trial may not be replicated in any subsequent confirmatory trials. Even if later stage clinical trials are successful, regulatory authorities may disagree with our view of the data or require additional studies, and may fail to approve or delay approval of our product candidates or may grant marketing approval that is more restricted than anticipated, including indications for a narrower patient population than expected and the imposition of safety monitoring or educational requirements or risk evaluation and mitigation strategies. In addition, if another Company is the first to file for marketing approval of a competing drug candidate, that Company may ultimately receive marketing exclusivity for its drug candidate, thereby reducing the value of our product.

 

9
 

 

We face significant competition from other biotechnology and pharmaceutical companies.

 

While we believe that our technology, development experience and scientific knowledge provide competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the development of drug candidates as well as in obtaining regulatory approvals of those drug candidates in the United States and in foreign countries.

 

Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drug candidates that are more effective or less costly than any drug candidate that we may develop.

 

Our ability to compete successfully will depend largely on our ability to:

 

identify drugs that have suffered set backs in the clinical development and regulatory process which we believe can be assisted by our platform’s ability to design a better study group;
attract qualified scientific, product development and commercial personnel;
obtain patent or other proprietary protection for our drugs and technologies;
obtain required regulatory approvals; successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new drugs; and
negotiate competitive pricing and reimbursement with third party payors

 

The availability of our competitors’ technologies could limit the demand, and the price we are able to charge for our services and for any drug candidate we develop. The inability to compete with existing or subsequently introduced drug development technologies would have a material adverse impact on our business, financial condition and prospects.

 

Established pharmaceutical companies and research institutions may invest heavily to accelerate discovery and development of novel compounds or to in license novel compounds that could make bfLEAP™ less competitive, which would have a material adverse impact on our business.

 

We may not be able to acquire the rights to any failed drugs or we may not be able to rescue failed drugs through analysis due to our technology or the lack of clinical data.

 

Our business model is based on the use of AI/ML technology, which technology may not uncover actionable insights or we may not be able to access sufficient clinical data to uncover such insights that lead to a successful project, clinical trial, or product. The failure of such projects, clinical trials or products would result in a loss of revenue from one of our three sources, which could have a material adverse impact on our business as a whole.

 

We may not succeed in acquiring the rights to failed drugs, which could limit one of our main sources of revenue.

 

Our business model is partly based on our ability to acquire drugs that have failed to pass Phase 2 or Phase 3 of the FDA approval process; however, there is no guarantee that we will be able to acquire the rights to such drugs, which would significantly impact our ability to generate revenue and as a result would have a material adverse impact on our business.

 

We intend to invest in early stage experimental technologies which have a high risk of failure.

 

To continue supporting our business model, we intend to invest in early stage and experimental technologies, some or all of which may not be useful to us. There is a risk that we will invest in technology that will not ultimately contribute to the success of our projects, which could have a material adverse impact on our business.

 

We are dependent on our collaborative agreements for the development of products and business development, which exposes us to the risk of reliance on the viability of third parties.

 

In conducting our research and development activities, we currently rely, and will in the future rely, on collaborative agreements with third parties such as manufacturers, contract research organizations, commercial partners, universities, governmental agencies and not-for-profit organizations for both strategic and financial resources. The loss of, or failure to perform by us or our partners under, any applicable agreements or arrangements, or our failure to secure additional agreements for other products in development, would substantially disrupt or delay our research and development and commercialization activities. Any such loss would likely increase our expenses and materially harm our business, financial condition and results of operation.

 

10
 

 

We extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house.

 

We rely on independent third-party contract research organizations (CROs) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs’ processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals could be adversely impacted.

 

We are a biotechnology company with no significant revenue. We have incurred operating losses since our inception, and we expect to incur losses for the foreseeable future and may never achieve profitability.

 

We have incurred significant operating losses since our inception. To date, we have not generated any revenue and we may not generate any revenue from sales of our clinical analytics services or drug candidates for the foreseeable future. We expect to continue to incur significant operating losses and we anticipate that our losses may increase substantially as we expand our drug development programs.

 

To achieve profitability, we must successfully develop and obtain regulatory approval for one or more of drugs and effectively commercialize any drugs we develop. Even if we succeed in developing and commercializing one or more drug candidates, we may not be able to generate sufficient revenue and we may never be able to achieve or sustain profitability.

 

We will continue to require additional capital for the foreseeable future. If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our drug acquisition efforts.

 

We expect to continue to incur significant operating expenses in connection with our ongoing activities, including conducting clinical trials and seeking regulatory approval of drug candidates. Our ongoing future capital requirements will depend on numerous factors, including:

 

  the rate of progress, results and costs of completion of clinical trials of drug candidates;
  the size, scope, rate of progress, results and costs of completion of any potential future clinical
  trials and preclinical tests of our drug candidates that we may initiate;
  the costs of obtaining regulatory approval of drug candidates;
  the scope, prioritization and number of drug development programs we pursue;
  the costs for preparing, filing, prosecuting, maintaining and enforcing our intellectual property
  rights and defending intellectual property-related claims;
  the extent to which we acquire or in-license other products and technologies and the costs to be able to obtain regulatory approval of such products;
  our ability to establish strategic collaborations and licensing or other arrangements on terms
  favorable to us; and
  competing technological and market developments.

 

Any additional fundraising efforts may divert our management from their day to day activities, which may adversely affect our ability to identify and acquire new drug candidates and to further the regulatory process of such products. Our ability to raise additional funds will depend, in part, on the success of our product development activities and other factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurance that we will be able to raise additional capital when needed or on terms that are favorable to us, if at all. If adequate funds are not available on a timely basis, we may be forced to:

 

  delay, reduce the scope of or eliminate one or more of our drug development programs;

 

11
 

 

  limit the amount of new products that we acquire or relinquish, license or otherwise dispose of rights on terms that are less favorable than if we were able to further the regulatory approval process; or
  liquidate and dissolve the Company.

 

If our operating plans change, we may require additional capital sooner than planned. Such additional financing may not be available when needed or on terms favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current and future operating plan.

 

We are increasingly dependent on information technology systems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.

 

We are increasingly dependent on information technology systems to operate our business. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems by employees, others with authorized access to our systems or unauthorized persons could negatively impact operations. In the ordinary course of business, we collect, store and transmit confidential information and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such information. Additionally, we outsource certain elements of our information technology systems to third parties. As a result of this outsourcing, our third party vendors may or could have access to our confidential information making such systems vulnerable. Data breaches of our information technology systems, or those of our third party vendors, may pose a risk that sensitive data may be exposed to unauthorized persons or to the public. For example, the loss of clinical trial data from completed or ongoing clinical trials or preclinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. While we believe that we have taken appropriate security measures to protect our data and information technology systems, and have been informed by our third party vendors that they have as well, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems, or those of our third party vendors, that could materially adversely affect our business and financial condition.

 

We must complete extensive clinical trials to demonstrate the safety and efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates, we will not be successful.

 

The success of our business depends primarily on our ability to further the regulatory approval process to increase the value of our drug candidates. Drug candidates must satisfy rigorous standards of safety and efficacy before they can be approved for sale which greatly enhances their value. To satisfy these standards, we must engage in expensive and lengthy testing of drug candidates.

 

We may not be able to obtain authority from the FDA or other equivalent foreign regulatory agencies to move on to further efficacy segments of the Phase 2 or Phase 3 clinical trials or commence and complete any clinical trials for any of our drug candidates. Positive results in preclinical studies of a drug candidate may not be predictive of similar results in human clinical trials, and promising results from early clinical trials of a drug candidate may not be replicated in later clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly, the results from the preclinical tests or clinical trials for our drug candidates may not be predictive of the results we may obtain in later stage trials. The failure of clinical trials to demonstrate safety and efficacy of one or more of our drug candidates will have a material adverse effect on our business and financial condition.

 

Delays in the commencement of clinical trials of our drug candidates could result in increased costs to us and delay our ability to successfully license or sell such products.

 

Our drug candidates will require continued extensive clinical trials to increase the value and desirability of the products. Because of the nature of clinical trials, we do not know whether future planned clinical trials will begin on time, if at all. Delays in the commencement of clinical trials could significantly increase our drug development costs and delay our ability to successfully sell or license our drug candidates. In addition, many of the factors that may cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to denial of regulatory approval of a drug candidate. The commencement of clinical trials can be delayed for a variety of reasons, including delays in:

 

  demonstrating sufficient safety and efficacy in past clinical trials to obtain regulatory approval
  to commence a further clinical trial;

 

12
 

 

  convincing the FDA that we have selected valid endpoints for use in proposed clinical trials; and
  obtaining institutional review board approval to conduct a clinical trial at a prospective site.

 

In addition, the commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease and the eligibility criteria for the clinical trial.

 

If we are unable to obtain U.S. and/or foreign regulatory approval, we will be unable to resell or license our drug candidates.

 

Our drug candidates will be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labelling, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required in the U.S. and in many foreign jurisdictions prior to the commercial sale of drug candidates. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that no drug candidate that we present to the FDA will obtain marketing approval which will significantly diminish the value and desirability of our product candidates. In connection with the clinical trials for our drug candidates, we face risks that:

 

  the drug candidate may not prove to be efficacious;
  the drug candidate may not prove to be safe;
  the drug candidate may not be readily co-administered or combined with other drugs or drug
  candidates;
  the results may not confirm the positive results from earlier preclinical studies or clinical trials;
  the results may not meet the level of statistical significance required by the FDA or other
  regulatory agencies; and
  the FDA or other regulatory agencies may require us to carry out additional studies.

 

We have limited experience in conducting and managing later stage clinical trials necessary to obtain regulatory approvals, including approval by the FDA. However, this risk would be mitigated in the event the Company is successful entering into a co-development agreement with a pharma partner for late stage clinical development. The time required to complete clinical trials and for the FDA and other countries’ regulatory review processes is uncertain and typically takes many years. Our analysis of data obtained from preclinical and clinical trials is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unanticipated delays or increased costs due to government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials, and FDA regulatory review.

 

We will rely on third parties for manufacturing of our clinical drug supplies; our dependence on these manufacturers may impair the development of our drug candidates.

 

We have no ability to internally manufacture the drug candidates that we need to conduct our clinical trials for the products that we acquire. For the foreseeable future, we expect to continue to rely on third-party manufacturers and other third parties to produce, package and store sufficient quantities of our drug candidates and any future drug candidates for use in our clinical trials. We may face various risks and uncertainties in connection with our reliance on third-party manufacturers, including:

 

  reliance on third-party manufactures for regulatory compliance and quality assurance;
  the possibility of breach of the manufacturing agreement by the third-party manufacturer because
  of factors beyond our control;
  the possibility of termination or nonrenewal of our manufacturing agreement by the third-party
  manufacturer at a time that is costly or inconvenient for us;
  the potential that third-party manufacturers will develop know-how owned by such third-party
  manufacturer in connection with the production of our drug candidates that is necessary for the
  manufacture of our drug candidates; and
  reliance on third-party manufacturers to assist us in preventing inadvertent disclosure or theft of
  our proprietary knowledge.

 

13
 

 

Our drug candidates may be complicated and expensive to manufacture. If our third-party manufacturers fail to deliver our drug candidates for clinical use on a timely basis, with sufficient quality, and at commercially reasonable prices, we may be required to delay or suspend clinical trials or otherwise discontinue development of our drug candidates. While we may be able to identify replacement third-party manufacturers or develop our own manufacturing capabilities for these drug candidates, this process would likely cause a delay in the availability of our drug candidates and an increase in costs. In addition, third-party manufacturers may have a limited number of facilities in which our drug candidates can be manufactured, and any interruption of the operation of those facilities due to events such as equipment malfunction or failure or damage to the facility by natural disasters could result in the cancellation of shipments, loss of product in the manufacturing process or a shortfall in available drug candidates.

 

We may rely on technology solution partners for the development and deployment of our AI technology

 

Our partners may experience technical, financial, operational, or security issues that reduce or eliminate their ability to support the Company. This could prevent the Company from generating revenue and eliminate our ability to operate.

 

In addition to the risks listed above, businesses are often subject to risks not foreseen or fully appreciated by the management. It is not possible to foresee all risks that may affect us. Moreover, the Company cannot predict whether the Company will successfully effectuate the Company’s current business plan. Each prospective Purchaser is encouraged to carefully analyze the risks and merits of an investment in the Securities and should take into consideration when making such analysis, among other, the Risk Factors discussed above.

 

Risks Related to Intellectual Property Rights

 

We rely on various intellectual property rights, including patents and licenses in order to operate our business.

 

Our intellectual property rights, may not be sufficiently broad or otherwise may not provide us a significant competitive advantage. In addition, the steps that we have taken to maintain and protect our intellectual property may not prevent it from being challenged, invalidated, circumvented or designed-around, particularly in countries where intellectual property rights are not highly developed or protected. In some circumstances, enforcement may not be available to us because an infringer has a dominant intellectual property position or for other business reasons, or countries may require compulsory licensing of our intellectual property. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property, could adversely impact our competitive position and results of operations. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements will adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or other proprietary rights.

 

As we expand our business, protecting our intellectual property will become increasingly important. The protective steps we have taken may be inadequate to deter our competitors from using our proprietary information. In order to protect or enforce our patent rights, we may be required to initiate litigation against third parties, such as infringement lawsuits. Also, these third parties may assert claims against us with or without provocation. These lawsuits could be expensive, take significant time and could divert management’s attention from other business concerns. The law relating to the scope and validity of claims in the technology field in which we operate is still evolving and, consequently, intellectual property positions in our industry are generally uncertain. We cannot assure you that we will prevail in any of these potential suits or that the damages or other remedies awarded, if any, would be commercially valuable.

 

14
 

 

The Company could be negatively impacted if found to have infringed on intellectual property rights.

 

Technology companies, including many of the Company’s competitors, frequently enter into litigation based on allegations of patent infringement or other violations of intellectual property rights. In addition, patent holding companies seek to monetize patents they have purchased or otherwise obtained. As the Company grows, the intellectual property rights claims against it will likely increase. The Company intends to vigorously defend infringement actions in court and before the U.S. International Trade Commission. The plaintiffs in these actions frequently seek injunctions and substantial damages. Regardless of the scope or validity of such patents or other intellectual property rights, or the merits of any claims by potential or actual litigants, the Company may have to engage in protracted litigation. If the Company is found to infringe one or more patents or other intellectual property rights, regardless of whether it can develop non-infringing technology, it may be required to pay substantial damages or royalties to a third-party, or it may be subject to a temporary or permanent injunction prohibiting the Company from marketing or selling certain products. In certain cases, the Company may consider the desirability of entering into licensing agreements, although no assurance can be given that such licenses can be obtained on acceptable terms or that litigation will not occur. These licenses may also significantly increase the Company’s operating expenses. Regardless of the merit of particular claims, litigation may be expensive, time-consuming, disruptive to the Company’s operations and distracting to management. In recognition of these considerations, the Company may enter into arrangements to settle litigation. If one or more legal matters were resolved against the Company’s consolidated financial statements for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against the Company that could adversely affect its financial condition and results of operations.

 

We rely heavily on our technology and intellectual property, but we may be unable to adequately or cost-effectively protect or enforce our intellectual property rights, thereby weakening our competitive position and increasing operating costs.

 

To protect our rights in our services and technology, we rely on a combination of copyright and trademark laws, patents, trade secrets, confidentiality agreements and protective contractual provisions. We also rely on laws pertaining to trademarks and domain names to protect the value of our corporate brands and reputation. Despite our efforts to protect our proprietary rights, unauthorized parties may copy aspects of our services or technology, obtain and use information, marks, or technology that we regard as proprietary, or otherwise violate or infringe our intellectual property rights. In addition, it is possible that others could independently develop substantially equivalent intellectual property. If we do not effectively protect our intellectual property, or if others independently develop substantially equivalent intellectual property, our competitive position could be weakened.

 

Effectively policing the unauthorized use of our services and technology is time-consuming and costly, and the steps taken by us may not prevent misappropriation of our technology or other proprietary assets. The efforts we have taken to protect our proprietary rights may not be sufficient or effective, and unauthorized parties may copy aspects of our services, use similar marks or domain names, or obtain and use information, marks, or technology that we regard as proprietary. We may have to litigate to enforce our intellectual property rights, to protect our trade secrets, or to determine the validity and scope of others’ proprietary rights, which are sometimes not clear or may change. Litigation can be time consuming and expensive, and the outcome can be difficult to predict.

 

We rely on agreements with third parties to provide certain services, goods, technology, and intellectual property rights necessary to enable us to implement some of our applications.

 

Our ability to implement and provide our applications and services to our clients depends, in part, on services, goods, technology, and intellectual property rights owned or controlled by third parties. These third parties may become unable to or refuse to continue to provide these services, goods, technology, or intellectual property rights on commercially reasonable terms consistent with our business practices, or otherwise discontinue a service important for us to continue to operate our applications. If we fail to replace these services, goods, technologies, or intellectual property rights in a timely manner or on commercially reasonable terms, our operating results and financial condition could be harmed. In addition, we exercise limited control over our third-party vendors, which increases our vulnerability to problems with technology and services those vendors provide. If the services, technology, or intellectual property of third parties were to fail to perform as expected, it could subject us to potential liability, adversely affect our renewal rates, and have an adverse effect on our financial condition and results of operations.

 

If any third-party owners of intellectual property we may license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed.

 

We may enter into licenses for third-party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for their intellectual property, in particular, those patents to which we have secured exclusive rights.

 

15
 

 

If applicable, our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents issue in respect of any such patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. In addition, our licensors may terminate their agreements with us in the event we breach the applicable license agreement and fail to cure the breach within a specified period of time. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could materially adversely affect our competitive business position, business prospects and financial condition.

 

Because our research and development of drug candidates often incorporates compounds and other information that is the intellectual property of third parties, we depend on continued access to such intellectual property to conduct and complete our preclinical and clinical research and commercialize the drug candidates that result from this research. We expect that future licenses would impose, numerous obligations on us. For example, under our existing and future license agreements, we may be required to pay (i) annual maintenance fees until a drug candidate is sold for the first time, (ii) running royalties on net sales of drug candidates, (iii) minimum annual royalties after a drug candidate is sold for the first time, and (iv) one-time payments upon the achievement of specified milestones. We may also be required to reimburse patent costs incurred by the licensor, or we may be obligated to pay additional royalties, at specified rates, based on net sales of our drug candidates that incorporate the licensed intellectual property rights. We may also be obligated under some of these agreements to pay a percentage of any future sublicensing revenues that we may receive. Future license agreements may also include payment obligations such as milestone payments or minimum expenditures for research and development. We expect that any future licenses would contain reporting, insurance and indemnification requirements. We are actively reviewing and preparing additional patent applications to expand our patent portfolio, but there can be no assurances that patents related to our existing patent applications or any applications we may file in the future will be issued or that any issued patents will provide meaningful protection for our drug candidates, which could materially adversely affect our competitive business position, business prospects and financial condition.

 

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.

 

We rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual property, and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary information, and in such case we could not assert any trade secret rights against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets. Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could materially adversely affect our business and financial condition.

 

Risks Related to Ownership of Our Securities and this Offering

 

Our management will have broad discretion over the use of any net proceeds from this offering and you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.

 

Our management will have broad discretion as to the use of any net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of any proceeds from this offering and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. We have no current specific plan for a significant portion of the offering proceeds and it is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for you.

 

Investors in this offering may experience future dilution as a result of this and future equity offerings.

 

In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. Investors purchasing our shares or other securities in the future could have rights superior to existing common stockholders, and the price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.

 

16
 

 

The price of our common stock may fluctuate substantially.

 

You should consider an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a significant loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this “Risk Factors” section and elsewhere in this prospectus, are:

 

sales of our common stock by our stockholders, executives, and directors;
volatility and limitations in trading volumes of our shares of common stock;
our ability to obtain financing to conduct and complete research and development activities;
our ability to attract new customers;
changes in the development status of the drugs we acquire;
failures to meet external expectations or management guidance;
changes in our capital structure or dividend policy or future issuances of securities;
our cash position;
announcements and events surrounding financing efforts, including debt and equity securities;
reputational issues;
announcements of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;
changes in general economic, political and market conditions in or any of the regions in which we conduct our business;
changes in industry conditions or perceptions;
changes in valuations of similar companies or groups of companies;
analyst research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;
departures and additions of key personnel;
disputes and litigations related to intellectual property rights, proprietary rights, and contractual obligations;
changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and
other events or factors, many of which may be out of our control.

 

17
 

 

In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.

 

We do not intend to apply for any listing of the Pre-Funded Warrants, Company Warrants or Underwriter’s Warrants on any exchange or nationally recognized trading system, and we do not expect a market to develop for the Pre-Funded Warrants, Company Warrants or Underwriter’s Warrants.

 

We do not intend to apply for any listing of either of the Pre-Funded Warrants, Company Warrants or Underwriter’s Warrants (collectively, the “Warrants”) on the Nasdaq Capital Market or any other securities exchange or nationally recognized trading system, and we do not expect a market to develop for the Warrants. Without an active market, the liquidity of the Warrants will be limited. Further, the existence of the Warrants may act to reduce both the trading volume and the trading price of our common stock.

 

The Warrants are speculative in nature and holders of Warrants have no rights as stockholders until such holders exercise their Warrants and acquire our shares of common stock.

 

Until holders of our Warrants acquire shares of common stock upon exercise thereof, such holders will have no rights with respect to the shares of common stock underlying the Warrants. Upon exercise of the Warrants, the holders will be entitled to exercise the rights of a stockholder only as to matters for which the record date occurs after the date they were entered in the register of members of the Company as a stockholder. Following this Offering, the market value of the Warrants is uncertain. There can be no assurance that the market price of our common stock will ever equal or exceed the exercise price of the Company Warrants and the Underwriter’s Warrants or the price of the Pre-Funded Warrants, and, consequently, whether it will ever be profitable for investors to exercise their Warrants.

 

Future sales of shares by existing stockholders could cause our stock price to decline.

 

If our existing stockholders sell, or indicate an intent to sell, substantial amounts of our common stock in the public market after the ninety (90) day contractual lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline significantly and could decline below the public offering price. Based on shares outstanding as of the date of this prospectus, upon the completion of this offering, we will have 6,881,582 outstanding shares of common stock, assuming the underwriter does not exercise its over-allotment option and none of the Warrants issued in this Offering are exercised. Of these shares, assuming no shares are purchased in this offering by our existing stockholders, 6,999,622 shares of common stock, plus any shares sold pursuant to the underwriters’ option to purchase additional shares, will be immediately freely tradable, without restriction, in the public market.

 

In addition, upon issuance, the 900,000 shares reserved for future issuance under our 2022 Equity Incentive Plan may become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. If our existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business.

 

After the completion of this offering, we may be at an increased risk of securities class action litigation.

 

Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. If we were to be sued, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

 

We have never paid dividends on our capital stock and we do not anticipate paying any dividends in the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.

 

We have not paid dividends on any of our classes of capital stock to date and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future indebtedness we may incur could preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain from an investment in our common stock for the foreseeable future. Consequently, in the foreseeable future, you will likely only experience a gain from your investment in our common stock if the price of our common stock increases.

 

18
 

 

If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.

 

The trading market for our common stock may be affected by the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline if one or more equity analysts downgrade our common stock or if analysts issue other unfavorable commentary or cease publishing reports about us or our business.

 

 

Provisions of our charter documents or Nevada law could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders, and could make it more difficult to change management.

 

Provisions of our articles of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders might otherwise consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. In addition, these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by making it more difficult to replace or remove our board of directors. These provisions include:

 

  limitations on our stockholders’ ability to call special meetings of stockholders;
  an advance notice requirement for stockholder proposals and nominations for members of our
  Board;
  the authority of our Board to determine the number of director seats on our Board;
  the authority of our Board to fill vacancies occurring on the Board;
  the authority of our Board to issue preferred stock with such terms as our Board may determine.

 

Our articles of incorporation grants our Board of Directors the power to designate and issue additional shares of common and/or preferred stock.

 

Our authorized capital consists of 100,000,000 shares of common stock and 10,000,000 shares of preferred stock. Our preferred stock may be designated into series pursuant to authority granted by our articles of incorporation, and on approval from our Board of Directors. The Board of Directors, without any action by our stockholders, may designate and issue shares in such classes or series as the Board of Directors deems appropriate and establish the rights, preferences and privileges of such shares, including dividends, liquidation and voting rights. The rights of holders of other classes or series of stock that may be issued could be superior to the rights of holders of our common stock. The designation and issuance of shares of capital stock having preferential rights could adversely affect other rights appurtenant to shares of our common stock.

 

We will indemnify and hold harmless our officers and directors to the maximum extent permitted by Nevada law.

 

Our bylaws provide that we will indemnify and hold harmless our officers and directors against claims arising from our activities, to the fullest extent not prohibited by Nevada law. If we were called upon to perform under our indemnification agreement, then the portion of our assets expended for such purpose would reduce the amount otherwise available for our business.

 

19
 

 

We are an “emerging growth company” under the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we may take advantage of certain exemptions from various reporting requirements that are not applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933 (the “Securities Act”) for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards.

 

We will remain an “emerging growth company” until the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act, although we will lose that status sooner if our revenues exceed $1.07 billion, if we issue more than $1 billion in non-convertible debt in a three year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last day of our most recently completed second fiscal quarter.

 

Investors may be unable to compare our business with other companies in our industry if they believe that our financial accounting is not as transparent as other companies in our industry. If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.

 

Because Vininder Singh, our Chief Executive Officer and director, controls a significant number of shares of our voting capital stock, he has effective control over actions requiring stockholder approval.

 

Mr. Vininder Singh, our Chief Executive Officer and a director, beneficially owns approximately 43% of the Company’s common stock. As a result, Mr. Singh possesses significant influence on the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. Accordingly, any investors who purchase shares will be minority shareholders and as such will have little to no say in the direction of us and the election of directors. Additionally, this concentration of ownership might harm the market price of our common stock by:

 

  delaying, deferring or preventing a change in corporate control;

 

  impeding a merger, consolidation, takeover or other business combination involving us; or

 

  discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

 

20
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” but are also contained in this prospectus. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “aim,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this prospectus include, but are not limited to, statements about:

 

our future financial performance, including our revenue, costs of revenue, operating expenses and profitability;

 

the sufficiency of our cash and cash equivalents to meet our liquidity needs;

 

our predictions about the property development, digital transformation technology and biohealth businesses and their respective market trends;

 

our ability to attract and retain customers in all our business segments to purchase our products and services;

 

the availability of financing for smaller publicly traded companies like us;

 

our ability to successfully expand in our three principal business markets and into new markets and industry verticals; and

 

our ability to effectively manage our growth and future expenses.

 

We caution you that the foregoing list may not contain all of the forward-looking statements made in this prospectus.

 

These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

 

You should refer to the “Risk Factors” section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result, of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities law.

 

You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

 

21
 

 

USE OF PROCEEDS

 

Assuming the sale of 786,938 Company Shares and Company Warrants at an assumed combined price of $6.63 per Company Share and Company Warrant, the last reported sale price of our common stock as reported on the Nasdaq Capital Market on January 25, 2024, and no sales of Pre-Funded Warrants and Company Warrants at an assumed combined price of $6.629 per Pre-Funded Warrant and Company Warrant, after deducting the estimated underwriter discount and expenses and offering expenses payable by us, we expect to receive net proceeds of approximately $4,546,007 from this Offering. If the underwriter exercises its over-allotment option in full, we estimate that our net proceeds will be approximately $5,257,399, after deducting the underwriter discount and estimated offering expenses payable by us.

 

Each $1.00 increase (decrease) in the assumed combined public offering price of $6.63 per Company Share and Company Warrant would increase (decrease) the net proceeds to us by approximately $786,938, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions. We may also increase or decrease the number of Company Shares and Company Warrants we are offering. Each increase (decrease) of 100,000 shares in the number of Company Shares and Company Warrants offered by us would increase (decrease) the net proceeds to us by approximately $603,330, assuming that the assumed combined public offering price remains the same, and after deducting the estimated underwriting discounts and commissions.

 

As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from the Offering. Accordingly, we will retain broad discretion over the use of these proceeds, if any. Generally, the we intend to use the net proceeds received from this Offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology.

 

DIVIDEND POLICY

 

Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.

 

CAPITALIZATION

 

The following table sets forth our cash, cash equivalents, capitalization and indebtedness as of September 30, 2023:

 

  on an actual basis; and
     
  on a pro forma as adjusted basis to give effect to the sale of the Company Shares and accompanying Company Warrant at an assumed combined public offering price of $6.63 per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

22
 

 

The pro forma information below is illustrative only and our capitalization following the completion of this Offering is subject to adjustment based on the combined public offering price of the Company Shares and Company Warrants, and other terms of this Offering determined at pricing. You should read the following table in conjunction with the “Use of Proceeds” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of this prospectus and our consolidated financial statements and related notes appearing elsewhere in this prospectus.

 

   September 30, 2023 (Unaudited) 
   Actual   Pro Forma(1)(2)(3) 
         
Cash and cash equivalents  $3,856,037   $8,402,044 
Debt  $446,050   $446,050 
Stockholders deficit:          
Series A Convertible Preferred Stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding (actual); 73,449 issued and outstanding (pro forma)   1      
Common Stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 issued and outstanding (actual); 6,881,582 issued and outstanding (pro forma)   61    69 
Additional paid-in capital   12,226,742    16,772,741 
Accumulated deficits   (8,457,978)   (8,457,978)
Total stockholders’ deficit   3,768,826    8,314,833 
Total Capitalization  $3,768,826   $8,314,833 

 

(1) Reflects the sale of Company Shares in this offering at an assumed public offering price of $6.63 per share, and after deducting the estimated underwriting discounts, and estimated offering expenses payable by us. The pro forma information is illustrative only, and we will adjust this information based on the actual public offering price and other terms of this offering determined at pricing.
   
(2) Each $1.00 increase (decrease) in the assumed combined offering price of $6.63 per Company Share and Company Warrant, would increase (decrease) the pro forma amount of each of cash and cash equivalents, working capital, total assets and total stockholders’ equity (deficit) by approximately $786,938, assuming that the number of securities offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 100,000 Company Shares and accompanying Company Warrants offered by us at the assumed combined public offering price per Company Share and accompanying Company Warrant, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders’ equity (deficit) by approximately $786,938.
   
(3) If the underwriters’ option to purchase up to an additional 118,040 Company Shares and/or Company Warrants, in any combination thereof, is exercised we would receive approximately $711,391 in additional net proceeds, based on the assumed combined public offering price of $6.63 per Company Share and Company Warrant, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us; and (ii) cash and cash equivalents, total shareholders’ equity and total capitalization would each also increase by approximately $0.73.

 

The total number of shares of our common stock reflected in our actual and pro forma information set forth in the table above excludes:

 

 

Warrants to purchase 2,893,954 shares of common stock issued as part of the IPO unit at an average exercise price of $7.96 per share, which expire on February 13, 2028;

     
  Warrants to purchase 108,849 shares of common stock at an exercise price of $5.29 per share, with terms expiring April 1, 2026 through February 13, 2028;
     
  Warrants to purchase 403,890 shares of common stock at an exercise price of $2.64 per share, with terms expiring April 1, 2026 through May 3, 2032;
     
  Options to purchase 438,500 shares of common stock at a weighted average exercise price of $4.41 per share;
     
  Warrants to purchase 274,284 shares of common stock at an exercise price of $0.0007 per share, with terms expiring February 7, 2030; and
     
  Warrants to purchase 115,185 shares of common stock at an exercise price of $2.50 per share, with terms expiring August 19, 2031.

 

DILUTION

 

If you purchase Company Shares and Company Warrants in this Offering, your ownership interest will be diluted to the extent of the difference between the combined public offering price per Company Share and accompanying Company Warrant and the pro forma as adjusted net tangible book value per share of our common stock immediately after this Offering. Some of the information that we provide in this discussion is on a pro forma to give further effect to our issuance and sale of 786,938 Company Shares and accompanying Company Warrants at an assumed combined public offering price of $6.63 per Company Share and Company Warrant, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

The net tangible book value of our common stock as of September 30, 2023 was $3,768,826 or $0.62 per share. Net tangible book value per share represents our total tangible assets (which excludes deferred offering costs, which were $0 at September 30, 2023 less our total liabilities, divided by the number of shares of outstanding common stock).

 

23
 

 

After giving further effect to the receipt of the net proceeds from our sale of 786,938 Company Shares and accompanying Company Warrants in this Offering, at an assumed combined public offering price of $6.63 per Company Share and Company Warrant, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of September 30, 2023 would have been approximately $8,760,883 or $1.27 per share. This amount represents an immediate increase in pro forma net tangible book value of $0.65 per share to our existing stockholders and an immediate dilution of $5.36 per share to new investors purchasing Company Shares in this Offering.

 

We determine dilution per share to investors participating in this Offering by subtracting pro forma as adjusted net tangible book value per share after this Offering from the assumed public offering price per share paid by investors participating in this Offering. The following table illustrates this dilution on a per share basis to new investors:

 

Assumed public offering price per Company Share and Company Warrant  $6.63 
Net tangible book value per share as of September 30, 2023  $0.62 
Pro forma net tangible book value (deficit) per share as of September 30, 2023  $1.27 
      
Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing shares  $0.65 
Pro forma as adjusted net tangible book value per share after this offering  $1.27 
Dilution in net tangible book value per share to new investors in this Offering  $5.36 

 

Each $1.00 increase (decrease) in the assumed combined public offering price of $6.63 per Company Share and Company Warrant would increase (decrease) the pro forma net tangible book value by $786,938 per share and increase (decrease) the dilution per share to new investors by ($1.00) per share, assuming the number of Company Shares and accompanying Company Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions.

 

Similarly, each increase (decrease) of 100,000 Company Shares and accompany Company Warrants we are offering would increase (decrease) our pro forma net tangible book value by approximately $603,330, or $0.68 per share and decrease (increase) the dilution per share to new investors participating in this offering by $5.53 per share, assuming that the assumed combined public offering price of $6.63 remains the same, and after deducting the estimated underwriting discounts and commissions.

 

The pro forma information discussed above is illustrative only and will change based on the actual combined public offering price, number of shares and other terms of this Offering determined at pricing.

 

If the underwriters exercise their option to purchase additional Company Shares and/or Company Warrants in this Offering in full at the assumed combined public offering price of $6.63 per Company Share and Company Warrant and assuming the number of Company Shares and accompanying Company Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses, the pro forma net tangible book value would be approximately $1.35 per share, and the dilution in pro forma net tangible book value per share to investors in this offering would be approximately $5.28 per share.

 

The table below summarizes as of September 30, 2023, adjusted pro forma basis described above, the number of shares of our common stock, the total consideration and the average price per share (i) paid to us by existing stockholders and (ii) to be paid by new investors purchasing our common stock in this offering at an assumed combined public offering price of $6.63 per Company Share and Company Warrant, before deducting underwriting discounts and commissions and estimated offering expenses.

 

   Shares Purchased   Total Consideration   Average Price Per 
   Number   Percent   Amount   Percent   Share 
Existing stockholders   6,094,644    88.6%  $12,224,742    70.1%  $2.01 
New investors   786,938    11.4%  $5,217,399    29.9%  $6.63 
Total   6,881,582    100.0%  $17,444,141    100.0%  $2.53 

 

In addition, if the underwriters exercise their option to purchase additional Company Shares and/or Company Warrants in full, the number of shares held by existing stockholders will be reduced to 2.7% of the total number of shares of common stock to be outstanding upon the closing of this Offering, and the number of shares of common stock held by new investors participating in this Offering will be further increased by 118,041, or 2.7% of the total number of shares of common stock to be outstanding upon the closing of this Offering.

 

24
 

 

Each $1.00 increase (decrease) in the assumed combined public offering price of $6.63 per Company Share and Company Warrant would increase (decrease) total consideration paid by new investors by approximately $938,938, assuming that the number of Company Shares and accompanying Company Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions. We may also increase or decrease the number of Company Shares and accompanying Company Warrants we are offering. Each increase (decrease) of 100,000 Company Shares and accompanying Company Warrants offered by us would increase (decrease) total consideration paid by new investors by approximately $603,330, assuming that the assumed combined public offering price remains the same, and after deducting the estimated underwriting discounts and commissions.

 

The total number of shares of our common stock reflected in our actual and pro forma information set forth in the table above excludes:

 

 

Warrants to purchase 2,893,954 shares of common stock issued as part of the IPO unit at an average exercise price of $7.96 per share, which expire on February 13, 2028;

     
  Warrants to purchase 108,849 shares of common stock at an exercise price of $5.29 per share, with terms expiring April 1, 2026 through February 13, 2028;
     
  Warrants to purchase 403,890 shares of common stock at an exercise price of $2.64 per share, with terms expiring April 1, 2026 through May 3, 2032;
     
  Options to purchase 635,500 shares of common stock at a weighted average exercise price of $4.21 per share;
     
  Warrants to purchase 274,284 shares of common stock at an exercise price of $0.0007 per share, with terms expiring February 7, 2030; and
     
  Warrants to purchase 115,185 shares of common stock at an exercise price of $2.50 per share, with terms expiring August 19, 2031.

 

The discussion and table above assume no exercise of the Warrants. To the extent that the Warrants are exercised, any outstanding warrants or options are exercised, any outstanding convertible notes are converted any outstanding restricted stock units vest, or new options or restricted stock units are issued our equity incentive plan, you may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

 

DESCRIPTION OF CAPITAL STOCK

 

The following description of the material terms of our capital stock and the provisions of our amended and restated articles of incorporation and bylaws are summaries and are qualified by reference to copies of the amended and restated articles of incorporation and bylaws, which are filed as exhibits to our registration statement of which this prospectus forms a part.

 

General

 

Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, including 5,500,000 shares of Series A Preferred Stock.

 

Common Stock

 

Common stock outstanding

 

As of January 25, 2024, there were 6,094,644 shares of common stock outstanding.

 

Voting rights

 

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of stockholders. The holders are not permitted to vote their shares cumulatively.

 

Dividend rights

 

Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available.

 

Rights upon liquidation

 

Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities.

 

Other rights

 

Holders of our common stock do not have any pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions.

 

25
 

 

Preferred Stock

 

Preferred stock outstanding

 

As of January 25, 2024, there are 73,449 shares of Series A Preferred Stock issued and outstanding.

 

Conversion rights

 

Each holder of Series A Preferred Stock may, from time to time, convert any or all of such holder’s shares of Series A Preferred Stock into fully paid and nonassessable shares of common stock in an amount equal to ten shares of common stock for each one share of Series A Preferred Stock surrendered.

 

A holder of shares of Series A Preferred Stock is not entitled to convert shares of Series A Preferred Stock if upon such conversion the number of shares of common stock to be received, together with the number of shares of common stock beneficially owned by the holder and its affiliates on the conversion date, would result in beneficial ownership by the bolder and its affiliates of more than 4.99% of the outstanding shares of common stock of the Company on such conversion date

 

Voting rights

 

Each holder of Series A Preferred Stock has no voting rights.

 

Rights upon liquidation

 

Upon our liquidation, dissolution or winding up, the holders of our Series A Preferred Stock shall not be entitled to any liquidation preference and are to receive any liquidation as if they were converted to common stock.

 

Warrants

 

Company Warrants

 

The registration statement of which this prospectus is a part also registers for sale Company Warrants to purchase up to 786,938 shares of common stock (or 904,978 shares of common stock if the underwriter exercises its over-allotment option in full).

 

Each Company Warrant is exercisable for one share of our common stock, with an assumed initial exercise price equal to $7.29 (assuming an exercise price equal to the public offering price per share) per share at any time for up to five (5) years after the date of the closing of this Offering. The Company Warrants issued in this Offering will be governed by the terms of the Company Warrants. The holder of a Company Warrant will not be deemed a holder of our underlying common stock until the Company Warrant is exercised.

 

Subject to certain limitations as described below the Company Warrants are immediately exercisable upon issuance on the closing date and expire on the fifth year anniversary of the closing date. Subject to limited exceptions, a holder of Company Warrants will not have the right to exercise any portion of its Company Warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of common stock then outstanding after giving effect to such exercise.

 

Upon the holder’s exercise of a Company Warrant, we will issue the shares of common stock issuable upon exercise of the Company Warrant within two trading days following our receipt of a notice of exercise, provided that payment of the exercise price has been made (unless exercised to the extent permitted via the “cashless” exercise provision). Prior to the exercise of any Company Warrants to purchase common stock, holders of the Company Warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein.

 

Warrant holders may exercise Company Warrants only if the issuance of the shares of common stock upon exercise of the Company Warrants is covered by an effective registration statement, or an exemption from registration is available under the Securities Act and the securities laws of the state in which the holder resides. We intend to use commercially reasonable efforts to have the registration statement, of which this prospectus forms a part, effective when the Company Warrants are exercised. The Company Warrant holders must pay the exercise price in cash upon exercise of the Company Warrants unless there is not an effective registration statement or, if required, there is not an effective state law registration or exemption covering the issuance of the shares underlying the Company Warrants (in which case, the Company Warrants may only be exercised via a “cashless” exercise provision).

 

We do not intend to apply for listing of the Company Warrants on any securities exchange or other trading system.

 

26
 

 

Pre-funded Warrants

 

The term “pre-funded” refers to the fact that the purchase price of our common stock in this Offering includes almost the entire exercise price of $6.629 that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.001. The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder, 9.99%) of our outstanding common stock following the consummation of this Offering the opportunity to make an investment in the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of our common stock which would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at such nominal price at a later date.

 

Each Pre-Funded Warrant is exercisable for one share of our common stock, with an exercise price equal to $0.001 per share, at any time that the Pre-Funded Warrant is outstanding. There is no expiration date for the Pre-Funded Warrants. The holder of a Pre-Funded Warrant will not be deemed a holder of our underlying common stock until the Pre-Funded Warrant is exercised.

 

Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise.

 

The exercise price and the number of shares issuable upon exercise of the Pre-Funded Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. The Pre-Funded Warrant holders must pay the exercise price in cash upon exercise of the Pre-Funded Warrants, unless such Pre-Funded Warrant holders are utilizing the cashless exercise provision of the Pre-Funded Warrants.

 

Upon the holder’s exercise of a Pre-Funded Warrant, we will issue the shares of common stock issuable upon exercise of the Pre-Funded Warrant within two trading days following our receipt of a notice of exercise, provided that payment of the exercise price has been made (unless exercised to the extent permitted via the “cashless” exercise provision). Prior to the exercise of any Pre-Funded Warrants to purchase common stock, holders of the Pre-Funded Warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein.

 

Warrant holders may exercise Pre-Funded Warrants only if the issuance of the shares of common stock upon exercise of the Pre-Funded Warrants is covered by an effective registration statement, or an exemption from registration is available under the Securities Act and the securities laws of the state in which the holder resides. We intend to use commercially reasonable efforts to have the registration statement, of which this prospectus forms a part, effective when the Pre-Funded Warrants are exercised. The Pre-Funded Warrant holders must pay the exercise price in cash upon exercise of the Pre-Funded Warrants unless there is not an effective registration statement or, if required, there is not an effective state law registration or exemption covering the issuance of the shares underlying the Pre-Funded Warrants (in which case, the Pre-Funded Warrants may only be exercised via a “cashless” exercise provision).

 

In the event we consummate a merger or consolidation with or into another person or other reorganization event in which our common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of such Pre-Funded Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised their Pre-Funded Warrants immediately prior to such fundamental transaction. Any successor to us or surviving entity shall assume the obligations under the Pre-Funded Warrants.

 

We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or other trading system.

 

Underwriter’s Warrants

 

The registration statement of which this prospectus is a part also registers for sale warrants to purchase up to 47,216 shares of common stock to the Representative of the underwriters as a portion of the underwriting compensation payable to the underwriters in connection with this Offering. The Underwriter’s Warrants will be exercisable during a period commencing at six months from the effective date of the Offering and ending five years from the effective date of the offering at an exercise price equal to 110% of the public offering price of the common stock. Please see “Underwriting – Underwriter’s Warrants” for a description of these warrants.

 

Warrant Agent

 

The Pre-Funded Warrants and Company Warrants will be issued in registered form under a warrant agent agreement (the “Warrant Agent Agreement”) between us and our warrant agent, VStock Transfer LLC (the “Warrant Agent”). The material provisions of the Pre-Funded Warrant and the Company Warrants are set forth herein, and a copy of the Warrant Agent Agreement is filed with the SEC as an exhibit to the registration statement of which this prospectus forms a part or are incorporated by reference herein.

 

Stock Options

 

As of September 30, 2023, we issued an aggregate of 458,500 stock options. Our directors and Chief Financial Officer were granted stock options to purchase a total of 195,000 additional shares of the Company’s common stock. The options have a 10-year term with an exercise price between $2.80 and $6.82. On April 16, 2023, the Company issued 40,000 stock options with an exercise price of $6.82 per share and a 10-year term to each director, Mr. Elsey, Mr. Enright and Mr. Hanson. On March 17, 2023, the Company issued 75,000 stock options with an exercise price of $2.80 per share and a 10-year term to our Chief Financial Officer, Mr. Saglio. Our employees were granted stock options to purchase a total of 196,500 shares of common stock, which have a 10-year term with an exercise price between $2.80 and $5.45. We also granted to service providers stock options to purchase a total of 67,000 shares of common stock, which have a 10-year term with an exercise price between $2.59 and $5.45. The relative fair value of the 2023 stock options using the Black-Scholes valuation model totals $738,600. As of September 30, 2023, the Company had 461,500 equity-based awards authorized but unissued available under the 2022 Equity Incentive Plan.

 

Anti-Takeover Provisions of Nevada Law, or Articles of Incorporation and our Bylaws

 

Our articles of incorporation and bylaws contain certain provisions that may have the effect of delaying, deferring or preventing a party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our Board of Directors rather than pursue non-negotiated takeover attempts. According to our articles of incorporation and bylaws, neither the holders of our common stock nor the holders of our preferred stock have cumulative voting rights in the election of our directors. The combination of the present ownership by a few stockholders of a significant portion of our issued and outstanding common stock and lack of cumulative voting makes it more difficult for other stockholders to replace our Board of Directors or for a third party to obtain control of our Company by replacing our Board of Directors.

 

The following provisions of the Nevada Revised Statutes (“NRS”) could, if applicable, have the effect of discouraging takeovers of our Company.

 

Transactions with Interested Stockholders. The NRS prohibits a publicly-traded Nevada company from engaging in any business combination with an interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless, prior to that date, the Board of Directors of the corporation approved either the business combination itself or the transaction that resulted in the stockholder becoming an interested stockholder.

 

27
 

 

An “interested stockholder” is defined as any entity or person beneficially owning, directly or indirectly, 10% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, controlling, or controlled by any of these entities or persons. The definition of “business combination” is sufficiently broad to cover virtually any type of transaction that would allow a potential acquirer to use the corporation’s assets to finance the acquisition or otherwise benefit its own interests rather than the interests of the corporation and its stockholders.

 

In addition, business combinations that are not approved and therefore take place after the three year waiting period may also be prohibited unless approved by the board of directors and stockholders or the price to be paid by the interested stockholder is equal to the highest of (i) the highest price per share paid by the interested stockholder within the 3 years immediately preceding the date of the announcement of the business combination or in the transaction in which he or she became an interested stockholder, whichever is higher; (ii) the market value per common share on the date of announcement of the business combination or the date the interested stockholder acquired the shares, whichever is higher; or (iii) if higher for the holders of preferred stock, the highest liquidation value of the preferred stock.

 

Acquisition of a Controlling Interest. The NRS contains provisions governing the acquisition of a “controlling interest” and provides generally that any person that acquires 20% or more of the outstanding voting shares of an “issuing corporation,” defined as Nevada corporation that has 200 or more stockholders at least 100 of whom are Nevada residents (as set forth in the corporation’s stock ledger); and does business in Nevada directly or through an affiliated corporation, may be denied voting rights with respect to the acquired shares, unless a majority of the disinterested stockholder of the corporation elects to restore such voting rights in whole or in part.

 

The statute focuses on the acquisition of a “controlling interest” defined as the ownership of outstanding shares sufficient, but for the control share law, to enable the acquiring person, directly or indirectly and individually or in association with others, to exercise (i) one-fifth or more, but less than one-third; (ii) one-third or more, but less than a majority; or (iii) a majority or more of the voting power of the corporation in the election of directors.

 

The question of whether or not to confer voting rights may only be considered once by the stockholders and once a decision is made, it cannot be revisited. In addition, unless a corporation’s articles of incorporation or bylaws provide otherwise (i) acquired voting securities are redeemable in whole or in part by the issuing corporation at the average price paid for the securities within 30 days if the acquiring person has not given a timely information statement to the issuing corporation or if the stockholders vote not to grant voting rights to the acquiring person’s securities; and (ii) if voting rights are granted to the acquiring person, then any stockholder who voted against the grant of voting rights may demand purchase from the issuing corporation, at fair value, of all or any portion of their securities.

 

The provisions of this section do not apply to acquisitions made pursuant to the laws of descent and distribution, the enforcement of a judgment, or the satisfaction of a security interest, or acquisitions made in connection with certain mergers or reorganizations.

 

Listing

 

Our common stock and tradeable warrants are listed on the Nasdaq Capital Market under the symbol “BFRG” and “BFRGW,” respectively. We have not applied, and do not intend to apply, to list the Pre-Funded Warrants or the Company Warrants on the Nasdaq Capital Market.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is VStock Transfer, LLC.

 

28
 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the section titled “Selected Consolidated Financial and Other Data” and the consolidated financial statements and related notes thereto included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled “Risk Factors” included elsewhere in this prospectus.

 

Overview

 

Bullfrog AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC, which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. Operations are currently conducted through Bullfrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced Artificial Intelligence / Machine Learning (AI/ML) analysis of complex data in the advancement of medicine. Our AI/ML platform (trade name: bfLEAP™) was created from technology originally developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL).

 

In February 2018, Bullfrog AI Holdings secured the original exclusive, worldwide, royalty-bearing license from JHU-APL for the technology. The license covers three (3)issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets including modifications and improvements. We entered into a license agreement in July 2022 that provides the Company with new intellectual property and also encompasses most of the intellectual property from the February 2018 license. Our objective is to utilize bfLEAP™ for a precision medicine approach toward drug development with biopharmaceutical collaborators, as well as our own internal clinical development programs. We believe the bfLEAP™ platform is ideally suited for evaluating pre-clinical and clinical trial data generated in translational research and clinical trial settings that lead to faster, less expensive drug approvals.

 

Our aim is to improve the odds of success in each stage of developing medicine, ranging from early pre-clinical through late-stage clinical development. Our ultimate objective is to utilize bfLEAP™ to enable the success of ongoing clinical trials or rescue late-stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies.

 

On July 8, 2022, the Company entered into an exclusive, worldwide, royalty-bearing license from JHU-APL for the additional technology. The new license provides additional intellectual property rights including patents, copyrights, and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. In consideration of the new license, the Company issued to JHU-APL 39,879 shares of common stock. In September 2020 and October of 2021, the Company executed amendments to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the original License Agreement, the Company granted JHU 178,571 warrants exercisable to purchase shares of common stock at $2.10 per share. Under the terms of the new License Agreement, JHU will be entitled to eight percent (8%) of net sales for the services provided by the Company to other parties and three percent (3%) for internally developed drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues. On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $275,000. The first of these payments for $75,000 was due in July 2023 followed by annual payments of $75,000, $75,000 and $50,000 in years 2024, 2025 and 2026, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $60,000, all other financial terms remain the same. As a result of this Amendment, the minimum annual payments are set to be $30,000 for 2022, $60,000 for 2023, and $300,000 for 2024 and beyond, all of which are creditable by royalties.

 

29
 

 

We intend to continue to evolve and improve bfLEAP™, either in-house or with development partners like JHU-APL. We plan to leverage our proprietary AI/ML platform developed over several years at one of the top innovation institutions in the world which has already been successfully applied in multiple sectors.

 

We have staffed our business using funds from our initial public offering and have entered into partnerships and relationships and recently completed our first commercial service contract with a leading rare disease non-profit organization for AI/ML analysis of late-stage clinical data. We have also acquired the rights to a series of preclinical and early clinical drug assets from universities, as well as a strategic collaboration with a world-renowned research institution to create a HSV1 viral therapeutic platform to engineer immunotherapies for a variety of diseases. We have signed exclusive worldwide License Agreements with JHU for a cancer drug that targets glioblastoma (brain cancer), pancreatic cancer, and others. We have also signed an exclusive worldwide license from George Washington University for another cancer drug that targets hepatocellular carcinoma (liver cancer) and other liver diseases. Additionally, we intend to gain access to later-stage clinical assets through partnerships or the acquisition of rights to failed therapeutic candidates for drug rescue. In certain circumstances, we intend to conduct late-stage clinical trials in an effort to rescue therapeutic assets that previously failed. In these cases, there will be a requirement for drug supply and regulatory services to conduct clinical trials. The success of our clinical development programs will require finding partners to support the clinical development, adequate availability of raw materials and/or drug product for our R&D and clinical trials, and, in some cases, may also require establishment of third-party arrangements to obtain finished drug product that is manufactured appropriately under (GMP) industry-standard guidelines, and packaged for clinical use or sale. Since we are a company focused on using our AI technology to advance medicines, any clinical development programs will also require, in all cases, partners and the establishment of third-party relationships for execution and completion of clinical trials. Over the next 24 months, the Company expects to spend approximately $2.1 million on service offering products, preclinical IND enabling activities and on R&D to enable future clinical trials evaluating our drug assets for new disease indications.

 

Since completing our IPO on February 14, 2023, aided by the receipt of the IPO proceeds, we have initiated several initiatives: investor relations and marketing to promote and raise awareness of the Company in the financial and business sectors, research and development, collaboration with J. Craig Venter Institute and in the quarter ended September 30, 2023, completed a preclinical study for our Mebendazole prodrug program. The Company is actively engaged in developing and seeking out new intellectual property as it strives to continuously evolve its AI/ML platform. Additionally, the Company has engaged a business development firm specializing in the biopharmaceutical industry to seek and secure a strategic development partner our Mebendazole program.

 

Internally, the Company has added incremental staff to accelerate execution, and the development of processes and custom scripts for use in performing analytical services for customers, while also launching initiatives targeting large public health data sources and seeking access to proprietary health data sources. We also transitioned our accounting and financial reporting systems and processes to enhance our internal control environment as a public company. Capital from the IPO was also used to retire two notes that were sold to fund the Company through the IPO that did not convert into common stock as well as other debts accrued over time to our staff, employees and consultants as well as obligations related to the acquisition of our licensed drug programs.

 

30
 

 

Our Strategy

 

The Company has a unique strategy designed to reduce risk and increase the frequency of cash flow. The first part of the strategy is to generate revenues through strategic relationships with biopharma companies. These relationships will be structured as a combination of fees and intellectual property based on the specific scope of the engagement. The objective of these engagements will be to uncover valuable insights to reduce the risk and/or increase the speed of the drug development process which can be achieved through manual or automated integration into the client’s workflow or analysis of discrete data sets.

 

In the future, the second part of our strategy involves acquiring the rights to clinical stage drugs, using our bfLEAP™ technology to design a precision medicine trial, conduct the trial with a partner, and sell the asset. This approach may also apply to earlier phases in the drug development process such as discovery and preclinical. In any case, the objective is to create near term value and exit and monetize as quickly as possible, preferably within approximately 30 months.

 

Critical Accounting Policies and Estimates

 

Our financial statements are prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, as well as related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates. There have been no material changes to our critical accounting policies and estimates as described in our Form 10-K.

 

Financial Operations Overview

 

Revenue

 

While we generated our first revenues in late 2022 from our services provided to a pharmaceutical customer, in Q3 2023 we completed our first commercial service contract and recognized revenue in the amount of $65,000. We have service contracts with two organizations and currently have multiple discussions underway, although there can be no assurance of entering into additional service agreements and business relationships in 2023.

 

Operating Expenses

 

We classify our operating expenses into two categories: research and development and general and administrative. Prior to 2022, most of our activities were related to: technology evaluation, acquisition and validation, capital acquisition and business development activities in general, which we believe have readied the Company for contract services while exploring strategic partnering and asset acquisition. These activities and related expenditures have been recorded and reported as General and Administrative in our Financial Statements. In 2022, we licensed two drug development programs from universities and also entered into a new license with JHU-APL for new IP and other enhancements used with our bfLEAP™ platform. In 2022, we expended appropriately $608,000 on license related payments for our bfLEAP™ AI/ML platform and our two drug development programs from universities. We expect that our research and development expenses will increase in 2024 as we initiate activities directed towards the development of service offering products, collaborations (JCVI) and preclinical studies aimed at generating the data to enable the filing of an Investigational New Drug (IND) application.

 

31
 

 

Research and Development Costs and Expenses

 

Research and development costs and expenses in 2022 consisted primarily of costs related to the acquisition of licensed technology. In 2023 we have initiated development activities on our licensed drug candidates and our discovery collaboration with JCVI. In addition to fees paid to external service providers, we are also allocating internal costs for personnel working on these efforts in addition to personnel costs related to our internal efforts to develop our product and service offerings using bfLEAP™. We anticipate our research and development costs could become significant as we execute on our business plan and begin conducting preclinical research and development activities directed at securing development partners and filing an IND for our licensed drug development programs described in this filing, as well as under strategic partnerships and for other drug development programs we may acquire. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates will be used in determining the expense liability of certain costs where services have been performed but not yet invoiced. We will monitor levels of performance under each significant contract for external services through communications with the service providers to reflect the actual amount expended.

 

General and Administrative Expenses

 

In anticipation of the IPO, a management team with deep industry experience was identified and engaged as employees and consultants to assist the Company in preparing for the IPO and subsequently, to operate and function as a public company. Through 2022, the primary activities included: technology evaluation, acquisition and validation, capital acquisition and business development activities which in general, have readied the Company for contract services while exploring strategic partnering and asset acquisition as noted above. In February 2023, the Company achieved its objective of completing an IPO and listing on NASDAQ. Our 2023 general and administrative expenses are significantly higher than our 2022 general and administrative expenses due to several factors. The primary increases in 2023 relate to new costs associated with being a public company such as D&O insurance, professional services engaged to support SEC compliance as well as higher salary and consulting expenses as we have hired additional staff and consultants. We have also increased our business development, investor relations and marketing efforts. We anticipate that our general and administrative expenses may increase in the future to support our service offerings, clinical and pre-clinical research and development activities associated with strategic partnering and collaborations.

 

Results of Operations

 

Comparison of Three Months Ended September 30, 2023 and 2022

 

Revenue and Costs of Goods Sold

 

We recognized $65,000 in revenue and $5,200 in costs of goods sold during the three months ended September 30, 2023 versus zero 2022.

 

  

Three Months Ended

September 30,

   Net Change 
   2023   2022     
Operating expenses:               
Research and development  $380,015   $39,421   $340,594 
General and administrative   983,929    601,131    382,798 
Total operating expenses  $1,363,944   $640,552   $723,392 

 

Research and Development

 

Our research and development expenses for the three months ended September 30, 2023 increased by $340,594, compared to the same period ended September 30, 2022, primarily due to the inclusion of the cost of salaries and consulting fees in 2023, as well the cost of acquiring access to additional technology from JHU-APL related to bfLEAP™ pursuant to Amendment 1 of the July 2022 License Agreement. We also completed a preclinical study related to our Mebendazole program in Q3 2023. In 2022, the majority of the research and development expenses were directly related to the acquisition of two drug development product candidates including Mebendazole.

 

General and Administrative

 

Our general and administrative expenses for the three months ended September 30, 2023 increased by $382,798, compared to the same period ended September 30, 2022, primarily due to higher salary and consulting costs reflecting an increased level of services as well as the initiation of investor relations and marketing efforts and the transition of our accounting and financial reporting process to support a public company.

 

32
 

 

Other Income (Expense), Net

 

Interest expense decreased $118,401 for the three months ended September 30, 2023, compared to the same period ended September 30, 2022 due to the majority of our debt converting or being paid off in the first quarter of 2023. Other income increased by $56,906 due to interest earned on our IPO proceeds which we hold in an overnight sweep account.

 

Comparison of Nine Months Ended September 30, 2023 and 2022

 

Revenue and Costs of Goods Sold

 

We recognized $65,000 in revenue and $5,200 in costs of goods sold during the nine months ended September 30, 2023 versus zero 2022.

 

   Nine Months Ended September 30,   Net Change 
   2023   2022     
Operating expenses:               
Research and development  $1,023,619   $448,375   $575,244 
General and administrative   3,067,940    1,424,383    1,643,557 
Total operating expenses  $4,091,559   $1,872,758   $2,218,801 

 

Research and Development

 

Our research and development expenses for the nine months ended September 30, 2023 increased by $575,244 compared to the same period ended September 30, 2022, primarily due to the inclusion of the cost of salaries and consulting fees in 2023 as we initiated our collaboration with J Craig Venter Institute and completion of a preclinical study for our Mebendazole prodrug program, as well as the cost of acquiring access to additional technology from JHU-APL related to bfLEAP™ pursuant to Amendment 1 of the July 2022 License Agreement. In 2022, the majority of the research and development expenses were directly related to the acquisition of two drug development product candidates including Mebendazole.

 

General and Administrative

 

Our general and administrative expenses for the nine months ended September 30, 2023 increased by $1,643,557, compared to the same period ended September 30, 2022, primarily due to higher salary and consulting costs reflecting an increased level of service as well the initiation of investor relations and marketing efforts and the transition of our accounting and financial reporting process to support a public company. The 2023 period also reflects approximately $120,000 in recruiting fees related to staff additions.

 

Other Income (Expense), Net

 

Interest expense decreased $157,788 for the nine months ended September 30, 2023, compared to the same period ended September 30, 2022 due to the majority of our debt converting or being paid off in the first quarter of 2023. The loss on the conversion of notes of $92,959 for the nine months ended September 30, 2023 was due to the conversion of the convertible notes. Other income increased by $142,218 due to interest earned on our IPO proceeds which we hold in an overnight sweep account.

 

Comparison of the Results of Operations for the years ended December 31, 2022 and 2021

 

In late 2022, the Company recognized its first service revenues of $10,000 related to an analysis contract with a small pharmaceutical company. The Company previously had not recorded any revenues. Through the end of 2022, the Company has an accumulated deficit of approximately $4,399,000. Net loss from operations in 2022 was approximately $2,455,000 versus $555,000 in 2021. The 2022 increase reflects the full year costs of engaging advisors and consultants and other costs associated with preparing the Company for its initial public offering including the costs related to auditing the Company’s past and current financial statements. Cash used in operations in 2022 was approximately $911,000 versus approximately $382,000 in 2021 and net cash inflows from financing activities in 2022 was approximately $967,000 versus approximately $387,000 in 2021.

 

33
 

 

Liquidity and Capital Resources

 

In 2022, the Company received net proceeds from the sale of Convertible Bridge Notes of approximately $1,016,000 and repaid the unsecured promissory notes sold in 2021 in the amount of $49,000. The Company sold one additional promissory note and received net proceeds of $100,000 in January 2023.

 

For the year ended December 31, 2022, the Company used approximately $911,000 on operating activities versus approximately $382,000 for the same period in 2021. The 2022 cash use included approximately $548,000 in salaries, approximately $634,000 in consulting and professional fees including legal, accounting and auditing fees, as well as consulting fees for operational activities and approximately $609,000 in technology license fees, patent cost reimbursements and minimum annual royalties which has been recorded as a research & development expense.

 

Through September 30, 2023, the Company has an accumulated deficit of $8,457,978 and funded its operations through the sale of common stock and debt. We anticipate that our expenses will increase in the future to support our service offerings, clinical and pre-clinical research and development activities associated with strategic partnering and collaborations, as well as acquired product candidates and the increased costs of operating as a public company. These increases could include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company including expenses related to services associated with maintaining compliance with exchange listing and Securities and Exchange Commission requirements, insurance, and investor relations costs.

 

The Company’s current operations include Bullfrog AI, Inc. and Bullfrog Management, LLC, which are wholly owned subsidiaries of Bullfrog AI Holdings, Inc., which is a holding company that depends upon the sale of its securities and cash generated through its subsidiaries to fund consolidated operations.

 

On February 16, 2023, the Company completed its IPO of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per unit for a total of approximately $8.4 million of gross proceeds to the Company. Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share, and one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125. In connection with the IPO, the Company also completed a 1-for-7 reverse stock split of our common stock.

 

In connection with the IPO, a SAFE and convertible loan agreement held by a related party converted into 55,787 shares of post reverse split common stock. Additionally, all outstanding convertible bridge notes and accrued interest through November 30, 2022 were converted into 276,289 shares of common stock and 276,289 warrants to purchase common stock were issued to the Convertible Bridge Note holders at conversion. The convertible bridge note conversions and the warrant exercise pricing was determined using a $25 million dollar company valuation immediately before the IPO.

 

Between April 5 and April 13, 2023, the holders of warrants exercised 436,533 warrants for common stock at various exercise prices and the Company received proceeds of approximately $1,495,000.

 

In the absence of significant revenues in 2023, management believes the Company’s capital resources are sufficient to fund planned operations for approximately 9 months from the date of this filing.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements, as such term is defined in Item 303(a)(4) of Regulation S-K.

 

34
 

 

OUR BUSINESS

 

Our Corporate History and Background

 

BullFrog AI Holdings, Inc. was incorporated in the State of Nevada on February 18, 2020. Our principal business address is 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878. All of our operations are currently conducted through BullFrog AI Holdings, Inc. BullFrog AI, Inc., a wholly owned subsidiary acquired through a share exchange, has the sole purpose of housing and protecting all of the organization’s intellectual property. BullFrog AI Management, LLC is a wholly owned subsidiary that handles all HR and payroll activities.

 

Acquisition of BullFrog AI

 

In March 2020, BullFrog AI, Inc. received an investment from TEDCO - the Technology Development Corporation of Maryland, a State of Maryland Investment Fund - pursuant to the issuance of a $200,000 convertible note with an 18-month term, 6% annual interest rate, and a 20% discount. In June 2020, BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. pursuant to an exchange agreement under which each share of Bull Frog AI, Inc. common stock was exchanged for a share of common stock of BullFrog AI Holdings, Inc.. Immediately prior to the share exchange, each outstanding common share of BullFrog AI, Inc. was split into 25 shares of common stock. Share amounts in our financial statements for 2021 and 2020 have been adjusted to reflect this forward share split and shares exchange. Pursuant to the agreement, 24,223,975 shares of the Company’s common stock were issued to the shareholders of BullFrog AI, Inc. in exchange for 100% of the outstanding stock of BullFrog AI, Inc. Upon completion of the exchange, BullFrog AI, Inc. became the Company’s wholly-owned subsidiary and the shareholders of BullFrog AI, Inc. held 100% of the common stock of the Company. As a result, BullFrog AI Holdings, Inc. assumed a total of $330,442 in net liabilities of BullFrog AI, Inc. Both of the entities were controlled before and after the transactions by the same controlling shareholder. This transaction is being accounted for as a common control transaction and all entities are being presented as if the transactions took place at the beginning of the earliest period presented.

 

BullFrog AI Corporate History

 

BullFrog AI, Inc. was incorporated in the State of Delaware on August 25, 2017. Vininder Singh is the founder, CEO and chairman of BullFrog AI.

 

Our Strategy

 

We plan to achieve our business objectives by enabling the successful development of drugs and biologics using a precision medicine approach via our proprietary artificial intelligence platform bfLEAP. We will execute our plan by doing all or any of the following: partnering with biopharmaceutical companies in a fee for service model to assist and enable them with their drug development programs, acquiring rights to and rescuing drugs that have failed FDA review following pivotal Phase 2 or Phase 3 clinical trials (we refer to this rescue process as “drug rescue”), acquiring rights to drugs that are in early stage clinical trials and have not failed FDA review, and discovering new drugs and biologics.

 

The process for enhancing and developing late-stage failed drugs is to:

 

  acquire the rights to the failed drug from a biopharmaceutical industry company or university,
  use the proprietary bfLEAP™ AI/ML platform to determine a multi-factorial profile for a patient that would best respond to the drug,
  Rapidly conduct a clinical trial likely with a partner to validate the drug’s use for the defined “high-responder” population; and
  Divest/sell the rescued drug asset with new information back to the pharma industry, following positive results of the clinical trial.

 

We also plan to deploy this strategy for all discovery and early stage clinical candidates. The common objective is to monetize our assets as quickly as possible with no current plan to commercialize any asset. As part of our strategy, we will continue evolving our intellectual property, analytical platform and technologies, build a large portfolio of drug candidates, and implement a model that reduces risk and increases the frequency of cash flow from rescued drugs. This strategy will include strategic partnerships, collaborations, and relationships along the entire business value chain.

 

35
 

 

We did not produce any revenues through 2021; we generated our first revenues in late 2022 from our services related to the relationship with a pharmaceutic company.

 

To date, we have not conducted clinical trials on any pharmaceutical drugs and our platform has not been used to identify a drug candidate that has received regulatory approval for commercialization. However, we currently have a strategic relationship with a leading rare disease non-profit organization for artificial intelligence/machine learning (“AI/ML”) analysis of late stage clinical data. We have acquired the rights to a series of preclinical and early clinical drug assets from universities and entered into a strategic collaboration with a world renowned research institution to create a HSV1 viral therapeutic platform to engineer immunotherapies for colorectal cancer. We have signed exclusive worldwide license agreements with Johns Hopkins University for a cancer drug that targets glioblastoma (brain cancer), pancreatic cancer, and other cancers. We have also signed an exclusive worldwide license with George Washington University for another cancer drug that targets hepatoceullar carcinoma (liver cancer), and other liver diseases.

 

Our platform was originally developed by The Johns Hopkins University Applied Physics Laboratory (“JHU-APL”). JHU-APL uses the same technology for applications related to national defense. Over several years, the software and algorithms have been used to identify relationships, patterns, and anomalies, and make predictions that otherwise may not be found. These discoveries and insights provide an advantage when predicting a target of interest, regardless of industry or sector. We have applied the technology to various clinical data sets and have identified novel relationships that may provide new intellectual property, new drug targets, and other valuable information that may help with patient stratification for a clinical trial thereby improving the odds for success. The platform has not yet aided in the development of a drug that has reached commercialization. However, we have licensed one drug candidate that has completed a Phase 1 trial and a second candidate that is in the preclinical stages. Our aim is to use our technology on current and future available data to help us better determine the optimal path for development.

 

Contract Services

 

Our fee for service partnership offering is designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. We provide the customer with an analysis of large complex data sets using our proprietary artificial intelligence / machine learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. Our service model involves a cash fee plus the potential for rights to new intellectual property generated from the analysis, which can be performed at the discovery, preclinical, or clinical stages of drug development. On September 28, 2022, BullFrog AI entered into a $185,000 service contract with Sapu Biosciences, LLC, a subsidiary of Oncotellic Therapeutics (OTCQB: OTLC). The scope of the contract is focused on uncovering novel insights related to oncology clinical data for one of their candidate programs.

 

Collaborative Arrangements

 

We will also seek to enter into collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. Our revenue from such collaborations will be based on achieving certain milestones as determined by each specific arrangement.

 

Acquisition of Rights to Certain Drugs

 

In certain circumstances, we may also acquire rights to drugs that are in early stage clinical trials, use our technology to produce a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs.

 

36
 

 

Our Products

 

Product/Platform   Description   Target Market/Indications
bfLEAP™ - AI/ML platform for analysis of preclinical and/or clinical data   AI/ML analytics platform derived from technology developed at JHU-APL and licensed by the Company.   Biotechnology and pharmaceutical companies and other organizations.
         
siRNA   siRNA targeting Beta2-spectrin in the treatment of human diseases developed at George Washington University licensed by the Company   Hepatocellular carcinoma (HCC), treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Has not yet initiated clinical testing.
         
Mebendazole   Improved formulation of Mebendazole developed at Johns Hopkins University and licensed by the Company   Glioblastoma. Has begun the process of clinical testing but has not received regulatory approval for commercialization.

 

On January 14, 2022, the Company entered into an exclusive, worldwide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three U.S. and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. This program is currently in the preclinical stage of development. The Company has not yet initiated development activities or IND-enabling studies on this asset; however, the plan is to conduct this work over the next 24 months. All R&D to date on this candidate has been conducted by the licensor of the technology, George Washington University.

 

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess lipids, or fat, build up in the liver. This condition, which is more common in people who have obesity and related metabolic diseases including type 2 diabetes, affects as many as 24% of adults in the US and is associated with risk of progression to more serious conditions, including non-alcoholic steatohepatitis (NASH), with associated liver inflammation and fibrosis, and HCC. Evidence in animal models of obesity suggest that a protein called β2-spectrin may play a key role in lipid accumulation, tissue fibrosis, and liver damage, and targeting expression or activity of this protein may be a useful approach in treating NASH and liver cancer (Rao et al., 2021).

 

In February 2022, the Company entered into an exclusive, worldwide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to mebendazole at any dose during the trial. The Company is currently formulating a strategy to find a partner to conduct additional clinical trials with this asset to enable evaluation of safety in humans.

 

We are able to leverage our drug rescue business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially derived from technology developed at JHU-APL. The bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The input data for bfLEAP™ can include raw data (preclinical and/or clinical readouts), categorical data, sociodemographic data of patients, and various other inputs. Thus, the bfLEAP™ platform is capable of capturing the “human experience” of patients in an unbiased manner, and contextualizing it against other disparate data sources from patients (e.g. molecular data, physiological data, etc.) for less biased and more meaningful conclusions (i.e. more ethical AI/ML). It is also uniquely scalable - the bfLEAP™ platform is able to perform analysis on large, high-volume data sets (i.e. ‘big data’) and also able to analyze highly disparate “short and wide” data as well. In terms of visualization, bfLEAP™ is able to integrate with most commonly used visualization tools for graph analytics.

 

We believe the combination of a) scalable analytics (i.e., large data or short/wide data), b) state-of-the-art algorithms, c) unsupervised machine learning, and d) streamlined data ingestion/visualization makes bfLEAP™ one of the most flexible and powerful new platforms available on the market.

 

37
 

 

Our Platform Technology

 

We will continue to evolve and improve bfLEAP™, either in-house or with development partners like JHU-APL. The bfLEAP™ platform is based on an exclusive, worldwide license granted by JHU.

 

We plan to leverage our proprietary AI/ML platform developed over several years at one of the top innovation institutions in the world which has already been successfully applied in multiple sectors. In terms of underlying intellectual property, we have secured a worldwide exclusive license from JHU-APL for the technology - this license covers 3 issued patents, as well as 1 new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, and also includes modifications and improvements. In addition, we have a unique business model designed to reduce risk and increase the frequency of cash flow.

 

The Company has recently licensed new technology from JHU-APL to evolve the bfLEAP platform to bfLEAP 2.0. This new and improved platform will enable more robust analysis of data with faster and higher precision prediction of the most important variables for identifying patient response to a drug.

 

Going forward, the Company will continue to evolve the platform and either develop or acquire new capabilities and technologies. These development efforts may be in house or in collaboration with an existing or new technology partners. The Company plans on hiring talent in data science and software development to bolster its in house capabilities.

 

Summary for CATIE Schizophrenia Case Study

 

The Company worked with the Lieber Institute for Brain Development to analyze data from the landmark CATIE trials. The CATIE trials were the largest trials ever conducted for anti-psychotic medications. BullFrog analyzed CATIE data from ~200 schizophrenia patients, with a library of almost 1 million genetic data points for each patient, more than 200 non-genetic attributes per patient, and 4 different medications used in the trial. For each of the four medications used, bfLEAP™ analysis revealed new, previously unknown relationships between individual genetic variants and negative patient symptoms. The genetic loci identified represent potential druggable targets, as well as potential stratifying criteria for future clinical trials in schizophrenia.

 

We performed another analysis on the data using our new advanced clustering algorithms bfLEAP 2.0 but focused on one particular drug named Olanzapine. Our bfLEAP™ 2.0 analytical results identified previously unknown, multi-dimensional associations among newly identified genetic variants, drug clearance, clinical trial sites, and clinical outcome variables in schizophrenia patients.

 

 

38
 

 

FIGURE 1 - bfLEAP™ Analytical Map

 

Each green node represents a different sampling of the data, and arrows point to attributes (blue nodes) which were found to be key indicators according to that sampling. Attribute importance is determined by how many samplings identify that attribute as an indicator (i.e., number of incoming arrows to each blue node).

 

 

 

39
 

 

Identification of clustered multi-variate associations (e.g., novel genetic variants, drug clearance, substance abuse) could help us 1) identify novel drug targets, 2) predict which patients are most likely to respond, and 3) identify modifiable factors that could contribute to better outcomes.

 

Summary for Cardiovascular Case Study

 

The Company worked with an international collaborator in cardiovascular devices to analyze data from an ongoing clinical trial for a new device. BullFrog analyzed data from ~55 patients, with a library of almost 15,000 unique attributes of data for each patient. The data also included adverse events, and key demographic information. For this collaborator, bfLEAP™ analysis was able to provide ground truth for the company - confirming multiple correlations and non-correlations within the data. In terms of actionable output, the analytical results confirmed at least two demographic co-variates for the ongoing trial, and also provided a starting point for deeper physiological and molecular studies.

 

Our Supply Chain and Customer Base

 

We have launched our businesses using funds from our initial public offering and through our partnerships and relationships. We have a strategic relationship with FSHD Society, a leading non-governmental organization, for AI/ML analysis of clinical trial data for patients with a rare neuromuscular disorder. We also have several other developing strategic relationships in the project design phase. The Company has executed a joint development deal for a biologics discovery phase opportunity that is directed toward targeted cancer therapeutics. The Company has also obtained exclusive worldwide rights to a Phase 2 ready glioblastoma drug and a discovery phase hepatocellular carcinoma drug from universities. Since we intend to conduct late-stage clinical trials with partners on rescued therapeutic assets, there will be a requirement of drug product or other significant services to plan and execute our clinical development programs. The success of our partnered clinical development programs will require adequate availability of raw materials and/or drug product for our R&D and clinical trials, and, in some cases, may also require establishment of third-party arrangements to obtain finished drug product that is manufactured appropriately under industry-standard guidelines, and packaged for clinical use or sale. Since we are a digital biopharmaceutical company, our clinical development programs will also require, in some cases, establishment of third-party relationships for execution and completion of clinical trials.

 

Our Market Opportunity

 

One aim of our business is to “rescue” drugs that have failed in phase 3 clinical trials by using our technology to analyze all available data with the goal of designing a precision medicine clinical trial that will have a better chance of being successful. The graphic below illustrates the estimated market opportunity for these failed drugs. The top arrow shows the number of failed phase 3 trials for several disease categories over a 5-year period. The arrows below provide our assumptions for narrowing or discounting certain parameters associated with the market size calculation. The final arrow shows the math behind the $47.1B. To date, we have not penetrated the failed drug market, however; we are actively searching for failed drug opportunities.

 

40
 

 

 

Identification of candidates with potential for rescue may be challenging and require significant resources, and once these assets are identified the Company may find it challenging to license them under favorable terms in order to create value for shareholders. Subsequent development of these assets for clinical testing may require significant effort and resources. Ultimately, these assets must undergo rigorous clinical testing and approval by FDA or comparable regulatory authorities in other countries in order to be marketed. A key part of our strategy is to partner our R&D programs. In addition, we do not intend on commercializing drugs and instead will seek to divest each drug asset to a company that will commercialize the drug. The Company may receive future royalties in come transactions.

 

The following graphic illustrates the global revenue forecast for applying AI in the pharmaceutical industry, as well as the increase in anticipated market spend and annual growth rate for AI solutions per certain application areas.

 

 

41
 

 

Intellectual Property

 

Patents

 

We have exclusive worldwide rights to the following patents related to our intellectual property:

 

Johns Hopkins University Licensed Intellectual Property:

 

Title   Serial Number   File Date   Application Type   Country   Status   Patent Number   Expiration Date   Assignee
An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity   62/112,706   06 Feb 2015   Provisional   US   Expired           The Johns Hopkins University
An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity   PCT/US2016/016968   08 Feb 2016   PCT   PCT - Parent   Expired       11 Aug 2016   The Johns Hopkins University
MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS   15/548,959   04 Aug 2017   PCT   US   GRANTED   11,110,079   08 Feb 2036   The Johns Hopkins University
Mebendazole Polymorph For Treatment And Prevention Of Tumors   16747414.7   08 Feb 2016   PCT   EPO   GRANTED   Pending   08 Feb 2036   The Johns Hopkins University
MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS   253854   08 Feb 2016   PCT   Israel   GRANTED   253854   08 Feb 2036   The Johns Hopkins University
An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity   2016800144274   08 Feb 2016   PCT   China   GRANTED   1ZL20168-0014427.4   08 Feb 2036   The Johns Hopkins University
An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity   201717028684   08 Feb 2016   PCT   India   GRANTED   352734   08 Feb 2036   The Johns Hopkins University
Mebendazole Polymorph For Treatment And Prevention Of Tumors   2017-541687   08 Feb 2016   PCT   Japan   GRANTED   6796586   08 Feb 2036   The Johns Hopkins University
CONTINUATION: Mebendazole Polymorph For Treatment And Prevention Of Tumors   17/402,131   13 Aug 2021   CON   United States   PENDING           The Johns Hopkins University

 

42
 

 

George Washington University Licensed Intellectual Property:

 

The provisional patent numbers 63/113,745 and 63/147,141 were both converted into a single PCT application (PCT/US2021/059245) with an expiration date of November 12, 2041, as shown in table below.

 

 

 

 

John Hopkins University Applied Physics Lab Licensed Intellectual Property:

 

Title   Serial Number   File Date   Country   Status   Expiration Date   Assignee
Apparatus and Method for Distributed Graph Processing   U.S. Patent 10,146,801   7/13/2015   US   Granted   3/2/2037   The Johns Hopkins University
Method and Apparatus for Analysis and Classification of High Dimensional Data Sets   U.S. Patent 10,936,965   10/5/2017   US   Granted   9/25/2038   The Johns Hopkins University
Generalized Low Entropy Mixture Model   U.S. Patent 10,839,256   4/2/2018   US   Granted   12/15/2038   The Johns Hopkins University

 

Licenses

 

We hold the following licenses related to our intellectual property:

 

Licensor   Licensee   Description of Rights Granted
         
Johns Hopkins University Applied Physics Lab   BullFrog AI, Inc.   Worldwide, exclusive rights for therapeutics development and analytical services
George Washington University   BullFrog AI Holdings   Worldwide, exclusive rights for therapeutics development
Johns Hopkins University   BullFrog AI Holdings   Worldwide, exclusive rights for therapeutics development

 

43
 

 

On February 7, 2018, we entered into a License Agreement (the “License Agreement”) with JHU-APL, a Maryland limited liability company (“JHU”). Pursuant to the License Agreement, JHU-APL granted the Company exclusive rights to intellectual property of JHU related to analytical services for applications in biological and chemical derived pharmaceutical therapeutics. The License Agreement provides for the grant of an exclusive, worldwide, royalty-bearing license by JHU to the Company, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In consideration of the rights granted to the Company under the License Agreement, the Company granted JHU received a warrant equal to five (5%) percent of the then fully diluted equity base of the Company, which was diluted following our public offering. Under the terms of the License Agreement, the Company is required to use commercially reasonable efforts to meet certain development milestones and minimum net sales milestones, and JHU will be entitled to eight (8%) percent of net sales for the services provided by the Company in which the JHU license was utilized, as well as fifty (50%) percent of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. The Company is also obligated to make minimum annual payments. These minimum annual payments to JHU were amended on September 3, 2020 to $20,000 in calendar year 2022, $80,000 in calendar year 2023, $300,000 in calendar year 2024, and $300,000 in calendar year 2025 and each year thereafter, which may be offset against royalties paid by the Company for the year in which the minimum annual royalty becomes due.

 

The License Agreement will, unless sooner terminated, continue in each country until the date of expiration of the last to expire patent included within the patent rights in that country, or if no patents issue, then for 10 years. The License Agreement may be terminated by the Company upon 60 days’ written notice in its discretion. The License Agreement may also be terminated by JHU if the Company is in material breach of the License Agreement and fails to cure such breach within a 60-day cure period commencing upon notice. A material breach by the Company may include a delinquency with respect to payment or the failure by the Company to timely achieve a specified milestone.

 

We also have exclusive, worldwide licenses to other intellectual property from JHU that are being held as trade secrets related to our algorithm libraries, pattern recognition, shallow-and-wide data sets, and time series correlation. We anticipate that new intellectual property (patents, copyrights, trademarks, trade secrets, etc.) will be generated through the course of executing our strategic development projects, and also through the course of improving, modifying, and scaling our bfLEAP™ platform. In October 2021, we amended the agreement with JHU-APL to include additional advanced AI technology. Currently, the latest patent grant date was in March 2021.

 

On July 8, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology (the “2022 License Agreement”). This license provides additional intellectual property rights including patents, copyrights and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. Under the terms of the 2022 License Agreement, JHU will be entitled to eight (8%) percent of net sales for the services provided by the Company to other parties and 3% for internally development drug projects in which the JHU license is utilized. The 2022 License Agreement also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual payments are set to be $30,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond, all of which are creditable by royalties. The financial terms of the new license agreement replace the original terms and are not duplicative.

 

George Washington University - Beta2-spectrin siRNA License

 

On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from GWU for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including HCC. The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. This program is currently in the preclinical stage of development. The Company has not yet initiated development activities or IND-enabling studies on this asset; however, the plan is to conduct this work over the next 24 months. All R&D to date on this candidate has been conducted by the licensor of the technology, George Washington University. The term of the agreement began on January 14, 2022 and ends on the expiration date of the last patent to expire or 10 years after the first sale of a licensed product if no patents have issued. The license can be terminated by the licensee upon 60 days’ written notice, or by the licensor if the Company is more than 30 days late in paying amounts owed to the licensor and does not make payment upon demand, or in the event of any material breach of the license that is not cured within 45 days.

 

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess lipids, or fat, build up in the liver. This condition, which is more common in people who have obesity and related metabolic diseases including type 2 diabetes, affects as many as 24% of adults in the US and is associated with risk of progression to more serious conditions, including non-alcoholic steatohepatitis (NASH), with associated liver inflammation and fibrosis, and hepatocellular carcinoma (HCC). Evidence in animal models of obesity suggest that a protein called β2-spectrin may play a key role in lipid accumulation, tissue fibrosis, and liver damage, and targeting expression or activity of this protein may be a useful approach in treating NASH and liver cancer (Rao et al., 2021).

 

44
 

 

In consideration of the rights granted to the Company under the license agreement, GWU received a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization.

 

Aggregate payments made to GWU to date include the $20,000 License Initiation Fee and an additional $6,550 to reimburse the licensor for past patent costs. Aggregate future milestone costs could reach $860,000 if the drug successfully completes clinical trials and is the subject of a New Drug Application (NDA) to the U.S. FDA. Future milestones on sales revenue are limited to $1M on the first $20M in net sales.

 

Johns Hopkins University - Mebendazole License

 

On February 22, 2022, the Company entered into an exclusive, worldwide, royalty-bearing license from JHU for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer, and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to mebendazole at any dose during the trial. The Company is currently formulating a strategy to conduct additional clinical trials with this asset to enable evaluation of safety in humans.

 

The license covers six (6) issued patents and one (1) pending application, with the term of the agreement beginning on February 22, 2022 and ending on the date of expiration of the last to expire patent. The license can be terminated by the licensee upon 90 days’ written notice, or by the licensor in the event of any material breach of the license that is not cured within 30 days. In consideration of the rights granted to the Company under the license agreement, JHU will receive a staggered Upfront License Fee of $250,000, with the first $50,000 payment due within 30 days of the effective date. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the license agreement, JHU will be entitled to three- and one-half percent (3.5%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $5,000 for 2023, $10,000 for 2024, $20,000 for 2025, $30,000 for 2026 and $50,000 for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. Aggregate payments made to date include the initial $50,000 upfront fee and an additional $79,232.53 to reimburse the licensor for past patent costs. Aggregate future milestone costs could reach $1,500,000 if the drug successfully completes Phase II and III clinical trials and is approved for sale and marketing by the US FDA. Future milestones on sales revenue are $1M on the first $20M in sales revenue, $2M in the first year cumulative sales revenue exceeds $100M, $10M in the first year cumulative sales revenue exceeds $500M, and $20M in the first year cumulative sales revenue exceeds $1B.

 

JHU - Mebendazole Prodrug License

 

On October 13, 2022, the Company entered into an exclusive, worldwide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. The term of the agreement began on October 13, 2022and continues until the date of expiration of the last to expire patent, or for 20 years from the effective date of the agreement if no patents issue. The license can be terminated by the Company upon 90 days’ written notice, or by the licensor in the event of any material breach of the license that is not cured by the Company within 30 days.

 

45
 

 

In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs totaling $33,265 and will be responsible for reimbursing licensors for future patent costs. Under the terms of the License Agreement, the licensors will be entitled to a four percent (4%) royalty on net sales subject to annual minimums upon first commercial sale of a licensed product, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Sublicense fee amount declines as the Company advances the clinical development of the licensed technology. The Company is required to pay minimum annual royalties (MAR) beginning in year 4 of the agreement. The MAR for year 4 will be $5,000, increasing to $10,000 in year 5, $20,000 in year 6, $30,000 in year 7, and $50,000 in year 8 and subsequent years. The Company will be responsible for milestone payments for patent issuance of up to $50,000 and clinical development milestones up to and including approval of an NDA totaling up to $2.3M. The Company will be required to pay a commercial milestone of $1M once sales reach $20M in the US, $2M when sales in the US reach $100M, $10M when US sales reach $500M, and $20M when US sales exceed $1B.

 

Competition

 

The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The immuno-oncology, neuroscience, and rare disease segments of the industry in particular are highly competitive. While we believe that our technology, development experience and scientific knowledge provide competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions.

 

Many of our competitors may have significantly greater financial resources, and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals, and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

 

The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, if any, the level of generic competition and the availability of reimbursement from government and other third-party payors.

 

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any medicines we may develop. Our competitors also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines. There are many generic medicines currently on the market for certain of the indications that we are pursuing, and additional generics are expected to become available over the coming years. If our therapeutic product candidates are approved, we expect that they will be priced at a significant premium over competitive generic medicines.

 

Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. If the product candidates of our priority programs are approved for the indications for which we are currently planning clinical trials, they will compete with the drugs discussed below and will likely compete with other drugs currently in development.

 

bfLEAP

 

The analytics industry and application of AI in healthcare is growing rapidly. Competition exists along the entire continuum of the drug development process from discovery to commercialization and beyond. We believe the weakness of the industry is the quality of the data and we believe bfLEAP provides several competitive advantages, that will position the Company for success, First, bfLEAP is highly scalable and can process data from small to extremely large complex data sets without the need for additional code being developed. Second, it is adept at processing and analyzing incomplete data and making predictions that we do not believe other technologies are capable of doing. Finally, bfLEAP has the ability to extract the most important features for analysis out of extremely large complex data sets using unsupervised machine learning algorithms, thereby greatly simplifying complex problems. Since data quality is a problem that exists in the healthcare industry, we see these as major differentiators. The ability to make predictions, find relationships and patterns and anomalies in extremely large complex data sets has been demonstrated by the Applied Physics Lab in other applications and sectors. Finally, the algorithms used by bfLEAP are proprietary and protected, having been developed at Johns Hopkins University Applied Physics Lab. We believe most of the competitors rely on open source algorithms and we also believe that we have already demonstrated our superiority via the August 2021 publication in DeepAI.org.

 

46
 

 

Government Regulation

 

The FDA does not currently require approval of AI technologies used to aid in therapeutics, but that could change in the future. The FDA will regulate any clinical trials conducted by the Company.

 

Our clinical development programs will, in some cases, require regulatory review of preclinical and/or clinical data by the FDA or other governing agencies, and subsequent compliance with applicable federal, state, local, and foreign statutes and regulations. The results of the clinical trials that we conduct will be evaluated by the FDA and other regulatory bodies. The comments and approvals that are obtained are expected to lead to milestone payments under the collaborative agreement. Accordingly, our ability to navigate the regulatory process is extremely important to the success of the Company. We believe that we have a competitive advantage in this process due to primarily focusing on drug candidates that already have some level of success in clinical trials. Previous success of a particular candidate in trials combined with our precision medicine approach to clinical trial design using our bfLEAP platform, will de-risk the development process and improve the chances for success.

 

Government Regulation and Product Approval

 

Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

 

FDA Approval Process

 

In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (FD&C Act) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications (NDAs), warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.

 

Pharmaceutical product development for a new product or certain changes to an approved product in the U.S. typically involves preclinical laboratory and animal tests, the submission to FDA of an investigational new drug application (IND) which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.

 

Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. The results of preclinical testing are submitted to FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to FDA as part of the IND.

 

47
 

 

Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a drug demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in rare instances, such as where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.

 

After completion of the required clinical testing, an NDA is prepared and submitted to FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product’s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, and the applicant under an approved NDA is also subject to an annual program fee for each prescription product. These fees are typically increased annually. Sponsors of applications for drugs granted Orphan Drug Designation are exempt from these user fees.

 

FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an outside advisory committee - typically a panel that includes clinicians and other experts - for review, evaluation and a recommendation as to whether the application should be approved. FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.

 

Before approving an NDA, FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, FDA will inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with current good manufacturing practices (cGMPs) is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.

 

Fast Track Designation

 

FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA must determine if the drug candidate qualifies for Fast Track Designation within 60 days of receipt of the sponsor’s request.

 

If a submission is granted Fast Track Designation, the sponsor may engage in more frequent interactions with FDA, and FDA may review sections of the NDA before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA’s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. While we may seek Fast Track Designation, there is no guarantee that we will be successful in obtaining any such designation. Even if we do obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A Fast Track Designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. Additionally, Fast Track Designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

 

Post-Approval Requirements

 

Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.

 

Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA. FDA also may require post-marketing testing, known as Phase 4 testing, REMS and surveillance to monitor the effects of an approved product, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration with FDA subjects entities to periodic unannounced inspections by FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.

 

48
 

 

Generic Competition

 

In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant’s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application (ANDA). An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as “generic equivalents” to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.

 

The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA’s Orange Book. Specifically, the applicant must certify that (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product (a Paragraph IV certification). The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carve out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents or certifies that the listed patents will not be infringed by the new product, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification, the NDA and patent holders may then initiate a patent infringement lawsuit in response. The filing of a patent infringement lawsuit within 45 days of the receipt of a such certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.

 

Exclusivity

 

Upon NDA approval of a new chemical entity (NCE) that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. Certain changes to a drug, such as the addition of a new indication to the package insert, can be the subject of a three-year period of exclusivity if the application contains reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the sponsor that were essential to approval of the application. FDA cannot approve an ANDA for a generic drug that includes the change during the period of exclusivity.

 

Patent Term Extension

 

After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug’s testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval up to a maximum of five years). The time can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years, and only one patent can be extended. For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the United States Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.

 

Other Healthcare Laws

 

In the United States, biotechnology company activities are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare & Medicaid Services (CMS), other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General and the Office for Civil Rights), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, research, sales, marketing and scientific/educational grant programs have to comply with the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act (HIPAA) and similar state laws, each as amended, as applicable.

 

49
 

 

Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

 

Data privacy and security regulations by both the federal government and the states in which business is conducted may also be applicable. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA requires covered entities to limit the use and disclosure of protected health information to specifically authorized situations and requires covered entities to implement security measures to protect health information that they maintain in electronic form. Among other things, HITECH made HIPAA’s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

 

Insurance Coverage and Reimbursement

 

Significant uncertainty exists as to the insurance coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of FDA-approved drugs for a particular indication. A payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.

 

50
 

 

Recent Developments

 

Since our initial public offering, which took place in February 2023, the following material developments occurred in our business.

 

APL

 

On May 31, 2023, the Company and JHU-APL entered into Amendment No. 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements, including additional patents and know-how, in exchange for a series of payments totaling $275,000. The Company paid the first of these payments in the amount of $75,000 due in July 2023 and will be followed by payments in the amounts of $75,000, $75,000 and $50,000 in years 2025, 2026 and 2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $60,000. All other financial terms of the License Agreement remain the same.

 

LIBD

 

On September 8, 2023, the Company entered a data use and technology partnership agreement (the “Partnership Agreement”) with the Lieber Institute for Brain Development (LIBD). The Partnership Agreement covers the right of BullFrog AI to leverage its bfLEAP™ platform to mine LIBD’s comprehensive brain data, including transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data to identify previously unrecognized relationships. The goal of the partnership is to identify previously unrecognized relationships between genes and pathways in the brain and the development of neurologic and psychiatric disorders, thereby facilitating the development of more effective treatments for diseases of the human brain. The collaboration will proceed in two stages, with the first involving unsupervised construction of graphical models to reveal relationships between brain diseases and genomic/biologic attributes, with the goal of identifying new biomarkers and drug targets across disorders. The second stage will involve creating disease-specific models that will enable identification of genes and pathways within these respective disorders. The Partnership Agreement has a one-year term of data exclusivity to complete the first stages of analyses, with a two-year extension option as performance milestones are met.,

 

As contemplated in the Partnership Agreement, on October 16, 2023, the Company and LIBD entered into a commercial agreement (the “Commercial Agreement”) that sets forth the key terms for commercialization of products and services developed under the Partnership Agreement. Pursuant to the Commercial Agreement, LIBD granted the Company a worldwide, royalty-bearing exclusive license so long as the Company receives net sales or income from the licensing of “Licensed Products” (as defined in the Commercial Agreement) in the application of machine learning and/or artificial intelligence for research and development in drug development, and specifically includes therapeutic products, patient selection strategies, and target identification, but excludes diagnostics and incidental uses of machine learning and/or artificial intelligence on data derived from research. Generally, “Licensed products” are any product or service which incorporates, results from, or is derived from LIBD’s Data (meaning finished brain-related data, including but not limited to DNA methylation, RNAseq, genomic, DNA methylation, cell-line, clinical, and imaging data, and the specified data set forth in the Partnership Agreement) and that the Company or its affiliate develops during the term of the Partnership Agreement, and any improvements thereof after the term of the Partnership Agreement, and all Licensed Products or services derived therefrom by the Company or its affiliates. Licensed Products may include, but are not limited to, biomarker and target identification, target validation, mapping unmet needs, identifying genetic risk factors and predictive modeling.

 

The Company was also granted the right to sublicense, to use the deliverables under the Partnership Agreement, and LIBD’s intellectual property rights in the data, to (i) use, sell, distribute for sale, have distributed for sale, offer for sale, have sold, import and have imported Licensed Products and (ii) to develop, have developed, make, have made Licensed Products that are derived from Licensed Products developed during the term of the Partnership Agreement, and any improvements made following the term. The Company is prohibited from sublicensing LIBD Data. The Company shall pay LIBD a royalty based on net sales of all Licensed Products sold by the Company and/or its affiliates.

 

The Commercial Agreement, generally, may be terminated at any time by either the Company or LIBD if either party defaults or breaches any material term of the agreement or files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver, trustee, or similar agent over its property.

 

51
 

 

Prodrug

 

On September 26, 2023, the Company announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma. The study assessed the relative efficacy of BF-222, a novel formulation of mebendazole that has been evaluated in clinical trials, and BF-223, a novel prodrug of mebendazole with improved solubility and bioavailability relative to BF-222, compared with placebo in mice that had been implanted with tumor cells as a model for human glioblastoma. Animals treated with BF-223 had an average survival time of 27.9 days compared with 27.3 days for mice treated with BF-222 and 23.4 days for mice given placebo. Mice treated with BF-223 were administered 80% of the dose that mice treated with BF-222 received, and improved outcomes for both treatment groups were statistically significant compared to placebo. In addition, animals treated with equivalent doses of BF-222 and BF-223 showed comparable and significant reduction in tumor growth compared to control animals during the study.

 

Employees

 

As of January 1, 2024, the Company has 8 full-time employees and consultants, including its Chief Executive Officer Vininder Singh and its Chief Financial Officer, Dane Saglio and 7 part-time employees, advisors, and consultants. None of these employees are covered by a collective bargaining agreement, and we believe our relationship with our employees is good. We also engage consultants on an as-needed basis to supplement existing staff.

 

Properties

 

Currently, the Company does not own any real property. All of the Company’s employees work virtually.

 

Legal Proceedings

 

The Company is not a party to any legal proceedings.

 

Corporate Information

 

BullFrog Holdings AI, Inc. was incorporated in the State of Nevada on February 6, 2020. Our principal business address is 325 Ellington Blvd., Unit 317, Gaithersburg, MD 20878. Our website address is www.bullfrogai.com. The references to our website in this prospectus are inactive textual references only. The information on our website is neither incorporated by reference into this prospectus nor intended to be used in connection with this offering. All of our operations are currently conducted through BullFrog AI Holdings, Inc.

 

Available Information

 

Reports we file with the Securities and Exchange Commission (SEC) pursuant to the Exchange Act, including annual and quarterly reports, and other reports we file, can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street NE, Washington, D.C. 20549.

 

52
 

 

MANAGEMENT AND BOARD OF DIRECTORS

 

Executive Officers and Directors

 

The following table sets forth the name, age and position of each of our executive officers, key employees and directors.

 

Name   Age   Position(s)
Executive Officers:        
Vin Singh   54   Chief Executive Officer and Director
Dane Saglio   66   Chief Financial Officer
Non-Executive Directors:        
Don Elsey   70   Director and Chair Audit Committee
William Enright   60   Director and Chair of Compensation Committee
Jason Hanson   54   Director and Chair of Nominating and Corporate Governance Committee

 

Vininder (Vin) Singh is the Founder, Chairman, and CEO of BullFrog AI Holdings, Inc. since its inception in August 2017. Over the past five years, he has built the Company from scratch and during that time he led strategy, built a highly experienced team of leaders, spear headed the acquisition and development of BullFrog’s core AI technology and drug assets, secured the first revenue, and raised approximately $2M in financing. In February of 2020, he formed BullFrog AI Holdings, Inc. and BullFrog AI Inc. became a wholly owned subsidiary designated as the holder of core intellectual property. Vin is a serial entrepreneur and experienced executive with 25 years of experience in the life sciences and biotechnology industries. He has extensive start-up experience having founded and built several pioneering investor backed companies including BullFrog AI, which uses machine learning/AI to enable drug development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc. (MXCT), a cell therapy company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global cell therapy services business. Vin has a BS in Electrical Engineering from Rutgers University, an MS in Biomedical Engineering from Rensselaer Polytechnic Institute, and an MBA from Johns Hopkins University. We believe that Mr. Singh is qualified to serve as a member of our board of directors due to the perspective and experience that he brings as our Founder and Chief Executive Officer, his extensive experience in the science and biotechnology industries and in the management of startup companies.

 

Dane Saglio joined BullFrog Holdings AI, Inc. as Chief Financial Officer in September 2021. Mr. Saglio brings more than 40 years of financial management experience in both public and private companies across a number of business sectors. Previously, Mr. Saglio has served as CFO at Seneca Biopharma, RegeneRx Biopharmaceuticals since 2011, New Generation Biofuels 2010 until 2011, and EntreMed from 2000 until 2008, all public companies in the biotechnology arena. Prior to joining the Company, Mr. Saglio was the CFO of Seneca Biopharma, initially as a consultant in August 2019 and then as an employee in April 2020 until the Company merged with Leading Bio Sciences, forming Palisades Bio, Inc. in April 2021. He previously served as CFO at Celios Corporation from October 2017 until July 2019 and Helomics Corporation, a personalized medicine company in cancer from October 2014 through July 2017. He began his career at Informatics Corp, now Computer Associates International and then at Bressler & Reiner, a DC-based real estate developer and homebuilder. Dane has a BS from the University of Maryland is a licensed CPA in Maryland (inactive).

 

R. Don Elsey has been a director and chair of the Audit Committee of our board since February 14, 2023. Currently, Mr. Elsey is the Audit Chair of OpGen, Inc., a precision medicine company. Mr. Elsey was the CFO of Lyra until his retirement in December 2020. Previously, from February 2015 to February 2019, Mr. Elsey served as Chief Financial Officer at Senseonics, Inc., a medical device company. From May 2014 until February 2015, Mr. Elsey served as Chief Financial Officer of Regado Biosciences, Inc., a biopharmaceutical company. From December 2012 to February 2014, Mr. Elsey served as Chief Financial Officer of LifeCell Corporation, a privately held regenerative medicine company. Mr. Elsey holds a B.A. in economics and an M.B.A. in finance from Michigan State University. We believe that Mr. Esley is qualified to serve as a member of our board of directors because of his extensive professional experience in science and biotechnology companies.

 

William “Bill” Enright has been a director and chair of the Compensation Committee of our board since February 14, 2023. He is a seasoned biotech executive with more than thirty-four years of experience in building and financing both privately held and publicly held companies and He is currently the CEO and a Director of Barinthus Biotherapurtics plc (NASDAQ: BRNS), which he helped to take public in April 2021. Prior to Barinthus, Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions, and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Precigen) with increasing responsibilities, culminating as Head of Business Development. Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Bill received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University. We believe that Mr. Enright is qualified to serve as a member of our board of directors because of his extensive professional experience in life science/biotech companies and in the management of public companies.

 

53
 

 

Jason Hanson has served as a director and chair of the Nominating and Corporate Governance Committee since February 14, 2023. Mr. Hanson has served as Chief Executive Officer and as a Director of enGene Inc. since July 2018. He also served as President of enGene Inc. from July 2018 to December 2022. Mr. Hanson effectively re-launched enGene from a small private company working in the GI discovery space into a clinical stage gene therapy oncology company trading on Nasdaq, implementing a new scientific, technical and strategic vision for the Company. From August 2016 to November, 2017, Mr. Hanson served as President and Chief Executive Officer of Ohana Biosciences, a biotechnology company based in Cambridge, MA, and as member of the Ohana Board of Directors and consultant to Ohana from November 2017 to June 2018. Mr. Hanson previously served as Executive Vice President and Chief Strategy Officer for NuVasive, Inc. from November 2015 to August 2016. Mr. Hanson served as Corporate Vice President of General Electric Company and member of the senior executive team of GE Healthcare, a global pharmaceutical, medical device and healthcare services business from May 2014 to October 2015. In January 2013, Mr. Hanson served as Company Group Chairman and Executive Vice President of Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Previously, he served in various roles at Medicis Pharmaceutical Corporation, including as Executive Vice President and Chief Operating Officer between July 2006 and December 2012. Mr. Hanson also served in numerous roles at GE Healthcare, including General Counsel roles, from April 1999 to July 2006. Mr. Hanson holds a B.S. from Cornell University and a J.D. from Duke University School of Law.

 

Corporate Governance

 

Role of Board of Directors in Risk Oversight Process

 

The board of directors has extensive involvement in the oversight of risk management related to us and our business and accomplishes this oversight through the regular reporting by the Audit Committee.

 

Director Independence

 

Messrs. Elsey, Enright and Hanson, three members of our Board of Directors, are independent using the definition of independence under Nasdaq Listing Rule 5605(a)(2) and the standards established by the SEC.

 

Committees of our Board

 

Audit Committee

 

Our audit committee consists of Don Elsey, William Enright and Jason Hanson, with Mr. Elsey serving as chair. Our board of directors has affirmatively determined that each meets the definition of “independent director” under the rules of The Nasdaq Capital Market, and that they meet the independence standards under Rule 10A-3. Each member of our audit committee meets the financial literacy requirements of Nasdaq rules. Our board of directors has adopted a written charter for the audit committee, which can be found on our website at https://ir.bullfrogai.com/corporate-governance/governance-documents.

 

The audit committee is appointed by the board of directors to assist the board of directors in its duty to oversee the Company’s accounting, financial reporting, and internal control functions and the audit of the Company’s financial statements. The role of the audit committee is to oversee management in the performance of its responsibility for the integrity of the Company’s accounting and financial reporting and its systems of internal controls, the performance and qualifications of the Company’s independent auditor, including the independent auditor’s independence, the performance of the Company’s internal audit function; and the Company’s compliance with legal and regulatory requirements. The Audit Committee met four times in 2023.

 

Compensation Committee

 

Our compensation committee consists of William Enright, Don Elsey and Jason Hanson, with Mr. Enright serving as chair. Our board of directors has adopted a written charter for the compensation committee, which can be found on our website at https://ir.bullfrogai.com/corporate-governance/governance-documents.

 

The compensation committee is responsible for reviewing and recommending, among other things:

 

  the adequacy and form of compensation of the board;
     
  the compensation of Chief Executive Officer, including base salary, incentive bonus, stock option and other grant, award and benefits upon hiring and on an annual basis;
     
  the compensation of other senior management upon hiring and on an annual basis; and
     
  the Company’s incentive compensation and other equity-based plans and recommending changes to such plans to our board of directors, when necessary.

 

Nominating & Corporate Governance Committee

 

Our nominating and corporate governance committee consists of Jason Hanson, William Enright and Don Elsey, with Mr. Hanson serving as chair. Our board of directors has adopted a written charter for the nominating and corporate governance committee, which can be found on our website at https://ir.bullfrogai.com/corporate-governance/governance-documents.

 

The nominating committee is responsible for, among other things:

 

  developing criteria for membership on the board of directors and committees;
     
  identifying individuals qualified to become members of the board of directors;
     
  recommending persons to be nominated for election as directors and to each committee of the board of directors;
     
  annually reviewing our corporate governance guidelines; and
     
  monitoring and evaluating the performance of the board of directors and leading the board in an annual self-assessment of its practices and effectiveness.

 

Term of office

 

All directors hold office until the next annual meeting of the stockholders of the company and until their successors have been duly elected and qualified. Officers are elected by and serve at the discretion of our Board.

 

54
 

 

Code of Business Conduct and Ethics

 

We have adopted a Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, employees or persons performing similar functions. Our code of ethics can be found at https://ir.bullfrogai.com/corporate-governance/governance-documents.

 

Family Relationships

 

There are no family relationships among and between the issuer’s directors, officers, persons nominated or chosen by the issuer to become directors or officers, or beneficial owners of more than ten percent of any class of the issuer’s equity securities.

 

Involvement in Certain Legal Proceedings

 

From time to time, we may become involved in litigation relating to claims arising out of its operations in the normal course of business. Currently there are no legal proceedings, government actions, administrative actions, investigations or claims are currently pending against us or that involve the Company or any of its affiliates which, in the opinion of the management.

 

EXECUTIVE AND DIRECTOR COMPENSATION

 

Summary Compensation Table

 

The following table sets forth all compensation awarded or paid to our principal executive officer and our two other most highly compensated executive officers during the past two fiscal years.

 

Name and Principal

Position

  Year  

Salary

($)

  

Bonus

($)

   Stock Awards ($)   Option Awards ($)   All Other Compensation ($)   Total Compensation ($) 
Vininder Singh   2023   $707,666   $-   $      -   $-   $               -   $707,666 
Chief Executive Officer and Director   2022   $179,000    -    -    -    -   $179,000 
                                    
Dane Saglio   2023   $310,000   $50,000   $-   $147,000   $-   $507,000 
Chief Financial Officer   2022   $30,000   $-   $-   $-   $-   $30,000 

 

Employment Agreements

 

On May 16, 2022, we entered into an employment agreement with Vininder Singh, pursuant to which he will receive received an annual base salary of $400,000, which is subject to bi-annual review by the Company. Mr. Singh will also be eligible for an annual bonus based on the achievement of certain goals and performance criteria established by the Board. Mr. Singh’s target annual bonus for the fiscal years ended 2022 through 2025 will be a minimum of twenty (20%) percent of the current base salary, with a maximum payout of up to one-hundred (100%) percent based on target achievement. For 2023, the criteria to determine Mr. Singh’s bonus will include the following: (i) the Company achieves $500,000 in sales; (ii) the filing of an Investigational New Drug (IND) Application with the FDA for mebandazole; (iii) the Company enters into two (2) strategic partnerships; and (iv) the Company commences partner negotiations with a third party for HSV-1, bf-114 or bf-222. Mr. Singh will also be eligible to participate in the Company’s stock incentive plan, subject to Board approval. The agreement with Mr. Singh shall continue until either his resignation, termination for cause by the Company, or death or disability of Mr. Singh.

 

55
 

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table summarizes the outstanding equity awards held by each named executive officer as of December 31, 2023. This table includes unexercised and unvested options and equity awards.

 

Outstanding Equity Awards as of December 31, 2023
                       
Option Awards
Name 

Date of

Grant

   

Number of

securities

underlying

unexercised

options (#)

exercisable

    

Number of

securities

underlying

unexercised

options (#)

unexercisable

    

Equity

incentive

plan

awards:

Number of

securities

underlying

unexercised

unearned

options (#)

    

Option

exercise

price ($)

  

Option

expiration

date

Dane Saglio  March 17, 2023   43,750    31,250        2.80   March 17, 2033

 

Director Compensation

 

The following table summarizes the compensation paid to our executive and non-executive directors during the year ended December 31, 2023.

 

Name 

Fees

Earned or

Paid in

Cash

($)(1)

  

Stock

Awards

($)

  

Option

Awards

($)(2)

  

All Other

Compensation

($)

  

Total

($)

 
Vininder Singh(3)                    
Don Elsey   39,375        197,200        236,575 
William Enright   39,375        197,200        236,575 
Jason Hanson   39,375        197,200        236,575 

 

(1)Represents cash compensation for service as a director and as chair of a board committee during the fiscal year 2023.
(2)Represents annual value of stock options issued during fiscal year 2023 under our 2022 Equity Incentive Plan.
(3)Mr. Singh did not receive additional compensation for his service as a director of our Company during the fiscal year 2023.

 

2022 Equity Incentive Plan

 

On November 30, 2022, our Board of Directors and shareholders adopted the 2022 Equity Incentive Plan (the “Plan”). Pursuant to the Plan, we are authorized to grant options and other equity awards to officers, directors, employees and consultants. The exercise price of each share of common stock purchasable under an award issued pursuant to the Plan, shall be determined by our compensation committee, in its sole discretion, at the time of grant, but shall not be less than 100% of the fair market of such share of common stock on the date the award is granted, subject to adjustment and conditions further described in the Plan. Our compensation committee shall also have sole authority to set the terms of all awards at the time of grant. As of December 31, 2023, there are 461,500 shares available under the Plan.

 

56
 

 

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

Other than compensation arrangements, including employment, with our directors and executive officers, and the other transactions discussed in the sections titled “Executive and Director Compensation”, the following is a description of each transaction that occurred in the last three fiscal years and each currently proposed transaction in which (i) the amounts involved exceeded or will exceed the lesser of (a) $120,000 or (b) 1% of the average of our total assets for the fiscal years ended December 31, 2023 or 2022; and (ii) any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.

 

On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, Tivoli Trust, our second largest shareholder (the “Investor”), with an amount of $150,000, with 0% interest. Under the SAFE agreement, if there was an Equity Financing before the termination of this SAFE, on the initial closing of such Equity Financing, this SAFE would automatically convert into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, which meant either: (1) the Safe Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation resulted in a greater number of shares of Safe Preferred Stock. This SAFE would automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this SAFE) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this SAFE under agreement; or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to the agreement. The SAFE was converted into 32,967 shares of common stock upon the Company’s initial public offering in February 2023.

 

On August 19, 2021, the company entered into a convertible loan agreement with a related party, with a principal balance of $99,900 at 9% interest. The noteholder had the right to convert the principal and interest into common shares of the Company. This loan included an original issuance discount of 5% and included 99,900 Warrants at an exercise price of $1, exercisable for 5 years from the issue date on the face of the Warrant. The maturity date of the loan was February 19, 2022. In May 2022, the Company and the noteholder agreed to cancel and void previous warrants and entered into a new agreement for 115,185 warrants with an exercise price of $2.50. The noteholder elected to convert the loan into 21,747 shares of common stock upon the Company’s initial public offering in February 2023.

 

On June 15, 2021, the company entered into a unsecured short term loan agreement with the Investor for an aggregate principal balance of $34,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan, including interest, was repaid in 2022.

 

On November 19, 2021, 2021, the company entered into an unsecured short term loan agreement with the Investor for an aggregate principal balance of $5,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan, including interest, was repaid in 2022.

 

On December 13, 2021, the company entered into an unsecured short term loan agreement with the Investor for an aggregate principal balance of $10,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan, including interest, was repaid in 2022.

 

On October 5, 2022, the Company entered into an exchange agreement with the Investor whereby all of his common stock, 734,493 shares, were exchanged into shares of Series A Convertible Preferred Stock. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. For a description of the rights and preferences of the Series A Preferred Stock, see “Description of Securities- Series A Convertible Preferred Stock”.

 

Related Person Transaction Policy

 

For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.

 

Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board of Directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of business conduct and ethics, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our Board of Directors, will take into account the relevant available facts and circumstances including, but not limited to:

 

  the risks, costs and benefits to us;
     
  the impact on a director’s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated;
     
  the availability of other sources for comparable services or products; and
     
  the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.

 

The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our Board of Directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our Board of Directors, determines in the good faith exercise of its discretion.

 

57
 

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND

RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information regarding the beneficial ownership of our common stock as of January 25, 2024 by:

 

  each of our named executive officers;
     
  each of our directors;
     
  all of our current directors and executive officers as a group; and
     
  each stockholder known by us to own beneficially more than five percent of our common stock.

 

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Shares of common stock that may be acquired by an individual or group within 60 days of January 25, 2024, pursuant to the exercise of options or warrants and convertible debt are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group. Percentage of ownership is based on 6,094,644 shares of common stock outstanding on January 25, 2024 and 6,881,582 after giving effect to the sale of 786,938 shares in this offering.

 

Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them, based on information provided to us by such stockholders. Unless otherwise indicated, the address of all listed stockholders is c/o Bullfrog AI Holdings, Inc., 325 Ellington Blvd., Unit 317, Gaithersburg, MD 20878.

 

Name of Beneficial Owner  Common Stock Beneficially Owned  

Percentage of

Common Stock Before Offering

   Percentage of Common Stock After Offering (1) 
Directors and Officers:               
                

Vininder Singh (2)

Chief Executive Officer and Director

   2,618,779    42.97%   37.27%
                

Dane Saglio (3)

Chief Financial Officer

   108,642    1.76%   1.54%
                
R. Don Elsey (4)   21,110    *    * 
                
William Enright (5)   21,110    *    * 
                
Jason Hanson (6)   21,110    *    * 
                
All officers and directors (5 persons)   2,790,721    44.53%   39.71%
                
Beneficial owners of more than 5%               
                
Tivoli Trust (7)   904,391    13.02%   11.52%

 

*represents less than 1%.

 

(1) Assumes (i) no exercise by the underwriter of its option to purchase additional shares of common stock to cover over-allotments, if any; (ii) no exercise of the Warrants; and (iii) 786,938 shares of common stock sold in this offering.
(2) Comprised of (i) 2,592,446 shares of common stock and (ii) 26,333 shares of common stock issuable upon exercise of common stock purchase stock options at an exercise price of $3.89 per shares.
(3) Comprised of (i) 47,142 shares of common stock and (ii) 61,500 shares of common stock issuable upon exercise of common stock purchase stock options at a weighted average exercise price of $3.00 per share.
(4) Includes 21,110 shares of common stock issuable upon exercise of stock options at an exercise price of $6.82 per share.
(5) Includes 21,110 shares of common stock issuable upon exercise of stock options at an exercise price of $6.82 per share.
(6) Includes 21,110 shares of common stock issuable upon exercise of stock options at an exercise price of $6.82 per share.
(7) Comprised of (i) 73,449 shares of non-voting Series A Preferred Stock, (ii) 115,185 warrants exercisable at $2.50 per share of common stock, and (iii) 54,714 shares of common stock related to two convertible debt instruments that converted at a discount to the IPO price. Assumes the conversion of all Series A Preferred Stock into common stock in an amount equal to ten shares of common stock for each one share of Series A Preferred Stock.

 

58
 

 

SHARES ELIGIBLE FOR FUTURE RESALE

 

Future sales of substantial amounts of our common stock in the public market or the perception that such sales might occur could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our common stock in the public market after the restrictions lapse. This may adversely affect the prevailing market price of our common stock and our ability to raise equity capital in the future.

 

After completion of this Offering, we will have 6,881,582 shares of common stock outstanding (or 6,999,622 shares if the underwriters’ option to purchase additional shares is exercised in full).

 

All of the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, unless the shares are purchased by our “affiliates” as that term is defined in Rule 144 and except certain shares that will be subject to the lock-up period described below after completion of this offering. Any shares owned by our affiliates may not be resold except in compliance with Rule 144 volume limitations, manner of sale and notice requirements, pursuant to another applicable exemption from registration or pursuant to an effective registration statement.

 

Any of the shares held by our directors, officers and holders of at least 10% of the Company’s outstanding securities will be subject to a ninety (90) day lock-up restriction described under “Underwriting” on page 60. Accordingly, there will be a corresponding increase in the number of shares that become eligible for sale after the lock-up period expires. As a result of these agreements, subject to the provisions of Rule 144 or Rule 701, shares will be available for sale in the public market as follows:

 

  beginning on the date of this prospectus, all of the shares sold in this offering will be immediately available for sale in the public market (except as described above);
  beginning ninety (90) days after this offering is completed, at the expiration of the lock-up period for our officers, directors and holders of at least 10% of the Company’s outstanding securities, 3,695,112 additional shares will become eligible for sale in the public market, all of which shares will be held by affiliates and subject to the volume and other restrictions of Rule 144 and Rule 701 as described below.

 

Company Warrants

 

The registration statement of which this prospectus is a part also registers for sale warrants to purchase up to 786,938 shares of common stock (or 904,978 shares of common stock if the underwriter exercises its over-allotment option in full). The Company Warrants will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date and have an assumed initial exercise price equal to $7.29.

 

Pre-funded Warrants

 

The registration statement of which this prospectus is a part also registers for sale Pre-Funded Warrants to purchase up to 786,938 shares of common stock for an assumed offering price of $6.629 per warrant (the combined price per Company Share and Company Warrant being sold to the public in this Offering, minus $0.001). The Pre-Funded Warrants will be exercisable immediately upon issuance, may be exercised at any time until all of the Pre-Funded Warrants are exercised in full, and have an initial exercise price equal to $0.001. Please see “Description of Capital Stock - Pre-funded Warrants” for a description of these warrants.

 

Underwriter’s Warrants

 

In addition to cash compensation, we have agreed to issue to the underwriter warrants to purchase an amount of shares of common stock equal to 6% of the aggregate number of Company Shares and/or Pre-funded Warrants issued in this Offering (excluding shares sold to cover over-allotments, if any). The Underwriter’s Warrants have an exercise price per share of $7.29 (110% of the combined public offering price of each Company Share and Company Warrant) assuming a combined public offering price of $6.63 per Company Share and Company Warrant. The Underwriter’s Warrants will be exercisable from time to time, in whole or in part, during the five-year period commencing 180 days from the closing of this Offering. We have registered up to 47,216 shares of common stock issuable upon the exercise of the Underwriter’s Warrants in the registration statement of which this prospectus is a part (excluding shares sold to cover over-allotments, if any).

 

59
 

 

Rule 144

 

In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of Rule 144.

 

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of the lock-up agreements described above, within any three-month period, a number of shares that does not exceed the greater of:

 

  1% of the number of shares of our common stock then outstanding, which will equal approximately shares immediately after this offering; or
     
  the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale.

 

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

 

Rule 701

 

Rule 701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701 and are subject to the lock-up agreements described above.

 

UNDERWRITING

 

WallachBeth Capital LLC is acting as the sole book-running manager and the representative of the underwriters of this Offering (the “Representative”). Subject to the terms and conditions of the underwriting agreement between us and the Representative, we have agreed to sell to the underwriters and the underwriters have agreed to purchase from us, at the combined public offering price per Company Share and accompanying Company Warrant, less the underwriting discounts set forth on the cover page of this prospectus, the number of Company Shares and accompanying Company Warrants listed next to its name in the following table:

 

Underwriter 

Number

of Company Shares and Accompanying Company Warrants

 
WallachBeth Capital LLC         
      
Total     

 

The underwriters are committed to purchase all the Company Shares and accompanying Company Warrants offered by us other than those covered by the option to purchase additional Company Shares and accompanying Company Warrants described below, if they purchase any such securities. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters’ obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers’ certificates and legal opinions.

 

60
 

 

We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.

 

The underwriters are offering the Units, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

 

Over-allotment Option

 

We have granted the Representative of the underwriters an option to purchase from us, at the public offering price, less the underwriting discounts and commissions, up to an additional 118,040 Company Shares (and/or Pre-funded Warrants issued in lieu of Company Shares), and/or 118,040 Company Warrants, in any combination thereof, less the underwriting discounts and commissions, within 45 days from the date of this prospectus to cover over-allotments, if any.

 

Discount and Commissions; Expenses

 

We have agreed to pay the underwriter a cash fee equal to eight percent (8%) of the aggregate sales price of securities sold. The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.

 

  

Per Company Share and accompanying Company Warrant

  

Total

Without Over-

Allotment

Option

  

Total

With Over-

Allotment

Option

 
Public offering price  $                  $            $           
Underwriting discount (8%)  $    $    $  
Proceeds, before expenses, to us  $    $    $  

 

The underwriters propose to offer the Company Shares and accompanying Company Warrants offered by us to the public at the combined public offering price per Company Share and accompanying Company Warrant set forth on the cover of this prospectus. In addition, the underwriters may offer some of the securities to other securities dealers at such price less a concession of $0.53 per Company Share and accompanying Company Warrant. If all of the Company Shares offered by us are not sold at the combined public offering price, the underwriters may change the combined offering price and other selling terms by means of a supplement to this prospectus.

 

We have also agreed to reimburse the underwriters for reasonable out-of-pocket expenses not to exceed $115,000 in the aggregate whether or not there is a closing of this offering. We estimate that total expenses payable by us in connection with this offering, other than the underwriting discount will be approximately $258,091. In addition, we have also agreed to pay to the underwriters a non-accountable expense allowance in the amount of 1% of the gross offering amount (including shares purchased upon exercise of the over-allotment option).

 

The underwriting agreement, however, provides that in the event the offering is terminated, any advance expense deposits paid to the underwriters will be returned to the extent that offering expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).

 

Underwriter’s Warrants

 

As additional compensation to the underwriter, upon consummation of this offering, we will issue to the Representative or its designees warrants to purchase an aggregate number of shares of our common stock equal to 6% of the number of Company Shares issued in this Offering (excluding any shares sold to cover over-allotments, if any), at an exercise price per share equal to 110% of the public offering price (the “Underwriter’s Warrants”).

 

The Underwriter’s Warrants and the underlying shares of common stock will not be exercised, sold, transferred, assigned, pledged or hypothecated or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Underwriter’s Warrants by any person for a period of 180 days from the effective date of the registration statement (the “Effective Date”) for this Offering in accordance with FINRA Rule 5110(e)(1). The Underwriter’s Warrants will be exercisable, in whole or in part, commencing 180 days from the closing of this Offering and will expire on the fifth anniversary thereof. We have registered the Underwriter’s Warrant and up to 47,216 shares of common stock issuable upon the exercise of the Underwriter’s Warrants in the registration statement of which this prospectus is a part.

 

Right of Participation

 

We have granted to the Representative a right of participation whereby, for a period of nine (9) months from the closing of this Offering, the Company will grant to the Representative the right to act as lead underwriter or book-running manager or placement agent for each and every future public and private equity and debt offerings of the Company, or any successor to or any subsidiary of the Company in any U.S. stock exchange during such nine (9) month period, according to the mechanism to be agreed upon by the parties in the placement agency agreement. The right of first participation shall only be in effect if the Offering results in gross proceeds of at least $4,500,000.

 

61
 

 

Discretionary Accounts

 

The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

 

Indemnification

 

We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.

 

Determination of Offering Price

 

The public offering price set forth on the cover page of this prospectus has been determined based upon arm’s-length negotiations between the underwriter and us based upon, among other things, the trading of our shares of common stock prior to the Offering.

 

Lock-Up Agreements

 

We and each of our officers, directors, and 10% or greater stockholders have agreed, subject to certain exceptions, not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock for a period of ninety (90) days after this offering is completed without the prior written consent of the Representative. The lock-up will not prevent the scheduled sale of any shares by the Company’s chief executive officer pursuant to his 10b-5 plan.

 

The Representative may in its sole discretion and at any time without notice release some or all of the shares subject to lock-up agreements prior to the expiration of the lock-up period. When determining whether or not to release shares from the lock-up agreements, the Representative will consider, among other factors, the security holder’s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.

 

62
 

 

Price Stabilization, Short Positions and Penalty Bids

 

In connection with this offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids in accordance with Regulation M under the Exchange Act:

 

  Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum.

 

  Over-allotment involves sales by the underwriters of securities in excess of the number of securities the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted by the underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any covered short position by either exercising its over-allotment option and/or purchasing securities in the open market.

 

  Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared to the price at which they may purchase securities through the over-allotment option. A naked short position occurs if the underwriters sell more securities than could be covered by the over-allotment option. This position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in this offering.

 

  Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when securities originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.

 

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of the securities. As a result, the price of our shares of common stock and warrants may be higher than the price that might otherwise exist in the open market. These transactions may be discontinued at any time.

 

Neither we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our shares of common stock and warrants. In addition, neither we nor the underwriters make any representation that the underwriters will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.

 

Electronic Offer, Sale and Distribution of Shares

 

A prospectus in electronic format may be made available on a website maintained by the Representative and may also be made available on a website maintained by other underwriters. The underwriters may agree to allocate a number of shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the Representative to underwriters that may make Internet distributions on the same basis as other allocations. In connection with the offering, the underwriters or syndicate members may distribute prospectuses electronically. No forms of electronic prospectus other than prospectuses that are printable as Adobe® PDF will be used in connection with this offering.

 

The underwriters have informed us that they do not expect to confirm sales of shares offered by this prospectus to accounts over which they exercise discretionary authority.

 

Other than the prospectus in electronic format, the information on any underwriter’s website and any information contained in any other website maintained by an underwriter is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter and should not be relied upon by investors.

 

63
 

 

Trading; Nasdaq Capital Market Listing

 

Our common stock and tradeable warrants are listed on The Nasdaq Capital Market under the symbols “BFRG” and “BFRGW,” respectively. We have not applied, and do not intend to apply, to list the Pre-Funded Warrants or the Company Warrants on Nasdaq.

 

Other Relationships

 

From time to time, the underwriters and/or their affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services it has received and, may in the future receive, customary fees. Except for the services provided in connection with this Offering and other than as described below, the underwriters have not provided any investment banking or other financial services during the 180-day period preceding the date of this prospectus.

 

Offers Outside the United States

 

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

 

EXPERTS

 

The financial statements of Bullfrog AI Holdings, Inc. for the fiscal years ended December 31, 2022 and 2021, as set forth in this prospectus and elsewhere in the registration statement have been so included in reliance on the reports herein of M&K CPAs, an independent registered public accounting firm, given on their authority as experts in accounting and auditing.

 

LEGAL MATTERS

 

Sichenzia Ross Ference Carmel LLP, New York, New York, will pass upon the validity of the shares of our common stock to be sold in this offering. Sheppard, Mullin, Richter & Hampton LLP, New York, New York, will pass upon certain legal matters for the underwriters.

 

64
 

 

WHERE YOU CAN FIND ADDITIONAL INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the exhibits, schedules and amendments to the registration statement. For further information with respect to us and our securities, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.

 

The SEC maintains a website, which is located at www.sec.gov, that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SEC’s website.

 

Upon completion of this offering, we will be subject to the information reporting requirements of the Securities Exchange Act of 1934, and we will file reports, proxy statements and other information with the SEC. All documents filed with the SEC are available for inspection and copying at the public reference room and website of the SEC referred to above. We maintain a website at www.bullfrogai.com. You may access our reports, proxy statements and other information free of charge at this website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information on such website is not incorporated by reference and is not a part of this prospectus.

 

65
 

 

BULLFROG AI HOLDINGS, INC.

INDEX TO FINANCIAL STATEMENTS

 

Audited Financial Statements for the Years Ended December 31, 2022 and 2021  
Report of Independent Registered Public Accounting Firm F-2
Consolidated Balance Sheets F-3
Consolidated Statements of Operations F-4
Consolidated Statements of Shareholders’ Deficit F-5
Consolidated Statements of Cash Flows F-6
Notes to Consolidated Financial Statements F-7

 

Unaudited Condensed Consolidated Financial Statements for the Three and Nine Months Ended September 30, 2023 and 2022  
Condensed Consolidated Balance Sheets F-21
Condensed Consolidated Statements of Operations F-22
Condensed Consolidated Statements of Changes in Stockholders’ Deficit F-23
Condensed Consolidated Statements of Cash Flows F-24
Notes to Condensed Consolidated Financial Statements F-25

 

F-1

 

 

BULLFROG AI HOLDINGS, INC.

AUDITED FINANCIAL STATEMENTS

2022 and 2021

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of Bullfrog AI Holdings, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Bullfrog AI Holdings, Inc. (the Company) as of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the years ended December 31, 2022 and 2021, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021 and the results of its operations and its cash flows for flows for the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

 

As discussed in Note 2, the Company had a going concern disclosure in the previous year due to continued net losses from operations and negative cash flows in operations. Auditing management’s evaluation of a going concern can be a significant judgment given the fact that the Company uses management estimates on future revenues and expenses, which are difficult to substantiate.

 

We evaluated the appropriateness of the removal of the going concern, we examined and evaluated the financial information along with management’s plans to mitigate the going concern and management’s disclosure on going concern.

 

/s/ M&K CPAS, PLLC  
   
We have served as the Company’s auditor since 2021.  
Houston, Texas  
April 25, 2023  

 

F-2

 

 

BULLFROG AI HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

 

   December 31   December 31 
   2022   2021 
   (Audited)   (Audited) 
ASSETS          
           
CURRENT ASSETS:          
Cash  $57,670   $10,014 
Prepaid expense   15,000    - 
Total Current Assets  $72,670   $10,014 
           
NON-CURRENT ASSETS:          
Property and Equipment, net   7,699    - 
Total Non-Current Assets  $7,699    - 
           
TOTAL ASSETS  $80,369   $10,014 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable  $543,993   $68,594 
Accrued expenses   416,072    68,557 
Accrued expenses-related party   566,916    285,666 
Deferred revenue   32,000    10,000 
Notes payable-related party   -    49,000 
Convertible notes, net of $0 and $12,962 debt discount, respectively   1,323,890    284,038 
Convertible notes-related party, net of $0 and $1,584 debt discount, respectively   254,850    253,266 
Total Current Liabilities  $3,137,721   $1,019,121 
           
TOTAL LIABILITIES  $3,137,721   $1,019,121 
           
STOCKHOLDERS’ DEFICIT:          
Series A Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 and 0 shares are issued and outstanding, respectively,   1    - 
Common stock, $0.00001 par value, 100,000,000 shares authorized; 4,021,935 and 4,622,789 shares are issued and outstanding as of December 31, 2022 and 2021, respectively   40    46 
           
Additional paid-in capital   1,341,662    587,415 
Accumulated deficit   (4,399,055)   (1,596,568)
Total BullFrog stockholders’ deficit  $(3,057,352)  $(1,009,107)
           
TOTAL STOCKHOLDERS’ DEFICIT   (3,057,352)   (1,009,107)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $80,369   $10,014 

 

The accompanying notes are an integral part of these financial statements

 

F-3

 

 

BULLFROG AI HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

           
   For Years Ended December 31 
   2022   2021 
         
NET REVENUES:          
Revenues, net  $10,000   $- 
TOTAL NET REVENUES  $10,000    - 
           
COST OF GOODS SOLD:          
Cost of goods sold   800    - 
TOTAL COST OF GOODS SOLD   800    - 
           
GROSS PROFIT   9,200    - 
           
OPERATING EXPENSES:          
Research and development expenses   609,270    25,000 
General and administrative expenses   

1,307,882

    327,329 
Payroll and salary   98,250    - 
Payroll and salary-related party   449,599    203,033 
TOTAL OPERATING EXPENSES   2,465,001    555,362 
           
(LOSS) FROM OPERATIONS   (2,455,801)   (555,362)
           
OTHER INCOME (EXPENSE):          
Interest expense   (347,145)   (40,395)
Other Income   459    9,917 
TOTAL OTHER (EXPENSE)   (346,686)   (30,478)
           
NET  (LOSS)   (2,802,487)   (585,840)
           
NET (LOSS) PER COMMON SHARE:          
Basic and diluted  $(0.70)  $(014)
           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:          
Basic and diluted   4,009,852    4,116,336 

 

The accompanying notes are an integral part of these financial statements

 

F-4

 

 

BULLFROG AI HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIENCY) EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

   Shares   Amount   Shares   Amount   Capital   Receivables   Deficit   Total 
   Series A Preferred stock   Common Stock  

Additional

Paid in

   Subscription   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Receivables   Deficit   Total 
                                 
Balances, December 31, 2020   -   $-    3,603,422   $36   $470,274   $(100)  $(1,010,728)  $(540,518)
                                         
Cash from subscription receivables   -    -    -    -    -    100    -    100 
                                         
Warrants issued with convertible notes   -    -    -    -    13,661    -    -    13,661 
                                         
Imputed Interest   -    -    -    -    4,539    -    -    4,539 
                                         
Equity compensation   -    -    -    -    9,385    -    -    9,385 
                                         
Equity compensation   -    -    1,019,367    10    89,556    -    -    89,566 
                                       - 
Net (Loss)   -    -    -    -    -    -    (585,840)   (585,840)
                                         
Balances, December 31, 2021   -   $-    4,622,789   $46   $587,415    -   $(1,596,568)  $(1,009,107)
                                         
Imputed Interest   -    -    -    -    9,221    -    -    9,221 
                                         
Equity compensation   -    -    -    -    340,152    -    -    340,152 
                                         
Conversion of convertible notes   -    -    205,984    2    226,136    -    -    226,138 
                                         
Reclassification of warrant   -    -    -    -    (11,097)   -    -    (11,097)
                                         
Shares cancellation   -    -    (112,225)   (1)   1    -    -    - 
                                         
Shares issuance for license   -    -    39,879    -    189,828    -    -    189,828 
                                         
Common stocks converted to Series A Preferred stock   73,449    1    (734,492)   (7)   6    -    -    - 
                                         
Net (Loss)   -    -    -    -    -                   -    (2,802,487)   (2,802,487)
                                         
Balances, December 31, 2022   73,449    1    

4,021,935

   $40    1,341,662   $-   $(4,399,055)  $(3,057,352)

 

The accompanying notes are an integral part of these financial statements

 

F-5

 

 

BULLFROG AI HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

 

   2022   2021 
   For The Years Ended December 31 
   2022   2021 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net (loss)  $(2,802,487)  $(585,840)
Adjustment to reconcile change in net (loss) to net cash and cash equivalents used in operating activities:          
Gain on debt forgiveness   -    (9,917)
Depreciation expense   1,045    - 
Shares issuance for license   189,828    - 
Stock-based compensation   340,152    98,951 
Amortization of debt discount   214,429    12,665 
Imputed Interest   9,221    4,539 
           
Changes in operating assets and liabilities:          
Prepaid Expense   (15,000)   - 
Accounts payable   475,399    (25,853)
Accrued expenses   373,273    27,384 
Accrued expenses-related party   281,250    85,666 
Deferred revenue   22,000    10,000 
           
NET CASH USED IN OPERATING ACTIVITIES   (910,890)   (382,405)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of Property and Equipment   (8,744)   - 
           
NET CASH FROM INVESTING ACTIVITIES   (8,744)   - 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from convertible notes payables   1,016,290    - 
Proceeds from convertible notes payables-related party   -    298,900 
Repayment of note payable and interest-related party   (49,000)   - 
Proceeds from notes payables - related party   -    88,400 
Proceeds from subscription payable   -    100 
           
NET CASH FROM FINANCING ACTIVITIES   967,290    387,400 
           
Net increase/(decrease) in cash and cash equivalents   47,656    4,995 
           
Cash, beginning of year   10,014    5,019 
           
Cash, end of period  $57,670   $10,014 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $5,757   $- 
Cash paid for taxes  $-   $- 
           
SUPPLEMENTAL DISCLOSURE of NON-CASH ACTIVITY:          
Reclassification of warrant  $11,097   $- 
Conversion of Convertible Note payable  $226,138   $- 
Cancellation of common stocks  $8   $- 
Shares issued for license  $189,828   $- 
Shares issued for services  $340,152   $20 
Warrants issued with convertible notes  $-   $13,661 

 

The accompanying notes are an integral part of these financial statements

 

F-6

 

 

BULLFROG AI HOLDINGS, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2022 and 2021

 

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Bullfrog AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development.

 

Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.

 

We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

 

The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for an a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.

 

Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings.

 

NOTE 2–SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

 

Use of Estimates in the Preparation of Financial Statements

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates.

 

F-7

 

 

Financial Instruments

 

The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments.

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:

 

Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

 

Revenue Recognition

 

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had no revenue. In Q4 2022 the Company recognized its first service revenues in the amount of $10,000 related to the achievement of a contract milestone under a contract with a Pharmaceutical company. In compliance with the agreement, we have met the following milestones – receipt of data for analysis; data conversion and staging for ingestion. For the years-ended December 31, 2022 and 2021, our balance sheet reflects customer down payment received in early 2022 and late 2021 as unearned revenue in the amount of $32,000 and $10,000, respectively. This unearned revenue represents payments received from a leading rare disease non-profit organization under a contract with a single deliverable. As is more fully discussed below, we are of the opinion that none of our contracts for products contain significant financing components that require revenue adjustment under FASB ASC Topic 606.

 

Revenue is recognized based on the following five step model:

 

  -

Identification of the contract with a customer

This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services

  -

Identification of the performance obligations in the contract

This step describes how distinct performance obligations in the contract must be handled

  -

Determination of the transaction price

This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer

  -

Allocation of the transaction price to the performance obligations in the contract

This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services

  -

Recognition of revenue when, or as, the Company satisfies a performance obligation

Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen

 

F-8

 

 

Contract Services

 

The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis.

 

Collaborative Arrangements

 

The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement.

 

Acquisition of Rights to Certain Drugs

In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

 

Cash

 

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $57,670 and $10,014, respectively.

 

Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

 

F-9

 

 

Accounts Receivable

 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

 

Allowance for Doubtful Accounts

 

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $0.

 

 

Inventories

 

The Company does not have inventory and does not plan to have inventory in the near future.

 

Cost of Sales

 

Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $800 as cost of goods sold which represents the 8% royalty on the $10,000 in service revenue in 2022.

 

Property and Equipment

 

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.

 

Advertising

 

The Company follows the policy of charging the costs of advertising to expense as incurred.

 

Income Taxes

 

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits.

 

Stock-Based Compensation

 

Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.

 

Net Loss per Share

 

We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, 927,373 and 753,174 warrants (post reverse stock split) were not included in the calculation of net loss per share, respectively. In addition, 486,571 and 56,242 options for common shares (post reverse stock split) were not included in the calculation of net loss per share, respectively.

 

F-10

 

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.

 

We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

 

The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842.

 

All staff are working remotely; therefore, the Company does not currently have a lease or rent office space.

 

Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate.

 

The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.

 

In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes.

 

In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements.

 

F-11

 

 

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

 

COVID-19

 

In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders.

 

Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services.

 

It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period.

 

The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock.

 

Going Concern

 

The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.

 

NOTE 3 – PROPERTY AND EQUIPMENT

 

 

Property and equipment consisted of the following:

 

During the year ended December 31, 2022, the Company acquired $8,744 of equipment and has accumulated depreciation of $1,045, for a net of $7,699.

 

Depreciation expense totaled $1,045, and $0 in the years ended December 31, 2022 and 2021, respectively.

 

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

 

As of December 31, 2022 and 2021, the Company had accounts payable and accrued expenses totaling $1,526,981 and $422,817, respectively.

 

NOTE 5 –NOTES PAYABLE

 

 

On May 5, 2020 the Company received an SBA PPP loan in the amount of $9,917, at 1% interest. The loan was forgiven on March 15, 2021.

 

NOTE 6 –NOTES PAYABLE RELATED PARTY

 

 

On June 15, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $34,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan and interest was repaid in 2022.

 

On November 19, 2021, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $5,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan and interest was repaid in 2022.

 

On December 13, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $10,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan and interest was repaid in 2022.

 

F-12

 

 

NOTE 7 – CONVERTIBLE NOTES PAYABLE

 

On March 27, 2020, the company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $200,000 at 6% interest. The maturity date of the loan was September 27, 2021. During the year ended December 31, 2022, the full amount of the loan and interest totaling $226,138 was converted into 205,984 shares of common stock (post reverse stock split) of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest divided by $5,000,000 times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion, being within the terms of the agreement.

 

On August 9, 2021, the company entered into a convertible loan agreement with an unrelated party to loan up to $195,000 at 9% interest, with a principal balance of $72,000, as of December 31, 2021. This loan included an original issuance discount of 5%, and included 195,000 Warrants at an exercise price of $1, exercisable for 5 years from the issue date on the face of the Warrant. The noteholder has the right to convert the principal and interest into common shares of the Company. The maturity date of the loan was February 9, 2022. During the year ended December 31, 2022, another $123,000 principal with an additional $6,150 original issuance discount, was loaned to the Company. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and entered into a new agreement for 225,000 warrants with an exercise price of $2.50. As of December 31, 2022, the loan was outstanding with a principal balance of $195,000, accrued interest of $35,078, amortization of debt discount of $8,393, and unamortized debt discount of $0. The warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and new warrants in accordance with the new terms were issued. We assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants. During the year ended December 31, 2022 the Company recorded an expense of $64,978.

 

On December 20, 2021, the company entered into a loan agreement with an unrelated party, with a principal balance of $25,000 at 6% interest. The maturity date of the loan was December 19, 2022. During the year ended December 31, 2022, the note principal was increased by $2,778 representing a 10% original issue discount pursuant to the enhanced terms mentioned below. As of December 31, 2022, the loan remained outstanding had accrued interest of $2,301. The loan was converted to common stock in February 2023 in connection with the Company IPO. Initially, the loan was estimated to be issued with 355,114 warrants. Subsequent to the entry into the December 20, 2021 the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $1M in face value of convertible bridge notes, as described in footnote 13. Pursuant to the enhanced terms, the warrants will not be issued until the note converts.

 

On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. As discussed in Footnote 2, a significant component of the Company’s plan to secure capital is the intention of the Company to seek to be listed on a national exchange through an initial public offering (“IPO”) of its common stock. WallachBeth was engaged in this regard and on April 28, 2022, the Company received net proceeds of approximately $775,000 from the sale of Convertible Bridge Notes and Warrants to several institutional investors as well as several individual accredited investors. In connection with the April 28th note sale, the Company paid approximately $91,560 in fees and expenses. In addition to the money received on April 28th, the Company also received $100,000 from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company sold one additional bridge note to an unrelated party, with a principal balance of $27,779. The Convertible Bridge Notes were issued with a 10% original issue discount and are convertible at the IPO at a 20% discount to the IPO price. The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price. The Convertible Bridge Notes maturity date was October 31, 2022. The Company has amended the Convertible Bridge Notes to extend the maturity date until December 31, 2022. The Company has filed an S-1 Registration Statement and conducted an IPO in February 2023. All of the Convertible Bridge Notes and accrued interest through November, 30, 2022 were converted at the IPO. Pursuant to further amendments to the notes, the maturity date was extended, interest accrued after November 30, 2022 though conversion will be paid to the holders in cash and the conversion right was revised to be equal to a $25 million dollar Company valuation, or $4.27, which was also established as the warrant exercise price.

 

As of December 31, 2022, the table below reflects the balances of the Convertible Bridge Notes sold pursuant April 11, 2022 agreement with WallachBeth. All notes are mandatorily converted at the IPO at the conversion ratio noted above and the purchasers will also be issued a warrant for each share of common stock issued upon conversion with an exercise price set by the exchange ratio. Due to the IPO price not yet being probable at year end, no current accounting for these warrants has been journalized.

 

F-13

 

 

Note Date   Purchase Price   Principal Balance   Original Issue Discount   Accrued Interest 
Note   Purchase   Principal   Original Issue   Accrued 
Date   Price   Balance   Discount   Interest 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $25,000   $27,778   $2,778   $1,708 
4/28/2022   $28,000   $31,111   $3,111   $1,913 
4/28/2022   $28,000   $31,111   $3,111   $1,913 
4/28/2022   $35,000   $38,889   $3,889   $2,392 
12/20/2021*   $25,000   $27,778   $2,778   $2,301 
4/13/2022*   $100,000   $111,111   $11,111   $7,111 
9/9/2022   $25,000   $27,778   $2,778   $1,088 
                      
Total   $1,016,000   $1,128,889   $112,889   $69,675 

 

* Notes sold by Company prior to the April 28, 2022 closing

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. The Company specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, if the equity securities underlying the conversion option are not readily convertible to cash, and the conversion option requires gross physical settlement of the underlying shares, the embedded conversion option may not meet the net settlement criterion, and therefore would not meet the definition of a derivative. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes. All conversions are contingent upon an effective IPO, which had not yet been considered probable.

 

NOTE 8 – CONVERTIBLE NOTES PAYABLE RELATED PARTY

 

On July 8, 2021, the company entered into a Simple Agreement for Future Equity (SAFE), with a related party, with an amount of $150,000, with 0% interest. Under the SAFE agreement, if there is an Equity Financing before the termination of this SAFE, on the initial closing of such Equity Financing, this SAFE will automatically convert into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, which means either: (1) the Safe Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation results in a greater number of shares of Safe Preferred Stock

 

If there is a Liquidity Event before the termination of this SAFE, this SAFE will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds, due and payable to the Investor immediately prior to, or concurrent with, the consummation of such Liquidity Event, equal to the greater of (i) the Purchase Amount (the “Cash-Out Amount”) or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the “Conversion Amount”). If any of the Company’s securityholders are given a choice as to the form and amount of Proceeds to be received in a Liquidity Event, the Investor will be given the same choice, provided that the Investor may not choose to receive a form of consideration that the Investor would be ineligible to receive as a result of the Investor’s failure to satisfy any requirement or limitation generally applicable to the Company’s securityholders, or under any applicable laws.

 

This SAFE will automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this SAFE) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this SAFE under agreement; or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to the agreement.

 

F-14

 

 

As of December 31, 2022 and 2021, the $150,000 received from SAFE was recorded at 6% imputed interest. The maturity date of the loan is defined by the SAFE agreement as discussed above.

 

On August 19, 2021, the company entered into a convertible loan agreement with a related party, with a principal balance of $99,900 at 9% interest. The noteholder has the right to convert the principal and interest into common shares of the Company. This loan included an original issuance discount of 5% and included 99,900 Warrants at an exercise price of $1, exercisable for 5 years from the issue date on the face of the Warrant. The maturity date of the loan was February 19, 2022. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and entered into a new agreement for 115,185 warrants with an exercise price of $2.50. As of December 31, 2022, the $99,900 principal and the $4,950 overpayment of the note remained outstanding and had accrued interest of $12,463.53. The warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and new warrants in accordance with the new terms were issued. We assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

 

The SAFE and the convertible loan agreement with accrued interest converted to common stock at the IPO.

 

The Company specified that an entity should adopt ASU 2020-06 as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, no derivative liabilities will be triggered from these convertible notes. See Note 7 for details.

 

NOTE 9 –RELATED PARTY

 

During the year-ended December 31, 2021, there were 57,143 shares of common stock (post reverse stock split) issued to CFO Dane Saglio, for services rendered.

 

As of December 31, 2022 and 2021, the accrued salary for related parties was $566,916 and $285,666, respectively. The increase reflects salaries accrued for employees, but not paid in the year ended December 31, 2022.

 

As of December 31, 2022, the Company accrued consulting fees to related parties of $90,000 for services provided to the Company.

 

During the year ended December 31, 2021, the Company issued options totaling 29,286 shares of common stock (post reverse stock split) to related party for services rendered. The options have an original life of ten years and vest at different rates over as much as 24 months. During the year ended December 31, 2022, the Company did not issue any options and recognized $1,803 of stock-based compensation related to outstanding stock options.

 

NOTE 10– SHAREHOLDER’S DEFICT

 

 Preferred Stock

 

The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.00001. As of December 31, 2021, there were no preferred shares issued. On October 5, 2022, the Company entered into an exchange agreement with the Investor whereby all of his common stock, 734,492 shares of commons stock (post reverse stock split), were exchanged into 73,449 shares of Series A Convertible Preferred Stock (post reverse stock split). Per the agreement the exchange was based on a 1 Series A Convertible Preferred Stock for each 10 shares of common stock. Each holder of Series A Preferred Stock may, from time to time, convert any or all of such holder’s shares of Series A Preferred Stock into fully paid and nonassessable shares of Common Stock in an amount equal to ten shares of common stock for each one share of Series A Preferred Stock surrendered. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. The Company evaluated the terms of the exchange and determined there would be no significant change in fair value and therefore no accounting entry recorded as a result of the exchange. The value of the Series A Preferred Stock was determined to be $315,000 which is the Investor’s basis in the common stock that was exchanged.

 

Common Stock

 

In June of 2020, BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock. Share amounts in our financial statements for December 31, 2022 and 2021, have been adjusted to reflect this forward share split and shares exchange. All of our operations are currently conducted through BullFrog AI Holdings, Inc. BullFrog AI, Inc., is a wholly owned subsidiary, has the sole purpose of housing and protecting all of the organization’s intellectual property. BullFrog AI Management, LLC is a wholly owned subsidiary that handles all HR and payroll activities.

 

The Company has 100,000,000 shares of common stock authorized at a par value of $0.00001. During year ended December 31, 2022, 734,492 shares of common stock (post reverse stock split) were exchanged for preferred shares as noted above, 205,984 shares of common stock (post reverse stock split) were issued for conversion of principal and interest of $226,138 by a noteholder, 112,225 shares of common stock (post reverse stock split) were canceled as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and 38,879 shares of common stock (post reverse stock split) were issued under a license agreement and valued at $189,828, see Note 12 for further discussion. As of December 31, 2022 and 2021, there are 4,021,935 and 4,622,789, shares of common stock (post reverse stock split) outstanding, respectively.

 

F-15

 

 

After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances.

 

Our Board of Directors and stockholders approved an amendment to our Certificate of Incorporation to effect a 1-for-7 reverse stock split of our common stock in connection with the offering, subsequent to the year ended December 31, 2022. As a result of the reverse stock split, every 7 shares of our outstanding common stock will be combined and reclassified into one share of our common stock. Unless otherwise noted, the share and per share information in this Form 10-K filing reflects, other than in our historical financial statements and the notes thereto, a proposed reverse stock split of the outstanding common stock of the Company at an assumed 1-for-7 ratio.

 

Stock Options

 

During the first quarter of 2022, 399,354 shares of options (post reverse stock split) were forfeited due to the termination of employment.

 

During the year ended December 31, 2021, the Company granted a total of 29,286 shares of options (post reverse stock split) to employees of the Company for services rendered. The options have an original life of ten years and vest at different rates over as much as 48 months. During the years ended December 31, 2021, the Company vested 1,310 of these options (post reverse stock split) and recognized $157 of stock-based compensation related to outstanding stock options. During the year ended December 31, 2022, 16,601 shares of these options (post reverse stock split) were vested and $2,010 stock-based compensation was recognized.

 

The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021:

 

Granted and outstanding, December 31, 2020   884,821 
Granted during 2021   29,286 
Exercised   - 
Forfeited   - 
Expired during 2021   (445,536)
Granted and outstanding, December 31, 2021   468,571 
Granted during 2022   - 
Exercised   - 
Forfeited   (399,354)
Expired during 2022   - 
Granted and outstanding, December 31, 2022   69,217 

 

   Options   Intrinsic Value of Vested Options   Weight Averaged exercise Price 
Vested and outstanding, December 31, 2020   104,795    12,706    3.36 
Granted and vested during 2021   1,310    157    2.66 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   (66,524)   (7,922)   (3.36)
Vested and outstanding, December 31, 2021   39,581    4,941    3.36 
Granted and vested during  2022   16,661    2,010    2.73 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   -    -    - 
Vested and outstanding, December 31, 2022   56,242    6,951    3.15 

 

As of December 31, 2022 and 2021, 16,661 and 1,310 options (post reverse stock split) vested, respectively, 0 and 66,524 (post reverse stock split) options expired and the outstanding stock options have a weighted average remaining life of 7.08 and 7.38 years, respectively.

 

As of December 31, 2022 and 2021, the fair value of options vested and outstanding was $ 6,951 and $4,941, respectively. The aggregate fair value of the options measured during the year ended December 31, 2022 and 2021 was calculated using the Black-Scholes option pricing model based on the following assumption:

 

   December 31, 2022   December 31, 2021 
Fair Value of Common Stock on measurement date  $4.76   $0.308 
Risk free interest rate   From 0.79% to 3.01%   From 1.26% to 1.33%
Volatility   89%   93%
Dividend Yield   0%   0%
Expected Term   4-10    10 

 

(1)The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
 (2)The trading volatility was determined by calculating the volatility of the Company’s peer group.
 (3)The Company does not expect to pay a dividend in the foreseeable future.

 

F-16

 

 

Warrants

 

During the year ended December 31, 2022, the Company granted a total of 123,660 warrants (post reverse stock split). The warrants have an original life of four to ten years and vest immediately and over 12 months. During the year ended December 31, 2022, 174,105 shares of warrants (post reverse stock split) were vested and amended with an intrinsic value of $337,269, 51,941 shares of warrants (post reverse stock split) were reclassified with an intrinsic value of $11,097, and 42,057 shares of warrants (post reverse stock split) with an intrinsic value of $1,883 were forfeited.

 

During the year ended December 31, 2021, the Company granted a total of 431,659 warrants (post reverse stock split). Of this amount 200,000 warrants (post reverse stock split), with a fair value of $12,462, were granted to advisors related to the Company’s IPO objective. The warrants have an original life of five years and vest 30 days before the intended IPO. During the year ended December 31, 2021, 0 shares of these warrants were vested. As of June 30, 2022, the warrants for 200,000 shares (post reverse stock split) were cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. In 2021, 138,929 warrants (post reverse stock split), with a fair value of $28,683, were issued for services rendered. The warrants have an original life of ten years and vest at different rates over as much as 36 months.

 

During the year ended December 31, 2021, the Company issued 92,859 warrants (post reverse stock split) with a fair value of $12,980, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of five years. During the period ending June 30, 2022, the Company determined that 50,735 warrants (post reverse stock split), with a fair value of $11,097, should not have been issued as further described in footnote 8. The fair value was reclassified to Additional Paid in Capital. As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous 99,000 warrants (post reverse stock split) and entered into a new agreement for 115,185 (post reverse stock split) and the exercise price increased to $2.50 from $1, with a fair value of $15,412. As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous 195,000 (post reverse stock split) warrants and entered into a new agreement for 225,000 warrants (post reverse stock split) with an exercise price of $2.50, with a fair value of $64,978.

 

The 92,859 warrants (post reverse stock split) discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and these individuals were or will be issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants.

 

The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021,

 

   Warrants 
Granted and outstanding, December 31, 2020   495,714 
Granted during 2021   431,659 
Exercised   - 
Forfeited   - 
Expired during 2021   - 
Granted and outstanding, December 31, 2021   927,373 
Granted during 2022   123,660 
Exercised   - 
Forfeited   (298,088)
Expired during 2022   - 
Granted and outstanding, December 31, 2022   752,945 

 

   Warrants   Intrinsic Value of Warrants   Weight Averaged exercise Price 
Vested and outstanding, December 31, 2020   479,940    127,480    0.98 
Granted and Vested 2021   137,552    22,208    3.15 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   -    -    - 
Vested and outstanding, December 31, 2021   617,492    149,688    2.80 
Granted and Vested 2022   174,105    337,263    3.15 
Exercised   -    -    - 
Forfeited   (94,665)   (12,980)   - 
Expired   -    -    - 
Vested and outstanding, December 31, 2022   696,932    473,971    1.96 

 

F-17

 

 

As of December 31, 2022, 752,945 warrants (post reverse stock split) are outstanding, and 696,932 warrants (post reverse stock split) vested, and the vested stock warrants have a weighted average remaining life of 7.13 years.

 

For the year ended December 31, 2022, the aggregate fair value of warrants vested was $324,283. The aggregate fair value of the warrants measured during the year ended December 31, 2022 was calculated using the Black-Scholes option pricing model and recorded as stock-based compensation.

 

For the year ended December 31, 2021, 927,516 warrants (post reverse stock split) are outstanding, 617,492 warrants (post reverse stock split) are vested with an intrinsic value of $22,208, and the vested stock warrants have a weighted average remaining life of 7.73 years.

 

As of December 31, 2021, the aggregate fair value of warrants vested was $149,688. The aggregate fair value of the warrants measured during the year-ended December 31, 2021 was calculated using the Black-Scholes option pricing model.

 

The number of warrants related to the Convertible Bridge Notes discussed Note 7 is not yet determinable, given some of the terms discussed in Note 8 have not been completed. Therefore, the warrants to be issued are not accounted for in our warrants outstanding. Due to the IPO price not being completed at December 31, 2022, no current accounting for these warrants has been journalized.

 

   December 31, 2022   December 31, 2021 
Fair Value of Common Stock on measurement date  $4.76   $0.308 
Risk free interest rate   From 1.86% to 1.97%   From 0.78% to 1.63%
Volatility   89%   93%
Dividend Yield   0%   0%
Expected Term   10 years    5-10 years 

 

(1)The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
 (2)The trading volatility was determined by calculating the volatility of the Company’s peer group.
 (3)The Company does not expect to pay a dividend in the foreseeable future.
 (4)After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances for all 2022 grant date stock prices.

 

Exercise Price   Expiration  Number of Warrants 
$0.0007   2030   274,286 
$2.10 - $2.66   2026 - 2032   460,445 
$3.36 - $4.27   2028 - 2029   115,277 
$6.51 - $7.80   2026 - 2032   1,484,929 
$8.125   2027 - 2028   1,461,227 
         3,796,164 

NOTE 11 – INCOME TAXES

 

As of December 31, 2022, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $4,399,055, that do not expire, that may be used to offset future taxable income, but could be limited under Section 382. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.

 

We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.

 

Tax position that meets the more likely than not threshold is then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. We file income tax returns in the U.S. and in the state of California and Utah with varying statutes of limitations.

 

The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following:

 

   2022   2021 
Non-Current deferred tax asset:          
Net operating loss carryforwards  $924,000   $339,000 
Valuation allowance   (924,000)   (339,000)
Net non-current deferred tax asset  $   $ 

 

F-18

 

 

NOTE 12 – MATERIAL AGREEMENTS

 

JHU-APL Technology License

 

On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, 1 new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an Amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five (5%) percent of the then fully diluted equity base of the Company, which shall be diluted following the closing of this offering. Under the terms of the License Agreement, JHU will be entitled to eight (8%) percent royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty (50%) percent of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual royalty payments are $20,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breech, the Company shall have 60 days to cure the material breech. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued 279,159 shares of common stock. (see note 10) Under the terms of the new License Agreement, JHU will be entitled to eight (8%) percent of net sales for the services provided by the Company to other parties and 3% for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $30,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond. As of December 31, 2022, we have accrued, $30,000 of the 2022 minimum annual royalty payments. See Note 10 for details on common shares and warrants issued related to this agreement.

 

George Washington University - Beta2-spectrin siRNA License

 

On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

 

In consideration of the rights granted to the Company under the License Agreement GWU received a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of December 31, 2022, there has been no accrual for royalties, since we have not begun revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

Johns Hopkins University – Mebendazole License

 

On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to mebendazole at any dose during the trial. 41.7% of patients who received mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021).

 

F-19

 

 

The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $250,000. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three- and one-half percent (3.5%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $5,000 for 2023, $10,000 for 2024, $20,000 for 2025, $30,000 for 2026 and $50,000 for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $250,000. The initial payment for $50,000 was paid and the remaining balance is deferred until the earlier of; we complete the IPO, raise $10 million in financing or until 9 months from the effective date of the license. As of December 31, 2022, the balance of accrued expense related to this license agreement was $242,671. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

Johns Hopkins University – Prodrug License

 

On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (4.0%) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $5,000 for 2027, $10,000 for 2028, $20,000 for 2029, $30,000 for 2030 and $50,000 for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $150,000. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of December 31, 2022, the balance of accrued expense related to this license agreement was $133,238. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

NOTE 13 – COMMITMENTS AND CONTINGENCIES

 

The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

 

NOTE 14 – SUBSEQUENT EVENTS

 

On February 14, 2023 the Company conducted its initial public offering of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per unit for a total of approximately $8.4 million of gross proceeds to the Company. Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share, and one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125. The offering closed on February 16, 2023.

 

In connection with the offering, the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock. Also, in connection with the IPO a SAFE and convertible loan agreement held by a related party converted into 55,787 shares of post reverse common stock. Additionally, all outstanding Convertible Bridge Notes and accrued interest through November 30, 2022 were converted into 276,289 shares common stock and 276,289 warrants to purchase common stock were issued to the Convertible Bridge Note holders at conversion. The Bridge Note conversions and the warrant exercise pricing was determined using a $25 million dollar company valuation immediately before the IPO.

 

Between April 5 and April 13, 2023, the holders of warrants exercised 436,533 warrants for common shares at various exercise prices and the Company received proceeds of approximately $1,495,000.

 

F-20

 

 

Bullfrog AI Holdings, Inc.

Condensed Consolidated Balance Sheets

As of September 30, 2023 and December 31, 2022

(Unaudited)

 

   September 30, 2023   December 31, 2022 
         
Assets          
Current assets:          
Cash and cash equivalents  $3,856,037   $57,670 
Prepaid expenses   352,433    15,000 
Total current assets   4,208,470    72,670 
           
Property and equipment, net   6,406    7,699 
Total assets  $4,214,876   $80,369 
           
Liabilities and Stockholders’ Deficit          
Current liabilities:          
Accounts payable  $110,503   $543,993 
Accrued expenses   122,257    982,988 
Deferred revenue   -    32,000 
Short term insurance financing   213,290    - 
Convertible notes   -    1,323,890 
Convertible notes - related party   -    254,850 
Total current liabilities   446,050    3,137,721 
           
Stockholders’ deficit:          
Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding, as of September 30, 2023 and December 31, 2022.   1    1 
Common stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 and 4,021,935 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.   61    40 
Additional paid-in capital   12,226,742    1,341,662 
Accumulated deficit   (8,457,978)   (4,399,055)
Total stockholders’ deficit   3,768,826    (3,057,352)
Total liabilities and stockholders’ deficit  $4,214,876   $80,369 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

F-21

 

 

Bullfrog AI Holdings, Inc.

Condensed Consolidated Statements of Operations

For the Three Months and Nine Months Ended September 30, 2023 and 2022

(Unaudited)

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Revenue:                    
Revenue, net  $65,000   $-   $65,000   $- 
Total revenue   65,000    -    65,000    - 
                     
Cost of goods sold:                    
Cost of goods sold   5,200    -    5,200    - 
Total cost of goods sold   5,200    -    5,200    - 
                     
Gross profit   59,800    -    59,800    - 
                     
Operating expenses:                    
Research and development   380,015    39,421    1,023,619    448,375 
General and administrative   983,929    601,131    3,067,940    1,424,383 
Total operating expenses   1,363,944    640,552    4,091,559    1,872,758 
                     
Loss from operations   (1,304,144)   (640,552)   (4,031,759)   (1,872,758)
                     
Other income (expense), net                    
Interest expense, net   (5,758)   (124,159)   (76,880)   (234,668)
Loss on conversion of notes   -    -    (92,959)   - 
Other (expense) income, net   56,924    18    142,675    457 
Total other income (expense), net   51,166    (124,141)   (27,164)   (234,211)
Net loss  $(1,252,978)  $(764,693)  $(4,058,923)  $(2,106,969)
                     
Net loss per common share attributable to common stockholders - basic and diluted  $(0.21)  $(0.16)  $(0.72)  $(0.45)
Weighted average number of shares outstanding - basic and diluted   6,094,644    4,752,959    5,667,997    4,669,952 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

F-22

 

 

Bullfrog AI Holdings, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

For the Three Months Ended September 30, 2023 and December 31, 2022

(Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
   Series A Preferred Stock   Common Stock   Additional Paid-in    Accumulated    Total Stockholders’  
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance at December 31, 2022   73,449   $1    4,021,935   $40   $1,341,662   $(4,399,055)  $(3,057,352)
Stock-based compensation   -    -    -    -    127,450    -    127,450 
Issuance of common stock (initial public offering), net of issuance cots   -    -    1,297,318    13    7,293,638    -    7,293,651 
Issuance of common stock for services   -    -    7,692    1    49,999    -    50,000 
Conversion of convertible debt to common stock   -    -    331,166    3    1,535,612    -    1,535,615 
Net loss   -    -    -    -    -    (1,325,547)   (1,325,547)
Balance at March 31, 2023   73,449    1    5,658,111    57    10,348,361    (5,724,602)   4,623,817 
Stock-based compensation        -         -    262,267         262,267 
Issuance of common stock pursuant to warrant exercises             436,533    4    1,494,654         1,494,658 
Net loss                            (1,480,398)   (1,480,398)
Balance at June 30, 2023   73,449    1    6,094,644    61    12,105,282    (7,205,000)   4,900,344 
Stock-based compensation        -         -    121,460         121,460 
Net loss                            (1,252,978)   (1,252,978)
Balance at September 30, 2023   73,449   $1    6,094,644   $61   $12,226,742   $(8,457,978)  $3,768,826 
                                    
Balance at December 31, 2021   -   $-    4,622,789   $46   $587,415   $(1,596,568)   (1,009,107)
Imputed interest   -    -    -    -    2,360    -    2,360 
Stock-based compensation   -    -    -    -    30,017    -    30,017 
Reclassification of warrant   -    -    -    -    (11,097)   -    (11,097)
Net loss   -    -    -    -    -    (566,359)   (566,359)
Balance at March 31, 2022   -    -    4,622,789    46    608,695    (2,162,927)   (1,554,186)
Imputed interest   -    -    -    -    2,361    -    2,361 
Stock-based compensation   -    -    -    -    209,323    -    209,323 
Conversion of convertible notes   -    -    205,984    2    226,136    -    226,138 
Shares cancellation   -    -    (112,225)   (1)   1    -    - 
Net loss   -    -    -    -    -    (775,917)   (775,917)
Balance at June 30, 2022   -    -    4,716,548    47    1,046,516    (2,938,844)   (1,892,281)
Imputed interest   -    -    -    -    2,250    -    2,250 
Stock-based compensation   -    -    -    -    51,536    -    51,536 
Shares issuance for license   -    -    39,879    -    189,828    -    189,828 
Net loss   -    -    -    -    -    (764,693)   (764,693)
Balance at September 30, 2022   -   $-    4,756,427   $47   $1,290,130   $(3,703,537)  $(2,413,360)

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

F-23

 

 

Bullfrog AI Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2023 and 2022

(Unaudited)

 

   2023   2022 
   Nine Months Ended September 30, 
   2023   2022 
Cash flows from operating activities:          
Net loss  $(4,058,923)  $(2,106,969)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   1,293    604 
Stock-based compensation   511,177    290,876 
Shares issued for license   -    189,828 
Shares issued for services   50,000    - 
Loss on conversion of notes   92,959    - 
Amortization of debt discount   20,000    174,998 
Imputed interest   -    6,971 
Changes in operating assets and liabilities:          
Prepaid expense   (337,433)   (15,000)
Accounts payable   (433,490)   51,946 
Accrued expenses   (796,865)   409,502 
Accrued expenses - related party   -    104,000 
Deferred revenue   (32,000)   22,000 
Net cash used in operating activities   (4,983,282)   (871,244)
           
Cash flows from investing activities:          
Purchases of property and equipment   -    (8,744)
Net cash used in investing activities   -    (8,744)
           
Cash flows from financing activities:          
Proceeds from issuance of common stock (initial public offering), net of issuance costs   7,293,651    - 
Proceeds from exercise of warrants   1,494,658    - 
Proceeds from convertible notes payable   -    961,190 
Proceeds from notes payable   100,000    - 
Payments of notes payable   (319,950)   - 
Repayment of note payable and interest - related party   -    (49,000)
Proceeds net of payments short term insurance financing   213,290    - 
Net cash provided by financing activities   8,781,649    912,190 
           
Net increase in cash and cash equivalents   3,798,367    32,202 
           
Cash and cash equivalents, beginning of period   57,670    10,014 
Cash and cash equivalents, end of period  $3,856,037   $42,216 
           
Supplemental cash flow information:          
Cash paid for interest  $93,916   $4,399 
Cash paid for taxes   -    - 
           
Supplemental non-cash activity          
Reclassification of warrant  $-   $11,097 
Issuance of common stock upon conversion of notes payable  $1,535,615   $- 
Conversion of convertible note payable  $-   $226,138 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

F-24

 

 

Bullfrog AI Holdings, Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

 

1. Organization and Nature of Business

 

Description of the Business

 

Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through Bullfrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development.

 

Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.

 

We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

 

The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.

 

Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in-house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings.

 

Liquidity and Going Concern

 

The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). We believe that the funds raised and notes that were converted from debt to equity in connection with the IPO now provide enough liquidity to fund operations beyond 9 months from the date of this filing.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation.

 

F-25

 

 

The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows.

 

The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period.

 

On February 13, 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.

 

Revenue Recognition

 

The Company recognizes revenue based on the following five step model:

 

- Identification of the contract with a customer
  This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.
- Identification of the performance obligations in the contract
  This step describes how distinct performance obligations in the contract must be handled.
- Determination of the transaction price
  This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer.
- Allocation of the transaction price to the performance obligations in the contract
  This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services.
- Recognition of revenue when, or as, the Company satisfies a performance obligation
  Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.

 

Contract Services

 

The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.

 

Significant Accounting Policies

 

There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

Impact of Recently Issued Accounting Standards

 

The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.

 

F-26

 

 

3. Notes Payable Related Party

 

At various times in 2021, the Company entered into unsecured short term loan agreements with a related party for an aggregate principal balance of $49,000, each with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loans and interest was repaid in 2022.

 

4. Convertible Notes

 

March 2020 Note

 

On March 27, 2020, the Company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $200,000 at 6% interest. The maturity date of the loan was September 27, 2021. During the year ended December 31, 2022, the full amount of the loan and interest totaling $226,138 was converted into 205,984 shares of common stock of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest, divided by $5,000,000, times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion being within the terms of the agreement.

 

August 2021 Note

 

In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $195,000 with a 5% original issue discount and a 9% interest rate. The loan provided for a maturity date of February 9, 2022. We borrowed $72,000 and $123,000 of principal in the years ended December 31, 2021 and 2022, respectively. The noteholder had the right to convert the principal and interest into common shares of the Company at the IPO at a 20% discount to the IPO price.

 

As December 31, 2022, the loan was outstanding with a principal balance of $195,000 and accrued interest of $35,078. The loan was paid in its entirety in February 2023.

 

In connection with the convertible loan agreement, the Company also issued 195,000 Warrants with an exercise price of $1.00 exercisable for five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void the warrants and enter into a new agreement for 225,000 warrants with an exercise price of $2.50. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

 

December 2021 Note

 

On December 20, 2021, the Company entered into a loan agreement with an unrelated party. The loan provided for a December 19, 2022 maturity, a 10% original issue discount and a 6% interest rate. The Company received $25,000 of proceeds from this note.

 

The note was automatically convertible into shares of common stock at a discount to the IPO price or based on the valuation of the Company, whichever was more favorable to the holder.

 

Initially, the loan was estimated to be issued with 355,114 warrants. Subsequent to the closing of the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $1 million in face value of convertible bridge notes. Pursuant to the enhanced terms, the warrants were issued concurrently with the conversion of the note.

 

Concurrent with the closing of the Company’s IPO, the note converted according to its terms into 6,939 shares of common stock. No gain or loss was recognized on the conversion.

 

Convertible Bridge Notes

 

On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. On April 28, 2022, the Company received approximately $775,000 of proceeds, net of approximately $91,000 of fees and a 10% original issue discount from the sale of Convertible Bridge Notes and Warrants to several institutional investors and several individual accredited investors. In addition, the Company also received $100,000 from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company received an additional $25,000 of proceeds, net of a 10% original issue discount from the sale of an additional Convertible Bridge Note and Warrant to an unrelated party.

 

F-27

 

 

The Convertible Bridge Notes were initially convertible at the IPO at a 20% discount to the IPO price. The Convertible Bridge Notes provided for an original maturity date of October 31, 2022.

 

In connection with the Convertible Bridge Notes, the purchasers were also entitled to conditional warrants to be issued upon completion of the Company’s IPO. The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price.

 

In the fourth quarter of 2022, the Company amended the Convertible Bridge Notes to (a) extend the maturity date until December 31, 2022, (b) provide that the conversion right would include interest through November 30, 2022, with interest accruing beyond that date being paid in cash and (c) revise the conversion price to be $4.27 based on a $25 million Company valuation. Additionally, the exercise price of the warrants was revised to $4.27.

 

Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into 269,513 shares of common stock. No gain or loss was recognized on the conversion.

 

5. Convertible Notes – Related Party

 

SAFE Agreement

 

On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, at a purchase price of $150,000. The SAFE provided for no interest and terminated after conversion upon completion of the Company’s IPO. The SAFE provided for automatic conversion into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, defined as either: (1) the SAFE Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation results in a greater number of shares of SAFE Preferred Stock.

 

In February 2023, the SAFE terminated and converted into 32,967 shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $63,626 loss on the conversion.

 

As of December 31, 2022, the $150,000 received from the SAFE was recorded at 6% imputed interest.

 

August 2021 Note

 

On August 19, 2021, the Company entered into a convertible loan agreement with a related party, with a principal balance of $99,900, an original issuance discount of 5% and a 9% interest rate. The loan provided for a maturity date of February 19, 2022. The noteholder had the right to convert the principal and interest into common shares of the Company at a conversion price based on a discount to the IPO price.

 

In February 2023, the related party elected to convert the convertible loan into 21,747 shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $29,333 loss on the conversion.

 

In connection with the convertible loan agreement, the Company also issued 99,000 Warrants with an exercise price of $1.00 exercisable for five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and enter into a new agreement for 115,185 warrants with an exercise price of $2.50. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

 

F-28

 

 

6. Notes Payable

 

In January 2023 the Company entered into a short-term note payable with a principal balance of $100,000, an original discount of 20% and a 9% interest rate. The note was paid in its entirety in February 2023.

 

In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $697,534 of the premium, repayments in 10 equal monthly installments of $71,485 each through December 2023 and accrued interest at 6.5%. The balance outstanding at September 30, 2023 was $213,290. The related balance of the premium of $307,735 is included in prepaid expenses.

 

7. Related Party

 

During the nine months ended September 30, 2023, the Company issued 75,000 stock options to its Chief Financial Officer for services rendered.

 

During the year ended December 31, 2021, the Company issued 29,286 common stock options to related parties for services rendered. The options have an original life of 10 years and vest over different periods for up to 24 months. During the three months ended September 30, 2023 and 2022, the Company recognized $430 and $450, respectively, of stock-based compensation related to these options. During the nine months ended September 30, 2023 and 2022, the Company recognized $1,290 and $1,350, respectively, of stock-based compensation related to these options.

 

8. Stockholder’s Equity

 

Preferred Stock

 

The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.00001 with 5,500,000 being designated as Series A Convertible Preferred Stock. On October 5, 2022, the Company entered into an exchange agreement with an Investor providing for the exchange of 734,492 shares of commons stock into 73,449 shares of Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock is convertible at any time into 10 shares of the Company’s common stock. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. The Company evaluated the terms of the exchange and determined there was no significant change in fair value and therefore the Series A Preferred Stock was valued at $315,000 which is the Investor’s basis in the common stock that was exchanged.

 

Common Stock

 

The Company has 100,000,000 shares of common stock authorized at a par value of $0.00001. During the year ended December 31, 2022, the Company:

 

  Exchanged 734,429 shares of common stock for shares of Series A Convertible Preferred stock as noted above,
  Issued 205,984 shares of common stock pursuant to a conversion of $226,138 worth of convertible notes principal and interest,
  Cancelled 112,225 shares of common stock as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and
  Issued 38,879 shares of common stock pursuant to a license agreement valued at $189,828.

 

After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances.

 

F-29

 

 

In February 2023, the Company completed its IPO for the sale of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per Unit for a total of approximately $8.4 million of gross proceeds. Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share, and one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.

 

In connection with the completion of its IPO, the Company issued an aggregate of 331,166 shares of common stock upon the conversion of certain outstanding convertible debt.

 

In connection with the IPO, in February 2023, the Company completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.

 

In February 2023, the Company issued 7,692 shares of common stock for consulting services and recognized $50,000 of compensation expense related to these shares.

 

In the second quarter of 2023, we issued 436,533 shares of common stock following the exercise of 436,533 warrants for proceeds of $1,494,658.

 

Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of September 30, 2023, 3,796,164 warrants and 507,717 options for common shares were excluded in the calculation of net loss per share. As of September 30, 2022, 5,270,617 warrants and 484,525 options for common shares were excluded in the calculation of net loss per share.

 

2022 Equity Incentive Plan

 

In November 2022, the Company’s Board of Directors adopted, and its shareholders approved the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of 10 years and any exercise prices shall not be less than 100% of the fair market value of one share of common stock on the grant date. The Plan authorizes an initial maximum number of shares underlying awards of 900,000 with an automatic annual 15% increase beginning in 2024. As of September 30, 2023, there were 461,500 awards authorized but unissued available under the Plan.

 

Stock Options

 

The following table summarizes the stock option activity for the nine months ended September 30, 2023:

 

   Number of Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2022   69,217   $3.06    7.08   $117,669 
Granted   438,500   $4.41    -   $- 
Exercised   -   $-    -   $- 
Forfeited / canceled   -   $-    -   $- 
Outstanding at September 30, 2023   507,717   $4.23    9.17   $102,441 
Vested at September 30, 2023   215,623   $3.97    8.64   $52,644 

 

F-30

 

 

The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below:

 

   2023 
Expected dividend yield   0%
Expected volatility   87% - 92%
Risk-free interest rate   3.4%-4.1%
Expected life (in  years)   5.0-6.0

 

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2023 was $3.20. No options were issued in the nine months ended September 30, 2022.

 

No options were exercised in any of the periods presented.

 

During the three and nine months ended September 30, 2023, the Company recognized $116,410 and $475,465, respectively of compensation expense related to stock options. During the three and nine months ended September 30, 2022, the Company recognized $51,536 and $290,876 of compensation expense, respectively related to stock options.

 

As of September 30, 2023, the total unrecognized compensation expense related to unvested stock options, was approximately $936,000, which the Company expects to recognize over a weighted-average period of approximately 2.1 years.

 

Warrants

 

During the nine months ended September 30, 2023 and 2022, the Company granted a total of 3,195,906 and 56,623 warrants, respectively. The warrants have an original life of ten years and vest immediately and over 12 months. During the nine months ended September 30, 2023, warrants to purchase 22,939 shares vested and had a fair value of $35,712. During the year ended December 31, 2022, 174,105 shares of warrants were vested and amended with a fair value of $337,269, 51,941 shares of warrants were reclassified with a fair value of $11,097, and 42,057 shares of warrants with a fair value of $1,883 were forfeited.

 

During the year ended December 31, 2021, the Company granted a total of 431,659 warrants. Of this amount, 200,000 warrants, with a fair value of $12,462, were granted to advisors related to the Company’s IPO objective. The warrants have an original life of five years and vest 30 days before the intended IPO. During the year ended December 31, 2021, 0 shares of these warrants were vested. As of June 30, 2022, the warrants for 200,000 shares were cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. In 2021, 138,929 warrants, with a fair value of $28,683, were issued for services rendered. The warrants have an original life of ten years and vest at different rates over as much as 36 months.

 

During the year ended December 31, 2021, the Company issued 92,859 warrants with a fair value of $12,980, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of five years. During the period ending June 30, 2022, the Company determined that 50,735 warrants, with a fair value of $11,097, should not have been issued. The fair value was reclassified to Additional Paid in Capital. In May 2022, the Company and the note holders agreed to cancel and void the previous 99,000 warrants and entered into a new agreement for 115,185 warrants and the exercise price increased to $2.50 from $1, with a fair value of $15,412. In May 2022, the Company and the note holders agreed to cancel and void the previous 195,000 warrants and entered into a new agreement for 225,000 warrants with an exercise price of $2.50, with a fair value of $64,978.

 

F-31

 

 

The 92,859 warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and these individuals were issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants.

 

During the nine months ended September 30, 2023, the Company issued the following warrants:

 

  In February 2023, in connection with the completion of the initial public offering, the Company issued 276,452 contingent warrants to certain debt holders with an exercise price of $4.27 and an expiration date 5 years from issuance.
  In February 2023, in connection with the completion of the initial public offering, the Company issued 18,000 contingent warrants as fees to the Company’s underwriters with an exercise price of $8.125 and an expiration date 4 years from issuance.
  As part of the sale of units in the Company’s initial public offering the Company issued 1,297,318 tradable warrants with an exercise price of $7.80 and an expiration date 5 years from issuance. Also, as part of the sale of units in the Company’s initial public offering, the Company issued 1,297,318 non-tradable warrants with an exercise price of $8.125 and an expiration date 5 years from issuance.
  In February 2023, as part of the Company’s initial public offering, the Company issued 153,409 tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $7.80 and an expiration date 5 years from issuance. Also in February 2023, as part of the Company’s initial public offering the Company issued 153,409 non-tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $8.125 and an expiration date 5 years from issuance.

 

During the three and nine months ended September 30, 2023, the Company recognized $5,050 and $35,712, respectively of compensation expense related to certain warrants. During the three and nine months ended September 30, 2022, the Company recognized $51,086 and $289,317 of compensation expense related to certain warrants. As of September 30, 2023, the total unrecognized compensation expense related to unvested warrants was $6,556, which the Company expects to recognize over a weighted-average period of approximately 0.4 years.

 

The following table provides details over the Company’s outstanding warrants as of September 30, 2023:

 

Exercise Price   Expiration  Number of Warrants 
$0.0007   2030   274,286 
$2.10 - $2.66   2026 - 2032   460,445 
$3.36 - $4.27   2028 - 2029   115,277 
$6.51 - $7.80   2026 - 2032   1,484,929 
$8.125   2027 - 2028   1,461,227 
         3,796,164 

 

9. Income Taxes

 

The Company has not recorded any tax provision or benefit for the three and nine months ended September 30, 2023 and 2022. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefits from deductible temporary differences, net operating loss carryforwards and research and development credits are not more-likely-than-not to be realized at September 30, 2023 and December 31, 2022.

 

F-32

 

 

10. Material Agreements

 

JHU-APL Technology License

 

On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five percent (5%) of the then fully diluted equity base of the Company, which shall be diluted following the closing of the IPO. Under the terms of the License Agreement, JHU will be entitled to eight percent (8%) royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty percent (50%) of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual royalty payments are $20,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breach, the Company shall have 60 days to cure the material breach. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights, and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued 279,159 shares of common stock. Under the terms of the new License Agreement, JHU will be entitled to eight percent (8%) of net sales for the services provided by the Company to other parties and three percent (3%) for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $30,000 for 2022, $60,000 for 2023, and $300,000 for 2024 and beyond.

 

On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $275,000. The first of these payments for $75,000 was due in July 2023 followed by payments of $75,000, $75,000 and $50,000 in years 2025, 2026 and 2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $60,000, all other financial terms remain the same. As of September 30, 2023, we have accrued $45,000 of the 2023 minimum annual royalty payments.

 

George Washington University - Beta2-spectrin siRNA License

 

On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

 

In consideration of the rights granted to the Company under the License Agreement the Company paid GWU a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, there has been no accrual for royalties since we have not begun to generate applicable revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

F-33

 

 

Johns Hopkins University – Mebendazole License

 

On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021).

 

The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $250,000. The initial payment for $50,000 was paid and the remaining balance of $200,000 was paid after the Company completed its IPO. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three and one-half percent (3.5%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $5,000 for 2023, $10,000 for 2024, $20,000 for 2025, $30,000 for 2026 and $50,000 for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, the balance of accrued expense related to this license agreement was $7,500 and $242,671, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

Johns Hopkins University – Prodrug License

 

On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (4.0%) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $5,000 for 2027, $10,000 for 2028, $20,000 for 2029, $30,000 for 2030 and $50,000 for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $150,000. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, the balance of accrued expense related to this license agreement was $0 and $133,238, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

F-34

 

 

PROSPECTUS

 

BULLFROG AI HOLDINGS, INC.

 

Up to 786,938 Shares of Common Stock

Warrants to Purchase up to 786,938 shares of Common Stock

786,938 shares underlying the Warrants

Pre-Funded Warrants to Purchase up to 786,938 shares of Common Stock

786,938 shares underlying the Pre-Funded Warrants

 

WALLACHBETH CAPITAL LLC

 

     , 2024

 

Through and including             , 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

 

 

 

 

PART II — INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13. Other Expenses of Issuance and Distribution

 

The following table sets forth an itemization of the various expenses, all of which we will pay, in connection with the issuance and distribution of the securities being registered. All of the amounts shown are estimated except the SEC Registration Fee and the FINRA filing fee.

 

SEC registration fee   $ 1,591  
FINRA filing fee   $ 2,500  
Legal fees and expenses   $ 235,000  
Accounting fees and expenses   $ 9,000  
Transfer agent and registrar fees   $ 5,000  
Miscellaneous fees and expenses   $ 5,000  
Total   $ 258,091  

 

Item 14. Indemnification of Directors and Officers

 

Nevada law provides that a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation (i.e., a “non-derivative proceeding”), by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he or she:

 

  Is not liable under Section 78.138 of the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation; or

 

  Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

 

In addition, a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor (i.e., a “derivative proceeding”), by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him or her in connection with the defense or settlement of the action or suit if he:

 

  Is not liable under Section 78.138 of the Nevada Revised Statute for breach of his or her fiduciary duties to the corporation; or

 

  Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation.

 

II-1

 

 

Under Nevada law, indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

 

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

 

To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any non-derivative proceeding or any derivative proceeding, or in defense of any claim, issue or matter therein, the corporation is obligated to indemnify him or her against expenses, including attorneys’ fees, actually and reasonably incurred in connection with the defense.

 

Further, Nevada law permits a Nevada corporation to purchase and maintain insurance or to make other financial arrangements on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him or her and liability and expenses incurred by him or her in his or her capacity as a director, officer, employee or agent, or arising out of his or her status as such, whether or not the corporation has the authority to indemnify him or her against such liability and expenses.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

 

The Company plans to enter into an underwriting agreement in connection with this offering that provides that the underwriter is obligated, under some circumstances, to indemnify the Company’s directors, officers and controlling persons against specified liabilities, including liabilities under the Securities Act.

 

Item 15. Recent Issuances of Unregistered Securities

 

In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act. The information provided below does not give effect to the proposed reverse stock split described in the accompanying prospectus.

 

II-2

 

 

On June 23, 2021, the Company signed two consulting/advisor agreements with entities engaged to facilitate the Company’s objective of seeking a public listing of its securities. Under these agreements, each advisor was to receive: (i) three (3%) percent of the fully diluted equity of the Company as measured by the equity table immediately prior to listing on NASDAQ or any other national securities exchange, with a true-up amount to be delivered within thirty (30) days prior to its expected listing day; and (ii) warrants with a term of five years to purchase 1,000,000 (in one case) and 400,000 shares of the Company’s Common Stock at $1.00 per share, which warrants will vest thirty (30) days prior to an expected going public transaction. Pursuant to these agreements, 817,786 shares of common stock were issued to each consultant as well as the above-mentioned warrants. In May 2022, these agreements were each amended so that one consultant (Newman) received 500,000 shares and the other advisor received 350,000 shares of common stock. All warrants were cancelled.,

 

In July 2021, the Company entered into a SAFE note agreement $150,000 with a related party. In August the Company entered into two bridge note agreements, one, in the amount of $99,900 with the same related party as the SAFE and the second with an unrelated party for $195,000. The notes were issued with a 5% original issuance discount and the purchasers received 115,185 and 225,000 warrant, respectively.

 

In November 2021, 400,000 shares of common stock were issued under a consulting agreement with Dane Saglio, for services consistent with the responsibilities of a Chief Financial Officer. In addition, a total of 972,500 warrants with exercises prices of $0.30-$0.38 were issued to consultants who have been engaged as Company management and advisors. These warrant agreements have vesting terms that range for 12 to 36 months. In addition, the Company issued 205,000 options to employees with an exercise price of $0.38 with vesting terms that range from 12 -24 months.

 

In December 2021, the Company initiated a placement of Bridge Notes seeking $1.5M in operating capital to ensure the Company had operating capital while it finished the audit of its financial statements and prepared the S-1 registration statement related to the IPO. In December, the Company sold a convertible promissory note to an unrelated party for $25,000. On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. As discussed in Footnote 2, a significant component of the Company’s plan to secure capital is the intention of the Company to seek to be listed on a national exchange through an initial public offering (“IPO”) of its common stock. WallachBeth was engaged in this regard and on April 28, 2022 the Company received net proceeds or approximately $775,000 from the sale of Convertible Bridge Notes and Warrants to several institutional investors as well as several individual accredited investors. In addition to the money received on April 28th, the Company also received $100,000 from the sale of a Convertible Bridge Note and Warrants to a related party in early April. The Company also received net proceeds of $20,000 from the sale of one additional Convertible Bridge Note in September 2022. The bridge notes are convertible at the IPO at a 20% discount to the IPO price and the purchasers will also a warrant for each share of common stock issued upon conversion. The warrant exercise price will be 90% of the per share IPO price.

 

II-3

 

 

Item 16. Exhibits and Financial Statement Schedules

 

(a) Exhibits

 

Exhibit No.   Description
1.1*   Form of Underwriting Agreement
3.1   Amended and Restated Articles of Incorporation of Bullfrog AI Holdings, Inc. incorporated by reference to Exhibit 3.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
3.2   Bylaws of Bullfrog AI Holdings, Inc. incorporated by reference to Exhibit 3.2 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
4.1*   Form of Company Warrant (included in Exhibit 4.3)
4.2*   Form of Underwriter Warrant
4.3*   Form of Warrant Agent Agreement
5.1*   Opinion of Sichenzia Ross Ference Carmel LLP
10.1   Acquisition Agreement with Bullfrog AI, Inc. incorporated by reference to Exhibit 10.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.2   Advisor Agreement between the Company and Greentree Financial Group, Inc. incorporated by reference to Exhibit 10.2 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.3   Consulting Agreement between the Company and Garrett Newman incorporated by reference to Exhibit 10.3 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.4+   Employment Agreement with Vininder Singh incorporated by reference to Exhibit 10.4 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.5   Patent License Agreement between the Company and George Washington University, dated January 14, 2022 incorporated by reference to Exhibit 10.6 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.6   Exclusive License Agreement between the Company and Johns Hopkins University, dated February 22, 2022 incorporated by reference to Exhibit 10.7 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.7   License Agreement between the Company and Johns Hopkins Applied Physics Laboratory LLC, dated July 8, 2022 incorporated by reference to Exhibit 10.8 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.8   License Agreement between the Company and Johns Hopkins Applied Physics Laboratory LLC, dated February 7, 2018 incorporated by reference to Exhibit 10.5 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.9   License Agreement between the Company and Johns Hopkins University (JHU) and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences, dated October 13, 2022 incorporated by reference to Exhibit 10.9 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
10.10   2022 Equity Compensation Plan incorporated by reference to Exhibit 10.10 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023
10.11   Amendment No. 1 to License Agreement between Bullfrog AI, Inc. and the John’s Hopkins University Applied Physics Laboratory LLC dated June 1, 2023 incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 5, 2023
10.12   Data Use and Technology Partnership Agreement dated September 7, 2023 incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 14, 2023
10.13++   Commercial Agreement by and between the Company and the Lieber Institute for Brain Development dated October 13, 2023 to the Company’s Current Report on Form 8-K, filed with the SEC on October 20, 2023
21.1   List of significant subsidiaries of Bullfrog AI Holdings, Inc., incorporated by reference to Exhibit 21.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
23.1*   Consent of M&K CPAS PLLC, an independent registered public accounting firm
23.2*   Consent of Sichenzia Ross Ference Carmel LLP (contained in its form of opinion filed as Exhibit 5.1 hereto)
24.1   Power of Attorney (included in signature page to this registration statement)
107*   Filing Fee Table

 

* Filed herewith
+ Management compensatory plan or arrangement required to be filed as an exhibit to this prospectus
++ Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the Company treats as private or confidential.

 

II-4

 

 

Item 17. Undertakings

 

(a) The undersigned registrant hereby undertakes:

 

  (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

  (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

 

  (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

 

  (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

 

  (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

  (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

II-5

 

 

  (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

  (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

  (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

  (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

  (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

  (b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

II-6

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on January 29, 2024.

 

  BULLFROG AI HOLDINGS, INC.
(Registrant)
     
  By: /s/ Vininder Singh
  Name: Vininder Singh
  Title: Chief Executive Officer (Principal Executive Officer)

 

POWER OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Vininder Singh and Dane Saglio, and each of them (with full power to each of them to act alone), his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and on his behalf and in his name, place and stead, in any and all capacities, to sign, execute and file this registration statement under the Securities Act of 1933, as amended, and any or all amendments (including, without limitation, post-effective amendments) to this registration statement, with all exhibits and any and all documents required to be filed with respect thereto, with the Securities and Exchange Commission or any other regulatory authority, granting unto such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing appropriate or necessary to be done in order to effectuate the same, as fully to all intents and purposes as he himself might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

 

Name   Title   Date
         
/s/ Vininder Singh   Chief Executive Officer and Director (Principal Executive Officer)   January 29, 2024
Vininder Singh        
         
/s/ Dane Saglio   Chief Financial Officer (Principal Financial and Accounting Officer)   January 29, 2024
Dane Saglio        
         
/s/ Don Elsey   Director   January 29, 2024
Don Elsey        
         
/s/ William Enright   Director   January 29, 2024
William Enright        
         
/s/ Jason Hanson   Director   January 29, 2024
Jason Hanson        

 

II-7

EX-1.1 2 ex1-1.htm

 

Exhibit 1.1

 

BULLFROG AI HOLDINGS, INC.

 

UNDERWRITING AGREEMENT

 

January ___, 2024

 

WallachBeth Capital LLC

Harborside Financial Center Plaza 5

185 Hudson Street, Ste 1410

Jersey City, NJ 07311

 

As Representative of the Several Underwriters Named on Schedule I hereto

 

Ladies and Gentlemen:

 

BULLFROG AI HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of [       ] shares (each, a “Firm Share” and in aggregate, the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), an aggregate of [      ] pre-funded warrants (each, a “Firm Pre-Funded Warrant,” and in the aggregate, the “Firm Pre-Funded Warrants”) to purchase one share of Common Stock (the “Firm Pre-Funded Warrant Shares”) at an exercise price of $[         ] until such time as the Pre-Funded Warrant is exercised in full, subject to adjustment as provided in the Pre-Funded Warrant, and an aggregate of [         ] warrants (each, a “Firm Warrant,” and in the aggregate, the “Firm Warrants”) to purchase one share of Common Stock (the “Firm Common Stock Warrant Shares” and together with the Firm Pre-Funded Warrant Shares, the “Firm Warrant Shares”) at an exercise price of $[      ] for a period of five (5) years, subject to adjustment as provided in the Warrant. The Firm Shares, Firm Pre-Funded Warrants and Firm Warrants are collectively referred to herein as the “Firm Securities.” The Company also proposes to grant to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, an option (the “Over-allotment Option”) to purchase up to an additional [       ] shares of Common Stock, representing up to fifteen percent (15%) of the Firm Shares sold in the offering (the “Option Shares”), and/or [        ] Warrants at a price of $0.01 per Warrant (the “Option Warrants”), or any combination thereof, in each case for the purpose of covering over-allotments of such securities, if any. The Option Warrants, Firm Pre-Funded Warrants and Firm Warrants are collectively referred to herein as the “Warrants”. The Over-allotment Option is, at the Underwriters’ sole discretion, for Option Shares and Option Warrants together, solely Option Shares, solely Option Warrants, or any combination thereof (each, an “Option Security” and collectively, the “Option Securities”). The Firm Securities and the Option Securities are collectively referred to as the “Securities.” The Securities shall be issued directly by the Company and shall have the rights and privileges described in the Registration Statement, the Pricing Prospectus and the Prospectus (as defined below). The offering and sale of the Securities is herein referred to as the “Offering.”

 

The Company and the several Underwriters hereby confirm their agreement as follows:

 

1. Registration Statement and Prospectus.

 

The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a registration statement covering the Securities (as defined in Section 4(f) hereof) on Form S-1 (File No. 333-[      ]) under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations (the “Rules and Regulations”) of the Commission thereunder, including a preliminary prospectus relating to the Securities and such amendments to such registration statement (including post effective amendments) as may have been required to the date of this Agreement. Such registration statement, as amended (including any post effective amendments), has been declared effective by the Commission. Such registration statement, including amendments thereto (including post effective amendments thereto) and all documents and information deemed to be a part of the Registration Statement through incorporation by reference or otherwise at the time of effectiveness thereof (the “Effective Time”), the exhibits and any schedules thereto at the Effective Time or thereafter during the period of effectiveness and the documents and information otherwise deemed to be a part thereof or included therein by the Securities Act or otherwise pursuant to the Rules and Regulations at the Effective Time or thereafter during the period of effectiveness, is herein called the “Registration Statement.” If the Company has filed or files an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term Registration Statement shall include such Rule 462 Registration Statement. Any preliminary prospectus included in the Registration Statement or filed with the Commission pursuant to Rule 424(a) under the Securities Act is hereinafter called a “Preliminary Prospectus.” The Preliminary Prospectus relating to the Securities that was included in the Registration Statement immediately prior to the pricing of the offering contemplated hereby is hereinafter called the “Pricing Prospectus.”

 

 -1- 
 

 

The Company is filing with the Commission pursuant to Rule 424 under the Securities Act a final prospectus covering the Securities, which includes the information permitted to be omitted therefrom at the Effective Time by Rule 430A under the Securities Act. Such final prospectus, as so filed, is hereinafter called the “Final Prospectus.” The Final Prospectus, the Pricing Prospectus and any preliminary prospectus in the form in which they were included in the Registration Statement or filed with the Commission pursuant to Rule 424 under the Securities Act is hereinafter called a “Prospectus.” Reference made herein to any Preliminary Prospectus, the Pricing Prospectus or to the Prospectus shall be deemed to refer to and include any documents incorporated by reference therein.

 

2. Representations and Warranties of the Company Regarding the Offering.

 

(a) The Company represents and warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date (as defined in Section 4(d) below) and as of each Option Closing Date (as defined in Section 4(b) below), as follows:

 

(i) No Material Misstatements or Omissions. At each time of effectiveness, at the date hereof, at the Closing Date, and at each Option Closing Date, if any, the Registration Statement and any post-effective amendment thereto complied or will comply in all material respects with the requirements of the Securities Act and the Rules and Regulations and did not, does not, and will not, as the case may be, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Time of Sale Disclosure Package (as defined below) as of the date hereof and at the Closing Date and on each Option Closing Date, any roadshow or investor presentations delivered to and approved by the Underwriter for use in connection with the marketing of the offering of the Securities (the “Marketing Materials”), if any, and the Final Prospectus, as amended or supplemented, as of its date, at the time of filing pursuant to Rule 424(b) under the Securities Act, at the Closing Date, and at each Option Closing Date, if any, did not, does not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences shall not apply to statements in or omissions from the Registration Statement, the Time of Sale Disclosure Package or any Prospectus in reliance upon, and in conformity with, written information furnished to the Company by the Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f). The Registration Statement contains all exhibits and schedules required to be filed by the Securities Act or the Rules and Regulations. No order preventing or suspending the effectiveness or use of the Registration Statement or any Prospectus is in effect and no proceedings for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission.

 

(ii) Marketing Materials. The Company has not distributed any prospectus or other offering material in connection with the offering and sale of the Securities other than the Time of Sale Disclosure Package and the roadshow or investor presentations delivered to and approved by the Representative for use in connection with the marketing of the offering of the Securities (the “Marketing Materials”).

 

 -2- 
 

 

(iii) Accurate Disclosure. (A) The Company has provided a copy to the Underwriters of each Issuer Free Writing Prospectus (as defined below) used in the sale of Securities. The Company has filed all Issuer Free Writing Prospectuses required to be so filed with the Commission, and no order preventing or suspending the effectiveness or use of any Issuer Free Writing Prospectus is in effect and no proceedings for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission. When taken together with the rest of the Time of Sale Disclosure Package or the Final Prospectus, no Issuer Free Writing Prospectus, as of its issue date and at all subsequent times though the completion of the public offer and sale of the Securities, has, does or will include (1) any untrue statement of a material fact or omission to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or (2) information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Final Prospectus. The representations and warranties set forth in the immediately preceding sentence shall not apply to statements in or omissions from the Time of Sale Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company by any Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f). As used in this paragraph and elsewhere in this Agreement:

 

(1) “Time of Sale Disclosure Package” means the Prospectus most recently filed with the Commission before the time of this Agreement, including any preliminary prospectus supplement deemed to be a part thereof, each Issuer Free Writing Prospectus, and the description of the transaction provided by the Underwriters included on Schedule II.

 

(2) “Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 under the Securities Act, relating to the Securities that (A) is required to be filed with the Commission by the Company, or (B) is exempt from filing pursuant to Rule 433(d)(5)(i) or (d)(8) under the Securities Act, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.

 

(B) At the time of filing of the Registration Statement and at the date hereof, the Company is an “ineligible issuer,” as defined in Rule 405 under the Securities Act.

 

(C) Each Issuer Free Writing Prospectus listed on Schedule III satisfied, as of its issue date and at all subsequent times through the Prospectus Delivery Period (as defined in Section 5(a) hereof), all other conditions as may be applicable to its use as set forth in Rules 164 and 433 under the Securities Act, including any legend, record-keeping or other requirements.

 

(iv) Financial Statements. The financial statements of the Company, together with the related notes and schedules, included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the Commission thereunder, and fairly present in all material respects the financial condition of the Company as of the dates indicated and the results of operations and changes in cash flows for the periods therein specified in conformity with U.S. generally accepted accounting principles (“GAAP”) consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP). No other financial statements, pro forma financial information or schedules are required under the Securities Act, the Exchange Act, or the Rules and Regulations to be included in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus.

 

(v) Pro Forma Financial Information. The pro forma financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus include assumptions that provide a reasonable basis for presenting the significant effects directly attributable to the transactions and events described therein, the related pro forma adjustments give appropriate effect to those assumptions, and the pro forma adjustments reflect the proper application of those adjustments to the historical financial statements amounts in the pro forma financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. The pro forma financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus comply as to form in all material respects with the application requirements of Regulation S-X under the Exchange Act.

 

 -3- 
 

 

(vi) Independent Accountants. To the Company’s knowledge, M&K CPAS, PLLC, which has expressed its opinion with respect to the audited financial statements and schedules included as a part of the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, is an independent public accounting firm with respect to the Company within the meaning of the Securities Act and the Rules and Regulations.

 

(vii) Accounting Controls. The Company will maintain a system of “internal control over financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by, or under the supervision of, its principal executive and principal financial officer, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

(viii) Forward-Looking Statements. The Company had a reasonable basis for, and made in good faith, each “forward-looking statement” (within the meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) contained or incorporated by reference in the Registration Statement, the Time of Sale Disclosure Package, the Final Prospectus or the Marketing Materials.

 

(ix) Statistical and Marketing-Related Data. All statistical or market-related data included or incorporated by reference in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived from sources that the Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources, to the extent required.

 

(x) Stock Exchange Listing. The shares of Common Stock have been approved for listing on The Nasdaq Capital Market (“Nasdaq”), and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from Nasdaq, nor has the Company received any written notification that Nasdaq is contemplating terminating such listing.

 

(xi) Absence of Manipulation. The Company has not taken, directly or indirectly, any action that is designed to or that has constituted or that would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.

 

(xii) Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Securities and the application of the net proceeds thereof, will not be an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended.

 

(b) Any certificate signed by any officer of the Company and delivered to the Underwriters or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.

 

 -4- 
 

 

3. Representations and Warranties Regarding the Company.

 

(a) The Company represents and warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date and as of each Option Closing Date, if any, as follows:

 

(i) Good Standing. The Company has been duly organized and is validly existing as a corporation or other entity in good standing under the laws of its jurisdiction of incorporation or organization. The Company has the power and authority (corporate or otherwise) to own its properties and conduct its business as currently being carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, and is duly qualified to do business as a foreign corporation or other entity in good standing in each jurisdiction in which it owns or leases real property or in which the conduct of its business makes such qualification necessary, except where the failure to so qualify would not have or be reasonably likely to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, or in its ability to perform its obligations under this Agreement, the Warrants, the Warrant Agreement (“Material Adverse Effect”).

 

(ii) Validity and Binding Effect of Agreements. This Agreement, the Warrants, the Warrant Agreement have been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

 

(iii) Contracts. The execution, delivery and performance of this Agreement, the Warrant Agreement, the Warrants and the consummation of the transactions herein and therein contemplated will not (A) result in a breach or violation of any of the terms and provisions of, or constitute a default under, any law, order, rule or regulation to which the Company is subject, or by which any property or asset of the Company is bound or affected, except to the extent that such conflict, breach or default is not reasonably likely to result in a Material Adverse Effect, (B) conflict with, result in any violation or breach of, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) (a “Default Acceleration Event”) of, any agreement, lease, credit facility, debt, note, bond, mortgage, indenture or other instrument (the “Contracts”) or obligation or other understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, except to the extent that such conflict, default, or Default Acceleration Event is not reasonably likely to result in a Material Adverse Effect, or (C) result in a breach or violation of any of the terms and provisions of, or constitute a default under, the Company’s Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”), or Amended and Restated Bylaws (“Bylaws”).

 

(iv) No Violations of Governing Documents. The Company is not in violation, breach or default under its Certificate of Incorporation, Bylaws or other equivalent organizational or governing documents.

 

(v) Consents. No consents, approvals, orders, authorizations or filings are required on the part of the Company in connection with the execution, delivery or performance of this Agreement, the Warrant Agreement, the Warrants and the issue and sale of the Securities, except (A) the registration under the Securities Act of the Securities and Representative’s Securities, which has been effected, (B) the necessary filings and approvals from Nasdaq to list the Securities and the shares of Common Stock underlying the Warrants (C) such consents, approvals, authorizations, registrations or qualifications as may be required under state or foreign securities or Blue Sky laws and the rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”) in connection with the purchase and distribution of the Securities by the several Underwriters, (D) such consents and approvals as have been obtained and are in full force and effect, and (E) such consents, approvals, orders, authorizations and filings the failure of which to make or obtain is not reasonably likely to result in a Material Adverse Effect.

 

 -5- 
 

 

(vi) Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. All of the issued and outstanding shares of capital stock of the Company are duly authorized and validly issued, fully paid and nonassessable, and have been issued in compliance with all applicable securities laws, and conform to the description thereof in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. Since the respective dates as of which information is provided in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company has not entered into or granted any convertible or exchangeable securities, options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company any shares of the capital stock of the Company. The Firm Securities and the Option Securities have been duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable, free and clear of all liens imposed by the Company; the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken; the shares of Common Stock issuable upon exercise of the Warrants have been duly authorized and reserved for issuance by all necessary corporate action on the part of the Company and when paid for and issued in accordance with the Warrant Agreement, such shares of Common Stock will be validly issued, fully paid and non-assessable; and the Securities and the Warrant Agreement conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus.

 

(vii) Taxes. The Company has (a) filed all foreign, federal, state and local tax returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof (except where the failure to file would not, individually or in the aggregate, have a Material Adverse Effect) and (b) paid all taxes (as hereinafter defined) shown as due and payable on such returns that were filed and has paid all taxes imposed on or assessed against the Company (except where the failure to pay would not, individually or in the aggregate, have a Material Adverse Effect). The provisions for taxes payable, if any, shown on the financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. To the knowledge of the Company, no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company, and no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company. The term “taxes” mean all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatever, together with any interest and any penalties, additions to tax, or additional amounts with respect thereto. The term “returns” means all returns, declarations, reports, statements, and other documents required to be filed in respect to taxes.

 

(viii) Material Change. Since the respective dates as of which information is given in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, and except as disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, (a) the Company has not incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock; (c) there has not been any change in the capital stock of the Company (other than a change in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants, upon the conversion of outstanding shares of preferred stock or other convertible securities, due to the vesting of outstanding stock grants or the issuance of restricted stock awards or restricted stock units under the Company’s existing stock awards plan, or any new grants thereof in the ordinary course of business), (d) there has not been any material change in the Company’s long-term or short-term debt, other than periodic accruals in the ordinary course pursuant to the terms of the Company’s outstanding debt, and (e) there has not been the occurrence of any Material Adverse Effect.

 

 -6- 
 

 

(ix) Absence of Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company’s knowledge, threatened against, or involving the Company or, to the Company’s knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus.

 

(x) Regulatory. Except as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus: (i) the Company has not received notice from any Governmental Entity (as defined below) alleging or asserting noncompliance with any Applicable Regulations (as defined below) or Authorizations (as defined below); (ii) the Company is and has been in material compliance with federal, state or foreign statutes, laws, ordinances, rules and regulations applicable to the Company (collectively, “Applicable Regulations”); (iii) the Company possesses all licenses, certificates, approvals, clearances, consents, authorizations, qualifications, registrations, permits, and supplements or amendments thereto required by any such Applicable Regulations and/or to carry on its businesses as now conducted (“Authorizations”) and such Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations; (iv) the Company has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product, operation or activity is in violation of any Applicable Regulations or Authorizations or has any knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, has there been any material noncompliance with or violation of any Applicable Regulations by the Company that could reasonably be expected to require the issuance of any such communication or result in an investigation, corrective action, or enforcement action by any Governmental Entity; and (v) the Company has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations or has any knowledge that any such Governmental Entity has threatened or is considering such action. Neither the Company nor, to the Company’s knowledge, any of its directors, officers, employees or agents has been convicted of any crime under any Applicable Regulations. “Governmental Entity” shall be defined as any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency (whether foreign or domestic) having jurisdiction over the Company or any of its properties, assets or operations.

 

(xi) Good Title. The Company has good and marketable title to all property (whether real or personal) described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus as being owned by it that are material to the business of the Company, in each case free and clear of all liens, claims, security interests, other encumbrances or defects, except those that are disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus and those that are not reasonably likely to result in a Material Adverse Effect. The property held under lease by the Company is held by it under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the business of the Company.

 

 -7- 
 

 

(xii) Intellectual Property. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (“Intellectual Property Rights”) necessary for the conduct of the business of the Company as currently carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. To the knowledge of the Company, no action or use by the Company necessary for the conduct of its business as currently carried on and as described in the Registration Statement and the Final Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. The Company has not received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other claims in this Section 3(a)(xii), reasonably be expected to result in a Material Adverse Effect; (C) the Intellectual Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 3(a)(xii) reasonably be expected to result in a Material Adverse Effect; (D) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 3(a)(xii), reasonably be expected to result in a Material Adverse Effect; and (E) to the Company’s knowledge, no employee of the Company is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company, or actions undertaken by the employee while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect. To the Company’s knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus and are not described therein. The Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus contain in all material respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons. To the Company’s knowledge, there is no prior art or public or commercial activity that may render any patent included in the Intellectual Property Rights invalid or that would preclude the issuance of any patent on any patent application included in the Intellectual Property which has not been disclosed to the U.S. Patent and Trademark Office or the relevant foreign patent authority, as the case may be. The Company has not, and to the Company’s knowledge, no third party has, committed any act or omitted to undertake any act the effect of such commission or omission would reasonably be expected to result in a legal determination that any item of Intellectual Property Rights thereby was rendered invalid or unenforceable in whole or in part. The manufacture, use and sale of the products or product candidates described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus as under development by the Company fall within the scope of one or more claims of the patents or patent applications included in the Intellectual Property Rights. Other than information disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, no government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property Rights that are owned or purported to be owned by the Company that would confer upon any governmental agency or body, university, college, other educational institution or research center any claim or right in or to any such Intellectual Property Rights.

 

 -8- 
 

 

(xiii) Employment Matters. There is (A) no unfair labor practice complaint pending against the Company, nor to the Company’s knowledge, threatened against it, before the National Labor Relations Board, any state or local labor relation board or any foreign labor relations board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company, or, to the Company’s knowledge, threatened against it and (B) no labor disturbance by the employees of the Company exists or, to the Company’s knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the Company plans to terminate employment with the Company.

 

(xiv) ERISA Compliance. No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA) or any of the events set forth in Section 4043(b) of ERISA (other than events with respect to which the thirty (30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or could reasonably be expected to occur with respect to any employee benefit plan of the Company which would reasonably be expected to, singularly or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company is in compliance in all material respects with applicable law, including ERISA and the Code. The Company has not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company would have any liability that is intended to be qualified under Section 401(a) of the Code is so qualified, and, to the Company’s knowledge, nothing has occurred, whether by action or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification.

 

(xv) Environmental Matters. The Company is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment which are applicable to their businesses (“Environmental Laws”), except where the failure to comply has not had and would not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability which has not had and would not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.

 

(xvi) SOX Compliance. The Company has taken all actions it deems reasonably necessary or advisable to take on or prior to the date of this Agreement to assure that, upon and at all times after the Effective Date, it will be in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof. (the “Sarbanes-Oxley Act”) that are then in effect and will take all action it deems reasonably necessary or advisable to assure that it will be in compliance in all material respects with other applicable provisions of the Sarbanes-Oxley Act not currently in effect upon it and at all times after the effectiveness of such provisions.

 

(xvii) Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

(xviii) Foreign Corrupt Practices Act. Neither the Company nor, to the knowledge of the Company, any director, officer, employee, representative, agent, affiliate of the Company or any other person acting on behalf of the Company, is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

 

 -9- 
 

 

(xix) OFAC. Neither the Company nor, to the knowledge of the Company, any director, officer, employee, representative, agent or affiliate of the Company or any other person acting on behalf of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

 

(xx) Insurance. Following the consummation of the offering contemplated hereby, the Company will carry insurance in such amounts and covering such risks as is adequate for the conduct of its business and the value of its properties and as is customary for companies engaged in similar businesses in similar industries.

 

(xxi) Books and Records. The minute books of the Company have been made available to the Underwriters and counsel for the Underwriters, and such books (i) contain a complete summary of all meetings and actions of the board of directors (including each board committee) and stockholders of the Company (or analogous governing bodies and interest holders, as applicable), since the time of its incorporation or organization through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all transactions referred to in such minutes.

 

(xxii) No Violation. Neither the Company nor, to its knowledge, any other party is in violation, breach or default of any Contract that has resulted in or could reasonably be expected to result in a Material Adverse Effect.

 

(xxiii) Continued Business. No supplier, customer, distributor or sales agent of the Company has notified the Company that it intends to discontinue or decrease the rate of business done with the Company, except where such discontinuation or decrease has not resulted in and could not reasonably be expected to result in a Material Adverse Effect.

 

(xxiv) No Finder’s Fee. There are no claims, payments, issuances, arrangements or understandings for services in the nature of a finder’s, consulting or origination fee with respect to the introduction of the Company to any Underwriter or the sale of the Securities hereunder or any other arrangements, agreements, understandings, payments or issuances with respect to the Company that may affect the Underwriters’ compensation, as determined by FINRA.

 

(xxv) No Fees. Except as disclosed to the Representative in writing, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to (i) any person, as a finder’s fee, investing fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who provided capital to the Company, (ii) any FINRA member, or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member within the twelve (12) month period prior to the date on which the Registration Statement was filed with the Commission (“Filing Date”) or thereafter.

 

(xxvi) Proceeds. None of the net proceeds of the offering will be paid by the Company to any participating FINRA member or any affiliate or associate of any participating FINRA member, except as specifically authorized herein.

 

(xxvii) No FINRA Affiliations . To the Company’s knowledge and except as disclosed to the Representative in writing, no (i) officer or director of the Company or (ii) owner of 5% or more of any class of the Company’s securities or (iii) owner of any amount of the Company’s unregistered securities acquired within the 180-day period prior to the Filing Date, has any direct or indirect affiliation or association with any FINRA member. The Company will advise the Representative and counsel to the Underwriter if it becomes aware that any officer, director of the Company or any owner of 5% or more of any class of the Company’s securities is or becomes an affiliate or associated person of a FINRA member participating in the offering.

 

 -10- 
 

 

(xxviii) No Financial Advisor. Other than the Underwriters, no person has the right to act as an underwriter or as a financial advisor to the Company in connection with the transactions contemplated hereby.

 

(xxix) Data Privacy and Security Laws. The Company is, and at all prior times was, in material compliance with all applicable state and federal data privacy and security laws and regulations in the United States, including, without limitation, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended by the Health Information Technology for Economic and Clinical Health Act, and all applicable provincial and federal data privacy and security laws and regulations in Canada, including without limitation the Personal Information Protection and Electronic Documents Act (S.C. 2000, c. 5) (“PIPEDA”); and the Company has taken commercially reasonable actions to prepare to comply with, and have been and currently are in compliance with, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company has in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) Protected Health Information as defined by HIPAA; (iv) “personal information”, “personal health information”. and “business contact information” as defined by PIPEDA; (v) “personal data” as defined by GDPR; and (vi) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. The Company has at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies: (i) it has not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.

 

(xxx) No Registration Rights. Except as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right (other than rights which have been waived in writing or otherwise satisfied) to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company owned or to be owned by such person or to require the Company to include such securities in the securities registered pursuant to the Registration Statement or in any securities being registered pursuant to any other registration statement filed by the Company under the Securities Act.

 

(xxxi) Prior Sales of Securities. Except as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company has not sold or issued any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulations D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, stock option plans or other employee compensation plans, pursuant to outstanding preferred stock, options, rights or warrants or other outstanding convertible securities or in connection with the vesting of any outstanding stock grants.

 

 -11- 
 

 

(xxxii) Compliance with Laws. The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the Company, including, without limitation, all statutes, rules, or regulations relating to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company and, without limiting the foregoing, include (i) the Federal Food, Drug, and Cosmetic Act (the “FDCA”), (ii) the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act and Laws applicable to hazardous or regulated substances and radioactive or biologic materials, (iii) the federal Anti-Kickback Statute, (iv) the False Claims Act, (v) the Civil Monetary Penalties Law, (vi) the Physician Payments Sunshine Act, (vii) the criminal False Claims Law, (viii) the HIPAA as amended by the Health Information Technology for Economic and Clinical Health Act and (ix) licensing and certification laws covering any aspect of the business of the Company (“Applicable Laws”), except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (B) has not received any warning letter, untitled letter or other correspondence or notice from any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws and/or to carry on its business as now conducted (“Applicable Authorizations”); (C) possesses all material Application Authorizations and such Applicable Authorizations are valid and in full force and effect and are not in material violation of any term of any such Applicable Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product operation or activity is in violation of any Applicable Laws or Applicable Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding nor, to the Company’s knowledge, has there been any material noncompliance with or violation of any Applicable Laws by the Company that could reasonably be expected to require the issuance of any such communication or result in an investigation, corrective action, or enforcement action by any Governmental Entity; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Applicable Authorizations and has no knowledge that any such Governmental Entity has threatened or is considering such action; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Applicable Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.

 

(xxxiii) Clinical and Preclinical Studies. The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all authorizations and applicable laws and the rules and regulations promulgated thereunder and any applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, the Company has not received any notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.

 

 -12- 
 

 

4. Purchase, Sale and Delivery of Shares.

 

(a) On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell the Firm Shares to the several Underwriters, and the several Underwriters agree, severally and not jointly, to purchase the Firm Securities set forth opposite the names of the Underwriters in Schedule I hereto. The purchase price for each Firm Share and accompanying Firm Warrant shall be $[       ] per Firm Share (92% of the public offering price for each Firm Share).

 

(b) The Company hereby grants to the Underwriters the option to purchase some or all of the Option Securities and, upon the basis of the warranties and representations and subject to the terms and conditions herein set forth, the Underwriter shall have the right, severally and not jointly, to purchase all or any portion of the Option Shares and/or the Option Warrants as may be necessary to cover over-allotments made in connection with the transactions contemplated hereby. The purchase price to be paid per Option Share shall be equal to $5.96. The purchase price to be paid per Option Tradeable Warrant shall be equal to $0.01. The purchase price to be paid per Option Non-tradeable Warrant shall be equal to $0.01. The Underwriters shall not be under any obligation to purchase any of the Option Securities prior to the exercise of the Over-allotment Option. This Over-Allotment Option may be exercised by the Underwriters at any time and from time to time on or before the forty-fifth (45th) day following the date hereof, by written notice to the Company (the “Option Notice”). The Option Notice shall set forth the aggregate number of Option Shares and/or Option Warrants as to which the option is being exercised, and the date and time when the Option Shares and/or the Option Warrants are to be delivered (such date and time being herein referred to as the “Option Closing Date”); provided, however, that the Option Closing Date shall not be earlier than the Closing Date (as defined below) nor earlier than the first business day after the date on which the option shall have been exercised nor later than the fifth business day after the date on which the option shall have been exercised unless the Company and the Representative otherwise agree. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Securities subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option Securities specified in such notice; (ii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total number of Option Securities then being purchased as set forth in Schedule 1 opposite the name of such Underwriter, subject to such adjustments as the Representative, in their sole discretion, shall determine and (iii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total number of Option Warrants then being purchased that the number of Option Warrants as set forth in Schedule 1 opposite the name of such Underwriter bears to the total number of Option Warrants, subject, in each case, to such adjustments as the Representative, in their sole discretion, shall determine. The Representative may cancel the Over-Allotment Option at any time prior to the expiration of the Over-Allotment Option by written notice to the Company (except to the extent the Representative has exercised the Over-Allotment Option in accordance herewith).

 

(c) Payment of the purchase price for and delivery of the Option Shares and/or the Option Warrants shall be made on an Option Closing Date in the same manner and at the same office as the payment for the Firm Securities as set forth in subparagraph (d) below.

 

(d) The Firm Securities will be delivered by the Company to the Representative, for the respective accounts of the several Underwriters against payment of the purchase price therefor by wire transfer of same day funds payable to the order of the Company at the offices of WallachBeth Capital, LLC, Harborside Financial Center Plaza 5, 185 Hudson Street, Suite 1410, Jersey City, NJ 07311, or such other location as may be mutually acceptable, at 9:00 a.m. Eastern Time, on the second (or if the Firm Securities are priced, as contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30 p.m. Eastern time, the third) full business day following the date hereof, or at such other time and date as the Representative and the Company determine pursuant to Rule 15c6-1(a) under the Exchange Act, or, in the case of the Option Securities, at such date and time set forth in the Option Notice. The time and date of delivery of the Firm Shares is referred to herein as the “Closing Date.” On the Closing Date, the Company shall deliver the Firm Securities which shall be registered in the name or names and shall be in such denominations as the Representative may request on behalf of the Underwriters at least one (1) business day before the Closing Date, to the respective accounts of the several Underwriters, which delivery shall with respect to the Firm Securities, be made through the facilities of the Depository Trust Company’s Deposit or Withdrawal at Custodian (“DWAC”) system.

 

 -13- 
 

 

(e) It is understood that WallachBeth Capital, LLC, has been authorized, for its own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Securities and any Option Securities the Underwriters have agreed to purchase. WallachBeth Capital, LLC, individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for any Securities to be purchased by any Underwriter whose funds shall not have been received by the Representative by the Closing Date or any Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.

 

(f) The Company hereby agrees to issue to the Underwriters (and/or its designees) on the Closing Date a five-year warrant (the “Representative’s Warrant”) for the purchase of an aggregate of [        ] shares of Common Stock, representing up to 6% of the Firm Shares. The Representative’s Warrant, in the form attached hereto as Exhibit A, shall be exercisable, in whole or in part, commencing on a date which is six (6) months after the effective date (the “Effective Date”) of the Registration Statement and expiring on the five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock equal to $[       ] (110% of the per Share offering price) (subject to adjustment as set forth therein). The Representative’s Warrant and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrant, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the offering of the Securities or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions. Delivery of the Representative’s Warrant shall be made on the Closing Date and shall be issued in the name or names and in such authorized denominations as the Representative may request.

 

5. Covenants.

 

(a) The Company covenants and agrees with the Underwriters as follows:

 

(i) The Company shall prepare the Final Prospectus in a form approved by the Representative and file such Final Prospectus pursuant to Rule 424(b) under the Securities Act not later than the Commission’s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by the Rules and Regulations.

 

(ii) During the period beginning on the date hereof and ending on the later of the Closing Date or such date as determined by the Representative the Final Prospectus is no longer required by law to be delivered in connection with sales by an underwriter or dealer (the “Prospectus Delivery Period”), prior to amending or supplementing the Registration Statement, including any Rule 462 Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company shall furnish to the Representative for review and comment a copy of each such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement to which the Representative reasonably objects.

 

(iii) From the date of this Agreement until the end of the Prospectus Delivery Period, the Company shall promptly advise the Representative in writing (A) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (B) of the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Time of Sale Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus, (C) of the time and date that any post-effective amendment to the Registration Statement becomes effective and (D) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending its use or the use of the Time of Sale Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time during the Prospectus Delivery Period, the Company will use its reasonable efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B or 430C as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission (without reliance on Rule 424(b)(8) or 164(b) of the Securities Act).

 

 -14- 
 

 

(iv) (A) During the Prospectus Delivery Period, the Company will comply with all requirements imposed upon it by the Securities Act, as now and hereafter amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act, as now and hereafter amended, so far as necessary to permit the continuance of sales of or dealings in the Securities as contemplated by the provisions hereof, the Time of Sale Disclosure Package, the Registration Statement and the Final Prospectus. If during the Prospectus Delivery Period any event occurs the result of which would cause the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package ) to include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its counsel or the Representative or counsel to the Underwriters to amend the Registration Statement or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) to comply with the Securities Act, the Company will promptly notify the Representative, allow the Representative the opportunity to provide reasonable comments on such amendment, prospectus supplement or document, and will amend the Registration Statement or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance.(B) If at any time during the Prospectus Delivery Period there occurred or occurs an event or development the result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or any Prospectus or included or would include, when taken together with the Time of Sale Disclosure Package, an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

 

(v) The Company shall take or cause to be taken all necessary action to qualify the Securities for sale under the securities laws of such jurisdictions as the Representative reasonably designate and to continue such qualifications in effect so long as required, except that the Company shall not be required in connection therewith to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified, to execute a general consent to service of process in any state or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise subject.

 

(vi) The Company will furnish to the Underwriters and counsel to the Underwriters copies of the Registration Statement, each Prospectus, any Issuer Free Writing Prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as the Underwriters may from time to time reasonably request.

 

(vii) The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.

 

(viii) The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid all expenses relating to the Offering, including, without limitation, (a) all filing fees and communication expenses relating to the registration of the Securities with the Commission; (b) all filing fees associated with the review of the public offering of the Securities by FINRA; (c) all fees and expenses relating to the listing of such Offered Securities on Nasdaq; (d) fees relating to background checks by the Representative; (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of such Securities under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f) the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers’ Agreement, Underwriters’ Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary; (g) the costs and expenses of a public relations firm for the Company mutually agreed upon by the Representative and the Company; (h) the costs of preparing, printing and delivering certificates representing the Securities; (i) fees and expenses of the transfer agent for the Securities of the Company; (j) the fees and expenses of the Company’s legal counsel and other agents and Representative; (k) fees and expenses of legal counsel for the Underwriters not to exceed $115,000 and (l) all reasonable road show expenses for the Offering.

 

 -15- 
 

 

(ix) The Company intends to apply the net proceeds from the sale of the Securities to be sold by it hereunder for the purposes set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus under the heading “Use of Proceeds”.

 

(x) The Company has not taken and will not take, directly or indirectly, during the Prospectus Delivery Period, any action designed to, or which might reasonably be expected to cause or result in, or that has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.

 

(xi) The Company represents and agrees that, unless it obtains the prior written consent of the Representative, and each Underwriter, severally, and not jointly, represents and agrees that, unless it obtains the prior written consent of the Company, it has not made and will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus; provided that the prior written consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses included in Schedule III. Any such free writing prospectus consented to by the Company and the Representative is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied or will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record-keeping.

 

(xii) The Company hereby agrees that, without the prior written consent of the Representative, it and any successors will not, during the period ending ninety (90) days after the date hereof (“Lock-Up Period”), (a) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock or the Company, (b) file or caused to be filed any registration statement with the Commission relating to the offering or resale of any shares of capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock or (c) enter into any swap or other arrangement that transfers to another in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (a), (b) or (c) above is to be settled by delivery of shares of capital stock of the Company or any successors or such other securities, in cash or otherwise, other than in the case of a Variable Rate Transaction (as defined below). The restrictions contained in the preceding sentence shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on the date hereof, which is disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the terms of which option, warrant or other outstanding convertible security are not thereafter amended, (iii) the issuance by the Company of shares of Common Stock upon the vesting of outstanding stock grants, (iv) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock (whether upon the exercise of stock options or otherwise) to the Company’s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus provided the grantee of any such equity award set forth in this Section enters into a Lock-Up Agreement (as defined below) in the form attached hereto as Exhibit B in connection with any such grant provided further that any such grant to advisors or consultants are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith within 180 days following the date hereof; (v) the filing by the Company of any registration statement on Form S-8 or a successor form thereto relating to an equity compensation plan described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus; and (vi) the scheduled sale of any shares by the Company’s Chief Executive Officer pursuant to his 10b-5 plan.

 

 -16- 
 

 

(xiii) From the date hereof until one year after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of Common Stock or any securities of the Company or any subsidiary which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock (or a combination of units thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price. Any Underwriter shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

 

(xiv) To engage and maintain, at its expense, a registrar and transfer agent for the Common Stock (if other than the Company).

 

(xv) To use its reasonable best efforts to maintain the listing of the Common Stock on Nasdaq.

 

(xvi) To not take, directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Securities.

 

(xvii) The Company further agrees that, in addition to the expenses payable pursuant to Section 5(a)(viii), on the Closing Date it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of the Securities; provided, however, that in the event that the Offering is terminated, the Company agrees to reimburse the Underwriters pursuant to Section 7 hereof. Notwithstanding the foregoing, any advance previously paid by the Company to WallachBeth Capital LLC against the Representative’s non-accountable expense allowance actually anticipated to be incurred, shall be applied towards the accountable expenses set forth herein; provided that the Representative will reimburse the Company for any remaining portion of the Advance to the extent amount of the Advance was not used for accountable expenses actually incurred by the Representative in the offering.

 

(xviii) As of the Closing Date, the Company shall have retained an investor relations advisory firm reasonably acceptable to the Representative and the Company and shall retain such firm or another firm reasonably acceptable to the Representative for a period of not less than six (6) months after the Closing Date.

 

 -17- 
 

 

(xix) On or prior to the date of this Agreement, the Company will have appropriate Directors’ & Officers’ (“D&O”) and Errors & Omissions (“E&O”) insurance with appropriate liability levels as reasonably determined by the Company.

 

(xx) Right of Participation. Provided that the Firm Shares are sold in accordance with the terms of this Agreement, during the period ended nine (9) months from the date hereof, the Representative shall have an irrevocable right of participation (the “Right of Participation”), for such period to act as lead underwriter or book-running manager or placement agent for each and every future public and private equity and debt offerings of the Company or any successor to any subsidiary of the Company (each, a “Subject Transaction”) in any U.S. stock exchange during such period. The Right of Participation shall only be in effect if the Subject Transaction results in gross proceeds of at least $4,500,000. The Company shall notify the Representative of its intention to pursue a Subject Transaction, including the material terms thereof, by providing written notice thereof by registered mail or overnight courier service addressed to the Representative. If the Representative fails to exercise its Right of Participation with respect to any Subject Transaction within ten (10) Business Days after the mailing of such written notice, then the Representative shall have no further claim or right with respect to the Subject Transaction. The Representative may elect, in its sole and absolute discretion, not to exercise its Right of Participation with respect to any Subject Transaction; provided that any such election by the Representative shall not adversely affect the Representative’s Right of Participation with respect to any other Subject Transaction during the period agreed to above.

 

6. Conditions of the Underwriter’s Obligations. The respective obligations of the several Underwriters hereunder to purchase the Shares are subject to the accuracy, as of the date hereof and at all times through the Closing Date, and on each Option Closing Date (as if made on the Closing Date or such Option Closing Date, as applicable), of and compliance with all representations, warranties and agreements of the Company contained herein, the performance by the Company of its obligations hereunder and the following additional conditions:

 

(a) If filing of the Final Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, is required under the Securities Act or the Rules and Regulations, the Company shall have filed the Final Prospectus (or such amendment or supplement) or such Issuer Free Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8) or 164(b) under the Securities Act); the Registration Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement or any part thereof, any Rule 462 Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus shall have been issued; no proceedings for the issuance of such an order shall have been initiated or threatened by the Commission; any request of the Commission or the Representative for additional information (to be included in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus, any Issuer Free Writing Prospectus or otherwise) shall have been complied with to the satisfaction of the Representative.

 

(b) The Common Stock and Warrants shall be approved for listing on Nasdaq, and satisfactory evidence thereof shall have been provided to the Representative and its counsel.

 

(c) FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.

 

(d) The Representative shall not have reasonably determined, and advised the Company, that the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus, or any amendment thereof or supplement thereto, or any Issuer Free Writing Prospectus, contains an untrue statement of fact which, in the reasonable opinion of the Representative, is material, or omits to state a fact which, in the reasonable opinion of the Representative, is material and is required to be stated therein or necessary to make the statements therein not misleading.

 

(e) Intentionally Omitted.

 

 -18- 
 

 

(f) On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representative on behalf of the Underwriter the opinion and negative assurance letters of Sichenzia Ross Ference Carmel LLP, corporate counsel to the Company, dated the Closing Date or the Option Closing Date, as applicable, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representative.

 

(g) Intentionally Omitted.

 

(h) The Underwriters shall have received a letter of M&K CPAS, PLLC, on the date hereof and on the Closing Date and on each Option Closing Date, addressed to the Underwriters, confirming that they are independent public accountants within the meaning of the Securities Act and are in compliance with the applicable requirements relating to the qualifications of accountants under Rule 2-01 of Regulation S-X of the Commission, and confirming, as of the date of each such letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, as of a date not prior to the date hereof or more than five (5) days prior to the date of such letter), the conclusions and findings of said firm with respect to the financial information and other matters required by the Underwriters.

 

(i) Intentionally Omitted.

 

(j) On the Closing Date and on each Option Closing Date, there shall have been furnished to the Underwriters a certificate, dated the Closing Date and on each Option Closing Date and addressed to the Underwriters, signed by the chief executive officer and the chief financial officer of the Company, in their capacity as officers of the Company, to the effect that:

 

(i) The representations and warranties of the Company in this Agreement that are qualified by materiality or by reference to any Material Adverse Effect are true and correct in all respects, and all other representations and warranties of the Company in this Agreement are true and correct, in all material respects, as if made at and as of the Closing Date and on the Option Closing Date, and the Company has complied in all material respects with all the agreements and satisfied all the conditions on its part required to be performed or satisfied at or prior to the Closing Date or on the Option Closing Date, as applicable;

 

(ii) No stop order or other order (A) suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof, (B) suspending the qualification of the Securities for offering or sale, or (C) suspending or preventing the use of the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus, has been issued, and no proceeding for that purpose has been instituted or, to their knowledge, is contemplated by the Commission or any state or regulatory body; and

 

(iii) There has been no occurrence of any event resulting or reasonably likely to result in a Material Adverse Effect during the period from and after the date of this Agreement and prior to the Closing Date or on the Option Closing Date, as applicable.

 

(k) On or before the date hereof, the Representative shall have received duly executed lock-up agreement, substantially in the form of Exhibit B hereto (each a “Lock-Up Agreement”), by and between the Representative and each of the parties specified in Schedule IV.

 

(l) On the Closing Date, the Company shall have delivered to the Representative executed copies of the Warrant Agreement and the Representative’s Warrant.

 

(m) The Company shall have furnished to the Representative and its counsel such additional documents, certificates and evidence as the Representative and its counsel may have reasonably requested.

 

 -19- 
 

 

If any condition specified in this Section 6 shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Representative by notice to the Company at any time at or prior to the Closing Date or on the Option Closing Date, as applicable, and such termination shall be without liability of any party to any other party, except that Section 5(a)(viii), Section 7 and Section 8 shall survive any such termination and remain in full force and effect.

 

7. Indemnification and Contribution.

 

(a) The Company agrees to indemnify, defend and hold harmless each Underwriter, its affiliates, directors and officers and employees, and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any losses, claims, damages or liabilities to which such Underwriter or such person may become subject, under the Securities Act or otherwise (including in settlement of any litigation if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant to Rules 430A and 430B of the Rules and Regulations, or arise out of or are based upon the omission from the Registration Statement, or alleged omission to state therein, a material fact required to be stated therein or necessary to make the statements therein not misleading (ii) an untrue statement or alleged untrue statement of a material fact contained in the Time of Sale Disclosure Package, any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act (Written Testing-the-Waters Communications), any Prospectus, the Final Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, or the Marketing Materials or in any other materials used in connection with the offering of the Securities, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, (iii) in whole or in part, any inaccuracy in the representations and warranties of the Company contained herein, or (iv) in whole or in part, any failure of the Company to perform its obligations hereunder or under law, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by it in connection with evaluating, investigating or defending against such loss, claim, damage, liability or action; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Time of Sale Disclosure Package, any Written Testing-the-Waters Communications, any Prospectus, the Final Prospectus, or any amendment or supplement thereto or any Issuer Free Writing Prospectus, in reliance upon and in conformity with written information furnished to the Company by such Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f).

 

(b) Each Underwriter, severally and not jointly, will indemnify, defend and hold harmless the Company, its affiliates, directors, officers and employees, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any losses, claims, damages or liabilities to which the Company may become subject, under the Securities Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus, or any amendment or supplement thereto or any Issuer Free Writing Prospectus, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus, or any amendment or supplement thereto or any Issuer Free Writing Prospectus in reliance upon and in conformity with written information furnished to the Company by such Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f), and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with evaluating, investigating, and defending against any such loss, claim, damage, liability or action. The obligation of each Underwriter to indemnify the Company (including any controlling person, director or officer thereof) shall be limited to the amount of the underwriting discount applicable to the Shares to be purchased by such Underwriter hereunder actually received by such Underwriter.

 

 -20- 
 

 

(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof, but the failure to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been materially prejudiced by such failure. In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of the indemnifying party’s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof; provided, however, that if (i) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (ii) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party), or (iii) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, the indemnified party shall have the right to employ a single counsel to represent it in any claim in respect of which indemnity may be sought under subsection (a) or (b) of this Section 7, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the indemnified party as incurred.

 

The indemnifying party under this Section 7 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is a party or could be named and indemnity was or would be sought hereunder by such indemnified party, unless such settlement, compromise or consent (a) includes an unconditional release of such indemnified party from all liability for claims that are the subject matter of such action, suit or proceeding and (b) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

 

(d) If the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering and sale of the Shares or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discount received by the Underwriters, in each case as set forth in the table on the cover page of the Final Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters and the parties’ relevant intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this subsection (d) were to be determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in the first sentence of this subsection (d). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any action or claim that is the subject of this subsection (d). Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount of the of the underwriting discount applicable to the Shares to be purchased by such Underwriter hereunder actually received by such Underwriter. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ respective obligations to contribute as provided in this Section 7 are several in proportion to their respective underwriting commitments and not joint.

 

 -21- 
 

 

(e) The obligations of the Company under this Section 7 shall be in addition to any liability that the Company may otherwise have and the benefits of such obligations shall extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act; and the obligations of each Underwriter under this Section 7 shall be in addition to any liability that each Underwriter may otherwise have and the benefits of such obligations shall extend, upon the same terms and conditions, to the Company and its officers, directors and each person who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act.

 

(f) For purposes of this Agreement, each Underwriter severally confirms, and the Company acknowledges, that there is no information concerning such Underwriter furnished in writing to the Company by such Underwriter specifically for preparation of or inclusion in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus, other than the statement set forth in the last paragraph on the cover page of the Prospectus, the marketing and legal names of each Underwriter, and the statements set forth in the “Underwriting” section of the Registration Statement, the Time of Sale Disclosure Package, and the Final Prospectus only insofar as such statements relate to the amount of selling concession and re-allowance, if any, or to over-allotment, stabilization and related activities that may be undertaken by such Underwriter.

 

8. Representations and Agreements to Survive Delivery. All representations, warranties, and agreements of the Company contained herein or in certificates delivered pursuant hereto, including, but not limited to, the agreements of the several Underwriters and the Company contained in Section 5(a)(viii) and Section 7 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the several Underwriters or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive delivery of, and payment for, the Shares to and by the Underwriters hereunder.

 

9. Termination of this Agreement.

 

(a) The Representative shall have the right to terminate this Agreement by giving notice to the Company as hereinafter specified at any time at or prior to the Closing Date or any Option Closing Date (as to the Option Shares to be purchased on such Option Closing Date only), if in the discretion of the Representative, (i) there has occurred any material adverse change in the securities markets or any event, act or occurrence that has materially disrupted, or in the opinion of the Representative, will in the future materially disrupt, the securities markets or there shall be such a material adverse change in general financial, political or economic conditions or the effect of international conditions on the financial markets in the United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable to market the Shares or enforce contracts for the sale of the Shares (ii) trading in the Company’s Common Stock shall have been suspended by the Commission or Nasdaq or trading in securities generally on the Nasdaq Stock Market, the NYSE or the NYSE MKT shall have been suspended, (iii) minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required, on the Nasdaq Stock Market, the NYSE or NYSE American, by such exchange or by order of the Commission or any other governmental authority having jurisdiction, (iv) a banking moratorium shall have been declared by federal or state authorities, (v) there shall have occurred any attack on, outbreak or escalation of hostilities or act of terrorism involving the United States any declaration by the United States of a national emergency or war, any substantial change or development involving a prospective substantial change in United States or other international political, financial or economic conditions or any other calamity or crisis, or (vi) the Company suffers any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, or (vii) in the judgment of the Representative, there has been, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, any material adverse change in the assets, properties, condition, financial or otherwise, or in the results of operations, business affairs or business prospects of the Company, whether or not arising in the ordinary course of business. Any such termination shall be without liability of any party to any other party except that the provisions of Section 5(a)(viii) and Section 7 hereof shall at all times be effective and shall survive such termination.

 

 -22- 
 

 

(b) If the Representative elect to terminate this Agreement as provided in this Section 9, the Company and the other Underwriters shall be notified promptly by the Representative by telephone, confirmed by letter.

 

(c) If this Agreement is terminated pursuant to any of its provisions, the Company shall not be under any liability to any Underwriter, and no Underwriter shall be under any liability to the Company, except that (y) subject to a maximum reimbursement of $115,000, the Company will reimburse the Representative only for all actual, accountable out-of-pocket expenses (including the reasonable fees and disbursements of its counsel) reasonably incurred by the Representative in connection with the proposed purchase and sale of the Shares or in contemplation of performing their obligations hereunder and (z) no Underwriter who shall have failed or refused to purchase the Shares agreed to be purchased by it under this Agreement, without some reason sufficient hereunder to justify cancellation or termination of its obligations under this Agreement, shall be relieved of liability to the Company, or to the other Underwriters for damages occasioned by its failure or refusal.

 

10. Substitution of Underwriters. If any Underwriter or Underwriters shall default in its or their obligations to purchase Shares hereunder on the Closing Date or any Option Closing Date and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed five percent (5%) of the total number of Shares to be purchased by all Underwriters on such Closing Date or Option Closing Date, the other Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed to purchase on such Closing Date or Option Closing Date. If any Underwriter or Underwriters shall so default and the aggregate number of Shares with respect to which such default or defaults occur is more than ten percent (10%) of the total number of Shares to be purchased by all Underwriters on such Closing Date or Option Closing Date and arrangements satisfactory to the remaining Underwriters and the Company for the purchase of such Shares by other persons are not made within forty-eight (48) hours after such default, this Agreement shall terminate.

 

If the remaining Underwriters or substituted Underwriters are required hereby or agree to take up all or part of the Shares of a defaulting Underwriter or Underwriters on such Closing Date or Option Closing Date as provided in this Section 10, (i) the Company shall have the right to postpone such Closing Date or Option Closing Date for a period of not more than five (5) full business days in order to permit the Company to effect whatever changes in the Registration Statement, the Final Prospectus, or in any other documents or arrangements, which may thereby be made necessary, and the Company agrees to promptly file any amendments to the Registration Statement or the Final Prospectus which may thereby be made necessary, and (ii) the respective numbers of Shares to be purchased by the remaining Underwriters or substituted Underwriters shall be taken as the basis of their underwriting obligation for all purposes of this Agreement. Nothing herein contained shall relieve any defaulting Underwriter of its liability to the Company or any other Underwriter for damages occasioned by its default hereunder. Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of any non-defaulting Underwriters or the Company, except that the obligations with respect to expenses to be paid or reimbursed pursuant to Section 5(a)(viii) and Section 7 and Sections 9 through 17, inclusive, shall not terminate and shall remain in full force and effect.

 

11. [Intentionally Omitted].

 

12. Notices. All notices and communications hereunder shall be in writing and mailed or delivered or by telephone, electronic mail or telegraph if subsequently confirmed in writing, (a) if to the Representative, WallachBeth Capital, LLC, Harborside Financial Center Plaza 5, 185 Hudson Street, Ste 1410, Jersey City, NJ 07311, with a copy (which shall not constitute notice) to Sheppard, Mullin, Richter & Hampton LLP, 30 Rockefeller Plaza, 39th Floor, New York, NY Attention: Richard A. Friedman, Esq. , and (b) if to the Company, to the Company’s agent for service as such agent’s address appears on the cover page of the Registration Statement with a copy (which shall not constitute notice) to Sichenzia Ross Ference Carmel LLP, 1185 Avenue of the Americas, 31st Floor, New York, NY 10036, Attention: Arthur Marcus, Esq.

 

 -23- 
 

 

13. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section 7. Nothing in this Agreement is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained. The term “successors and assigns” as herein used shall not include any purchaser, as such purchaser, of any of the Shares from any Underwriters.

 

14. Absence of Fiduciary Relationship. The Company acknowledges and agrees that: (a) each Underwriter has been retained solely to act as underwriter in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship between the Company and any Underwriter has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Underwriter has advised or is advising the Company on other matters; (b) the price and other terms of the Shares set forth in this Agreement were established by the Company following discussions and arms-length negotiations with the Underwriters and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised that the Underwriters and their affiliates are engaged in a broad range of transactions that may involve interests that differ from those of the Company and that no Underwriter has any obligation to disclose such interest and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and (d) it has been advised that each Underwriter is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit of such Underwriter, and not on behalf of the Company.

 

15. Amendments and Waivers. No supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. The failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.

 

16. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision.

 

17. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York.

 

18. Submission to Jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. EACH OF THE COMPANY (ON BEHALF OF ITSELF AND, TO THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS RESPECTIVE EQUITY HOLDERS AND CREDITORS) AND THE UNDERWRITER HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE, ANY PROSPECTUS AND THE FINAL PROSPECTUS.

 

19. Counterparts. This Agreement may be executed and delivered (including by facsimile transmission or electronic mail) in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument.

 

[Signature Page Follows]

 

 -24- 
 

 

Please sign and return to the Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the Company and the several Underwriters in accordance with its terms.

 

  Very truly yours,
   
  BULLFROG AI HOLDINGS, INC.
   
  By:  
  Name:  
  Title:  

 

Confirmed as of the date first above-mentioned by the Representative of the several Underwriters.

 

WALLACHBETH CAPITAL, LLC

 

By:    
Name:    
Title:    

 

[Signature page to Underwriting Agreement]

 

 -25- 
 

 

SCHEDULE I

 

   

Number of Firm

Securities to be

Purchased

 

Total Number of Option

Securities to be

Purchased

Underwriter   Number of
Firm Units
  Number of
Option Shares
  Number of
Option Warrants
WallachBeth Capital, LLC            
             
Total            

 

 -26- 
 

 

SCHEDULE II

Pricing Information

 

Number of Firm Units

Number of Option Shares:

Number of Option Warrants:

Public Offering Price per Firm Unit: $

Public Offering Price per Option Share: $[*]

Public Offering Price per Option Warrant:

Underwriting Discount per Firm Unit: (8% per Firm Unit)

Underwriting non-accountable expense allowance per Firm Unit: (1% per Firm Unit)

 

 -27- 
 

 

SCHEDULE III

Free Writing Prospectus

 

 -28- 
 

 

SCHEDULE IV

Lock-Up Parties

 

 -29- 

 

EX-4.2 3 ex4-2.htm

 

Exhibit 4.2

 

THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS COMMON STOCK PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS COMMON STOCK PURCHASE WARRANT PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE COMMENCEMENT DATE OF SALES IN THE OFFERING (DEFINED BELOW) TO ANYONE OTHER THAN (I)WALLACHBETH CAPITAL LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF WALLACHBETH CAPITAL LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS 180 DAYS FROM THE COMMENCEMENT DATE OF SALES IN THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE COMMENCEMENT DATE OF SALES IN THE OFFERING].

 

BULLFROG AI HOLDINGS, INC.

COMMON STOCK PURCHASE WARRANT

 

Warrant

Shares:1__________________________

Initial Issuance

Date: __________________________

 

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, WallachBeth Capital LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [    ], 20242 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), on or prior to 5:00 p.m. (New York City time) on the date that is five (5) years following the Initial Issuance Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Bullfrog AI Holdings, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

 

Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

 

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

 

1 Equal to 6% of the Company Shares sold in the offering

 

2 Date that is 180 days from the Initial Issuance Date

 

-1-
 

 

Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.

 

Commission” means the United States Securities and Exchange Commission.

 

Common Stock” means the common stock of the Company, par value $0.00001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

 

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

Registration Statement” means the Company’s registration statement on Form S-1 (File No. 333-[____]).

 

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

 

Trading Day” means a day on which the Common Stock is traded on a Trading Market.

 

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

Transfer Agent” means VStock Transfer, LLC, the current transfer agent of the Company, and any successor transfer agent of the Company.

 

Underwriting Agreement” means the underwriting agreement, dated as of [    ], 2024, among the Company and WallachBeth Capital, LLC as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with its terms.

 

-2-
 

 

VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Common Stock Purchase Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

Warrant Agency Agreement” means that certain warrant agent agreement, dated on or about the Initial Exercise Date, between the Company and the Warrant Agent.

 

Warrant Agent” means the Transfer Agent and any successor warrant agent of the Company.

 

Warrants” means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.

 

Section 2. Exercise.

 

a) Notwithstanding the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

 

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $[__]3, equal to 110% of the public offering price, subject to adjustment hereunder (the “Exercise Price”).

 

c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

  (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

 

3 Equal to 110% of the public offering price per share.

 

-3-
 

 

  (B) = the Exercise Price of this Warrant, as adjusted hereunder; and
       
  (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).

 

d) Mechanics of Exercise.

 

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Underwriting Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.

 

-4-
 

 

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

-5-
 

 

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

-6-
 

 

Section 3. Certain Adjustments.

 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b) Reserved.

 

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

-7-
 

 

e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Stock (not including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)(each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Common Stock (or shares of common stock, as applicable) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting(A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Business Days of the Holder’s election (or, if later, on the date of consummation of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

-8-
 

 

g) Notice to Holder.

 

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

h) Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

 

Section 4. Transfer of Warrant.

 

a) Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

-9-
 

 

b) New Warrants. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant Register. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section 5. Miscellaneous.

 

a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

 

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

 

d) Authorized Shares.

 

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

-10-
 

 

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding the foregoing, this exclusive forum provision shall not apply to suits brought to enforce a duty or liability created by the Exchange Act, any other claim for which the federal courts have exclusive jurisdiction or any complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, other employees or agents. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.

 

-11-
 

 

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h) Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878 Attention: Vininder Singh, Chief Executive Officer, email address: vin.singh@bullfrogai.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.

 

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of the beneficial owner of this Warrant, on the other hand.

 

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

o) Warrant Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.

 

********************

(Signature Page Follows)

 

-12-
 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

  BULLFROG AI HOLDINGS, INC.
     
  By:  
  Name: Vininder Singh
  Title: Chief Executive Officer

 

-13-
 

 

NOTICE OF EXERCISE

 

To: BULLFROG AI HOLDINGS, INC.

 

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment shall take the form of (check applicable box):

 

  [ ] in lawful money of the United States; or
     
  [ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3) Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

     

 

The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

     
     
     
     
     

 

(4) Accredited Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

___________________________________________________________________________________________

Signature of Authorized Signatory of Investing Entity:

 

___________________________________________________________________________________________

Name of Authorized Signatory:

 

___________________________________________________________________________________________

Title of Authorized Signatory:

 

___________________________________________________________________________________________

Date:

 

___________________________________________________________________________________________

 

-14-
 

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant.)

 

FOR VALUE RECEIVED, [  ] all of or [  ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name:  
   
Address:  
  (Please Print)
   
Phone Number:  
   
Email Address:  

 

Dated:________________ ___, _______

 

Holder’s Signature: _______________________________________

 

Holder’s Address: _______________________________________

 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

-15-
 

 

EXHIBIT B

 

[Form of Election to Purchase]

 

(To Be Executed Upon Exercise of Warrants not evidenced by a Global Certificate)

 

The undersigned hereby irrevocably elects to exercise the right, represented by Warrants evidenced by this Warrant Certificate, to receive ____________ Warrant Shares and herewith (i) tenders payment for such Warrant Shares to the order of Bullfrog AI Holdings, Inc., a Nevada corporation, in the amount of $ _________ in accordance with the terms hereof, or (ii) if permitted, makes the payment by the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 3.3.7(b), to exercise this Warrant with respect to the above number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 3.3.7(b).

 

The undersigned requests that a certificate for such Warrant Shares be registered in the name of ___________________________, whose address is _____________________________ and that such certificate be delivered to _______________________________, whose address is _____________________________________. If the number of Warrants being exercised hereby is less than all the Warrants evidenced by this Warrant Certificate, the undersigned requests that a new Warrant Certificate representing the remaining unexercised Warrants be registered in the name of ___________________________, whose address is _____________________________ and that such Warrant Certificate be delivered to ______________________________________ whose address is _________________________________.

 

  Signature,
   
Date:  
   
  [Signature Guarantee]

 

-16-

 

EX-4.3 4 ex4-3.htm

 

Exhibit 4.3

 

FORM OF WARRANT AGENT AGREEMENT

 

This Warrant Agent Agreement (this “Warrant Agreement”), dated as of [__], 2024 (the “Issuance Date”) is between Bullfrog AI Holdings, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), and VStock Transfer, LLC, a California limited liability company (the “Warrant Agent”).

 

WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated [__], 2024, by and among the Company and WallachBeth Capital, LLC, as representative of the underwriters set forth therein (the “Representative”), the Company is engaged in a public offering (the “Offering”) of up to (i) [  ] shares (the “Shares”) of common stock, par value $0.00001 per share (the “Common Stock”) of the Company (or, to the extent that the purchase of shares of Common Stock would cause the beneficial ownership of a purchaser in the Offering, together with its affiliates and certain related parties, to exceed 4.99% of the then issued and outstanding Common Stock, in lieu of the Common Stock, pre-funded warrants to purchase one share of the Company’s Common Stock (the “Pre-Funded Warrants”)), and (ii) one accompanying five-year warrant (each, a “Warrant”) to purchase one share of Common Stock (“Warrant Shares”) at an exercise price of $[  ]1 per share;

 

WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) a Registration Statement on Form S-1 (File No. 333-[___]) (as the same may be amended from time to time, the “Registration Statement”), for the registration under the Securities Act of 1933, as amended (the “Securities Act”), of the Shares, Warrants, the Representative’s Warrant and the Warrant Shares, and such Registration Statement was declared effective on [●], 2024;

 

WHEREAS the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in accordance with the terms set forth in this Warrant Agreement in connection with the issuance, registration, transfer, exchange and exercise of the Warrants;

 

WHEREAS, the Company desires to provide for the provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

 

WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Warrant Agreement.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company with respect to the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the express terms and conditions set forth in this Warrant Agreement (and no implied terms or conditions).

 

 

1 Equal to 100% of the public offering price per share.

 

-1-

 

 

2. Warrants.

 

2.1. Form of Warrants. The Warrants shall be registered securities and shall be evidenced by a global certificate (“Global Certificate”) in the form of Exhibit A to this Warrant Agreement, which shall be deposited on behalf of the Company with a custodian for The Depository Trust Company (“DTC”) and registered in the name of Cede & Co., a nominee of DTC. If DTC subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, book-entry form, the Company may instruct the Warrant Agent to provide written instructions to DTC to deliver to the Warrant Agent for cancellation of the Global Certificate, and the Company shall instruct the Warrant Agent to deliver to DTC separate certificates evidencing the Warrants (“Definitive Certificates”) registered as requested through the DTC system.

 

2.2. Issuance and Registration of Warrants.

 

2.2.1. Warrant Register. The Warrant Agent shall maintain books (“Warrant Register”) for the registration of original issuance and the registration of transfer of the Warrants. Any person in whose name ownership of a beneficial interest in the Warrants evidenced by a Global Certificate is recorded in the records maintained by DTC or its nominee shall be deemed the “beneficial owner” thereof, provided that all such beneficial interests shall be held through a Participant (as defined below), which shall be the registered holder of such Warrants.

 

2.2.2. Issuance of Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue the Global Certificate and deliver the Warrants in the DTC book-entry settlement system in accordance with written instructions delivered to the Warrant Agent by the Company. Ownership of security entitlements in the Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained, (A) by DTC and (B) by institutions that have accounts with DTC (each, a “Participant”).

 

2.2.3. Beneficial Owner; Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the Person in whose name that Warrant shall be registered on the Warrant Register (the “Holder”) as the absolute owner of such Warrant for purposes of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Warrant Agent or any agent of the Company or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished by DTC governing the exercise of the rights of a Holder of a beneficial interest in any Warrant. The rights of beneficial owners in a Warrant evidenced by the Global Certificates shall be exercised by the Holder or a Participant through the DTC system.

 

-2-

 

 

2.2.4. Execution. The Warrant Certificates shall be executed on behalf of the Company by any authorized officer of the Company (an “Authorized Officer”), which need not be the same authorized signatory for all of the Warrant Certificates, either manually or by facsimile signature. The Warrant Certificates shall be countersigned by an authorized signatory of the Warrant Agent, which need not be the same signatory for all of the Warrant Certificates, and no Warrant Certificate shall be valid for any purpose unless so countersigned. In case any Authorized Officer of the Company that signed any of the Warrant Certificates ceases to be an Authorized Officer of the Company before countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant Certificates, nevertheless, may be countersigned by the Warrant Agent, issued and delivered with the same force and effect as though the Person who signed such Warrant Certificates had not ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by any Person who, at the actual date of the execution of such Warrant Certificate, shall be an Authorized Officer of the Company authorized to sign such Warrant Certificate, although at the date of the execution of this Warrant Agreement any such Person was not such an Authorized Officer.

 

2.2.5. Registration of Transfer. At any time at or prior to the Expiration Date (as defined below), a transfer of any Warrants may be registered and any Warrant Certificate or Warrant Certificates may be split up, combined or exchanged for another Warrant Certificate or Warrant Certificates evidencing the same number of Warrants as the Warrant Certificate or Warrant Certificates surrendered. Any Holder desiring to register the transfer of Warrants or to split up, combine or exchange any Warrant Certificate shall make such request in writing delivered to the Warrant Agent, and shall surrender to the Warrant Agent the Warrant Certificate or Warrant Certificates evidencing the Warrants the transfer of which is to be registered or that is or are to be split up, combined or exchanged and, in the case of registration of transfer, shall provide a signature guarantee. Thereupon, the Warrant Agent shall countersign and deliver to the Person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may be, as so requested. The Company and the Warrant Agent may require payment, by the Holder requesting a registration of transfer of Warrants or a split-up, combination or exchange of a Warrant Certificate (but, for purposes of clarity, not upon the exercise of the Warrants and issuance of Warrant Shares to the Holder), of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with such registration of transfer, split-up, combination or exchange, together with reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental thereto.

 

2.2.6. Loss, Theft and Mutilation of Warrant Certificates. Upon receipt by the Company and the Warrant Agent of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of a Warrant Certificate, and, in case of loss, theft or destruction, of indemnity or security in customary form and amount, and reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate if mutilated, the Warrant Agent shall, on behalf of the Company, countersign and deliver a new Warrant Certificate of like tenor to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated. The Warrant Agent may charge the Holder an administrative fee for processing the replacement of lost Warrant Certificates, which shall be charged only once in instances where a single surety bond obtained covers multiple certificates. The Warrant Agent may receive compensation from the surety companies or surety agents for administrative services provided to them.

 

2.2.7. Proxies. The Holder of a Warrant may grant proxies or otherwise authorize any Person, including the Participants and beneficial holders that may own interests through the Participants in the case of Warrants, to take any action that a Holder is entitled to take under this Agreement or the Warrants; provided, however, that at all times that Warrants are evidenced by a Global Certificate, exercise of those Warrants shall be effected on their behalf by Participants through DTC in accordance the procedures administered by DTC.

 

-3-

 

 

3. Terms and Exercise of Warrants.

 

3.1. Exercise Price. Each Warrant shall entitle the Holder, subject to the provisions of the applicable Warrant Certificate and of this Warrant Agreement, to purchase from the Company the number of Shares of Common Stock stated therein, at the price of (i) $[  ]2 per whole Share, subject to the subsequent adjustments provided in Section 4 hereof. The term “Exercise Price” as used in this Warrant Agreement refers to the price per Share at which Shares of Common Stock may be purchased at the time a Warrant is exercised.

 

3.2. Duration of Warrants. Warrants may be exercised only during the period (“Exercise Period”) commencing on the Issuance Date and terminating at 11:59 P.M., New York City Time (the “close of business”) on the fifth anniversary of the Issuance Date, [●], 2029 (“Expiration Date”). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.

 

3.3. Exercise of Warrants.

 

3.3.1. Exercise and Payment. (a) Subject to the provisions of this Warrant Agreement, a Holder (or a Participant or a designee of a Participant acting on behalf of a Holder) may exercise Warrants by delivering to the Warrant Agent, not later than 5:00 P.M., New York City Time, on any Business Day during the Exercise Period an election to purchase the Warrant Shares underlying the Warrants to be exercised (i) in the form included in Exhibit B to this Warrant Agreement or (ii) via an electronic warrant exercise through the DTC system (each, an “Election to Purchase”). No later than one (1) Trading Day following delivery of an Election to Purchase, the Holder (or a Participant acting on behalf of a Holder in accordance with DTC procedures) shall: (i) (A) surrender the Warrant Certificate evidencing the Warrants to the Warrant Agent at its office designated for such purpose or (B) deliver the Warrants to an account of the Warrant Agent at DTC designated for such purpose in writing by the Warrant Agent to DTC from time to time, and (ii) unless the cashless exercise procedure specified in Section 3.3.7(b) or (c) below is permitted and specified in the applicable Notice of Exercise, deliver to the Company the Exercise Price for each Warrant to be exercised, in lawful money of the United States of America in cash, by certified or official bank check payable to the Company or bank wire transfer in immediately available funds to:

 

BULLFROG AI HOLDINGS, INC.

Bank Name: [____]

Routing (ABA)#: [____]

Beneficiary Account Name: Bullfrog AI Holdings, Inc.

Beneficiary Account Number:[_______]

 

No ink-original Election to Purchase shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Election to Purchase form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender the Warrants to the Company until the Holder has purchased all of the Warrant Shares available thereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender such Warrant to the Company for cancellation within three (3) Trading Days of the date the final Election to Purchase is delivered to the Company. Partial exercises of a Warrant resulting in purchases of a portion of the total number of Warrant Shares available thereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Election to Purchase within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of a Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face thereof.

 

 

2 Equal to 100% of the public offering price per share of common stock

 

-4-

 

 

Any Person so designated by the Holder (or a Participant or designee of a Participant on behalf of a Holder) to receive Warrant Shares shall be deemed to have become holder of record of such Warrant Shares as of the time that an appropriately completed and duly signed Election to Purchase has been delivered to the Warrant Agent, provided that the Holder (or Participant on behalf of the Holder) makes delivery of the deliverables referenced in the immediately preceding sentence by the date that is one (1) Trading Day after the delivery of the Election to Purchase. If the Holder (or Participant on behalf of the Holder) fails to make delivery of such deliverables on or prior to the Trading Day following delivery of the Election to Purchase, such Election to Purchase shall be void ab initio.

 

(b) If any of (i) the Warrants, (ii) the Election to Purchase, or (iii) the Exercise Price therefor, is received by the Warrant Agent on any date after 5:00 P.M., New York City Time, or on a date that is not a Trading Day, the Warrants with respect thereto will be deemed to have been received and exercised on the Trading Day next succeeding such date. “Business Day” means a day other than a Saturday, Sunday, or other day on which commercial Banks in New York City are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day. The “Exercise Date” will be the date on which the materials in the foregoing sentence are received by the Warrant Agent (if by 5:00 P.M., New York City time), or the following Trading Day (if after 5:00 P.M., New York City time), regardless of any earlier date written on the materials. If the Warrants are received or deemed to be received after the Expiration Date, the exercise thereof will be null and void and any funds delivered to the Company will be returned to the Holder or Participant, as the case may be, as soon as practicable. In no event will interest accrue on any funds deposited with the Company in respect of an exercise or attempted exercise of Warrants.

 

(c) If less than all the Warrants evidenced by a surrendered Warrant Certificate are exercised, the Warrant Agent shall split up the surrendered Warrant Certificate and return to the Holder a Warrant Certificate evidencing the Warrants that were not exercised.

 

Notwithstanding the foregoing in this Section 3.3.1, a holder whose interest in a Warrant is a beneficial interest in certificate(s) representing such Warrant held in registered form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made pursuant to this Section 3.3.1 by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject to a holder’s right to elect to receive a Definitive Warrant pursuant to the terms of this Warrant Agreement, in which case this sentence shall not apply. Upon giving irrevocable instructions to its Participant to exercise Warrants, solely for purposes of Regulation SHO, the holder whose interest in the Warrant is a beneficial interest shall be deemed to have exercised such Warrant, regardless of when the applicable Warrant Shares are delivered to such holder

 

3.3.2. Issuance of Warrant Shares. (a) The Warrant Agent shall, by 11:00 a.m., New York City time, on the Trading Day following the Exercise Date of any Warrant, advise the Company, the transfer agent and registrar for the Company’s Common Stock, in respect of (i) the number of Warrant Shares indicated on the Election to Purchase as issuable upon such exercise with respect to such exercised Warrants, (ii) the instructions of the Holder or Participant, as the case may be, provided to the Warrant Agent with respect to the delivery of the Warrant Shares and the number of Warrants that remain outstanding after such exercise, and (iii) such other information as the Company or such transfer agent and registrar shall reasonably request.

 

(b) The Company shall, by no later than 5:00 P.M., New York City Time, on the second Trading Day following the Exercise Date of any Warrant and the clearance of the funds in payment of the Exercise Price (such date and time, the “Delivery Time”), cause its registrar to electronically transmit the Warrant Shares issuable upon that exercise to DTC by crediting the account of DTC or of the Participant, as the case may be, through its Deposit Withdrawal Agent Commission system.

 

-5-

 

 

3.3.3. Valid Issuance. All Warrant Shares issued by the Company upon the proper exercise of a Warrant in conformity with this Warrant Agreement shall be duly authorized, validly issued, fully paid and non-assessable.

 

3.3.4. No Fractional Exercise. No fractional Warrant Shares will be issued upon the exercise of the Warrant. If, by reason of any adjustment made pursuant to Section 4, a Holder would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round up to the next whole share.

 

3.3.5. No Transfer Taxes. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, the Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached to the Warrant duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Election to Purchase and all fees to DTC (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

3.3.6. Date of Issuance. The Company will treat an exercising Holder as a beneficial owner of the Warrant Shares as of the Exercise Date, except that, if the Exercise Date is a date when the stock transfer books of the Company are closed, such Person shall be deemed to have become the holder of such shares at the open of business on the next succeeding date on which the stock transfer books are open.

 

3.3.7. Restrictive Legend Events; Cashless Exercise Under Certain Circumstances. (a) The Company shall use it reasonable best efforts to maintain the effectiveness of the Registration Statement and the current status of the prospectus included therein or to file and maintain the effectiveness of another registration statement and another current prospectus covering the Warrants and the Warrant Shares at any time that the Warrants are exercisable. The Company shall provide to the Warrant Agent and each Holder prompt written notice of any time that the Company is unable to deliver the Warrant Shares via DTC transfer or otherwise without restrictive legend because: (i) the Commission has issued a stop order with respect to the Registration Statement, (ii) the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, (iii) the Company has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, (iv) in the case of a Warrant, the prospectus contained in the Registration Statement is not available for the issuance of the Warrant Shares to the Holder, or (v) otherwise (each a “Restrictive Legend Event”). To the extent that the Warrants cannot be exercised as a result of a Restrictive Legend Event or a Restrictive Legend Event occurs after a Holder has exercised Warrants in accordance with the terms of the Warrants but prior to the delivery of the Warrant Shares, the Company shall, at the election of the Holder, which shall be given within five (5) days of receipt of such notice of the Restrictive Legend Event, either (i) rescind the previously submitted Election to Purchase and return all consideration paid by registered Holder for such shares upon such rescission, or (ii) treat the attempted exercise as a cashless exercise as described in paragraph (b) below and refund the cash portion of the exercise price to the Holder. Notwithstanding anything herein to the contrary, the Company shall not be required to make any cash payments or net cash settlement to the Holder in lieu of delivery of the Warrant Shares.

 

(b) If a Restrictive Legend Event has occurred, the Warrant shall only be exercisable on a cashless basis. Upon a “cashless exercise”, the Holder shall be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing (A-B) (X) by (A), where:

 

  (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the Exercise Date if the Holder’s Election to Purchase is (1) both executed and delivered pursuant to Section 3.3.7(a) hereof on a day that is not a Trading Day, or (2) both executed and delivered pursuant to Section 3.3.7(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Election to Purchase, or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Election to Purchase if such Election to Purchase is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 3.3.7(a) hereof, or (iii) the VWAP on the date of the applicable Election to Purchase if the date of such Election to Purchase is a Trading Day and such Election to Purchase is both executed and delivered pursuant to Section 3.3.7(a) hereof after the close of “regular trading hours” on such Trading Day;
       
  (B) = the Exercise Price then in effect for the applicable Warrant Shares at the time of the exercise of the Warrant, as adjusted as set forth herein; and
       
  (X) = the number of Warrant Shares that would be issuable upon exercise of the Warrant in accordance with the terms of the Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

-6-

 

 

Notwithstanding anything to the contrary herein, a “cashless exercise” may occur after the earlier of (i) 1 Trading Day from the Initial Exercise Date of this Warrant or (ii) the time when $10.0 million of volume is traded in the Common Shares, if the VWAP of the Common Shares on any Trading Day on or after the closing date fails to exceed the Exercise Price in effect as of the Initial Exercise Date (subject to adjustment for any stock splits, stock dividends, stock combinations, recapitalizations and similar events). In such event, the aggregate number of Warrant Shares issuable in such cashless exercise pursuant to any given Notice of Exercise electing to effect a cashless exercise shall equal the product of (x) the aggregate number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise and (y) 1.00.

 

If Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees that, in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised and the Company agrees not to take any position contrary thereto. Upon receipt of an Election to Purchase for a cashless exercise, the Warrant Agent will promptly deliver a copy of the Election to Purchase to the Company to confirm the number of Warrant Shares issuable in connection with the cashless exercise. The Company shall calculate and transmit to the Warrant Agent in a written notice, and the Warrant Agent shall have no duty, responsibility or obligation under this section to calculate, the number of Warrant Shares issuable in connection with any cashless exercise. The Warrant Agent shall be entitled to rely conclusively on any such written notice provided by the Company, and the Warrant Agent shall not be liable for any action taken, suffered or omitted to be taken by it in accordance with such written instructions or pursuant to this Warrant Agreement.

 

3.3.8. Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the number of Warrant Shares issuable in connection with any exercise, the Company shall promptly deliver to the Holder the number of Warrant Shares that are not disputed.

 

3.3.9 Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 3.3.2 above pursuant to an exercise on or before the Delivery Time, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

-7-

 

 

3.3.10 Beneficial Ownership Limitation. The Company shall not affect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of a Warrant, pursuant to Section 3 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Election to Purchase, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of the Warrants with respect to which such determination is being made, but shall exclude the number of shares of Common Stock (a) which would be issuable upon exercise of the remaining, non-exercised Warrants beneficially owned by that Holder or any of its Affiliates or Attribution Parties and (b) which would be issuable upon exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 3.3.10, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rule and regulations promulgated thereunder (the “Exchange Act”), it being acknowledged by the Holder that neither the Warrant Agent nor the Company is representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder or beneficial owner is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 3.3.10 applies, the determination of whether a Warrant is exercisable and of which portion of the Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of an Election to Purchase shall be deemed to be the Holder’s determination of whether such Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and which portion of the Warrant is exercisable, and neither the Warrant Agent nor the Company shall have any obligation to verify or confirm the accuracy of such determination and neither of them shall have any liability for any error made by the Holder or any other Person. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 3.3.10, in determining the number of outstanding shares of Common Stock, a Holder or other Person may rely on the number of outstanding shares of Common Stock as reflected in (a) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (b) a more recent public announcement by the Company or (c) a more recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”). If the Company receives an Election to Purchase from a Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Election to Purchase would otherwise cause the Holder’s beneficial ownership to exceed the Beneficial Ownership Limitation, the Holder must notify the Company of a reduced number of Warrant Shares to be acquired pursuant to such Election to Purchase (the number of shares by which such purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of a Person that represents that it is or is acting on behalf of a Holder, the Company shall, within one (1) Trading Day, confirm orally or in writing or by e-mail to that Person the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Beneficial Ownership Limitation to any other percentage not in excess of 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 3.3.10 shall continue to apply. as specified in such notice, provided that any increase in the Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Company and any such increase or decrease will apply only to the Holder and its Affiliates and Attribution Parties and not to any other holder of Warrants. The provisions of this Section 3.3.10 shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3.3.10 to correct this subsection (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained. The limitations contained in this paragraph shall apply to a successor holder of the Warrant.

 

-8-

 

 

4. Adjustments.

 

4.1. Adjustment upon Subdivisions or Combinations. If the Company at any time after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time after the Issuance Date combines (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 4.1 shall become effective at the close of business on the date the subdivision or combination becomes effective. The Company shall promptly notify Warrant Agent of any such adjustment and give specific instructions to Warrant Agent with respect to any adjustments to the warrant register.

 

4.2. Adjustment for Other Distributions. In the event the Company shall fix a record date for the making of a dividend or distribution to all holders of Common Stock of any evidences of indebtedness or assets or subscription rights, options or warrants (excluding those referred to in Section 4.1 or other dividends paid out of retained earnings), then in each such case the Holder will, upon the exercise of Warrants, be entitled to receive, in addition to the number of Warrant Shares issuable thereupon, and without payment of any additional consideration therefor, the amount of such dividend or distribution, as applicable, which such Holder would have held on the date of such exercise had such Holder been the holder of record of such Warrant Shares as of the date on which holders of Common Stock became entitled to receive such dividend or distribution. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.

 

4.3. Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which each Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of the Warrants). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable contemplated Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date [and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Business Days of the Holder’s election (or, if later, on the date of consummation of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant Agreement in accordance with the provisions of this Section 4.4 pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of the Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of the Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term “Company” under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.

 

-9-

 

 

4.4. Other Events. If any event occurs of the type contemplated by the provisions of Section 4.1 or 4.2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, Adjustment Rights, phantom stock rights or other rights with equity features to all holders of Common Stock for no consideration), then the Company’s Board of Directors will, at its discretion and in good faith, make an adjustment in the Exercise Price and the number of Warrant Shares or designate such additional consideration to be deemed issuable upon exercise of a Warrant, so as to protect the rights of the registered Holder. No adjustment to the Exercise Price will be made pursuant to more than one sub-section of this Section 4 in connection with a single issuance.

 

4.5. Notices of Changes in Warrant. Upon every adjustment of the Exercise Price or the number of Warrant Shares issuable upon exercise of a Warrant, the Company shall give prompt written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of Warrant Shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in Sections 4.1 or 4.2, then, in any such event, the Company shall give written notice to each Holder, at the last address set forth for such holder in the Warrant Register, as of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event. The Warrant Agent shall be entitled to rely conclusively on, and shall be fully protected in relying on, any certificate, notice or instructions provided by the Company with respect to any adjustment of the Exercise Price or the number of shares issuable upon exercise of a Warrant, or any related matter, and the Warrant Agent shall not be liable for any action taken, suffered or omitted to be taken by it in accordance with any such certificate, notice or instructions or pursuant to this Warrant Agreement. The Warrant Agent shall not be deemed to have knowledge of any such adjustment unless and until it shall have received written notice thereof from the Company.

 

5. Restrictive Legends; Fractional Warrants. In the event that a Warrant Certificate surrendered for transfer bears a restrictive legend, the Warrant Agent shall not register that transfer until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the Warrants must also bear a restrictive legend upon that transfer. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the transfer of or delivery of a Warrant Certificate for a fraction of a Warrant.

 

6. Other Provisions Relating to Rights of Holders of Warrants.

 

6.1. No Rights as Stockholder. Except as otherwise specifically provided herein, a Holder, solely in its capacity as a holder of Warrants, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant Agreement be construed to confer upon a Holder, solely in its capacity as the registered holder of Warrants, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of share capital, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights or rights to participate in new issues of shares, or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of Warrants.

 

6.2. Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.

 

-10-

 

 

7. Concerning the Warrant Agent and Other Matters.

 

7.1. Any instructions given to the Warrant Agent orally, as permitted by any provision of this Warrant Agreement, shall be confirmed in writing by the Company as soon as practicable. The Warrant Agent shall not be liable or responsible and shall be fully authorized and protected for acting, or failing to act, in accordance with any oral instructions which do not conform with the written confirmation received in accordance with this Section 7.1.

 

7.2. (a) Whether or not any Warrants are exercised, for the Warrant Agent’s services as agent for the Company hereunder, the Company shall pay to the Warrant Agent such fees as may be separately agreed between the Company and Warrant Agent and the Warrant Agent’s out of pocket expenses in connection with this Warrant Agreement, including, without limitation, the fees and expenses of the Warrant Agent’s counsel. While the Warrant Agent endeavors to maintain out-of-pocket charges (both internal and external) at competitive rates, these charges may not reflect actual out-of-pocket costs, and may include handling charges to cover internal processing and use of the Warrant Agent’s billing systems.

 

(b) All amounts owed by the Company to the Warrant Agent under this Warrant Agreement are due within 30 days of the invoice date. Delinquent payments are subject to a late payment charge of one and one-half percent (1.5%) per month commencing 30 days from the invoice date. The Company agrees to reimburse the Warrant Agent for any attorney’s fees and any other costs associated with collecting delinquent payments.

 

(c) No provision of this Warrant Agreement shall require Warrant Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties under this Warrant Agreement or in the exercise of its rights.

 

7.3. As agent for the Company hereunder the Warrant Agent: (a) shall have no duties or obligations other than those specifically set forth herein or as may subsequently be agreed to in writing by the Warrant Agent and the Company; (b) shall be regarded as making no representations and having no responsibilities as to the validity, sufficiency, value, or genuineness of the Warrants or any Warrant Shares; (c) shall not be obligated to take any legal action hereunder; if, however, the Warrant Agent determines to take any legal action hereunder, and where the taking of such action might, in its judgment, subject or expose it to any expense or liability it shall not be required to act unless it has been furnished with an indemnity reasonably satisfactory to it; (e) may rely on and shall be fully authorized and protected in acting or failing to act upon any certificate, instrument, opinion, notice, letter, telegram, telex, facsimile transmission or other document or security delivered to the Warrant Agent and believed by it to be genuine and to have been signed by the proper party or parties; (f) shall not be liable or responsible for any recital or statement contained in the Registration Statement or any other documents relating thereto; (g) shall not be liable or responsible for any failure on the part of the Company to comply with any of its covenants and obligations relating to the Warrants, including without limitation obligations under applicable securities laws; (h) may rely on and shall be fully authorized and protected in acting or failing to act upon the written, telephonic or oral instructions with respect to any matter relating to its duties as Warrant Agent covered by this Warrant Agreement (or supplementing or qualifying any such actions) of officers of the Company, and is hereby authorized and directed to accept instructions with respect to the performance of its duties hereunder from the Company or counsel to the Company, and may apply to the Company, for advice or instructions in connection with the Warrant Agent’s duties hereunder, and the Warrant Agent shall not be liable for any delay in acting while waiting for those instructions; any applications by the Warrant Agent for written instructions from the Company may, at the option of the Agent, set forth in writing any action proposed to be taken or omitted by the Warrant Agent under this Warrant Agreement and the date on or after which such action shall be taken or such omission shall be effective; the Warrant Agent shall not be liable for any action taken by, or omission of, the Warrant Agent in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than five business days after the date such application is sent to the Company, unless the Company shall have consented in writing to any earlier date) unless prior to taking any such action, the Warrant Agent shall have received written instructions in response to such application specifying the action to be taken or omitted; (i) may consult with counsel satisfactory to the Warrant Agent, including its in-house counsel, and the advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered, or omitted by it hereunder in good faith and in accordance with the advice of such counsel; (j) may perform any of its duties hereunder either directly or by or through nominees, correspondents, designees, or subagents, and it shall not be liable or responsible for any misconduct or negligence on the part of any nominee, correspondent, designee, or subagent appointed with reasonable care by it in connection with this Warrant Agreement; (k) is not authorized, and shall have no obligation, to pay any brokers, dealers, or soliciting fees to any person; and (l) shall not be required hereunder to comply with the laws or regulations of any country other than the United States of America or any political subdivision thereof.

 

-11-

 

 

7.4. (a) In the absence of gross negligence or willful misconduct on its part (which gross negligence or willful misconduct must be determined by a final, non-appealable court of competent jurisdiction), the Warrant Agent shall not be liable for any action taken, suffered, or omitted by it or for any error of judgment made by it in the performance of its duties under this Warrant Agreement. Anything in this Warrant Agreement to the contrary notwithstanding, in no event shall Warrant Agent be liable for special, indirect, incidental, consequential or punitive losses or damages of any kind whatsoever (including but not limited to lost profits), even if the Warrant Agent has been advised of the possibility of such losses or damages and regardless of the form of action. Any liability of the Warrant Agent will be limited in the aggregate to the amount of fees paid by the Company hereunder. The Warrant Agent shall not be liable for any failures, delays or losses, arising directly or indirectly out of conditions beyond its reasonable control including, but not limited to, acts of government, exchange or market ruling, suspension of trading, work stoppages or labor disputes, fires, civil disobedience, riots, rebellions, storms, electrical or mechanical failure, computer hardware or software failure, communications facilities failures including telephone failure, war, terrorism, insurrection, earthquakes, floods, acts of God or similar occurrences. (b) In the event any question or dispute arises with respect to the proper interpretation of the Warrants or the Warrant Agent’s duties under this Warrant Agreement or the rights of the Company or of any Holder, the Warrant Agent shall not be required to act and shall not be held liable or responsible for its refusal to act until the question or dispute has been judicially settled (and, if appropriate, it may file a suit in interpleader or for a declaratory judgment for such purpose) by final judgment rendered by a court of competent jurisdiction, binding on all Persons interested in the matter which is no longer subject to review or appeal, or settled by a written document in form and substance satisfactory to Warrant Agent and executed by the Company and each such Holder. In addition, the Warrant Agent may require for such purpose, but shall not be obligated to require, the execution of such written settlement by all the Holders and all other Persons that may have an interest in the settlement.

 

7.5. The Company covenants to indemnify the Warrant Agent and hold it harmless from and against any loss, liability, claim or expense (“Loss”) arising out of or in connection with the Warrant Agent’s duties under this Warrant Agreement, including the costs and expenses of defending itself against any Loss, unless such Loss shall have been determined by a court of competent jurisdiction to be a result of the Warrant Agent’s gross negligence or willful misconduct (which gross negligence or willful misconduct must be determined by a final, non-appealable court of competent jurisdiction).

 

7.6. Unless terminated earlier by the parties hereto, this Agreement shall terminate 90 days after the earlier of the Expiration Date and the date on which no Warrants remain outstanding (the “Termination Date”). On the Business Day following the Termination Date, the Agent shall deliver to the Company any entitlements, if any, held by the Warrant Agent under this Warrant Agreement. The Agent’s right to be reimbursed for fees, charges and out-of-pocket expenses as provided in this Section 7 shall survive the termination of this Warrant Agreement.

 

7.7. If any provision of this Warrant Agreement shall be held illegal, invalid, or unenforceable by any court, this Warrant Agreement shall be construed and enforced as if such provision had not been contained herein and shall be deemed an Agreement among the parties to it to the full extent permitted by applicable law.

 

7.8. The Company represents and warrants that: (a) it is duly incorporated and validly existing under the laws of its jurisdiction of incorporation; (b) the offer and sale of the Warrants and the execution, delivery and performance of all transactions contemplated thereby (including this Warrant Agreement) have been duly authorized by all necessary corporate action and will not result in a breach of or constitute a default under the articles of association, bylaws or any similar document of the Company or any indenture, agreement or instrument to which it is a party or is bound; (c) this Warrant Agreement has been duly executed and delivered by the Company and constitutes the legal, valid, binding and enforceable obligation of the Company; (d) the Warrants will comply in all material respects with all applicable requirements of law; and (e) to the best of its knowledge, there is no litigation pending or threatened as of the date hereof in connection with the offering of the Warrants.

 

7.9. In the event of inconsistency between this Warrant Agreement and the descriptions in the Registration Statement, as they may from time to time be amended, the terms of this Warrant Agreement shall control.

 

7.10. Set forth in Exhibit C hereto is a list of the names and specimen signatures of the Persons authorized to act for the Company under this Warrant Agreement (the “Authorized Representatives”). The Company shall, from time to time, certify to you the names and signatures of any other Persons authorized to act for the Company under this Warrant Agreement.

 

-12-

 

 

7.11. Except as expressly set forth elsewhere in this Warrant Agreement, all notices, instructions and communications under this Agreement shall be in writing, shall be effective upon receipt and shall be addressed, if to the Company, to its address set forth beneath its signature to this Agreement, or, if to the Warrant Agent, to Equiniti Trust Company, 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120, or to such other address of which a party hereto has notified the other party.

 

7.12. (a) This Warrant Agreement shall be governed by and construed in accordance with the laws of the State of New York. All actions and proceedings relating to or arising from, directly or indirectly, this Warrant Agreement may be litigated in courts located within the Borough of Manhattan in the City and State of New York. The Company hereby submits to the personal jurisdiction of such courts and consents that any service of process may be made by certified or registered mail, return receipt requested, directed to the Company at its address last specified for notices hereunder. Each of the parties hereto hereby waives the right to a trial by jury in any action or proceeding arising out of or relating to this Warrant Agreement.

 

(b) This Warrant Agreement shall inure to the benefit of and be binding upon the successors and assigns of the parties hereto. This Warrant Agreement may not be assigned, or otherwise transferred, in whole or in part, by either party without the prior written consent of the other party, which the other party will not unreasonably withhold, condition or delay; except that (i) consent is not required for an assignment or delegation of duties by Warrant Agent to any affiliate of Warrant Agent and (ii) any reorganization, merger, consolidation, sale of assets or other form of business combination by Warrant Agent or the Company shall not be deemed to constitute an assignment of this Warrant Agreement.

 

(c) No provision of this Warrant Agreement may be amended, modified or waived, except in a written document signed by both parties. The Company and the Warrant Agent may amend or supplement this Warrant Agreement without the consent of any Holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties determine, in good faith, shall not adversely affect the interest of the Holders. All other amendments and supplements shall require the vote or written consent of Holders of at least 67% of the then outstanding Warrants, provided that adjustments may be made to the Warrant terms and rights in accordance with Section 4 without the consent of the Holders.

 

7.13. Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of Warrant Shares upon the exercise of Warrants, but the Company may require the Holders to pay any transfer taxes in respect of the Warrants or such shares. The Warrant Agent may refrain from registering any transfer of Warrants or any delivery of any Warrant Shares unless or until the Persons requesting the registration or issuance shall have paid to the Warrant Agent for the account of the Company the amount of such tax or charge, if any, or shall have established to the reasonable satisfaction of the Company and the Warrant Agent that such tax or charge, if any, has been paid.

 

7.14. Resignation of Warrant Agent.

 

7.14.1. Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving thirty (30) days’ notice in writing to the Company, or such shorter period of time agreed to by the Company. The Company may terminate the services of the Warrant Agent, or any successor Warrant Agent, after giving thirty (30) days’ notice in writing to the Warrant Agent or successor Warrant Agent, or such shorter period of time as agreed. If the office of the Warrant Agent becomes vacant by resignation, termination or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent, then the Warrant Agent or any Holder may apply to any court of competent jurisdiction for the appointment of a successor Warrant Agent at the Company’s cost. Pending appointment of a successor to such Warrant Agent, either by the Company or by such a court, the duties of the Warrant Agent shall be carried out by the Company. Any successor Warrant Agent (but not including the initial Warrant Agent), whether appointed by the Company or by such court, shall be a Person organized and existing under the laws of any state of the United States of America, in good standing, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed, and except for executing and delivering documents as provided in the sentence that follows, the predecessor Warrant Agent shall have no further duties, obligations, responsibilities or liabilities hereunder, but shall be entitled to all rights that survive the termination of this Warrant Agreement and the resignation or removal of the Warrant Agent, including but not limited to its right to indemnity hereunder. If for any reason it becomes necessary or appropriate or at the request of the Company, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

-13-

 

 

7.14.2. Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.

 

7.14.3. Merger or Consolidation of Warrant Agent. Any Person into which the Warrant Agent may be merged or converted or with which it may be consolidated or any Person resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party or any Person succeeding to the shareowner services business of the Warrant Agent or any successor Warrant Agent shall be the successor Warrant Agent under this Warrant Agreement, without any further act or deed. For purposes of this Warrant Agreement, “person” shall mean any individual, firm, corporation, partnership, limited liability company, joint venture, association, trust or other entity, and shall include any successor (by merger or otherwise) thereof or thereto.

 

8. Miscellaneous Provisions.

 

8.1. Persons Having Rights under this Warrant Agreement. Nothing in this Warrant Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any Person or corporation other than the parties hereto and the Holders any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.

 

8.2. Examination of the Warrant Agreement. A copy of this Warrant Agreement shall be available at all reasonable times at the office of the Warrant Agent designated for such purpose for inspection by any Holder. Prior to such inspection, the Warrant Agent may require any such holder to provide reasonable evidence of its interest in the Warrants.

 

8.3. Counterparts. This Warrant Agreement may be executed in any number of original, facsimile or electronic counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

8.4. Effect of Headings. The Section headings herein are for convenience only and are not part of this Warrant Agreement and shall not affect the interpretation thereof.

 

9. Certain Definitions. As used herein, the following terms shall have the following meanings:

 

(a) “Adjustment Right” means any right granted with respect to any securities issued in connection with, or with respect to, any issuance, sale or delivery (or deemed issuance, sale or delivery in accordance with Section 4) of Common Stock (other than rights of the type described in Section 4.2 and 4.3 hereof) that could result in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights) but excluding anti-dilution and other similar rights (including pursuant to Section 4.4 of this Agreement).

 

(b) “Trading Day” means any day on which the Common Stock is traded on the Trading Market, or, if the Trading Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market in the United States on which the Common Stock is then traded, provided that “Trading Day” shall not include any day on which the Common Stock is are scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00 P.M., Eastern Standard Time).

 

(c) “Trading Market” means NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange.

 

(d) “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company

 

[Signature Page to Follow]

 

-14-

 

 

IN WITNESS WHEREOF, this Warrant Agent Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

  BULLFROG AI HOLDINGS, INC.
     
  By:            
  Name:  
  Title:  
 

 

 
  VSTOCK TRANSFER LLC
     
  By:  
  Name:  
  Title:  

 

-15-

 

 

EXHIBIT A

BULLFROG AI HOLDINGS, INC.

COMMON STOCK PURCHASE WARRANT

 

Warrant Shares:__________________________  

 

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [  ], 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Bullfrog AI Holdings, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

 

Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

 

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.

 

Commission” means the United States Securities and Exchange Commission.

 

Common Stock” means the common stock of the Company, par value $0.00001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

 

-16-

 

 

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

Registration Statement” means the Company’s registration statement on Form S-1 (File No. 333-[____]).

 

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

 

Trading Day” means a day on which the Common Stock is traded on a Trading Market.

 

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

Transfer Agent” means VStock Transfer, LLC, the current transfer agent of the Company, and any successor transfer agent of the Company.

 

Underwriting Agreement” means the underwriting agreement, dated as of [  ], 2024, among the Company and WallachBeth Capital, LLC as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with its terms.

 

VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Common Stock Purchase Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

Warrant Agency Agreement” means that certain warrant agent agreement, dated on or about the Initial Exercise Date, between the Company and the Warrant Agent.

 

Warrant Agent” means the Transfer Agent and any successor warrant agent of the Company.

 

Warrants” means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.

 

-17-

 

 

Section 2. Exercise.

 

a) Notwithstanding the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

 

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $[__]3, subject to adjustment hereunder (the “Exercise Price”).

 

c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

  (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

 

3 Equal to 100% of the public offering price per share.

 

-18-

 

 

  (B) = the Exercise Price of this Warrant, as adjusted hereunder; and
     
  (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).

 

d) Mechanics of Exercise.

 

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Underwriting Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.

 

-19-

 

 

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

-20-

 

 

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

-21-

 

 

Section 3. Certain Adjustments.

 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b) Reserved.

 

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

-22-

 

 

d) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Stock (not including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)(each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Common Stock (or shares of common stock, as applicable) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting(A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Business Days of the Holder’s election (or, if later, on the date of consummation of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

-23-

 

 

f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g) Notice to Holder.

 

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

h) Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

 

Section 4. Transfer of Warrant.

 

a) Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

-24-

 

 

b) New Warrants. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant Register. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section 5. Miscellaneous.

 

a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

 

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

 

d) Authorized Shares.

 

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

-25-

 

 

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding the foregoing, this exclusive forum provision shall not apply to suits brought to enforce a duty or liability created by the Exchange Act, any other claim for which the federal courts have exclusive jurisdiction or any complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, other employees or agents. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.

 

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

-26-

 

 

h) Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878 Attention: Vininder Singh, Chief Executive Officer, email address: vin.singh@bullfrogai.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.

 

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of the beneficial owner of this Warrant, on the other hand.

 

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

o) Warrant Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.

 

********************

(Signature Page Follows)

 

-27-

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

  BULLFROG AI HOLDINGS, INC.
     
  By:  
  Name: Vininder Singh
  Title: Chief Executive Officer

 

-28-

 

 

NOTICE OF EXERCISE

 

To: BULLFROG AI HOLDINGS, INC.

 

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment shall take the form of (check applicable box):

 

  [  ] in lawful money of the United States; or
     
  [  ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3) Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

     

 

The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

     
     
     
     
     

 

(4) Accredited Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

___________________________________________________________________________________________

Signature of Authorized Signatory of Investing Entity:

 

___________________________________________________________________________________________

Name of Authorized Signatory:

 

___________________________________________________________________________________________

Title of Authorized Signatory:

 

___________________________________________________________________________________________

Date:

 

___________________________________________________________________________________________

 

-29-

 

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant.)

 

FOR VALUE RECEIVED, [  ] all of or [  ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name:  
   
Address:  
  (Please Print)
   
Phone Number:  
   
Email Address:  

 

Dated:________________ ___, _______

 

Holder’s Signature: _______________________________________

 

Holder’s Address: _______________________________________

 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

-30-

 

 

EXHIBIT B

 

[Form of Election to Purchase]

 

(To Be Executed Upon Exercise of Warrants not evidenced by a Global Certificate)

 

The undersigned hereby irrevocably elects to exercise the right, represented by Warrants evidenced by this Warrant Certificate, to receive ____________ Warrant Shares and herewith (i) tenders payment for such Warrant Shares to the order of Bullfrog AI Holdings, Inc., a Nevada corporation, in the amount of $ _________ in accordance with the terms hereof, or (ii) if permitted, makes the payment by the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 3.3.7(b), to exercise this Warrant with respect to the above number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 3.3.7(b).

 

The undersigned requests that a certificate for such Warrant Shares be registered in the name of ___________________________, whose address is _____________________________ and that such certificate be delivered to _______________________________, whose address is _____________________________________. If the number of Warrants being exercised hereby is less than all the Warrants evidenced by this Warrant Certificate, the undersigned requests that a new Warrant Certificate representing the remaining unexercised Warrants be registered in the name of ___________________________, whose address is _____________________________ and that such Warrant Certificate be delivered to ______________________________________ whose address is _________________________________.

 

  Signature,  
     
Date:    
     
  [Signature Guarantee]  

 

-31-

 

 

EXHIBIT C

AUTHORIZED REPRESENTATIVES

 

Name   Title   Signature
Vininder Sing   Chief Executive Officer    
Dane Saglio   Chief Financial Officer    

 

-32-

EX-5.1 5 ex5-1.htm

 

Exhibit 5.1

 

A close-up of a logo

Description automatically generated

 

January 29, 2024

 

BullFrog AI Holdings, Inc.

325 Ellington Blvd., Unit 317

Gaithersburg, MD 20878

 

Ladies and Gentlemen:

 

We have acted as counsel to BullFrog AI Holdings, Inc., a Nevada corporation (the “Company”), in connection with the Registration Statement on Form S-1 (such registration statement, as amended through the date hereof, the “Registration Statement”) and the prospectus forming part of the registration statement (“Prospectus”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the proposed offer and sale by the Company (the “Offering”) of (i) shares of the Company’s common stock, par value $0.00001 per share (“common stock”), including shares that may be sold pursuant to the underwriters’ over-allotment option (the “Shares”); (ii) warrants to purchase shares of the Company’s common stock (the “Company Warrants”); (iii) pre-funded warrants to purchase shares of the Company’s common stock (the “Pre-Funded Warrants”; (iv) shares of common stock issuable upon exercise of the Company Warrants (the “Company Warrant Shares”), including shares that may be sold pursuant to the underwriters’ over-allotment option; (v) shares of common stock issuable upon exercise of the Pre-funded Warrants (the “Pre-Funded Warrant Shares”), including shares that may be sold pursuant to the underwriters’ over-allotment option; (vi) Underwriter’s warrants that will be issued by the Company to the underwriter (the “Underwriter’s Warrants,” collectively with Company Warrants and Pre-Funded Warrants, the “Warrants”); and (vii) shares of common stock issuable upon exercise of the Underwriter’s Warrants (the “Underwriter’s Warrant Shares,” collectively with Company Warrant Shares and Pre-Funded Warrant Shares, the “Warrant Shares”), including shares that may be sold pursuant to the underwriters’ over-allotment option.

 

In rendering the opinions below, we have examined the Company’s articles of incorporation and bylaws, both as currently in effect, the Registration Statement, and the exhibits thereto, and such other records, instruments and documents as we have deemed necessary in order to render these opinions. In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents.

 

Based upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that the Shares and the Warrants, when issued and paid for as set forth in the Registration Statement will be duly issued, fully paid and non-assessable, and the Warrant Shares will upon exercise and payment therefor will be duly issued, fully paid and non-assessable. In addition, the Warrants are legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

 

 

1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036

T (212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW

 

 
 

 

A close-up of a logo

Description automatically generated

 

The opinions expressed above are subject to the following additional exceptions, qualifications, limitations and assumptions:

 

A.Our opinions expressed herein are limited to the laws of the State of New York and Chapter 78 of the Nevada Revised Statutes and are based upon the laws of the State of New York and Chapter 78 of the Nevada Revised Statutes in effect on the date hereof and as of the effective date of the Registration Statement. We do not express any opinion herein concerning any other law. We assume no obligation to revise or supplement this opinion in the event of future changes in such laws or the interpretations thereof or such facts.

 

B.The opinions expressed herein are subject to (a) the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors’ generally, including without limitation the effect of statutory or other laws regarding fraudulent transfers or preferential transfers, and (b) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, liquidated damages, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding in equity or at law.

 

This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act in connection with the filing of the Registration Statement and may not be relied upon for any other purpose without our prior written consent in each instance. without our prior written consent.

 

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the use of our name under the caption “Legal Matters” in the Prospectus. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, and the rules and regulations of the Commission promulgated thereunder.

 

Very truly yours,

 

/s/ Sichenzia Ross Ference Carmel LLP

 

Sichenzia Ross Ference Carmel LLP

 

 

1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036

T (212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW

 

 

EX-23.1 6 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the inclusion in this Registration Statement on Form S-1 of our report dated April 25, 2023, of Bullfrog AI Holdings, Inc., relating to the consolidated audit of the consolidated financial statements for the periods ending December 31, 2022 and 2021, and the reference to our firm under the caption “Experts” in the Registration Statement.

 

/s/ M&K CPAS, PLLC  
www.mkacpas.com  
Houston, Texas  
   
January 29, 2024  

 

 

 

EX-FILING FEES 7 ex107.htm

 

EXHIBIT 107

 

Calculation of Filing Fee Tables

 

Form S-1

(Form Type)

 

Bullfrog AI Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

  

Security

Type

 

Security

Class Title

 

Fee

Calculation

or

Carry

Forward

Rule

  Amount Registered   Proposed Maximum Offering Price Per Share   Maximum Aggregate Offering Price(1)(2)   Fee Rate   Amount of Registration Fee 
Fees to be Paid  Equity  Common Stock, par value $0.0001 per share(3)  457(o)   904,978    6.63   $6,000,004    0.00014760   $885.60 
   Equity  Pre-Funded Warrants(4)(5)  457(g)                    
   Equity  Common Stock issuable upon exercise of Pre-Funded Warrants(5)  457(o)                    
   Equity  Company Warrants (4)  457(g)                    
   Equity  Common Stock issuable upon exercise of Company Warrants  457(o)   904,978    7.29   $6,597,290    0.00014760   $973.76 
   Equity  Underwriter’s Warrants(4)  457(g)                    
   Equity  Common Stock issuable upon exercise of Underwriter’s Warrants(6)  457(o)   47,216    7.29   $344,205    

0.00014760

   $50.80 
      Total Offering Amount           $12,941,499        $1,910.16 
      Total Fees Previously Paid                     $ 
      Net Fee Due                     $1,910.16 

 

  (1) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(o) under the Securities Act.
     
  (2) Includes the price of additional Company Shares and/or Pre-funded Warrants that may be issued upon exercise of the option granted to the underwriters to cover over-allotments, if any.
     
  (3) This registration statement also includes an indeterminate number of securities that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”).
     
  (4) No fee required pursuant to Rule 457(g) under the Securities Act.
     
  (5) The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants issued in the offering, and the proposed maximum aggregate offering price of the Pre-Funded Warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and Pre-Funded Warrants (including the common stock issuable upon exercise of the Pre-Funded Warrants), if any, is $2,847,002.
     
  (6) Represents warrants to purchase an amount of shares of our common stock equal to 6% of the number of Company Shares and/or Pre-funded Warrants issued in this Offering (excluding any shares sold to cover over-allotments, if any), at an exercise price per share equal to 110% of the combined public offering price.

 

 

 

GRAPHIC 8 forms-1_001.jpg begin 644 forms-1_001.jpg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�!Y]H_C0ZE\)I=& MO_\ 0O&_@.YCFN--D?=*$MG!#HW_ "T5H"1N'KSBOHRWN([NWAGC(:.1 ZL. MX(R#7CGC3P+H^M_$Q;;48R+'Q18-]GOK:39+;WD*D;HW'3?"_3HVPY!JE\)O MB5J'@_PC;Z5XTC6.RTF:325UZ($Q[H9/*C2X7K'(R^601E6W#% &+\9/#VDV M/QD\/R7ZS'P_J-O<7&KQQ$!;.;"0PWP/56#,JEAT^4]J["'XMKX%AF\.^+1< MZCX@M%_8VHVNTD7(7("X56\S)&"I(SD5D^(/$>@>,O%$]SI.O6]Y_;$ M'_"+1/\ 8VN((92S22AN@)(3'/&1WZ5SF@:'X&T_P?I-K=ZSJEUJ-YKDVCV& MO,CQW]Q(#)"T3%*6RQPX'*]^,U]B:9XZ\3?!G2=%CU"(>,? $T$:6&M6L: MPW=G%M CCN$^XQVX 8;,H7;2[Y9Y8P/.M6!2> M'/9XSAE^N,'M4WC+Q)#X0\+ZGK$XW+9P-($'5VZ*H]RQ 'UKPRTM?"K:M9-; M_P!L6^G37KZ99@0F.\TF[!P8X[A6W>6?^>3;@,=AQ5[Q3J'B>'Q9H?AZ\#>- M= T]UUN]GL80E\(T)$"2QY"R'S/F^7!/E_=KRRSJK[3;KX?_ 'U5)&W:Y0*/917!0^&;*Z\&PR30+<:=>^*K33TCD'RO:VZ_9E7'I ME9/SJY\6OCEX7\3Z%+I.BZBMWJ-E>03WEBR%)5C1&G7*, ?OQJO3@FM[Q%9V M_A/X4^$=/GNH1/IFHZ;]M8N/W([B1 MUT_6+.;3KELO)?60D)1 /XI48",COE#W->?Z'XJ\/:5\5M=T3QEK>DZ);75Q M'K=[;/<9*[V+QZ9Z!4DS+)C@LP%9_P"VMX^OKK0]%\5:1,;6ST?5VM]&N(T5 MVNKD1L)K@9!_=(,J".K9;L*_,CQM\0M6C\172^86=7W2S3?O'E8\EB3]:VR_ M X_.<:LORV*E/E*C8^. MOAOK4>G7,-_;7EA,L,ULX=&.PE2".#SBO*K_ .)UIX@U+X<:9##<:[?6]DNM M76GZ./#VKZOXHN[708H=,GCALK*1Y#;J2KEWD&-S80CY1CG'(SDT?X2O MIOA]]3&J6*176B1PW-Q=QO&EQ^[3]Y,"V$V ':5P06.>@K6_:*\>:?H/P]UK M1D=KO7M2M_LMMI]M\TA,C!%9_P"XF6QN; K.UZWD233U\9#^W=6EVG2_!6EM MF!=O1Y2?]9M(YD?"+V&:W/G3BKRS\.:?X7E\C4HFMFL+?2+74M4LFC@DCAC* MNT;Y!.]L88?Q8QGK7E7P4^)GPY\4^.+CP!:>*WM]1NH?[/BBO=-,#SE6B$T3 MR$X)*PD*!_>->U^*-!NO%WC[0_"VO:U _B:ZM9=5CTVW#&TTJ",A$**&4M)E MSB1NZ_=Q5&ZTWX4^&(_&%MX]LM(FN=+U=IH)IK=7OF$J)(C1[!YFXN6P1WH+ MYI-6N=G\5+JY;2[>TU#2[;0K+3]0AFTJ625;E+V5"0D1@4!@I4ECS\H7)Z5\ M6?'#]D/4]>T$_$W0];AD:UDB^S:=JLOE_P!I)%U>W#?=#%<)'R64 ]6Q7KJZ M+\3_ (E>)-5BAM+Q/#>GA$\O4)DGU.TM7.XVT>2%,TB8+[SN"D+DYY^BOAIH MO@K5+@7]E)-JNNVBB.4ZT2;VSQ@;/*8 0CCHBA>.*"#Y<^*W[-5I^T]X7TS7 M?AKIE]X6O?LRO+?7UR]O97;!?FB$!)8,&!7< H&#FOCRV^"?C_0/B!H7@2TL M+BR\3:Z_D26UTFUH)48AV5SD;=OSA^F"#7ZWQM_PK;Q_Y+?)X;\3SEHV_@M- M0(RR^RS 9'^V#_>K&^,%QH&@_$[X>>(]411=V+7Z0S1H7F8- !Y2*.69F*X MH'9O89X \2Z%\%_ NE>&M4T+5/"FG:3;+";RZA\ZV8@?,YFCR,DY)) ZU\Q_ MMT_M3W&K^ ['P[X,ECETO7;ORFGAK)9Z.DB_V=X3A/F27$I.8Q.!_K92<8B'RKU.<9%?2?V?]$\6>)+CQ MOXRT.T/B:ZB6*UAMB4_LR%>%=+M8O)TDW*HZ6N MMQ+?18] _P L@^I8TG_"5>,M"7_B;>$UU.%?O76@W0D./7R9 K9]AF@#K->T M"P\3:;+IVIVZW5G-C?$S%)88(5"1QH,*J@8 ^E?4#I%[G!M-6C:TD!]/G !/T)KL(Y$FC5T8.C#(93D$>H- ' ZX MG]E_&;0+HC]QJVEW.G29&0TD;+-&#_P'SOSJUJ7PFTF6ZDOM&EN?"^IN=S76 MCR>4'/J\1!C?\5S[U7^+P_L^Q\/ZX/E.DZQ;3NWI$[&*3_QV0UZ!F@#SU]7\ M<>$\#4=-A\76"];K20(+L+ZM QVL?96_"M/2_B5H_B&VN8]+NEDUB&%I!I5V M#!<[@,[3&P#=>,@$5U_!KS'XX?#+6?B9X?6PT/4-*T6]SD:E?:?]IFA/9H2& M78P]>: +_P '?C-X>^-?A<:OH5Q\\,A@O;"4@7%E.IPT4B]B"#ST/:O0*^$_ MAC^PS\4_@AXZD\7^%OB;I]WJ$SE[VUO[:58=0!.667!/).?FZ@G-?55I\68= M+DAM?%VF77A6[8!?.N!YMD[?[%PN5_[ZVT >A457M;R&^MXY[>6.>&0;DEB< M,K#U!'!J>@!:*3ZNUD)=X+MH8XVS]U%'&!Z44*.*QV(^JX"BZM2S;2Z)=6?897P]' M&X2688O$1H45+E4I7=Y6O9)?BS]F/ ?BVZU*:\T'7D2W\3::%^T+&,)=1GA+ MF+U1NX_A;(-5-4\?7FO7\^C>"X(]2OH6\NZU2;/V&R/<%A_K9!_<7\2*^*/V M9?B?XD_:;M4T#4M>8:KI%HUYIU_M*3WL9(5[6XE4Y\H\ XY.0<\5]T?#+6M- MU/PW'!8:>NBO8G[+=:3@*UI,OWD('4=PW\0(-8TJJJ1O9I[-/=-;IGD9ME=7 M*,4\+6:;LFFM4TU=->31RGC#X6QZ;X)UO4H99M:\81HM^FK7F#,\L#"5$0=( MTRN-BX&#WKTW0=6AU[1;#4[=MUO>01W$;>JNH8?SJ[(JLC*PRI&"/:N!^#C' M3]"U'P\Y_>:#J,]BH/7R2WF1'Z;' '^[6QXQZ#7 ?"'_ $O3O$.K'[VI:W>3 M _[*/Y*_^.Q"NOU[4DT70]0U"0@1VEO).Q/HJEOZ5Y3X-\37>@^!O#?A;0+1 M=5\5O81SW".3]GL?,&\RW##IRQ(0?,WZT =WXP\!89-2UB\)6STNV MP9IV]?\ 90=W/ %>7?$CPQ>:?X93QMXGN([WQ!IE[:WD,,)/V73HUF5F2('J MVW[TAY/L.*[C2]&T+P#'>7FMZ]!+K]\N+S5KZ9(Y7XX2,$_(B]D7]3S7R%\: MOB'-KEY?^"M/\27VI>#]*B2V=VN29-2=U$C--( "RC<% ''RUY&:9E2RO#O$ M54VEIIW>QXV<9KA\EPLZ7;Z]I5YIMV&>UNXFAE56*DJPP1D=.#7QE^S+^TI:^$=S[FN6X^GFF%ABJ-^67?<=I_P^TC3?%#Z] LRWK0^2%:4F)?E5 M2P3H&(103WVBNHID!;/P/+%XCTV\L/';*UM'96;^5>6\@P0 MQDZ/#G# G(;TS7UR1GFORO\ ^"CEOJT7QLU5VW 3:7%]@;'5!G<%]PV[\ZX< M74G3@E3:3DTKO97ZOT/MN$,IPN<9E[+%W<(1E-I:.7*MEZG30_\ !1CQ;=:+ M)H]_I>F2RR6OV9[NUF9+@'&UI "2-V,\>M?1E\WP^^,G[.MYXB\,6BV\^FV M2.>']S>6SQ;24D*]3QGG(.EM9B.>QNB46>7RGW&.0?==1CJ"#T..M>_GV25>&<90PSQ4<0JD>: MZ6L3WL91RG.LFQ.8X/"/#3H22W;4TW:VO5;Z'W':_P#"<:!##,M*DC M5Q#=;;6^4$9&UP/+DX]0OU-7M/\ B9X?UN=M(U5)-%U&9=CZ9K"]&BMYV34K?3[?[58W*&*>,^6HR4/)4]F&0?6F_$+ MQ)IFH3/X:MM&A\7:Y(H;^S7 ,5L#P))Y""(E_P#'CV%>;*X)V#='$WEC\3VK8T7X ZAH,T.K0>(?MNKHC(EAJ M4)N=-MU;K'!&QWQ#'&X-D]_2O%?"OB36O@+XVTJ+Q':72>&]#U"?2[RX@W7, M%E#=#S(#&P^<0YVC:Z_*5.#C- 'K^@^&X-%FU^_T+P[/JME8>)C//;K>L;AG MBB'[V%3\K8,C#R\C..I/%-:/^PGH$VO:)\4/A#\1;ZWOED6_LY]0?[=!.#U5I 0Y##*G. M30!U'B+QM\)/!^GZ3JU[8R)KFD2?VR8]6E=9;1HG6-X1(?XE$1"H>&$5;'[* M?Q.T3]I+P_J.KVEO?:$= UNY\NSAO699EE.]99 0.2"<&M;Q9HO@K5+] M$^(_@=;.YUJ0)?W$J^;:F5%*@I*#GRV&2>!][YL$US_@GX,^'OV+?%^J>(M( MU9HO /B#RX+VSO9 SZ=("?+F1NKQ_,5/!*@@\@&@#V.^^&OASP]IJWD^H36* M6EP^HF[OKK,?V@\B:0,0&93]*\V\.Z[)KFCW/C.Q\=:+9^)KX.D=O<7444%U M:*2(1*H8[),98..FX @BMGXL>/I?B)H-OX3\+Z%F>'-/,4+:'X/MG:;4[K +10J M2=BY(5I#@=< &@#B/C)\3-?^.GQF\,2Z-'<:5X\6V.A:N^EY=7EBF(\Y3'G> MA7YCCT^E?6&I:OX3T/X01_#+4-"U6^TW4;>YNI=0N+D1W6H7%O*PD9F#EP[/ M$V!C(4"O%_!/P#G;XU^-M6TU+[X:K9>5:Z7H>CS![T33H EL)/X,@;W/.%W5 MZU\8/'&L?!#X=VFB7T%B_B+PPL=S?ZR\*3IJ<+N/]&B=ERDK*S$@\@+G)W4 M)XF;P_\ %9M B\2^'KHZ=H^D/'%:V-_+'$C9=!#$BJ Q/D_,QZ=LUQ]Q^R+\ M.?%FL:9]J\(PPI<6LA-Y)K5PB?:$+YA.%^ZNPY*YKXM?$"X^&^FOX9N[71[_ %F\ M\G3;?4[&U$9B@EW_ .NC*LJL-HPN<-GH*=-RHU57I-QDE:Z=G;M='HTLPQ%* MB\-&;Y&[N/2ZZV[GEOPI^&/A'PK$MYH'AS^P9I]-D$-^^KW$3+.N_,<;*-R+ MM7)8XSG&":]F\!^*K;P;\&8M2T*P-K'J&V06MQ<'Y)G81L_F$?*NX;BQ&>^, MU\->+?VBOC!X)\5Z)X5U^X\-VBN+> W4-C;2Q2VGF8.\@8 QNR.,$5[MX+O? M$WBC]I>_70YK[Q!X N;.2;2K06T5K;7&W8DD3,PPL:[B<@%B",#FLXPC#96, M\5BZ^.J>UQ$W)V2N^RV7HCM]:^)FE?\ ".Z9X;TS3_[&UN^\0Q0:OXAO0]Q9 MK+!.'9GN'PTV=F0#@8]!7K5O\0O /PQT?5-5LM0G\9:LT;W%_?::OVVYGV== MSI\J*",!<@#L*^)?CS\'/B))^TAI7A&ZU>\D\/Z]:1ZA=VN@PD0VME$S+*J1 MJ!O**S#< "V[I7U/X[_93\ _%CX6BW^'-]_PB=U'$JV=_HL[Q1-(@ "7$:D! MN@SN&X'FK.(^5-/\0?$^/]J72_BIXST[6/!_A[Q%*ME)*"$FT_3)G\N$."#Y M8+!3N(!^\>*Y;PY\=(?"_P"U%XKOK3-WX.U#5C;PW]\SW$-M(A$45[(YR7"9 M+8)P2P->.^(KCQ%\/_B%+HWCRXU'6;C3=2C@U"R?4'FCNH4;+(.2'#"> MF:^W?V==0\-VNN>&$N_ ;>#;+4)9[![;7]J_:;:6(F%$C8?,@*Y+LJP_\ 'OJEB_E74)]G'4?[)R#Z5E^,/&%C\)-$T.SL-"NM1CNKA;"RT_36 MB4K\I8N/\3?&CQE+I9CT'X<:O'?2,%\^]N[$I"IZN%%Q\[#LN0# MZUXN,SG+LOJ*GBZ\82:NDVD[=[,N,)2^%-GB/[8WQT\3?"WP\O@>>XL-5OM0 MC$\>L"/RYX85;AGC'RB7<.'4XX)P*^ [C]J#79_%4&K3>*=:FU.WD)AU![@L M8V/!9-O&4"V-O<6VM+I[C5?^$CUBQ6XD(!MH)5BEC=]=MB7BE5FB8 ,<[E1R/937K<.O MAO.*N)J9SC.2,8WI\KLGYZ;GZS'/*&093@X972IU*M2_MN97:UT6NRMV/TS_ M &+?C1)\=-4NYO%MS_:?BG1H$^PS$ 1"W<8:1%''F$X#-UQ@#%?8&M8^ GBBWOM:T.34KC6]-\G1H=+U2QD-W&N'DD4-,,@ *>/6OLU?C1JZ+ M_P DU\1_^!6G_P#R37R='B+*\/3Y,3BH)ZVO))M)M7W\CY3BFG@I9I.>61_= MR2=DM$VE=+R3/6*05Y)X=^.&I^+;[6+#2_ .L?;M+E2&YCO+NTC1&=-Z_,LK M9&/3-;%YKOCN.U>XNX/#'ABV'_+:^O9+@K]<+&O_ (]7U-*K"O"-6E).,DFF MM4T]F?'';ZCI-CK$!@OK6"\A/'EW$:N/R(KD&^#^C64K3Z#=:CX7G;D_V3=, MD1/J86S&?Q6N(D\::MK9:&Q\8W^M3YPR>$]#0QK[&:;(]#U>VN+2 M1 =2 L;E&"Y5@ZDHS @'&U:^;-7_ &H/&/BVSM_[*URXT>PL8UM&:!HI)KN= M% EEDD (Y;. N!CKS777WP!;QAJLFCWC?VGJ18?:=+LI?]&L5/\ S]3J H;_ M &(P7/\ >QS7++^S#X9\%^"+@_\ "276BWUKK4^E3Q1VXFAN9 Q9&CC9@4_= MY/WN<9.37SV=X7&XK#L?$J+7-$U^87NI:2(9DOUC"&:&0L%#@<;P489'48-?0P/7%?,/P]^"&D_"K M7$TR;4K^WO-<83:;XLM)?(EDDVY-G*@^0@#+(""&!/<5Z]]N\<>$]OVNS@\8 MZ<#S/8!;:]0>IB8[)/\ @)4^BUZ6!IUJ6&A#$RYII:OS/5RREB*.$IT\7+FJ M):ONST.H;BWCNHFBEC66)AAD=0RL/0@USGASXD:#XGN#:6UY]GU)?OZ?>H8+ ME/8QO@_EFNHR*[STS@KGX3V%C=27GAF_N_"=Y(=S_P!GL#;2'U>!LH?J #[U M2O\ QAXI\"V-Q<>)=*AUC2[=&DDU713M=449+26[G(X_N,WX5W-UKFGV1*3W MMO%)D#8TJALDX QGN>*\N^)_C&/Q9X:UW0-+DTT6DL;:??:C?WPA6UDE!14\ ML NSDG ' )[U,KJ+MN;4(PE5BJCM%M7].I\&?&[_ (*+>+[KQ%*=!U+_ (1O M1RY%K#!$LD\B X#NQ!QGT%>O?L<_MS:G\1_%-EX8\63Q:D=0)CL]3C01.LH& M=DBC@YQP?6OE;QW^PSXYUS4U6PU3P])Z+YN%'R0KQR22M:SP>!AE%#&TL1*6 M+E*TH-:*-_\ +8_9L9B,JJ5L3EWL*4<+"#<*B^-R2NM;W;;T:/U4B[U)6'X< M\5:/XG^UC2=0AO\ ['+]GN/))_=2#^$^]6]*UK3]>@EET^\AO8H9GMY'@<,% MD0X9#CN#P14'XF:-%%% !1110 4444 %%%% !1110 444FZ@!:*0'-+0 445 ME^(?$>F>%-)GU36=0M]+TZW7?+=74@CC0>Y- %C5-5L]#T^>^O[B.TLX%WRS M2G"H/4FN8F^+'A15_=:Q!>'[='IS+:YE*7#G"HVT?+[D].]?-DW[:7ACXW?$ MZW^'WAEK6/PH,SZOXBU20PK+%&01';)U9F8 GMGBO4;5O",VIZU-H>D^)]= MFU2[AO9_L]K)';^9$VY"CR!$QD\X))]: ,G]H*^\(?&;X?ZQX.GU6;3+K[5& MD-S):N5216?$G;='F.0%@?X37P/XA_8!@UC4Y[ZU\:W+1M=1PRB'0Y9%9I&* MI(AWC*,RD ^HK]!+CX4W'B:2Z$OA"6TL[RZ2YD&J:RI90CNZQJD:-A-TCG;N MZMUK=F\*>&/AW?:(=0O+B"XU+5H(;.UC8RH)\/Y<8&.(T+LPST)!]*Z<#BL1 MEN)>+P>#7TAX8DO-8\37GB.TU[2[JZTNY;2 M]7:SMY(([V.-//D0 M80.-OS*HZ=^!S7%0^%(OA5XFO-(T%(?"]GK=RUS#AT=U^TMX.M---X_ M]J&,NJ(!I\G[P-G:X)&-AP<,2!7,Z+X_UZZ^*EQ<:%X()+N^TR?2))(1:ZK;ZI-YIM[-23'):R8 M"RVZ%FW+]Y0:G!*PBD: M+R\;(L.&+D98+Q@==#S"U\7/%WQ#\5>&]9TO2M7T6UTMBFG:CJ-G:.T:F:18 M6@BDD;$D@#DE@ %QSSQ7H?@GX">'=!T==-C\0:UK$$9_T@2:D0)9,8+2"/&6 M(]>U?"/[3G[(?B7X2>(-%N-&\3:UX@^'MY>(IL#=S/<6,0(9R54_,BKD[P,C MJ:^UO"^O:;\ ? =I:MX)FT[0%5/*N]%N5OS=.X^4D,5E=W^C?E0!UVK>&? 7 MPWTI]5N-!LAM8)%N@^TW$TA.%CCWY9G)X %>-_$WX.V?CSQ!I6I^+8]4T37M M;CEBM!H8C:*PMX(7F$,JL,2RL%;G'!X& *]%^'_B+2O&WB)?$>OZI:PZZNY= M/T&XS7TUR+6\3;LMW6W MD9L\YR\>]1CU/(K&M1IXB#IUHJ47T9S8C#T<53=*O%2B^CU1Y-\"/@Q\-M3\ M&7AM]).K7#3^3=WFHL))PZ@$*KJ!LP&Y5<8.0:O>(?V6]%ED,MEIFBZY%U^Q M:]9KO'^YW"O1OA'-I%]X'L=0T72)-$LKQI)3:3-ND5P[*Q=LG)R MOJ:[0<>E.G3A1@J=-6BMDBZ5*G0@J5*/+%;);(^59/A#X4\,S-'=?\)C\,KC M.U+RSU26ZT[_ ("_S*H_WU6NJA\%>/O#6DR:UX:^(\OC&TMXFECMKQ/.-P0I MVH"AV]<= #7T RJRE2 5(P0>AKA]0^$NBM=/?:,UQX7U%N3<:/)Y*N?]N+[C M?BN3ZUJ;' 3>)?B3K$FNZ/<6TUG-;W=M%8ZEIEH\:,KGYV: MX_XF#QEJ&F^)'_X1U_$M[!J,"6=U)8H#:6OG 2K&LX 8_VHV/EN?H5KD_'WQ8T3Q7:Z;X/M+^;2M?UR]CM7 MT^]C:VNXH%8/,^UL<;5(W D'=P:32DK,UIU)T9*=-M-=4>/>(O!>H6FO:G+I MWA]3I@O46&==#A,N2DA\OB/)CWB-2PR,'.[DXVM-USQGX7TV;3K.PNM*C:8. MT<6E".,W!W@Q#"8: @1YDZ)5\1WUOJGA"&T^R6%M"&"_ M:AM4Q(P.))"=^<'Y0ISCK7S-^S+K6A_M&-<^#M<\7:SX8\9Z.SOX?6WOG\F4 MHY*RL&8^8Z\ QYVE1D"ERI.YK4Q5:K'DE)M;VZ'UQ\0/%EUK']CK\.Q97,FG MNS:EJ%L\:R16:'!MXV(X9BV0./N&MWP?>CX16::?K5G$VD3-O'BBQ4LDSG^* M\'+(YS]\DH?]GI7F'P)_X2G7/#NI>#]4UK1[[Q-HUW<6]]IVM:4#!=*)6_?P MNC!GC)/OM/!KMYOAK=6$;>?X"AD+##R^'-[F:_U[0-S64$# M//!/$PGLI94 RF6RGS8X-.N])OOAK! OA/4_&7A6&.0R2Z+K%H;RSD!Y(CF5 M9%A/ID[?4"OE36O'\.L^,/%)N]1:YUDZE(US)=*L4LH.-AP#MP%VK\O'R^]? M-Y]F.(RS#>WP\.=W2]/-GR7$V<5\FP*KX:ESSNEY)=VCU]M-GT/X5OKWPCCM M+XKIT::U#+?O9R:9=%0)I&AQ\\;98LC#'<=ZXO\ 9/C^-?P)\1/8Z5I=O\0_ M!-\S3W5EHEXLL5LQY\R&4X16)ZIGGZUX1XJU[7KKQEIC>!EO;_Q%;-AK?3X6 MG27D$1RH 4D Z[6Z5ZUK7[1WQ&\(^ Y9;W0;SP'J\$GVA)M+>,6D=R.I^SEO MD$G1X<8.=R@$5WY7C*F-PD*]6'+*6Z/2R7&U5>,<$UX/\2%\+^ [[6?!W MBK5O$%WJ%C 3I7BK1[T7%Q) PP([I9,HI3[A8#I@D#-<7X5_:OU?]H5=-T_X MB:9-HFF1NJMKNFZ9));1$<%V9!YBL3V#!1W%>H^//"O@;X=?#V^\1>"?'FF: MS?:3#YL=KJTB74LA*E&BC*D,HD#%2N"#G)Z9KU)-13;/?HTY5JBIQW;LOF?* M/PS_ +;U&/3?%WQ#\?\ B#3?!T2SPZ/''I9@.,^@-?*VJ:PUQ'YURXAMX%/ MEQ*3Y<"9)*H.RYSP*\TU+XH7 NB+*VC$'\+29+-[^U>?D^6Y_P 6XB=+)*=X MPW;LDNUV]-3^DGPOPGP;@:-7B:;G5J?95_G9*S:7=GWK\$?VK- T'Q[XR\5^ M)[&X?Q!K5T]SIRY#6EJ[*$ 8]1P%4OV4&O5OC;^RM\/?$GPG'B?5-9O6U.ZG MMKB]UNUU)S;S/-,JO+Y;,4(4.0O' 45^9GA3QVFN3?9;F-8+IAE"I^5_;V-? M4/P'\>WVI6!\'ZCJ,:VMO/;7FF2ZE(SQ6++88XLA&8YR-^0 #@5A568Y- MCWE><4^6HOZ6VC3Z'B\0<(Y-F&4//^&*C=-?%'5V[[ZJW6Y[-\&_"VI_L^^* M-:TF#Q3J$/PX6UC$7B/4+18[JRAGE)/E1$\1NZ?ZPKQR0O>O>[KX@:9X;\.B MS^'F@-J4VJ?-::I? O\ VA/VE16_>7!!YWG:@_O"N&_X3+PSI?Q;\5)9W:^/ M/$OD6<=OJU^IO+>SPLAD;;$I&0S#$:#=[@.A&:]@_ SQS3/\ @G_J'QG\&>)O'/B' MQ9>W7CK4KJZFM541BVG9&(4N=N<,5.,$ #%>D?"'QRW@G3_A['?ZG>>(K/2; MG[+>WZ2>>^F>="\?V6:,#>M>&_!V_\??!/0[KP_X@MY_#VE7]]#JL M.I+$M]'-=0R(&F6<,5P3M#<]2OO1HBHQE-\L4?H+:ZAI/B[XS:)J6ES6M^EG MH-PPO+=@_P LLR*%R.G,9XKB_CUH%[JEWJ%A\.=4/A;QT]JUU?:M#,(K:.+! MVK<+]UG<\+_$!\Q.!SP6N>#5NOB;XD3PWXPU63Q=?6EK:VL^DSQ6\3LVZ266 M=(UVF-05)/4DX!R:C@\ Z3I6I+X5\2:,=1M+:=)?$OC*WDFNUNF(RD4JDDQ, MW&XX(1!C(S2WV'.G*#M-6/DW]GCQYJOB/XV?\)+XBL?!MQ>Z/:1V"3>(G>WM MH-A(#1[ RO*ZS)IUQ;7\WDZ7,UH DB^9 M^\D4+MV%NM0Z]\-?&GB3PQJ$:174_@B:&46O@V\NBM]@H0CM,3R <,+=C@8&6SQ3 M(.0U35+_ %;6O"'B'PQX,\56G@*SU.1YU9VN_,)C94D@M4+L$R?O@X]!7;WW MQJTC29+.&[T/Q5;S7.X&>G-=9=_$+3?!J2ZSJ&H0^,_B;?I] MCL-+TA6N([=R/]1"%R%4?>=R06P>>@K\[XCX&RSB?$PQ6-W:S#((D M#A?EZ5A^'?@CIND?$*WM[75O&,5E9O8M;Z39:!>Q7MI'!;7$4L4<@3(0O<%@ M,<+D5]?:;\/=9UKP^EE+X0L$OY'-Q=:YX@G_ -*DG15@.Y1G@ 2# %ZZGB?^T)8[^]AV732QBXV2/$O[Q&W!=A(S][MG&:[:/"N'P]%8 M>E6FHJ/+]G9;:\NZ[DNM-OF=CQJZT?PC\-_BGX-\16NH>*=&TW0(6LK?0;OP MS-(R0&)D\N)_+\P;GI->Y_\ #0/AI=7M]*DL?$D6IW,/VF&TDT&Z226, MG&Y5*G-?-9CX:93F MKA+%U*DG!63NKVO?6T=7=O4UAC*L+\MM?(]$^&NFZ[J6O>/M;FU34_ GAJZO M+=U?4--^R3W 6 *S!IQE5R,9 S[UT5GIN@:S>;_#?AR\\=WN<'6M>G=K)3Z[ MY,A_^V:'ZBO!_P!EWX4^(H_^$2O/B!\0=6OVOK..\TC2]6A2[L)XW4/L1Y,X MF7N#SW7BOL+Q7XZT[P?'!;M'+>:I<_+9Z59KNN)S_LK_ J.['"CUK]-P.#I MY?A:>$HWY8))7WLMKG(VY-M[LYNZ\"RS:?)>^.O$:_V5;IN;3-//V'3H4'9L M'>X_WFQ[56TFWOO&MBFG>&+5O!O@I3@WD$(@NKY>_D)C]TA_YZ-\Q[ =:TM. M\#W_ (LOX=7\;/'<-$XDM-!A;=9VA'1G_P">T@_O'Y0>@[UZ(JA?K7>(RO#O MAO3?"FDQ:=I=I'9VL?.U!RS'JS'JS'N3R:\Q\1Z;H%OXU\2:9K$=Y.FH6W_" M0Q+9PN#$((U@FVN.KL&QM'4,?6O1/$'CO0/"N!JNK6MI(WW86?,K>RH,L3[ M5YAXF\>7^L>,?#,NC>#IY%U!+K3(=3UTM91_.@D($?,A!$)^\JDX&* /0/[) MT7XD?#VSA%O)#I-]:12VH"^7+ -H:)E_NNG&/0BN2L_B99:3::CX3\::VNG^ M([./8+BTDVS7T)X2XA5C*!PP]"*T].^&.KW.GVUGK'B:X@TZ")8H]+T( M?9854# 4R',C#'JPJIXO^&OAGPKX?&JZ6UAX3U32W^TVNM7#8P^,%)I&.YXW M'RL">^1R!0!\,?&2X^,6M_&RR^'W@OQ)KOBLWD"WD']OZ='!<6$3-P[R8#(G M!.XA2<=#7UCX4^!OQ.T'PCIEIK7Q-N_%T\*9NM/N6Y$%OMR5D^9CC&/F8FN^\3ZQX(^"/P]NKC67L=#\,VJ$R+, 1*3 MU&TY,CM^))KY^^ \D7[1]U?^-_"T-QX$\*Z5J#1Z+9J1+'=W"CYKF6W;*)M# M$*JXQN)ZC- 'JFF?!W2?"-C"O@[9^'+6%;35)+C3&U!=32!1\DBA7* \G/S.'R."5'%9/Q"M];UOP; M?Z!XVTRZ;2IT_>ZWX3JVR !74GI+@?,OUQ0.[V/8_[$\0>&[*2VT>.UU.>\FFN+N] MO+EH7#NW!50C [5P ,C[M-^&/PPM_AC:7UK9ZA=WMO=R+<.MV^\B8C$C@_[9 MYQVKNJ*!!1110 4444 %%%% !1110 4444 ,;IS7YU?';_@JG??#7XPZQX7\ M/>#+75M'T2\:RO+J^N7CFFD1L2>6%X4 Y SG.*^]/&GBQ/".E17/V2:_N;FY MCL[6UA(5III#A5W'A1ZD],5\-_%;]E/X+?&'XK)XQO5UKP^NJ0MJ>J1VLT0M M9Y5#&0#/1OD;<5)Y/3FOI,AJY52Q$Y9M!RARNR7?IU,:JFX^X[,^KO ?[05C M\3/!>C>(_#7AG7]4M-4M4N8]MJ(D7<.5+R,H.#D9&1Q6TVL?$+5FQ:>'M(T. M/_GIJ=\UPQ_X!$HQ_P!]5P?PATO2+KP1I%Q\*/$*Z1816J%?#5].M[;PID@ MJ&+Q$D'E6QUP*[F/XFW&@MY'C/19]!(./[2@S<6#^_F*,Q_\# QZU\]4Y>=\ MFW0V]27_ (0_QAJB_P#$R\;/:(W6'2+&.+'T=]Q_2J&J_L]^#?%4*Q^*;:\\ M7JIW!=H(X-6Z@#Y_NO MV&?A"NL6VKZ/X?F\+ZM;2"6"^T.]DMY(V'0CDC\,8KW33+5[&Q@@EN)+N2- MAGFQO?'=L<9JY10 5ROBOX=Z'XVOM&OM6M&GN]'NDO+*5)7C,4BLK#[I&1E1 MD'/2NJI,B@"GJ6H6^CZ=%M4^'YU' M69(9_#E];I(N]23.K@&,(H^8N)B51[@C_62(,C:"#TSDU#X__:8UCX1^!!8^%H)O&/PTU"W>U-GXCM)K M74]'\P$+&SX =/[C<],=A7U]\>O@#IOQDUCP+JMS;P377AW5X[MUF4%9K8_Z MV(^H.%/X5XW^U1X5NO!/A'^SI+.WU7P[K=U;Z<^J7(#7=K;J6D2S=CRZ%@-C M=1R#ZUR8K$+"T)UK744V_D2Q! 7&N,Y%>!D>>+ M.83DJ;BX_J?+<.<21X@A.4:3@XV^=SZ7UKPOI/B2'RM5TRTU&->@NH%DQ[C( MX/TK#T_X9Z1H85M*$UE)#(TUMYDKSI;R%"A9%ZFRGJ+:TMXL_F MK4 =9I.O:;KULMQIM_:ZA PR)+699%/X@UHUXY>?LRZ#?Z@+Z?7_ !$EX&W& M>SNX[1V/NT4:D_B:R?%7P:F\,17.L#XBZQ_9T:[GM?$.H2M /8/&R,,^G)- M'I_Q&\=6?P[\*WNLWEO<7S1KM@L;.(R3W4I^Y%&HY+$_EUK\UM#U#XE?%3]K M:9O%UM8Z?K.N:;=:?9QWSK-;:(A3<%&,@31K\VW.[ZU MX+UC1_"48:66^TK5;B>\NU7G=Y"(CGNY'I6C\'?!?P>UK1+"XO-+TFSU M>ZU"75(+34(C!*F]B(T D WCR]H.,Y- '#P_L#_#3P?I:SV_B.+7=8AAD8Q^ M)KI9;6>9E/S[ R[&SW!/XUPWA/X4_"SX/2>#;+QI96,5PHDCN_$VDZD)FBO& M?S(9HVB/F1X.Z/!4@ C)XK[KMOAKX0M\-!X:T=.X9;*/^>*S?'G@&PU_P;J6 MFV%C:6EZ8_,LY(H54QSH=\9'']Y10!\_7GBKPEKGAGQ5+H/BVW'C'0M7NK_1 M-4MB9I6=D5]CA%.Z.3E64\'KU%7O@M_P4(^'?Q T.R@\1W,GA?Q:2()]+EA= MQ)-T/E,H.03V.".E=1\,?#>@_$37O%.M_9I-(U*=K*X%UIDAMYH)#;JLJY'# M 2*_# CVKXA^+/P9LOAWXF\?7VDZ:?&]K!JWVN;6+>W\[[!;LH9U9P/*\S>6 MXQQCD8- 'WEXF^.TGB6YET'P7INM7-W&ZIJ6I1ZGO=RVUF;B%21+/@[W9OFRNX;C@=*^]=/TR M[\#ZYI.GV^LPW^F-:WKWXM;)-MI(L:M%Y<4?W%^]A3EF/>E**EHR7%2W/S8^ M.&L>)/!OQ"N?['L[JWL#I\=YJ%KI\4EG;B4%U$VU #&0N.>"1UX->_\ PTC\ M5Z+I.C:[K;^$=:O#_VO+JSM_B] MH[+K=_+9:F8K[4K&\M)+10HE*K)(I !=HQAL+P .M9'Q.^'^C?%CX@6C_"BT M@GM]8G*SC2HKA;6UE8 + 7D55+,02 ,#DBGZ%+38^Y?&'B;XG_ 'POJ_CQ=$ M\(R: L8GU73-.O9O(W,P43PJ5^5CD;@#ANO6O(OC7\5H?BEHLUIJMIX?LHTT MN2_BN-/T]KDR32(5B4R*S%< LV6 P0,UPOCKX+WWPW^ /C*)9YX+JWL8HM0T MGQ+J,AOMV\?OK6)&\HH<@ ?/TZ@\4OP ^$>FWWPKN)?%^F7,LLR,9[2^U-[3 M&=RQ&*%>"X6/JPSDX[5G4C[2#@^IV8+$?5<33Q"6L))_<[GRYXDLY-0T*]@C M!\UH\!?4^E>'R$JQ7HR\$'C%?J9-^S_\/VU+PU%9Z$SVFH:='J%U,]]+(T*D MCI?!'X3>)VCN(O MRMSYD[2K)>7,;-"KJ(7X48\P.#N8;1ZU] MCX<<45>"?;X?$T^>G4:=T]4U^A^J>(.:Y;QFZ&+P([-H1E8GW.W95'K7N%IJ4FC3?V@@_=V[*TC>7NVKO&3TZU]-:#\%_A-8 MZY=:1IW@J_C@COO*\Y;R7?);+&QDG4E65QJ3&:X_="X&P8SMZ89>3S7SG%^95^+,[CF4HJ$(I)*]W9=_ M,ZLFX@R[AOA?$Y53,O*^[!SR>,DE@U>P:Y\1/'WB_6/#K"*)M-L[8:^+R.P66+Y MAMMG($PW#+%ATY6O(-+_ &>?!O@_X7^)[ZU\&>+$U.]TV>>/5-$S);0*(F_< ML9&#;<_,V1TZ&O%_V<=%\:6\>@Z_JNHK_9ENBC2=/UV]6"T*IN,R]3]\X:]AP[PK7XCHT55Q"E975U%:*_D M=_X+^*SZ;K4=UX?UB\TG5$.8Y8W,;GV!SS]#7W?^SG^V9-8^"9=(O]$M+[6+ M60R-))J(MI;]I&):0[U(+ _>8D #'L*_)_35EN-2MXK8$SLZ[-O7.>M?:W[, M.B?VO\0KN26SM;]+/2KJY:&\NFM@<+]Y64YW#K@5['&/#.&X+SFAA,OKNI"H MKM-W:Z:V-J>9QXZX9QF.S/#QA5H6<9Q5K^1])_"33/$>K167B31?!VLW.NSW M$][;WMGKT_2;77_!OA'PII=AH>O+K=U81):6>E^* MV\B,$R&.16$<8/WCT&<#FI9O ?B6/P_JLOB>V\7:EJ>H6HBU*XE2QNX7C4[A M%'EDV1@C\>IKS3^?3X7T/P#X.T?X=_VMK6F>.-4^)Y$EY_Q(W62VB!42(\S M,5&U@S9Z\BOI?]CCXP:W+X9N_B!\0-)UO6[19!IFE:EIMK#]ALHU $G[M2OE MLQQND(Q[CFO ?&_[3'B72?'FM:/X?M(_#>F:Q=Q07]O?0)#;3X 1M\<3%-K M#+(\_".X\1_"KPI_PAOBFX6#PA;M+=HUK;7=C8W*RL7=9)UC+!?FP M%R!C')H ]3_:B_;/TKX>?#?4K'2+:_@\7ZI ;?38ITC.W>,&7Y';[JDD>IQ7 M&_L=_%S6_&'P'T;2%NM0TVUT:7ITEY>3R!BQ8NZ\9>%?"N@Q7,%A*D-K/J236@5UP9;=74&*0\'(8+&\L_%MP/L^G M/%97.GRSSMQEF**L@4'<0V[@5Z+??M@?#*QTV[O/[8NKE;5Q%)':V$TK;RF>)/B1)JGA6+PCX7US3_ !1IOV15^WZK8RVPTUD "B.9$P\JD<# MQQDUYKI/QR\6Z+)>3Z/JZB7SY(7UG4+9+B_OMC;?WCD[556# *@ ( )Y->M_ M#W]GSP)\$/#2W#>/]?\ $ZNP@@TZRU8K'=2-TB2*-N23W!'C7]A;^'+>]\0:6Z)=7 M[7 M[(K("8Y-O+%CM;*@=NO->G_\(+XD\1?-XC\5S11-]ZPT&/[+%]#(SE\<1#"TXXMWJ)*[\SG_ Y\/_#_ (2^;2]*M[:8C#7!7?._ M^](V6;\36#\:]UGX3M=809?1M2M=1)'41I*!)_XXSC\:[]FVUS/Q 6POO!.O MVM_CW#$%8T^O)[ UQ?@'Q5XB^+G@W1?[)E?0=$^R11W>LM@W=RZJ%<6 MZ<[%)!_>-SZ"O4?"WA/2_"&GFSTJV6WC+;I7)+23/W>1SR['U)I73V$FGL?' M?BC]D74/^&@-,^(4NA:7?:7H=G'J%UH^FV:VUO=7(<_NH$'WBBC?EOO$ =Z^ MS/#^O6/BC1[35=.F6XLKI!)$Z]QZ$=B#P0>A%:G6O*_$%POP7UB]\0X*>"KY MS+JL:@D:=,?^7E5'_+-SPX'0X;UIC//OVE/@!X8^+6MZ?::M)J&M^(M2+0:; M:SW;"TTV(#][I/+%172_L]NVE)&-^ M9F"M^*A378_#72[G5)[WQGJL30ZEK"JMK;OUM+$',47LS??;W8#^$5Z!0!RG MC[X<:-\3-(.EZZ+N2P;[T5M=R6^_V8HP)'L:\63_ ()\_!FUOH+ZPT;4-+O8 M)!+# )]:T]%^*FBZE?+IUZTV@ZNW33]7C^SR-_N$_+)_P$FNSK-UK0-.\16;6F MJ6-O?VK=8KF,.OUYZ&@#0XHKS[_A7NJ^&9#)X1\03V4/7^R=4+7=I]%)/F1_ M@Q'M7S-^US^WQXD_9JO-)\.CP5:3^*;R(W3RSWA>R$ ;:&0J Q)8'@@8]Z]# M+\OQ.:8B.%PD>:$[@61XR><$ \'H17T6*Y\5A:N"K2P]>/+.+LUV8XR4E=#J***YR M@HHHH :S!5+'H!FO,H_V@O".[ANO[$M6EAM/L$8D!9!!C&S:>.G'2@#@KGXL:!\2+. M#1WT.>^:^L(]3M+>2Y6!W8(LN5<$&/8&'[P'&00#Q7,WWBOX<6-C=W&I^$IK M#3M'TMIPLTF [+$DIA\O=\TF)EP[=2QYKUN3X1^$I(6B_L:&$&T6Q'DNR%(1 MC"*0?E' '&,XK'\0^%?#VBZM9!_"O]KQZOLTJZN6E$FQ" @+(Y);A1N8<@(, MGB@# M?C#H'AAM2DL?#;64+6\&H&172(3F98V8C/&Q/,77 MN8*L:[<*HS\H^1136E]>7=]HS*JPZ3(46"VVD%#&54.I7 M:,'=D4 <_H'@_1_%6BV_B/PG<77A"]O SM_9S*83(&(82P\QO\P() !]Q7+? M&'XZ>-?V??"[:WKW@P>,='@;;/J>@S^4T*]GEA<$J/4J2!7M>AZ)9^'-,M]. MT^WCM;.W7;'#&,!1G)_$DDD]R:L7ME!J-I-:W,"7%O,ACEAD4,KJ1@@@]010 M!\S_ 1_;7N?CY?O!X7^&.NSVT+A+C4);N!+>#/]YB>OL!7T_&Q906&#CD9S MBO"OAS^RCX;^&^H>((M)::RTJ\N_M^FM9S-#=:;(PQ+&DB_>C)"D*V0.1BNI MFUCQ7X)OH[.2^L?&-NXS';231VFJ;?9;MZUR$7QJC^(^L-X8\'W/\ 9FIJ M2M_>:E'Y;6>"0R11M_KI>#TRJ]3Z5Z+X1\'Z?X.TYK6QC MLDCGEF/Z=N*0&;X+^'MOX:N[O6+R3^UO$]^H%[JTJ!7<#[L:#^"->RCZG)KL M>E+6/XD\2:?X1T>XU/4[CR+2$%1%'+,3P .37C/CW17\7:9'=>,]+;4-0UPM9:+X7!#?8D* MEGF;L9P@W%NB' 'K7=^'/#NH>)-6B\5^*XA;30Y;2]',-7U7QW) UQ;"*2RT.#@$VZD[Y1G@&5QP?[JKV-*45);?L&NS 2?9@<>6MPPZ#IMG'MG!YJ_P"']8M-8F\" M:G!X3L8TU"RVQXE4W&GHRDE54#!C&,$@CJ,9J34]%N/A>+J?3[1M5\#7&YK_ M $4)YCV(;[TD"_Q1._#1^;[0MJG]JV:'N'4 SH!W!#X_O5/H_P /!>O::FH M^!_%OB;0+=N$;1]:E,:L/X6BD+8(_ND BNAT^YF^'-C!J>@R2>(?A]<)YPM[ M=C--IJ'G?#WDA'=/O)VXX%CQ#8^'I'B\4>'?$]CX:U6\A^T)>+,GV6_C&/\ M71$@.!D#<,,,]>U;G4<^_P +OB[X=(;0OBLFKH,D6_B+2T8?3?'AC6-XT^+7 MQ9^#?AG4O$/B_P /^'=0\/Z7"9[O4K&[>)E0=2(SDDDD #WKT^'XK:/IMC1V)::/,IQ'Y9QEMQZ#K7,?&Z3P)\7_AOXE\"ZOKGE0:KI<,T MAM06FBCF8_9Y57'.73('?::UH^S]I'VOPW5[;VZB=[:'SOX#_P""KW@GQMK$ M6C_\(9KUIJMR2EI&&B=)Y,$JN[/RYQU(XKU[P?\ $_PEXPU:'6/&&KR7&KQ- MOMM)DM7-I8'_ &57=O''BO[. MSTVRFW3AAF.5LC!4=3MR..M?]^IE1=1QO/@KPWX@_!?P9I^O:;JMY>76DZ)9PLD-K$SW$DEU+PH6)PX("!N *Y^3P3-: MWRVOPYU"?7K@[7D$<4MA;P@@$&2XB=$!QSM"$^U?-FQ[;-\)].T]6DT#5-4\ M+N.0MA=$P#ZPR;DQ] *\2^+'Q,\2^#8SK.DZQ%XTDT2.5)+BQB>WMK< VT00RJ\K*<;@,+U/-8UH MN=-Q@[,SJ*HX25*7+)IJ_JK'SEK>KZI;IJ\T/B'5;:\U M+=RQ7;HD[=\A9CG/ M%8?B3X9^"?!.L--J.F>(GTRS=TDTZ\OXI+8(I1 6D5?,D3=(H(!W=0:Z33?# M/ACQ9X9L-9@U:1=%=UN(-)&E30Z3MQQ%%<1[YH\>S8]4%?,Y%E^.P*J?7*O- M=Z:MGQO#.5YEEJJ_VA6Y^9Z:MV\]=CEOCA\!=%;Q#/XF\1:'#>:U,H^VQ1ZE M&UXK@C9<1V]M'C"C[RL"&7OFNX^%%O\ $+^VX-.\*Z;H?PW>Z@6]$T\LDUKK M,>.9HK4CY3CD@."N>AKL_AKJ7P\AU)]*\.>(KKX?Z]-ND.G3723PW/JT;3!M MZ^P(/M7->)+W7/"=S+H&E/I_CC0&OO-BU6TWZ>GAN[?[K"<;T"LY^Z#@$D$ M'%?6'VQY%^U]\ _C=XZ\F_\ $,NF^)M-TO?N>:^M+/QT MVA7EO'\=[>_@U.W#7$#1QA]#:-"/WHV'#.,@D/DC.0 *^*OB]>?#UD\6_P#" M+^*O$U[J]SJRNDD_T&-3+Y\*( MNV$MA5;,M6_L;X617L@MKF6R%S):1N"(HFD88*H3PY!QG)!P* MVIU(5(\T'='G8O"5\%5='$P<)K=-6:/4?%7[4/AWP>O@_7]&\+^'+N_U>6:2 M?PJUK%Y=G"T:"VD255R6+9)/)8=:O]#A-C>W9C0V<6LK'%:O %VM%( MX4LK-\I#="<[NM7N_";XB26&CQ>'M4TV"(O':S:=O^Q@NZ M,J2KM.QL%@<=&YK;_P"&E+?Q-X#M]3CUWP/9>*XK;R9])M+&6[N+RW9E!A , M05"HSA0VWL?6O)/$GQ0;7_BA\3_#5])'"/$LL=CYPM4C6U:,J""""P1/F 4, M%R U<+\1? _@[1_$VCV7A74+A=+BMPFI7JW/G22R!N<84*"1GA20..:YJV(H MX=7J32/;R_)ZN_ .MM+9M8 MEH]-BAD9GCRMO&=Y4#!8CG(PP(KI/@SKGA?XW>+-$\,Z'J4VGZ=8Z#,;F/3H M([>YCD1XD7$CAWVX9\,"N>P%>5^*/B-\//!O@WPK:>$M"DUJVFM&A\4:1?JR MB:8(52XCD.2) 68_+P<#(K6_X)XPZ*OQ6D^P/:X>T_9S_ &=/$T=K8Q>*;J^^W3M; MP0R7Z[I9%C\PJH:+.=GS ]QTS7UMK>DOK&B:AIX;R_M=O)!O>(2*-RE$VNGS3365O8PR(+%C:&"%X&=F92KXDV9VKC:O% M?RWD7$6,Q49ULSS&I3G'X;;[/R?4]=8G$8:DZ&'DU"6Z3T?JMF<=X:_9H_9G M&N6^FZ/XCN3J=U&DL2B]&7612R .T6 6 ) SDXZ5Z=X!_9K^&=YX:U-/"OB# M4M0T?4)&M[J:WO()T=TX*AS$2",_PD=:/A'^R1:^!]3MM0\2:F_B&XM(=.^S MPQO)%;"XM8B@G>+.UFW$E<@XKUCX<>!'\ Z?K-KYD4J7VK76HHL,>Q8EE8$) MCVQVK7/.*,6I3J8/,:M6I'EUEUO>]G9/33L%'$8B-#ZJY-4W]F^GW7L>:>,_ M"-W\!_!&H^*/#/B[Q"VIVLMA"&U:X6\1H?M4,?E,#'O,>UV^56'YU5N?VA/" MDFGW-UXUOV\4ZR#MM;=9<:8LQ^Z&MAAE4=27#G /-=]\?K>2?X6WT:3K:.U_ MIBBXD)58B=0M_F)'0#KFN.M_V;=>^+WD>*/$NI:;XGL8_-@L-.O+$6!N+'O$NGWEA=6^M37-JS(]PS)('(*?+RI50/N@ 5[AHGQ M9\+^'_ 0C\*Z;J>M>%;* E-0U F"RCA[+YUQ@LH' &#QQ7RK^T'^R[X>\#S: M+XR\/>$]8\"WNEW]N;R"SD%W93Q-(%:1)OF\N09R-RX/<5H_MHZIK]G\,]!M M+?QT/%_A>[NL-F"*.YB94RB3-&0&'L47D5^LXFLZ%)U$KV/1R'*UG&94<#*? M*INU^RW=O.VQF>.OVC/#.K6NK:9X=UN/PG;WP\E[*PL'N;&7+C?0UZS?W7PTUO3K2'Q-X?;Q;KMY$K6&H&]$UFZL<"83J%2U4$?QJI&,%V^E?I9_P3[^*FB>&O#WB71/$MS"GVQX9;:P\@ MRR3L4(D4* <@87CWKU,RRK'9+/#K%SA-5H\RY7>VE[,^JQ^5Y/B+_#VF^.+&2)0+S2[-0VG+USY"@"8=,S M;^,X%=AXA\+_ L7P[;ZG:Z5'JYU!O)L;/2[B3S+R7_GFH5A@C^(G 49SBN< MUSQ?)X%N+1/ &B>)+6_OI2EKX?O+/;873]3A78-"OHXK-^'^K>.9/$5W=^*]0TOP3XBU M_P MX/-L&NHV@"_NX(9S(J KDDH1NW,>#7<^,O",#:EH-EK=]>:OJ&L%M+>^ MCV0&-%;[2KJH&,J\2X^G>@#'T_X1ZOX@TVVU3PQ\5_%&CV,T2K%;R00/Y>T; M2"C( &R#D8'.:AOM%\?>$B-WQUTA]O\ RSUW2+8$_BDBFNV_X4OX1T_3\:E] MJO;6%2\AU#4)3#ZL[+N"#)R3P!R:YO2]%T[Q0S6W@#P]IFBZ/NVR^))K%3OQ MU%K&P^<_]-&^4=MU '!ZY\>_&GA?=;VOB'PCXZU48,>EZ3878G<$X#,4WJB_ M[1XKQ;XW2>,->U+^W?%GAV33K/5YX8);RT\Z&U5(T8Q0%7P7D>"+26+3;?$]PV^YO)?FGN7_O2/U)_0=@*P/C;=:6W@/4--O\ 3K?6 MI+^&6.#3KEMJ3,D;2'YOX=JH3N'((%<6,H2Q6'G1A+EU#%;B-G :-D7[PP3VR.M? MI+X=\6Z+XFAWZ5J=K?%1EDAD!=/]Y>J_B!7BGP?^$WA7PO\ $"TNM$\/6OEK MI$-\;JYN9[FXM))5&U%+DKR W(YQCUKU_P 1?#7PYXGF2>^TF'[8AREY;YAG M0^JR(0P/XUY.1Y96RS#NE7J<[;OY+T/ X;R?$9-AG0Q%7VC;OUT]+G4Y%>9^ M+H1\3O%H\(X$OA[3=ESK@/*7#GF&T/J#]]QZ!1WK-\;0^)?AII,4_A_Q-+JE MS79<0.IRLB@_,C* M0""1VKSGQ9^T"WP?L=)TKQQ% 'O MM%(OW?6EH *\YA^.'AV\U)=/M4U"YO7M[BYAB6T8>C5 MYSXJT?P9X'_L_6;G2E?4+??;:;;VX9II9)"Q*1IGEB7;GL&/(% $,GQHLH[& M*Y&E:BPFT!=>B41@F56P! N"29\)^"?MFE02^(-+L;6Z6V-G;V5 MF6Q96G&V'?GYF&T988Y''3-+KOP_T#1M-N=0M?#L6H7,=JUOY/G>7YD9SOW, MQQD@MECR"OV?_#]MX$\(Z#>1 MZS<:0?$-W#=7,33N=RJJ2..-Q#$C P%!KTOP/\;]+\<>(+;2K2RN())[1;H2 M2%2!E%Y[5O6GA70?&-C9:W76GB#=,GEW,4+[6\LL.1@JO? MM36^%^BVVV;2$DT.]6)84O+$KYB* !P'#+D@ %L9('6LZM6=>I*K5DY2EJV] MVP2459%JW\9_;/%5WI$&GSRP6PM)![7$010T<3%N7W[BS'!QW.:E?0?B*;/75N_[7 MFNVL52*:VO $-S\GE-& X(5+8>9!%<*H$IWQY:)MP).<'-= MUHMCK5GIL=YX)\31^)-*V_)IVM2,YQZ)<@;U_P"!AOPKEO$W@?QF-/U74+&? M6$U.9K:'R+._P9,0Y>5&+61O%]M=>$9XP<)J M";HIB/X8I5RDA/8 Y]J?X9\.W_B[5+?Q9XFA\DQ?/I&C,0R62GI+)CAIF'?H M@.!W-<3H?PC\<:]'8:SXGU^UN[R&(>1X=U2V^V64)*@,[G(8R'UR0N3C/6O( M/C]\1OBI^S!;1Z[H'@R%?#:M_I$ECJ4EUIZ^N^!TW09_O*V/>I ^F/B9>3:Y M<6/@FPE:*ZUH,U[-'PUM8J?WKY[,_$:^[$]J[BQL;?3[&&SMHEAMH8UBCB48 M54 P /; KXI_9N_:BUSQIXDOO%OBW3]'\/Z1K17;?>;)/*D,?RI"J@_NTSN; M:?=PWMK(,I-;R!T/XB@"BO@W1%U*QU :7:K>V,9AM9U MC :&,_PJ>P]JV\=*6B@#S/5-!U#X;W]QK7AJU>\T6XI^(?#EJVJ6^IVDB&SL_+*G=:]X7U'P?JUQXE\)P>>9CYFIZ"I"QWOK+%V2<#\'Z'G!H Q]%\#>&O MB!X5WZ7JMX) S'(8>E8/B;X"Z1X;CU34K&UUS5% MU"RMM/O(;>X69XXH6+"6**3*EOF(PN#CH,UU%Q:VOB:#_A./!&H0V&JJ"MW% M= QP703[T%TG5)%Z!_O+[BJ6B_M 6_C2WFM?#6D2WNM6HQ?1W'7(X,8;/M0!E>&_"?A_7M2UB'0]?U32I+;2[/3P\D"1M#9QCA!YB?,IP06; M)^\*76[?0?%5QJVG^'H;S7Y;Q[=;V]LHX4L[;R8VCSYKKL#;6;[F2.V,5X5J M7Q4T?QQ\>=?\ G5M3\0^(H8H[RTDTL1/8W-TJY>S*#;YD"+_ ,]&X.2"*],\ M:>.O'5OX9/AK5;+3_AQ>#[77->UZWT/1UE-QI4\:B*2)5W1J[M*S+(KQ]BO\6:W?"OB_3]'\.:? MH/@71-2\26=C$+>&ZV^3;?*,9:>3 ;WV@UDZ;I/PN\#"RM+O4X=>U*UB2&'[ M;,U_, H 6,9"]. ,52UWXI:Y\3]VC_ ^T'5I=+CE:VU+6I MB(]N,PPF3 M!W'H7"G;VYH 2ZN/B#\3M>?1;7Q!;:!I=K)LUBZT*+?Y7K;17$@RTI_B954) M[GBO1?!?PA\)?#^S2'1=%@@902;B4&:=V/)9I&)8L3R3GFL?0_#?C/3]*MM- MT]= \):;"NR.&UCDO95'<[FV*6/4D@Y/K69XAT_3/#MS OB;QAK_ (BU:1@\ M&DV4OEO,1R +> +D>[<>] 'GGC+0?!GB#P3;0KX:N+&XU";4K2T,NT+83Q12 MR.6^8G+^2<8SS@\5S?PQM?A'X8TFWL?A39^+)=9GMH[F:P\,W=SL#E0<3/(? M*7!X^;TKV^S\.37T'VWQ#8:7X1T&.22>&S\Q3=))(&5I'GSMC9E=@0N?O'YJ MK_ FXT#PKI.N^%[*YT^&+1]4ECA:*9"98)/WL3,V?F.'(R?[M 'EMU\'?BW\ M3FM1XL&@QZ0LYE?2]72.9BH^ZLCVZJ9"/=E'L:YB;]E3Q[X45K6R73[_ ,-2 M3N\^CZ%J3Z<7A;[R*\@) ')VEB/<5]#?&CXV:5\,?#7FVVHZ7<>(+BYM[:RT MVYN1NF:69(\[5.[ #%O^ UQWC)?B-XR2WL[F]T"WT=26NK*W2X4WGHCN'R(_ M51C/0G%?-9MQ'E>12A',*R@Y7:NF[VWV-84YU+\BO8_/CX^^)(Y/$\VC6E]K M-SI.FLQC37)_.N(3C!C\P$AU4# 8'!%?+^I?$K4&NV-J8X+<,0JLH8L,]3FO MO#XX?!F^\ZMIO-*10Z),904G2!D*[LAM\B ]0P/2O>X%SK@ZKC*^* MXA_>0DE[/W9-6?HNVQ^NYOQ56P.28' /$^'-_9Z_P"![R#3K_2X[06]OI9M+26*--L= MV95&=P &1P'X)/%9OA/]F32=#A@L(/'HE:YO?L,\TN@7*K;7!F\A8I6W85BX M(QGWZ5]=V?P ^*$-K%#?_$6WUE;>$P6RW\$DL4*[=H B+>60!P,KFOBGQ!EV!FWS8J,6JDDK=K7?5GQC^S6DT]_JM MAJ'A;4O$%I=+!<%HY51%9&/E--%(,30YR2 ">.,U]*:#\,]%^(VN7'C+Q!_9 MNJW"7%S ;/PQ,-/=X FS8T3[6*AE!7:QP 05YKK/#=]KGP9\01>"_$L>A^)( M+;1%GT_47T%IS'%YLQ%M(P<$8,;LI /&1VKY^^,WB[6=#^'.BW.F3>!Y=,G M\Y]/5QJ<#RL7PZ2GK\V,ITP*^MPN.H8_"K%X67-"2NFKZKYGYG1HNI7C2EI= MI'BM]H=IHNL7T4,OVQQ,VZX9<$DGD#/. >.?2N7UCX@:=I-P\"![ET.UO+QM M!],GK6[J'F?V?#S-DG.=V>28(#Q]V4^@KYG\/R3 MKK-IY&?,\U<;>O49_2OJ7X5M)_PL;0/+.";I0>THIM32MJE=-=GWL>^>-/@BV3XL MTK4M0?PC9Z.'NC97DPL_,B*?O&NY2JLTBEB=@QD #.%UO+'X/6%UX2^(NC>'];T5[JWN%TO M2YS>7*F0D&2Z16RK J" ,5YWU/"_\ /M?F<\5@>&_BEI'A_4/A]I_Q \ 7>C7N MH) E[).6@@NU1CLG1F<*!*&42O-?"GQVU7XB:?HOA;Q#:V_B/6+6_\ MVVU?6+J3R\,V&,[;P$50>& RO:N_^,G@GQ'\5-8^'WPWU"]LWU;1Q?V-L+)& MDBG.5>)8YF8B4,&7DX*A23TH^I87_GVON0KL^@_BW\&Y?B0T.C>!_A_I>C7^ MBO#K%W+/J9DBN$4[X[1EB)5C)M#B?#?]HC5?'\%C;:?J&@0Z^MU% M9WOA>.VD%Q8*0=SY+Y90%P"%QSSTQ5;]EOX2>-?AW\-[2RTOQS;7NG3,TDL. MIZ47NK2X7Y)(2XD&Y59"HSZ#'%?//[7'[+WB?3_CEX/\3:'X@AT[4O%UXVGS M:A9H;)+:Z"EE.0QQY@&.O+5T4Z<*2Y:<;+R$?57A_P 8>*_']EH_]KVB6EC- M%+?QE;:A=WBS:K/I0 M#A4A)ACE4 ;&,G.['W0!U)KK?@CX;\<2>#1977Q1O-6NK5C;W46J:3%]LM)0 M/FBD.HP0:U?A7H?C34O!L,QN)]/D#Z;!(V896CY9AD\*#SZU MHTI*S+IU)TI*<'9KJCQW0?A#I^HR:3=#PKH=VMU%? 75UH*I*9(XE:,L0!@! MRR=.<5+X?;5(O#^D1VWA&WM(7AO6^PPZ?&9;R5&81SLHCVA %!^5E/S#@UT_ MQVUOXC^&[JVT[3;NXU&&&R:]?6VM(D1+@2JT6\+]U$V\@CYMV.U;+> _%WPY M\366KWGQ)U2ZM_$,R6VJ736EN8X+G&(#&C(0D1.4P/5*7*KW?0Z:F,KU8N$I M-IZO7=]WW+O@?Q'>#P#+JQ%I<>-5MIX;* NB7$T:DF-%C."5)&?E SCI6;J& ML:Q\0-4T;3OM.F^*="M)/M4]EJZ?V9<:C.O"HD;*5D6,Y)X4;L#MFK/Q@^&E MW<6-I;2^*+S5?$NJ3+:Z:6L+1)5D')E\Q8@ZK&N6)![ =Z-6_9EU=?"MKI=M M\2M6O([4%B=>MX;L'/+$2;1(G.3D-Q5'&0ZU''H&GW5M_9FI:!ILA)ET3Q!: M-?:03_L31%C![%3@==M>8>*?CYI_PW\3>"WFN+S4--M);BY7299TN)(U$17_ M $>YS^\3GA),,/7M4EQ'\1-)T^2U\,>+/$(TG3Y"MUXB\]-1TU$ .1&&196* MG^Z2H]37A_Q.AT3Q-J&EIIZW^N^)9KIIY-5N9?-@U"?8K(J+Y:R9.,;2NU3_ M !<5A6E.-.4J:O)+1=_+YF=6;ITYSC#F:3LKVN[:?B?4/@[XX^%/C-XFT^U\ M5WUU9)=2 Z=X>N+9X;-WZH)I"/WTG<*<+GH#UKZ=AC2&-41515&U548 [ 5 M^;^D_!+XB^.]8ATZPTB70[L/'/\ ;M1=4BBVL'#(PSYAR.-H(KZ T7XO>//! M.K1Z'\2-:C\-7DC^7:ZOJ6E(^G71[#SHF4(Q_P!HX^G2O&R?%XW&47+&T^22 M>B\CYO(,=F&/P\JF84?9R3LEKJOF?5%>/ZEJUUK.O^+/%=G:0ZA;>&;2;3M. MM[A]L4UP &N7)P>.%CSC^%O6E\;^+/B#X5\+O=PKX;U>YNV2UL?LSS0M)-*= ML94'>#R<]>@J7PC+XI\!>%['19? K7\%O%MDGL-4AE,SGF1RLFPG7Y9FCTP3L$'1=\1;@>EU '4^#T;X@>+IO&$XSI-GYEG MH43=&7.)KK'^V1M4_P!U<_Q5Z3@#M7(Z!X\\&FQ@L]+UW2DM;>-8HH4N44(H M& H!/8"NGM;ZVOEW6]Q%.O7=$X8?I0!SWBOX9^&/&\,L>M:-:WGF JTNS9+S MZ.N&'YU\=_'S_@FK;^(83JGP[\2WUEJ5N?,BTO6KN2X@SG(\N1B6C.0.N1]* M^[:* /#?A+\8?$#^"K*'Q9X1U"WU/3$%CJCZ1^(M/BAA7=-]IG$+1 ==RO@C\169XXT.]T'5AXST"!KB_M MXQ%J6GQ\&_M1SQ_TU3DJ>_*]ZY?XF+\/_BAI&G02>&--\=:KJ\.^QLYH1GR^ M\DSXS'&IZYYR, 9H Y77OVZ/ =QXNL?"/@:*Z^('BB^F\BWM]* 6WW=R\S._\ $TR;%*9\BPC/6& 'H/5^K'VXKYN^"_[% MM[\(OC1K_BK0[RUL5M[2&'3EN;3S;=I)5W7 0;@RJO" @YQG.:^BE\;>)M!? M9XA\)S7$'?4-!D^U1_C$<2#\ WUH ] K-U_0=/\ $VES:;J=JE[938\R"3.U ML'(SCW KYGO/VVO#O@3XW3^#?%&H0'P_?A)M.UF,%6LG;AK:[0\H0W1B.AY] M:^H;.\@U"UBN;>5+B"90\%=(NM4U*X6VL[==SNW?T4#N2> M!R2: /'?&W[3.A^"_C[9^!K_ %"WLK*WT.?5-2N)F V/D>5&/5B-QP.3E:V- M-\)VOQJ8:YXLBAN=.7G2M%28,;+(XN)&4\7!'3!^0' YS7@'A']@R'XN^--7 M^)7Q?N[J?4-:O&NXO#]JYC2"'/[I)7^\2%"_*,8Z5]=^"OA_X=^'.CQZ5X:T M>UT:P3I#:IC/N3U8^Y- '">(/&U]\!=)FOO%5Q<:UX*MR!_;4<1DN[%2< 7" M*/WB#IYBC([CO7.7'QH\ _'W6M+\,Z)XITG4_#Q07^KAIU3[0@;$=KM;!.YA MN88^ZH'\5>K_ !+U+2]+\#ZP^KVHU"QE@:W:Q*[C=-(-BQ =RQ('XU\-_!7] M@^;P;X\\53Z[H.G:_+IS6]UI=C?[OLEQ!*K,\:N#E98R-@8Y!QR,&@#[#\&? M KPAX1T.]T6QTZ"Z\.W%R]Y;:=<(LL=DTG,BPL>50GD 'C)Q6+)^S3HFAZC) MJ7@G6-8\"Z@QW,NEW)>UD/7Y[>3\T]1%/HMP MGES6OH-O=?1ERI]:Z2]U*TTN$S7MU#:1 9+SR! /Q)H \MU3Q9\3/A_;A]2\ M,V_CS3XQ\]YX?;[/> ?WC;.2&/\ N-^%/\/?M,^ M=MYGNM5?P]/#D36VN0M M:/$1U!+?+GZ&M^;XQ>'Y[@V^C_;/$MR.-FC6K3IGT,O$8_%J\8_:4\'^*/B; MX-2^MO =O!)IMU'>2>=<))J$\*9)1408/][:6.<<XT6WMI+BTN\#"JT$.4$B]GED;.,,,5TTG@Z^^* M>AR:IH^A7]WXBTL&"&;Q!>Q6HM)$.?(:QA!7RR?X&P".1ZU[BGQ-7P_&(O$/ MAS5/#T:G:9XX/M5H/H\.2![LHJIJ5G9>*+Q/%?@36=/?Q%&@1_+F#07\0_Y8 MS@'.?[KXRI]N*]P^C/ACPO\ L=^)M+^+EN__ DX\._%*,3Z[ \<&VRG?S1E M(7'5-K%>!E>XQ7UI??"G1O&GQ"T/1O$$5]KT=AI[:IJ5OJUZ]S&)I,1Q)C(7 M*D2,,#M6?\0?&7@[Q-XM\(W7B>\7PS<6\5_:S+>3""ZTVZ B9&5O7@[6&58> MO(KCOA[\4&\8:EXB75==CL-!U+4GM+GQHK"&.^@MUV1VD1Z12$;F9NX8[>>F M?M(>"?#_@VUEL+^VL=*MQ]GCM0C+,CC_EF8L;_ #,]1C)- M<)JGQHTO2=/M-(\*O9>'-*B4107=U TDS(/^?:R0&20G^\P [\UQFH:2TVIK MXC\/:=)HOBK(8^-/&5[%;.ZXP5-J,LT>.B80CUK0T/9VO/%WC]0+**3P9HK' M_CZN4#:C,O\ L1GY8<^K9;V%5FUKX=?!G>+C5;6WU2X_ULDTIN=0NF]\9D8^ MP&/:O'#\1H-7OIK+XB^.=4G7S!'!%X/A>/3+O<<*HFC!?<>ZNP]B:]*\+S:/ MX+POA7X:RZ?+-R+O4)(+62;/--?^)NFW&G:)\-Y M+W2;A2CW7C#%I;.I[B AI6'U5?K7P%'^RY%J/Q\OEU@W.A^"9;R6&TC\/12H M=6N(@OF6UFC,6"Y8CS&.!M;GBOO/QA\2?B!;WPTO3+'PW::O(OF&VN+B2X%K M'_SUGD&Q(U],Y+= #7SK\YUJ] ;^R[#Q )YK<8SF7;#M M09XR3UKYA^'/C[Q)^T]\5A#/9ZY>641,LLIFGN_[.B/&R-4*C>_3+D GVXK[ MU\ >";GP1H,.F>"OAYI^AQ+R=0U^=#<.QY+R+&&9B?\ ?%?*9UPOE7$$H2S& MES.-[:M6OOL:TZM2E?DE:Y\W_$Z36?%^H:?XRO/#%XT6E+#HNZ(8GWK MMG^R_NR3\K;'PXX.:P],_9J6ZTEM3OO",'AT0Z9;VFH6^I>*(HY/)\]9XI)X MU@.QVV!<\$JN.U?3UCX7\3_&?7)CK7BAE\):5< 1IHEN+=;N\0\E7;<6BC/' M/5A_LUVUQ\';6-=?>RO6%QJ]E;V+8#X=\,?99O!5PZQ>%=&NUNK>65 MOF^U*HMF!+ E5D+#'S=#77S?M/\ B>V\+R:W+\-66,&%8[)-7$EU,\LC(D:1 MK$3ORC$J<$ 9->1_M%?&CQ!^S;^UE9/X8DDN++1_#UCIM];LF4GAP6RX'&X% M\@^M<%XS_:H^(?P_NW\5^%M>T.XL?&$[ZD&ATH%K*95$9C)?(639M+!2?O>] M>5BN!,AQ\81Q-#F4+VU?5W>N[U+CB*T=I'K_ ,3O OB#XW6M[\2=:LSX2-H@ 6"JC?ZS*GL*M_'7X>^-/BMX7MM8TFP:6U\/ M,9M%\1:9:FVO[X+@B.2!2#]G.#\R\G@A<9S]A@<#A\NPT,)AH\L(JR6KLOF9 M^IXKKW[-/AQ;6\U;3]8U7[$JW%P+*TT]&\F*)!(^TO+R%5AP3N[$ \5 MPFM_L.Z#K&H:P;?6=?G.U@\^*' MB*^T2X\!W,K1I-#K[6EW+-/;VCH(GPAP6R!M"_>'/4U[SX9U?P/XD;5-)%)P#MSR!7;ELZV3UWB9RYXQVND[65KIVN?%FD_L8^%?!-BVI7?B36!J*Q+,UK-IT0 ME2)R%23B78%8L!DMUXXKU#X7_!71_#OB*XFTR_U'4];%ENMS*L%J+-F9U+_- M+^\8"-P 5.1SBOJ30%\+_$UK"W\.^'YKY_)BM;^\OFQ!:6\AW8QBN[\:? ?P]XV;4WN);ZRFU"T6TF:SF"J0N[8VT@\C*<=A$ER49)II)*]][M:ZGR;XL_8]^'/QJU72-(\*Z[> MV>L?9[J]U"[N(4^T1.-H G3 /S2...F =IJ;X+^#_C+^STT'@&^U31-$TNXN M'@TV_N[$2V-_*>5B>089"R_=SR2"O89@T&;PM\,/'&H2_$Z>_P##TD=R=)T' MQ_H1DMK>80$JZR*F55]Q.05*G;TIGQ]_:$\2_#?PW':ZI>:/\8?AUK8,4&L0 M%%>-AR$D,1RDHX97&.F>HK4^,-/XP?LWZW-]I\:7OP[T/2?$6EJ]X=8\':D( MTDV#),MK.FQP0#D9S@FO ETRVMKA?$I\EM4D4W1B@'E6BLRC<(HU(V<# 92" M*]H^!_[76J?&S1=%^'^O:!K-S#/^LT7O].TU=0BLFM;+6#]GC\U@ \2^7QL+#O?=8^"^E^.= 6(^+MR91N,J3W4BLO2_B?K?PXL['Q%HE_8W5G?W-M%>>$-2'V.XDDN& 1[6$0BU>R MS^YE)7!+[00&)X8$'@UG^!OB5XS7Q!XBT3PS)HFNZK>WHOA;7%I/;FT$L8\V M2?YR(PLB,"IY+=.M6OB'\=M-UK7+2+PO'<:3\4-'9UFTW68OLXCMV7,D/M)\7^#))->M?$NCO>:RLF#/JLD4BDR)V$R+(V M$'&%V]:HH\9_:(\9>+_A+\*/BD^HR6]WJFM7MEI$NJ)?NS"?RA(YCB* !-K8 MV@C&,M[!Y8Y8L;F0J@R)'(!,G0[1DC%>P:M\=K'XDS1 M+=2.-,FSY>BLTEM:#!QF^NBOS'_IC'D>I/6J>B?LVK\)K'P[KWB>_P#[=LK2 M&'2M6L804MXK3[L;9'++&Y!8< AB2#BOJ.2;2O#>AO*YM=.TFSB+,0%2&*,# MT' &* /&(]0\"PZ')K/C#QCI6M66FQ^:FEV;K%IULJ_=2.W!_>'L-V2?2N;N M&T[QAXWT#QGKTFD26W]BWUSIMA-.@MK"VV*(R\BYP[;OF8?=!V@<<^CZ'X/M MOBEK$'BCQ!H\"Z-;DMHNE75LN2",&ZF4C[S#[JG[H.>IX^)U_9,;JK:M'\6O"NG3V.M^']+^*/AR1=DMNI5;@IWR MKC#?B&-;GAGX"C3_ !)KMQ=7EQ;:=<2%K-=.O)(I%&XD9(.?E4A<,6Z<8'%: M/C#PQ_P@GAC4=97QCXD06D1:.&2[68/(>$0!DYW,0/QH ^=-%\?:-:_$2VMO M"M\?!D>A?O8_!WCEGAM)+YPRE+>0D^250\#?VCO#^O:HFA>(( M9O!OB9N%TW5BH2?_ &H)Q\DJGL0<^U9V@_ W7)/!\5CK'B*WU26\9KR_MM6T M:WND:XD^:3D\\$X'TKP[X^_LOS^$O 6IZ_I^IV%C9Z:AF^QVZRJFPL/,$4;N MRHQ&>%QTZ5C5J.G!S2O8F&O#MI?33ZQ9R3VL9< MV<-PK3N>R*@.2Q. !ZFJ_P -_#EYI]C=ZSK0SXBUJ07-ZNOS4OVTZ&SC-JD<2PXDAN(?\ 6(PY5E8<[@<'/6OL7X3_ +2OB'6O#NCV M6L^'[.UU;R(XWN-0U80+<28 R?W9$;G@E'PV2>*^=R3.WF_M+TW#E_$^.X>X MA_MWVO[IPY'UZGT'J'@W0=5R;W1-.NR>\]I&Y_45@S_!7P5<.7&@06SG^*T= MX/\ T!A4"[%U(R"NN*0?\ R%4B^*/&_P#%X(ML?[.M(?\ VG7U M!]F0_P#"I-.C7.GZWX@TY>BBTU23:/P8D4'P#XCM5VV'CW5(U':\MH+G/U++ MFOBWX\?%#XH> _CU#:_"6#5'UF\02ZQX7MW_ +4L8Y"?E?[N(F8=5!'KQFO< MO!GQK^,WBK2Y]#U#X+8D0W-Y9ZE')!9JV,EU/2;&2(]Q]\#J =IK?B+ MXBZ3K4/AW1-7T/Q)KRXRQZ<$9]6\%:>]M9^ M M5FFFD,UU>S7UN\]U*>LDC;N2?R'0<5>\0>/]7CT/4#??#_4I+06\AE2:YMC& MR[3E6S)T/3\::U=@+K?$+7;10UWX$U=TQDR:?<6]PI]Q^\4D?A7E'[2WQ8U" MU^%.J:KH5SKO@[6=-3[1_P 3'3Y8K>X3^*!Y0"JEA]U@V0:_-'PK^WM\;-%^ M(EA)I_B&YETZ&\$$/A6:-9+<0^9@6_(W$A?E#9SP*_7GQO\ "3PU\;])T<^, MK"XO+"-$N#HLEPZ6_F%0?WJ*1O*YQSP*^BSC(L3D?LOK#B^=75G?[S*G5C4O M;H?"'P%\0_LO_&C4?(\9>$[C0_%EP=TTNJ:A/=6]P_!=+2Q^&WC>/2].C.Z/2+NX2_M%_V5#-OC7V5J[[PO\*O!O@>U%MH/A?2= M*B"[?]'M$4D>A;&3^)J34/ACX1U3)N?#.DR,>=_V.-6_,#-?.&IC_P#":>*M M"C!UKPLVHV^<&^\.R_:!C^\86PX'LI8ULZ'\2/#GB*8V]IJD*WB_>L[G,$ZG MT,;@,#^%9H(X-?ES_P %&OV./!5O'('LV!G_ M +/N"W78N259< ,:=IMY>B?2=-O@1 M) FW#L%/*JQP0/8GO7U-7)J%/)X9E'$QA@JCO%;4:%7$-JC!RLKNR;LN^@FTMSUGQ!KUAX7TNYU/4KA;6R MMUW22-^@ [DG@ )_$ML]K96[;])T.;_ )8>EQ..AE(Z M+T0'UR:PO[#LC!. MV)3U/&YO]FNN;QMXGUK:-!\&W$43?\O>N3K:HOOY:[G8>W%:GPU\!67PY\'Z M;HMI#;H]M$%FEMX@@ED/+O\ B2376T >2Z_\(_$/CJZ@O];\4+HNH6I)MI_# MEL(9H?;SGRS+ZJ1@UAZ!X=T;P7JT%CX^TR.^OY) MKXFU!WN;:[8] WF$K;R M_P"S@*>Q[5[M5/4M-M=8L9K*]MH[NTF79)#,@9'4]B#0!+;PQ0Q*D,:QQ@<* M@ ^F*\W_:,\92>!?A#X@O[7G4;B,6-DHZM-,=B@?F3^%.;3-=^%O[S2$N/$ M7A53E]*9]]Y8KW,#$_O$'_/-CD=B>E>=_%#Q)8?%SQQX!T/2[M;W28[V*]NP MF<^9N.V-U/*LJI(Q4\C% '4? W1[WP3J5[X>U-YWN;JUCOXC=2;I#M.V7 #% M0@+H% QWR*]IKYZ\(>&_$W@[XKZ/?^(KAI(]1FNK"$M.9!@QM+GJ>IC0=LXZ M#'/T+0 FT8QVKE/$'PT\,>(I#<7FD6ZW?7[9;9@G'OYD9#?K75,P523QCK7S M]XV^(&K?&#Q!<>!_ WTHE)A4$.B2$#<%?(SS]35+X+_"C3?C=\1'TC5]:OM(T9 M;9I7@M9/+CO;@,-@4GY3(HR?E^8#VK[ U7X1:3X?D\%^'X=#T_6="FNY?[2; M4K%;B2240-YO?#*STO7]%L8"DTZM;VMI]E2,I, MZI)&HP4.U5(8'/>ODZ.0JGFGRV]#X>CPRJ.AYGI M/P3\._!C4'AUQ-0U/PM.P$6M&[='M">/+N_+VED)Z2DGT;'6O;M'^&_A'30D M]CH.F$D K<>0LCD=CO;)/US7+:AJ&K_"VQF_MYF\3>"E0K+J$H#7=E'_ --U MZ31XZL/FQU!KA;'QYJ>AVUQ=?#&TD\3> C\S75PKF#33GYFMOXYXUY)C ^7' M!QP/K#[@]G\::;X?NO"M_9^)%LT\/R1E;I+IA'"4ZX)R,=*_-;Q1J$%QK6J? MV@9I)8;F1(5OWD+06X8^2L?F?,L>S:5/<$[KQ_X"02S7>GK< M.@+(JAGP3$@4RON]8\#TKP,XRQYI2C3C4<+.]UU\CYG/\HJ9UAX4(5G!1E?3 M^D>"_!+PW8:MX,67Q!XCUO5O$%Y=S-I_A0X_M"SN5>.]\27FZ?>""#;:<),[(AT:8#YN<>T/PE^%:?& M'1FD\9H9O[.E^QW3ONCO;UHUQ&V>&@M]A5EC7!;.6ZXKV2+3_%OPYMXXK CQ MAH,*A5M9-L.H0(.@1AA)0!V(4^]>S2@Z=.--N]DE?T/?P]-T:4:3E?E25WN[ M+=G"_L6?!W3/A+\,;M82DVM:EJ-S)J4X7!\R.5HUC^BJH_[ZKT+QYK%WXBU= M/!.BSO;W=S'YNJ7\1YL;0G& >TLG*KZ#+=A7!>&_BUI^A^(?&>DZ3')=-LBNK#*JKH69N@&3FM[POXAMO"]M-IGA^&7QSXLNIC-JE] M:D+;FX/4RSGY45?NJ@R0 !C-;&YZGI.EV?AW2;:PLH4M;&UC$<4:\*B@<5Q^ MH?%&.^NI;#PG82>*K^-BCR6[A+.!N_F3GY<*B,E>#?M;>![Z:Q\ M-?$KPW\-=+T;PKI,274CR:A$UK=Y4<-:C;\W&#CD[1GI7V;XD\<6Z?%R9U@D MU:[T6U^Q:;I=J09;B]F :5O152/RP7/ \QN_%K?M6?M=ZAHOBB#X5_#*ZM%\4WP,=YK; M2*T>FKM)8*!_&%!//3TS5KXS?"C2M)\8#2+/4M2\,^#=/T7SVN=,DV_V'-*Y MC$R<;EB;R0) O3.>A-?/?P8^"_AS0_V@M.\22V-]%X?TBR>\N-,F9IY7O@56 MWC+D#>9]XE5\ MG4Y#P@N=RN.I&".:Z;XK?$Y_V<[K6M"31O\ A--934PT>IV=\\<%RUU"#*L\ M:Y9YB%)(&0-_!'2OI3PIX9NM7U+Q'8Z;#;PZUKTS2>*-9C4/#8*P ^PP9X>7 M;PQZ DL-!<;EDW21,Z\M*J.? MF/)7Z&@#&_8T_:ZTGQ1H^HZ#<>%FT:>RE-Q.NG2O=2;3@&5XS\Y "A25!Q@9 M'>OJ_6?'^F6_@'4O$^G7MOJ%G;VKRQ2PN'5W ^5>.Y; Q[U\H?"7]@WPK;V& MB^-O"WB;7_"_BRWED:.ZCF6:,2)*R$,A W*0N"">'L2P0?..,_>H ]%\1? ;3_B)^SR_@+6E#2W=C MO-PZ_/%>-^\\T>X<_P Z_)#P_P"%]1\!^.-?\':_X-37[J"9K"XM)IY8/*DR M525"IP>?F&0:_8BU^)E_X;AC;Q=9Q#377='XDT@F:Q=<<-(!EHOJ'?BCX_P!9^*5WIUGM_#WB MRQ\%^/O#^@6^M0*'GU2W55MKFX8%EN%##"LXQE2<[CQD5=U'0]=_9RU274M& MD?4_!<\F9[6XDP("3T9OX3Z2=#P'_O5B>-O&G@KXS:]JUI9:Q#:W7]BPO;75 MK8_:;RVNUG?,4JJK$K\JAD/!!.#WH ]7\6?L_P#A;Q%"+G2X)/#.M0;I+'5- M(E:%K:0C&\(#L(/<$ZQ<7W@WP)H]S:^*M.B"ZUI.M3JEG8@G M FLY')<;QRL; A=PSC&*R_B)X@U;PWX?L=3T.[L?"_Q \-R/XN7 MSF8S"5AY@XP4;Y<8V]JX*S\:ZS9>)/[?T#5)O#<$GZ)-1\3Z?-J\+^5J,TDCHP?EA^3 (8#@1 MGIDYS77:=\ ?$^DZ5?PV?B+P_JVEZ>))4GEG>"40!]OF!"&)BWDJIZG'?-?) M\0TR%V2?RSR1O #K&0" ":]K_ ."=/[2'AO5-)U#P M5K,EKH_BN\OGOH<(L45[N5V,UX1\+FN/B1J#>']6NFG\ M-^&)%?3XY 0VM0Y/V>Y<'K$F-H'\3)N/:FR^$=3\=WUY8>#O$MW'X(MV"W"Z ME(;NUU&52"8(7SY@A'1V#$'H. :N>./$GB#P7>:/XDU'PE<6\FBGR+BZT0BY MM9K!B!*I48=-F ZY!^Z1WKT#U#WI5VUYXT$3?'N*41KYT?AM@7QS@W*X!/X& MNE\+^-M"\:6"7>A:M::I;LH8-;RAB 1D9'4<>HKSW2/'WAK5OVBM1TRT\0:7 MB^)OB)'8Z@VB:':OX@\1X!-G;MMCMP>C7$G2-?;[Q["N(\8>']0M&L)=5NX M_$'CG5)3;:5:[,6.GDC,DZ1'J(URQ=\DG &,UZ=I&BZ+X!T66*S@BTZPA5II MI">3@9:21SRQ]2237,_#FTG\5:I>>.-0A:)[Z/[/I-O*,&"Q!RK$=FE/SGVV MCM0!YCX7^%O@OP[\<+3PY!X)M2MKI'VO^VKFWD)GN%=,N,_NOX\GC.[/I7L/ MC'X6>'?',3?VG8*MR1@7EL?+G'MN'WA[,"/:N"_X6AXI@E\,I<6UG#/=ZC<6 MUQ'';NPF5+E(@D9)RIV.9"3G.PU[:*SC3C3^%6,H4H4_@5CP*3P%\1?A'(TW MA'4AXDT93N;2KH?,H_V5)_\ 0"/I71>#?VB]!URZ&EZ_%)X4UQ2$>UU#*Q[C MP,.0,9[;@,]LUZVS!1DU\O?&_P"*GPP\::HV@^(M?TC1=$MVVW>N7!VW,Q'6 M&T8#..S2#CL,FM#4]1O-6E\1ZM=:!X'6#3X_-(U?Q#;Q+MA8_>CB.,23GN>0 MO4\\5V_AGPOIW@_2(M/TV#R;="6+,2SR.?O.['EF)Y)-?%?A/XOZ-X+UZWT' MX&>-)_'T.E 'L6M?$V$:A-H_AFS?Q-K<9VR0VK!;>V;_IO-]U/] MT9;VKS7XL?VSH*:7?^*M1LKWSO.G$,D#'38)(PK1VZ1Y'FRR$D*TA_@.!G%; M'_"RW\&ZOIFA:9X9M;'0)]7;28;BW) 4 +B78%Y!+=%Y.0&ROX&O)-)^+?B6;Q!:6SK8O"VH/;K=+9M_I\0D";D(/R^6 MI+GKP,<5;\-_%#Q5J/B#0K>X:S;3)+^YMYKB"WQ)=HK 1NBEOE3DEF!..XZU ME+TJ .4\=V>OWT6FQZ%=M9?OV:ZDCV;M@C;:!N!'W]M>867AWQ]J6 MBZ-%K$.I#Q#"MT#JT-\J(!EA&LD:D+\^1D[3M XKWKKUHVCTH ^?O#_@GXC: M?+X2:\G>XT:Q^WF_L5O&6YE$D4@B!.2#@[ !N.TDG-.T_P &^/K76-!N=)DN M+&WCMIA+#K%TTJ6I82[8>&)<;FB.YLG"<$=*];\?6MQ>^$]1@L].DU6X>,". MTANC;,YS_P ] 1C'7KSC%7?"MC-IOAO3K6Y::2XB@1)&N'#R;@.=S#J?>@#R MSP]<>)M#^%=OX-O;BZG\?26TMM]L9)I85=Y'VRM.%QPA#=<\8%=]\,=-UO1/ M!MCIOB&=+K4[(-;O=1NSB=%)V/EOFR5QG/.0:ZVDV@=!0 M%%% !1110 4GZ MTM>/>.O@OJ?B;Q'/K%CK"VEQ)J=K>)YAD(BCBA$97:#@DD,PZ)- M'FW1KJUB6\[[*0MRF1*1_J^OW_\ 9ZU^07CK_@G+\2M3^,.HV^EZAHNH>&]4 MU68P:\VHQ@ M(6*.F=WFKGE1D\5^DJ7"V-]=>'].U.ZU6+4F6S9A(T$+JR!(R!SA=K=C MG.>,5[^3YYC,CE4E@VESKE=U?0QJ4XU+!+ M)/$%E<13QZA-&H5B6/[P2'&2I'>O6[[Q1HVFW5O;7FK6-I<7'^IAGN41Y>97'QWU3Q5\/= CD@40 M>*K<.GB'1=TL<%GP+B5XOOQ,H.WN QZ\5[;X1UOPL-&L['0-4T^6RMXEBACM M[A&VJ 0#D'Z\T@.HHI-P(R#D4M !1110!5OKZVT^'SKJ>.WBW*GF2L%7). M ,GU)Q7S+X:\+7?C3XQ7GB[0+N/2=5\FXU&.22/?;S1EQ;6Z2IZ-'',V\?,- M_P"%>C?M78N/V?\ QC8I$]Q>7UI]EM(8FP[SL04VGU!&[_@-?+W["26*/%4\B;].M M6$*;N6N&&(T^I8K4/[0FC:'JWP?\32ZZ(H[:QL9;R.ZDP&MY(UW(Z-_"VX#! M%?F7X7^-EU^T9;V?@_X@7.M#PVVLR:YJVH:;;/=3S 1JD4+!%P@4 _-TYSVH M ^B?AK^TY/\ M">'?!GPVTW7IM+U*>P0^(]7:"1I?,)^>"+:#U[L2![XK[3\ M"^!](^'OA^WT?1;5;:TA'/=Y&[NY[L:\.\:?$'X?_LJ_#SP[I_@O1-/M-6\1 M2PVFBZ; JK).SE1YTK=2J@Y))Y/%>IW/Q.^V7#Z7X8LG\4ZM#A)YX#Y=E ^. M?,F/'OM7<: )/C-=7VF^!;G4--,@O;.>&9#$,MCS K8&",[6;&01G!(XK&\- M_$_7O$NA:=;Z7H$EYX@-M'_:$UUF"RLYBH+*TF,NPSRJ _A6)\3_ ;K$W@N M76_$VNRWM[:7EG/%8Z>6M[*#%S%GY0=TAQGES^ KVV-550$ "]@!@4 <)8_# M/^U+B&_\8:BWB6^C;S([9E\NQ@8$/"5M_;?CB]'[NUB&Y M;-3_ ,M9>P]0#]3QU /SZ^+'@OXQ^&?C!I&L_P!N6FH^-]*NVO+;1K6$0-&S M8R\<:_)(LI &%.6.*KY?#NN"-Y[K7K\#6+&: 27%O,C(#%"_V==+AT^:[\7LVO^)KH^=+J!*-5^'OBBYNM!N)?%VJ6L8\Z_TZ/?\ NE/$6IA?D( SB9?G7NOJ M >OZO_Q1_P 5-.U0?+I?B-!IUV>R7<8+0.?]Y0T>?4(*7Q7\:-(T..^338WU M^ZLD9[G[&P%O:@=3-.?D3Z9)]J\]M[.Y_:.\):K;:UKBV-TB;T\/::^V."0' M=#(\WWIU) (9<+VQD5I_#V2W^+UKIBP:=#I7A+0V"75C#&$CN]2B.UX\#K%$ MZY_VFQZ4 >?ZY\*[_P")7C#P=X]^)*/;)JCR:1!HVG2O -.@E1FA9I1AV=BI MW9P/G QQ7LFFZ?XG^%MG':6=I'XJ\.0#;'%;1I;W]N@[;1A)L#TVL?0UN_%S M1YM7^'VK+:@M?6J+?6V.OFPL)5 ^I3'XUT.AZQ!KVAV&IP,&M[RWCN$;MM90 MP_G0!F^%?'.C>,(9&TV\$D\?^NM)E,=Q"?1XV^9?RQ7-_$3XI?\ "/PZE8:% M#'J.L6=L]S=22'_1M/C"D[YF'\1Q\L8^9CZ#FN>\6:;#\9=92W\-Q?84L)=L M_C*V)CFB8?>BM7'^L;L6.4'/4UROBKP_K/P_M=&\"06O_"2Z#J5Y]LO)K-,: MH]M$PDF,R])F9MHW@@G.,4 >A_ WX>KX4\*QZOJ2BZ\6ZX/MVK:C(N))99/F MVC^ZJ@@!1P,5;\:-_P (U\0/"OB$';;7;-H=[Z8E.Z!C])5V_P#;0UTGAGQA MHWBZS-QI5['.D7$L1RDD)_NNAP5(]Q7R=\>/VMK*\\4^(/AQH!TWQ)=2+&T% MY:2-MTUH\,\DKX(=U?;M5/Q-<^(Q%/"TI5JKM%;OL88BO3PM&>(K248Q5VWV M.N\>:X=:^(7Q"M9+;[3HUJUC9W:2<)?2>5NBL@?[K2.SR>B+SUKQ?PW8ZG#X MEM-2T2:>Y\,V<\D":W%'M^V2'F:*)CP90"XMW/W4!7[Q%<]X0\5R:UX@LO#/ MQ \2QV/AB^N[S4+[5+=9$GN;B4;I(SC=@N@*!AT7A:!J.I:''%]GBAM]/DM;=%7H4D=1R" 0PYSS6.#QE''TE6P\KQ9RX#,,/F= M%8C"RYHL]P\#Q:)!X5TP>'5C71FB#VWE="IYR>Y8G.<\YSFN"^/OA6+7KCP1 M>-+):W%IK*PPWD/W[9YHV595/LX3([@D=Z\#\&_&CQ1\-_$9\.7LL>EZ%JDI MDM+^33I[PB0]0JC8NYB0& .-QR/O5W?Q0N;S6O NI3WTOCS5'M0EXJKIOV&V M7RG60D[0&QM5NK'%=QZ)VGP#^(&F6/P]N+#Q!JMCI^LZ/J5[:Z@LTHA3S/M, MA#)N(RC#H?8CM52Q^)^B^(/BMKVH65KJ/B6#3[*/2K5-,L7GC)<^;.2Q 7_G MDO7L:^1_C%J5M\*_";?$'PC::EX7\5KK5U8PB^BCNH=2B,IE$M8G MC"?6/A/INL:MKWB.X^&TRQLT5IX=TX/I5X1]U4+%L2$#'1&Y[U[%X&T[Q[X8 MTEXCX=TN35+N5KN_OKK5#NN)V^\V%C.% PJCL% KPS]O*P\>:Q\);.;4=/TZ M+3;34(Y+A-+N)9F.595+!D4;03UKEQ=:5&A*I!7:1]!P_@:.99IA\'B) M+KF^\-QCP?<36"PO_9Y:<11AF++!"%)E4[LA3DQ\E3@8KX/\;:3JD/B*Z,]I M=$R.3&YA;!7L!Q^E?1W[&?A7QG??$7PO!H8:PUJ.>2:"XNX6,<,84Y+#'3!( M_$5ZV99'_9.68+,Z>-565=KF@DM+J_>^GF?J,J.3YM5QV61P'L/J\9.-2[WC MMS='?H?:6L7S>,M)T:X\-H/AWXQTF RZ3##F[U75S*,L"5X:"0YW.Q)5AD[2 M*[+X9>!="^.VDZA%XET\:'<:=.UOJ?AV.5CJ4=SM*E[JZ)\QPP)*A2%(/?I5 M*Z\%V'@K4DE_LZ_T3Q#+)YTXN9P9;B7DF>PN_N!^3F [5<'&T&H/&_BR\T^? M2_'FE20Q^.H56SM;B",I:>*8=P'V&9.L5R">%;E3G!*UQGX>8.M:;XT\)7UW MX,\/VTNKW7AY/L]Q/IZ^5=OH9P8XI1]V5G7**ZX=65SC&:]2N]0\#?$3PVM] MH^I_V0[:'';M9?9SYVGPI<(0TD6-VY9(PFWOS6+X.\;:;H>CZ?\ %=KF:XGO M9I+#Q="8R)[69CB.$QGE?)D"Q@=P^?XJZ3Q#I]]I4.G>)M1MKH>+-_:,\<>"[+31(=,(N;#5[QXMLMG*T8E M-FI/,<_[E@Q'W0?>KVF_%)/#_A_2_!>AO]BTA8HX_P#A+(R98+"U;/\ KEQF M&X)!4(W"GDG K&^*WPHMOA7K7ACQQX%EAL;1]1M$OKB24R6X=V\L74V#\ZN' M(9NH)##O0!V>FV/B+]F]M.T72=.O/&'P\D?RH(U8-?:03R(_26$\X)P0>,G- M>RZ'KEEXFTF.[MM_D2K\T=Q&8W7L5=&Y![%-6TWQ%INI)<2ZS-E;>+:^3*T_ M1E8#L22#TYK]4-'\%Z[I=KH6L7%I=:9IMC;ZHUUIK7Y=%69$\M%"DX7Y6^;J M,D\9K-T?P%KVJ^#M#N]#U"*U@2.^GCU:+4 \<-O*LFR'@D?*2IR,CY><8KZ; M*,^KY/2KT:48M559W5[>AC4I*HTWT-[Q1\,[[Q=XG\-Z?XFG?Q!>RSC4+V01 ME;"Q@A((BACZ;G?:-S98@$\#BO=EZ8KY^\*_#3Q-<>';>\MM0?;<>'[JRA07 MN4!>=)(&POR[C&&RPX^;'2M"U_XD?P[3P+XETV^EO+U)+6&9X&:T\R4NT$7G M [01E1@< CCI7S)L=3XX9O'7B:#P5;9.G0A+W795/'E9S%;9]9",GT13ZBO1 M8XUC0*BA548"J, #TKD_A?X%M/A_X1L=.@LX;6Z:-'O6BY\V?: S$]SQU]J[ M"@"/REX.T$J5ZE1E^@P.:Y7 MXT^%=9^)GPAUFSTWP=9:7I4=D8M-M+ZQCEOYW/RQA(R-MNN2.3E@.PKV#PM\ M,],\.W0U&=I-8UO8$.I7Q#2*HZ+&H&V)1_=0 5V.T4 >#_LE?LPZ9^SAX!CM M"L=UXIU!5EU;4 .6?'^J0]D7H/7K7KGBSP7H?CC37T[7M*M=5LV_Y9W,8;!] M0>H/N*W:* /D;XKZ3XI_9JCAF^&?_"2>)]/DOLVO;6-#G/EW&=T)'8<_ MC7SE^S?^W)XE^&?Q&G\.?%.>\N/#MW<%$?4#ON-(9F.W)QDI@@'N,9K].-6T MFUUO3KBQO8A/:7"[)8R2 R^G%>,:O^Q'\%-:D>2X\"6(E1#&\,B JRGJ"/0UXQI_[/NK?"JU3_A5'B:?2;2$<>'=>9KW3W']U&)\ MR'/JI(]JV--^/2Z'>PZ7\1-$N/ VHR,(X[N=O.TVX;_IG8*L9\V5BC)M)SC;\V>F01[UVU% "+]T5PGQVU8:'\%_'-Z>/*T6[Q]3$P' M\Z[RO-OB"6\<^(+'P/#S9,%O];.6T)RFT@_,H;\*^P/#_B;2 M_%&GB]TF_AU"U/'F0.&P?0CJ#[&K\-M%;[_+C5 S%VVC&6/4GW-FI:6_E2$_P"V/NR#V8&@#L/\YI:\]/B#Q=X, &N:=_PDNF+P M=4T:/%P@]9+;^+ZQD_[M&[1IK3X36TX&I:I&2DFM MR(W^HMS_ ,\0P^:3^+&!ZU-\&='Q)?V_A[0((UCA\.Z))Y,*H. LLW#, . M-J[5^M9/PW\5>$/A[=>,]#;5M)TK3K+5FN8$\]$18YHDD..>S%A7$WT'3?$VM:N+$B-].U_8+K3V_N%0H(!]>0>QJCXA_;"^&FFZA%I6BZ MM+XUUV;/E:3X9@:]G;'4G;\H ]S7QY^U)^UIXXU#QA9Q:7X)USX800R")_$E MQ9N-2>$G# 8PH7!SM)/U% 'WQ\;!YGPF\4%.6CLVDX_V"&_I7:6C^9:Q.#]Y M%/Z5\53?M%WN@_"FT\$-X2%S<:AHK>5JJZNDT$T,@95N'8;VWL&]&M]"U:YM"L>IVI:[EV(H!:/)55?GJ^ HYR3Q7F1S/"2Q' MU137/VZGE2S3!1QCR]U5[5=$[GNGQ*^*^LZMXBE\ ?#6*/4/%FT#4-4D&;/0 MXV_CE/\ %+C[L8Y]:K> M+\+_!Q+K2M"6\\<>-KIO,U.\@ EN9Y3U,TI.R)< M_P )/'I6%X%_9U\6V_@J/1+_ ,7KX5L7D,MQ9^&K=?.N6/WFN+J7<\CL<[B, M>E>AZ'\#;+1=/2SC\0Z\ENO_ "RMKL6R-[D1J,GW/->F>J3MX/\ $'C)!)XN MU0:?IWWCH>CRM'&1_=FGX:3W"[5^M;EKK'A#P78)907VCZ1:QCB!9XXQ^6>3 M6='\%?"?#7-A-J$G]^]O)I3^K54\4>'/#7@;0VNM,\':?J&I2.L%I:QV:,\L MS'"@L1\JYY+'H : / _C:_AC4O$=JOPR\3+HOBV4/)=7&G*[VL41!R'5%.UY M#\H ZY)(XS4GP7^/EGX+\17?AG5O">K>&;F\LQ?KI;6Y6$2Q#9--#(Y"F.10 MLF2<@DYKZ/\ AWX+'@[29C<21W.L7\GVK4+N.,*)92.B@=$4851V ]Z^;O\ M@IK\,_$GQ*_9^MU\+V+:E>Z=JD5S-:6Z;KB6$JR,L8')Y925'4#VKNP.'AB\ M53P]2:A&32T2[U/2= BN])A4^;?3:Q:+!&,._!K:+=3:/X0\*Z->RVLT=]$*0['4=06 M"]A7QA^P1\ ?&FE^,IM<\7:/XG\/?#YDVS+"CPK+= CR7>/J54[OFVD D9Q7 MZ+:9\)_#NB_%J62726U>TU;3%G%UJ):Z N(GP_>+M27P7X M*U*]TRT3S+:!OLUM;Q *TI^6,;0.FXK4G@#PR/"'@[2]*+;Y;>$&>0]9)F^: M1S[ERQ_&O$-3Y^\)?&%UX?6-&>ZO-(NIFN'B )99+B9CE!U/ MRBOE32_V)]2\(Z]:Z_HOBN6VTV\CFNK.&73VN+UK%6 \R:%""$8$-D'CC(K[ MK^+GBNUU*ZFT1O,ET33_ "YM86'EKN5B/L^GIZO(V"P[+U^]6EI_PYDNO#6I MZAXCO+BQUK5 L][+ILFPVL$?S):1G'^K4<$#[Q+'O6-6E3KTY4JBO%Z-&%>C M3Q-*5&M'FC)6:?5'@WP7^ ]O;^*GUO2O&-KK?B71U,UK:RZ2NY<;23P:^F?"?Q M]7OFT?4K1]!\11KNDTVX(.\#J\+CB5/<%/ MOA#QY)J7BWP]J.J66JW3K$=2AE,4?==3[=QW'%>=_"7QAJ>K MVNN_"WQRP3Q?I=HT7FM]W5+)E*)]&[@]:U_#OQ%N/#]FD^I:BOBGPMG M:GB.R7,MKZ+=Q+R,?\] /]X#K7._M/7FE:?X+T;QWIMRJ>)],O(1H.H6A#"9 MY3@P.1PT+KNW#VR.16M6I"C"52H[)*[-ZU:&'IRK5':,4VWY(X#P#9Z?XD^' M4EE>6EM+KMYXC.D-=SH&>WB$4,ET5)^Z-L; D>M=CX;6/1?'R>/)+7RO >H3 MM::;&20EA*^%-[L/"I.1MS_",'^,U\O:;\0K[1_$4D^M26__ CM_JMQ?ZI; M:>C1O"EPRB<1L2?EVK@YYVEJ^X?B]XHB\(_#.>^M]!M/$.E>0(I-+DNUMC-" MR\)%N!#-C&%X/I7!E^9X;,HN>&E=+1]#R\KSC!YQ"53!RYDG9Z6$^)V@^)O$ MGBGP[;:#K4^BVD<4\UU-#*R_,&BV912-_&_AOEYY[5Y[/H?CGQ3+J%MK]Q?( MDFLV]W#!I.ILODV+R!9H)P -J('PEVJV\18N[%B MSRN>K.QY9CZDUZI[<6XNZ/GWQUH-EXLU;0(O"D\UU86TTHU1=*MI28S\@B#% M K$<2<]/6HO"?A?Q5I.LRR65OK0>WF:;5OM.#O072M$MH#S\T(<$+P1CO7K/ MQB?6;>ST>ZTV\GM;:UNO-NO+D,4<@P JRR[@4CR22>1P,U4TKQ)I>A?%3Q@U M_>QPF]DTVTM$W9,\C0L0J#N<<\=AFHY8WT1TRQ5::M*3.9F_X2/[=)+XMM]4 MNO#L[M-;1A4\F"$R9<7JMP-L8R/09Q\U<-:_!5_%6O:EXS\%-!>^%%D9+/PY MJDSO::H0"KW,4F\B\[5KJ,\VMEG M!4'L\O*#T&X^E? W[27[0&O?L^_'3Q=X?^'6MR>&["SM+)8-'C@$]I)*4/F M*V?+.U@01QQ5G*6O'GQ L['QY<7?V;4SIL<@L]=T3408[FZN$!V^:5.V2:W' MS)-_&0H;D9KVF']IW2_&C03LC64&HV-UMO;\;MTQ>!@QD'WR9.-K'@CI3K_ M %JUN+5+..%F#QA$T_RF$K#'$8CQG/MBOD_2RTT/OR'P4WP8CEU?2$FUK1;XF;Q':R 233R,/GOD'= MO[Z#@J!CD:EI5T_C2UV3:!=M=I&T<+('1_M8)&Z,, 5&688R MO6NUM?#ODZR;'XPR+KUS>#[/I^K,NS3!N&/+6/I#-G^)N6XP1TH\*_"O0?B) M^SWX=T^SLK**ZL4$UC<*H(6ZB+)O9AR=X7#'.2&^E7?#D^M7GA2Y2.T;Q?HJ MEK34_#.J.K7]C(O#Q)(W$JCJH?!(*D-5EG6^&-$?$=P]RLH(T?6) MO^7M /\ 4R'_ )[*/^^QSUS7EOQ+\%W4?CM?#/AZ.+PI)XD5H8+JWF5DNH!^ M\NQ)!G@ ' QC[[$&M>/4+";0KO3&>[\1^#D(\VWE#+K&@.#E6*GYV1#R&^\O M^T*YOPG-=?$[4-2O+O44G\26R@>#M:*;(;^&V=M\J'/WI'!61?[H! Q0!Z]I M/C]O"C6NC^+M-7PZ5VP6^H6Y+Z=-CA0LG_+(]/E?'U-1^'ROQ(\;/XB)\WP_ MHK/;:5W2YN/NS7(]0.8U/^\1VK,U[QN/B-X7T?0=*0)JGB2-X[R*10QT^!#M MNF<'HRG,:Y_B(K(U&WA^$%Q;:1\/+J2_NHT5%\%KF>+;TW!\_P"B^N6.WVH M]S)"KD\ 5YIXN^-%AIMO>_V(BZNUI\MQ?-)Y=C;-G&'FP=S9Z)&&8GC%<3>^ M,DUMIU^)EY<^&2C;8?!UOE?MA)^51,O-T6/&U"!SR*W_ (?Z?8^*O$]PNL1V MMC>>'_+:S\)0A1'I:R+NCF=1P\K _>'"G('.30!F^$?A=KGQ(UZW\6_$>\FO M+2W;S-+\-,GE6L)[32PY.Y_17)([\\#W15"@ # ' IU% !1110 4444 %%% M% !534--M=6LY;2]MH;RVE7:\$Z!T<>A4\&K=% 'E+?!N?PC<27GP]UR7PR6 M.YM'N ;G2Y#[1$YB)]8R/H:\ _:>_;\UC]FF33=!U7P)'=>,+I#/A;\&P, ) M7S$<#>22"-K*"*^SKFXCL[>6>9ML4:EW;T &2:^*?VK/AI\-?VI-$L=6URWU MWP_KNEND-K>6BPF1[69?,1I%9]NQ@"RAB'SQC)Q7L9/+ 0QL)9G%RH]4M_(S MJ<_*^3<]<_9!_:LT_P#:L\"WNL0Z:VBZOIWT71[7 DN;@G&X]%4#EF/8#FB,95)*$%=OH!I M^*?$EKX2\/WNKWI(M[6,N57[SGHJ*.[,2 !ZD5B?#/PW>:3I-QJ>L*O_ D. ML2_;;_:_'+P5^U3XRAA\(ZW%JOA[PWLO[V)T M:*2>Z8D0CRV 8HF"Q.,;MH[5]"UI5HU,/-TJT7&2W35FA)IJZ'4445F,3VKE M/B/X[M?AOX3N->O;6ZO889881;V2J99'ED6-%4,0/O..I%=77EG[2=E=7WPI MNDM+.ZU":/4-/G,%G TTI1+R%W(102<*I/ [5S8B4Z=*4Z:NTG9=W;0"O_PO M*]'_ #3CQ5^=G_\ )%?)G[:2W?Q8UKPLFD>$[C1=;)D5X=4NK&WEN@S6JM^I^=VK_LK_$58?[5EM-*CT^X62>*ZDUNT"21B386!\SD M!B%/OQ7OG[./P:\5^!=2\-ZGK]OJ-GHMT9+.+4/#FLV@GGE;<%AA%-1\/ZGXLM8=%UM-9DM=2\,7HZ5Z^WQ*T[D_V7XC_\)V^_^-5Y?I.M-XL_ M:D@U/P_K%]H-Q'I4&BR&\TYXRSL;N]?1U]\$/#.K6IAU$ZGJ$#C#0W>H2R*?8@G%>9?' M;XT_%[X&>'3K4?@;2_&FDP#-S?:9/+&\(_O/"02!ZD$@>UZ79?V98K-:3VSW M(DDAW@!FD\HL$48^]\V.XQS7UYX^\.V_B37/!,KRPQS:=JWV^)Y#P^V"12B\ M_>.\'OPIJ/X:Z&^GQZ]<3G19+B\O6\S^Q<^2%4;51E)P' Z^I/->#_8N$^O? MVAR^_P"NE^]CYG_5W ?VE_:G*_:>NE[;V'>'?BWH^IRV]GJ*2:#J%P T,5\5 M\JX!&&;AC)?^%YU#*I/66T MW<*WU>\ M?3'INJZI:Z)IMS?WLR6UG;1M+--(ZAJ\A'WI M,=(QSW.!0!Y7XD\$^+)-8U.ULM18ZC?7T6H26 M _B OB+4M/\ [741'4_[0M+)KK][/'DXE?YON*Q (7' '&>N/XR\(^+O"%NN MJWFIMI%E!JJW,QFOSY;D%M\P.<(K C"]L?=KOI/#U]X+\*:=XK>PN-.OM$U" M6ZGL9;HW1CL)=JS1*Y))4 "09[H?6O5O%&BVOC+PAJ6ER%9+74K.2'?U&'0@ M,/S!H ^;H?C!%\;?$FA:-X$\5V,%UH]XVI26M\98)+[:>($0[2PP78G!4<9% M>_?$3QJ?"&@!X(TFUB];[/8VSM@-,1G$G^(/ MB#2K/3-=>7-MJUCM@FL5M@8O,21<8)9)&.<@AAFN8TWQ)JGCSQ@UUXPDGF\% M6N+0Z]%"57[.3N6*=%_U3381I'' 3:IV[C0!ZQ\'_!IU:2V\07KR76GVTDDN MGM,N&O;E_P#7:A(/5_NQ@_=0>_'L5U:I>6LMO*-TI)P!0!SW@?P)I?P_T=M,TB.1+5I6F M(D;<=Q_ >@KHVZ5PM[\5;.XO)M/\,V4_BO4HSM=;' MH6]))S\B_09/M50^! MM>\7+O\ %^M-#:-UT71':&#'I)+_ *R3WQM% &#XX;PO<:]*WA[[=)XT/RLW MAD!G_P"WG/[HKZ^9SZ5\^?&KX;^/M-\)XUJXTW0].GO(9[2QTD[K,WP+%6D# MB1KRQ]3^)->+_\ M"$W/[1.NV7Q$\1W=YX5\.: TS:%IXE4AI%#*;Z?^$@<[5Z8')YK*I3C6@Z()K*WU?6O#=I:7G$[)J;K\F2IY,8V@ ME67'7@XK[#T#X7>*O#%]8ZU/J=I\1IK>!%@CU-?L[6H _P"78C*#_>9=Q_O5 MQFM_ WPAXNDTN#3_ !K,?$EYI?VG3KJW@"I.^YY8IS@;!N8DE3RP!([UT_@W MX_:GX;\*Z==?$K3UM+20FWD\2:9$S6<YYN6Y3@\IING@X\J;N^H_XA:3X)^(FJ:=>:[ITG@KQ_I.=>5"SKE)4)X*[CP3P*]2^'WC(>,-'9[B);75K.0VVH6BMN$4P')4]T8?,I M[@BM>WN-)\7Z.DT4EIK&EW*Y5EVS0RJ?S!%>1>.OA))X#N)/&'P]GNM!OH=O M]IZ?:CSH+VV7.0(7.T.F=R[<< CO7IGL'K'C+PO9>-O"FKZ!J,8EL=2M9+29 M&[JZE3_.OSY_9-\%^(/"_P 3O&WBOQY>7FO77@60>&-$M+B0O)/=L-L00'OY M94!NH#'L*^TM(^('B&STN"_U/2(?$&C3QB:+5_#K%\QD9W/ Y##CKM)[\5Y% M\//B'X/\2?%;QKXP6]:YMH]0A@TC1H8,7-W=?9PKW"P\,S$?*"P #'(S0![ MMX*\/_\ "$Z#?:GK=U&^K79;4-7OF.$#!<[03TCC4;1[#// M/$6J:%I@\5_$/QZUPUG/<+B'1[$J(XW3=\ID**Q9NB@]B*^OOB5X@O\ Q1J, MR^-M03PYX'TF);[6M'MI-S2J?]1:3R#[[R'DQIQM !)S7@4G[*=U\*[#XL?$4:?9WOBVVNQXPM_#RE+35= M+TV)+@:A%%/!T@ EDO[J2? M5=27I\Q5 MY&[GJ2%S2LA63W/,/@SXJ O[/QEXDTF^2:ZWWEQIE]9F&&T#'F_T^+)#)_ST M'+C.[US]HKLO&7A/Q?\ "W4I_&>@>(_[6MF6.'5[/5K4/FW4 MX%QNBVLSQ@\GKMSZ5UVDZ79WGQ$\?:+?VZ7.GZI;V=Z87&Y75HS$WZQU7L_$ M@^%+]0C_L!U8:5K5\X"O&%YMIV/_+11G!_C4>H- '#_ !AOM7U#2+"2 M7PN/^$CU)EM-)U_PQ?J\XWCE:_9Z1X/LUG MM?#^K:L,M;L2K7,4$).689"H7P-N0 <5K:]XV^'EOX@66[>^UO1M,87.K:UJ M$.7O;LB-=>3;:>I_ACDP<2=-TO4G@8%?&NO\ AK]IKP+\=+;XCV/@>ZNH M;.);%M/L[]+[[39 Y\F5LAG(!X8C(XK[BN_$7C#3;&XBU[PO;:C9E&66ZT2_ M"_(1R?+EVD<9.=U?(?P;_P""@^G^#?B%JG@7QKJ4FL>&+>\>WTKQ3LS-''N^ M5+D+G=M^[O7/3O7UQ]N?:?P]^).F?$32(;FU$MA?[%:ZTF]0Q7=HY'*21GD8 M/?H:[&N)U+P[X7^)EI:ZG;74*?A M_E=?MW\3:*O35M-A_P!*B7UG@'WO]Z/_ +YH ]'HK+T'Q%IOB738K_2[Z&_L MY!E9H7W#Z'T/L>:T]P]: %HI,BEH **** "N)USXN>&O#FM?V5?WDT=[]HBM M-J6LKKYLBED7B:A)9WEUY#R)*]9?X0^#_,FDCT"TMVFNQ?2_9T M\H238 W,%QG.!D'@XYK-U_X8^%M(TUM0A\.-?S6L_P!L2&&T1)8FBN/*=VW?,6,F-O5L'L,U MZ-X/^(EAXMTC4M0$$^G0V#XF6Z R%\M90_RD\%'4^M4[7P-X8\8:+I&H3Z.P MA:9M5BMKK]/L?AG:Z"%@T*]N=&L6E,MQ:Q@2K.QP#N, MF3C: N!P * -?PGXJ_X2FS%TNG7=C#(BS0FY"_O8FSM<;2<9 S@\\BNAKGO# M'@G2/"'V@:5;-;B3 &<*NXG:HR< <'?#VOZ9;>)= N5U4V%Y=K&KQ[64B3GY.#D,P MQQ7TO=>)=*L9YX+C4K2WF@B^T2QRSJK1Q_WV!/"^]>)ZSX#TF\\0Z[+)XNT) M+*2.>],,CJ)6\]HF!G8,#Y:F-=K Y^;V%=6#Q57 XB&)HNTHM->I,HJ2<7U/ MEG]@?]B_QK\,?%EYXNU[Q/!X8OKRP:&QL=,N8;I[F(L-TC#E60$#!'<]J^Z6 MT#Q]9\V_BK3=0QT6]TSR\_4H_P#2O.=%^$4%MKEGJTGQ!$&JZ/;$,NGS0JEO M9R,TDA.Y2?F)7YVX(7)&3FO<[/5K*ZFFMH;R&>XMPIEC616= 1D%@.F1S75F MF98C-\5+%XEWG+>VFPJ<%37*MCD_[2^(VGY,VC:%JP'1;.]D@8_]]J0*2/XA M>(;5B-3\!:M"!_%I\\-V/_0E/Z5U<.O:;<:E-IL5_;2ZC"H>6S653*BGH63. M0.1UK3KRRSX\^.7_ 4"N/@W>-9S_"OQ)#(Y(@NM7"VT$F/0C=GZ9S7H_P ! M_C]-X\\-V^N^--<\+Z#-J2"6ST>SN_FBC/0R22$;F/H!@5[%XH\(Z-XVT>?2 M=>TNUU?39QB2VO(A(A_ ]#[BN7^'/P5\/?#'P]/X>TR$W/A_SFEM=/O@LZV@ M;EHT9AG9GD YQF@"QX@^+WAKPUXA\,:5>:E O_"132VUC=)*K1-,BAA&6!X+ M G'N,5F?#35+36/$GB769+N'[;JEXT-G;F0>8;2VS&&"YS@OYASTY%?./_!1 M3X/VU]\/?",GA'0;:UUV;Q#!:0O80K$[/*"J@E0,?,!SVKT_X!?L@:3\)/"5 MO]JUG59_&-Q$/[1UFUO71F/7RU!R-BDG&1SUH ]=\3>$Y/$'BKPU>-&/LNFR MR7$DJRLC[@N(U !Y7)).?05UE<+_ ,*]\06+9T[Q]JZ@=$U&""Z7]$0_K1_9 MOQ&T_'E:UH6K*/\ G[LI+&=/U2\M ME8K]4]!)C9+QV8 GUKF?AQX/^'$>L:_8:58QZ<-6D%W=^$]4M1&(K@<--'$X MXW#&=F5R,UO^%_CIX9U3P[I=W>SWEC-<6L4K"YL)U&2H).[81C/O5S5M<^'7 MQ MXX+[5=&OF5LQ%KI(YXV]4;(=3[C% ''+\-]/U/XGBTT..*N^$/#/B;X11W3)I4/B:UNC&LG]ER"&6-(QM5_+? MB1V!RV".161\*+/Q1IMAK/B/0+F'Q-I>I:I.RV.HS8NS#$WE)LN.C<( M+X:5XMU"W:74IE;%K]C (,DV/NRG[L<@Y!R3D"L3Q=^UM\+[K2[^"X235$52 MMN+VP;[-!?@%?>)M-GO7U#4/"ECJ($L]O;N$M>L_BW MH(\%^&;(>'M L8!#JKW022<@Y!2V!R'#'.;CD'/'/3LM+^$,OP\M5C^'VH?V M/:J=S:/?[KBSE;NV2=Z,>Y!/TK%\3^#?%\,-G*EA8WU[IJ;+#5=!(LKN!1_" M87S&\9QS'NP>V#5SP+\>K.\N/[%\9V\G@_Q'&VQ4U2,VT%[Z/"[':2>Z9R/> MMSI-ZU^*2:3+':>+].E\+71;8MS,WF6,I[;9QP,^C[3]:[N.1)D5T8.C#*LI MR"/4&H98;;5+-HY4BNK69<%6 ='!_0BN(F^&<_AUS<>"]6DT%@=QTV8&?3Y/ M;RR:-9895,;HPX92,$'\*\4_X22^\*^ -:\%1RL? M$-E=QZ)IKG[\D-P<6\H_W(R^?>$^M=A#\4)_#]PMKXSTJ3P^YX74H29]/E/_ M %U S']' ^M>*_M%_%#3_A_\1M)\<6L5OJ<.CV8L3&LX N;N[R+7;SAMFUF) M[*YH K:M]MM?%%_\"O"2@0?:(M0GN%.4MK.1%+(X'3]XKL0>NX#O7TEX;\+Z M3X%\*Q:7$$BT^WC/FRW!'[PGEWD)X)8Y)SZU\Q_#.SUGP7XFT+6],@?6O$GB MN>(M35X;![B3$L219&]U0JRC /K7T!:_"U=6F6Z\7ZE-XHN@=RVTJ^5 M8Q'T6 '#?5RQ^E '!-JVH:5JDLOP@LY-?LV8FYTVX+=8N+C4K7!N?"VUK.&U/HZ9W3+Z.25/I7K\,,=M"D<4:Q1( M,*B* %'H *^;?V^_!OB7Q%^SWKE[X(LKB3Q79M&1/II*7GV39I7>RN]WZ"D^5-GT+8C3-+TT1V?V6UL+=>%@VI%&H'MP M!7&3>/-5\:3-:>"8(Y+7)63Q%>*?LB8ZB%>LS>XPON:_+?\ X)N^ ?'?B+XW M!+FRU0^!8XY&UNVO_-2UF8*?+5U. SA\<'/?-?K=XHU^U\#^&[F_>W9X;9 L M-K;IS(Y(6.)%'%C552R3YH[:]#*E4]I'FM8\SUCP?;?V MY#X7L;JXU#Q'JD7G:YK]T^ZY@LATNUM=+33X(( MX;..+R$A51M5 ,!0/3%<[\._"MQX?TZXO]599O$6K2?:]1F'(#D86)?]B-<* M/H3WKH-:N[NQTJYN+"S.H7<:%X[02",RD?PACP"?>O -CB=%^#MGH>L:'>0: MA<-#I=I;VPMV1<3-"CI$Y;J,"1\@<'(]*BL[6'P[\2M6T*[ACFT;Q1"U];PR MH&C-P@"W$1!X.Y=KX]GKS;1?V^OA?)KEQH?BBXU+P+KMK(8;BRUZT:,1N.V] M<@_7H:Z[XA?$3PAXL\%0:_X?\6:+=W^ES+J>GR1WT?[QH_OQ@9S\Z;EQ[B@# M(UCX'ZC\-=0FUKX:W5SI]NSF6XT*%P4ZY)B1OE8?[!Q[,.E=#X7^-^^SD?Q% M:?9[:!O+FU:S1C!"W=;B(_O+=O\ >!7ONQ4E]^TOX$M=%@O+?56U2ZN+=9X- M,TV%[BZE! X5%'8G!)X%>._$;6+3Q=')XEU:VUBRU255M].T?1=.D*74A(,< M-X[A1<9(P4X4#/-2VD7"//)1///VA/VI-.^'_P#PD/@_X;:E#JMCJS":66$G MR=.9CF>.%Q]X2#G X4EL=:\<\"?M0VF@WVIW&N^#+'7+F^*-_:"SM'>6Y2,( MJQ2+@H@P/E7%?-_Q>U;4K==3FE1;&]EO&%U'&NP0DL=R@#[H!XXKR'1=5NK' M58'MI&,WF* H;[W/3WKUS][^5+L?J1\*-.\0?%6XT_6M+G_X3*QM+]KNU\/ZTQ\II MR KWM].H^4@C]W$=QV@9ZU]*>&]0M='U6/5/B7:WUMXCC.([R]BWZ7:^ULR9 M1!_MOAO?M7S)_P $\[;Q)K4/B_3]-UZ31=*1H99&CMDE8RG(^4L<*<#T-?9S M?">ROH3'K.NZ]KJ-]^.ZU QQMZC9$$&/8U\[@\0\104Y:,_-.*,JI9+FU;!4 M9QTE_XTT#2])_M2\UK3[?3MGF"ZDN4$97&J7BG2[SP_I\DOC'PQX=\9Z+$/GO$MX8 M+A5]6BE^0_16KO/E1OPV\?ZE<>!M%_X1W1M8\:B2 .VO:A1,%) 1U"C.0..E)X!^* M_P /M+5=%^&V@32W=Y^_&E6T'V&%&S@DF7:H]]@:G^-OB1JFFP7C:UXCM]$6 MVB,LVD^&(/MVH!1R0TK#9&?OQ:AX9U3X(V>N^*M*UWQWXFUJ!5A?6IY$M8;ER4 M0VZ,><$A\QHQQSFN=UOX2V4?A7QAXAN-)%KJ9M;[6;FVNKZ266T15#Q@I_J] M[EE# CJ7XXJW\*_BY\/_ /A/?!E[X1BNO$!ATR*[D\.,K7-Y:W+J5D,,A&$2 M%0Q*,0HW?+C@5\[E67XO!3J2Q%9S4G=>1\ED>58[+ZM:>*KNHINZ6NGW[&G' MH_CJ'PCI'P^CL;'PY?S-&-(U*&Q^SSZE*&W>>K$%P\>2[YV_*.F#7IG[,OPN M^'6M>'[C7-07_A*/%.FW$R:E?ZU)YZ^".U<5\:+SXG_ M !6\/ZA\3/AY M.?A?\+_$'A8>'M1M-;*7"3ZO(K+Y=G=V NH+C=C"C'$8VY.\=*E^".@P>'=-U[3XM&TW1F MM=7N(%CTVU,*21#!1N>6X;&[VKS/]G'XCZMXB_9I^$VI::T4)O^NUM,-LOY@^AKY>_:0_X*4^,?@GX MMB\'P>!K,:[:QK+?7&INZ1R*XRGEQJ25R.N2?:OK35/VD/#FEV_B*\DAF.GZ M+9_:C.6"-<2;%;R8U/5L2)SG'S5XE^TE^S/X)_:=\33ZYJ?AW4K;5=+TVWG_ M +4TG4H4^U0/EEBE5@0"!N(/7'U%>_D=;+J.,C+-:;G2L[I;WZ&553E&U-V9 M[)^RC^T/:_M,_".T\8Q6!TJ[6XDL;VSW;EBN$"E@C=U(92/K7LW6OG'X4^(_ M"WP9\$W?@_P3X4NHK/0X%N!;W-RD-)?"VCV% MQ_9LUYJ%]*EO!IZ2*A,K*6*LYX !Y]J\C%2I2Q$Y89-4VWRI[I=$:1O97W. MNHK%\)^(K;Q=X;_%+X3CXE;F:\6$BPFLXT<-@-(Z-O M^4CLA'?ACU'%>D44 >#R?LY75Q!<++XB:1YK2&.0A702R1F,@, WRH/+Z+@_ M,2:7!IJ75W!Q''&I$C$@@@L3NSGC KTRH+J-I;>1% MV[F4@;UW+G'<=Q[4 ?/L7[.]MXH\*:SIMAXN232[[3FT^*\L(T:0L4C1Q(>0 MRYB4[1ZFNOT?X=ZQX&\77WB&Q _ M#-UX5T62WO9;2XOI[A[F>>RMS!'([8YV%CC@ =>PKJ* /+O"_P +[_2_&R>( M9KV."W\VZN_L,:9E:6YP7263.'5"/E(&<8';GU&BB@ HHI-U 'GOC)1XC^(W MA'0=N^&Q9]!O$C)]NT>=YA'HKW'Q!^U5\/?B!X)L8+GQ!9:0_]NQV M>K6US+_Q[QP2EY&)[QL(AAN^\4 >G>$O@#X0T?PMHUK)HD$%_;V<4:;\ESL)%[,I*C((Y![U<7X@76J2)!:>% M/$48D.PW%Q:K (L\;L.W..O2L:U-5J!BOM?X=_&+7='TW2_#GB;PK=K MKME;1P3QV\ZO-*54 NB/M,H.,Y0FIX=)\>6D?@MH8-0NM8M+F8ZC<7%TJ0W- MOODPLI4XW$>602IXZ8K?\0:%XU\:6/V/5?#OA,6V':&0QJ1HSTWXP>%;^X-M-J/]DW@^]:ZM$UH MX/I\X /X$UI^+O!^A?$CP^VF:Q:PZGITV'5N"58HZ!83R>78^(M M-EVVQ8_=CNX&!C1^V\*%;U!KK]:\4>+/AS8F[UNYT?Q!I0_Y>%D^P71]@C$H MY]E()]*\JU/X7?%#Q[#J,5GXEU0^'[J,H%\52M;3R ]EBM\ +C/^L7/3@UB: M?\)8?ACJ5M+XQ\!ZQXR\/PH,ZC=7IU273"H^_&H()BXZ; R^XH 9XF_;*\1? M9KG1[;P5_9^KR!YA-K2LENEJQ(A8Q_>D=@,E>![UX_\ !GPCH7C[Q!XON?&G MB:VTGQ'M:YT^W^SJ^FXE!1YDMS]UQA1\N"O7)R:]5^+O@WX8_$#3=.\1^!_% MFF:'?.HM?LQA5_\[W/DO^%F6=2E*RPUM$O3 M\[G-ZA^U-HU[X(/AWQ"SP^+]#9+B"ZL89)HKF2UD7,@4+N3>@R,C&'ZUZ3I7 M[0,WQGN+E?AFM[+9Z7YJ7VH260:)IC;LT<2[CR0^S./6OA#]J[Q[H6J>(%T/ M2]+\5^'_ !HMQ';SV&MW1+6DV0BR)-DF2-T.W&['0]J]X_8L^"?Q \._"W4; MC0]?A\+^);?6+BWO=.OX)'C9TVC$J[MI!'((7.#P:^F/K3WC3=2^*E]<>';W M6-)ODTJ/2KI=2AL9HH[F6X(;8=G4-\J;<8QO;.*BTO3_ (ESWT?^DZG!82:/ M,D!N3B:VD,;E=Y)(>4/Y:C<"2#G/&#N:E\6/'?P]M86\7> _[3M@/WVK^&+H M2P)_M/%)M=!^8]ZK>,OVKO#'@?PM9>(]6TK6H=$FN4MY+];7?!#OR QD4E3S M@8SGF@"Q?:#XZ^PW CU&ZLUN/#=O$_V6%'>&]#?O7105+2D9[^F,5C^'=2\8 MZ3XFTO5?$TY@\%6ND-"9TD-P?MGF@!W7YW+D<=2!R,\9JI:_$*'4(;CPW9:] M=6-YXDN3- VL7:M)9:=L7S)XW9N0^3L X!?CA37N_AW3K#1]%L[#2Q&EA:Q+ M% L;;@% P.>_U[T;[@>;63:KXJ\4SRK=Z]+HU]M^Q7MA*(+:.VV$/O# ,)-X M],],'&:WKCX0:0UO(TEUK.HS;3A+O6;DH[8X# /C'X5UE[X@T_3]7T[3+BY2 M.^U#S/LT#'YI @RY ] "/SK(\6?$#3O"DL-D4FU'6;D$VVDV2^9<3>^/X5]6 M; % '@/@W]A'P-IGB;4/&GCYH_%>M7$IN6AN/DTZT4=$",>']+TS2H3Y;^(I;!%MTP>1;1X'FG_:X3W-;5OX%U3QM)'=^.)8VM M5;S(?#EFY-JGH9VZS,/3[@[ ]:] AA2WB6.)%CC1=JJH Z #L* /CW2?@- MH>B?'+Q%HVJ:4FLV<.E0WEAJ%V?!'P,T32MX M7M)'A!DCW*[[6 ."!GK]*\3_ &OM)^(?Q _:'>V\$ZQJGA?1?#NB6QU[6+"= MX@D+/%6OS)&'DU2Z\07*&;(SNP MCA0/3%?C/$?!N<9MFZ=-V]U.2M;?;34[:->G3ARRA=]SX 71(KZ2SM MK'P?H/B/6YM9M//@FT=1:SPN;EI(5DP&C9EB4;)!O4X.2#3?ACX"/Q/\56W] MB?#?28XEMTO?LU]I%O!%$AOY8V6XW /D0QX C.=PS7W+>>$OAI'>26>E7OBC MQ#J ;:]^;X M'^!MI_XIFU7CU?\ QKS'XI?LBZSX7TV34-(_:%\5:!GYA%K=\TB3,.V4*L2? M8$UK^#=#?Q?#IV@2:;K^A>*)+8/->:UXDOX;6X X:6UC\S?,#C=M.W /-?"9 MCP'GN+QBQ%','".GNIRMIOUZFWUN$OCA=]WN=I^SZOC/6?@1X*EFUK3_ WH MT>E1?Z8H-S=R(!C@ Z5^\1344F>9TL>9:I\)+OXC6\:>.KRWEL$(:/1 M=(C\J&/'(W3$>8W_ '8/:O./$GA#3_#?CC2_AOX0UN'3;::!M>U#1=4(E@E M@BD!$8?_ %OS.,L,G"C.*^B/$&MVOAO1;W4[U_+M+2%II6_V5&<#W-?"7[9O M@OQ7;>!? WCW2#*&87!7^&GC&W?2/B!X7A M/]CW>JVI66>SZ>2ZN,RH/NLASE2/3-?7-O9^//!<,440N.CPS="?\ =8@^AH X MKX-S:9\(M6N/#4&F)X?T6^O"MQI:MN33-1<=$)_Y=YP,HW0,-O>OF_X[_LV: M[I_[87P[^U:KJ&J^ M>UI+FV6^N7E2QE0^9);C<3C.T%?4<=J^E/B?H.H1V: MP^(Y8I)UC-O8>*%79# MV^E^+O"MW;SHMZZI)*T4BLD@'=BH8';P3R."*3DHJ[>AI2I5*TU3I1MAI^SKP<9=FFG^))6%KG@_2/$?GC4;&.Y,T'V:1F)!,>[?MR#D?,,UNT5H M8'()\+O"R0SP#0K-[>:V%F\+IN0Q!=NW:>!P "1R<#TK-\?:#I6D^$+XKX=. MIVK&)KBUM+C[.Y6, (5;()( 51UX%>@UC>)/">E>,+%+/5[-+VVCE6=(W) M$B_=;@]10!F6?@+0&F:_72HUN)Q')(TVXME2&&WVL6<[>8MG=.HCA<-E6C**K*PZ [NE=6JB-0HZ 8%/H I:7I5IH>FV]A86 M\=I9VZ".*&)<*BCH *NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !117DWQ1^*NN^!;J^-CH4>H6-I]DW2-(P=_.=PVT8P2H M0<9R=PZ]" >K5^='_!4K]H#XD_"OQ#X1T#PGJ]]X9T.^M)+J;4K F.2><.5\ MKS.P5<':.NZOJ#4/BSXDDOO%\_P!'>XC6W=%,T_3YLG< R\#< MN:]C)\;0R[&PQ&(I*I".\7L_^&,ZD7.+2=CRW_@G'\8/BM\0/@O>6EWI5IK% MGI-X;:RUC5+IK=ID(W,IVQMYA5B?F]^:^M%'Q%NN2_AK3_;;/<$?CE*\\T>[ MUW3+J]\->%[BWTC2;/6+:UL#8:5&L"Q,K--$RD?*$"'YOO$D<\BN]\':Y?6A MURY\0:['+9F_ECT\7<4=LXB3AL 8W#=G!/.![US9AB:>+Q52O2IJ$9-M16R\ MAQBXQ2;)?^$<\=761/XQL[4'_GQTE01_W\=JKW7PSU?5(9(M0\?>()$D7:PL M_(M>#Z%(P1^!J'X/^-O$7BV/61XDTB?29DNC/8"6-5$ME)DPGY6;Y@ 1 MD"O2:X"SXS\??\$S_"?B+67US0O&'B+1M<\SSDNKV?[<1(#D-N?YNOO7N/P_ M^!MGI_AZUM_%^GZ;K>M0?))J,)E*W('20H[':Q[@$BO6Z* /%]!^&7A3PM\< M=76UT#3XAK6DPWA5K9&!FAD,;,,C@[6CSCKUKY4\/_LCP^/OVY_'[:M 8/!N MD7,&L26:KMCO'E7=%%@<;058GZ8[U]J>-&&G_$KP'J'::6[TUSV_>0^8OZPC M\Z9\,Q_:OB/QMKYQBZU/[%$?6.W01Y'L6W&@#O(HD@C5(U"QJ JJHP !T %2 MMTH)Q7)^(_B5HWAVZ%AYLNIZPP^32]-C,]PWU4?='NQ ]Z ,+P[I_BRW^+VO MW-Y),?"LEN/L_G2 @RY3:L:@G #Y. 26Y[5X]^V9^UL_P '--F\)>#89-6^ M(%]#D+;1--_9T3#B5P ?F/\ "OXU[1]A\:^,]IO+I?!NEMUM;%UFOY!Z-+]R M/_@ )_VJWO"_P^T#P?YKZ9IL45W,V^>\D'F7$[?WGD;+,?J: /CW]C'XH>(? M$'@;3O L\.L>$]25Y9[O6]0TR6>;4)I79W9)&7RXSSU?)]!7U3'\%?"FW&*[W:*6@#SG^S/&'@A2=+N3XPTE3G[#J M,@2^C7TCG^[)CT?!_P!JK]G\4=,U73]2^R)*FM65N\SZ)?*;>ZRJEMNUNH./ MO#(KMZ\<^/\ \)_%_P 4M+CL_#6O:/X>=%.V^NM-:>[C)_YYR!QL_ 4 ?*_B M+Q%XI^*5UHOB71O!^GV7PLU"Z%Y?:CI]Z+D02KD9,>S=!)N8*R8VL<9]:^FO MA=X=T'Q9X7AN_"7B75]'NK/%MY$E"@_/!("G((/W1UXKY\^$?[(_P 6 M_@-<:S:OJVG^,_!.L$-JNC6LS0W#L&#":$.-GF CE2<,.#7T5H&AZ#?PVLO@ M/43H7BO2X5@DM;^,QR3QK_RRNX3@L/1QRO8XXH \_P#VD?V4M>^-&G6=V9]# MU/Q-I4B36&K2P-9W)V,&\J4IN5T./08)R,5N?#CXRQV_C"\OM8T#5-#MM>L( MKDCR?M"+=6Q,%QS%NQCY =V#\M>P>$/'D7B"XGTN_MFTCQ':C_2=+F;+8_YZ M1MTDC/9A]#@\5Y9XU;_A6OQ8TF\ \K3+K4!?QD<*GG 07B_3)BEQZ[C0![#H M?CSP]XH &E:S9WKM_P LXY1O_P"^3S^E?#W_ 49\,^(O#_@6:^M+?1=*\-Z ME?16LT.G"87%Y(3N3S5XCZJ3G&9JFBV=W-G_ %YB E'T M<88?G7QU^TM\&?&WQN6Y\(?#BUFO?">GSF.YN=:U;=:_;%ZB%6RW[L$@GIN/ MM0!R_P"S-\$_B9\/VTC4_B=:7M]X%FM$=+:S:.ZFM@HS$EPN#)Y(!)VH< GF MOK6\\.?"_P#X1>]\4VLUO8:59PM<3ZCI=X\'E*HR<[&&#[$9KYV^ .F_'3]F MV2U\*:]<:5X]TZ48M?#MI?L^H6J_WDD9=J1C_IH0/0UZ%>>&=*\4:K<:S\0K M;5/!6L2.&CM;6T9=/B96RK32(&BNFS@YDX]A0!\L^'_$7[0'Q"^-TOCKP+X; M\13Z/'#)I^CS:YAO(LG898/.,;FQG)'I7V1X%TOQK\,_"RZKK@\.VNJWDBI= MOJDSM=W,K$!5:X0L&))X4+@=A4NH?M!/X$LTAN?LGQ!9HR;7_A$'66]EP.-] MJ"=HXP64X'H*^/\ 5/B9\>OB)\6-/^)=[X"DO_#'A^62:QT.2=5MK [2!-*- MP)E49/S8Y]*-MRHQ(/LC>+_$ M'B?69)@&FM6M_L]G W=3'$1NQZY;->Z?">3P_P"/+S_A,=)6SMO">G;X-%@M MU6--WW9KJ0=F/W5WGB*55N,))M=F>MC,GS'+J:JXNA*$7LVFDSG/ MAQXBU#Q-X?O(4O?#^G7>M,TVJWFK7:SW4[N,%%MU("HJ_(H9N .E;/PL^&]G MJ%O?:'XLU&_\27N@7'V6.&\G(M3;D!K>18DPI!0@9.>5([5O^(O$/A+Q5=26 M>E^%;?QQJ.=CO;VL9@B/??+]$\2:C>2>%](OI!I5 M_I_A:\FA"+)GR'DF)RV'.T[0H >N@\/-E5!@'T4]>_%>:_LF_&[Q;XFT>#P-K_\ :_AKQ+EKF^UF^TEI MKF]:1B0RG:$C X4,X;I7TGH?P8O/ ]J8/"7BJ\TJ(G<\=[:PWAE;U>1AYC?] M]5\H_M:>(_B)K?C?0++P#8WNM^/M"E.[Q!X6L9X4@C/WK>[V^_O/<>(?#*\+K4<>ZZ MM%[?:47[ZC_GHHS_ 'AWKO\ 3=2M-8L8;RRN8KNTF7?'-"X9''J"*S],\::! MK: V.M6%WNZ"*X0G\LUQ/BWP\WPSL]1\5>&+F+3+:%6N;[1Y\_8KON=@'^JE M)X#*,$D9!H L^-,^-O&FE^$5.[3K/9JFL8Z,JM_H\!_WW!8C^ZGO4/QCO+%; M[PC:WRQ_9(=1;5IV<9V1VL;2[A[[_+'_ *OG#Q-^V9:_!O3[N*30;B[^(.J M3M>ZM9WC>4E@Q'[N$M_$%CV@8^O>O#?$O[;FK_%+4H/[7M+&RM?+^R23::S. MT4+2H\AVDG).Q1]![UYT\?0IR<6]M]'9>K/N<'P5G>.PT<52H^[)75VDVNZ3 M=V?:/PATNX^(7B"X\1ZDA^QPWC7S(W26^*X13ZK;Q;5'^VS'L*][ KE?A?<: M'<^ M$D\-RK-HK6RM;2JLVM=1LX+ZV;K%<1AU^N#WJ_67X@U^Q\+Z3/J6I7"VME#MWRL"<;F" MJ,#DDLP'XTR#B-3^%HT6RN7\.ZO=:5:>6WF:5?C MQ\3+J^\17^I211EFN'M[6W7=Y5O$I.%4$DA0.@S7[$:Q\<_"EG;!HKF34$:_ M.F2+!'CRY1G=NW8X&#TR3C@&O@WXE?L;^%_B!=>(-7L-1UR'0EU9XP]M9PR& MWW.1YFWS-WEY.!D!B#P*PC3H3QV&EC(N5",KS2=FT?H_">;4,JH8V:DH8B44 MJ%?AG:Z-HCS_P!GZ(\UA+-=PF*1Y8F( ME=E/(RV3]*]+-Z>6_P!KU*F24W##-*R?5]6M=!9QG3S+(J%/,:GM<7&;?-;5 M0:V;MKKL>FTMTO;:!@'ADNH]JSQDD+(A!/!QT.#C!(YKI* MY#\Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ I-HI:* $VBN8^(6L'0/".HWZ:@=):% 5NU@\\H20!\AX.2 M<<],YKJ** ,CPO:2#_5LQ4$E?;-/U;PWI&O-"VIZ7 M9:@T7,9NK=)2G^[N!Q^%:E% #54+C P*=110 4C=*H2ZYI\.\/>6ZE Q9?-7 M(VC+<9[=ZQM/^)'AO5KK3[6RU6.ZN-061K>.-6+,$.')X^7!X^;% 'A_[9G[ M2G@WX#:/X=&N70%7:67)/)-6OV<_P!HCP?X MT^$^C/X/>]\4:HPD-UI]G 1-!<,Y=Q.6PL8RW!8\CIFO%/V[OV8[/]J75/#? MBWP;XST>WUFVTZ2'[/?RE;:YM5D=O,650=I5A)UZA3CI7H/[$'PI\-?LO_#V MXTBZ\4V^LZ[KF=8O)+5)##'&BE!CY> -K#YL$D<"OJ:V'RB.3TZM*JWBG+6- MM$ON,%*I[1IKW3W7_A&?%OC)F;Q!J@\/::QXTG19"9F7TEN2,_@@ ]ZZGPYX M1T?PA9FUTC3H;&)CEC&/GD/J[GYF/N2346B^-M"\1S0P:=JEM=W$MO\ :TAC M?Y_*W%-Y7J!N!7GN"*N_\)%IPUX:+]KB_M0P?:?LF[]YY6[;OQZ9XKY8W-+I MTI:** "BBB@ HHHH 05S?BKP+HWC!8FU&T/VJ'F"]@8Q7,!]4D7YA].GJ*Z- MONUY[XD^-GA[PQXFO=!N(M5N]1LXHI9UT_3I;A8UD#%,LH(R0IX]JYJU>GAX MN=62C%=6[+[P.<\7^"?$EM#"9WF\3P69WV>J696#6;!O53PDZ^JG;N[YKY9_ M:>_:R6?08O"C645SXDTZ<33:N5:"., =#"P#(Y'#(> 1P37US)\?_#S*?^)= MXC Q_P! 2?\ ^)K\LOVA?A;X_P#B!XP\4WFA>&-;U6'4-5EFAF6V9?.C+D@8 M// QP?2O-6887&5J6'I8J,8RDHRE=-13W;/N^%:.6\^(Q>:14E2BY1@W;GET M7F>M^&_^"CGCNX6:SNKC2]1BDC\HS6L>R>$$8,B8."P&2,\9KZT\,_%S2-5\ M#:+:>$-07PUX8: *FHW"^=J%R?XUM[=RR'R=(DE=8 MSC"EU!]#QGC->QG5+ 9#F'U6ACXUZ3BIUMCW;PM%JFG6LL?@[PA)8_:&WS:UXHF*37#'^-T&97^C%<=@*W M1\--0UY0?%?B6^U6-OOV%@?L5J1_=(0[F'U:LF[_ &C/"]A:S75Q8^(HH(4, MDDC:+/A5 R2?E["O1M%U>V\0:19:I92>;9WL$=S!)@C=&ZAE.#TR"*YL/B\/ MBTWAZD9I=FG^1^=:K='*2?!/P.+>);?PY9Z=)&-J7&GJ;:8?62,ACSZDU\M? MMU_#^7P3\.8=6TS5-2GCNKN.TO9+B0,_E$$A6D #,I( PV:^@O&'Q0\4^'_$ M'V>WT".YTPZO%IPD$,[S&-D4F0!1@C+$9R -IZUP]UXB\8>-K&'3O$&EPW6E M2ZL+>ZL[C3B[W$?&$0%-J[3\Q+= #R36F(I.M2E33LVMSVLES".5YC1QLX\T M8--KO8_%[Q!XHU2/7IQ]JD@>*4K'$K8 /''>OT4_P""<.E2>/)-?LM=@FOM M$M[>"Z-G)*PMA#QQTKVK3?@/X=\4:O8R6FDZ3=VYU>2'[1-X8 MCC?[-&@9U?>HVDGA&'7-;'P^UGQ#X*;3(;'P8OAR"]UNXM[JRCTY86\E9$\M MY'7*[%B9_GR,L/3->QFF*H8^E@Z=##1HNC&TI+>6B6I]+7XC]IA\=1J5)5?; MM.*D[J%G?[[::6/IFQLX+"UCM[:".V@C&U(H4"(H] !P*S_%WARW\7>&M1T> MYXBO(6BW=T8CY6'N#@_A7(>,O'-Q9ZYIB:9J&W2Y(W+3V-H;[S;C<@2 [,[ M59FSQTZUZ-'R@R,5YY\ P=[#4$]+B([6/_ N&'LU= M:J+&,*H4=>!BO/)/^*-^+22?'M-N)&Y,K6R"3_OH#/ZUY3XB^%&BZ]X[LO# M6CW&J:7IVGHNI:K]EU"4Q[LG[/%ARPR6!?Z)[BNQ^)GBSQ5X;\0>'AHFF?VC MI=P9%O56(LZMM^3YNBKGKG!Y[]*X73_B5XWT:'0K[7]"MM&@U#5!#J%PT18> M675M UN?EY^U=I>O6/COQE;7C7-Q?1ZI(;B63)>2/<2&) M[Y&.E>$^!?MLGB2V^S+(0K_O"JG;M[YK]M?BE)_PEHU36/!FGZ+XCCM;6!OM M4-LEV9YC*1)'N7/S+& 0/]H9XK UCX7:W;:?K4]GH]I$))+&6!(=(C1X(VBS M,@"*2S!^"><9/85[.59M/+,EQ>3JC&?MFWS-:J_^1^C8SB2AC\QP>92YH.A& M,7%/1\O;31/J:G[!%KJ-K^SWI?\ : =8Y+F=[4/U\DOQCVSFOH\>U?/DO_"> M6MKK$%K)>:9$39F"&VM&"VJ 9>WC"K@LQ&#*N5&X\"M:&Y^(7VS69$GO WV_ M3W2-H-R0PFXC6>W4,,,1&68RJ2/8&OGZ%+V-.-.][)(^-S7&_P!I8ZMC.7EY MY.5NUWL>X5E^(- LO$NFO8:A#YUJ[QR-'N(^9)%D4Y'HR@_A6K16YY1Y[B_E8SMS)@C&.F""<]SZU8NOACHL;"\-SJ-N\-PMXTL= MVP)V [4;U1VGN9;N[MQ;1SBXDD;M=)110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% 'DT?P%LK?Q5IVO6NI/:WEG>WUZ7%LA:5KF5I2I).-JEL=,D*.11I MOP%M+*:WFDU65IU^T-/M:\4:9X7^-GCG M^U;L6(N+;3&A,B-B0".4'! YP:^AMM1-;QR'+1JY]6 -?-<09)2XAR^>7UIN M,96U6^CN:TJCI34ET/GSQ!\1?"^I^']3LHM:MFEN;66%59I(P2R%0"RKE>O4 MZ3Z6T^\Z*F M*G4:;2/S=^%7P?MM-N+*_P#%WB;3(+K3[?3I(8+%69IKB"-Q(GVC;OCB+, 5 M7[RUZC^S[=:=\/)O%LVJW6F:+:ZK>13VFGV=P9Q J1*C#*HJ[21D9&XY^8DU M]2^!?"\VDS:[<7BS WM_(\,%Q.TXBA7Y4V[B=N[!; XYKK?LL/\ SQC_ .^! M77F/ \,SI5*5?$2M.RT25DG?3U%#$RIM-):'SAXZ^)GAJ\\$^(+>WUF*::73 M[A(XT1RS,8V &WDDU[-\)8WA^%O@V*1&CD31;)61A@J1 F01V-=2+6'_GB@ M_P" BI%4+T&*]/A3A'#\)TZM/#U934VF[]+&=:M*O).70DHHHK[XYSSSQMXF M\2Z5\0O!FFZ7I5S<:%?3RC4[^* 2)$-AV*QW ISSNP>F*[V:%+B-HY%5XV&U ME89!![$5*1FEH H:=H]CH\;1V%G;V,;'^( M[N-K2PBU:.VT^R)SY$*P(<9[DL23]:]R\9>#=&\?^&[[0/$&GPZGI-Y&8Y;: M9<@CU'H1U!'(KPK]F'X.P?LS>*O%O@6*YDNM+UB?^VM(N9?OF,*(Y(&]70[3 MGN&!H ^DZYKXD>*3X'\ >(O$(19&TNPFNU1NC%$+ '\172UY)^U:UU_PSOX[ MAL86N+VYT]K:"%/O.\C*@4>Y+4 E\.)+/"UQBZC"@1[,J2TI(/R!-Y MQQDXYXQ7D7[(O[$FB? O2[/7O$"1ZWXYDC#&XD7=%89'^KA![CH7Z^F*^J64 M,NT].E 'CWQ#\=:W?V]@GPZDBU"/S?\ 29;&)9OG#)MB;D!%*ER6Y^[CO6/8 M?%3QU<>,M/M+C0VL-,;#S_:+)DS&H@$[E]V$52\Q!/WM@%>[1P1PJ1&BH#UV M@"N ^%"^(V77E\1O=W1^VL8)[N/R@4/5$3LB] ?XNM &;XA\97&M:U8SZ#?W MU[HR1%5?0D2;?=[AA)MW1-AR.G./1;3Q%8Q&34O#MP-0C1/O2P@8GC_X%&6X]56N]J.2-9(V1U#*PP5/ M0CTH KV&H0:K8V][:R"6VN(UFBD7D,C $$?4&N"UQO\ A._B59:&GS:3X?V: MCJ']V2Z8'[/"?]T9D(_W:X"W^/G@KX%2:[X'\1^)=.M-4TF5I-(TZ:Y437-O M*"\$2C/W@Q,>#T&VO6?AGX;G\.^&T-\RRZQJ$C7^HS+SOGDY(!]%&%'LHJY4 MZE-)R5D]O,5T=Z:QU.X@,=O< MJY0QL>X8 X^M &[)(L:[G8(.F6.!4"^(OA!XYUNX MUN%]=DNM*?48[NP@NK]B0@1UV-A!A%9D;;R25(S75W'PEGOK74K&\\F\LK[7 MH]2?SI7=DB"KO"9^Z2RX !P QH _+3]I#]B?XQZW^T/XHGT[0KCQ18:YJ\MU M:ZU;R*\*I(Y*I*V?W;("%P?[O%?K-\&_#=_X%^%?A/P_K6HKJ6JZ980V=S=, M^XR2J@!&>Y[?A7">,/@SJ6H332Z7-8Z=?7FKR7;JDI0-%L"QG&#EE^9C@ Y; MAA4>G_!WQ!I]O=6]U#:ZV+K5X[LW4VH/'-"H9F:9#L/S$%5"=@IY.>/I,US_ M !.;X>AAJZ2C25E96?S,:=&-.3DNI[PS 9R< =:BM[J"X!\F:.7;U\M@V/RK M@=#TZ\^'UM?6)TC4=>M]0U*XNE:UE27RHY".)#*ZGN>!D5?^&?@.W\!V.J0P MVEO;/>:C+O#-W%I5K<6EG-YTVH- GRAPHIC 9 forms-1_002.jpg begin 644 forms-1_002.jpg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end GRAPHIC 10 forms-1_003.jpg begin 644 forms-1_003.jpg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forms-1_004.jpg begin 644 forms-1_004.jpg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end GRAPHIC 12 forms-1_005.jpg begin 644 forms-1_005.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" (D \\# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH *KWG_'G/_US;^56*KWG_'G/_P!X"T444@"BBB@ HHHH M1J:V.E.:HI/EC9O;-2VNH&5KGB+3O#UH]SJ5Y%9Q+R3(P'Y>M>#^._VI8D+V MWA>U\]\E?MLXP@_W5[_C7C/Q&US4=>\8ZN-1O9KM(;J1(D=LK&H. O3\:YS M:><=^M?EV9\25W*5*@N6VE^I^V9+P7A^2&(Q;YF[.W0T?$'B35?%5XUUJ]X] M[-SC<X_F:Z\=ZY#X3_P#).="_Z]Q_,UUX[TWN M M%%%( HHHH **** "HI /+;_=J6HY/]6W^Z:F6PUN?G_P",/^1PUW_K]D_] M"K(K7\8?\CEKO_7[)_Z%617\]8O_ 'B?JS^M\O\ ]TI?X5^04445QGH!1110 M 4444 ?HW1117])G\;A1110 WUKR[]HSXQ3_ *^%M_XM@TQ=7DM98X_LKR> M6&W-C.<'I7J/>OFS_@H)_P FTZT>XNK?'_?5:4HJ52,7U9,G9'%? ?\ ;\G^ M,'Q0TKPG?^%H=&BOPZQW:71D_>*NX+C ZX-?0?QV^+"_!7X7ZQXMDM5OWLU7 MR[9G*>:[' 7.#BORD\*0R?#FT^''Q&MC)AM7>.9L\#8RY'XJQ_*OL#_@H]X_ M%Y\/?!/ANQ8M)KUS'=[%/WH\#;_X\PKV<3@Z<:\(PV9Y]&O)PE*0OPK_ ."B M6I_$;XC>'O#$O@JWL$U2X$#7"WA?RL@G.,<]*^W-V,9_/%?D?\,/"8\"_M>> M%-!VLCV=_"LF[J6,>6_4U^F?QL^*,/P?^'NI>)I-.N-6DMP%ALK5"SRR'A1Q MT'J?2N;'8>%.<(TEN:8>I.:DI[H[W=2[C7Y[Z'^T%^U1\4],E\3>%?#5G;Z# MN<+']G7/R]0N_EL=..]>K_L@_M>:Q\;/$&I>$?%FF167B"QA,JW%L"$E"G:X M93T8''3BN5X6I&+EO;_@/P)KOB!+<7DFFVKW(MRV MW?M'3/:OBF\_X*$>,-,^('BCP_/X$?& M_P 9/&_P1^*TWQ2TA=)M8=.<64;VODREBN3]4 QSUK3ZK.%I3VT)]O&[2/2_ MV3?VI+S]I:TUV>YT"/0_[-=% CG,N_<">X&.E?0NXXK\[O\ @G1XQTGP!X ^ M(WB'6[Q++2K)H7EF;C/RM@#U)Z 5WWP=_:V^*'[0GQ/N=,\)^&=+L?"5O,6N M-2O1(7A@SP"1P9&'0"KQ&&:G+D7NHBC6O%?TKY _:._;,UKP? MX\@^'7PTTE=>\5,ZPSW,BEUCD89"(HZG'))X%>?3_M:_'?X$ZWIC_%KPQ;3Z M)?/CS+>,(P7^+:R\;@.<&L(X.K.-UIY=7Z&TJT(NQ][WU_#IMI-=7JN(G9L\(>^,=>E>4_ MM5?%KQ)=? O3]6\ Z&/$VA>(+>0:A<;"?LMLR A^#P1D]?2OD?\ 8M^(7Q!\ M#:Y=6?@?PLOB/3-1N[>/4KG8Q^RQ[B-V1P."3SZ5O1P;J4IU+ZQZ&52MRRBN MC/U:!.X]Q3ZAC)ZFGJW>O-\CKWU'T4W>*3S*8#O2HRV,8&<\4]F%(KMPD.GVDDW)QN8*=H'N3@4DG)\JZ@?+/QO\ ^"A3?"_XF:SX5TGP MM#K<.FL(WO'N]FZ3&64 ]#Q7T%^SW\9K?X[?#2P\4P6PL9I7>&XL]^XPR*> M5SWXP?QK\_\ ]ECX.M\>[?XK>(]8@^URO93);L_)^U/E\@^H 'YUWO\ P30^ M(4NC>)_$W@+4'\LSC[7;QMP?.0[9%QV./Y5[E;"THTI1BGSQLV>93K5)5$W\ M+NCZ0_:P_:?NOV;-,T&ZMM"BUS^TYI(BLDYB\O:N0>ASFO3?@WX^E^*'PT\/ M^*9K1;"74[<3-;*^X1DD\9[]*^1O^"I?_(M^!R#_ ,O4_/\ P"OH_P#9)Q_P MSKX%'_4/3^9KDG1A'"QJK=LZ54?MN3I8]<=MJD]<#-?*GP9_;1U+XJ?'&\\ MS^$1ID$#W"C4!,S9\LX&05'7ZU]52#Y&^E?%OP"_:NU[XC?M%W_@N]\-Z'86 M,,ETHO+.(BX;RS@$GISWKGHTW)2?+>R+JRY>76Q]I*WXT;CVKXK^+O[<7B#X M4_M!7WA&XT:SNO#-DZ*TD(9KN7!5M_%>I^%;+P[ MX2N95%O;RQ"4[6Y19&ZJQ%7'!U)8_LZ?&F#X[_#.Q\3):_8+IF:"ZM=V1'*IPV#Z'J/8UG_M0>,O&7@GX M7W=[X*\/CQ'J4DGD36I4MM@93O?CG(%<_LY1G[-[[&D9J4>9;&EX)_:+\'_$ MCXA:IX1\-7O]K7FF0>?=74 S GS;=H;^(Y]*\Y_:L_:ZN_V<-:T&QMO#<6N+ MJ4+2M(]SY7EX(&.ASUKX5_9?\?>/OA_XXU>[\ >%AXGU*[18;RW,;'R(S)DO M@>A)'X5[)_P4L>2;Q!\.YKF/R;AM/>25,?=;*DC'L _!L>D^!],LT3[;=QB6>X6-0&DV'HG!Y%>U_LB_M6O\>O#FL)K]O!IN MN:*!+?4PM2,93BKI/N=$*\9[1],9--W'G&..M? M!OBC]M'XF_%KQ[?^&_@GX?AN+.R9E^W7$?F/*%.#)S\JJ3TSR:TOAC^VEXX\ M(_$RU\!_&?0H=+N[IUCCU"%=FQFX4L!P5)[BE]3JVOUWL7[>%S[BS7D?[2_Q MPG^ /PY/B:WTE=9D^TQV_P!F>0Q_>.-V<'I7K,;?*"#D5\L_\%'/^3>F_P"P MC 2?Q-98>*G5C&75EU).,&T>1K_P5"UAB-OPZC<'H4O&/U_@KJ_AW_P4PT37 M=>M;#Q3X:FT"":18C>PS>:D1)P"XP"%SWQQ5[_@G_J?ABR^!8CUFYTF&\_M" M?"WSQB3;GC[W./2O!_\ @H9J/P_OO&^C_P#"'M8R:JEN_P#:DFF[?+(S\BG; MQOZ_ABO:C0HRKRH^S?JCS_:3]GS\Q]G?M/?M(R_ #P1I'B+3]*A\01ZA<"%% M,_EKM*[@X8 Y%=U\$_B1-\6/ACH?BN>R73I-1B\PVJ/O"P,]/2OBG]K2 M.^C_ &-_A+%J =;PF(/YG#?ZLXS^&*K_ G^-7QMO_@MHVC_ F\'+)INA0F M*[UF\"L9Y,EBL2G@@ \]ZXY85>QO'>[1K&L^=7[+0_1AGYHW&OD#]D#]L/6O MB_XFN_!?C2T@M]?AC:6"[MU\L3;#AT9#T8'T]*P?BM^UU\3_ !!\6+SP#\)_ M"K&>U=H_ME_;-NN"GWF7<-H0>IKD^J5%4Y'IUU>ATQK0DKH^W]Q_6EW=:_/* M3]LCXW? _P 9:?I_Q7\/6DUE=LI(CC$;^7G!>-EX./0U] ?M7?M':S\%/AOX M;\2^&;.RU!]6G6/;?;MH1DW C;WZ4Y86JG%=Q*M!MKL?11<\9%&[/3I^M? 2 M_M@?&WXL76A-\-_"7F:?$T4.IWHM#)"\[$;P&/1%!Z]:V_'7[=7BSX:_&Z_\ M(ZGH%EJ6FV)6%OL*M]HGF:,$*H/'+D#Z5K]1J\W);7U(6(@_0^XO,)[4;ORK M\\OB)^U?^T7\,=4TW7?$WAG3]%T#49,VVG/&&#+UV,_WE?;ZUTFK?M:?&;XP M://JOPB\%+;:%I\6Z\U"]02.TH7+I&IX(7VYJ?J56RGT[WT*]O!MQ/NO)Y[T M;QFODO\ 8U_:XU;XY:AJ7AGQ3:0V^OV$8F2ZM@52X3.&!4_=93UKG_CA^UU\ M1Y?BU/\ #KX5^%7FU"!FB-]?6['SG7[Q3/R[%[L:B6&J1G[-[E1K1E'F1]I[ MNE)N.X"OSRU?]KSX]? CQ)IL?Q1\/V4^GW9W>7'$(R\8/S^6Z\;AZ&OKOXD? M'O0?AK\(4\?7NZ>SG@CEM+5<>9.\@!6,>_//TI5,-4I\K>O-M84:T9-KL>IY M/M^-)N*_2OSXT?\ :4_:;^+=G=>)?!'A>RA\-Q,P2,0AB^WJ 6Y8_3O7K'[) MO[94_P :-7O_ MXLTZ/2/$]G&T@E@#"&=4XD!!^ZRXY!IRPE2,6][;Z@JT) M-'U@&S]:-QXKX2\]I=IPS\_*J9Z9Y M-3> ?VT/B!\/?B-9>#/C;H,6G/>,J)J%NNQHRYPK$#AD)XR.E..#JV\][=0] MM"[/N;=2[FSTR*^7OVROVH/$7[/,/AF3PY8:=J2ZH)&D-Z6. H!!7;ZYKVSP M!XRN_%7PJTKQ/<5C[&<8*I;1NQ?M(\W+U.T+'M M7EVJ?M'>#+#XJ:7\/(+_ /M#Q-?.R-;VHW+;[1D^8W0'';K7S=\%_P!M3XC? M%35O&FG1>'-+N=0TG3Y[G3[:UW[[B9'VJI!/0CTKY3\-^.O'=C^T;+XJL/#( MN/B ]W+/)H/EG F9<,F!SQ7H47$<5WI.I1EHH2V[.!U!X' MYUU?P+^/D?B+]G/_ (6+XHM['0H+<323QV*E8@J'@*#W/3ZURNE+V5U'K:YK M[2\TK]+GOF[_ &A1N.#QFOS[L_VM/CW\>-8U"3X4>%[6TT6R;K<(KL5/W0S- MQN(YP*Z_]GO]M?Q)K?Q+3X<_%#1ETS7FD-O%>6Z% )@/N2+VSV(XI/"U(J[& MJT&S[4W%@<=12;CVKXL^-G[7'Q'N/BQ-\.OA7X7>>]@=H3?WENQ\YU&6*9&W M8O\ >-<+J7[7OQY^!?B;38/BEX?L9["\.1''&(RZ@X8HZ\9'7!IQP=2=FNO2 MXY5HQ9];?M+?&ZX^ ?PT?Q5;Z4NLR+<1V_V5Y?+'S'&=V#TIW[-GQJN/CU\, MX?%5QI2:-))T?MHQOHT?2VI7IL=-N[D+O, M,3R!3QG )Q^E?+W[-_[:%]\>OB;?>%I_#$.CQ6T,LOVE+HR%MC[<8P.OUKZ; M\0?\B_JG_7M)_P"@&OS4_P""=V&_:.UPD<_9+G_T::>&HQJ4JDI;I%U9./+; MN?IP'ROOG%.W'(Y^M?'/[2'[9WB'X'_'*U\+1:787'AU88;BYFD#?:"K?>" M<$^E<3\4?VH/VB-)TT>-K+PA!X<\",X:W^TPB:4Q$_*TO==PQT]:PCA*DDGT M>VI3K03:['W[GO2%MM> _L^_M16'Q8^#NI^,M;A71I=%#KJ<:ONC&U=V]#Z, M.@KYRC_;(^-OQS\97=I\)?#=O%IMJ2=DT0D;R\_*TKMPI/8"CZK5YI1:MR[B M]O#E374]]_:Q_:NO/V;+CP_':^'HM=_M1)&)DG,6S9C@<'.=&C.2E) M=#I=2*<4^I]A;J:SE5)Z5^?FG?M9?'KX\:QJBJ.3]>E=EX>UJ/Q%H M.GZK C1Q7MO'<)&_W@KJ&&??!K\M/VZ/&'C3Q5\34M?%GA]-$L=+FDAT:<(1 M]LAW9WY/!_"OK/\ 9\^,7Q,OOA/XHO\ Q;X2CT&+0=+271Y&1@MXJQ'!.3R. M!T]:WJ8-QH0JWU9"KWJN"6A]5;F]*7=7YU>'O^"@7Q-\=^';O2=!\)VUYXWN M)?\ 0X].B:5(H #N=@>K9Z#I5S7OVSOC?\(;;PT/'?AG2HAJG[TR7$;QS^6K M;7W(O"L.3CZ5F\%53LQ_68'Z$;C[4JM7+7WCJPL?AW/XM,JG3X]..H!\\%?+ MWC\Z^>OV/?VG/''[1/B/Q"VKZ1IFG^']-0!);7?YC2,37+&C-QE+H MC7VBT\SZOW4+TI.PIU9FH4444 %%%% !1110 57O/^/.?_KFW\JL57O/^/.? M_KFW\J .7^$__).="_Z]Q_,UUX[UR'PG_P"2?JS^M\O_P!TI?X5^04445QGH!1110 4 M444 ?HW1117])G\;A1110 UJ^;?^"@O_ ";/K?\ U]6__H5?2->&?ME> M?^ M)?P+U30?#.GG4]7EN(72W#A,JKWLY@W/^K.YV_("O MK'X'_ 7Q+8_L=^(? /B72_[/UR^%SLM6=6^8X,9R..2!7FO[$?[+GCKX=?%U M_$?C30_[)MK.Q:*U9Y5DWR-\IQCOMR:^@CB*5JK;U5^7YGDNE)J"MIL_O.!U MN$P_\%$U4]%UN/MV\OBOM[]IWX[67[/_ ,.9-FK/G+P M;K7[3?[0_AU=5T._TGP3X5N2QBDAC6+,?.=G!)'7GBN#_8#M9;/]J/5[>XN/ MM=S!:W<4UQDGS'#X9@?<@FNQ^&/PQ_:IT'P[_P *^M'L_#WASYHCJ-PZ2/!& M3\PB(.<>G%7OV9?V;_B-\#/VD)+V_P!&?4/#31RVCZTLB_.&P1)MSD9(Y[\U MW>TA"%6":LUI8Y^64G!VU3U/,OV>=-AU3]NRZ2= ZP:G>S*" ?F4-@U^@?[1 M'_)#?&__ &"YO_0:^3?@7^SO\1/"/[7=]XNU;P\UKX*M(TR#[3J%Y82PV\((&]B.!S7#C*T9U*;3T21U48M.; M:ZGX[^!?"OC#QUX(?A3<>&;6UM]/UW29"UPL:X:Y5ONS'U/8^AJ/]@3X(^,/A1H_BZU\:Z'_9 M?VYX1$KR*XE4*P88'UQ7 M^SC\2O@)^TX_BGX<:$^K^$IYO,DB2=4 AD.9(B M"1T)R*[,1B*>(4J2=ENF<].E*F^?S/$? O\ PG-Y^UCK_P#PALEE#XP;4+WR MFU;F,#<<]>^!Q7N7QD^#_P"TA\5O#$.B^-=4\'#3?M"RQ9G$#-* &D"(\>#? M &O_ M_8MUSPYXCDMWU.STVZ&ZTE\Q-AR5 ;Z&O'_\ @EIC[)X[&,8>WZ=. MC5]=+\*[*S^#4W@&QGF6W_LUK!+BX_CG\9O MB%\0QI/CGX>KX:T+[*\GVX1.O[P?=7))'/I7U+2,N['-;2K0E&R@D0J@&.M>=>$_B\F@?M$V7Q M"L;%]#MIM4^TRV62?+BD.)%R0,CDGI7Z[Z7X'T#3=-M+2+1[ Q6\2Q)NMD)P MHQG.*^5_V[/V8]7^)]CX<::2=['*_\%/+Z+4O!?@"[@8-!--+)&PZ$&/(_2OI7]DH_P#& M.O@8]<:>O\S7RI\9O@;\7/B=^SO\--%?PM))XDT-YK>[@:X3(0+M1RJ6=DL5Q S [&!.1D5SUI06%5).]I?AJ;1C)U5) M]CTA_P#5M_NU^87[(/\ R>MJO_7:_P#_ $*OT]D^6-AZK7P1^S9^SK\1/ _[ M4NH>*M=\/-8Z#)+>,MWYRMD.?DX!SS6.$G&,*B;W0\1&4G"RZGG7QCLXK_\ MX*$6L$Z!XFU:TRK#(.%!'ZBOK3]O2-6_9E\2!@"%E@*Y'3YQ7BWQ$_9Z^(>M M?MJ6GC2R\/--X774;>8WPF7 15 9L9SP:^B?VOO ^N_$;X#:YH/ARQ_M+5KA MXC%;A@N[:X)Y/'05M.I"]&SVW^\48/FG=;GE_P#P33;/P.U'DG&JR?\ H*U] M0^+,_P#"*ZT0>?L-?^O,]/\ KL:O_P#!4;#>+O! (R#:2J>?5Q67X5_9O_:"^ /Q*U2Y\!V% ME>1WCM%_:+NK1O 7W#*D@JPKT3]N+X$_$7XN7W@:Y\/Z'_;%S96!2_D2545) MCMW#D^N>E>K[2F\5&KS:6_0Y8PE[*4;:GTKI-C!:?L\06D:*+=?#N @&!CR. M:_.S]DF2YM_#/QJ^PLZS_P#"-R;/+^]]\Y/UQFOTIM="OH_@ZFC-;G^TQHOV M;R-P_P!9Y6W;GZU\F?L._LZ^.?AOXP\7/XV\/'3M*U'3OLJ[I5<2Y*-+O?%NI^$6UJQC40);W8A/B%?>(?@[>0:EIETQ"VLC ,(RV?+D1B VT]"#5[P#^R?\5OB]\7+?QW\7 M]0_LR*%D9K.SN-KS!#E8@%.%3/7)S734JQY_;4Y)*WS]"%!QCR-79]S>&8;F MS\.Z9;WA5KN*VC28J% ;![\YKYM_X*/?\F]G_ +",'\S7U'#&(XU1>%48 MQZ5\_P#[;GPW\2?%+X+MHOA?3CJFJ?;8I?LX<)\H/)R>.*\C#R4:\9/:YW2C M^[Y?(^.OV*IM'?[3);FV6V$@^0XSG(Z^U?1GPP_P"" M#D5]"[?:NK%8RK*I)1EH84.-5CC74\!$ "' 'I7K?[%5E%9_LV>$!"BHLD#2L .K%B2?K7*?M[?"?Q7 M\7?AWH>G>$M);5KVWO\ SI8PZKA-I&%]#UVT^PZM:6 MY2>W+!MIR>XXJ95(_5%"^MQ\C]NI=+'PI^RY(EI^W%JQSY<276HEO0#YC7H. ML_M;?$OXT?%*]\,?![0=.MOL[/$NI7,:M,T:G:TC,>%&>W/XU-\!?V;_ (A> M%_VL-3\4ZWX=:U\-3SWV+LS*=R2!@IP#GG-<[R MNI)%AE++A8G8MLE1B,XSU%>C*5"I/WFKJ*MVOYF'+."?*M+GD_[67@OXE^$= M7\/7'Q0\31:_JM]&[6\5NV4ME5AD= .?I7T%^WE\O[,_PT(YQ)#_ .B*X?XX M?LI?'OXC6EEXL\0RV_B;Q-,WDG2;1U2.RA'(*\[>3UP:]=_:>^$7C[XK?LY_ M#W2-*\.-+XAL6C-]8-,H,.V/8>MMA*#O-Q6Z/4/V&]- MAT_]FOPJT*!#9E \L* 6QG/!%"2U5CM/^"G '_"G] X_Y MBH_#Y#7>?L2V4$'[*^A>6@'FPW#R8_B8LP)K/_;R^%?BKXN?#72--\(Z6VK7 M]OJ F>(2*F$VD9R>.]=G^RWX)UOX?_L_:)X?UZR-AK%O!,LML6!VDLQ R..X M_.L?:1^IJ">MS>47[=.VECXT_8%V1_M0>)L#:JP7>.>@\TUW?C3]KWX@?%#X MN7/@SX/:#I[3VLLD"ZE=1!YG5.'?)("K^9J?]C[]GKX@?#?X]:_KWB;P\VFZ M/=17"1W!G5]Q>0E>!SR*YOQ1^RG\8_@E\8[SQ=\+%@U:TNIY)(6WJ'C21LM' M(K$9 ]1UKLJ3HU:W-)KX5;M:+2T@;*VVT G@ #G(_*O3OVTI+O_AFGX.HH8V/DJ9 !@;Q#\OX]:@^-W[+G MQ^^*VBVOBKQ1/:Z[X@$GD1:#9NJ):PD$E^NW.0,@$]:^F9_@5-\:/V7=#\%^ M+[)]!URVM(U1CAVMKB,85N.H/?V-.5:G"--MIV>MM@A&4IRLMT=-^R;';Q_L M[^!A9JH0Z>K,$/\ &>6_'.:I>/-5\!P^"?'D7A:70U\31V%WYD=EY:W7G>6Q M;I\V>N<5\O\ A?X9_M4? ?3;KPEX46TU30I'8PW"NKB+=U*;B"GKC'!KTC]D M_P#8TU3X=>*+[QS\0+F&_P#$EY'(J6L;;UC\S_6.[="Q!(]LFN"I&"G*JYZ/ M4VC*2C&GRZGS)^QK;?%:ZU#Q%_PJNZT6WO1&AO?[6!+%225V\=,YS7I/QD_9 MO^/OQEU;39?%VI^$3JUE&1:+%="%V0G/(QD@$5J>)/V2_BW\!_B9>>*_@U=P MW^G7+L5M)& =$9MWE.K$!U!Z$5+X6_95^+_QP^*UEXP^+E\-(M;9T)MK2?;( MZ(N?4UZ$Z\92]M"26GS,.5I.$ENS)_X*+6%YIO@WX66>H%3?V]F MT4Y1LC>J*&Y[C(K[!^#;JO[.7AXL<*- 4D^@\K.:X;]L/]FJ]^/'@73(/#L\ M,&M:*^ZVAN&(CEC*[63=V/3!/I7A/P_^%O[45]X/7X=W-S;>&/":I]G>_E97 MN%A/5$8$DC''3O7(I1K890YDFG(R#E393D?]_J MB^'Q/_#Q>][G^UKGYL_[->E_L6?LX>.?@_\ &C6]0U_1&LM"^R26UK>-*K&8 M[Q@X'(R!FL'XQ?LP?%[P?^T1>_$/X\;?,QA3G[/5=;GJO\ P4H /P!M.P_M6'^35XAQ_M"?#;XJ_%K]EK0-*U#28M3\=_;8[B^M;9U1 6Y'.. 1WK MK?V?/@5>?\,KCX>^/-+-C/=^YN- A\ M6G:\PF\I;OD#:>>,#VI M5X4YSE6Y]']YI2,/VOOB#\4_BY>>#?@_H%AY]K*]NNJ7<0:=U3AW MR&?M;>"_BIX9C\/WOQ2\3PZW?7QE%M:0-E;8+@D\ 9XZ>E>L>)O MV5_C)\$_C)?^+?A8D.K6UU-)+"Y=0R+(,O@?XJT/1;7[;JMY8F*"W# ; MVR.,FJJU(NG12>V_WDQB_:3=M['Y\_ \W0_8M^,JVV[_ (^;??@XQ&0-Q^F* M^@O^"94=DGPK\121*OV\ZF1.>-VT(-H/XD_F:L_L6_L\>(?"/PQ\=>&/B'H1 ML+;6Y%3[.T@?>ACVL1@]C7F.G?LU_'S]F?QM?S_"Z>#7-'O&VKYCKAD!^7S4 M8CY@.,BNNM5I574IQEJVO39&$*7XG\4WS& M*:PMI52.RA494#)P,DG@5[%^T%^R1XC^*_P=^'S:3Y4'B[P[IL=K-IUPX"RK ML&Y0W3<#^%$*M.E&E%RORO44HRG.;7G[*WQE^#6M7US\+/$0US3HY M,-)H]VJR\:,CP/822",R1GIM)XR#VJ;X*Z'\;K_P"%/C+P]\0M M-MX81I'V'1;:$J)68(5PQ!.<_+R<5Q.<*E"FD_A9O:4:SOLT>,?\$O=/@F\: M>,KQT5KF&SBC1R.55FR7?ZR3J$^1R WW!^"_SK\\=*^# M[:A^T>OPWMIA>6JZT;=FB.Y3;J^YLXXSMXS[5^QFF:;#I-A;6-L@CM[>)8HU M X"J, ?I75C^6C348?;U,L/>TWQ!:FVU&TCNXB./,'(^AZC\#7,+X=U_P )X.@WW]JV M"\?V9J3Y<>T*K<6QW8;(S2URFC_$'3K^\%A=I)H^JXYLKX;&;W4]&' MN*ZG=4C'44@.:6@ HHHH 1>E,D_U;?[IIZ]*9)_JV_W34RV&MS\__&'_ ".6 MN_\ 7[)_Z%616OXP_P"1RUW_ *_9/_0JR*_GK%_QY^K/ZWR__=*7^%?D%%%% M<9Z 4444 %%%% 'Z-T445_29_&X4444 -:D^E/I/QH CVDMR*7:3QVIP/OFC M<.YH ;M.W%)LZC]?6I-U&X9QWH C"GOS2[6]:?Q2TM (E5L#C]:=M/I3Z*+ M,VGTI-K=J>>G7% Z4P&;3TI=OMS3Z*GE0$8C-&&STX^M24FX460"*NWMBEVB MA6!Z4M.P"U.W"EH :!A>E)M/I3Z3T_A0%/;\:DH MI6 9M. ,4FTY%/W4FZF WRSBCRSGTI_/I1D5/+Y ( >_--QS4E,;[U4 JT;J M2E6@ (.,"DQ[4O\ #0M%@$VG/M]:-I]:?10!$L97V_&EVD=/SI^:* &[31M/ M>G4M $>TT%3WP:=_%1N]*5@&>66SGFE";>:>M!-/T%89L/4=:-AQ@\U)10,9 MM/7-)Y9]13_TH!]\T 1A?SI1'USD_C4E)]: &;#2>6>G:I-PHW"IY0&JI7 Z MTGET\]**>FP#"K=N*7R_?BGT4P(]AY]?:C:<^U244K 1E6XQ1Y9%/I:+ ,VG M_P"O0%/?!I]%,!O;&*;M//\ C4E% $84]*7::?12L S:?6@+\O3%/HI^0$>P MY_\ KT;#QZCO4E% $;(31M/IGTS4E%+U CVGG\NM&P_6I**8$90_6CR^^.?> MI**6@$>T_4U\_?M1>"_C3XLFT?\ X55K]OI%GY4D6H0S2+&6ST96(/;TKZ%I M*J$N27,D)JZL?)'[)G[&NH?!WQ)=^,?&.H0:MXFG1DAC@)9(-QRS%C]YCZ^Y MKZU53QGTI?PIU74J2K2YI$0IQIJT0HHHK,T"BBB@ HHHH **** "BBB@!-HI MI4\\ T^B@#+UKP_8>(;5K;4;2*[A[+(O(]P>H/N*YAO#_B'PHI.A7G]KV:C_ M )!NI29=?:.4\C_@6:[NFLISD4 )-H^I@9-G?#8Q_W6/## MZ&NJ\P5FZQH-CKUO]GU&TBNXNPD7)7W!Z@^X-C82?]ENC?@:ZC*J M-QXI &0.:9(P\M^?X367KWB?3O#MKYVHW26JMPBLF(FFNK/ZXR_\ W6GZ+\@HHHKD M/0"BBB@ HHHH _1NBBBOZ3/XW"BBB@!.]>&O@9I5AJ/B=KM8;^X^S M0+9P-,[/C.-HYZ5Z,S5\F?M^)?3Z?\,DTN6*#4V\1QBUDN!F)9,?*6]LU=** ME447LR)NT;G?^"/VQ?AWXZ\3VF@P3:GI.HWIVVR:O8/:K*W]U2P&3[5[:LPV MEMZX]=U?!WQE7X@^$_''PXUSXQWFB>(=#M]3\NU@\/IY,J7#+A'8'DJ#@D ] MJR[#Q7>+^PM\0[J76[G[?_;MRD5PUVQF7,XVJISD<'@>E=DL,N13B]_\SGC6 M?-RR/LF[^-'ARU^(U[X(>:X_MZST\ZK*HA/E^0.N&]?:N&U+]M#X=:7X/T+Q M+*^J2Z?K4\UM9K#9.\KO$<,-@Y%>->%96D_:52221GE?X;1EV8Y8MY7))[FO M'?#\>M3_ [^ ,?AZ>UMM>;Q!?\ V2:^4M"DF_CZ?H=KK%M+9Q+-(VIV#VT>TG& S 9->J+,&8@.K =<-TK MY%^.:?%?PS^S1\1+GQYK>D7%X$B.GSZ#&]NT?SC.X]>O3%>=^-/"E_\ #GP- M\,]/M?%FM6EU\1KNVAU[7+J]9F1/+#>7%SB/.[&1Z"L%04HW3LKV-/:-.S1] M_K(C*"K!QZ@YH,J#)+KC.#\U? OC35M8_95^('BCPQX+\0ZEK>DS>&)=1%MJ M-P;I]/G4$"7<>1GK7+>./!/=;O]2\4:M93:E!/J!:.Y9F#, M50'Y0N<$ X]:%A=$U+1[$NMRMJQ^B'B378_#>AWFJ2VUU>1VJ&1H+./S)7Q_ M=4=3[4:#KD>N:+9ZELELXKI!(L5XOER+D=&4]#[5YK^U%>7%C^SCXUN+>>:V MN$TPLLT#E'4\<@CD'Z5\KZII_C&;3_".NZWX=UOXA>!Y_#5K'#:Z)J3QW6GS M%?GF90P9V/7)R*5.ASPO?K8.]:T MW5/#.KWLVFPQZBR1VQ0EE++G)#8P >*SC1YFU)VL4ZFBMU/T=,BJI9R$'3QO\ 44DG2$1:; 9I/F/WB!_".YKX@\$:]K?[57COP?X4 M\:>(]2T71X/#,>HM;Z==&UDU" LNGXDNLDKV/T=BNT,<;NPB\P M JKD _2IVD6-2S,% [DXKX9^-VE^*=/^)&N:MXG\,:]XS\%W-E NG3^&]2:. M;1U$8WN8E.2^>"N0017$:S\7M T/XEZ'X%N9)_[>UBVDNK18 MXB8C&APV7Z U\/\ B/6/B;X#^&9\'ZK=:MX?\-:QXF@T^PU6^O$EO(;-\[XF MD5CM((QDG/-=KI?PXT_X5_MH_#O0],UZ_P!;L5T::18M2NC<2VS'C[YYPWWL M&M(X5)ZRZ/\ '6>FA]>>-?B)H/P^@L)=>U*.Q6_N4L[56^]-,YPJ@5TAF15 M!,BA2."6KX__ &_O!MAXBNOA?)=SW,)N==CTY_)F**J2=6![..S=JR9_!*_% MS]HC6?ACK/BC6-&\)^#M'@.G65G?F&:[9@,S/)U;%91HQE!2OW_ J51QE:W8 M^VMPW8S7-:?XUM]0\7:EH'V&_@FL8TD>]F@V6TF[LCGJ?45XE^Q5XPUG7O"O MBW1-6U:7Q!!X>%?NY;^(CIFO _VB->U>S\??'P6^K7T"V]AI MY@6.Y<+"2ZY9 #Q[_C50P[E-POL'M5RJ1^ABRKR-ZY7KSTH\Y-H?>NWJ&W<5 M\ Q_"_4+'XX> _"$'CGQ*--\9^'FOM:D>^8O*47.$/\ !GU7M3/#NO:U8_L> M_&G36UN]NE\/ZI/9V%U+.QGCC610 7!S_P#KJGA7:Z?;\78S]OU:/T#69".=5U75?$-Q;VVJ07MZ9H+F M)D&XB/\ AV^H]*POBMX@6[\*ZIX\\'W'BF^N8?$4:?\ "::A?^3"3YH4V\$ M.&0?=Z?C1]4;:2>_^=B_;*US](6D51EG STR<5S7B#XB>'_#/B/1= U'4HK? M5]89EL[0G+R[1EC] .]?)7_".W'[2GQP\=:1XI\6ZKH5EX9L+8Z=9Z?=FV"L M\09KAL8+#)Z'BN5\>?"#2]6^-WP4TG4/&E_XM^V6DT$VNPW@1G$)RH1E/!'0 M\DGO3CA5&?).72_X"=9VO%'Z!>8JC+,H'KFE\Q,D;P3U/S5X=^U]<3Z'^S3X MRDLKB>VGALU6*:*0K(,,!G<.<^]?,T7PZU+2_B5\(]&M?''B58O'.C%M:DDO M6)=50,53/W..,CFLJ>']JN:]E_EJ7*IR]#]"O-3;OW+L_O9XH\U./G7YNGS= M:^"? ^I:QHO[/7[1/AW^V]1N[3PY=W%KIMQ<7#-/#&!D /U]\UJ>-_$EPOPW M_9@$&L3?:+K4K0S>7=,7G7:N[?@Y89/.23CQ!K,#W-JJQ$Q,B'!RW8^U?%?A MSX>K\3)/CKJ>J>.-:TNZ\.ZM=3:?!;ZBT:6[JK,'9<\@XP!TZU1L_B=X@US7 M/@UXUOLWFOP^$-2E#LOS2O'D"0CWQGTJ(X7F=KE.LDC]& P5BI8;O3=S63XJ M\3VOA'0;O5[]F%I:KN?RUW-C..*_//X;:=\0M2T?PAX_\+P>+=2\6W]ZDVH: MA?:E&=-O+=G(=$B+<87H,9XK[<^.;F3X2ZTY3:WD*2GH]MR?+GC$BJ>NT\@XJ/P_XBCUU+EUMKBV% MO*83]ICV%B.I [CWKY[T_2[GP7XA^']U:ZK>S2:K'LN8Y)"49=F0-O0 5E#Q M1JMGX'U6&+49HC>^('M'N"Y)CC+'(!/2OG8YH[>]'7]=#Z.63J4G[*=T[6T\ MVOT/JBXO(H(9)3*NQ5+':<\5C>#?&VF^.-*74=-D;[.S-&!*-K94X/!^E>$7 M&BGPE\3O#^EV&L7=]9R64TAAGN#)@E.3]#[UR6FZ1-I_PO3Q1:ZG=V][;ZCM MABBD*Q &3!R!US[U#S2:G\&BO?4TCE%-T[N>KM;3O??[C[#\SWI'F16 ,B@^ MA:O/]/\ B9<3Z_;:/)X?U!@T2EM16/-ODKG.?2O)[:UG\;3>.=>OM>NK&^TN M62&UACFV)"BC^[WS7H5LPA32<5?KVV//HY;*I)JJ^5*VN^[LMCZ9,R@ [E_[ MZIK3JJ;MZA3T.ZODO0[?4/%4O@'37U*]@CO()1,\<[!BNOM:O;#3] B6.S@2X*,U['T<\B\!6&?K2><.?G7CKS7RKI'C+5-+AT/Q'>7\US!IMY-IDEP7.V:+!V MLPZ$@CK6=8^+-;TW3]:TZ6YG:Y\321S6+LY)4/(00I[#&*S_ +9AS*/*]?Z7 MWFL>'ZLKM23M_3^Y:GU"?&.EG7)=(6[C?4(H?/>(=D]:K^$?'6F^-K*:ZTZ1 MQ%%,UNWFC8=R]<9KPSPYX(MK;XU7EG)U1NKF6U80_#\:C=3FW"V DDG49*G9DM_6OGA=0FT[5_"FI MZ4=3@AO+T1O>WEP6:\5LDG9G %>EB,U0:/= MW_Q \1>#K?5-7NK2.^TV19VMY=AEVG^9KB>;:I*&KVU/1_L6R;Y]([Z/M?YZ M'T=XP\::=X*T0ZIJ$K"V\Q8\Q*7.YC@<"I+7Q7#=:Q%IRP7&^2W$XG\O]U@] M!N]?:OF+6[RZLO"_BWP[]LDOK#3-0M_L\LS[RNYQ\C-[5TOB_P 27_A_QS>W M-E+(7@\/*\<83C9*VGYE_V/M!.\G?\ )6_,^DA-N& R M[O3-(UP-P4.H?ZUX'X-\'VMM8Z#XI_X3*YBOKE?-N%GN-\=QD9*!2>,>U<7X MJUXG*K)\^-B)G!7MT[5TRS+DIJ4HV.2&5>TGR1GY;- M:GTS-XMTN'7X=$:[3^TY(S,L Y.T=2?2GZ#XBBU[[6(X;B#[-*8F^T1[-WNO MJ/>O"W\+VFI_M 63W$\Z-)IZ7S%92I+@<#Z>U<^WB[5=(\&>*3;W\T4]SKYM M#<%RWD1EL$CTXK!9G*+;G'9M?=8W_LJ,DE3G=M)[=VU^%CZH659#\KJV.O-( M9T! $B_G7SLUE)\,_&?AZUT?6KJ_M]6C<75M<3>;GYE<9'I=XOPSN_%8 MUS4!?V>HLD$?GDH%\S!!]YZ5X_X6NKG0_B9X:6 MSBU#3[._MW,D5[<&1[@!<[V&3@_2NNMCU3E&-M[?B<.'R]UXS:EM?YV/ICSE MZ;USTQNI/-#9"NI/IFOF#0=.NKJW\:^))+Z^EFT:\F:S@\]O+5AW(SSC/2J7 MA&+Q%NT/7M,&JW%Y<3*]Y+=7*F">,GYMJ[N,#^5<2S1W7N.S\_.QZ$LG24G[ M1:66W5J]CZN:948*74.W\)--\\1\NZK]37RIXUU@:A8:MKFCRZK<7-O>C&K2 M7!2.,AL&.-,X('3I72>/H]T-[!-UG97)BECD(R7V@Y;K6BS M6][0V,%D\K1YIV;OIYKH?14W*6\C1.NH-F6 M)@?N$^U>D5[-*HJL%-;,\>M2E1J2IRW0^BBBMC$**** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M:R[NV:=10!EZQX?T_P 0V9MM1M([N'L)%Y'N#U%&R.M38]J6E+WM&&VJ/D_P"*'[.^O6NJZAJNC.NJ6UQ*TYAQB523G _O M"O%[F&6RN&M[J"2VN%;YHY%((/IBOT4D7Y3BN1\8?##0/'%NT>J:>CR_PW$8 MVR#\17PN9<,PQ$G5P[LWT/TO*.-*^$4:.+CS16EUN?"VX+U-+7L7CO\ 9GUO MP^TESH9QYL/43\NOW!11N[T5YC/<6H4444 ?HW1117])G\;A1110 MQA7G'QH^!7AOXZ:3IUAXD:^2'3Y_M-NUC.8763& <@=J]*I#BG%N+NA/56/ M/"W[%OP\\+>)+'7'.LZ]>V+![9=:U%[J*)QT8*W>JNM?L+_"S7-0UJYFLM2B MCU:0S2V<-\ZVZ2DY,B1] WYU]$?+2[1Z5I[6IW(]G#JCRW3_ -GOPKIOC >) MHENSJ:Z,NA#=/\GV8+M'&/O8[YK&T3]D_P #>'[/PA;VRZAY?A6]EO\ 3=]Q MDB20Y;?Q\P]!7M7%+D4O:3[A[./8Y#XF?#C2/BQX*U/POKHF;2[]0LPMY-CX M!R,'!QR*R_%WP1\*>//A_9^#M=L&OM'LXHX[8LY$L)10J.KCHV!UKT/:*#]: MCF:V=B[*]SP_PQ^S/X6^$_AOQ$?"^E'7=K1WUWJFIZQ]K@@B1LM%;KG"@D=AFOT7VAJ M=Q6T*TX>9$J<9*QR_CGP/IOQ%\&ZGX8U<2MIFI0&WG\E]C[3Z''!XKSJX_91 M\(,VG3:;?Z]H5Y9V*::+K3-2:)YK=1PCCD'ZX%>V8I362G);/0KE323.3^'? MPYT+X7^&HM#\/6?V.P1FD()W-*['+.[=V)KY4^#_ .QGI_BY/&%Q\1M'U+39 MY_$,]Q;I;WC1)>6Q;*B11PRGT/-?:VT>E+@54:LH7Y7N2X)V\CQ[XC?LN^!/ MB9;Z0E]I]QI<^CPBVL;S1[@VT\4(&/+#+_#]:BNOV5O $WPWM/!$%A/9:+;W ML>HEH)B)I;A#GS'?!W$GK7LN%HXI>TGT8^2-K6/(/$W[,OA;Q-XAN];CU#7M M$O[Z!;>^.E:BT*W2*NT!PR<4N10JDUU#DCV/&+/\ 96^'MC\,[[P-)I]UJ&C7TOVF M>2]NGEN#,#Q('/1A[53\ ?LB> OASXLTKQ-I8U2;6M/1T2ZOKUIWD5AC#D]0 M!P*]RVCTI<"CVDTK)AR1['GWQ@^"OAKXX^&8]$\3PW#6T,PN(9K.4Q2PR#/S M*P'%<=XR_9'\ ^-[?1EODU2WO]*M5LH=4L[YXKN6$#&R60??_'UKW';1M'I2 MC.<4DF-Q3=SDOA[\-O#_ ,+?#-MH'AJP33],@R1&I)9V/)9B>68GJ:X;QA^R MOX(\<:MXNU'4TU W'B>*&'4!'<[05C(*[./EZ#->S$4<4>TFG=/4.56L>&/%K?:CJ_AW3SIED?._=B$C!W+CEO>O,_BS^SQ;^&/@#\2]"\!6-Y MJ&K>(I6OC;23;FDG9U+!20 ![5])?A151K3BTTQ>SBU:Q\Z_"']D?P5X97PW MXDOM)NV\06MC&OV&\NFEMK68H!(8XSPIR34^H?L2_#C4K&_T]SK2:5=77VY- M-2_86UM/NW>9$F/E.?K7T'MHVU4JU23YN82IQ2L>)?$/]DGP!\3+ZTO]2BU& MSU2"U6S>^TV\>WEN8E4 +*1]_@4WQ'^R'\.O$7AWPSHHT^[TJT\.,7TZ33;H MPRQ9.6RPY.X\FO;]H]*-H]*CVM3N/V<.QQ_CWX::1\2_ -[X/UH7#:1>0B"; MR9=LA48Z-CKQUK$;X"^&&\2^"]=/VLWWA*T-GIA\[Y1&5"D.,?,<#K7IFT4; M124Y+9@XQ?0\R\,_L_\ A+PQ:^-+:&WN+JU\77#W.IPW4N]79QA@O P,5PF@ M_L._#/P[>:5=VD.K-<:7>+>6;7%^[B$JU>NX%)M'I3]K/^8%"*Z'Q;\.OV/;/QUXC^)%U\0=' MU/3A>:_)/9/:WK0B\M3SM8+P4)['FOH)_P!GGPHX%%5*M.3NV1&E&)X)H?[%_PVT#Q=;Z]96^JQ&VN#=0 M::-1D%G%*3DLL8X'TKUSQ9X7M/&&@7>D7N\6ERNQ_+;#8SVK>XI>.E85/WJY M:FJ-H7IM.&C1Q-Y\+](O)M ED$P;1!BUVOQTQ\W'-HW&B3:'IMI#)&?M=QYLTS,,&6 M%P=-:?[0?WGS[MV[KZ9KT#8-V:7@]1Q6-# 4J,>7?>_S.G$YE7Q4U-NUK;>1 M4M[5+.TCA0GRXU"COP!@5\Z>/O 6K77BC5;BU\&R3RW>Y$N+:[VP2*> TB>H MKZ7QQTIF/RJ\3@X8J*C+2QEA,;/!S=2.K9Y;X!^$%IHMCX;NM09WU?2H613& MV$R_4$=\5J>-/@WH'CC4AJ%VL]M=[?+>:UE,9D7T;'6N_"@+P*-HW9K3ZI1Y M%3<;I$RQV(E5=;F:EK^)Q&H_"GP_JG@U?"[VIATM0-JPG# @YSN]345S\(=" MO-3T*]:&19=&4):@/@;1TR,E)M [4WA:+W@NGX;&<<57C>TWU_'%?@?%XBU/Q)+XEL[FT$NH,\#PS%3/'[XX*FKWBCX3C5OB M5HD$6G21^'K:P>+SH7V"%Q]T#!R#7N6U=V<4>6OI7$LMH)*-M+W/0>:XEU'4 MYNEDNBTL><)\#O#D7A630%CG%K-,L\LOF9EDD4Y!9C6F?ACHTGB!M:E222JQQR12E2X4C ;'4<$;Z6\MDN+JY9#&LEW*9&B4\87TI__ IK0%\'W'AQ39;<6W8!QTS7H''I01GVHCA:,5RJ*L.6,Q$IUKPAIVN^&Y-% MO8S-8-$L14GG '!![&N8T[X(Z%INK:?J*3WTUW8C;%)/.7^7&-OTKTCCTI#Z M8YJY8:C.5Y1U,XXFM35H2LF%X-5BM8WDBU*=KBX29MRDL.0/:N< MT?X$^&=%UR+4(/M1,3F2*V:=O*C)SG"^E>G;1Z4FP9R!2^K47:\5IL4L57CS M.,W[VYY?>?L_>&+Q;V-C>);7U2K,?6M_//3BG;:6NJ,5%*,=D6HKKS-:5:I0DITI--=CY*\>?LSZUH/F76 MAR_VM9CGR6($J#V_O5X_/;3V-Q)!<026D\?!CD4AC^!K]%513T% M.(RFJV$;OC"SH,.I^HKXK'\+TZUYX9V?;H?I&5<;8G#VAC%SKOU_X)\+8]:* M]C\>?LRZWH'F7.A3?VM:*,F%OEE ]O6O';JWDL)F@NXGM9E.UHYE(.1]:_/, M5EV(P ]"\12B34 MM+MKMUX#21C/Y]ZZ3\*3BLITXU%:44_4TA4G3?-"33\B2BBBM3,8S%:;YR_W MU'XBG[0W7FOEKX._!/P_\3M+\1ZWKMYK=QJ#:_?P[HM4FC1429@JJH. ./P MIJ-TV)GU%YR?WU_[Z%)YJ?WU_,5XY_PR7X%;_EMK_P#X.9__ (JC_ADKP+_S MVU__ ,',_P#\519=PN^Q['YJ?WU_,4>:G]]?S%>._P##)?@7_GKKW_@YG_\ MBJ/^&2O O_/;7_\ PXM>Q[%YJ?WU_,4>:G]]?S%>._\,E>!?\ MGMK_ /X.9_\ XJC_ (9*\"_\]M?_ /!S/_\ %46CW#7L>Q>:G]]?S%'FI_?7 M\Q7CO_#)7@7_ )[:_P#^#F?_ .*H_P"&2O O_/;7_P#PVO\ _@YG_P#BJ/\ ADKP+_SVU_\ \',_ M_P 51:/<->Q[%YJ?WU_,4>:G]]?S%>._\,E>!?\ GMK_ /X.9_\ XJC_ (9* M\"_\]M?_ /!S/_\ %46CW#7L>Q>:G]]?S%'G)_ST7\Q7C?\ PR7X%_Y[:_\ M^#F?_P"*I?\ ADOP+_SUU[_PNO?^#F?_ .*H_P"&2_ O_/77O_!S/_\ %46CW#7L>Q>:G]]?S%'F MI_ST7\Q7CG_#)?@7KYVO_P#@YG_^*I?^&2_ I_Y:Z]_X.9__ (JBT>X:]CV+ MS4_OK^8H\U/[Z_F*\=_X9+\"_P#/77O_ Q['YJ?WU_,4>: MG]]?S%>._P##)?@7_GKKW_@YG_\ BJ;_ ,,F^!/^>NO?^#F?_P"*HM'N&O8] MD\U/[Z_F*/-3^^OYBO'?^&2_ O\ SUU[_P ',_\ \51_PR7X%_YZZ]_X.9__ M (JBT>X:]CV+S4_OK^8H\U/[Z_F*\=_X9*\"_P#/;7__ _\ !S/_ M /%4?\,E^!?^>NO?^#F?_P"*HM'N&O8]B\U/[Z_F*/-3^^OYBO'/^&2_ O3S MM?\ _!S/_P#%4O\ PR7X%_YZZ]_X.9__ (JBT>X:]CV+S4_OK^8H\U/[Z_F* M\=_X9+\"_P#/77O_ _\ !S/_ /%4G_#)7@7_ )[:_P#^#F?_ .*H MM'N&O8]C\U/[Z_F*/-3^^OYBO'?^&2_ O_/77O\ PVO\ _@YG_P#BJ+1[AKV/8_-3^^OYBCS4_OK^8KQS_ADKP+_S MVU__ ,',_P#\52_\,E^!?^>NO?\ @YG_ /BJ+1[AKV/8O-3^^OYBCS4_OK^8 MKQS_ (9*\"_\]M?_ /!S/_\ %4O_ R7X%_YZZ]_X.9__BJ+1[AKV/8O-3_G MHOYBCSD_YZ+^8KQS_ADOP+_SUU_'_89G_P#BJ/\ ADSP)_SUU[_PNO?^#F?_ .*I/^&2_ O3SM?_ M /!S/_\ %46CW#7L>Q^:G]]?S%'FI_?7\Q7CG_#)7@7_ )[:_P#^#F?_ .*H M_P"&2O O_/;7_P#P_\',__ ,51:/<->Q['YJ?WU_,4>:G]]?S% M>._\,E^!?^>NO?\ @YG_ /BJ/^&2_ O_ #UU[_P._\,E^!?\ GKKW_@YG_P#BJ3_ADOP+_P ]=>_\',__ ,51 M:/<->Q['YJ?WU_,4>[W#7L>Q^:G]]?S%'FI_?7\Q7C?_#)G@7_GMK__ (.9_P#X MJG?\,E>!?^>VO_\ @YG_ /BJ/=[AKV/8O-3^^OYBCS4_OK^8KQW_ (9*\"_\ M]M?_ /!S/_\ %4?\,E>!?^>VO_\ @YG_ /BJ+1[AKV/8O-3^^OYBCS4_OK^8 MKQW_ (9*\"_\]M?_ /!S/_\ %4?\,E>!?^>VO_\ @YG_ /BJ+1[AKV/8O-3^ M^OYBCS4_OK^8KQW_ (9*\"_\]M?_ /!S/_\ %4?\,E>!?^>VO_\ @YG_ /BJ M+1[AKV/8O-3^^OYBCS4_OK^8KQW_ (9*\"_\]M?_ /!S/_\ %4?\,E>!?^>V MO_\ @YG_ /BJ+1[AKV/8O-3^^OYBCS4_OK^8KQW_ (9*\"_\]M?_ /!S/_\ M%4?\,E>!?^>VO_\ @YG_ /BJ+1[AKV/8O-3^^OYBCS4_OK^8KQW_ (9*\"_\ M]M?_ /!S/_\ %4?\,E>!?^>VO_\ @YG_ /BJ+1[AKV/8O-3^^OYBCS4_OK^8 MKQW_ (9*\"_\]M?_ /!S/_\ %4?\,E>!?^>VO_\ @YG_ /BJ/=[AKV/8C*G: M1?\ OH4F\?PL#],$5XX/V2_ H_Y:Z^?^XS/_ /%5A_#'P79?#G]I'7-"TFZU M!]-D\.Q71@OKUYQYAG(+#<>.,"CE3O9A=Z*Q[]N5<;G&?8G_/1/SK\[?,N/^@AJ'_@;+_\51YE MQ_T$-0_\#9?_ (JC_6["_P C)_U-Q?\ .C]$_-7^^GYBCS5_OI^8K\[/,N/^ M@AJ'_@;+_P#%4>9B?]]4> M8O\ ST3_ +ZK\[?,N/\ H(:A_P"!LO\ \51YEQ_T$-0_\#9?_BJ/];L+_*P_ MU,Q?\Z/T1\Y/^>B?]]4>+ ML-)VY6)\&XM*_.C]$_-0<;U_[Z%'G+_>7_OH5^;GA^XO+C1;25]2U!Y&7+,; MV7)Y/^U6CNN/^@AJ'_@;+_\ %4Y\68:#<7%Z"CP;BY)24UJ?HEYB?\]$_.CS M$_YZ)^=?G;YEQ_T$-0_\#9?_ (JCS+C_ *"&H?\ @;+_ /%5/^MV%_D97^IN M+_G1^B7FIW=?^^A2^:G]]?\ OH5^=>ZX_P"@AJ _[?9?_BJ/,GR!_:%^6/3_ M $Z7_P"*I_ZW8;^1A_J9B_\ GXC]%/-3^^O_ 'T*/,3^^OYBOSJ$D^X#^T=0 M.?\ I]E_^*IQ>>/[VHZ@,?\ 3[+_ /%4O];L*VDH,/\ 4W$_\_$?HEYB_P!] M?S%'F+_ST7\Q7YVM).HS_:.H ?\ 7]+_ /%=*19+AN5U+4&[?\?LO_Q5'^MN M&C:\'J+_ %-Q7_/R)^BGG)_ST7_OH4GG+_?C_P"^A7YV^98O\ ?3\Q1YB_WU_,5^=O MF7'_ $$-0_\ V7_ .*H\RX_Z"&H?^!LO_Q5'^MV%ZP8_P#4S%_SH_1+S V< M,#]#3U'%?+O[(=QW=4N)WD"L2^2-Q.,@#\J^HH_NU]EA< M1'%48UH;,^'Q>&G@Z\J$]T/HHHKK.0:>M>,_LM_\B3X@_P"QDU+_ -*&KV:O M&?V6_P#D2O$'_8R:E_Z/:KC\$O5$]4>SK2TU?NTZH*"BBB@ HHHH **** "B MBB@ I,BEJ":80122,,[06X]!0!Y=XA_:$T/0_C9H?PV,,D^I:E"TDETA'E6S M8RB/[L <5T7@WXD0^,M8\7:=;VLD$WAV]^Q2M(1B5M@;(]J^2=:^!OQ)\5>& M?'?Q*TF\2P\2:IJHU>RTJXM2;E4M7*PQJ^> R \8[U[)^S+-K.KV?Q"UK6-( MN=)NM7O%N/(N(]K%_( 8#/7Y@: /3M%^*6FMH/\ :/B&ZL/#Q,SQK'+>(^Y5 M;:&R#WJS\1OB);?#_P"'^J>*_)_M.UL[?SUCMV'[P=L-TYXKY"^!_P (KS4K MRP7Q-X7N)[:&RUC$>H0DH)'F8H<'C<1T_2O1G\/Z_>?L-SZ-%;35;">&TNI4:2337F5IH55B#N /'2O,_#_ .SG'I_A;3?$ M&I:_KWB'5=.T1Q8Z??R@QV\KP;3A /O#.!7@OAOX7ZQX3T/X):II7A*^AU/R M=536(XE:-Y596*).1V)Z9H ^Z=-^('AK6KJ]M[#7]/NYK,9N4CG4^4/5N:BF M^)7A:WT^._F\0Z:EC(QC2X:Y0(S XP#GUKX1TWPYJ.KS:6-%TN;8OAV_@OK6 MQTQ[9(9F'$$CMS*^<\GTXKU?Q9\%[&\N_#EBOA/?I=GX)N@MNL)\J.[9?[O> M3/3O0!]0V/C30M6O+FULM:L+J>V0231Q7"LT:GG^'O$$=W)IFM MV%]':?\ 'RT,ZL(0.I8YXKX=L_A=JG@^X\&7FE>#;V1F\#W4.HQ)N0S3$\)* M>I;&<=\"L:?PIKNNZA,?#=C/<:4OAN%+V/3=->RBDV2J9(.3F1PN[YCSUH ^ M]?\ A97A7^Q9-8'B+33I<;;'NQA.>M:=KXATZ^CLY+>_MYDO%WVQC<' MSAC.5]1CTKX/\0Z9H5Y\3M-\3>&/!]_X<\ PN8]3U&ZT]Y[6>X\L!"+3T&"" MV.M=AX7BO_A_#\.O%=Y9ZQ>^';74]1*;;-DDC652(AY(Y5&(XSTS0![_ /$+ M]H?PU\/_ !9X?\,S2I=:SKRSFRC6550M$,LK,3\I[FE1:QJ5 MCI6H:A&K0VDUPNYF(R57GFOS[\8^&M=\1VOA/Q+JG@;5+8SWVM QR6IDGMC+ M_J<]UW&N\M=#@\,_VY:?$CPCJ7BW4M2L+#_A'K>&!BX"QC$22#_5,&ZDXH ^ MS+7QYX>OM8FT>UUJQN=6A4L]E'.ID 'MFN M?VB+&Z\$Z+XD&E7"PZEK/]CK M#N&8V\QDWGVRIKYE^'VFZC=>+_AN]GI$FDZI9ZQ.^J:=!IKB2QC*, L]R?\ M69./:O0-+\*ZVOP9\&VATJZ-S#XS-Q)&8L%(O.<[V']WI0!].0^./#\^L#28 M=;T^34SG%HMPID.#S\N>U:E+-%(]K,K"U,:%R7 MY]!7Q#K7P?\ $]G\+CJ&C^';ZU\:/\1;F6._2-OM"V[,P5L_\\^1QTKT;PGH MEEJWCWX9V^B^%KZW\0:79ZC!KM\UHT065H6 $CXPS,W0^] 'V@GB#372V9;^ MW*W63 ?,'[S'7;ZUQ?C+X\>"_!?AF]UNXUJTN[6TN$M)1:S*[+([!0" ?4U\ MG+)J/B;1_AOX6M?"OB*ZD\/V>I0ZMY<;0,LC)M$22'JQYP>E<_HO@S[=X!U7 M3[;PQ.N* /OB/QMH4FH6VGC6+(:C M%SGI5I/$6F/J1TU=0MFOU.#;"0;QQGIUZ5\>>,O@]-XBL_B M5XPM+"32]=T>[M-8T3474QNT,,09H0>RG!!'K7J/[-\5E<>&=!\5:WI4_P#P ME7C*275O-:+>;8,!A"_\("@4 :GB/X\>*X/'FOZ%X9^'L_B.ST,1B\OEO$B^ M9E+;54\DX%=#\-?VAO"?Q&^'-OXS%XNB::]Q):.NI.(VCG1BKQGGD@BO#?&' M[-%_\5/BE\5M:@\0>(_#.H!8(].^P71@MKEA$3RH^\"?ES[UYS8Z++I_AOX8 M3ZEX0O/"6@:&;[3M5L+BP:_BAOB>)VCS\^_J'YZT ??%OKEC>-"(+RWF::+S MXA'(#OC_ +P]1TYJA>>/?#NFQVS7FN:?;+B\U\AW.C^+/A=\ M(?"7C30-&UC7M7L[BZT^/37C*2_9;IB%?8#PJMA@#T!KA_&?PEU#P)\3)(M: MM-0?1KSPDEK87JV#7J?;&RTL:*#^[E+'AO:@#[SU#QUX>TG4K:PO=I H,@)"@'D\ U\^>"_"NJP>*-,T MB^>]B\:0>*&NYQ'IA\WR-Q/F-='@QE<<5Z;KG[.=I\5OCUXUUC5=1\1:+%%# M9Q6SZ9>M;Q3X4DGC[V./SH ]W;X@Z9HNG:4WB>\L_#NI7P4"QNKE=V\_PCUQ MZUH?\)EH8U+^SCK-B+\J6%O]H7?M'4D9[5\Q_%+2]'\-_%+Q4?%>A7FNV6H> M'8+#P_.(&N/WB@JT:D [)"V#NXKQ73_@AXTOOAA\9OL_AZ]B\9%;&.SNF!\] MX51#*D3$\G&%)]'GU6/Q'ICZ; Y22Z%RNQ&]"<]:^%=.\%ZSK-]KFI>&K35Y-(@T&SM]2B MM]/-G;7&R13+"$)R\N V6'7FM;XA7'AS5OB!X;OO"7PZGLO"GFA;_P 1W%E( MUK%,L>%7[(,;V[;B,9H ^W-0\>>'M)T>WU>\UNQM]+N,"&[>=1')GIAL\USN MD_'+PMKOQ1N? =C?1W6M6]BNH-Y; HT;$ !3GD\U\6^!_#6HV/@#3V\3QZKI MT-KK.H&SN+S2FN;2-'Y1'M^H5A]UATKMO@O'%\,OB8WC7Q3X5ET*V?POE+F" MU9@-LO)SU7(=:G^S:7H]L1YMS)U)_V5 Z ML>E.XM N-?U MOP8^@3EFU2Q$)-T6^6.'(#-QF@#Z?TSXAZ'>VVAFYU&UL+W6+=;BVL9IE$K@ MJ#@#/.,UA> OC9H'CC5-3TL7$-AJUG?36(L)YE\V4QG!91GD5\6:KX&UNQTW MXAZ1KGAG5M0\<:VM@_A&^B5CY4:*ORHXXB"'.X<9KJ/#/A_[/H]MX:'A2_B^ M)W_"1QWKWYMF5MB@&27SL8V=1C/.: /L76OB9X>TAM1MO[7LIM4LK9[I]/6X M7S2JJ21C/7BD^%_CZ'XG> =%\46MK):0ZG )T@E(+*#V-?G;XR\-^(_$&FVR M6'A.^T[7H_%%Q)>V%M9.TUM"2P$LMRW+HX_A' S7VC^S;J\?AWX;^!?!>IV] MQ8Z^=(^UM;21E=BAR"#Z'VH AOOVG%L_$NW) W5Y=JWQ9_P"% MC_&;^P?%FBZQH_A?0]74:=96^G.PU&X4_+-+(!@("<_45GW]]JLEO>_"YO#^ MHIXCN/&0OTF6 _9_L9E#^>9?N] >#S0![WX:_:&\->+_ (D>)?"&F?:)Y/#U MH+N\U#RR(#R040_Q$8.<5D?#_P#:.3QIXJTK3;GPY>:3IVNK/)HNH22*ZW2Q M'YBRCE"<$C-+?:#=Z=\:-:NM)TI41O##) Z1!8GN"[G:<<$DXS]:\"^!O@\6 M/C[PU<^&8M:MO&#)=1^(X]6B=[/3BV3F)6^56]Q=06,>]K>TC,DLAZ!5 ZDDBO-]+_ &DH[>TUQO%WAR\\+76FZ>NJI;S, M)#-;L=JX(Z.6PN/>K7C:^\=_#GPGJOB.[U>'Q/#I\#2C1[73<2W3#[J @GJ: M\'T^^O/C/\.?B!K#Z=JES\1;ZQMY9-/N+)X(+:"*0,+>$G[QQNR>YQ0!ZI=? MMS.GQ>#]0? MQLM[]@;P^'!V.$W[VDZ!-I'->.^+OCMJ6FZQ+\0?#'@?5M>BT_1[?188GM'7 M-T[@N=I&=L8!R1Z46_Q\\-6.NZGXM\1ZF3J^O7.E/NLW=?FD2,C) M5.%5?:@#ZB^%OQ&C^)6A7%Z;";2K^SN7LKVQF8,T,RXRN1P1SUKMJ\?_ &9X M=%L_ANB:++JET&NI)+N^UBW,%Q=7#'+R%3T!)X'8"O7U^Z* %HHHH **** " MBBB@ HHHH **** "BBB@ HHHH 97C>G?\G:ZO_V*L'_I0U>R^E>-:=_R=MK' M_8JP?^E#5<.OH3+H?-OQ*_Y*EXR'_42;_P! 6L"M_P")7_)5/&7_ &$C_P"@ M)6!7\^9Q_P C"KZG]'9-K@*7^%!1^E'TZ]J[?X=?#=/'<%W//?'3PC>3;9P/ M.DVD[?R%<.&P\\3-PIJ[.[%XJE@Z?M:KM$XBBM6Q\)ZUJDLZ6>G371MY3!)Y M> P/0^AIT7@_6IKZ>SCTRX-U;X\V';ADSTS1]5K](/7R)^NX;9S5_4R/\X- M'I_G-=CX?\"2W$^N6NMP3V5Q86#7D49XW$'@Y[BJ-]X.N/+T5=.CNKZ[U"W% MRT10 +]#Z5N\OK\G-RLYHYIAG/V:EM]W?W\)D:#R_N\XX]O>JMUX/UVSU*'3Y=+G6[E M7=%'@'>!U(/>E+!5XMW@RH8_#5%\:7X&/1Q6EJ_AG5M CADU+3YK))ON-)C! M/OBNB^'/P]B\;M>-=ZC_ &9;0%8XY?[\K?=7\<44\'5JU?8QC[PZV.P]&C]8 MV675-4N6BM[>/H47V]33C@Z\TY*-DB*F88: MG)14DVW8YCL#C%%=;H/@.Z;Q39:3KMK/8?;0RPMD^LY-/OKBUE& M)8)6C;V(.,5-3#SIP522TV-*6,I5YNG3E>RO\B*CL?I11V/TK&G\:]3KE\+, MOPQ_R+]E_P!&[6757"K+>"0C=C M^+;TR?6O8PM2E&C*#DHRNNE]/(^>QU'$2Q,*L8N44GHG;7HV=?:>!-.E\#R: M2U@W_"2-IW]JBZV'.,\1[NG2L/0M%M=$\'Z+JG]G6NI:QK$SQP+?-B"%5ZY] MZ1/C=XBC\0I?"4&P4;/[+X\LIMQC.,XK(LO'4<>EW6E:CHT&IZ/)<-<06KN5 M-NS$DA6].>E>S]:R_F]W1VMM^)X*P>9QC)2U3:;L]==U^3.^\->#S=:]KRZE MXEM_Z%)7U)']VOEO\ 9!_Y&_Q=_P!>EM_Z$]?4 MD?W:_?,E_P!PI^A_.^??\C*KZCZ***]P\$0UXQ^RW_R)7B#_ +&34O\ T>U> MS5XS^RW_ ,B5X@_[&34O_1[5G[#ZT^B@"+ MRC_>IBVXC&%X&( !/N?6G^7TQP,YZ5)10!'Y7 MJ7;PQQF265AR M=JCG@4 =KY;#^+OGTY]Z/*QGID]> ?<^MAQH\ MDMQ]WRMF=P8'[I&#P:9X3^+7A3QQX#;QEHNLP77AE5D=M0SA J$[SSZ8H G^ M(GPZTOXH>'3HFL2W2V#RK)(MK.8C(%/W"1_">XK>TW2;?2;&ULK1%@M;5%BA MC0<(JC 'Y5YI\/?VGOAY\4O$7]A^'M;,^I,C2PQS0O$)T4\M&6'S#Z5S=[^W M#\(--\07FCW?B22VGL[AK6XGDM9/)CD!P5+XP.: />C'Z$#TIACW9#?/G Y M(/OBH;+4K?4-/AO;6:.>TFC$L, M-1\+Z+K27>M6)82P[&4-M.&V,>&P>N*VK#XD^&]2D\0I;ZO;R?\ "/OY>IL& M^6V;;NPQ^G- '3^62>6SQC%)Y>6SGG&,]ZX3X:?&[P=\7FU!?"FLQZH;%L3* MJE"!V89'*G'6NE\5>+M(\$Z#=:SKE_'INFVPW2W$S85?;W- &IY(+%\ ,1@M M@9QZ9]*=Y?HV/2O++;]IKX=7G@&Y\91^(HVT.WF^S2MY;>:LNA>0IQD*<'/*@\^OM2^ M6?7GUZ?C7F&H?M,?#?3? -CXQF\46O\ 8%])Y-K,@+/+(.L:IC.X>E=QX1\6 MZ7XY\.V6MZ'>)J&EWB"2&XC/WA].QH U1%MR =HZX4 #\?K2+;J%"X7;U*A0 M 3]*EZ=3C\*\SM?VCOA[>_$(^"(/$<$GB+>8E@ .QW'5%?&TL/3- 'I31B12 MK88=PP!%5]2TNWU:TDM;N)+BUD&UX7&58>E9&F^/-"U;Q5?^&[/4X+G6M/B6 M:ZM8F#-$K$@;O3I6#XZ^.G@GX:Z]I6C>(M=AT[4M3.((&R3C.-S8^Z,\9- ' M;V]C%9V\<$"+'#&H5(U P .@^E3+'M&%X^@P!^%<-J/QH\(Z3X[L_"%SJRQZ MY=!?*C"DH2PRHW],D=*V/!WC[1O'MO?W&BW)NXK&[DL9GVD#S4X=1ZX- '0- M'T/<# /?\Z3R?FW9^;&/?'Y5,O2EH @\GYF/][&2 >.F3WJNVD6SZ@E\T2M M>)&8EF(Y"DY(J_10!'Y?X^Q%-\D;L]>,<@9QZ5-10!%Y ]:;Y(5BP"@M]X@8 M)^I[U/10!'Y?!]/SI/* R1P?8 5+10!"L(5< !1Z*,#GO]:7RO3I4M% $7E\ MGG\AC\:D^M+10 4444 %%%% !1110 4444 %%%% !1110 4444 ,KQO3O^3M MM8_[%6#_ -*&KV2O&]/_ .3MM7_[%6'_ -*&JX=?0F70^;OB5_R5+QE_V$C_ M .@+7/UO_$SY?BIXRS_T$F_] 6L"OY\SA_[?5]3^C\E_W"E_A7Y"'.#CGVKT MK2_B%HOAGP_X=LH-._M6>TF-[+(9#'Y^!VKS;]11].N<^QKEPN-G@Y. M5/=FV,P%/'J,*WPK7\#W&:XT'6/#'C&]L]8FTVPO;V";[1&I#1R$ LN!SC-/ MM/$NF^,'\8S)?RV=DFEP6O\ : 4^8Q&07P.>3^->'QW4T=L]NDKK;N06B!^0 MD=R*6*YG@CDCBF>*.08=8R0' /\ %[5[G]MKF7NZ6_$^:_U;]U_O-;Z>FG^1 MZM=?$31/)ELX[N2Z2#0VT]+QXSF>4X/?D#CO2:9\0M$%K864MU);AM%.GR7B MJ=UO+U_$?2O)0HSTI%';]?2N/^V:[=VEK^1VQX>PW+9R?_!/4/!^N^%]!CN8 MKG59+^[26-TNKM)&C9%Y*JH/7KC/K5C4O'6C:QJ_C:,:C-9VFLPQBWN%5@ 5 M'/ Z9Z9KRCCT_2E/?'2J6=5>50Y4HK[QRR&A*3J2DVW^EO\ (]9TGXB:+:KH MUO)/)&JZ0]A)>(AS YY!'_UJ31_'>C^'9O"VG?VE)J,.EF>2;474Y)=2%49Y MKR;/_P"O%''H#[4O[:K66B#_ %=P[D_>?_!_IG8ZIXI@U+X>-I4EW)/J/]J/ M= 3$G$9_VC_*M#1_&VB>&_!>FZ>-..L7INC>SJ9#%Y>_P!*\^V@8& 1 MWSWHQT_BKF_M2K&;K)+FM8ZWDM&5'V#D^7FO9'K7B3QYH4EAXL?2[QX+K68H M&\M05*2#[ZY_K5G0?BAI%IX7T2$S065_IL+Q2+/ [LQ;/*D<<^_K7CB_+[T< M]^>,]_E8]G\%?$#PGHMK93RS>1=K',+E9X MW9]SDXV$':J\]*Q[W45_X1'P1JL5PUFEA>S1O<1IO,;%B0<=P17F ^7H.^>F MM7_;4YI0J1VVMZK_ ",_]7Z=.3G3G>[OKVL_ M\SUR/5-)\5_$#PN^G2F6\@=[B_GC#)"<9.X*W0GO7F'BB]CU+Q)J]U'_ *J: MY=EQZ;NM4K6[N+-F:">2!V!4M&<':>HJ+UKAQF/>*ARM6=[GHX+*U@:KG&5X MVLOON%'8_2BCL?I7ET_B7JCVI_"9GAG_ ) %D/\ IF2@ MNG19,\9^O]:]K#T:=6K4E5V7_ /!QF(K4:=*-%V M=+B-I5NH6S"JJ<,23T KG8[5IKQ;:-D=VD\M'SM1N<<$U[1::]::]*V@ZM<6 M]Y>K:^9.8I!!%(Y(/D*PZ 9R?7%>6Z]I-HGC*XTO1YU>S:<112NXVC/7YO0> MOM6N+PE*'+.CJF[6ZG+E^/KU7*G75FE>]OQN7M5^'&IZ?I,&HP36NJ6LTPM@ MUH^[;*3@*??-+KGPVU30["2Z:>SO!%(L-S';29:V=NBOZ9KT+5(U\"V7A_3+ M)K27P]I]W'=WUX)U:2:0G!PN?NCBJ7B2./1-%\9*][:W+^([Q#8I%*&+ D?, MV/N@>]>G++\+%-+>WXGC1S;'3E'71OMNK_AIJ<%KW@/4M!323,8+AM3.V!;= M]V&SC:?Q-6O$'PSU/P_IMS>RW-G=+9NL=Y%;R;GMF/0/[UU_BCP[]E\+^!X[ MF_M8$T]P+R2WN%9XJI?/8VJ&YB:SET^<&6^4<%I .^/ M6LY9;AE3J3ZI*U_0V6<8N52E%.Z;:>GG;3Y'CGA_07\0730K>VNGHH!>:[?: MN3P!]36O/\-=:MO$PT-TA^T>5YYN-_[H1]=Y-:W@WPOX9\7>(85MS<6&GV0\ M^XCU"=0T[9X5/J?6NIAUJ[OOB#K":W)9V$NI:8]I8K'.'CC4#"@L.,FLJ. H M2IQE4W;MH]&OT.G$YI7C5E&DM%&]FM4_U[GGM_\ #V_TZ]M(I;VQ^RW41EAU M+S?W!4<$Y]0>W6GZI\-]1T;5+6SNKFS2*YA^T17QDQ"T?-O'6EZ9J,]CI7A^UB\J +<*V(4 MZ]_O'M6\LMH13<%=726OWHY:>;XKFBIRLDFWIVV:]3C;[XEE>.)-2N_'7AV)8K>WTZWG MCMM/AMYA(0@(RQQT)P*Y?XK31S?$37&BP5\T#Y?[V!G]:\O&X6C3I.5.ZM*V MOH>MEN.Q%:K"-5I\T;^FIZ/^R"/^*N\7#_IUMOYO7U)'TKY;_9"_Y&[Q;_UZ M6W\WKZD3[HK]?R;7 4WY'Y!GO_(QJ^H^BBBO,?LM_\B5X@_P"QDU+_ M -'M7LU>,_LM_P#(E>(/^QDU+_T>U7'X)>J)ZH]G6EIJ_=IU04%%%% !1110 M 4444 %>3?M$6/B.]\!7L_AW6;[1I+)'N)3I--1GFU$+J#>*&C4W4$?EE MVAQTQD<'TKV'2O@/:Z7X?OO"XU&=_#$]@MLMJQ_>+<;B[7&?[Q8Y_"N=?]EM MY-!5W\9ZHWC-;A98_$P $R1@;?*V]-I7B@#Q_5OCQXVU[1]4N+#59M,?P#IW MVZYE:,%-8E64Q[9/12HSQW->D?$SXI>(_%=Y\.O"NAW$_AR?Q3I4FL7&JVP# M- (XQ)Y:@^I_2ND\0_LK^']>L='LEO[RSL88?LVJPPMC^U8MV\I(>V7R<^^* MT_&?[/EGXHL+=+?6;W2K^QE']G7T)&^TM]H1K=?]DKQ0!?\ V;?B5??%KX0: M+XDU*!;>^F,D,RQ_=9HW*;Q]=N?QKL]9\86&BZE::=+YLM[%;'P[HEO\ 9=-LDV1IG).3DL3ZDDG\:Y[4O^2WZ3C@G29O M_0Q0!Z#&P9R\ M5:-#J\-O)YD!DR'B.,$JP.1D<&@#P3XW^//"[_!OQ7I7PUTZ/4M3U_5ETZ?JD.D3S+([6& M]5N7^7C9E@?"7PCX7L-%LM,T&UL[;19&EL(XT_U+L"&<>YSU-:.K M> ] UW6%U/4-)M[R_6W>U\Z5=Q,+_>0^JGTH \"^)7Q2\/>%_%_PWFT#2?"_ MB6TO+J.VT\6$R_;H-Z8:5%3J@'7->$:[8>-H?@?XXN'&@O\ #^^U^]M=4N8M M/\[4+"U:4B2<H3) M.W\*ZZS\$Z+IFCWNDVVFP)IMXTCW%J4RDK2$E]P[[LT (+;7-%\%:?IVJ6TGFQ7$*L"CGJP&<9.3F@#Q;P3<:;>6/P M$M](N+7^W/M5S]N2WV_: FUQ-YA'(YQG/>JKV>E>"/#G[3EG;6I73DFCWHKG M<&DBP9&;T!.2?05]*>&?@CX)\&^++_Q+HWA^VL=:O"QFNHP<_,#_"^G&.Z@DU M.]25+FX# I&JJ?O9[&O6/A[\&?!WPH^UGPKH5OHYN\"9H0264=%R3PH[ 5=^ M('PT\-?%30UT;Q9HUOKFF"42_9[I)]9\RXTBUG1[33\18MUD ^4.1U)[FNDL_'G@KX>^%O&VO:G;:?J<0\73IX< MM)F40RW3(%.S/R@9W9/3K7M>F_LM_"_1]!U+1;+P?9VNG:BZ/&]0\)V5WHVFL7M+60';$QSELYSDY/)H ^=M'N/ MAU^SC\*['4O$=_H?B_Q7K.KW%WI-I$Z-;K>S++I)8CSSLV]#CK63->>"?BA\4-, M\(>"[_P]HOA/PSJ?VR]OXYD^TWU[DY@A.=W!/+=^E?84T N8GBD&Z-U*LOJ" M,$5Y)IO[)GPET?Q#;ZY9>!].M=4MYS3F@#E_AOX7T7P3^U% MXVMM+MTLXFT*VN+AF;+2.9')9F)Y_P#K5XE^T? -!\8_%+6] OM!\3?\)+H4 M<=PMY.HFTH*"J/%G.X.> %YSBOMO_A$]*?6+S56L8CJ-W;_99[C;AI(@3A3[ M?XURFI? 'X?ZK/H\UUX4L9GTH@VFY#\G.0#_ '@#R,\ T ?,=_\ ";5M%^#/ MA?Q)=:Y-:7EY96#3:7- &N9;Q(PD>UR=P^7)(]J])_93^*S:^D?AB/0[73=- MC@EFM;NWFW2SM'($E>9?X69O7FO?M6\)Z;KUYIEQ?6JW,FFR^?:[ONQO@C./ MH>*Q?!_PC\)> M8U/5- T6'3[[47+W,D>?F).3C/ R>3CO0!VJ_=%+2+PH%+ M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 -KQO3_P#D[35_^Q5@_P#2AJ]DYKQK3_\ D[;5_P#L58?_ $H: MKI_:]"9=#YF^*.HVEO\ %?QDDMS'&ZZDQ(8\_<6N;_MJP_Y_(?S-?6&@Z;9W M.J>*I)K*WGD_M>7+R0JQ(VICDBM?^Q]-Q_R#+(_]NZ?X5^<8[AZEB,1.K*33 M;/U'+N(:N'PT*48IV1\0]/4 MU]B?V-IO_0,L_P#P&3_"@Z-INUC_ &;9@;3P+9,]/I5KAJBFGSO@V:FZA4A.F3UR:Z)/&BKH?^);9?^ R?X5M/ARDIR<:C5SF_ MU@G4A%2IIV_!GQQ_:FG8P;J(\YQD\'UH_M?3]N/M<..HQG@U]C_V+IO_ $"[ M/_P'3_"D_L;3/^@99_\ @.G^%8?ZMTGHYLZ?]9*NW(CXX75M.3D74(]LG\J7 M^UM/W9%W"I^IQ7V-_8^F_P#0,LO_ &3_"C^Q]-_Z!EE_P" Z?X4/AFEUF]1 MKB6K=?NT?'']J:<.EU"![?RI?[4TY?F%U"IQVK[&_L?3?^@99_\ @.G^%']C MZ;_T#+/_ ,!T_P *?^K5*2M*HQ1XCJ)W5-'QR=6TYN3=Q=,=\FC^UM/Y!NXL M?C7V-_8VF?\ 0,L__ =/\*/[&TT?\PRR_P# =/\ "E_JS1T7.P_UDJN]H*Y\ M(+2ZNI;F:^B>65F=V)/+$\FOL+^Q]-_Z!EE_P" Z?X4O]CZ=_T#;+_P'3_" MM'PY2E'E=1V,UQ!.-3VBI+F:L>8_L=W4-UXL\6O#*LJ"TMP2O^\]?52D-TKR M?X>V4%G\3-;6WMX;93I=N2L,84']X_7'>O5T'RU][@J"PM"%).]D?FN85WB< M5.JU:['T445WGG"&O&/V6_\ D2O$'_8R:E_Z/:O9J\9_9;_Y$KQ!_P!C)J7_ M */:KC\$O5$]4>SK2TBTM04%%%% !1110 4444 %)QUI:9N//R^U "[12[1Z M4SS.W4TO/I0 I44FU>E&X[?>C^%O"/@[4?'.LZ;"DVJ)92K%%9* MWW4+MPSL.=HKM_#;8U+Q1_%_Q.)>W^RM>+6NK:I\ _BQ\0+F_P#">N^(O#OB MZYAU6QU#0[?[0\"5?X<'H>G->/4M[65SZ.BW[&-CV:'QGI4-KIC:O=V MWA^_OHU9=-U&X6.=6/\ !MSR0>,BK6K>)M%\/MMU;6=.TMOEPEY3W MKY3_ &G(_&?CO^UK?3_!$UDEYHD+Z?/_ &6+R]N)2VXP-(#BWV=)_"QU>&/X>6]G!+>QF1!>A/F1>>9 ?Q!-3RJU[FKJ-.R/H#Q5X MPTGPCIL]S?ZI86DK6\DUM%<7*QFY*J6"ID\YQU%/M(\'W[Z&+-- M?TY[]I%N%Q;LIQY>WJW'.1Q7S3I_@[4]'TVS?QU\.=8\;C4/!D>EZ1&L!G;3 M[M P>-\G]T3P=YZUT6C_ U\8MX8^&]C8Z9>:;JMKX$U'3C))E?LERX CC=N MS'H#0H*V_4GVD[WL>ZZE\8-.A^)WA/PAI-_#T-KJLZZ[I]Q_94+SW<<%RK/$J@DE@#QTQ7RY\,O# ?XG?"V\T+X M4ZKX5ET'2;RTUF_O(?)CN+HPE=I;/S;GS\_O65X-\+>,O%OQ4\/W>H>$QH=J MVGZK9ZGI]OI'V>U@>1"(XWF)_P!(!;D,>YI\D;V3$JDNQ]4>#?BQX5\=>!;7 MQ;8:O:PZ),H;SKJ94\HDD!7]&XZ5TUE>6VI6*75I=0W5G*ADCN+=P\<@'<$= M:^++/P3K,WPN^%]HGA36M$T[PG?36_B.RATM9)9I?F$5R(CQ.@]?>OHS]GCP M?:^#? -Y!9/JWV:^OI[Q4UJ 6\B%\_ZN($^6A/1:F4+%QJ2EH<=8_M82?V-_ MPDVJ_#W6-.\"+?26,OB)95E2%EE,7FO&/F";AR>U>OV_BV*37-4M)X8;32K. MUBNTU>2Z3RKA'!/W:?K%CK4_A]M"T:QAU#1X#+))+!QE4 M_C52 67T^M4XJQ'/*Y]'#Q3H;:,VL'6M/&C(<'4&N5$ /IOSBF77B[P_I^EV MVHW.O:7;:=='$%W-=HL4W^XQ.#^%?+FH:7XEU+P;X%U/Q/X DU;PEHNOW)U# M1-+L/*EU"V*;8+N2TSUW.\MY+AXO/2-) 6>/\ YZ 9 M^[[]*IWGBO0M/LX[NZUS3K:TDE,*3RW*JK..J@YZBOE-? ?Q#^%?PG\">+-+ MT&[U/Q?IK7FFMH<;&6>'3[MCY4;'OY)(/M1XP^"=_P""=8\&P7L>J7WA6V\. M/922:;IZZ@T6H.Q>9GC8\%]W#CIBG[-7W*]L[WL?5^I>(]'T?RCJ&L:?8+*H M:(W%RB>8#T*Y//:I?[:TXV*WJZC9M8L_EBZ$R^66Z;=V>N:^=O"_P4L5^)?P MPBU'0;[6?#^A>&KE8I]?3E76GZE/IC:MKWPZEFE_MZRT%=UZ)-O[B11U*J22<<]*Y M[]FNX^(%MXZALO%NCZI8>%X='.G^&Y_LPAAG@1]WFW48_P!7/MXYY/)IQBI0 M?9;WV-VBF"X3[*+DNH@V>9YA88V8SNSTZ5ROA'XN>!_'VK7.E>&O%6F M:YJ=L/WUK9SAI5&<$X[CZ4K.X&['Q;I=UK]HCO M/80SAGB5!ERQZ# Z\U-H/Q2\&^*M#U'7-'\4:;J6CZ;N^W7T-P#';8&2')Z> MU.S%S+N=/14%C?6^K6-O>VC#/45/4E)W"E6DI5HZE=4) MX#_Y*=K7_8+M_P#T8]>I+7EO@/\ Y*=K7_8+M_\ T8]>I+7M0^%'S%?^+(6B MBBK,!M>,_LM_\B5X@_[&34O_ $>U>SFO&/V6_P#D2O$'_8R:E_Z/:KC\$O5$ M]4>S+]VG4BTM04%%%% !1110 4444 %>1?M!W5OIWA6WOK[7-3TFRAE*BSTE ML7-_,PQ'$I^OI7KM>8?&;X#^'?CE;:5!K]QJ-L=,F-Q:R:;J?%KQKK7AGQ9E?$#QYXF M\6:Q\+_#T>H3Z+I^NZ)+JNH7MFX27SHX0ZH#Z;N2/2O1/$7[-/@?Q)#X8M[J MQN!;Z"@BABBG*K<(.0L__/1<\D'N:M^+OV>_"7C+2;FPOA>Q+-="[2:VN"DD M!"A2D3#[J$#&T4 5/V5_'NL_$GX(Z#KNO/YVIRF6*2;;M\T)(RA\>X&:V]2_ MY+=HW_8*F_\ 0A76>&_#]AX6T6TTK2[6.TL+5!'%#$,!5'\SW)]ZY/4O^2W: M-_V"IO\ T(4 >AT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 44FZC=0 M%%)N% "T4F12T M %%%% ""O&M-_P"3M=8_[%6#_P!*&KV45XUIO_)VNL?]BK!_Z4-5PZ^AG/IZ MD/AP_P#$P\4G_J,2_P#H*5MI,Z?=D(!X_=MQ[9K%\--MU#Q00.?[8E_]!6O! M?$GCJ7X$>-_BSIC/))#K>F+K^@I*Y8M=/^YDA3/^T00HKQZBO49]+1DHT8W1 M]*+,Z[BLN[UVOP?Q'XU NH037$T"W<32Q$&6,2@-&3TW#^'VSUKYC\6?%'5_ MV9?A[H6DQ:QHUW=:7I4=]J&GWRRW%]=2N0T@)7B($DX9NN.*R?$?BR"'Q!\3 M_$!TM;^*_NO#DR6<\K( 9L8.5(.5W=.G%1R/H4ZB2/K6:\%G#+//OFSXY>/_''C'P]\7-(\+Z?HH\,^&-/ M6SU.74'9;JXEDC#L(\<*%!ZGK5+Q-^T9>_"+PGX26VO]!O=/L],TQ9M%$ M@>&?AUI&A6=UI_AJWUK4)-8D=X460'9;Q]9-CX3T MG3O$FI:_;6*QZQJD<<5W>;B6E1/NKST ]!6K133L H9E;*DJ?:E:1VX+,1[F MFT4@"@_=;Z'^5%!^ZWT/\J%N@?4YOX;_ /(A:-_N-_Z$U=)7-_#?_D0M&_W& M_P#0FKI*N7Q&=/X0HY. O#=<=_:BCG@CJ.GM4&K/AC]MN[LUN-.O;:?P;>^' M+'Q)937^FZ8 OB6:X# ,-W7K@G':N2_;P\37OBJ^\4W7B3PAXCC\/Z#9V5OX M8F^R%[/S9&1IKB9^@?'R+^-?=DGPL\%W7BA?$MQX2T>;Q"#G^TI+53-N'\1) M'7ISUKQ -=$:G+;38XIX=R;L]S MR_PW\6-6UF'2K.]^&^L:=X.FTF-YO$FI2)'!%'Y0W"6+.X#J#[5\O7&J7>B_ MM26]Y%_PC.KWM]X0U&#P_)\/0!%9!48JUT!U8C !/>OOEK=);;R)$1[%?AGX/\"W5U=>'/"VDZ#=W))GFLK94>3/;..ASTIJJFW* MP.C*R5SX0_9MUC4SI/PR\"C5?#WB'2O'EEJ%KJUEI]BJ:MHI^;?/+R3UW M5%?>&U^&LFM);:BGC?P9!JECH^H3[%TVQU6\A4BWM&6MLLH+ =#WQ4LW@'PO=>&#X?=NTQX 8"2Y)R<]>:;K+HB%0<=F8GP4^)47Q=^&>D>*(=-&CK<;X7L M48-'$\;%"(B.&CXX(X-=Q5;2]+LM#TZVT_3;*&PT^U3RX+:V0+'$G]U5':K- M<\G=MG9"+C%7"E6DI5J>IIU0G@/_ )*=K7_8+M__ $8]>I+7EO@/_DIVM?\ M8+M__1CUZDM>U#X4?,5_XLA:***LP&UXS^RW_P B5X@_[&34O_1[5[,>M>,_ MLM_\B5X@_P"QDU+_ -'M5Q^"7JB>J/9E^[3J1:6H*"BBB@ HHHH :S;0:X?Q M-\9O!7@W4!8ZQXDL[&\(RT)8L5^N,XKMIE\R)U(X8$=<5\P?$?\ MKP?XZ?P MYX&L?!.CVHM1>W=]XL;=+=.[$80DY(&#F@#Z0T77M/\ $%C'=Z;?P7]M)C;+ M X8'VXZ5I;1Z5QGPX\&Z=X8TDW5I9V=I>:BJ3WO]FL?LSR[<%D'8?2NMDN$A M4O)*D2#C+D 4 3;1Z4;14?F94D,".N<\5&M[#Y1E^T1&+.#)N&W\Z +&T>E) MM'I437*+L#2*A?[N6'S?3UI9)EC7=)(L:=,L<"@"3 4 #@5Y]J7_ "6[1O\ ML%3?^A"O0=V[\Z\^U+_DM^C_ /8*F_\ 0A0!Z'1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2?Q4M% #*RM8\3 M:7H+(-1U*VL3)]T3R!2WTS6H?O5\)?M^>)[SPW\2?",]OM=$MI 8I.58$C]: MZ,/0^L5%!NUS.I+DCS'V5_PLCPO_ -#!8?\ ?X4#XD>%_P#H8-/_ ._PK\M_ M^%O(W+:9$./[E'_"W(_^@9%_WS7T']BK^<\[Z\_Y3]2C\1_"_P#T'[#_ +_K M3?\ A8WA?_H8=/\ ^_ZU^7'_ MY/^@;'_WS1_PMY#_S#8Q_P&E_8J_G#ZZ^ MQ^H__"QO"_\ T,&G_P#?]:6'X@>'+J:.&+7K!Y)&V*JSKEF]!7Y'5_P!.\5#_ *B\O_H*5B>/O@]X9^)NN>%]6UVTDGO_ M Y=_:]/>&4H-_HX_B7V]13M-\8Z-H^M>*[6^U*.UN1J\I,95F."JX/ K1_X M6'X8_P"@S'_WZ?\ PKRJT9>T;1])1G!THIG*^/\ ]GKPE\2- M1VT5Y9VMULBNC;A1$[C&2RA1T/-=W_PL3PQT_MJ+'_7)_P#"D_X6)X8_Z#47 M_?I_\*.6H'[K8Q7^"GAO_A+M<\112:C;W>MV0L-1M8KHBUN$">6':/&-X7C= M6-K7[,_@S6+72(HIM9T6;3-.&E)>:3?-!-<6@Z0S$??'7W&:[7_A8?AC./[9 MBQUQY+_X4G_"Q/#(_P"8W%_WZ?\ PHM40?NNYGZ/\(_#'AW5/"U_I=B;%_#5 MI+9:9#%(?+2.0#=N!^\3CKZYK2\"^!=)^'6B2:3HR31V4ES+>,LS[V\V5MS\ M^A/2F?\ "Q/#''_$ZC/_ &S;_"E_X6+X8_Z#,7K_ *E_SZ4G&;&I4TSH:*Y[ M_A8GAC_H,Q?]^7_PI?\ A8GAC_H,Q?\ ?I_\*7+(OVL.C.@HKGO^%B>&/^@U M%_WY?_"C_A8GAC_H-1?]^7_PHY9![6/_X6)X8_Z#,?_?E_\*/^%B^& M/^@U%_WY?_"CVTCW.AHKGO\ A8GAC_H-1?\ ?I_\*7_A8GAC_H-1?]^7 M_P *7+(/:1[G045S_P#PL3PQ_P!!J+_OR_\ A1_PL3PQ_P!!J+_OR_\ A1RR M[![2/U M=%_PL+PQS_Q.8_\ OT_^%.5.?,33G%1W.AHKGO\ A8OAC_H-1?\ ?E_\*/\ MA8OAC_H-1?\ ?E_\*GVUCW.@HKGO^%B>&/^@U%_WZ?_ I?^%B>&/\ H-1?]^7_ M ,*7+(/:1[G09H]/;I7/_P#"Q/#'_0:C_P"_+_X4?\+$\,?]!J/_ +\O_A3Y M)=B?:1[G045S_P#PL3PQ_P!!J+_OR_\ A1_PL3PQ_P!!J+_OT_\ A2Y9%>TC MW.@I17/?\+$\+_\ 0:B_[\O_ (4W_A8GAC_H,P_]^G_PI\DNPO:1[G1> _\ MDI^M?]@NW_\ 1CUZD.E>/?"_7-.USXD:]+IUVMU''IMNK,JD8.]SWKV!>IKU MHWY5<^=K/FJ-H=1115F(VO&?V6_^1*\0?]C)J7_H]J]G->,?LM_\B5X@_P"Q MDU+_ -'M5Q^"7JB>J/9E^[3J1:6H*"BBB@ HHHH 9)_JSGBOB_\ :NT_P'XR M\?1R^--1GBM;/3LZ%-I[F%H7T@$;2Y/RMNYYSS0!^D?PODU"7X=^'GU6***_^Q1B6.(@J M#MXQCCD8_.O._P!J&[\-:;X8T^]\27;NR2O'I^C+=>0NHW++A$8Y'W>M>D?# M?+> ?#S,NQFL8LJ%V@?*.W:J_P 0/A/X2^*D-K!XLT*UUR*TG'>CQ%\'/!OBS2[K3M6\/6M[975T+V:*1>&F& '_(?E M0!R/[(OB#6?$WP#\-7VNO++?$2()9\[Y(UD8(QSW( K6\4ZC-IWQET)X+*2^ M9M.E4K'P4!8<_2O1=.T^WTJQAM+2".WM85"1PQ+A54= !7$:E_R6[1\?] J; M_P!"% '?1MN]CZ5)357'UIU !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M"Y?[P_.@,&Z$'Z&HLP)**0>E+5 %%%% #*_//_@I1((_'OA0GI]G?^8K M]#*_.S_@IFVWQYX2_P"O9_YBO0R__>$<^(_AL^4EN,J,TOGCTK.6X&TE:OPYF#_%[P./^HM#_P"ABN;^ MT#U_6MGX9S;OC)X& _Z"\'_H0KFQ4OW4EY&U*_.C]M5;I3Z8HZ4^OSX^C"BB MB@!.U>-:;_R=IK _ZE6#_P!*&KV3M7C>F_\ )VNL?]BI!_Z4M5T^OH3+H:?@ M>WB>7Q0S0Q.W]LR@EHPQ^ZG#)[/Q"]PUC8L+L,-M/851@_:6^&5U=:O#%XIAD?2=R7Q6%]L;JVWRP< M8+[N-HYJ'WZ_9K?_ORO^%I&5&"2#WQ2]Z]AWCN>Q_9;=>EK;G_MDO\ A1]G@QG[/;_] M^4_PKA/&GQ232?@GK/C_ $.#[8MKIKWUM#=HT8=@N=K \@ UP.@_&SX@^&=6 M\#M\1M#T1O#OC%XK:TU7P_(^ZRN9$W1QS(_56Z;AW%"4NXG*)[S]EM_^?:W' M_;%?\*3[+!_SZP?]^5_PKS*Q^/&@:+H-U?\ BG7--\W^U;C3H(M'CDF9S&>4 MV8R7 Y;' K5\8?'CP)X!CTAM>UY+-M73SK.%87DE:/IO9%!*K[FG[VP_=.X^ MSP?\^T'_ 'Y7_"E^SV__ #ZP?]^5_P *\^\0_M#?#KPKXFM] U3Q/;VVJS") MM@1FCB$G^K\R0#;'NR,;L=:U6^+OA!/#NHZX=2)B,B(R8VAS_=S6;XI_:2^&W@GQ'=Z#K/B>*TU>R9([N!87?[, M6P5,C 84'(Y-+WMQWB>C_9K?_GVM_P#OTO\ A2?9[?K]GM\>GDK_ (5DKXST M1O$T7AU-0CEUN:R_M&.TCY/VF"2*\2_:7^-GB7X<^,M"T+2]8T_P + M6^H:;<7MO?W=L;F74+R,@)8QQC^)LCGOFE[VB)=K7/H/[/ ?^7:W_P"_2_GT MIWV>'_GVM_\ ORO^%AP?6NFH=U*Q44FKD?V>#_GVM_\ ORO^%'V>#_GVM_\ ORO^%244]2N5$7V6 M#_GVM_\ ORO^%+]GM]K_ .C6_P!T_P#+%?3Z5)33]Q_]T_RHN[H3BK,Y7X7P M0M\/=#+6]NQ,;98PJ2?G;VKJ/L\'_/M;_P#?E?\ "N:^%O\ R3W0_P#KDW_H M;5U-5*3YA1BK$7V6#_GU@_[\K_A1]E@_Y]8/^_*_X5+14\S*LB+[+!_SZP?] M^5_PH^RP_P#/M;_]^5_PJ6C'OFCF861%]EA_Y]K?_ORO^%+]G@_Y]K?_ +\K M_A4GU.**+L5D1_9X/^?:W_[\K_A1]G@_Y]K?_ORO^%24?RHNPY41_9X/^?:W M_P"_*_X4GV6#_GU@_P"_*_X5)SS2T78QYLMV+1115$C:\9_9;_P"1*\0?]C)J7_H]J]G->,?LM_\ (E>( M/^QDU+_T>U7'X)>J)ZH]F7[M.I%I:@H**** "BBB@".;YHV'J"*^"OBKX9^( MG@_5=3O?&^G^%+;PVDTKZ?J5I:F3RXF8D"1,[BPR,D5][2*6C90=N1C/I7Q? MXH_9/LK7Q#JGBG5?CUJ@%U>,J?VG)#+#;.Q/[I QVYQQB@#ZP\ R)-X*T-XY M8IHVLXRLD*%$<;1R%/(KHJR/#-BVE^'M-LS=G43# B"[( \W &&P.*7Q'XHT MKPCI,VJ:UJ$&F:?#_K+BY<(@/IS0!K45EW7B#3[/1'UB:Z2/38X?M+7+'Y1' MC.[Z8KB;/]H?P!?:%/K">((TTZ&98#++&Z;G;H%!&6_"@#TNDKC-6^+W@[1( M=)FOM?L[>+5 #9R,_P LBG@-GL,\*O'N@>!],BU#7-4@T^SD8)')(?OD M\C:!R?K0!T?I7GNI?\EOT?\ [!4W_H0KMM-U*UU>QAO+*>.[M)E#Q31,&5U/ M<&N)U(;OC=HY[#2IC_X\* /0Z*0-FEH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHI,B@!:*3M, S[49]J-P]:-P]: %HI,BDWB@!U%%% !1110!&W;-?GQ\:OV@-4T'X[^+ MM&O]3OK?3[62-+1+5L!!MYS7Z$/VK\C?VK[CR_VD_&:@_P#+9/\ T&O5RV$: ME:TD<>*;4+H]'_X:*C_Z#VK?]_#2_P##1"?]![5_^_AKYH^U#WS2_:!_DU]A M]7H?RGC>TGW/I7_AHB/_ *#NK_\ ?PT?\-$1_P#0=U?_ +^&OFK[0/>C[0/? M\Z?U>C_*A^TEW/I;_AHJ/_H/ZM_W\-=Y^R7\;-8\>?M#3:0-2NKC0X],DD$5 MPQ)+ C!KXK-P&Z U]"?\$\9C)^TG= ]M)D_F*\W'TJ4*$G%:G3AY2=1)L_4! M>E+2+TI:^+/;"D)I:* &5^S?\,&_$ON^C#_ +>*BTK]D_QK\-_B)X)U?5Y],\N+ M58&\N";"O$/BMY+RVT#6KB[N;@7J"R-NZL(_L]NHRK %?VA:7>0(XPT^^.623&%X'\7TKZ\\*^)= M,\=:';ZSH%P-2TJX++%=0J0C;3M8_F"/PKEM8^)O@J[OO$/A_62L_P#8\MO; M:A;W%F98M\Q_= +@YSCKT%)/9"Y5J[GS-HG@6^^,WPX^('A*R/\ :'C*P\16 MFN:AJPO0]AK,HPPBCF0 )A1C'8CFNXO?@)J^O?"OQ_%8>$_^$9\6:VMJ8O[2 MU8WI:G]@ATG0--ADN[F/3[<*J*.2V MU1RU:FAZE#XAT73]6L@[V-[ ES#(R$$QNH92??!%-SN_=",5;<\]\=:)XI^) M'[/&N:1=:);Z1XOU/2'MAI?VD21QS;=H7S!P0?6N!T/P/\2_B9=?#S3?&7AN MP\%^&?!\\%[.J7HN9]1GACVQJ@'"IG).:]X;Q+I2PZM(+Z&0:0,7Z1'>UL<9 M&\#G..<5/HNIVWB+1[34]-9KFQND$T4GED%T/0X/(S[U*EJQ\J/F+4/@?XOL M/"M[$GA0ZAXC;Q#J.JZ7JNFZD+:XTWSL>7(#T96_B4]JVX_ _P 6/ GQ&T[Q MG;Z+I'Q$U/4_#MOH^KK+.+8VMQ&V3*A((,;=P.XKZ.CC=MRA&;GG"_I2$'Y@ M00>X(YQ_2CG>X>*?C5)XBL[-=#\8M&EM< !I&A6#8Q;N-K M9/UKV+&/;^E##*LK*&5EVD>H/6CFNK#]GUN?-?[$^BZMJ7AG6?&OB*6*]U.Z MD&@Z==QY(DT^T)2-QG^\>3ZXJI\>/@AXO\6_$S5-9M/#=MXWTC4K""VTV1]0 M^R7/AVZC8L)X2>Q)#$CGC%?3%G8V^G6L=K9VT-G;QYV0VZA$4$Y( '3G^=6/ M;KS^(I7UN0HNS1XI^S/\/O'GPYL/$UI\09;;5MB?] MG3-2[I >'?$G]J[2OA5XJMM/U[P7XFB\/2ZC%I7_ E:P#[$MS)@*N,[BN3] MZK/QK_:>L/@;<2S:IX+\2ZIX>L_)_M'Q%I\"_9+02D!223ENO.*^>OVNM/U? MXC?$"PM_"FD>/;WQ[I6L6LECH]Y 9/#E:16B;.9MIL^R%UBVFT-=8 M@\RYLGMOMD1C4EWC*[A@?WL=J\@\(_M5Z7XA^(DO@K5_!OB/P;KCZ=)JUBFM M1*!?V\?+,F#P<#H:O^'M/^,.ER:7K&N:YHS:#:Z3&U[X4T[3LW?G"$;TBFSC M.[.*^;_AKHVM:I^U1;^+O"FC>.-:\-/HUW;^))/'4!66U!!*V]DS=R>..*.7 M5H')V1[Y\-/VK(/B/X?NO$[_ _\1^'_ 7!93Z@/$FHM$UNZ19R JG=N.#B MH/"_[9/A'Q%X+\1Z[>:7J^@SZ.+=AI-ZBM=WPN5#6H@"GYC+D87J.]>&?!_X M?VDW[1FD)\-/"GB[PK\+X],O(O&%CXF65;&X9\[8HXG)!;)/*\5D:_\ !W5/ M"NBW_P 0? /A/5?"^B6&L);:18K U[J$4.2LNI^2Y.YAC;&A^ZISWIV5TR+R MU/OK2;R6^TVRO)K233YKB%96M)^7A+*"4;_:&>:N5YS^SUK'B_Q%\'] O_'4 M+P>))5D\QIHO)FFC#'RI9(_X'90"1VS7HU1+(/\ L9-2_P#1[5E.I%I: M@H**** "BBB@"M?1M+97$:OY3-&RAQU4D<&OA+PU^S+_ &W8ZMIWB/Q5I&L: M?ITEY/86KWP0SWTK$^=,K'*E1C^E?>FV7BGPJ= M5U>;$C3VMN<1C!(\PJ1R0#P>N* /0/@;]ET_P%IWAZ+Q#'XDO-'A2VNKR-@Z M[P/NAN^.GX5S'[8WA>T\5?L]^*H;C3VU":WA6XMH5!8^:K#:<#K]*]+\!KX? MD\,V5UX9M;:VTBY030BWC"!@?4#O]:WY(A(I!4,.X8 @^V* /"==\2:5>? F M7P[J3WYO+?PY:SWT%G"3.L3*H)4=R,'BO%[77M.T/XA:'J-Q?7FN_#+19?+M M]0N+//EW$MN058!?F Z9QQTK[572[9+N2X%M&)Y4$;R;1DH,X7ZZ)X1\3QZS:7E\?%>B-%X9LUM6?RBU MR6" 8^1L$&O2_'5Y'INM_#;6-;6\NM#\,Z9/HVJ1&!G1;YKQ(/4^] 'D'['OA_5_#/ M[/\ X;LM:AEM[S][((9@0T<;2,R*0?08K5\96VK77QCT%='O(;.9=/E,K3IO M#)N&0!ZUZDJE5 /;%M "Y]J6F\>M&X>M #J*** "FM3J* ,KQ%K%OX=T*^U2YW&WLX6GD"#D MJHR<5XI8?M=:%J5G#=VVBWTD$J[E;>OX9YKT[XP-CX5^*SZ:;-_Z :_';0?$ MU_I]F8X+N2.(MPH)XYZ5[&7X6&*;Y^AQXFLZ25C]0_\ AJ[2?^@%?_\ ?2T? M\-7:5_T ;[_OI:_,X^--5_Y_9?S-'_";:I_S^R_]]&O;_LK#^9P?6ZEMC],? M^&KM*_Z -]_WTM'_ U=I7_0!OO^^E_QK\SO^$VU7_G]E_[Z-+_PFNJ?\_LO MYFG_ &3A_,/K=7L?IA_PU=I.GSQ.FAB)U)6:/MY?NBEI%Z4M?/'I!1110 QO>OQ__:XFV_M-^-5'_/9? M_0:_7]NJ_7%?E)^TI\)?&?CC]HOQQJ&A>&[S5;%;A8Q+;KD;@O->A@:].A4Y MZKLCFQ$7*-DCP@S\FC[179_\,\_%#'_(BZK_ -\4?\,\?%#_ *$;5/\ OBO> M6:X7_GXCS5AY=CB_M'M1]H-=E_PSO\4?^A'U;_OW3O\ AGCXH?\ 0C:M_P!^ MZ?\ :V$_Y^(/82['&?:-OO7T1_P3HDW?M+W?.?\ B4R?S%>4_P##._Q/_P"A M$U7_ +XKW7]@_P"&GBKX?_M)RR>(=#NM)2XTF15%P,<@BN/%9AAJU)PIRNV; MT:,HS3L?I<.E+2=12U\X>H%%%% #?\:^2_VJ+XV/Q*TEMVP_9#A@?>OK/WKX ME_;6E@A^*GAM+R]FLK26T8&2$9*G-8U<+/&1=*&[)E6C17//8Q5\;76U?]-E MZ?WCU]*7_A-KO_G]E_,UYPND>'QG_BK+S\AS[T-I.@8_Y&VZ'X5Y:X1Q?],X M_P"U\.CT?_A-+O\ Y_)OSI?^$TNO^?R;_OHUYK_8_A__ *&Z[_[YH_LGP]_T M-UU_WS1_JGC/(K^UZ'<]'_X3:Z/'VR7_ +Z-94OB"2^\9^&A-*TG_$PA"LQR M!\PKC_[*\/\ 0^++O_OD50A_LZQ\?>#;;3-;NK^67582_FKP!O%73X8QE"2G M/9#CFE"I[D=S]25^Z/\ =I],7[H^E/KUDK'6%%%%,!O85XWIO_)VVL?]BI!_ MZ4-7LG:O&M._Y.VU?_L58/\ TH:KI_:]"9=#7\"XW>)^?^8S-_Z"E?-_QYUR M_P#@W\5O$MII(> ?%;3([#3A&IV#5U/ED\="8V))]J^D? ?WO$Y R/[8F_\ M05K>O-+LM0DMI+RRM[J6T?S+:6>)7:!\?>4GH<<9%FF?%O[0WBE M?A!H[>$O"MYK=EJW@OP_;2*\6HI96,;9&'5#S<,QSN4>M2>(O&FK6=S\2-=M MKYK'5+N;PL\]Q"N,^:%\Q<$< Y(-?86K>$]"\074-UJNB:?J5U"FV*:\MDD9 M!GH"1TJ9O#VDR>:&TJR<2%/,#0J0^S[A;CG;QCTHYDDNY;IW/C+]HWQ4FNZA M\9X/%/Q"O_"-SH-C%!H.@6TNV*\ADB#&4QXS*78[?]FL3XF_&6[\/Z'I4_AG M4-8L>1';'F=65B">QK[BU/PGH6M:A%?:CH6FZC>1 M)Y27%U:I)(J?W0Q&<4R]\%^'-2NHKJ\\/:7=W42"..::T1V1!C"@D=!V],4< MRT)]FSY8^'EEIGAGXG?M#72:]>VWB@P+?6NGS71S*C6I;SEC/W@&Z'M61:^. M)O&/_"-:7XX^)>I>!-'M?!5MJ]C>VLXMFU.[8-YDC/C#E,#]V/6OL63PWI$V MI'4I-'LI-2:+[,UXT"^:8NGEEL9*^WI4.J>#?#VM6MI:ZCX?TO4;6S(-M#=6 MB2)!_N C@<#I4\R$X2/E#PWK?C3XQS?!+1M<\6ZUX<.M:1J4NH2::?(FU!(G M"P2MD?*2H#?B:]I_96\4:MXI^#\#ZWJQYLOB8ZBBBJ(&UXS^RW_ ,B5X@_[&34O M_1[5[-7C/[+?_(E>(/\ L9-2_P#1[5E.I%I:@H**** "BBB@ M!&^Z:^-_VT?AEXB\3^)=.UW0;.^2+3;&5\=?%RUTQM3T701:Z8LIN=8O9(OM +'Y553@@ <_6@#ZE^% ;-=/\$Z':Q_9BD-I&@-G M_J3A1RG^S5KQ1XHTKP7H=SK&M7L6G:;;+F6XF.%7_P"O0!LY'3/-%8]QXDTV MV\/MKLUY&FDB#[2;ICA?*QNW?E7!6O[37PWNO!,WBZ/Q- =!BN?L;3F-@PE_ MN[,9Y^E 'JNZC"/#L?A^74?$-K;1:]AM/=LD3 ]#[#MDUJ^.OB M/X=^&NAIJWB'4XM/T^1A&DK?,69CQ@#J* .J]*\]U+_DMVC?]@J;_P!"%=II M.I6NL:=;WUC/'=6EPH>.:(Y5U/0@UQ>I?\ENT;_L%3?^A"@#T.BBB@ I,TFX M-TH_ 4 .HI** #/M1GVH_&C\: %HINZE^E "T444 %-;MQFG4T>AZ4 <3\5? MBIH_PC\-IK6LK*UO).MO&D(RS.W3^5>;?\-B^&><:+K!'_7(?XURG_!1F8P? M BVE5BCKJD!5EXP>:^"K7XF>($MXT&H-M48&1[U[V P%+%0YINQY^(Q$J4K( M_2#_ (;%\,_] 76/^_(I?^&Q/#'_ $!-8_[]"OSB_P"%G^(.O]H-^5'_ M' MQ%_T$6_[YKTUE&'_ )CF^MS['Z/?\-C>&/\ H":Q_P!^12']L3PS_P! 36#_ M -L17YQ?\+2\0?\ 01/Y4?\ "S_$'_/^P_"AY3A^X?7*G8_16^_;2\):;:S7 M%UI.JPP1KEG>( 8KV_POX@M?%?A_3]8L]QM+Z!9XMPYVD9%?B]XR\=ZOK&A3 M6MS?,\1'*],U^O'P#/\ Q9?P4?\ J%P_^@"O&S#"4\-94W<[,/6E5O<]"HIJ M_>-.KQSM"D:EI&H XWXP<_"OQ8/^H;/_ .@&OQ3L+K9%C.?F/\Z_:KXQ;_\ MA5GBL1JK2-ITRJ&Z9*$5^7OAW]B'XKZWH]M?V,6BRV]PN]&:[ (SR,BO1PF. MHX*_MI6N<>(I2JI]>W?\ #!?QD_Y]=#/_ &^TO_#!?QC[ MV^B#_M\%>K_;V 6\SC^JU>QX?]J]Z/M9]:]O_P"&#/C'_P ^VB?^!@H_X8+^ M,G_/KH?_ (%BC^W\#_.'U6KV/#WN_D;Z5]W?\$N9/,\'^-F/_007_P!!KP-O MV#?C(%8FWT/8!S_IHKZ<_P"">OPYUWX6Z?XXT;7?LSW/VU)-UI)N7H1BN/%9 MGAL53Y*4KLZ*%"I3ES2V/L9?NBEI%^Z*6O%/0"BBB@"-NWKVKXM\4>.M3\(_ M%KQ;_JOF!A_:6'/:_P#A=WB+_H+2_G1_PN_Q#_T%Y/\ MOJO%/[&_ZG2/_P !Z3^QO^IRC_\ >G_ *L8_8/[2PY[=_PN_P 1+TU63_OJ MKOP%\57WBCX_1SWUU)#@>#_:# 3_ ,Q2 M$?\ CPKEQ+?LI)G30_BQ9^OR?=7Z4^F_PBG5^=GW04444 -KQO3?^3M=8_[% M6#_TH:O917C6F_\ )VNL?]BK!_Z4-5T_M>AG/IZF9H?B#Q#I^K>*8M-T2TOK M1=7EQ-->")L[5S\N*U_^$N\7_P#0KZ?_ .# ?X53\-KMU+Q5_P!AB7_T%*VZ M\ZK6<9M6/?H4(RIQ=RC_ ,)=XQ_Z%C3_ /P8#_"C_A+O&7_0L:?_ .# ?X5> MQ[45C[?R.CZO'N4?^$N\9?\ 0L:?_P"# ?X4?\)=XR_Z%C3_ /P8#_"KU&/: MCV_D'U>/HH]OY!]7CW*/_"7> M,O\ H6-/_P#!@/\ "E_X2_QA_P!"OI__ (,!_A5VC'M1[?R#ZO'N4?\ A,/& M'_0KZ?\ ^# ?X4?\)AXP_P"A7T__ ,& _P *O44>V_NB^K+N4?\ A,/&'_0K MZ?\ ^# ?X4?\)AXP_P"A7T__ ,& _P *O44>V_NA]6CW*/\ PF'C#_H5]/\ M_!@/\*/^$P\8?]"OI_\ X,!_A5ZBG[;^Z'U:/GTJ]2'[K?0_P J?MKM>Z)X=6>IQ_PY\5^*X? VC)#X M:L9(UB8*S7X!/S-[5T?_ EWC#_H5M/_ /!@/\*R/AKC_A ]'X_Y9M_Z$U=+ M5SK>]\),HK+V MK[%_5EW*7_"7>,?^A7T__P &(_PH_P"$N\8?]"OI_P#X,1_A5VBCVK[!]7CW M*/\ PE_C+_H6-/\ _!@/\*/^$N\9?]"QI_\ X,!_A5ZBCV_D/ZO'N4?^$O\ M&7_0KZ?_ .# ?X4?\)?XR_Z%?3__ 8#_"KU%/V[[!]7CW*7_"8>,?\ H5]/ M_P#!@/\ "D_X3#QA_P!"OI__ (,!_A5ZBCVS["^KQ[E'_A,/&'_0KZ?_ .# M?X4G_"7>,?\ H5]/_P#!A_\ 6J_13]N^P?5X]R#X=ZIJNJ?$S7'U33H-.F72 M[=4C@G\T%?,?DGM7K"]*\N\"8_X6=K1_ZA=O_P"C'KU):]&+YDF>#5CRS:%H MHHJC,;7C/[+?_(E>(/\ L9-2_P#1[5[-7C/[+?\ R)7B#_L9-2_]'M5Q^"7J MB>J/9UI::O2G5!04444 %%%% #9/NFOBO]LO5Y-/^*7ADWMO;VUB(S# \^G? M:/M;."<;\<8(4;?>OM23[IKYO^/MCXVU;X@:1%X#:\GU2RA6>2UO;='TN09X MWLW(?C^&@#V;X9W5]>> =!FU&R73KYK1/-M8TVA"!C 7L, <>]<#^UWX77Q5 M\ ?%<'V"34KJ*W\ZVMXE+L9 PQ@#J:]9T5KUM*M#J*0IJ)B4W*P$E!)CYMOM MFKICSD^HQTH ^??'%VFL_L]?\(S&ES+K=KHEC=W5C'&1)Y(*%ACOPIR*\OO- M5T.\^,FF>/H=/F'P^LT6UN)%L2(&N?(*[C%CG!PN[%?8T>DVL>H2WJPH+R5! M$\N.2HS@?K3UL(%A\@0Q"W_YY>6-OOQTSF@#X U[PEJVD^%O%9U/3K_5)/$V MBM!X:L?LQ;RF:X+*B\?NV (;/' KTCQQ'-9>(/AGJ^MQWUYH?AS1Y]+U:,VS M21+>-;@)N0CYCGC/K7UYY"LT99%8H=RDC.WC''I2-:K(I5T61G2N6C&=PWC*UZ@HQUY)K@-1_P"2W:1_V"IO_0A0!W\8(7GK2M]WGBG4QN]) M^0'S3^TY^T7JOP=\:>&]%L9K>UM=1MY)9+B:/=AE( K@&_:T\1]5U[2S[^3P M?I7 _P#!3:;R?B#X*SWLY?\ T(5\B+?R[5&YC^-?5X&C0G13G&[/)KSG&=HL M^]_^&M/$O_0=TO\ []4G_#6GB3_H.:;_ -^J^"_MTG]]OSH^W2?WF_[ZKT?J M^&_D1S^UK'WI_P -;>(_^@YIO_?NE7]K3Q'_ -![31]8J^"_MTG]]OSIOV^7 MCYVQ]31]6PO\@_;53[HF_;,\1V/B+P_8IJ%AJ3:A?16TD,<6"$=L%OPK[DC[ M?2OQ%\"W9;XI>#MQS_Q-;<9SVWBOVZ7G&/2OF\RIPIU$H*R/2PTI2B^8DHHH MKR#K"FMTIU-;M0!\E?\ !2V5;?\ 9\A+$*/[3@Z_C7YH)JUNJ\W2#GU-?K;^ MUO\ 9%\$Z+)?6<5_;QZI&S6\Z[D; /!%>40>*/ACY*M7?NE&YC/"JL^9L_.G^V+?_GY7\S1_;%O_ ,_*_F:_1K_A)_A;_P!$ZTG_ M ,!UI/\ A)OA=_T3O2?_ '6E_K;_<,_J"[GYS?VQ;_\_*?F:/[8MO\ GY3\ MS7Z,_P#"3?"[_HG>E?\ ?A:7_A*/A=_T3S2/^_"T_P#6UV_AC67KN?FSK>JP MR:=(%N%9MIK]KOV?W63X(^"6!RITJ#G_ ( *^5?'^O\ P^F\)W\6E^ ]'M+F M6-A]H^SJ2@QUKZU^"RHGPG\*B-%2,:?'M"]!QTJHYL\SWC:QI##JALSN%[TM M(.M+5&H4UJ=36H Y'XL.L?PU\3,Y"JMC*23T^Z:^!] ^*,6EZ9#%'JOE_(N4 M$A '%?>WQ?19/A?XJ5QN5M/F!_[X-?F;X3\76%KHL%O=:'9W;Q#:)2@R5'J: M/[&6:_:M8X\1C5@[:;GIW_"Y!_T&?_(M+_PN0?\ 09_\BUQ/_"::+W\-67_? M H_X330_^A:LO^^!3_U-6_M#B_MJ/\IVW_"XU_Z#/_D6E_X7$O\ T&?_ "+7 M$?\ ";:'_P!"S9?]\"C_ (3+1/\ H6;+_OD4_P#4U_\ /P/[:C_*SM)OC LB M,O\ ;'+ @_O:]T_8IU:+5(?%DJ3+,WGH2RMG/!KY4;QIHJQOM\-V>[!Q^[[U M]%_\$^Y1>:;XWN/+2-I+Q/ECZ#Y3P*B7#JRU>UYKG1A\Q6*ER)'V$O2EI%^Z M*6F>B%%%% #&ZK7Y=?M%S&/X_P#C$<_\?"]/]VOU&;M7Y5_M+3>7^T-XQ7// MGJ?_ !VO:RG2N>3F7\$Y7[2?4_G1]J_VC^=9/VC'?I2?:?>OL^9GR-C7^T#_ M "*/M ]?TK)^TGUI?M'J:.9A8TS<*>E>S?L-R"3]HB<9R?[-D_F*\&:XKVW] M@^;S/VC9Q_U#)/YBO-S"3^K2/1P*7MXGZ2T^BBOA#[,*3O2T4 -;J*^ O^"B M3^7X]\+_ /7N_P#,5]^_Q5^??_!1MMOCSPJ?^G9_YBO0R]\M='#C?X+/F5;C MY1@Y.*/M!J@DWR@Y[4OF^U?;\Z/CK6+WV@T?:#5'S?\ 9;\Z7S3Z'\Z/:"+O MV@UI>!9BWQ5\&#_J*0_^ABL#SO8_G6GX DW?%KP4,_\ ,6@_]#%G+T. MG#K]Y$_9B/[B_2G4B_='TI:^!/MPHHHH 05XUIO_ "=KK'_8JP?^E#5[**\: MTW_D[76/^Q5@_P#2AJN'7T,Y]/4A\._\?_BC_L,2_P#H*UM+$S+N$;%?4*<5 MB^'"/[0\59&1_:\O_H*5\J?&CX@7FF_%;XGP_P#"R=;\.ZSHMK92>&] TQ?- M2ZF92=C1A3N#-@'/:O(J+FJ21]'1GR48L^Q.V>U%>-S?'C6=+\4Z5X7F\%7- M]JR:%!K6MWJ7"Q0:?&P/FE@>K ACM%9W@O\ :TT+QAXFTJP;2FL]*UDS+INH MI=+*Y6,%MT\8'[H,JD@FLG!G2JB=CW7J<#DT[R9,@-&RGJ-PQ7B/Q<^,#:KI MOA?1/A_XAMUU'Q1K:Z,VM6Z>9]@0+ND90>#(1P,UB?&+P9JOPK^$VIM;^./$ M6NB?4[!%DU.93) 3.@;:ZX(##C%)1;=A2J).R/H@J5QD8STS0JECA02?0"O" M+[XZQ> YO%LJZ5K/B6Y3Q/;Z+'8M.A_?2QC;Y/\ =CSU!]:B\1?')M9^'WBO M^U]%UCPAKWAW5;2RO["QND:4&5U*%)>A5@PS^5/V;!5HZ^1[WZ>]'\6W&:\P MM/C)J6N^.+_2/#O@J]UGP_I=V-/U#Q#'<*B0W&T,RK&>7"Y&2/6JFE?'Q;GX ME6O@G5]"CTB\U.&Z:PDAU*.YD+1*21*B\QDCD9IUB>N,AC;!&#V%*\; MH 6C9 >A92,UXQ^S]JE]=?LZ37\]W+=7ZG4V6YG3Z8 _"O!OV?\ MXO:K<>(_"4Z>,O$NK?\ $KN]3\7V_B.+9:I;1EMLEJ3]Y@V!\O:K5-MV,Y5E M&S/MVC!]*\(\'?M:Z/XJU>TM9-!N+6UU.SN+[39;:X6YEF2%=Q26-1F-F7D M_2NF\!_&B^\>>!;_ ,3VOAA! B![2UCU*-GF'=9NGDL.,ANE1RR-%4BUN>H_ M_JI5ZUX=;?M26!\)>.]5O-#/]J>#O)^V:;I]]'=).DO^K\N5>"3TQVJS)\?/ M$LMYIVBV7PQO[OQ;3IN;G">U+VUCW/:"#M#_PM MP#FDKYO\3?%3Q)X/_: \37-AX4U/Q+;0^%+:_N=+2[6*.P568R$YX+@9Z=<5 M[UX0\467C?PII/B'3?,^PZI:I=0K*,.JL,[6]Z.5VN$9J3LC6HHHJ34*#]UO MH?Y44'[K?0_RH6Z!]3FOAM_R(FC_ /7-O_0C72US?PW_ .1"T;_<;_T)JZ2M M)_$9T_A"BBE!"\_>QSM[UF:"^6Y7<%8KZXXI5ADD4%8W8'H0I(KY#_:JU7QM M\-_'/@F^\)?$76+OQ=X@UR*"U\'Q(AM6LN/,+(!G"\_.?6KO[:&FZYX+TF+Q M%X>^(GBK2O%OB&^M=)TCPY83HMF;ER Q"XS@ EJV5.Z3ON.SU#86CB1E& M 2* MO!-KH?Q"U+QCXG\8:9?+J_A_6;%?C+\2? FCZ M_P"$_%FNZEHNI:D+>4ZUXL9/.T2+&+NX^3/REOEA7J[T75_^$@TM[=5@U3?O^U!1C>Q_O$Y)%;%<[T=CJ34E=!11 M2KUH&)X#_P"2G:U_V"[?_P!&/7J*UY?X#_Y*?K?_ &"[?_T8]>H+7M0^%'S- M?^*QU%%%68"&O&/V6_\ D2O$'_8R:E_Z/:O9J\9_9;_Y$KQ!_P!C)J7_ */: MKC\$O5$]4>SK2TU>E.J"@HHHH **** &2?=YKXR_:ZTOQ1??$S2M1TV#6M2T MJQM2N-#O0JV9*MN:= >.2I#'M7V5=!FMY0OWRA ^N*_/'3_"U_;>)-!75?#W MC6)%U&_?Q)+:1LZZI"9,PQN<\Q@=,=J /N3X5-?-\.?#C:E=)>7WV*,RS(VX M,<>O!=+L[[4K_ #'>C=:Q6RF66=<9)51R1CG- '8^E>?ZE_R6[1_^P5-_Z$*Z MWPWXBT[Q9HMKJVDWD=_I]R@>*>(Y5@?ZBN2U'_DMVD?]@J;_ -"% 'H5-;[M M*O2D;- 'QO\ M@?#3PO\1OBQX7B\57E]:6,-@^QK)@&!+#K7F[?LC_!1NGBW M7,_[3@5WG[:EUY/Q6\+0R7ZZ=!-82*92F[G<*\E'AU,#_BLK<^A\NL)8',ZS MY\-.T3CJ8G#TY6J;F[_PR+\%O^ANUK_OL4?\,B_!;_H;M:_[[%87_"-Q_P#0 MY6__ 'Q2_P#"-I_T.5O_ -\5']F9W_S\9G]>P9N?\,B_!;_H;];_ .^Q2?\ M#(OP5[^+M:_[[%8G_"-I_P!#E!_WQ1_PC:=?^$S@S_USJO[+SO\ Y^!]>P1) MJW[.OPO\(Z]X;N_#^N:QJ.JQ:G \:3,-B_..M?I/%]T?0?RK\P[J--'\2>&H MH_$<>J7$^IP 0K'C"[QSFOT\C^Z/I50H8NA[N+?O'52JTZRO2V)**0=*6MC8 M*C;\ZDJ,J@!KWL!E^&Q5/FJPNSY_'8BI M2GRP9ZZ=!L_^AP;_ +]"E_L*R_Z'$_\ ?D5Y-]L_VS^='VK_ *:?K7J_V1@; M?PD>9]=Q'<]9_L&S_P"AQ/\ WZ%)_8-E_P!#B?\ OR*\G^U?[?ZTGVS_ &S^ M9I?V1@/^?:%]>Q'<[WQQ#9:)X;O9U\4/=R^6P2%8OO''>OT2^!)8_!WP>7.6 M.F1$_P#?(K\G?$5Y_P 2V0 YX;J<]J_6#X$_\D;\'?\ 8,A_]!%>-F&#H87E M5&-CV\OKU*U^<] HHHKQ4>R%%%%,#C?BY_R2_P 5?]@Z7_T U^2FF77^BJ,X M&*_6OXO?\DO\5_\ 8.F_] -?CYIMU_HXP:^BR=VYG<\'--5&QTRW V\M3?M" M^IK'^T?[5)]H]Z^HYU;<^?Y6;/VA/4T?:$_O-6+YQ_OFE^T>_P"M3[3S%RLV M6NEV-\V.*^Q/^"<4GF>'_&?M>H/_ !TU\0R7&5/S<8K[5_X)JR>9X9\:'I_I MR]/]VO(S25Z%K'K9;&U78^U5^Z*6D7[HI:^./J0HHHH :W:OR=_:BF*_M&>, MA_TW3^5?K"W45^3/[4MO<3?M'>,WAM;F>+SE&Z&!G'W?4"O5RV2C6NV>=CHN M5.R//_M!]Z=YK>M4/LM]WT^__P# 5_\ "E^RWO\ T#K_ /\ 5_\*^H6(IVW M/F_JT^Q=\UO4?G1YK>H_.J/V.]_Y\+__ ,!9/\*7['>_\^%__P" LG^%/ZQ# MN3]7GV+C3-W->[_L"2;OVD+CG/\ Q*Y?YBOGS[+?_P#/AJ!_[=9/\*]^_8"A MN+7]I"7[1;3VZR:3(4\Z)DSR/45P8ZK&=&23.[!T91K)M'Z;T4T TZOD#ZD* M*** &5^?'_!1R.6Z^(7A:*&.6>2.U=F6)"W&1SQ7Z$>M?._Q@NCIOQ=L;E(X MI76RZ21AA@M[UU863C531SXB*E3:9^9PCN>/]#O[_P"%.%O<=?L=[_X# MO_A7Z:+X\DZG1M-R><_9U_PIW_"P)O\ H$:;_P!^%_PKZ%XBMO8\!4:3ZGYD M^3<#DV5Y_P" [_X4>3<'_ESO?_ =_P#"OTV_X6#+_P! ?3?_ '7_"C_ (6# M+_T!]-_\!U_PJ?K%;L/V-(_,GRK@?\N5YG_KW?\ PK7^'=O%N/*FMU;[*8E*CRV(SR#S6QX;_Y"'BG_ +"\ MO_H*ULUX]9\M1GT]"*E2BF<<_P ,[2X^(VN^*KF[:=-6T9=>XK\GEY8EMW M7)W8KG/AE\$;KX:36=I#XBAU#P[8*Z6M@^EQ+/L).$EFQE@N3]0*]4^E ^7I MZ8K'F=K&WLHG$?$OX3Z/\1?#,6EHY\.7=I=)J&G:GI<2QR6MRARL@P,-CH0> MHKF]2^"OB7Q=X2OM&\9?$2X\0-/<6L\S1Y+??L^VNI:M>WAUR>%KOQ+;^)"@B&%>%0HASZ''6I/%7[/]KXHN/'4 MIUN:TD\5WUG?.4B!%L;;;A1Z[MO/UKU6@=ZKGD3[&-FNYY-8?!+5_#_B_6-0 M\.>/+[1/#6MWAOM0T%+97+S%-KF.4\H' !]L5S/@']DNR\"^-/#OB!/$/VL: M#]K%K$+()/<+<*P/GS9S(RYZGTKW^C^5/VCW0>RCL<5X"^&D7@/X:R>$8+][ MV.3[7FZ9-K#SRQ)V^VX_E7)3?LW:9<>%? >BOJTY?PK%-:F[6(*]]:RJRRP2 M#L#NS]17L5%+FE=M=1^SC9(\L^'_ ,&]6\ 6\=G;^+HI]-L[9[;3E72HHYX5 M/W&EE RY0?GWKG)OV68M6TSQDNK>*)FU7Q-'!'/=:9:"UA3R7WJQB4X9F/#' MN#7NW\NM%3S,%32/!=,_90M;#0?'5A)XAC\[Q1T*1CCYN] M=5XV^#>IZQXOL/%7A3QG<^#?$,.FKI%SQ:5:K:+<,-ID [D=JW_ *\45/.VK%Q@H[!1114F@4-]UOH?Y44-_JS] M#_*A;H3ZG-_#?_D0M&_W&_\ 0FKI*YGX;?\ (AZ/_N-_Z$U=-5R^(SI_"%&> M5SR >E%%0:'SMJ'[+7BC_A=NM?$S1?BM-IFL:DJP)'Y M'K7=>*/@C%XT^,'@GQQK.MSW4'A.WD%IHXB'E273#!N6;U]NU>G;0>@_*E^O M2M/:.R78P]DM7W.9UCX=Z%J%Y?ZO:Z58Z=XJN(7BC\11VRM=PLRE0X;KD?TK MR'X&?LO>*/@;]HM=/^*DVH:5>32W=];RZ2BW%W-(#B1YLY)5CG\*^A/Q-'I[ M4E4DM!NC%V/'/!/[/=UH?Q(M_'GBSQ?)XUU^P@EMM)_T".TALED^\Y1!\\G8 MDU0\3?LKVGB?PCJEM<>)KH^,-2U9-:E\430+*WFQD^5#Y1X,2*OGZ4W4E=,7L8VL<=\(_AK9_"#P!IWA:RO)=16U9Y9;R90K32R,6=PHX5O4%KR_P'_R M4_6_^P7;_P#HQZ]17M7M0^%'S.(_BR%HHHJSG&GK7C/[+?\ R)7B#_L9-2_] M'M7LU>,_LM_\B5X@_P"QDU+_ -'M5Q^"7JB>J/9UI::O2G5!04444 %%%% " M=:;M*]R?>GT4 -"!(-'\>Z+X;\0O\.])E:&WTFZ1GO()I(BCR*AY*9P*^WVC# MOPPZ#>ZIJ7Q TIK2S1?F2RD:8R;)B?N+M; M.?6N[\<^&M6\-ZQ\/O%3:%?ZI%X0TZ3P_=6\ W.\LD(02HO\2AN,U];[/PI/ M+_SZ^] 'E'[+?P_U;X8?!/0M!UH!-3C,LTL2MGR_,=F"Y]@15WQ):3WGQGT0 M6]X]E(NFRLQ10V\;QE?:O3 NT5Y]J7_);M&_[!4W_H0H ]!5=J@>U#?=IU-; MTH ^!_\ @H=-Y/Q!\(#]JR,5LI-PC M0M_$/2OE!=2QCY)_^_#?X5]?@*L848J3/E<91 .V*_%[P;=%OB)X2<1S&)=5MP6\I@/OCU%?M GW1_NU\IF MD_:54[GT>71<*;5B6BBBO'/6"F_Q4ZD[T ?+'_!1%_+^!UNWIJD:+-=FP@GU2+S)E&2,9KY^M_V$]/N(EDB\>*83T)3! MKZ++\0J5*S/!QV']I.Z/EO[4W]ZE^V-Z_I7U-_PP;9_]#VG_ '[I?^&#++_H M>X_^_8KTOKRZGG?5&?+'VQZ3[8WK7U/_ ,,%V7_0]Q_]^Q1_PP;:?]#W'_W[ MI_7HC^JL^1_$%T6TV7G^#^E?KW\!?F^#/@P_]0N'_P!!%?#_ (V_8GT[P_X: MO;F3QH)V2-BD2Q\LV.E?44@Z4M>(CV I#VI:0]J8''?%U7D^%_BE(UWNVGRJ%]RI%?FYH/[&OQ4U M31[6[L],L)()D$BG[4,\],U^E?Q0;;\//$1'&+.3^1KYK\'^(;JPT.V2"ZDC M4QJ<;CC.!P*]/!N:OR'GXJ,&ESGSO_PQ3\7?^@1I_P#X%K1_PQ3\7/\ H$Z? M_P"!:U]2?\)=J7>\?'U-'_"7:C_S^2?]]5ZO-B+?$>9[.EV/EO\ X8G^+O\ MT"=/_P# M:7_ (8G^,'_ $"K#_P+%?4?_"7:E_S^R?\ ?5'_ EVH?\ /Y+^ M9H;Q'\R'R4NQ\M-^Q3\7=I+Z58 'D_Z4.!7TC^P9\.=<^&-KXUTG74A2Y^U1 MR#R9-XY!K0G\6Z@T#J;R3[OJ:ZC]F.7SK_Q2Y)8F1"Q)SV-<&*E5]G:;T.O" MPC&I>)[ZOW12T45XQZX4444 ,;[PKYEA\23>'?B'XM6""VD66]);SHE;/'J1 M7TTWWEKX^\276SXE>*5!Q_I9_E7;A(J4W3S2/1?^%D3_\ /A8_^ ZT M?\+*N?\ H'V/_@.M><_;&]5H^V-_>%+V-*X^>1Z,WQ*N>UA8_P#@.M9'PYUJ M;7OCM;7%Q'"C+9RA1#$%XXXXKDOMA]7\3; DX_T(_SKJPO\5'/7^!F.EP0J_-VIWVP^M8?VGY5P^.*/M7^V:^B MU/&BM-4;?VP^M'VH^M8?VK_;H^U?[=(=O(W?MC>M8&L71.NZ".A-]%_Z&*=] MJ_VJR;ZXW>)/#X!W?Z=%_P"A"L:U_9LJFO?1]UI]Q?I3J:GW%^E.KYH]X*** M* &]J\:T[_D[;6/^Q5@_]*&KV7M7C>F_\G:ZQ_V*L'_I0U73^UZ$LI:!>00Z MEXI26YAA;^UY3MDD53]U>Q-;/]H67_/]:_\ ?]?\:H>&/!/A_6M0\4W=_H]M M>7)U>4&64'. JX[UO?\ "M/"7_0N6/\ WR?\:\^I3CSN[/9HUIQII)%#^T;/ M_G_M?^_Z_P"-']H6?_/_ &O_ '^7_&KO_"L_"/\ T+EC_P!\G_&C_A6?A+_H M7;'_ +Y/^-9^RAW-O;S[%+^T+/\ Y_[7_O\ +_C1_:-G_P _]K_W_7_&KO\ MPK/PE_T+MC_WR?\ &C_A6?A'_H7+'_OD_P"-'LH=Q?6)]BE_:-G_ ,_]K_W_ M %_QH_M"S_Y_[7_O\O\ C5W_ (5IX1_Z%RQ_[Y/^-+_PK3PE_P!"Y8_]\G_& MCV4>X?6)]BC_ &E9_P#/_:_]_P!?\:/[2L_^?^U_[_K_ (U=_P"%9^$?^ARAW*]O+L4O[0L_P#G^M/^_P O^-)_:-F? M^7ZT'_;=?\:N_P#"L_"/_0N6/_?)_P :/^%9^$?^A?8 MI?VE9_\ /_:_]_U_QH_M"T_Y_K4_]MU_QJ[_ ,*U\)?]"W8_]\'_ !H_X5IX M2_Z%VQ_[Y/\ C2]E#N'MY/H4O[0M.][:#_MLO^-']H6?_/\ VO\ W^7_ !J] M_P *T\)?]"Y8_P#?)_QI/^%9^$O^A=L?^^3_ (T>RAW#V\^Q2_M"S_Y_[7_O M\O\ C1_:%G_S_P!K_P!_E_QJ[_PK/PE_T+MC_P!\G_&C_A6GA+_H7;'_ +Y/ M^-/V4>X>WGV*7]HV?_/]:_\ ?]?\:/[0L_\ G^M?^_Z_XU=_X5IX2[>'+$CU MVG_&C_A6?A+_ *%VQ_[Y/^-'LH=P^L3[%+^T+/\ Y_[7_O\ K_C2?;[0JW^G MVOW6/^O7T^M7O^%9^$O^A>NAQWPXU"T7P)HX:\M581MD&91_$WO72_VA9_\_P!:_P#?]?\ &L?X:_#S MPM=> ='DET"RD=HF+,5/7>U=)_PK/PC_ -"Y8_\ ?)_QJYTH\VX1Q$^78I?V MA9_\_P#:_P#?]?\ &C^T+/\ Y_[7_O\ K_C5W_A6?A+_ *%VQ_[Y/^-'_"L_ M"7_0NV/_ 'R?\:CV4"O;R[%+^T+/_G_M?^_Z_P"-']H6?_/_ &O_ '_7_&KO M_"L_"7_0NV/_ 'R?\:/^%9^$?^AR@'MY=BE_:%G_S_P!K_P!_ MU_QH_M"S_P"?^U_[_K_C5W_A6?A'_H7+'_OD_P"-'_"L_"/_ $+EC_WR?\:/ M91#V\NQ2_M"S_P"?^U_[_K_C2_VA9_\ /_:_]_U_QJY_PK/PC_T+EC_WR?\ M&C_A6?A+_H7;'_OD_P"-'L8]Q>WF4_[0L_\ G_M?^_Z_XT?VA9_\_P#:_P#? M]?\ &KG_ K/PE_T+MC_ -\G_&C_ (5GX2_Z%VQ_[Y/^-'L8=P]O/L4O[1L_ M^?\ M?\ O^O^-+_:-I_S_P!I_P!_U_QJY_PK/PE_T+MC_P!\G_&C_A6?A'_H M7+'_ +Y/^-+V4.XUB)]BK\/[B*?XF:X8IHIE&F6^6C8,!^\?TKU7<<=*\O\ M _A_3/#_ ,4=9BTRPAL(WTJW9EA& 3YD@KU!:[XKE21XM27--MCJ***HS$-> M,?LM_P#(E>(/^QDU+_T>U>S5XS^RW_R)7B#_ +&34O\ T>U7'X)>J)ZH]G6E MIJ_=IU04%%%% !1110 4444 %%%% !11368\T +D4M>8^(/V@O!WAOX@6W@V M\OI!J\I5'98R8;=G&461^BENU:_Q.^+7A_X3:/;W^O32A+B40PP6T9EED;KE M5') ')- ';UYYJ7_ "6[1O\ L%3?^A"NM\-^(;#Q9H=IJ^F74=YI]W&)89H^ MC*:Y'5)%C^-FCEF5?^)5-]XX_B% 'HE1M\U,6[AZF:/_ +[%#74.T_O8_P#O ML4 ?/'QUOH])^+&B7'D02R"P8#SXPXQN'8U77Q_IZXSH&FY[_P"BIU_*L7]J M34!;_$G0W5@0;%N5.1]X5YQ_PD05@=V3CTKV\/RRIQYCR:RESOE/8_\ A/\ M3_\ H7M,_P# 9/\ "C_A/+#_ * &E_\ @*G^%>.?\)$G][]*7_A(5_O5T6'?0-+Q_U[)_A7CO\ PD*]-_/TH_X2 M)<^==X]\36^M76CP1:=9640O8&_?KFC8(*_;X!@_[PK]!$NH54?OH^@_B%>7C+CA;\KN6**A^U0_\ /:/_ M +Z%'VJ'_GO'_P!]"N ["7N*/6HOM4/_ #WC_P"^A1]IB_Y[1_\ ?0I,#QG] MJ286_@_1V_ZB,?\ (UY!;ZP?*!WD>@SQ7J/[7-RB^ ]+='5L:C'T(/8U\\)K M"I&%SDCBO9P;2AJ>9B8MRT.Y75''_+4_]]4[^UF_YZ?^/5PW]LHO5J/[;7U_ M2N_FB6QP3GM7U=\&_F^%WAAO^G%/Y5\/^)M6\S1[I5YQ&W?VK[9^#-U$ M/A3X6+2H/] C)RP]*\O&-:6.["Q:O<[NBH?M4/\ SUC_ .^A2?:X?^>T?_?0 MKS#O)Z3N*A6[A/66//\ O"G?:H?^>T?_ 'T* .8^*G'PY\2?]>,G_H)KX[\. MZA_Q)[8$Y(1?Y5]??%:XCD^&_B4"1"?L,G1A_=-?#&A:EY.GPJQZ(/Y5Z>"D MHIW//Q2;M8[[^T>/_KTG]J?[1%:-MSAY7V.K_M3 M_;-+_:9_O5RG]L#^]_*F_P!L)_?_ )4N:/<7++L=5-J9\I_F_AKU/]DN?SYO M%1SG][&/T-> 2:PK1N-PSCCFO;OV.+E/+\5EG53YZ?>8#L:X<9)."L=F&B^: MY].T5 +J''^OC_[[%'VF+_GM'_WV*\8],GHJNMW"3@RQYZ_>%+]I@_Y[)_WT M* )6^\*^)/&UT8/BEXL ./\ 3?Z5]K?:8N/WT?\ WT*^$_B1=B+XM>+1G*FZ M['VKMP;2F[G-B-8V+:WOS8W_ *TYKSC[X_.N:%^G9B:/MR>M>TI1L>7RLZ/[ M9_MTGVO_ &_UKG?MT?O^=+]N3UI\R#D9T?VP@??KHOV?;HS_ !RA&<_Z'*?Y M5YU_:*]-QKLOV:[T-\=$W,JH+*7ECCTKEQ$E[-FU&+51,^U^U+47VJ'_ )[1 M_P#?0I/M,/\ SV3_ +Z%>">N3457^UPY_P!='CI]\4X74/\ SVC_ .^A0!)_ M%7RC^T_,(OB5IO.,V9_G7U2UU#_SVC_[Z%?)/[5TH7XD:0RN"&M#R"/6NG"_ MQ#&M\)Q'VP8'-)]L'JU8:W@P.>M+_: 7^*OH%*/<\?D9M?:E]6H^U+ZM6+]N M'][]*3^T!_>/_?-/F0UUN\4^'E_P"G^$?^/"J1OQ_>-4X[K=XP M\,G. VH0C)Z#YA7/6FN1HTIQ?,F?HTOW!]*?4"W4(4#S8^G]X4OVJ'_GO'_W MT*^=/:)J*B6XC=@%D1CZ!@:D% "=J\;TW_D[76/^Q4@_]*6KV3M7C>F_\G:Z MQ_V*D'_I2U5#KZ$RZ&OX%_UGBC_L,R_^@I7FGCS]IZ7P5XP\4Z3;^ =6U_2O M"\,$^L:O8SIB".5=VY8SRVT DXKTOP)_K/%'I_;,P/\ WRE>%7GP&U7XE?'; MXJ_VOKFO>'O!^I1:?')::?B.'5D6,AE+D9&/NG'8URR5ZCN>A%OV:L>_V_CG MP[S6XN$CDF6093:A..NY0+XFTKQUHEM?(\TVGK!:M<.KKNEN WI4N.]A M\[MJ?6]SXTTKR]5BT[4+#5=6TV%Y9M+M[V,S(0,[6&?D)]3P*;I_C;2Y=-T6 M75+VQT2^U6)7AT^XO(_,+$?<7GY\>HX-?,WP?T6TL_AAK7AC_A5NL:)\0K;0 MKRWU/7)[7:MY.V[=MFS^]\P\CZUDKX3U?PWY\@W5S=Q^6 MZ8SYC<_NQ[-S5^W\5:)=:;%J4.MZ;+IDC;$OEO(S S>@?.,^V:^3?'?P]\0M MJOC'4KKPQJ6O>&(O'D.J:EHUODOJ-B(0"T:Y_>*KX.WOBL+4/A1>^-KK5+_2 M? FI:'\/M7\5Z3-;^&KB(PMMB!%Q=&$']TAXX[XHY4^H M:3J%IJEHV0MQ93K+&2.HW*3S7F/B3X]7,/C#4O"_@SP3JGCW5-(V_P!J/9R) M!;VC,,B+S'^\^.PJG\"? [> /BA\7+>ST9M$\+SW]K/I<21[+9SY7[QHA_O= M<=Z\QU[1=0^&-]\1_#6O>&O%>L^'?%NK/KNF:YX2R9DD9>;>4J=R%6 P>A%/ ME2D"D^6[/I2Q\:6L?A6SUOQ'&/!WGC][:ZQ.D;0/TV,Q."?I5^_\3:-I=G'= M7FLZ=:6DD?F13W%VB1R)_?5B>5^E?&U]\/?'MOX9^#^I>+DUR[L-.T^\M]0M MUM!J-S;3R/F%YHC]_*?*3_":ZKP_\";&X\1_!73;[1=6U[PII\&J33_\)#'S M;-*,HDJ#@#/W5[<4635PYV?4,_B#2K?1QJ\VJ64>D[!(-0:X06Y0]#O)V\_6 MDC\0Z3<:7'J::OI[Z9*<1WRW2&!SZ!\X_6OCFU^'.M^'_A[X-_MCP;JFM^"_ M#_B_4YK_ ,,PH9'-HS$6LB19^>)3R$]*BNOA+K/B'X=^*!9>#=0TCP=KOC73 M[W3?"TJE)8+9&433&,']VC$$[:.5"<]-#[ 3QSX:FAM98_$>CR174WD0.+^( MB60=40[N6]JATWQ<+C5O$=M?VL>DV6C,O^GW%T@CFC9#8;'5)+O3;"/1_-C:?RR";BTZ&-N@SWYKOM<;XBZA M^RFW]DZ#;Z)\0)=-4'1K/"K&I;#I$#PK&/H#T)H?NE!=:TNP M\ >#/%FE?"Q]6MM0UO[=:B/5;2<#:T,;$YF@9B">R\XK[Y=A(Q91M5_F"^@J MI15DQ0EJQ*:W^K?Z'^5.IK?ZM_H?Y5GU1L]F4^(OVHOACX3\<0>$-8 M\4+9:W/.+6,2VT@@$QZ1&7&T-[9JQ\1OVEOAO\)?$$&B>*_$7]EZA(8PQ^S2 M210^8<(9) -J;NV31J3SH].HJK-J-M;:>]_-.BV*0F=KC=E/*"[M^?3%>>?# M[]I;X;_%+Q=>>&/#?B+[5X@MH_--C<6\D$DD?]]-P&]?<4F453TG4H-:TNSU&VW MM:7D*SQ&1"K%&&5)!Z<=JN4BM]0HHHH QO#X_P"+K:O_ -@FW_\ 1DE>@+7 M>'_^2KZO_P!@FW_]&25WZUU+9'FS^)BT444R!#7C'[+?_(E>(/\ L9-2_P#1 M[5[-7C/[+?\ R)7B#_L9-2_]'M5Q^"7JB>J/9E[BG4Q>].W5!0M%-W"G4 %% M%% !1110 44E+0 4WO3J3UH ^)/B'\*?$\_Q$^)?AJWT2^?_ (3;5-/OK+7T M^:&&./'F;F_@*[<8[YKLOBQI>K2>+/!?Q!C\/ZMJ-MH$%YHTVFQINE9WC*). M$Z%2>_I7U+L.W /OS1L.XD'''3/7WH \G_97\!ZK\-_@AX?T768S#J2B2>6 MG_5>8Y8)^ (KT#7O"&F>))(9+^V\V6'.R120PSU&1VK;1=J]^2^@EMU* M(UMQ[UQ'CKQ)I_Q8\6:UIMM87>FVF@&X_LO0X]-8/=3A@9;AI,= M" P"YYS7H6FZ7I'Q<;XBW\.DR7?AF;P];6?DS0-$)[B-"V-N!DJ1C-/F?<5E MV*/B+X(_ _PM:Z5-=G:?L;?#J\MH;B M"YU::&5 Z2)?,0RGH17B_P ;]&E;PGX-AO9-2T"VC\(B"*?3[,S274V1_HC# M!V@XK[&^&Z31^ ?#B7%G]@G73X ]MT,1"#BCGEW#ECV/+++]C/P#9WL%R'U6 M1H9!(JR7C%<@Y%>F?\*OT!O^7>4?]MF_QKK5Z4M3S.6XTE'8Y#_A5OA__GA- M_P!_6H_X5;X?_P">$W_?UJZX=*6D,Y#_ (5;X?\ ^>$W_?UJ/^%6Z O/V>7_ M +_-77TAZ4 >9^,?@#X5\<:,-.U"*[6$2"56AN&5@1[UQ;?L5?#_ .\9=8X_ MZ?6KZ VTC?=/>GS-;"Y4]SY/\8_ ?X)^ M4M=/UW7=4L;NX 9(VO'.U2< M@ M<#W--T[X%_!#5O%I\-V>NZE<:KVC2]--)C\66'@F:V MN='&L6\;ZMXBATYKAVM5?BVC('#,>OH*QOAK:V5MJ7AOP7I^FWD6L:?XGEU" M6:6V88LS&=K^9CH591UZBJYY=Q:/_:6B:CJUY:^88V9;UPR..JLIY!^M/P MWX:^*_\ 9MC/HT-EXFM]4LGBM3)'Y@()E9/XTSUKT']DN#5[_2O&6OZHYE76 M=8:>WE%M]G#J$ +*G8$@XI-R*]*TOX.^'-) MTVTLH;>?R;:,1)NF8G _&NWQ3J3DWN-)+8Y#_A5OA_\ YX3?]_6JAKGPYT2R MT._FBAF5TA9@WG-P0#[UWU8_BK_D6M2_ZX-_*D,YG0?AOH=YHEA-)#,TCPJS M-YKZ?R%:M '$7WPB\.ZAI]U M:RV\WEW$9C?$K9P1CUKS9_V*_A_@#S=751T47K5] 4UO6FI..PG%2W/F'QA^ MR[\)O NBOJFN:EJUG8JRIN:\8EF/15 Y)^EN4CV MW7.-P'4H2,,!ZBO/9M3\,>*M2TOX9:IX?O=(BTM89M0F73W+:I MJ(A BVR ?<0]6SUKTWX'WMMK'BKP!IUAI=Q;WOAS3[N+5)IK4CO^^:NOHJ1GF/A? MX?Z-?2ZT)8Y6\J]>*/\ >M\J@# ZUO\ _"K= _YX3?\ ?UJE\$_Z_7O^PB__ M *"*ZJ@#D/\ A5V@+R+>4_\ ;5JX'Q)^R1X%\3:M<1_#O]GZ6VO9AXEU M0+:G!5KJ0/+SC,8QEQGTKZ[UZ>&UT:_EN8VFMXX'>6)1DNH4Y4#OD5\&Z;X] MTGQK\4?#/C[4K&\L]/T*[$%KH4.F.J:=9D,N^7Y?G;=M/M3YY]6*R['HVI_! MWX$:/H.F:Q<^(]06SU+/V7;>.TDF/O80#/'?CBKY^ ?P16XT& >);N2;7N=- MCCU(EKD8ZJ.XKD_&GC_2_!W@6UGC\.W$6L>)]1O_ .S-5:P:8:98RL=\A&/E M++G"XYS5W5OASX>TG5/V=M0\%Z5=W=A:7C0KJ$L+>"O!>M?VG8IJ$ESY1BS-=,PP>]>Q>M+GVJ> M:7> -'C\::;9 M+%,+=K:1V3S6Y8$8/6M[_A5N@MSY,O\ W]:I;[_DH6E_]>DG\Q74CI0!R/\ MPJW0/^?>7_O\UU-;;2U\R[DFO'C")S\_(Y4XZBLR/X;_L_SZ/- MJ$7B?4IXX91 \*74AF5R,@>7C/3GI6AH/C#1WDO?$[:+>:EH7A_PC!87]DUD MRF>Z5@1"%(^8@KUYZUPFC_$K0?"^AZ_X[L=.N;[Q_P")KY(&GETJ3[-I *80 M[=OS!%P"0.33YY=QQ[!X=_90^%GC#1[?5=(U'5+VPN!F.>.^8@\X(]B#U MK$W_ M ']:NOHJ1G-:5X#TG1KZ.[M8I$F0$#=(2#^%=(.E+10 WM7C>F_\G:ZQ_P!B MI!_Z4M7LG:O&]-_Y.VUC_L5(/_2EJJ'7T)ET-?P+S)XG_P"PS-_Z"E:-_P", MM TN^CT^^\0:78WIQMM+J\CBDYZ?(3W[5G^ U_>>)S_U&I?_ $%:\-TOX9># M/B%^T%\,]?FOGFUF\MED)MK?[A6( M-@2OD9&>,&ERZVN7S::GTPVJP+=163WT:W;+OBM3,!(RCJP4\D>XI;K58+-8 MQ=7T5J)WV1^=($\QST49/)]NM>">)?$/BS1/BIX4T>%-%\2>*W\+:A,E_P"2 M(_/N8SA%5L_(I/5?6N*A^+FMZEI7ANQ\27L.K>+K;Q58V^I:3JNE"&72O,1C M^[ .&&0=K@]*23Z@I(^M?,,9!+%67@>W>E\YF8DN2Q'4G)/M7R?=_'CXCKX5 MD^*BZOHX\)+XB_L8>#VMQY[0>?Y)/G9SYV?FVXI?&OQE^*>GS_%#Q'I6NZ5; M^&O ^K6UO'H\UCNFO8I!'N1Y,_*1OX(]*?(VQ*2Z'U7-SN%E1O494UYY\=O US\6OA+-HMA MJUOH5Y??9[FW:\.()G!606\O(RC_ '2!R0:\8\+_ !6;P#:3^'+#PCIGP^\5 M67BC3M.\1:?8R":PGCN!@2P'HNX=NH]ZE;NXV_Q/K/S&23F[O",^GQ:8TRAHXC/L$@F/?EOPKGO' MGQP^*/PI'B[2M0UW0_$6I)HEMKNFZA':B*.T+S)&T4R@\H=V58^E/E>PYSS7R]JGQP\>_"'5/%UEXJU'2O&QM_"P\2V$E MC!Y'V5S($,4@!.8\G<&]*OZ3\3/B)X'\:>&=)\5>(M)\66WBO0KK5+;^S[00 MOITT40D &"=\1#8R?2CE<1*6NQ](^9M53O"@?=^;&/84HG+;?G)(Z<]*^']> MU3XK>// 'P<\6:YX_M;&77O$UKY%OIEB(X[;+,HWL3\_ Z'@U]M6T,EO;QQ3 MS_:KA %DN, "5@.6P.G/:BUAQDI,L>?)OW[VS]:9SD'))'O1126FYM9#_.D9 MLF1R<=VIGO112UM9C22"FG[C_P"Z?_0:=33]Q_\ =/\ Z#1V%+8YCX6_\D[T M7_KDW_H;5U-GUS4;H9\&_M0?% M#P9\;?C;H_PAO=;TOPAX3\+:G#J_B'7+Y#'+=72'Y+6W^7YB<_,V:O\ _!0? MQC8:IX4U;P]IGCO2K/R(;66Z\$S:67O=:PRM&D4X7=AE[@XZ]*^R[SP;X>U" MN2.O%6)_#^EW5[!>7&E6-S>6XQ#<36R-)'_ +K$ M9 ';%7HK(P=.3;/)O"OCOQ[#:Z)/JWP^TW0/AS#HD=U=WMQJ!>[M46 ,8S!C MYL%_%WPXUG3=5U_P *ZA#XEN[JZC9K MMYY"9KS>HX11P%Z\5-KGA>V^'%GJ?BC0+VZ\3> M+UFSTI-5\3!A:WUU""D3 MS*@!-I; ;0<-V[TQ6[)]QP.3@_RK\O=)\ M_%&X^."P3>%]1&D?\)!).+MD('E[^#N_NU5&G&:DVQ2E:Q^EE]XST+3=:M-' MN]6L[;5;SF"SDF42/CT&:VMVU>:^1O""_#B2'Q2WQ FB;QO%KC*R3RD7ZC>H M@$(Z[2,?=XZU%X\^)GB/2_$NO:]!XV^P7>E:BNFVW@TJI,\&T 2E?O$D'=D< M?+66Q9]?;CD8!H+'CBOAM?$'Q):WBG?XBZAG_A'5\2-&(%YD$VWR>GW"*I>$ M_'7Q.^)6H6L[>/[K1X-8UB?38[>U@4BTC6#S PR.6R/UH ^Y]0U*VT>QFN[V MXCM;6%=TDLI 5%]2:?9ZA!J-K'IKH?V0O'EOXP_9_P!8L/#^GW^G M7F@M<6*I?.6E>X"$[U!_@+'Y>V,4 ?0$'C;0[KQ%+H,.KV';/X&:+?\ A%XY_C(E_&9/)?.I-<&0B59 ?FV[?7C%17_Q MP\<>#?!@\4:;XT/B_7M0BNH+GP_A3_9I1L"4A>5V>_!H ^]/,]J1GV@DG ]Z M^&?!/Q+^(>O^%=*TJ3QC*+K4=;M81JL3)+,B.A9T.T;0O' //-54^-GBCQ/X M^U_2[7Q)?7NC7UGJ&GAV5(Q"T"G#Q(/F#9')- 'W%:ZU97M]:X M2"-Y)7$<2C<7;@"BWN$NHUDC=9(V&Y'4Y!'KFOACP!\;/$OCK6/%<-UK-UJN MA:MX=N[N$7 6-8G3(!B0?,HQQ@\U]=_"!B?A;X29F+-_9EON)/.=@S0!V=%) MN'K1F@!:CD^Z:?FJM^T:V<[32"* (V^1C@*N.3F@#-TW6-%UB\NX=/NK&[NK M1S'<+"RL\;>C8]JL6M]IK6TLEO-:FUA+"5XF78K?Q XX!KXFL]6TNX\::]XM M^%TL,BV%I)HT6D:;.F>B<[2:@^&_AU-;_ &7_ (@VT$NN:/%I M&LW5P4FF99KE_E/[QNI&[G H ^W]4U+3=-TU[_4)K>WL(%$AN)ROEH.S9/2H M_#?BC2/%U@NH:)J-MJEBQ*BXM7#H6!Y&:\0^/T>C^,?@?8>&+_Q=9>%I+I+) MI[F[RRJA .''8-C&3Q6Y^R_)#;^$=4T>UMM/6STF_:T@U#24"VU^ H/FJ/7G M!(H ]MHIJ_=%+F@!:*3-&: %HI,T9H 6D;[IHS37;Y3CF@#'GU;2)]:&D27- MG)JNSS19L5:0)_>P>:AL_$^@WGV^:UU*QD6PREU)'(I\C'9CVKYCUO\ X0SQ M1\>+[P]X4UNVTW7[%9;O5-=DN]]RTK(56UB4G)"]2!T%>,:MJ$EGIXT[3(=/ ML;46*VFK7]E=&2&607 "W%W_ '5;!)!YZT ?H?INJ6&O:;'>V%U!>V4XRL\+ M!D<=.O>HM#U[2=>AE?2;^UOHH)/(N.]/\ V0XQI7BG4K%;K3;Y9M$M;@R:(Q\B M,Y(*R\G]]ZGK0!]7KTI::K?**7- "UC^*O\ D6=3_P"N#_RK8K'\5?\ (M:G M_P!<&_E0!)X7_P"1=TS_ *]T_D*U*RO"_P#R+NF?]>Z?R%:F: %I&Z49IK,- MO!H R]9U;3-*AB;5+NVM8YI!#&;E@H9ST4 ]35>ZUK0].U*STFYNK&WU"YR] MK9R% \A'=1_6O(_VJ(?#USX3G&I7-G;:_%:32:8=08K&2 "P3D#S<#Y:^=H] M6N-7OKSQ/J,EK'>PM9V]II.J;O[39'C"^9%SD8)SP* /N;3=:T36M0O;:RNK M*\O;%PMS%&RM)"W8-[U=DFM;&9%=X89KE\(.$:0XS^-?'_P+UJ#2?B=HT:VU MA86NGV5X-4UJUN_,-]AAB2"=0U/3=5M-&CU26R MTF,+_HSQ&(DW!(^]N[>@H ^S4^[3J2C- "TUNWUI, M/"GAG3X[_5-3TO3K*Z;9'/.Z*DI] >]<'^TYXE\4Z%X$CLO"VE7FH3:I(UM= MW5F-SVMN5.]Q_M$<"OG:XTG2?%7P:^'LU]JUEH?]AZ=>36^F^)XO,%\5 M6.,8Z\T ?9C>)?#WVC3K274=/,^H1[[*!W7,Z^J ]1]*UII[73[??.T5O"I" MAG(4!CP!]:^$_&VK7=WJEOJL&D6/]N:Y8:=+I\+S>5=Z+M*KY<,75E?EOE_& MNN_:U\9:AK%Q:64=CJE]H>A-:SS76E-E)+TRH#'(1TVCM[T ?9$?'4U)5/39 M#<:?;3%2IDB1RIZ@D U:W"@!U%)FC- '+7W_ "4+2_\ KTD_F*ZJN5OO^2A: M7_UZ2?S%=3F@!:*3-&: &2-M .>G6N0;XC>"I&OY#KVDN^F?-=OYJ'[/S@%C MVK5\:/Y?A/66,_V8"SE!FVEC'E3\V!R<>U?&7PCDT+X>:?J_AQK?2/B%HE]H M4NJ7WB&U@VA)%)*P7.>Y;& >: /K4_$[P1#H;:M_PD6D)I!E\MKH3((BY_A) M]:V%U71%T/\ M?S[$:08_/\ MF%$13'WL^E?'6H_ #P_H/@/P58W7B+1?#TM MZMSK=Q:ZK#F"ZF=0P09.T!00N.N.E=3\1/%1\8?!+P%IEM)IWA_[3>6RZE;2 M<6UM;Y(#NO\ SS.!C/'- 'U/HNI6&L:?;WNF3P7-C,NZ.6W(*,#Z$5IUXS^S M/<(_@F_L((;7R--U.:U2\L&_T:[ P?,C'8<]N,BO9: %HI,T9H 6BDS2T -[ M"O&M._Y.VUC_ +%2#_TH:O9>U>-:?_R=MJ__ &*L/_I0U73^UZ$RZ&QX#^]X MHX_YC$W'_ 5KFO%O[-OPY\=>++OQ'K>A-=ZO>+&MU(EU)''<+&,()$4@,.HQ M5K0_%EEX5U3Q+9:E:ZC#.^JR3+Y5FSJZ%5PP([5K?\+0T/\ YY:K_P" #USR MC+FNCMIRCRJ+&^*OA+X0\::'IND:CHD*V.ED-IRVC&%[,@8_=LI!4$=JS-?^ M /@'Q1X3T_PYJ6A"XTS3Y#-:'[0ZSPR$89EE!W9.>>:U?^%H:'_SQU7_ , ' MH_X6AH?_ #QU7_P >CV.J?^ $E3R3N/FIF+_P ,[_#G_A.#XO/A>!M=\_[7 MN\QO($__ #V\K.S?WW8[5KWWPE\(:AIWB2QN-&CDM?$DRW.K(7.+J1<89O\ MOD=/2G?\+/T3_GCJW_@ ]'_"T-#_ .>.J_\ @ ].,*@E*FB[XN\ Z#X^\--X M?U_3UOM(9440!RA3;PI# @@CM7-6_P"SS\.K3P1J'A%/#<+:%J$HGNHWD9II MIA]V5I2=VX8X.>*V/^%H:)_SQU7_ , 'H_X6AHG_ #QU7_P >DH2[#YZ9Y[X MX_9;\,77PK\4^$_!FFVNB3^(&MC>SW+O(+A8I%;YR22QV@C/O4?C#]E/PO-\ M*/$GA7P?IUKI%_K@MTN[R\D>;>D;*QC+,2=N 0 ..:]&_P"%H:'_ ,\M5_\ M !Z/^%GZ&>D6JY_Z\'I\DT+FI]S,\#? ?P)\/-/U.UT?PY;QC5H%@U$W#-.9 MT"X\O+D_(/[HXJ/P1^S[\/?AS<7UQX?\/);7%W UI)++*\K+ W6)"Q.U#GH, M5K_\+0T3_GEJO_@ ]'_"T-$_YXZK_P" #T>SFP4J97UCX,^"]>^']IX(OM#C ME\,694VUBDC*865MRLK@Y5@.J?^ $E'_"T-$_YXZK_X /1[.8*5-'549KE/^%H:)_SQU7_P M7O1_PM#1/^>.J_\ @ ]+DF:<\.YU>:6N3_X6AHG_ #QU7_P >C_A9VB?\\=4 M_P# "2CV<^Q/M(=SJ\T-_JW_ -T_RKE/^%H:'_SQU7_P >@_$_0R'_=:H>"/ M^/"3GBCV<]- ]K"VY)\+?^2>:'_UR;_T-JZBO,_A_P#$#2])\%Z59W=KJL-S M#&P=#I[G:=QKH/\ A:&A_P#/'5/_ DIRISYMA*I"VYU>:6N3_X6AHG_/'5 M?_ !Z7_A:&A_\\M5_P# !Z7LYA[2!U6:6N3_ .%H:)_SQU7_ , 'H_X6=H?_ M #QU3_P >E[.?8?M(]SK,T5R?_"S]$_YXZK_ ."]Z/\ A9^A_P#/'5/_ D MI^RD'M(]SK**Y/\ X6?H?_/'5/\ P >E_P"%H:'_ ,\-5_\ !>]'LIC]I#N= M717)_P#"T-#_ .>&J_\ @ ]+_P +.T3_ )XZI_X 24>SGV#VL'U.JS2UR?\ MPM#1/^>.J_\ @ ]#?%#0_P#GEJG_ ( 24>SF"J1-/P[_ ,E5U?\ [!-O_P"C M)*] 6O,? NK1^(/B%K&H6=O=I9C3K>'SKJ!H\N')K[P3H M%WXBM/\ 4:C(^94P.,''7TS3[OP#_:'BM/$]SX*T.?Q"L?DC49'S*$Z8SCG@ MU\DZQ>>(;KQA?W,%MKUI>2>+8[2S\3OJ!6PBY7,;QY^Z1E<>IKW#6OVC/%-G MXVUBUL-&CN=%TG41ID^^,KYAVY>;SU=(CU?^P=250G_ BNC!/(^RC$ MO2+.=G3IGG%1V/AN]T_R3:^$]%A\J4S(8Y,8-?VB/$OB#0=4 MTJ2>&/SK2'48+[3D:+R?WZJ8PQ^^"/XA7;?M&^(M9\'WF@W>F7T\4WB/26T2 M*/S2%^TR%2CJ/[P&>: /5-8\(W6O^'9/#]_X3T6[T-F!-E)(3&QSGICUJWI. MEZOX?+G3O#>DV32*J.MO,4WA.%' [#O7REX7^)GC'PGJ=GILMY=:I)X"TV2S MU!+AR%N;Z63;#YQS_=.ZO1O%'[0'Q!\+>+]&\%S6&CW6OZAJD-I]K0MY/D21 M&3=C/WA@T >IVWP]%GXME\40>#=#A\1S(4?5(WQ.01SDXZ^]8W@7X,VGPY74 M'TGPAHXNK_S#=WD\V99Q(Q9U8XZ9)KY>USXN^.(_@/X[TS2-55[C2'EN[[4+ MB9A/M>X"A83G@ 9_E7H?[1UCK_BB'X2:=I>GZOXC-QIKSW%AINJ?87EQ$I\Q MG[]2<4 >[:!X 'A>U%MH_@K0[&V2X-VB0R8 F/\ 'TZ]OQIMG\/8],UB[U2U M\$: FIW6[S[B.3#.6&&)X[]_6O,-+^+FH? OPYH7AO5=(ETZ[O\ 3MVD6>HW MAN9Y+LR;6@:7^+@@_A3+GXF^*[CXA>-/"'AU+6#5U@>^N)KZ1GC55BY2,9X. M3U[4 >DWGPFL+[0;C1I_ /A^32[@J9K7=\CE<[<\=JVH?#=_';?98_"NBQVQ MA2W,(?Y3&A^12,=!Z5\Y>"/VLO$@>'1+#17UB/0([*VU.3!>:X>9*WM]&TZ*WC4)'&MP0$ & ,8KQ M?QA\>O'7@[6K'PG=66FW'B-UGN9+JS5IHVAC&5!0D"UO'+W,0E^60GJS<[MOL2/'^ZM3*@" M(JCG:,@D^U?,6F^+/&/C#0]"\%:-XBU;QB]UX@U"ZN[J*[^RR3;5#"/>>D:Y M. /2F!]T:UX.G\1VUS;ZIX/T2_@N(%M)HYWSYD(Z+TZ U=\/:7J_A'2+?2]& M\.Z3INFVJ[(;>WG(11[#%>0?$]O$GC+]D_2=.\&7LW]NZD+>S$EY>B"?&[#K MYN?O<$9[UU?[*<0T?P'>^'IK:]M-6T:^>VOXKV[-T?,P#E9#U!!%(#TC[=XM M[:3IX_[>3_A1]M\6_P#0)T__ ,"3_A74J!M%+Q0!ROV[Q=_T"=/_ / D_P"% M'V[Q=_T"=/\ _ D_X5U7%'% '*_;O%W_ $"=/_\ D_X4?;O%W_0)T__ ,"3 M_A75<4<4 +LU_PS\<#<)JK3:>*==M]3;6?$NEK=:9;7>H-<6MT[28\QE'^JVY_*@#ZNTOP* M^B^'[30['P7H=MI%H^^"S64[$;U QUJ3PCX)E\!1WB>'?!^B:,MU*9KA;24K MYK=F) KQ_P"#OQ(UB?\ 99\;:[_:_P#;6O65Q??Z6S$*).P'LN3CZ5N_L\:; M=>"?&CZ"FKZAK5AJ&@VVLS2ZA<&8K<.QW;3G@'TH ]D^W>+O^@5I_P#X$'_" ME^W>+O\ H$Z?_P"!)_PKJ5^[2\4 &]2_ZX-_*@#G=!O/%*Z'IXATRP>/R5P3.?3Z5 M?^W>+O\ H$Z?_P"!)_PK5\+X_P"$=TW_ *]T_D*U>* .5^W>+O\ H$Z?_P"! M)_PH^W>+?^@3I_\ X$'_ KJN*0@4 ><^*?"][XXMK>VU_PIH^K06\RSPK^!VU3Q18^(KSP;H<^NV*%+6]:3,D2] <=*S?VFFUFW\ VUU MH^L2:0(-2M&N?('[R9#,H,8;L#G%>$_?$S?'B76].N=0A\.Z1=6=M=:U# M>;(--8J-\3V__+3.0=W:F!]!Z7\.(]&EUF2Q\$Z#;R:L2=0:*0@W.3R&X[YS M6XUKKS"Q#:!I+&R'^BYF/[KC&%]/EKQ_X8Z-J/@7]H(VXU6_U'P]K6F27$6H MWEZ)X[Z<,&8HO_+,*#BO/M+\1>*]2_:(N?%.L_VI;^&K?Q'_ &'!=6]^! AQ MA$^S]PQ."?>D!]8_;O%G_0)T_P#\"3_A2?;O%W_0)T__ ,"3_A74TO% '*_; MO%W_ $"=/_\ D_X4HOO%N>=*T_'_7P>OY5U/%)CWH \U\)7GB99M;\G3;)R M;]]^ZY22ZN+&41S7"@\0JW^T>,#DU\^Q^'_$OB33]&\,Z]K>KZ#IUAHU[K MEBZWI6YPKCR!,V?FPO4>] 'T9J'@F35?$VG>(;[P?H4^MZ:NRTOFE_>0@=E. M/_U5?CT?5%M[JW_X1G2%M[N7[1/&9B!+)D')X^]D#\J^3?&$?B7Q-KWA7XCZ MV;R?PSI&FV/VV&SU8PO#(S ;VB'WL\'GKFN^_:4NK]O&EQJDUWK2Z98:(MWH MRZ/*0@N]V2;@ ]-N,;N.M,#Z(6^\68 &DV ';%R>W;I3OMWBW_H$Z?\ ^!!_ MPK0\(ZA-JGA71[VY&VYN+2&65?\ :9 3^M;7%(#E?MWB[_H$Z?\ ^!)_PI?M MWBW_ *!.G_\ @2?\*ZGBB@#S6]O/$W_";::3IMCY_P!EDPOGG&,CVKH/MWBW M_H%V'_?\_P"%+?$?\+"TO_KTD_F*ZGTH Y7[;XM_Z!.G_P#@2?\ "C[=XM_Z M!.G_ /@2?\*ZKBB@#DI+WQ7(C*VD:C^!6\/V^IVNF^#-" MLK?5)#)?1POA9G/.6&.:[_Q!;O=Z-?0QW9L'E@=!=#K#D??_ ZU\G_#GP%< M75SXHM-(^(&L:EX*N;1;.ZUR[O1YE[J <[A;L?N#&%)% 'N?BGP/+XXTVUT_ MQ#X.T35K*U=98(9Y"PC9> 5XX&*75/!4NM6=W:W_ (.T.XM[NW6UN(Y)/EDA M7E4Z=!7S7X'O/&=Y^SWX[TI?%=_H.J^&=9D$T$[>?PWET;EDE4Y.V0_>!R*]JXH Y7[=XN_Z!.G_P#@2?\ "E^W>+?^@3I_ M_@2?\*ZGBCB@#GM-NO$,E\HO]/LX+7'+Q3%FS],5T*_=%(<-UYI=P]: 5XQ MI_\ R=IJ_P#V*D/_ *4-7L]>,Z=_R=MJ_P#V*L/_ *4-5PZ^AG/IZG5ZU\:/ M ?AW5+C3=4\7:18ZA;';-;7%PJNA]"#TJK_PT%\,O^AXT/\ \"TKB?@YX3T3 M7/'GQ;FU'1[&^E7Q'M$EU DCX$$?&2.F?YUZO_PKGPI_T+6D_P#@%'_A0U%: M,I7>ISO_ T%\,?^AXT+_P "DI?^&@OAE_T/&A_^!25T7_"N?"G_ $+6D_\ M@%'_ (4UOAYX349/AO1P/4VISW_ T%\,?^AWT+_P "TI?^&@OA ME_T/&A?^!25T'_"NO"??PUI!_P"W*/\ PH_X5SX3_P"A;TC_ , H_P#"E[GF M&IS_ /PT%\,O^AXT+_P+2D_X:"^&?_0\:'_X%)6Y=>!?!ME"9;G0-%MX5X,D MMK$JC/3DBI%^'?A!@"OAO1R",@BSCY_2JM#S%[QS_P#PT%\,_P#H>-#_ / I M*/\ AH/X9?\ 0[Z'_P"!:5M1>!O!=Q/+#%H.AR31?ZR-+:(LGU&.*G_X5WX3 M/_,M:3_X!1_X46AYA[QS_P#PT%\,O^AWT/\ \"TH_P"&@OAE_P!#QH?_ (%) M70_\*[\*?]"UI/\ X!1_X4G_ KOPI_T+6D_^ 4?^%'N>8]3G_\ AH3X8_\ M0\:%_P"!:4?\-!?#+_H>-"_\"DKH/^%=^%/^A:TG_P H_\ "HKGP+X,LX_, MGT'1((\XW2VL2C/IDBE[GF&IB?\ #07PR_Z'C0__ *2C_AH+X9?]#QH?_@4 ME= /AYX3(!'AO2,8SG[''_A2?\*]\),H(\.:.0>F+.,_TIVAYAJ8'_#07PR_ MZ'C0_P#P+2C_ (:"^&7_ $/&A_\ @6E;Z_#OPDV?^*=T8O>.?_ .&@/AG_ -#QH?\ X%I1_P - ?#/_H>-#_\ M M*V[GP-X-LXS)<:!HMO&#C?+:Q*,GH,D5(/A[X28 CPWHY!Y!^QQ_X4>YYA M[WD<_P#\-!?#/_H>-#_\"DH_X:!^&?\ T/&A_P#@4E=#_P *[\*?]"UI'_@% M'_A1_P *[\*?]"UI/_@''_\ $T6CYAKY'/\ _#07PS//_"<:'_X%I1_PT%\, MC_S/&A_^!25OM\/?"2L%;PYHZLW0&SCR?TH_X5WX4_Z%O2/_ #C_P *+1\P MU\C '[07PS_Z'?0__ M*/^&@OAE_T.^A?^!:5OCX=^$^_AK2!_VYQ_X4O_"N M_"?_ $+6D_\ @''_ (4_<\P]XY__ (:"^&7_ $/&A_\ @4E)_P - _#/_H>= M#_\ I*Z'_A7?A/_ *%K2<_]>4?_ ,34,O@;P9!+'%+H.B1S2<(CVL09_H,< MT6AYCU,7_AH'X9_]#QH?_@4E'_#07PR_Z'?0_P#P+2N@_P"%=>%./^*:TC_P M"C_PH_X5WX3_ .A:TC_P"C_^)H]SS#4Y_P#X:#^&/_0\:%_X%I1_PT%\,O\ MH>-#_P# I*Z'_A7?A/K_ ,(UI'_@''_A1_PKOPG_ -"UI'_@%'_A1[GF&ISW M_#07PR_Z'C0__ I*/^&@OAE_T/&A_P#@6E;Z_#WPD_*^'-';Z6-#_P# I*/^&@OAE_T/&AY_Z^DK MH?\ A6_A/_H6=(_\ H__ (FC_A7/A3_H6=)_\ H__B:7N>96HSPG\1/#/C@W M \.Z]8:S]FQYPLY@^S/3=BNG7I7A?PST>QT?]I+XD0:?96]C"--T_P#=6T8C M7^/G XR:]S7[M$ERNP(=1114C&CO7C7[+?\ R)/B#_L9-2_]'M7LH[UXS^RU M_P B3X@_[&34O_2AJTC\$OD3U15^,7[3FF?"?QA9^&(_#VK>(]:NK8W7D:9# MYFR,'&3S7 _\-6V<O, M[?\ ;*UVY\;)H"WD#7_]LM9?9_LPV>2'QU]:X:-&MB93<9V47V/I<14P.7TZ M,9T.=RBFWS-;]#H+GX\:'>>'M2T27X,^+'TS4;@W=Q#]C.&EW [P<\'('2LJ MZ^+7AK4-6DU&7X0>-G>0CSX/*<03,!MWNF<,<=Z]-\%Q>(?B98ZUXMNO'=UH M;Z?J\MM;V<)5;2&.-P-LBG[VX?SK@?$W[0OB3PK\7=7M5F;5+>"2Z^S6I;9# MA4&U2.XR>M5[*JM.?\#'ZY@/^@7_ ,F9B6?Q$\&V*LO_ IKQE*)-&;5/@[XKO&T>X6[LM]C_J9%& P]>*VS^T%X MHT"8KXVTFVTS4=+N)5EATV4O%<1M$KQ$_7<..U,\5?'[XD>"?!<=YKVA>']- MU6^D$FGM]H,L'K@^ M)3)\%_%1/B0H^IL+,@W#*,*2<\$ #I65IOQ1\*Z/27S0NT$L3DX7M7K7P'^*6K?&;Q%K4US,]EI]QI%M)':Q#'V>9EP[(>O6LN MRT75O!?B?Q[J4OC'Q!J]MX7MTNK:QN[D-',6C+%7XYY%'LZO_/S\!_7,!_T" M_P#DS/)M8\9> M>LS;77P1\7"W=W>:.&W=1/N;<1)@_,-W//2MKQM\9/#WCR M'1AJGPE\<1?V3&8K*:SB>%XE( *Y4], 5LZ]^TCXZ\*G2I-:LM%T[5-6TT7D M$#2O) L9(*@*!DN1U/2NJ^ _QDUOXH_&._6ZD\C1Y/#5K>KIX'R17#.5=E^N M*/9U/^?C^X7US ?] O\ Y,SSU?B_X7>P\.6EW\&O&&I+X>G^U:;)?6[RR02D MYW;B6D+Q2/D;2"5.2IZ8K[;\M/[ MH_(4OEI_=7\A1[.K_/\ @'UW _\ 0+_Y,SX;A^)G@ZSU>UU&V^"WBZSGMXHX MBMM;LJW C V&4 _.5'0FGZM\3O!NM6ME!>?!/Q8RV#2O:,EJP:%I&W,RG/!S M7W!Y:?W%_(4OEI_=7\A1[.K_ #_@'UW _P#0+_Y,SX5G^(GA2?38K5OA)XZ\ MV.5I_MZHXNG+?>#2@[B.V*]#TG]KP:+IMO8V?PK\7Q6MO&(XD^QDX4#W-?4W MEI_=7\J/*3^ZOY4O9U?Y_P !_7#\+O%V/^O'_P"O7TWY2?W5_*H+F,K# M)Y03S0IV;AQNQQFCV=7^?\ ^N8#_ *!?_)F?*4/[4&GPZAJEY_PI_P 5//JA M1KLR6!<2E1A<@GL*Y&_^)?@N^L?LJ_!'Q99#[4]ZLUG:M%(LC_>(8'(STQ7H MNC?$[XAZ7\9M;\"W%W9:SJ/]AR:C!'=6X@B2XS\J1-_'&!C-<_H'[3WB5?V; M],U/5)+"3XFZQ)>6]G&J;+8/"Y#.?]A0.OK3]G4_Y^?@'US _P#0+_Y,S%UK MXO\ A?Q#I,>EW?P<\9"SAA2&*.*!T,6PY1DP>'!_BZUO>#?VF++P+I?]G:1\ M)_&$<32&61I+4O)*YQ\SL3DGCOZ5[A+/XJ\7?";0KO0-1M+#6[ZWMYKB^:$2 M*JE09"B]V]*I?L\>-]1\?>"KR?59OM5U9:C-9>=)#Y4LBHV 9$_A8TO9U?\ MGY^ ?7,!_P! O_DS/._^&TKGM\+O%_\ X __ %Z/^&TKC_HE_B__ , ?_KU] M->6G7:OY"CRT_N+^0H]G5_G_ #ZY@/^@7_R9GS)_P -I77_ $2[Q?\ ^ /_ M ->C_AM*Z_Z)=XO_ / '_P"O7TWY2?W5_*CRD_NK^5'LZO\ /^ ?7,!_T"_^ M3,^9/^&TKK_HEWB__P ?_KT?\-I77_1+O%__@#_ /7KZ;\I/[J_E1Y2?W5_ M*CV=7^?\ ^N8#_H%_P#)F?,O_#:5S_T2[Q?_ . /_P!>D_X;0N._PN\7?^ 1 MKZ;\M/[J_E2-&N/NC\A1[.K_ #_@'US ?] O_DS/DV\_:BLM1UZ#6KCX1>+) MM0AMWM$E:Q/$;'YEQGD&N<\+?&#POX-U*[OK'X->+I)[A/* N[5IEBCSD1QJ MQ(1K>(O&WCGP;\7M)L]5O;)M*UA[A;:S2#;!##'&65WE/\ RT)'W:X7 MX9_M+ZK#K6MR^(;Z34K*.Q$\5K/9BW:2Y>4JB6S?\M(STS3]G5_Y^?@'US _ M] O_ ),S-7XZ>&XM!N-%C^"_BJVTJXN6O);:*T9$DD;[Q(!YSZ4O@#X\:-\- MENCHGPE\:(]QA7DN('E95!.U 6/"C)P!7L7P)\<>+/B1\)=6U'4OL,?BI;RZ MMHHT :&!E/[M6QUQD9IOP9\5>(V\>>*?"7B35!J\^EV\$[7,ML("9'SN$8'6 M,$<&E[.I_P _/P#ZY@/^@7_R9G(?\-HW/_1+O%__ ( G_&C_ (;2N/\ HE_B M[_P!_P#KU],K&@'13^ I?+3^XOY"CV=7^?\ /KF!_Z!?_)F?,W_ VE<_\ M1+O%W_@#_P#7JEK'[9%Q>Z3>0-\+_%R+)$R[OL?J.M?4WE)_=7\A67XG14\/ M:DRK@B!B" /0TO9U?Y_P&L9@.N%_\F9\W:3^V1<66F6MNGPO\7%8XE4'[%Z" MK7_#:5U_T2[Q?_X _P#UZ^B/#*K)X?TYF4,Q@4EB.O%:?E1_W!^0I^SJ_P _ MX#^NX#IA?_)F?,G_ VE<_\ 1+O%W_@#_P#7I?\ AM&Y_P"B7>+_ /P!/^-? M37E)_=7\J1HE[*N?H*/9U?Y_P)^N8#_H%_\ )F?*?B#]JVW\5:6VGZI\)?%M MS9LZN8VLB!N5@RGKZXKD]=^+WAKQ%XB;6;WX/>-);F4JUQ ('6WN&0 *TB X M8@=_:O;?VFOC'<_#'PJ(/#TEH?%%P5EBCN2-L5N& DD(^AX]S7*_%3Q7XPL? M'GA*W\-^);EIM6M5U&735M$>VAM8DW2.[]?G/ I^SJ?\_/P#ZY@?^@7_ ,F9 MYOHWQ8\,:#<7,]I\)/'&Z:-XD#Q2$6Z,!;RTF,4H.ZZFF5=W/]U1^M'LZO M\[^X/KF!_P"@7_R9G ?\-HW/_1+?%_\ X TO_#:5U_T2[Q?_ . /_P!>OIL1 MI_<7\A1Y2?W5_*E[.K_/^ ?7,!_T"_\ DS/F7_AM*Y_Z)=XO_P# '_Z])_PV MA=9_Y)=XO_\ '_Z]?3GEI_=7\A3?+0L/E'Y"E[.K_/^ ?7,#_T"_P#DS/D[ MP_\ M?3:>^I%/ACXMD\^[:4XL\XR!Q^E:_\ PVE<_P#1+O%__@#_ /7KW3P7 MB2;7=PW;=0D R.@P*Z?RT_N#\A1[.K_/^!3QN >V%_\ )F?,G_#:5U_T2[Q? M_P" /_UZ#^VE<[?^27>+_I]A_P#KU]-^4G]U?RI&2,?PC\J?LZO\_P"!/US M?] O_DS/C#XJ?&_P_P#&;1(-&\5_!_QE?V,%PMU'"MNT>)5Y#?*>W6LF^^(_ MA35M#T_2;WX2>.KF"PWB.61)#,4)^:-GSEEZ<&OH?]I;Q%XP\-^!+1? UO-) MK5Y?10&2UMQ*\4)/SL%/M7FOC'QEXFO/A#H^H^%/'%^_B-K_ /LI8)[)!+<7 M1;!21?X=HR>-[K3=:\20V-WH]K8F#2ULMRZP9,"60O_#@DC'M79_';QAX MLTGQ5I3Z=>ZEHOA2'3Q>:A>Z=9K-@EAPQ/08STH]G4_Y^?@'US _] O_ ),S M'A_;*FMT6*/X6^+ECC 5 +$@ =/P%2?\-HW/_1+_%__ ( G_&OHW2+B#4-+ ML[J&07$,T".DV!\ZE00WXU=\M/[H_*E[.K_S\_ /KF!_Z!?_ "9GS)_PVE=? M]$N\7_\ @#_]>D_X;1N?^B6^+_\ P!KZ<\I/[J_E2>2G]T?D*?LZO\_X!]

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end GRAPHIC 13 forms-1_006.jpg begin 644 forms-1_006.jpg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forms-1_007.jpg begin 644 forms-1_007.jpg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end GRAPHIC 15 ex5-1_001.jpg begin 644 ex5-1_001.jpg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end GRAPHIC 16 ex5-1_002.jpg begin 644 ex5-1_002.jpg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bfrg-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes Payable Related Party link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Convertible Notes Payable Related Party link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholder’s Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Material Agreements link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stockholder’s Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Convertible Notes Payable Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Vested and Outstanding Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Black Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Stock Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Vested And Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stockholder’s Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Material Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 18 bfrg-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 19 bfrg-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 20 bfrg-20230930_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Business Contact [Member] Related Party, Type [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Receivables from Stockholder [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Debt Instrument [Axis] SBA PPP Loan [Member] Financial Instrument [Axis] Short-Term Debt [Member] Legal Entity [Axis] Maryland Technology Development Corporation [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Convertible Loan Agreement [Member] New Agreement [Member] Loan Agreement [Member] Convertible Bridge Notes And Warrants [Member] Wallach Beth [Member] August 2021 [Member] Short-Term Debt, Type [Axis] Convertible Debt One [Member] Convertible Debt Two [Member] Convertible Debt Three [Member] Convertible Debt Four [Member] Convertible Debt Five [Member] Convertible Debt Six [Member] Convertible Debt Seven [Member] Convertible Debt Eight [Member] Convertible Debt Nine [Member] Convertible Debt Ten [Member] Convertible Debt [Member] Simple Agreement for Future Equity [Member] New Loan Agreement [Member] Title of Individual [Axis] Chief Financial Officer [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Exchange Agreement [Member] Investor [Member] Note Holder [Member] License Agreement [Member] Derivative Instrument [Axis] Equity Option [Member] Warrant [Member] Advisors [Member] Convertible Bridge Debt Agreements [Member] New Agreements [Member] Warrant One [Member] Prior Agreements And New Agreements [Member] Class of Warrant or Right [Axis] Tradeable Warrants [Member] Non-Tradeable Warrants [Member] Twenty Twenty Two Equity Incentive Plan [Member] Underwriters [Member] Tradable Warrant [Member] Non Tradable Warrant [Member] Over-Allotment Option [Member] Unvested Warrants [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Exercise Price [Member] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] JHU - APL Technology License Agreement [Member] Award Date [Axis] 2022 [Member] 2023 [Member] 2024 [Member] New License Agreement [Member] Other Parties [Member] Project [Axis] Internally Development Drug Projects [Member] George Washington University - Beta2-spectrin siRNA License Agreement [Member] Johns Hopkins University - Mebendazole License Agreement [Member] 2025 [Member] 2026 [Member] 2027 [Member] Johns Hopkins University - Prodrug License Agreement [Member] 2028 [Member] 2029 [Member] 2030 [Member] 2031 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Contact Personnel Name Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Assets Current assets: Cash and cash equivalents Prepaid expenses Total current assets NON-CURRENT ASSETS: Property and equipment, net Total Non-Current Assets Total assets Liabilities and Stockholders’ Deficit Current liabilities: Accounts payable Accrued expenses Deferred revenue Short term insurance financing Notes payable-related party Convertible notes Convertible notes - related party Total current liabilities TOTAL LIABILITIES Stockholders’ deficit: Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding, as of September 30, 2023 and December 31, 2022. Common stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 and 4,021,935 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively. Additional paid-in capital Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Statement [Table] Statement [Line Items] Debt discount Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding Income Statement [Abstract] Revenue: Revenue, net Total revenue Cost of goods sold: Cost of goods sold Total cost of goods sold Gross profit Operating expenses: Research and development General and administrative Payroll and salary Payroll and salary-related party Total operating expenses Loss from operations Other income (expense), net Interest expense, net Loss on conversion of notes Other (expense) income, net Total other income (expense), net Net loss NET (LOSS) PER COMMON SHARE: Net loss per common share attributable to common stockholders basic Net loss per common share attributable to common stockholders diluted WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: Weighted average number of shares outstanding - basic Weighted average number of shares outstanding - diluted Balance Balance, shares Cash from subscription receivables Warrants issued with convertible notes Imputed interest Stock-based compensation Equity compensation Equity compensation, shares Net loss Conversion of convertible notes Conversion of convertible notes, shares Reclassification of warrant Shares cancellation Shares cancellation, shares Issuance of common stock pursuant to warrant exercises Issuance of common stock pursuant to warrant exercises, shares Common stocks converted to Series A Preferred stock Common stocks converted to Series A Preferred stock, shares Issuance of common stock (initial public offering), net of issuance cots Issuance of common stock (initial public offering), net of issuance cots, shares Issuance of common stock for services Issuance of common stock for services, shares Shares cancellation Shares cancellation, shares Shares issuance for license Shares issuance for license, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Loss on conversion of notes Depreciation Shares issued for license Shares issued for services Stock-based compensation Amortization of debt discount Imputed interest Changes in operating assets and liabilities: Prepaid expense Accounts payable Accrued expenses Accrued expenses - related party Deferred revenue Net cash used in operating activities Cash flows from investing activities: Purchases of property and equipment Net cash used in investing activities Cash flows from financing activities: Proceeds from issuance of common stock (initial public offering), net of issuance costs Proceeds from exercise of warrants Proceeds from convertible notes payable Proceeds from convertible notes payables-related party Proceeds from notes payable Payments of notes payable Repayment of note payable and interest - related party Proceeds from notes payables - related party Proceeds net of payments short term insurance financing Proceeds from subscription payable Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental cash flow information: Cash paid for interest Cash paid for taxes Supplemental non-cash activity Reclassification of warrant Issuance of common stock upon conversion of notes payable Conversion of convertible note payable Cancellation of common stocks Shares issued for license Shares issued for services Warrants issued with convertible notes Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Property, Plant and Equipment [Abstract] Property and Equipment Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses Debt Disclosure [Abstract] Notes Payable Notes Payable Related Party Notes Payable Related Party Convertible Notes Payable Convertible Notes Payable Related Party Convertible Notes Payable Related Party Related Party Transactions [Abstract] Related Party Equity [Abstract] Stockholder’s Equity Income Tax Disclosure [Abstract] Income Taxes Material Agreements Material Agreements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Use of Estimates in the Preparation of Financial Statements Financial Instruments Revenue Recognition Use of Estimates Cash Concentrations of Credit Risk Accounts Receivable Allowance for Doubtful Accounts Inventories Cost of Sales Property and Equipment Advertising Income Taxes Stock-Based Compensation Net Loss per Share Impact of Recently Issued Accounting Standards COVID-19 Going Concern Basis of Presentation Contract Services Significant Accounting Policies Schedule of Convertible Debt Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Schedule of Stock Options Activity Schedule of Vested and Outstanding Options Schedule of Black Scholes Option Pricing Model Schedule of Stock Warrant Activity Schedule of Vested And Outstanding Warrants Schedule of Outstanding Warrants Schedule of Deferred Taxes First service revenue Unearned revenue Cash balances Allowance for doubtful accounts Cost of services Royalty percent Number of options Reverse stock split Payment to acquire equiment Accumulated depreciation Property and equipment net Accounts payable and accrued expenses Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Notes payable Accrued interest Original issuance discount rate Repayments in installments Outstanding balance Prepaid expenses Short term loan Accruing interest rate Interest rate Short term loan Purchase Price Principal Balance Original Issue Discount Accrued Interest Note Date Principal balance Interest rate Maturity date Conversion of stock, value Conversion of stock, shares Fully diluted equity Principal balance Original issuance discount rate Number of warrants Exercise price Warrants term Unamortized debt discount Accrued interest Warrant expenses Prncipal balance increase Fees expense Sale of stock value Conversion discount rate Debt description Maturity date extended Conversion value Conversion price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Convertible notes payable related party Number of warrant shares Warrant exercise price per share Principal amount Repayments of debt Notes payable Loss on the conversion Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Number of shares issued Accrued salaries Accrued consulting fees Number of shares issued for services Stock-based compensation related to outstanding stock options Original life Number of Shares, Outstanding at Beginning Number of Shares, Granted Number of Shares, Exercised Forfeited Expired Number of Shares, Outstanding at Ending Weighted-Average Exercise Price, Outstanding at Beginning Weighted-Average Remaining Contractual Term (Years), Outstanding Aggregate Intrinsic Value, Outstanding at Beginning Weighted-Average Exercise Price, Granted Aggregate Intrinsic Value, Granted Weighted-Average Exercise Price, Exercised Aggregate Intrinsic Value, Exercised Number of Shares, Forfeited / canceled Weighted-Average Exercise Price, Forfeited / canceled Aggregate Intrinsic Value, Forfeited / canceled Weighted-Average Exercise Price, Outstanding at Ending Aggregate Intrinsic Value, Outstanding at Ending Number of Shares, Vested at Ending Weighted-Average Exercise Price, Vested at Ending Weighted-Average Remaining Contractual Term (Years), Vested at Ending Aggregate Intrinsic Value, Vested at Ending Beginning value, Options Beginning value, Intrinsic Value of Vested Options Weight Averaged exercise Price, beginning value Options Granted Intrinsic Value of Vested Options, Granted Weight Averaged exercise Price, Granted Options Exercised Intrinsic Value of Vested Options, Exercised Weight Averaged exercise Price, Exercised Options Forfeited Intrinsic Value of Vested Options, Forfeited Weight Averaged exercise Price, Forfeited Options Expired Intrinsic Value of Vested Options, Expired Weight Averaged exercise Price, Expired Ending value, Options Intrinsic Value of Vested Options, Intrinsic value Weight Averaged exercise Price, Ending balance value Fair Value of Common Stock on measurement date Risk-free interest rate, minimum Risk-free interest rate, maximum Volatility Expected dividend yield Expected life (in years) Expected volatility, minimum Expected volatility, maximum Beginning balance Granted Exercised Forfeited Expired Ending balance Beginning balance Warrants Granted Intrinsic Value of Vested Warrants, Granted Weight Averaged exercise Price, Granted Warrants, Exercised Intrinsic Value of Vested Warrants, Exercised Weight Averaged exercise Price, Exercised Warrants Forfeited Intrinsic Value of Vested Warrants, Forfeited Weight Averaged exercise Price, Forfeited Warrants, Expired Intrinsic Value of Vested Warrants, Expired Weight Averaged exercise Price, Expired Ending balance value Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Exercise Price Expiration Period Number of Warrants Preferred stock, par or stated value per share Conversion of convertible securities, shares Number of common stock Preferred stock value Stock split, description Common stock, par or stated value per share Conversion of convertible securities, shares Conversion of convertibe notes value Shares cancelled Shares issued value Common stock, shares outstanding Number of options forfeitures Share based compensation granted Original life Award period Warrants shares vested Share-based payment arrangement, expensed and capitalized, amount Share-based payment arrangement, expensed and capitalized, amount Option vested shares Option vested expired shares Weighted average remaining contractual term Fair value of warrants Share based compensation granted Contractual life and vesting period, description Intrinsic value Warrant shares Warrants reclassified with intrinsic value Warrant shares, forfeited Fair value of warrants Warrant shares forfeiture Warrants and rights outstanding term Warrant shares Warrants shares, outstanding Vested shares Intrinsic value Conversion of convertible notes value Shares cancelled Additional shares issued Issue price per share Gross proceeds Sale of stock, description Shares, issued for services Value, issued for services Warrant exercised Proceeds from exercise of warrant Award authorized under the plan Increased payment award, percentage Weighted-average grant-date fair value of options granted Compensation expense related to stock options Unrecognized compensation expense Weighted-average period Warrant shares, forfeited Weighted average period term Compensation expense Unrecognized compensation expense Net operating loss carryforwards Valuation allowance Net non-current deferred tax asset Operating loss carry forward Warrant percent Royalty percent Percentage of sublicense Maintenance fee Royalty payments Common stock issued Sublicense fee based on revenue Accrued royalty expenses Licence initiation fee Upfront licence fee Annual minimum royalty payment License fee initial payment Fianance raised Accrued expense Subsequent Event [Table] Subsequent Event [Line Items] Converted common shares Converted common shares Warrants exercised Gross proceeds Common Stock, Par Value $0.00001 Per Share [Member] Maryland Technology Development Corporation [Member] Convertible Loan Agreement [Member] Series A Convertible Preferred Stock [Member] Exchange Agreement [Member] Advisors [Member] Convertible Bridge Notes And Warrants [Member] Wallach Beth [Member] Share based compensation arrangement by share based payment award options vested and expected to vest outstanding granted. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding exercised. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding forfeited. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding expired. Percentage of warrant issued. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding intrinsic granted. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding intrinsic exercised. Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Intrinsic Expired. JHU - APL Technology License Agreement [Member] Share based compensation arrangement by share based payment award options vested and expected to vest outstanding intrinsic forfeited. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price granted. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price exercised. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price forfeited. Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price expired. New License Agreement [Member] George Washington University - Beta2-spectrin siRNA License Agreement [Member] Johns Hopkins University - Mebendazole License Agreement [Member] Johns Hopkins University - Prodrug License Agreement [Member] License And Royalty Agreement Disclosure [Text Block] Tradeable Warrants [Member] Year Twenty Twenty Two [Member] Year Twenty Twenty Three [Member] Year Twenty Twenty Four [Member] Year Twenty Twenty Five [Member] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested And Expected To Vest Outstanding [Table Text Block] Year Twenty Twenty Six [Member] Year Twenty Twenty Seven [Member] Year Twenty Twenty Eight [Member] Year Twenty Twenty Nine [Member] Year Twenty Thirty [Member] Year Twenty Thirty One [Member] Stockholder equity subscriptions receivable. Adjustments to additional paid in reclassifications of warrant. Issuance of stock for license. Receivables with imputed interest amount. Increase decrease in accrued expenses related parties. Proceeds from convertible notes payable related party. Stock issued for services. Warrants issued for convertible notes. Cancellation of common stock. Reclassification of warrant. Conversion of convertible note payable. Percentage of royalty. Convertible Notes Payable Related Party Disclosure [Text Block] Simple Agreement for Future Equity [Member] Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding exercised. Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding granted. Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding forfeited. Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding expired. Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding number. Investors [Member] Accrued expenses-related party. Convertible notes payable related party current. Payroll and salary-related party. Use of Estimates in the Preparation of Financial Statements [Policy Text Block] Covid 19 [Policy Text Block] SBA PPP Loan [Member] Notes Payable Related Party [Text Block] Fully diluted equity. Original issuance discount rate. New Agreement [Member] Loan Agreement [Member] Convertible notes payable related party. New Loan Agreement [Member] Note Holder [Member] License Agreement [Member] Number of stock shares cancelled. Warrants reclassified with intrinsic value. Class of warrant or right number of securities called by warrants or rights forfeited. Warrants intrinsic value forfeited. Share based compensation arrangement by share based payment award non-options contractual life and vesting period description. Convertible Bridge Debt Agreements [Member] New Agreements [Member] Warrant One [Member] Share based compensation arrangement by share based payment award warrants non-options vested and expected to vest outstanding aggregate intrinsic value. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic granted. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic exercised. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic forfeited. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic expired. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price granted. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price exercised. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price forfeited. Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price expired. Percentage of royalty on net sales. Percentage of sublicense. Other Parties [Member] Internally Development Drug Projects [Member] Increase decrease in sublicense percentage based on revenues. Licence initiation fee. Upfront licence fee. Non-Tradeable Warrants [Member] Convertible Debt Two [Member] Convertible Debt Three [Member] Convertible Debt Four [Member] Convertible Debt Five [Member] Convertible Debt Six [Member] Convertible Debt Seven [Member] Convertible Debt Eight [Member] Convertible Debt Nine [Member] Convertible Debt Ten [Member] Shares exchanged for each convertible preferred stock. Substantial Doubt About Going Concern [Policy Text Block] Conversion discount rate. August 2021 [Member] Stock issued during period value for license. Warrant Expiration Period. Unrecognized compensation expense. Stock issued during period shares for license. Significant Accounting Policy [Policy Text Block] Loss on the conversion. Share based compensation arrangement by share based payment award options grants in period intrinsic value. Share based compensation arrangement by share based payment award options forfeitures and canceled intrinsic value. Share based compensation arrangement by share based payment award options vested contractual life and vesting period. Class of Warrant or Right Forfeited. Gains losses on connversion of notes. Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Revenues Cost of Revenue Gross Profit Operating Expenses Operating Income (Loss) Interest Expense GainsLossesOnConnversionOfNotes Nonoperating Income (Expense) Shares, Outstanding Shares Issued, Value, Share-Based Payment Arrangement, Forfeited Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Gain (Loss) on Extinguishment of Debt ReceivablesWithImputedInterestAmount Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents ReclassificationOfWarrant Stock Issued StockIssuedForServices WarrantsIssuedForConvertibleNotes NotesPayableRelatedPartyDisclosureTextBlock ConvertibleNotesPayableRelatedPartyDisclosureTextBlock LicenseAndRoyaltyAgreementDisclosureTextBlock Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Prepaid Expense OriginalIssuanceDiscountRate Convertible Notes Payable [Default Label] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired Share-Based Payment Arrangement, Expensed and Capitalized, Amount Warrants and Rights Outstanding ClassOfWarrantOrRightForfeited Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance PercentageOfRoyaltyOnNetSales EX-101.PRE 21 bfrg-20230930_pre.xml XBRL PRESENTATION FILE XML 22 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
9 Months Ended
Sep. 30, 2023
Entity Addresses [Line Items]  
Document Type S-1
Amendment Flag false
Entity Registrant Name BULLFROG AI HOLDINGS, INC.
Entity Central Index Key 0001829247
Entity Tax Identification Number 84-4786155
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 325 Ellington Blvd.
Entity Address, Address Line Two Unit 317
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code (240)
Local Phone Number 658-6710
Entity Filer Category Non-accelerated Filer
Entity Small Business true
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Business Contact [Member]  
Entity Addresses [Line Items]  
Entity Address, Address Line One 325
Entity Address, Address Line Two Unit 317
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code (240)
Local Phone Number 658-6710
Contact Personnel Name Vininder Singh

XML 23 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Current assets:      
Cash and cash equivalents $ 3,856,037 $ 57,670 $ 10,014
Prepaid expenses 352,433 15,000
Total current assets 4,208,470 72,670 10,014
NON-CURRENT ASSETS:      
Property and equipment, net 6,406 7,699
Total Non-Current Assets   7,699
Total assets 4,214,876 80,369 10,014
Current liabilities:      
Accounts payable 110,503 543,993 68,594
Accrued expenses 122,257 982,988  
Deferred revenue 32,000 10,000
Short term insurance financing 213,290
Notes payable-related party     49,000
Convertible notes 1,323,890 284,038
Convertible notes - related party 254,850 253,266
Total current liabilities 446,050 3,137,721 1,019,121
TOTAL LIABILITIES   3,137,721 1,019,121
Stockholders’ deficit:      
Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding, as of September 30, 2023 and December 31, 2022. 1 1
Common stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 and 4,021,935 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively. 61 40 46
Additional paid-in capital 12,226,742 1,341,662 587,415
Accumulated deficit (8,457,978) (4,399,055) (1,596,568)
Total stockholders’ deficit 3,768,826 (3,057,352) (1,009,107)
Total liabilities and stockholders’ deficit $ 4,214,876 80,369 10,014
Nonrelated Party [Member]      
Current liabilities:      
Accrued expenses   416,072 68,557
Related Party [Member]      
Current liabilities:      
Accrued expenses   566,916 285,666
Notes payable-related party   $ 49,000
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Debt discount   $ 0 $ 12,962
Preferred stock, par value $ 0.00001 $ 0.00001  
Preferred stock, shares authorized 10,000,000 10,000,000  
Preferred stock, shares issued     0
Common stock, par value $ 0.00001 $ 0.00001 $ 0.00001
Common stock, shares authorized 100,000,000 100,000,000 100,000,000
Common stock, shares, issued 6,094,644 4,021,935 4,622,789
Common stock, shares, outstanding 6,094,644 4,021,935 4,622,789
Series A Preferred Stock [Member]      
Preferred stock, par value   $ 0.00001 $ 0.00001
Preferred stock, shares authorized   5,500,000 5,500,000
Preferred stock, shares issued   73,449 0
Preferred stock, shares outstanding   73,449 0
Series A Convertible Preferred Stock [Member]      
Preferred stock, par value $ 0.00001 $ 0.00001  
Preferred stock, shares authorized 5,500,000 5,500,000  
Preferred stock, shares issued 73,449 73,449  
Preferred stock, shares outstanding 73,449 73,449  
Related Party [Member]      
Debt discount   $ 0 $ 1,584
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Revenue:            
Revenue, net $ 65,000 $ 65,000 $ 10,000
Total revenue 65,000 65,000 10,000
Cost of goods sold:            
Cost of goods sold 5,200 5,200 800
Total cost of goods sold 5,200 5,200 800
Gross profit 59,800 59,800 9,200
Operating expenses:            
Research and development 380,015 39,421 1,023,619 448,375 609,270 25,000
General and administrative 983,929 601,131 3,067,940 1,424,383 1,307,882 327,329
Payroll and salary         98,250
Payroll and salary-related party         449,599 203,033
Total operating expenses 1,363,944 640,552 4,091,559 1,872,758 2,465,001 555,362
Loss from operations (1,304,144) (640,552) (4,031,759) (1,872,758) (2,455,801) (555,362)
Other income (expense), net            
Interest expense, net (5,758) (124,159) (76,880) (234,668) (347,145) (40,395)
Loss on conversion of notes (92,959)    
Other (expense) income, net 56,924 18 142,675 457 459 9,917
Total other income (expense), net 51,166 (124,141) (27,164) (234,211) (346,686) (30,478)
Net loss $ (1,252,978) $ (764,693) $ (4,058,923) $ (2,106,969) $ (2,802,487) $ (585,840)
NET (LOSS) PER COMMON SHARE:            
Net loss per common share attributable to common stockholders basic $ (0.21) $ (0.16) $ (0.72) $ (0.45) $ (0.70) $ (14)
Net loss per common share attributable to common stockholders diluted $ (0.21) $ (0.16) $ (0.72) $ (0.45) $ (0.70) $ (14)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:            
Weighted average number of shares outstanding - basic 6,094,644 4,752,959 5,667,997 4,669,952 4,009,852 4,116,336
Weighted average number of shares outstanding - diluted 6,094,644 4,752,959 5,667,997 4,669,952 4,009,852 4,116,336
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Receivables from Stockholder [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 36 $ 470,274 $ (100) $ (1,010,728) $ (540,518)
Balance, shares at Dec. 31, 2020 3,603,422        
Cash from subscription receivables 100 100
Warrants issued with convertible notes 13,661 13,661
Imputed interest 4,539 4,539
Stock-based compensation 9,385 9,385
Equity compensation $ 10 89,556 89,566
Equity compensation, shares   1,019,367        
Net loss (585,840) $ (585,840)
Issuance of common stock for services, shares           29,286
Balance at Dec. 31, 2021 $ 46 587,415 (1,596,568) $ (1,009,107)
Balance, shares at Dec. 31, 2021 4,622,789        
Imputed interest 2,360   2,360
Stock-based compensation 30,017   30,017
Net loss   (566,359) (566,359)
Reclassification of warrant (11,097)   (11,097)
Balance at Mar. 31, 2022 $ 46 608,695   (2,162,927) (1,554,186)
Balance, shares at Mar. 31, 2022 4,622,789        
Balance at Dec. 31, 2021 $ 46 587,415 (1,596,568) (1,009,107)
Balance, shares at Dec. 31, 2021 4,622,789        
Net loss           (2,106,969)
Balance at Sep. 30, 2022 $ 47 1,290,130   (3,703,537) (2,413,360)
Balance, shares at Sep. 30, 2022 4,756,427        
Balance at Dec. 31, 2021 $ 46 587,415 (1,596,568) (1,009,107)
Balance, shares at Dec. 31, 2021 4,622,789        
Imputed interest 9,221 9,221
Stock-based compensation 340,152 340,152
Net loss (2,802,487) (2,802,487)
Conversion of convertible notes $ 2 226,136 226,138
Conversion of convertible notes, shares   205,984        
Reclassification of warrant (11,097) (11,097)
Shares cancellation $ (1) 1
Shares cancellation, shares   (112,225)        
Issuance of common stock pursuant to warrant exercises 189,828 189,828
Issuance of common stock pursuant to warrant exercises, shares   39,879        
Common stocks converted to Series A Preferred stock $ 1 $ (7) 6
Common stocks converted to Series A Preferred stock, shares 73,449 (734,492)        
Balance at Dec. 31, 2022 $ 1 $ 40 1,341,662 (4,399,055) (3,057,352)
Balance, shares at Dec. 31, 2022 73,449 4,021,935        
Balance at Mar. 31, 2022 $ 46 608,695   (2,162,927) (1,554,186)
Balance, shares at Mar. 31, 2022 4,622,789        
Imputed interest 2,361   2,361
Stock-based compensation 209,323   209,323
Net loss   (775,917) (775,917)
Conversion of convertible notes $ 2 226,136   226,138
Conversion of convertible notes, shares   205,984        
Shares cancellation $ (1) 1  
Shares cancellation, shares   (112,225)        
Balance at Jun. 30, 2022 $ 47 1,046,516   (2,938,844) (1,892,281)
Balance, shares at Jun. 30, 2022 4,716,548        
Imputed interest 2,250   2,250
Stock-based compensation 51,536   51,536
Net loss   (764,693) (764,693)
Shares issuance for license 189,828   189,828
Shares issuance for license, shares   39,879        
Balance at Sep. 30, 2022 $ 47 1,290,130   (3,703,537) (2,413,360)
Balance, shares at Sep. 30, 2022 4,756,427        
Balance at Dec. 31, 2022 $ 1 $ 40 1,341,662 (4,399,055) (3,057,352)
Balance, shares at Dec. 31, 2022 73,449 4,021,935        
Stock-based compensation 127,450   127,450
Net loss   (1,325,547) (1,325,547)
Conversion of convertible notes $ 3 1,535,612   1,535,615
Conversion of convertible notes, shares   331,166        
Issuance of common stock (initial public offering), net of issuance cots $ 13 7,293,638   7,293,651
Issuance of common stock (initial public offering), net of issuance cots, shares   1,297,318        
Issuance of common stock for services $ 1 49,999   50,000
Issuance of common stock for services, shares   7,692        
Balance at Mar. 31, 2023 $ 1 $ 57 10,348,361   (5,724,602) 4,623,817
Balance, shares at Mar. 31, 2023 73,449 5,658,111        
Balance at Dec. 31, 2022 $ 1 $ 40 1,341,662 (4,399,055) (3,057,352)
Balance, shares at Dec. 31, 2022 73,449 4,021,935        
Net loss           (4,058,923)
Balance at Sep. 30, 2023 $ 1 $ 61 12,226,742   (8,457,978) 3,768,826
Balance, shares at Sep. 30, 2023 73,449 6,094,644        
Balance at Mar. 31, 2023 $ 1 $ 57 10,348,361   (5,724,602) 4,623,817
Balance, shares at Mar. 31, 2023 73,449 5,658,111        
Stock-based compensation 262,267     262,267
Net loss         (1,480,398) (1,480,398)
Issuance of common stock pursuant to warrant exercises   $ 4 1,494,654     $ 1,494,658
Issuance of common stock pursuant to warrant exercises, shares   436,533        
Issuance of common stock for services, shares           436,533
Balance at Jun. 30, 2023 $ 1 $ 61 12,105,282   (7,205,000) $ 4,900,344
Balance, shares at Jun. 30, 2023 73,449 6,094,644        
Stock-based compensation 121,460     121,460
Net loss         (1,252,978) (1,252,978)
Balance at Sep. 30, 2023 $ 1 $ 61 $ 12,226,742   $ (8,457,978) $ 3,768,826
Balance, shares at Sep. 30, 2023 73,449 6,094,644        
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:        
Net loss $ (4,058,923) $ (2,106,969) $ (2,802,487) $ (585,840)
Adjustments to reconcile net loss to net cash used in operating activities:        
Loss on conversion of notes 92,959 (9,917)
Depreciation 1,293 604 1,045
Shares issued for license 189,828 189,828
Shares issued for services 50,000    
Stock-based compensation 511,177 290,876 340,152 98,951
Amortization of debt discount 20,000 174,998 214,429 12,665
Imputed interest 6,971 9,221 4,539
Changes in operating assets and liabilities:        
Prepaid expense (337,433) (15,000) (15,000)
Accounts payable (433,490) 51,946 475,399 (25,853)
Accrued expenses (796,865) 409,502 373,273 27,384
Accrued expenses - related party 104,000 281,250 85,666
Deferred revenue (32,000) 22,000 22,000 10,000
Net cash used in operating activities (4,983,282) (871,244) (910,890) (382,405)
Cash flows from investing activities:        
Purchases of property and equipment (8,744) (8,744)
Net cash used in investing activities (8,744) (8,744)
Cash flows from financing activities:        
Proceeds from issuance of common stock (initial public offering), net of issuance costs 7,293,651    
Proceeds from exercise of warrants 1,494,658    
Proceeds from convertible notes payable 961,190 1,016,290
Proceeds from convertible notes payables-related party     298,900
Proceeds from notes payable 100,000    
Payments of notes payable (319,950)    
Repayment of note payable and interest - related party (49,000) (49,000)
Proceeds from notes payables - related party     88,400
Proceeds net of payments short term insurance financing 213,290    
Proceeds from subscription payable     100
Net cash provided by financing activities 8,781,649 912,190 967,290 387,400
Net increase in cash and cash equivalents 3,798,367 32,202 47,656 4,995
Cash and cash equivalents, beginning of period 57,670 10,014 10,014 5,019
Cash and cash equivalents, end of period 3,856,037 42,216 57,670 10,014
Supplemental cash flow information:        
Cash paid for interest 93,916 4,399 5,757
Cash paid for taxes
Supplemental non-cash activity        
Reclassification of warrant 11,097 11,097
Issuance of common stock upon conversion of notes payable 1,535,615    
Conversion of convertible note payable $ 226,138 226,138
Cancellation of common stocks     8
Shares issued for license     189,828
Shares issued for services     340,152 20
Warrants issued with convertible notes     $ 13,661
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization and Nature of Business
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Organization and Nature of Business

1. Organization and Nature of Business

 

Description of the Business

 

Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through Bullfrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development.

 

Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.

 

We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

 

The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.

 

Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in-house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings.

 

Liquidity and Going Concern

 

The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). We believe that the funds raised and notes that were converted from debt to equity in connection with the IPO now provide enough liquidity to fund operations beyond 9 months from the date of this filing.

 

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Bullfrog AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development.

 

Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.

 

We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

 

The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for an a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.

 

Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings.

 

XML 29 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation.

 

 

The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows.

 

The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period.

 

On February 13, 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.

 

Revenue Recognition

 

The Company recognizes revenue based on the following five step model:

 

- Identification of the contract with a customer
  This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.
- Identification of the performance obligations in the contract
  This step describes how distinct performance obligations in the contract must be handled.
- Determination of the transaction price
  This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer.
- Allocation of the transaction price to the performance obligations in the contract
  This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services.
- Recognition of revenue when, or as, the Company satisfies a performance obligation
  Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.

 

Contract Services

 

The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.

 

Significant Accounting Policies

 

There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

Impact of Recently Issued Accounting Standards

 

The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.

 

 

NOTE 2–SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

 

Use of Estimates in the Preparation of Financial Statements

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates.

 

 

Financial Instruments

 

The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments.

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:

 

Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

 

Revenue Recognition

 

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had no revenue. In Q4 2022 the Company recognized its first service revenues in the amount of $10,000 related to the achievement of a contract milestone under a contract with a Pharmaceutical company. In compliance with the agreement, we have met the following milestones – receipt of data for analysis; data conversion and staging for ingestion. For the years-ended December 31, 2022 and 2021, our balance sheet reflects customer down payment received in early 2022 and late 2021 as unearned revenue in the amount of $32,000 and $10,000, respectively. This unearned revenue represents payments received from a leading rare disease non-profit organization under a contract with a single deliverable. As is more fully discussed below, we are of the opinion that none of our contracts for products contain significant financing components that require revenue adjustment under FASB ASC Topic 606.

 

Revenue is recognized based on the following five step model:

 

  -

Identification of the contract with a customer

This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services

  -

Identification of the performance obligations in the contract

This step describes how distinct performance obligations in the contract must be handled

  -

Determination of the transaction price

This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer

  -

Allocation of the transaction price to the performance obligations in the contract

This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services

  -

Recognition of revenue when, or as, the Company satisfies a performance obligation

Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen

 

 

Contract Services

 

The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis.

 

Collaborative Arrangements

 

The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement.

 

Acquisition of Rights to Certain Drugs

In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

 

Cash

 

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $57,670 and $10,014, respectively.

 

Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

 

 

Accounts Receivable

 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

 

Allowance for Doubtful Accounts

 

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $0.

 

 

Inventories

 

The Company does not have inventory and does not plan to have inventory in the near future.

 

Cost of Sales

 

Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $800 as cost of goods sold which represents the 8% royalty on the $10,000 in service revenue in 2022.

 

Property and Equipment

 

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.

 

Advertising

 

The Company follows the policy of charging the costs of advertising to expense as incurred.

 

Income Taxes

 

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits.

 

Stock-Based Compensation

 

Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.

 

Net Loss per Share

 

We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, 927,373 and 753,174 warrants (post reverse stock split) were not included in the calculation of net loss per share, respectively. In addition, 486,571 and 56,242 options for common shares (post reverse stock split) were not included in the calculation of net loss per share, respectively.

 

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.

 

We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

 

The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842.

 

All staff are working remotely; therefore, the Company does not currently have a lease or rent office space.

 

Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate.

 

The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.

 

In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes.

 

In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements.

 

 

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

 

COVID-19

 

In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders.

 

Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services.

 

It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period.

 

The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock.

 

Going Concern

 

The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.

 

XML 30 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment
12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment

NOTE 3 – PROPERTY AND EQUIPMENT

 

 

Property and equipment consisted of the following:

 

During the year ended December 31, 2022, the Company acquired $8,744 of equipment and has accumulated depreciation of $1,045, for a net of $7,699.

 

Depreciation expense totaled $1,045, and $0 in the years ended December 31, 2022 and 2021, respectively.

 

XML 31 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accounts Payable and Accrued Expenses
12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Expenses

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

 

As of December 31, 2022 and 2021, the Company had accounts payable and accrued expenses totaling $1,526,981 and $422,817, respectively.

 

XML 32 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Notes Payable
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Notes Payable

6. Notes Payable

 

In January 2023 the Company entered into a short-term note payable with a principal balance of $100,000, an original discount of 20% and a 9% interest rate. The note was paid in its entirety in February 2023.

 

In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $697,534 of the premium, repayments in 10 equal monthly installments of $71,485 each through December 2023 and accrued interest at 6.5%. The balance outstanding at September 30, 2023 was $213,290. The related balance of the premium of $307,735 is included in prepaid expenses.

 

NOTE 5 –NOTES PAYABLE

 

 

On May 5, 2020 the Company received an SBA PPP loan in the amount of $9,917, at 1% interest. The loan was forgiven on March 15, 2021.

 

XML 33 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Notes Payable Related Party
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Notes Payable Related Party    
Notes Payable Related Party

3. Notes Payable Related Party

 

At various times in 2021, the Company entered into unsecured short term loan agreements with a related party for an aggregate principal balance of $49,000, each with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loans and interest was repaid in 2022.

 

NOTE 6 –NOTES PAYABLE RELATED PARTY

 

 

On June 15, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $34,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan and interest was repaid in 2022.

 

On November 19, 2021, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $5,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan and interest was repaid in 2022.

 

On December 13, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $10,000, with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loan and interest was repaid in 2022.

 

 

XML 34 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Notes Payable
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Convertible Notes Payable

4. Convertible Notes

 

March 2020 Note

 

On March 27, 2020, the Company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $200,000 at 6% interest. The maturity date of the loan was September 27, 2021. During the year ended December 31, 2022, the full amount of the loan and interest totaling $226,138 was converted into 205,984 shares of common stock of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest, divided by $5,000,000, times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion being within the terms of the agreement.

 

August 2021 Note

 

In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $195,000 with a 5% original issue discount and a 9% interest rate. The loan provided for a maturity date of February 9, 2022. We borrowed $72,000 and $123,000 of principal in the years ended December 31, 2021 and 2022, respectively. The noteholder had the right to convert the principal and interest into common shares of the Company at the IPO at a 20% discount to the IPO price.

 

As December 31, 2022, the loan was outstanding with a principal balance of $195,000 and accrued interest of $35,078. The loan was paid in its entirety in February 2023.

 

In connection with the convertible loan agreement, the Company also issued 195,000 Warrants with an exercise price of $1.00 exercisable for five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void the warrants and enter into a new agreement for 225,000 warrants with an exercise price of $2.50. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

 

December 2021 Note

 

On December 20, 2021, the Company entered into a loan agreement with an unrelated party. The loan provided for a December 19, 2022 maturity, a 10% original issue discount and a 6% interest rate. The Company received $25,000 of proceeds from this note.

 

The note was automatically convertible into shares of common stock at a discount to the IPO price or based on the valuation of the Company, whichever was more favorable to the holder.

 

Initially, the loan was estimated to be issued with 355,114 warrants. Subsequent to the closing of the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $1 million in face value of convertible bridge notes. Pursuant to the enhanced terms, the warrants were issued concurrently with the conversion of the note.

 

Concurrent with the closing of the Company’s IPO, the note converted according to its terms into 6,939 shares of common stock. No gain or loss was recognized on the conversion.

 

Convertible Bridge Notes

 

On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. On April 28, 2022, the Company received approximately $775,000 of proceeds, net of approximately $91,000 of fees and a 10% original issue discount from the sale of Convertible Bridge Notes and Warrants to several institutional investors and several individual accredited investors. In addition, the Company also received $100,000 from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company received an additional $25,000 of proceeds, net of a 10% original issue discount from the sale of an additional Convertible Bridge Note and Warrant to an unrelated party.

 

 

The Convertible Bridge Notes were initially convertible at the IPO at a 20% discount to the IPO price. The Convertible Bridge Notes provided for an original maturity date of October 31, 2022.

 

In connection with the Convertible Bridge Notes, the purchasers were also entitled to conditional warrants to be issued upon completion of the Company’s IPO. The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price.

 

In the fourth quarter of 2022, the Company amended the Convertible Bridge Notes to (a) extend the maturity date until December 31, 2022, (b) provide that the conversion right would include interest through November 30, 2022, with interest accruing beyond that date being paid in cash and (c) revise the conversion price to be $4.27 based on a $25 million Company valuation. Additionally, the exercise price of the warrants was revised to $4.27.

 

Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into 269,513 shares of common stock. No gain or loss was recognized on the conversion.

 

NOTE 7 – CONVERTIBLE NOTES PAYABLE

 

On March 27, 2020, the company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $200,000 at 6% interest. The maturity date of the loan was September 27, 2021. During the year ended December 31, 2022, the full amount of the loan and interest totaling $226,138 was converted into 205,984 shares of common stock (post reverse stock split) of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest divided by $5,000,000 times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion, being within the terms of the agreement.

 

On August 9, 2021, the company entered into a convertible loan agreement with an unrelated party to loan up to $195,000 at 9% interest, with a principal balance of $72,000, as of December 31, 2021. This loan included an original issuance discount of 5%, and included 195,000 Warrants at an exercise price of $1, exercisable for 5 years from the issue date on the face of the Warrant. The noteholder has the right to convert the principal and interest into common shares of the Company. The maturity date of the loan was February 9, 2022. During the year ended December 31, 2022, another $123,000 principal with an additional $6,150 original issuance discount, was loaned to the Company. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and entered into a new agreement for 225,000 warrants with an exercise price of $2.50. As of December 31, 2022, the loan was outstanding with a principal balance of $195,000, accrued interest of $35,078, amortization of debt discount of $8,393, and unamortized debt discount of $0. The warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and new warrants in accordance with the new terms were issued. We assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants. During the year ended December 31, 2022 the Company recorded an expense of $64,978.

 

On December 20, 2021, the company entered into a loan agreement with an unrelated party, with a principal balance of $25,000 at 6% interest. The maturity date of the loan was December 19, 2022. During the year ended December 31, 2022, the note principal was increased by $2,778 representing a 10% original issue discount pursuant to the enhanced terms mentioned below. As of December 31, 2022, the loan remained outstanding had accrued interest of $2,301. The loan was converted to common stock in February 2023 in connection with the Company IPO. Initially, the loan was estimated to be issued with 355,114 warrants. Subsequent to the entry into the December 20, 2021 the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $1M in face value of convertible bridge notes, as described in footnote 13. Pursuant to the enhanced terms, the warrants will not be issued until the note converts.

 

On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. As discussed in Footnote 2, a significant component of the Company’s plan to secure capital is the intention of the Company to seek to be listed on a national exchange through an initial public offering (“IPO”) of its common stock. WallachBeth was engaged in this regard and on April 28, 2022, the Company received net proceeds of approximately $775,000 from the sale of Convertible Bridge Notes and Warrants to several institutional investors as well as several individual accredited investors. In connection with the April 28th note sale, the Company paid approximately $91,560 in fees and expenses. In addition to the money received on April 28th, the Company also received $100,000 from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company sold one additional bridge note to an unrelated party, with a principal balance of $27,779. The Convertible Bridge Notes were issued with a 10% original issue discount and are convertible at the IPO at a 20% discount to the IPO price. The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price. The Convertible Bridge Notes maturity date was October 31, 2022. The Company has amended the Convertible Bridge Notes to extend the maturity date until December 31, 2022. The Company has filed an S-1 Registration Statement and conducted an IPO in February 2023. All of the Convertible Bridge Notes and accrued interest through November, 30, 2022 were converted at the IPO. Pursuant to further amendments to the notes, the maturity date was extended, interest accrued after November 30, 2022 though conversion will be paid to the holders in cash and the conversion right was revised to be equal to a $25 million dollar Company valuation, or $4.27, which was also established as the warrant exercise price.

 

As of December 31, 2022, the table below reflects the balances of the Convertible Bridge Notes sold pursuant April 11, 2022 agreement with WallachBeth. All notes are mandatorily converted at the IPO at the conversion ratio noted above and the purchasers will also be issued a warrant for each share of common stock issued upon conversion with an exercise price set by the exchange ratio. Due to the IPO price not yet being probable at year end, no current accounting for these warrants has been journalized.

 

 

Note Date   Purchase Price   Principal Balance   Original Issue Discount   Accrued Interest 
Note   Purchase   Principal   Original Issue   Accrued 
Date   Price   Balance   Discount   Interest 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $25,000   $27,778   $2,778   $1,708 
4/28/2022   $28,000   $31,111   $3,111   $1,913 
4/28/2022   $28,000   $31,111   $3,111   $1,913 
4/28/2022   $35,000   $38,889   $3,889   $2,392 
12/20/2021*   $25,000   $27,778   $2,778   $2,301 
4/13/2022*   $100,000   $111,111   $11,111   $7,111 
9/9/2022   $25,000   $27,778   $2,778   $1,088 
                      
Total   $1,016,000   $1,128,889   $112,889   $69,675 

 

* Notes sold by Company prior to the April 28, 2022 closing

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. The Company specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, if the equity securities underlying the conversion option are not readily convertible to cash, and the conversion option requires gross physical settlement of the underlying shares, the embedded conversion option may not meet the net settlement criterion, and therefore would not meet the definition of a derivative. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes. All conversions are contingent upon an effective IPO, which had not yet been considered probable.

 

XML 35 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Notes Payable Related Party
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Convertible Notes Payable Related Party    
Convertible Notes Payable Related Party

5. Convertible Notes – Related Party

 

SAFE Agreement

 

On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, at a purchase price of $150,000. The SAFE provided for no interest and terminated after conversion upon completion of the Company’s IPO. The SAFE provided for automatic conversion into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, defined as either: (1) the SAFE Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation results in a greater number of shares of SAFE Preferred Stock.

 

In February 2023, the SAFE terminated and converted into 32,967 shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $63,626 loss on the conversion.

 

As of December 31, 2022, the $150,000 received from the SAFE was recorded at 6% imputed interest.

 

August 2021 Note

 

On August 19, 2021, the Company entered into a convertible loan agreement with a related party, with a principal balance of $99,900, an original issuance discount of 5% and a 9% interest rate. The loan provided for a maturity date of February 19, 2022. The noteholder had the right to convert the principal and interest into common shares of the Company at a conversion price based on a discount to the IPO price.

 

In February 2023, the related party elected to convert the convertible loan into 21,747 shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $29,333 loss on the conversion.

 

In connection with the convertible loan agreement, the Company also issued 99,000 Warrants with an exercise price of $1.00 exercisable for five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and enter into a new agreement for 115,185 warrants with an exercise price of $2.50. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

 

 

NOTE 8 – CONVERTIBLE NOTES PAYABLE RELATED PARTY

 

On July 8, 2021, the company entered into a Simple Agreement for Future Equity (SAFE), with a related party, with an amount of $150,000, with 0% interest. Under the SAFE agreement, if there is an Equity Financing before the termination of this SAFE, on the initial closing of such Equity Financing, this SAFE will automatically convert into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, which means either: (1) the Safe Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation results in a greater number of shares of Safe Preferred Stock

 

If there is a Liquidity Event before the termination of this SAFE, this SAFE will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds, due and payable to the Investor immediately prior to, or concurrent with, the consummation of such Liquidity Event, equal to the greater of (i) the Purchase Amount (the “Cash-Out Amount”) or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the “Conversion Amount”). If any of the Company’s securityholders are given a choice as to the form and amount of Proceeds to be received in a Liquidity Event, the Investor will be given the same choice, provided that the Investor may not choose to receive a form of consideration that the Investor would be ineligible to receive as a result of the Investor’s failure to satisfy any requirement or limitation generally applicable to the Company’s securityholders, or under any applicable laws.

 

This SAFE will automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this SAFE) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this SAFE under agreement; or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to the agreement.

 

 

As of December 31, 2022 and 2021, the $150,000 received from SAFE was recorded at 6% imputed interest. The maturity date of the loan is defined by the SAFE agreement as discussed above.

 

On August 19, 2021, the company entered into a convertible loan agreement with a related party, with a principal balance of $99,900 at 9% interest. The noteholder has the right to convert the principal and interest into common shares of the Company. This loan included an original issuance discount of 5% and included 99,900 Warrants at an exercise price of $1, exercisable for 5 years from the issue date on the face of the Warrant. The maturity date of the loan was February 19, 2022. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and entered into a new agreement for 115,185 warrants with an exercise price of $2.50. As of December 31, 2022, the $99,900 principal and the $4,950 overpayment of the note remained outstanding and had accrued interest of $12,463.53. The warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and new warrants in accordance with the new terms were issued. We assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

 

The SAFE and the convertible loan agreement with accrued interest converted to common stock at the IPO.

 

The Company specified that an entity should adopt ASU 2020-06 as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, no derivative liabilities will be triggered from these convertible notes. See Note 7 for details.

 

XML 36 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Related Party
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Related Party Transactions [Abstract]    
Related Party

7. Related Party

 

During the nine months ended September 30, 2023, the Company issued 75,000 stock options to its Chief Financial Officer for services rendered.

 

During the year ended December 31, 2021, the Company issued 29,286 common stock options to related parties for services rendered. The options have an original life of 10 years and vest over different periods for up to 24 months. During the three months ended September 30, 2023 and 2022, the Company recognized $430 and $450, respectively, of stock-based compensation related to these options. During the nine months ended September 30, 2023 and 2022, the Company recognized $1,290 and $1,350, respectively, of stock-based compensation related to these options.

 

NOTE 9 –RELATED PARTY

 

During the year-ended December 31, 2021, there were 57,143 shares of common stock (post reverse stock split) issued to CFO Dane Saglio, for services rendered.

 

As of December 31, 2022 and 2021, the accrued salary for related parties was $566,916 and $285,666, respectively. The increase reflects salaries accrued for employees, but not paid in the year ended December 31, 2022.

 

As of December 31, 2022, the Company accrued consulting fees to related parties of $90,000 for services provided to the Company.

 

During the year ended December 31, 2021, the Company issued options totaling 29,286 shares of common stock (post reverse stock split) to related party for services rendered. The options have an original life of ten years and vest at different rates over as much as 24 months. During the year ended December 31, 2022, the Company did not issue any options and recognized $1,803 of stock-based compensation related to outstanding stock options.

 

XML 37 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholder’s Equity
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Equity [Abstract]    
Stockholder’s Equity

8. Stockholder’s Equity

 

Preferred Stock

 

The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.00001 with 5,500,000 being designated as Series A Convertible Preferred Stock. On October 5, 2022, the Company entered into an exchange agreement with an Investor providing for the exchange of 734,492 shares of commons stock into 73,449 shares of Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock is convertible at any time into 10 shares of the Company’s common stock. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. The Company evaluated the terms of the exchange and determined there was no significant change in fair value and therefore the Series A Preferred Stock was valued at $315,000 which is the Investor’s basis in the common stock that was exchanged.

 

Common Stock

 

The Company has 100,000,000 shares of common stock authorized at a par value of $0.00001. During the year ended December 31, 2022, the Company:

 

  Exchanged 734,429 shares of common stock for shares of Series A Convertible Preferred stock as noted above,
  Issued 205,984 shares of common stock pursuant to a conversion of $226,138 worth of convertible notes principal and interest,
  Cancelled 112,225 shares of common stock as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and
  Issued 38,879 shares of common stock pursuant to a license agreement valued at $189,828.

 

After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances.

 

 

In February 2023, the Company completed its IPO for the sale of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per Unit for a total of approximately $8.4 million of gross proceeds. Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share, and one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.

 

In connection with the completion of its IPO, the Company issued an aggregate of 331,166 shares of common stock upon the conversion of certain outstanding convertible debt.

 

In connection with the IPO, in February 2023, the Company completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.

 

In February 2023, the Company issued 7,692 shares of common stock for consulting services and recognized $50,000 of compensation expense related to these shares.

 

In the second quarter of 2023, we issued 436,533 shares of common stock following the exercise of 436,533 warrants for proceeds of $1,494,658.

 

Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of September 30, 2023, 3,796,164 warrants and 507,717 options for common shares were excluded in the calculation of net loss per share. As of September 30, 2022, 5,270,617 warrants and 484,525 options for common shares were excluded in the calculation of net loss per share.

 

2022 Equity Incentive Plan

 

In November 2022, the Company’s Board of Directors adopted, and its shareholders approved the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of 10 years and any exercise prices shall not be less than 100% of the fair market value of one share of common stock on the grant date. The Plan authorizes an initial maximum number of shares underlying awards of 900,000 with an automatic annual 15% increase beginning in 2024. As of September 30, 2023, there were 461,500 awards authorized but unissued available under the Plan.

 

Stock Options

 

The following table summarizes the stock option activity for the nine months ended September 30, 2023:

 

   Number of Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2022   69,217   $3.06    7.08   $117,669 
Granted   438,500   $4.41    -   $- 
Exercised   -   $-    -   $- 
Forfeited / canceled   -   $-    -   $- 
Outstanding at September 30, 2023   507,717   $4.23    9.17   $102,441 
Vested at September 30, 2023   215,623   $3.97    8.64   $52,644 

 

 

The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below:

 

   2023 
Expected dividend yield   0%
Expected volatility   87% - 92%
Risk-free interest rate   3.4%-4.1%
Expected life (in  years)   5.0-6.0

 

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2023 was $3.20. No options were issued in the nine months ended September 30, 2022.

 

No options were exercised in any of the periods presented.

 

During the three and nine months ended September 30, 2023, the Company recognized $116,410 and $475,465, respectively of compensation expense related to stock options. During the three and nine months ended September 30, 2022, the Company recognized $51,536 and $290,876 of compensation expense, respectively related to stock options.

 

As of September 30, 2023, the total unrecognized compensation expense related to unvested stock options, was approximately $936,000, which the Company expects to recognize over a weighted-average period of approximately 2.1 years.

 

Warrants

 

During the nine months ended September 30, 2023 and 2022, the Company granted a total of 3,195,906 and 56,623 warrants, respectively. The warrants have an original life of ten years and vest immediately and over 12 months. During the nine months ended September 30, 2023, warrants to purchase 22,939 shares vested and had a fair value of $35,712. During the year ended December 31, 2022, 174,105 shares of warrants were vested and amended with a fair value of $337,269, 51,941 shares of warrants were reclassified with a fair value of $11,097, and 42,057 shares of warrants with a fair value of $1,883 were forfeited.

 

During the year ended December 31, 2021, the Company granted a total of 431,659 warrants. Of this amount, 200,000 warrants, with a fair value of $12,462, were granted to advisors related to the Company’s IPO objective. The warrants have an original life of five years and vest 30 days before the intended IPO. During the year ended December 31, 2021, 0 shares of these warrants were vested. As of June 30, 2022, the warrants for 200,000 shares were cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. In 2021, 138,929 warrants, with a fair value of $28,683, were issued for services rendered. The warrants have an original life of ten years and vest at different rates over as much as 36 months.

 

During the year ended December 31, 2021, the Company issued 92,859 warrants with a fair value of $12,980, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of five years. During the period ending June 30, 2022, the Company determined that 50,735 warrants, with a fair value of $11,097, should not have been issued. The fair value was reclassified to Additional Paid in Capital. In May 2022, the Company and the note holders agreed to cancel and void the previous 99,000 warrants and entered into a new agreement for 115,185 warrants and the exercise price increased to $2.50 from $1, with a fair value of $15,412. In May 2022, the Company and the note holders agreed to cancel and void the previous 195,000 warrants and entered into a new agreement for 225,000 warrants with an exercise price of $2.50, with a fair value of $64,978.

 

 

The 92,859 warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and these individuals were issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants.

 

During the nine months ended September 30, 2023, the Company issued the following warrants:

 

  In February 2023, in connection with the completion of the initial public offering, the Company issued 276,452 contingent warrants to certain debt holders with an exercise price of $4.27 and an expiration date 5 years from issuance.
  In February 2023, in connection with the completion of the initial public offering, the Company issued 18,000 contingent warrants as fees to the Company’s underwriters with an exercise price of $8.125 and an expiration date 4 years from issuance.
  As part of the sale of units in the Company’s initial public offering the Company issued 1,297,318 tradable warrants with an exercise price of $7.80 and an expiration date 5 years from issuance. Also, as part of the sale of units in the Company’s initial public offering, the Company issued 1,297,318 non-tradable warrants with an exercise price of $8.125 and an expiration date 5 years from issuance.
  In February 2023, as part of the Company’s initial public offering, the Company issued 153,409 tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $7.80 and an expiration date 5 years from issuance. Also in February 2023, as part of the Company’s initial public offering the Company issued 153,409 non-tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $8.125 and an expiration date 5 years from issuance.

 

During the three and nine months ended September 30, 2023, the Company recognized $5,050 and $35,712, respectively of compensation expense related to certain warrants. During the three and nine months ended September 30, 2022, the Company recognized $51,086 and $289,317 of compensation expense related to certain warrants. As of September 30, 2023, the total unrecognized compensation expense related to unvested warrants was $6,556, which the Company expects to recognize over a weighted-average period of approximately 0.4 years.

 

The following table provides details over the Company’s outstanding warrants as of September 30, 2023:

 

Exercise Price   Expiration  Number of Warrants 
$0.0007   2030   274,286 
$2.10 - $2.66   2026 - 2032   460,445 
$3.36 - $4.27   2028 - 2029   115,277 
$6.51 - $7.80   2026 - 2032   1,484,929 
$8.125   2027 - 2028   1,461,227 
         3,796,164 

 

NOTE 10– SHAREHOLDER’S DEFICT

 

 Preferred Stock

 

The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.00001. As of December 31, 2021, there were no preferred shares issued. On October 5, 2022, the Company entered into an exchange agreement with the Investor whereby all of his common stock, 734,492 shares of commons stock (post reverse stock split), were exchanged into 73,449 shares of Series A Convertible Preferred Stock (post reverse stock split). Per the agreement the exchange was based on a 1 Series A Convertible Preferred Stock for each 10 shares of common stock. Each holder of Series A Preferred Stock may, from time to time, convert any or all of such holder’s shares of Series A Preferred Stock into fully paid and nonassessable shares of Common Stock in an amount equal to ten shares of common stock for each one share of Series A Preferred Stock surrendered. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. The Company evaluated the terms of the exchange and determined there would be no significant change in fair value and therefore no accounting entry recorded as a result of the exchange. The value of the Series A Preferred Stock was determined to be $315,000 which is the Investor’s basis in the common stock that was exchanged.

 

Common Stock

 

In June of 2020, BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock. Share amounts in our financial statements for December 31, 2022 and 2021, have been adjusted to reflect this forward share split and shares exchange. All of our operations are currently conducted through BullFrog AI Holdings, Inc. BullFrog AI, Inc., is a wholly owned subsidiary, has the sole purpose of housing and protecting all of the organization’s intellectual property. BullFrog AI Management, LLC is a wholly owned subsidiary that handles all HR and payroll activities.

 

The Company has 100,000,000 shares of common stock authorized at a par value of $0.00001. During year ended December 31, 2022, 734,492 shares of common stock (post reverse stock split) were exchanged for preferred shares as noted above, 205,984 shares of common stock (post reverse stock split) were issued for conversion of principal and interest of $226,138 by a noteholder, 112,225 shares of common stock (post reverse stock split) were canceled as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and 38,879 shares of common stock (post reverse stock split) were issued under a license agreement and valued at $189,828, see Note 12 for further discussion. As of December 31, 2022 and 2021, there are 4,021,935 and 4,622,789, shares of common stock (post reverse stock split) outstanding, respectively.

 

 

After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances.

 

Our Board of Directors and stockholders approved an amendment to our Certificate of Incorporation to effect a 1-for-7 reverse stock split of our common stock in connection with the offering, subsequent to the year ended December 31, 2022. As a result of the reverse stock split, every 7 shares of our outstanding common stock will be combined and reclassified into one share of our common stock. Unless otherwise noted, the share and per share information in this Form 10-K filing reflects, other than in our historical financial statements and the notes thereto, a proposed reverse stock split of the outstanding common stock of the Company at an assumed 1-for-7 ratio.

 

Stock Options

 

During the first quarter of 2022, 399,354 shares of options (post reverse stock split) were forfeited due to the termination of employment.

 

During the year ended December 31, 2021, the Company granted a total of 29,286 shares of options (post reverse stock split) to employees of the Company for services rendered. The options have an original life of ten years and vest at different rates over as much as 48 months. During the years ended December 31, 2021, the Company vested 1,310 of these options (post reverse stock split) and recognized $157 of stock-based compensation related to outstanding stock options. During the year ended December 31, 2022, 16,601 shares of these options (post reverse stock split) were vested and $2,010 stock-based compensation was recognized.

 

The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021:

 

Granted and outstanding, December 31, 2020   884,821 
Granted during 2021   29,286 
Exercised   - 
Forfeited   - 
Expired during 2021   (445,536)
Granted and outstanding, December 31, 2021   468,571 
Granted during 2022   - 
Exercised   - 
Forfeited   (399,354)
Expired during 2022   - 
Granted and outstanding, December 31, 2022   69,217 

 

   Options   Intrinsic Value of Vested Options   Weight Averaged exercise Price 
Vested and outstanding, December 31, 2020   104,795    12,706    3.36 
Granted and vested during 2021   1,310    157    2.66 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   (66,524)   (7,922)   (3.36)
Vested and outstanding, December 31, 2021   39,581    4,941    3.36 
Granted and vested during  2022   16,661    2,010    2.73 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   -    -    - 
Vested and outstanding, December 31, 2022   56,242    6,951    3.15 

 

As of December 31, 2022 and 2021, 16,661 and 1,310 options (post reverse stock split) vested, respectively, 0 and 66,524 (post reverse stock split) options expired and the outstanding stock options have a weighted average remaining life of 7.08 and 7.38 years, respectively.

 

As of December 31, 2022 and 2021, the fair value of options vested and outstanding was $ 6,951 and $4,941, respectively. The aggregate fair value of the options measured during the year ended December 31, 2022 and 2021 was calculated using the Black-Scholes option pricing model based on the following assumption:

 

   December 31, 2022   December 31, 2021 
Fair Value of Common Stock on measurement date  $4.76   $0.308 
Risk free interest rate   From 0.79% to 3.01%   From 1.26% to 1.33%
Volatility   89%   93%
Dividend Yield   0%   0%
Expected Term   4-10    10 

 

(1)The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
 (2)The trading volatility was determined by calculating the volatility of the Company’s peer group.
 (3)The Company does not expect to pay a dividend in the foreseeable future.

 

 

Warrants

 

During the year ended December 31, 2022, the Company granted a total of 123,660 warrants (post reverse stock split). The warrants have an original life of four to ten years and vest immediately and over 12 months. During the year ended December 31, 2022, 174,105 shares of warrants (post reverse stock split) were vested and amended with an intrinsic value of $337,269, 51,941 shares of warrants (post reverse stock split) were reclassified with an intrinsic value of $11,097, and 42,057 shares of warrants (post reverse stock split) with an intrinsic value of $1,883 were forfeited.

 

During the year ended December 31, 2021, the Company granted a total of 431,659 warrants (post reverse stock split). Of this amount 200,000 warrants (post reverse stock split), with a fair value of $12,462, were granted to advisors related to the Company’s IPO objective. The warrants have an original life of five years and vest 30 days before the intended IPO. During the year ended December 31, 2021, 0 shares of these warrants were vested. As of June 30, 2022, the warrants for 200,000 shares (post reverse stock split) were cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. In 2021, 138,929 warrants (post reverse stock split), with a fair value of $28,683, were issued for services rendered. The warrants have an original life of ten years and vest at different rates over as much as 36 months.

 

During the year ended December 31, 2021, the Company issued 92,859 warrants (post reverse stock split) with a fair value of $12,980, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of five years. During the period ending June 30, 2022, the Company determined that 50,735 warrants (post reverse stock split), with a fair value of $11,097, should not have been issued as further described in footnote 8. The fair value was reclassified to Additional Paid in Capital. As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous 99,000 warrants (post reverse stock split) and entered into a new agreement for 115,185 (post reverse stock split) and the exercise price increased to $2.50 from $1, with a fair value of $15,412. As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous 195,000 (post reverse stock split) warrants and entered into a new agreement for 225,000 warrants (post reverse stock split) with an exercise price of $2.50, with a fair value of $64,978.

 

The 92,859 warrants (post reverse stock split) discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and these individuals were or will be issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants.

 

The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021,

 

   Warrants 
Granted and outstanding, December 31, 2020   495,714 
Granted during 2021   431,659 
Exercised   - 
Forfeited   - 
Expired during 2021   - 
Granted and outstanding, December 31, 2021   927,373 
Granted during 2022   123,660 
Exercised   - 
Forfeited   (298,088)
Expired during 2022   - 
Granted and outstanding, December 31, 2022   752,945 

 

   Warrants   Intrinsic Value of Warrants   Weight Averaged exercise Price 
Vested and outstanding, December 31, 2020   479,940    127,480    0.98 
Granted and Vested 2021   137,552    22,208    3.15 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   -    -    - 
Vested and outstanding, December 31, 2021   617,492    149,688    2.80 
Granted and Vested 2022   174,105    337,263    3.15 
Exercised   -    -    - 
Forfeited   (94,665)   (12,980)   - 
Expired   -    -    - 
Vested and outstanding, December 31, 2022   696,932    473,971    1.96 

 

 

As of December 31, 2022, 752,945 warrants (post reverse stock split) are outstanding, and 696,932 warrants (post reverse stock split) vested, and the vested stock warrants have a weighted average remaining life of 7.13 years.

 

For the year ended December 31, 2022, the aggregate fair value of warrants vested was $324,283. The aggregate fair value of the warrants measured during the year ended December 31, 2022 was calculated using the Black-Scholes option pricing model and recorded as stock-based compensation.

 

For the year ended December 31, 2021, 927,516 warrants (post reverse stock split) are outstanding, 617,492 warrants (post reverse stock split) are vested with an intrinsic value of $22,208, and the vested stock warrants have a weighted average remaining life of 7.73 years.

 

As of December 31, 2021, the aggregate fair value of warrants vested was $149,688. The aggregate fair value of the warrants measured during the year-ended December 31, 2021 was calculated using the Black-Scholes option pricing model.

 

The number of warrants related to the Convertible Bridge Notes discussed Note 7 is not yet determinable, given some of the terms discussed in Note 8 have not been completed. Therefore, the warrants to be issued are not accounted for in our warrants outstanding. Due to the IPO price not being completed at December 31, 2022, no current accounting for these warrants has been journalized.

 

   December 31, 2022   December 31, 2021 
Fair Value of Common Stock on measurement date  $4.76   $0.308 
Risk free interest rate   From 1.86% to 1.97%   From 0.78% to 1.63%
Volatility   89%   93%
Dividend Yield   0%   0%
Expected Term   10 years    5-10 years 

 

(1)The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
 (2)The trading volatility was determined by calculating the volatility of the Company’s peer group.
 (3)The Company does not expect to pay a dividend in the foreseeable future.
 (4)After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances for all 2022 grant date stock prices.

 

Exercise Price   Expiration  Number of Warrants 
$0.0007   2030   274,286 
$2.10 - $2.66   2026 - 2032   460,445 
$3.36 - $4.27   2028 - 2029   115,277 
$6.51 - $7.80   2026 - 2032   1,484,929 
$8.125   2027 - 2028   1,461,227 
         3,796,164 

XML 38 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Income Taxes

9. Income Taxes

 

The Company has not recorded any tax provision or benefit for the three and nine months ended September 30, 2023 and 2022. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefits from deductible temporary differences, net operating loss carryforwards and research and development credits are not more-likely-than-not to be realized at September 30, 2023 and December 31, 2022.

 

 

NOTE 11 – INCOME TAXES

 

As of December 31, 2022, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $4,399,055, that do not expire, that may be used to offset future taxable income, but could be limited under Section 382. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.

 

We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.

 

Tax position that meets the more likely than not threshold is then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. We file income tax returns in the U.S. and in the state of California and Utah with varying statutes of limitations.

 

The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following:

 

   2022   2021 
Non-Current deferred tax asset:          
Net operating loss carryforwards  $924,000   $339,000 
Valuation allowance   (924,000)   (339,000)
Net non-current deferred tax asset  $   $ 

 

 

XML 39 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Material Agreements
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Material Agreements    
Material Agreements

10. Material Agreements

 

JHU-APL Technology License

 

On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five percent (5%) of the then fully diluted equity base of the Company, which shall be diluted following the closing of the IPO. Under the terms of the License Agreement, JHU will be entitled to eight percent (8%) royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty percent (50%) of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual royalty payments are $20,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breach, the Company shall have 60 days to cure the material breach. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights, and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued 279,159 shares of common stock. Under the terms of the new License Agreement, JHU will be entitled to eight percent (8%) of net sales for the services provided by the Company to other parties and three percent (3%) for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $30,000 for 2022, $60,000 for 2023, and $300,000 for 2024 and beyond.

 

On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $275,000. The first of these payments for $75,000 was due in July 2023 followed by payments of $75,000, $75,000 and $50,000 in years 2025, 2026 and 2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $60,000, all other financial terms remain the same. As of September 30, 2023, we have accrued $45,000 of the 2023 minimum annual royalty payments.

 

George Washington University - Beta2-spectrin siRNA License

 

On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

 

In consideration of the rights granted to the Company under the License Agreement the Company paid GWU a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, there has been no accrual for royalties since we have not begun to generate applicable revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

 

Johns Hopkins University – Mebendazole License

 

On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021).

 

The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $250,000. The initial payment for $50,000 was paid and the remaining balance of $200,000 was paid after the Company completed its IPO. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three and one-half percent (3.5%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $5,000 for 2023, $10,000 for 2024, $20,000 for 2025, $30,000 for 2026 and $50,000 for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, the balance of accrued expense related to this license agreement was $7,500 and $242,671, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

Johns Hopkins University – Prodrug License

 

On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (4.0%) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $5,000 for 2027, $10,000 for 2028, $20,000 for 2029, $30,000 for 2030 and $50,000 for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $150,000. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, the balance of accrued expense related to this license agreement was $0 and $133,238, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.

NOTE 12 – MATERIAL AGREEMENTS

 

JHU-APL Technology License

 

On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, 1 new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an Amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five (5%) percent of the then fully diluted equity base of the Company, which shall be diluted following the closing of this offering. Under the terms of the License Agreement, JHU will be entitled to eight (8%) percent royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty (50%) percent of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual royalty payments are $20,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breech, the Company shall have 60 days to cure the material breech. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued 279,159 shares of common stock. (see note 10) Under the terms of the new License Agreement, JHU will be entitled to eight (8%) percent of net sales for the services provided by the Company to other parties and 3% for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to 25% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $30,000 for 2022, $80,000 for 2023, and $300,000 for 2024 and beyond. As of December 31, 2022, we have accrued, $30,000 of the 2022 minimum annual royalty payments. See Note 10 for details on common shares and warrants issued related to this agreement.

 

George Washington University - Beta2-spectrin siRNA License

 

On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

 

In consideration of the rights granted to the Company under the License Agreement GWU received a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of December 31, 2022, there has been no accrual for royalties, since we have not begun revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

Johns Hopkins University – Mebendazole License

 

On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to mebendazole at any dose during the trial. 41.7% of patients who received mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021).

 

 

The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $250,000. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three- and one-half percent (3.5%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $5,000 for 2023, $10,000 for 2024, $20,000 for 2025, $30,000 for 2026 and $50,000 for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $250,000. The initial payment for $50,000 was paid and the remaining balance is deferred until the earlier of; we complete the IPO, raise $10 million in financing or until 9 months from the effective date of the license. As of December 31, 2022, the balance of accrued expense related to this license agreement was $242,671. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

Johns Hopkins University – Prodrug License

 

On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (4.0%) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $5,000 for 2027, $10,000 for 2028, $20,000 for 2029, $30,000 for 2030 and $50,000 for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $150,000. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of December 31, 2022, the balance of accrued expense related to this license agreement was $133,238. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.

 

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

NOTE 13 – COMMITMENTS AND CONTINGENCIES

 

The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

 

XML 41 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

NOTE 14 – SUBSEQUENT EVENTS

 

On February 14, 2023 the Company conducted its initial public offering of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per unit for a total of approximately $8.4 million of gross proceeds to the Company. Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share, and one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125. The offering closed on February 16, 2023.

 

In connection with the offering, the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock. Also, in connection with the IPO a SAFE and convertible loan agreement held by a related party converted into 55,787 shares of post reverse common stock. Additionally, all outstanding Convertible Bridge Notes and accrued interest through November 30, 2022 were converted into 276,289 shares common stock and 276,289 warrants to purchase common stock were issued to the Convertible Bridge Note holders at conversion. The Bridge Note conversions and the warrant exercise pricing was determined using a $25 million dollar company valuation immediately before the IPO.

 

Between April 5 and April 13, 2023, the holders of warrants exercised 436,533 warrants for common shares at various exercise prices and the Company received proceeds of approximately $1,495,000.

XML 42 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Policies)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Use of Estimates in the Preparation of Financial Statements  

Use of Estimates in the Preparation of Financial Statements

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates.

 

 

Financial Instruments  

Financial Instruments

 

The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments.

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:

 

Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue based on the following five step model:

 

- Identification of the contract with a customer
  This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.
- Identification of the performance obligations in the contract
  This step describes how distinct performance obligations in the contract must be handled.
- Determination of the transaction price
  This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer.
- Allocation of the transaction price to the performance obligations in the contract
  This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services.
- Recognition of revenue when, or as, the Company satisfies a performance obligation
  Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.

 

Revenue Recognition

 

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had no revenue. In Q4 2022 the Company recognized its first service revenues in the amount of $10,000 related to the achievement of a contract milestone under a contract with a Pharmaceutical company. In compliance with the agreement, we have met the following milestones – receipt of data for analysis; data conversion and staging for ingestion. For the years-ended December 31, 2022 and 2021, our balance sheet reflects customer down payment received in early 2022 and late 2021 as unearned revenue in the amount of $32,000 and $10,000, respectively. This unearned revenue represents payments received from a leading rare disease non-profit organization under a contract with a single deliverable. As is more fully discussed below, we are of the opinion that none of our contracts for products contain significant financing components that require revenue adjustment under FASB ASC Topic 606.

 

Revenue is recognized based on the following five step model:

 

  -

Identification of the contract with a customer

This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services

  -

Identification of the performance obligations in the contract

This step describes how distinct performance obligations in the contract must be handled

  -

Determination of the transaction price

This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer

  -

Allocation of the transaction price to the performance obligations in the contract

This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services

  -

Recognition of revenue when, or as, the Company satisfies a performance obligation

Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen

 

 

Contract Services

 

The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis.

 

Collaborative Arrangements

 

The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement.

 

Acquisition of Rights to Certain Drugs

In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties.

 

Use of Estimates  

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

 

Cash  

Cash

 

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $57,670 and $10,014, respectively.

 

Concentrations of Credit Risk  

Concentrations of Credit Risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

 

 

Accounts Receivable  

Accounts Receivable

 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

 

Allowance for Doubtful Accounts  

Allowance for Doubtful Accounts

 

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $0.

 

 

Inventories  

Inventories

 

The Company does not have inventory and does not plan to have inventory in the near future.

 

Cost of Sales  

Cost of Sales

 

Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $800 as cost of goods sold which represents the 8% royalty on the $10,000 in service revenue in 2022.

 

Property and Equipment  

Property and Equipment

 

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.

 

Advertising  

Advertising

 

The Company follows the policy of charging the costs of advertising to expense as incurred.

 

Income Taxes  

Income Taxes

 

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits.

 

Stock-Based Compensation  

Stock-Based Compensation

 

Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.

 

Net Loss per Share  

Net Loss per Share

 

We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, 927,373 and 753,174 warrants (post reverse stock split) were not included in the calculation of net loss per share, respectively. In addition, 486,571 and 56,242 options for common shares (post reverse stock split) were not included in the calculation of net loss per share, respectively.

 

 

Impact of Recently Issued Accounting Standards

Impact of Recently Issued Accounting Standards

 

The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.

 

We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

 

The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842.

 

All staff are working remotely; therefore, the Company does not currently have a lease or rent office space.

 

Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate.

 

The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.

 

In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes.

 

In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements.

 

 

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

 

COVID-19  

COVID-19

 

In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders.

 

Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services.

 

It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period.

 

The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock.

 

Going Concern  

Going Concern

 

The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.

Basis of Presentation

Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation.

 

 

The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows.

 

The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period.

 

On February 13, 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.

 

 
Contract Services

Contract Services

 

The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.

 

 
Significant Accounting Policies

Significant Accounting Policies

 

There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

 
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Notes Payable (Tables)
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Convertible Debt
Note Date   Purchase Price   Principal Balance   Original Issue Discount   Accrued Interest 
Note   Purchase   Principal   Original Issue   Accrued 
Date   Price   Balance   Discount   Interest 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $250,000   $277,778   $27,778   $17,083 
4/28/2022   $25,000   $27,778   $2,778   $1,708 
4/28/2022   $28,000   $31,111   $3,111   $1,913 
4/28/2022   $28,000   $31,111   $3,111   $1,913 
4/28/2022   $35,000   $38,889   $3,889   $2,392 
12/20/2021*   $25,000   $27,778   $2,778   $2,301 
4/13/2022*   $100,000   $111,111   $11,111   $7,111 
9/9/2022   $25,000   $27,778   $2,778   $1,088 
                      
Total   $1,016,000   $1,128,889   $112,889   $69,675 

 

* Notes sold by Company prior to the April 28, 2022 closing
XML 44 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholder’s Equity (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Schedule of Stock Options Activity

The following table summarizes the stock option activity for the nine months ended September 30, 2023:

 

   Number of Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2022   69,217   $3.06    7.08   $117,669 
Granted   438,500   $4.41    -   $- 
Exercised   -   $-    -   $- 
Forfeited / canceled   -   $-    -   $- 
Outstanding at September 30, 2023   507,717   $4.23    9.17   $102,441 
Vested at September 30, 2023   215,623   $3.97    8.64   $52,644 

The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021:

 

Granted and outstanding, December 31, 2020   884,821 
Granted during 2021   29,286 
Exercised   - 
Forfeited   - 
Expired during 2021   (445,536)
Granted and outstanding, December 31, 2021   468,571 
Granted during 2022   - 
Exercised   - 
Forfeited   (399,354)
Expired during 2022   - 
Granted and outstanding, December 31, 2022   69,217 
Schedule of Vested and Outstanding Options  

   Options   Intrinsic Value of Vested Options   Weight Averaged exercise Price 
Vested and outstanding, December 31, 2020   104,795    12,706    3.36 
Granted and vested during 2021   1,310    157    2.66 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   (66,524)   (7,922)   (3.36)
Vested and outstanding, December 31, 2021   39,581    4,941    3.36 
Granted and vested during  2022   16,661    2,010    2.73 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   -    -    - 
Vested and outstanding, December 31, 2022   56,242    6,951    3.15 
Schedule of Black Scholes Option Pricing Model

The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below:

 

   2023 
Expected dividend yield   0%
Expected volatility   87% - 92%
Risk-free interest rate   3.4%-4.1%
Expected life (in  years)   5.0-6.0

 

   December 31, 2022   December 31, 2021 
Fair Value of Common Stock on measurement date  $4.76   $0.308 
Risk free interest rate   From 0.79% to 3.01%   From 1.26% to 1.33%
Volatility   89%   93%
Dividend Yield   0%   0%
Expected Term   4-10    10 
Schedule of Stock Warrant Activity  

The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021,

 

   Warrants 
Granted and outstanding, December 31, 2020   495,714 
Granted during 2021   431,659 
Exercised   - 
Forfeited   - 
Expired during 2021   - 
Granted and outstanding, December 31, 2021   927,373 
Granted during 2022   123,660 
Exercised   - 
Forfeited   (298,088)
Expired during 2022   - 
Granted and outstanding, December 31, 2022   752,945 
Schedule of Vested And Outstanding Warrants  

   Warrants   Intrinsic Value of Warrants   Weight Averaged exercise Price 
Vested and outstanding, December 31, 2020   479,940    127,480    0.98 
Granted and Vested 2021   137,552    22,208    3.15 
Exercised   -    -    - 
Forfeited   -    -    - 
Expired   -    -    - 
Vested and outstanding, December 31, 2021   617,492    149,688    2.80 
Granted and Vested 2022   174,105    337,263    3.15 
Exercised   -    -    - 
Forfeited   (94,665)   (12,980)   - 
Expired   -    -    - 
Vested and outstanding, December 31, 2022   696,932    473,971    1.96 
Schedule of Outstanding Warrants

The following table provides details over the Company’s outstanding warrants as of September 30, 2023:

 

Exercise Price   Expiration  Number of Warrants 
$0.0007   2030   274,286 
$2.10 - $2.66   2026 - 2032   460,445 
$3.36 - $4.27   2028 - 2029   115,277 
$6.51 - $7.80   2026 - 2032   1,484,929 
$8.125   2027 - 2028   1,461,227 
         3,796,164 

 

Exercise Price   Expiration  Number of Warrants 
$0.0007   2030   274,286 
$2.10 - $2.66   2026 - 2032   460,445 
$3.36 - $4.27   2028 - 2029   115,277 
$6.51 - $7.80   2026 - 2032   1,484,929 
$8.125   2027 - 2028   1,461,227 
         3,796,164 

Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Schedule of Black Scholes Option Pricing Model  

   December 31, 2022   December 31, 2021 
Fair Value of Common Stock on measurement date  $4.76   $0.308 
Risk free interest rate   From 1.86% to 1.97%   From 0.78% to 1.63%
Volatility   89%   93%
Dividend Yield   0%   0%
Expected Term   10 years    5-10 years 
XML 45 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Deferred Taxes

The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following:

 

   2022   2021 
Non-Current deferred tax asset:          
Net operating loss carryforwards  $924,000   $339,000 
Valuation allowance   (924,000)   (339,000)
Net non-current deferred tax asset  $   $ 
XML 46 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 13, 2023
Feb. 28, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
First service revenue     $ 65,000 $ 65,000 $ 10,000
Unearned revenue         32,000 10,000
Cash balances             57,670 10,014
Allowance for doubtful accounts             0 0
Cost of services     $ 5,200 $ 5,200 $ 800
Royalty percent             8.00%  
Number of options             753,174 927,373
Reverse stock split             1-for-7 reverse stock split  
IPO [Member]                
Reverse stock split completed a 1-for-7 reverse split of our common stock.              
Common Stock [Member]                
Number of options         507,717 484,525 56,242 486,571
Common Stock [Member] | IPO [Member]                
Reverse stock split   completed a 1-for-7 reverse split of our common stock.            
XML 47 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]        
Payment to acquire equiment $ 8,744 $ 8,744
Accumulated depreciation     1,045  
Property and equipment net 6,406   7,699
Depreciation $ 1,293 $ 604 $ 1,045
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accounts payable and accrued expenses $ 1,526,981 $ 422,817
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Notes Payable (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Feb. 28, 2023
Sep. 30, 2023
Sep. 30, 2022
Jan. 31, 2023
May 05, 2020
Short-Term Debt [Line Items]          
Repayments in installments   $ 319,950    
Short-Term Debt [Member]          
Short-Term Debt [Line Items]          
Notes payable $ 697,534     $ 100,000  
Accrued interest 6.50%     9.00%  
Original issuance discount rate       20.00%  
Repayments in installments $ 71,485        
Outstanding balance   213,290      
Prepaid expenses   $ 307,735      
SBA PPP Loan [Member]          
Short-Term Debt [Line Items]          
Notes payable         $ 9,917
Accrued interest         1.00%
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Notes Payable Related Party (Details Narrative) - USD ($)
1 Months Ended
Dec. 13, 2021
Nov. 19, 2021
Jun. 15, 2021
Dec. 31, 2021
Sep. 30, 2023
Dec. 31, 2022
Notes Payable Related Party            
Short term loan $ 10,000 $ 5,000 $ 34,000 $ 213,290
Accruing interest rate 5.00% 5.00% 5.00% 5.00%    
Interest rate 1.00% 1.00% 1.00% 1.00%    
Short term loan       $ 49,000    
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Convertible Debt (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Original Issue Discount $ 0 $ 12,962
Convertible Debt One [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price 250,000  
Principal Balance 277,778  
Original Issue Discount 27,778  
Accrued Interest $ 17,083  
Note Date Apr. 28, 2022  
Convertible Debt Two [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 250,000  
Principal Balance 277,778  
Original Issue Discount 27,778  
Accrued Interest $ 17,083  
Note Date Apr. 28, 2022  
Convertible Debt Three [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 250,000  
Principal Balance 277,778  
Original Issue Discount 27,778  
Accrued Interest $ 17,083  
Note Date Apr. 28, 2022  
Convertible Debt Four [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 25,000  
Principal Balance 27,778  
Original Issue Discount 2,778  
Accrued Interest $ 1,708  
Note Date Apr. 28, 2022  
Convertible Debt Five [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 28,000  
Principal Balance 31,111  
Original Issue Discount 3,111  
Accrued Interest $ 1,913  
Note Date Apr. 28, 2022  
Convertible Debt Six [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 28,000  
Principal Balance 31,111  
Original Issue Discount 3,111  
Accrued Interest $ 1,913  
Note Date Apr. 28, 2022  
Convertible Debt Seven [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 35,000  
Principal Balance 38,889  
Original Issue Discount 3,889  
Accrued Interest $ 2,392  
Note Date Apr. 28, 2022  
Convertible Debt Eight [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 25,000  
Principal Balance 27,778  
Original Issue Discount 2,778  
Accrued Interest $ 2,301  
Note Date [1] Dec. 20, 2021  
Convertible Debt Nine [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 100,000  
Principal Balance 111,111  
Original Issue Discount 11,111  
Accrued Interest $ 7,111  
Note Date [1] Apr. 13, 2022  
Convertible Debt Ten [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 25,000  
Principal Balance 27,778  
Original Issue Discount 2,778  
Accrued Interest $ 1,088  
Note Date Sep. 09, 2022  
Convertible Debt [Member] | Wallach Beth [Member]    
Short-Term Debt [Line Items]    
Purchase Price $ 1,016,000  
Principal Balance 1,128,889  
Original Issue Discount 112,889  
Accrued Interest $ 69,675  
[1] Notes sold by Company prior to the April 28, 2022 closing
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Notes Payable (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2023
Apr. 28, 2022
Dec. 20, 2021
Aug. 31, 2021
Aug. 19, 2021
Aug. 09, 2021
Mar. 27, 2020
Sep. 30, 2022
Apr. 30, 2022
Aug. 31, 2021
Dec. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
May 31, 2022
Short-Term Debt [Line Items]                                
Conversion of stock, value                       $ 226,138 $ 226,138  
Conversion of stock, shares                           205,984    
Unamortized debt discount                     $ 0     $ 0 12,962  
Amortization of debt discount                       20,000 174,998 214,429 12,665  
Proceeds from notes payable                       $ 100,000      
Convertible Bridge Notes And Warrants [Member]                                
Short-Term Debt [Line Items]                                
Conversion of stock, shares 269,513                              
Debt description               The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price.                
Convertible Loan Agreement [Member]                                
Short-Term Debt [Line Items]                                
Principal balance       $ 195,000   $ 195,000       $ 195,000            
Interest rate       9.00% 9.00% 9.00%       9.00%            
Maturity date         Feb. 19, 2022 Feb. 09, 2022       Feb. 09, 2022            
Conversion of stock, shares 21,747   6,939                          
Principal balance                     $ 123,000     $ 123,000 72,000  
Original issuance discount rate       5.00% 5.00% 5.00%                    
Number of warrants 99,000   355,114   99,900 195,000         195,000     195,000   225,000
Exercise price $ 1.00       $ 1 $ 1         $ 1.00     $ 1.00   $ 2.50
Warrants term         5 years 5 years         5 years     5 years    
Unamortized debt discount                     $ 6,150     $ 6,150    
Accrued interest                     35,078     35,078    
Proceeds from notes payable                           123,000 $ 72,000  
Conversion discount rate                   20.00%            
Convertible Loan Agreement [Member] | August 2021 [Member]                                
Short-Term Debt [Line Items]                                
Principal balance                     195,000     195,000    
New Agreement [Member]                                
Short-Term Debt [Line Items]                                
Principal balance                     195,000     195,000    
Number of warrants                               225,000
Exercise price                               $ 2.50
Unamortized debt discount                     0     0    
Accrued interest                     35,078     35,078    
Amortization of debt discount                           8,393    
Warrant expenses                           $ 64,978    
Loan Agreement [Member]                                
Short-Term Debt [Line Items]                                
Interest rate     6.00%                          
Maturity date     Dec. 19, 2022                          
Principal balance     $ 25,000                          
Original issuance discount rate     10.00%                     10.00%    
Accrued interest                     $ 2,301     $ 2,301    
Prncipal balance increase                           2,778    
Proceeds from notes payable     $ 25,000           $ 1,000,000              
Maryland Technology Development Corporation [Member] | Convertible Loan Agreement [Member]                                
Short-Term Debt [Line Items]                                
Principal balance             $ 200,000                  
Interest rate             6.00%                  
Maturity date             Sep. 27, 2021                  
Conversion of stock, value                           $ 226,138    
Conversion of stock, shares                           205,984    
Fully diluted equity             $ 5,000,000                  
Wallach Beth [Member]                                
Short-Term Debt [Line Items]                                
Fees expense   $ 91,560                            
Wallach Beth [Member] | Convertible Bridge Notes And Warrants [Member]                                
Short-Term Debt [Line Items]                                
Principal balance               $ 27,779         $ 27,779      
Maturity date               Oct. 31, 2022                
Original issuance discount rate   10.00%           10.00%                
Exercise price               $ 4.27     $ 4.27   $ 4.27 $ 4.27    
Proceeds from notes payable   $ 775,000           $ 25,000                
Fees expense   91,000                            
Sale of stock value   $ 100,000                            
Conversion discount rate               20.00%                
Debt description               The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price.                
Maturity date extended               Dec. 31, 2022                
Conversion value               $ 25,000,000     $ 25,000,000          
Conversion price                     $ 4.27     $ 4.27    
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Notes Payable Related Party (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Feb. 28, 2023
Dec. 20, 2021
Aug. 31, 2021
Aug. 19, 2021
Aug. 09, 2021
Aug. 31, 2021
Dec. 31, 2022
May 31, 2022
Dec. 31, 2021
Jul. 08, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Conversion of stock, shares             205,984      
Simple Agreement for Future Equity [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable related party             $ 150,000   $ 150,000 $ 150,000
Interest rate             6.00%   6.00% 0.00%
Conversion of stock, shares 32,967                  
Loss on the conversion $ 63,626                  
Simple Agreement for Future Equity [Member] | Related Party [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Notes payable                   $ 150,000
Convertible Loan Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable related party       $ 99,900            
Interest rate     9.00% 9.00% 9.00% 9.00%        
Original issuance discount rate     5.00% 5.00% 5.00%          
Number of warrant shares 99,000 355,114   99,900 195,000   195,000 225,000    
Warrant exercise price per share $ 1.00     $ 1 $ 1   $ 1.00 $ 2.50    
Warrants term       5 years 5 years   5 years      
Maturity date       Feb. 19, 2022 Feb. 09, 2022 Feb. 09, 2022        
Principal amount             $ 123,000   $ 72,000  
Accrued interest             35,078      
Conversion of stock, shares 21,747 6,939                
Loss on the conversion $ 29,333                  
New Loan Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Number of warrant shares               115,185    
Warrant exercise price per share               $ 2.50    
Principal amount             99,900      
Repayments of debt             4,950      
Accrued interest             $ 12,463.53      
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Related Party (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2023
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                
Accrued salaries             $ 566,916 $ 285,666
Accrued consulting fees             90,000  
Number of shares issued for services 7,692   436,533         29,286
Stock-based compensation related to outstanding stock options   $ 936,000     $ 936,000   1,803  
Original life         8 years 7 months 20 days      
Stock-based compensation         $ 511,177 $ 290,876 $ 340,152 $ 98,951
Share-Based Payment Arrangement, Option [Member]                
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                
Number of shares issued for services               29,286
Original life               10 years
Stock-based compensation   $ 430   $ 450 $ 1,290 $ 1,350    
Chief Financial Officer [Member]                
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                
Number of shares issued               57,143
Number of shares issued for services         75,000      
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Stock Options Activity (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]        
Number of Shares, Outstanding at Beginning 69,217 468,571 884,821  
Number of Shares, Granted 438,500 29,286  
Number of Shares, Exercised  
Forfeited (399,354)  
Expired   (445,536)  
Number of Shares, Outstanding at Ending 507,717 69,217 468,571  
Weighted-Average Exercise Price, Outstanding at Beginning $ 3.06      
Weighted-Average Remaining Contractual Term (Years), Outstanding 9 years 2 months 1 day 7 years 29 days    
Aggregate Intrinsic Value, Outstanding at Beginning $ 117,669      
Weighted-Average Exercise Price, Granted $ 4.41      
Aggregate Intrinsic Value, Granted      
Weighted-Average Exercise Price, Exercised      
Aggregate Intrinsic Value, Exercised      
Number of Shares, Forfeited / canceled 399,354  
Weighted-Average Exercise Price, Forfeited / canceled      
Aggregate Intrinsic Value, Forfeited / canceled      
Weighted-Average Exercise Price, Outstanding at Ending $ 4.23 $ 3.06    
Aggregate Intrinsic Value, Outstanding at Ending $ 102,441 $ 117,669    
Number of Shares, Vested at Ending 215,623 56,242 39,581 104,795
Weighted-Average Exercise Price, Vested at Ending $ 3.97 $ 3.15 $ 3.36 $ 3.36
Weighted-Average Remaining Contractual Term (Years), Vested at Ending 8 years 7 months 20 days      
Aggregate Intrinsic Value, Vested at Ending $ 52,644 $ 6,951 $ 4,941 $ 12,706
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Vested and Outstanding Options (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Beginning value, Options 39,581 104,795
Beginning value, Intrinsic Value of Vested Options $ 4,941 $ 12,706
Weight Averaged exercise Price, beginning value $ 3.36 $ 3.36
Options Granted 16,661 1,310
Intrinsic Value of Vested Options, Granted $ 2,010 $ 157
Weight Averaged exercise Price, Granted $ 2.73 $ 2.66
Options Exercised
Intrinsic Value of Vested Options, Exercised
Weight Averaged exercise Price, Exercised
Options Forfeited
Intrinsic Value of Vested Options, Forfeited
Weight Averaged exercise Price, Forfeited
Options Expired (66,524)
Intrinsic Value of Vested Options, Expired $ (7,922)
Weight Averaged exercise Price, Expired $ (3.36)
Ending value, Options 56,242 39,581
Intrinsic Value of Vested Options, Intrinsic value $ 6,951 $ 4,941
Weight Averaged exercise Price, Ending balance value $ 3.15 $ 3.36
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Black Scholes Option Pricing Model (Details) - $ / shares
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Fair Value of Common Stock on measurement date   $ 4.76 $ 0.308
Risk-free interest rate, minimum 3.40% 0.79% 1.26%
Risk-free interest rate, maximum 4.10% 3.01% 1.33%
Volatility   89.00% 93.00%
Expected dividend yield 0.00% 0.00% 0.00%
Expected life (in years)     10 years
Expected volatility, minimum 87.00%    
Expected volatility, maximum 92.00%    
Warrant [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Fair Value of Common Stock on measurement date   $ 4.76 $ 0.308
Risk-free interest rate, minimum   1.86% 0.78%
Risk-free interest rate, maximum   1.97% 1.63%
Volatility   89.00% 93.00%
Expected dividend yield   0.00% 0.00%
Expected life (in years)     10 years
Minimum [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Expected life (in years) 5 years 4 years  
Minimum [Member] | Warrant [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Expected life (in years)     5 years
Maximum [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Expected life (in years) 6 years 10 years  
Maximum [Member] | Warrant [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Expected life (in years)     10 years
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Stock Warrant Activity (Details) - Warrant [Member] - shares
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Beginning balance     752,945 927,373 927,373 495,714
Granted     3,195,906 56,623 123,660 431,659
Exercised   436,533    
Forfeited (200,000)       (298,088)
Expired        
Ending balance         752,945 927,373
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Vested And Outstanding Warrants (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning value, Intrinsic Value of Vested Options $ 4,941 $ 12,706
Weight Averaged exercise Price, beginning value $ 3.36 $ 3.36
Intrinsic Value of Vested Options, Intrinsic value $ 6,951 $ 4,941
Weight Averaged exercise Price, Ending balance value $ 3.15 $ 3.36
Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance 617,492 479,940
Beginning value, Intrinsic Value of Vested Options $ 149,688 $ 127,480
Weight Averaged exercise Price, beginning value $ 2.80 $ 0.98
Warrants Granted 174,105 137,552
Intrinsic Value of Vested Warrants, Granted $ 337,263 $ 22,208
Weight Averaged exercise Price, Granted $ 3.15 $ 3.15
Warrants, Exercised  
Intrinsic Value of Vested Warrants, Exercised
Weight Averaged exercise Price, Exercised
Warrants Forfeited (94,665)
Intrinsic Value of Vested Warrants, Forfeited $ (12,980)
Weight Averaged exercise Price, Forfeited
Warrants, Expired
Intrinsic Value of Vested Warrants, Expired
Weight Averaged exercise Price, Expired
Ending balance value 696,932 617,492
Intrinsic Value of Vested Options, Intrinsic value $ 473,971 $ 149,688
Weight Averaged exercise Price, Ending balance value $ 1.96 $ 2.80
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Outstanding Warrants (Details)
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Class of Warrant or Right [Line Items]  
Number of Warrants | shares 3,796,164
Exercise Price [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 0.0007
Expiration Period 2030
Number of Warrants | shares 274,286
Exercise Price One [Member]  
Class of Warrant or Right [Line Items]  
Number of Warrants | shares 460,445
Exercise Price One [Member] | Minimum [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 2.10
Expiration Period 2026
Exercise Price One [Member] | Maximum [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 2.66
Expiration Period 2032
Exercise Price Two [Member]  
Class of Warrant or Right [Line Items]  
Number of Warrants | shares 115,277
Exercise Price Two [Member] | Minimum [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 3.36
Expiration Period 2028
Exercise Price Two [Member] | Maximum [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 4.27
Expiration Period 2029
Exercise Price Three [Member]  
Class of Warrant or Right [Line Items]  
Number of Warrants | shares 1,484,929
Exercise Price Three [Member] | Minimum [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 6.51
Expiration Period 2026
Exercise Price Three [Member] | Maximum [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 7.80
Expiration Period 2032
Exercise Price Four [Member]  
Class of Warrant or Right [Line Items]  
Exercise Price $ 8.125
Number of Warrants | shares 1,461,227
Exercise Price Four [Member] | Minimum [Member]  
Class of Warrant or Right [Line Items]  
Expiration Period 2027
Exercise Price Four [Member] | Maximum [Member]  
Class of Warrant or Right [Line Items]  
Expiration Period 2028
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholder’s Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2023
Feb. 13, 2023
Nov. 30, 2022
Oct. 05, 2022
Feb. 28, 2023
Nov. 30, 2022
Jun. 30, 2022
Jun. 30, 2020
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
May 31, 2022
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Preferred stock, shares authorized                 10,000,000           10,000,000   10,000,000      
Preferred stock, par or stated value per share                 $ 0.00001           $ 0.00001   $ 0.00001      
Preferred stock, shares issued                                   0    
Number of common stock       10                         10      
Preferred stock value                 $ 1           $ 1   $ 1    
Stock split, description               BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock                        
Common stock, shares authorized                 100,000,000           100,000,000   100,000,000 100,000,000    
Common stock, par or stated value per share                 $ 0.00001           $ 0.00001   $ 0.00001 $ 0.00001    
Conversion of convertibe notes value                     $ 1,535,615   $ 226,138       $ 226,138      
Shares issued value                   $ 1,494,658             $ 189,828      
Common stock, shares outstanding                 6,094,644           6,094,644   4,021,935 4,622,789    
Reverse stock split                                 1-for-7 reverse stock split      
Number of options forfeitures                               399,354    
Share based compensation granted                             438,500   29,286    
Original life                             9 years 2 months 1 day   7 years 29 days      
Share-based payment arrangement, expensed and capitalized, amount                             $ 511,177 $ 290,876 $ 340,152 $ 98,951    
Option vested shares                                 16,661 1,310    
Option vested expired shares                                 (66,524)    
Weighted average remaining contractual term                             8 years 7 months 20 days          
Warrant shares                                 92,859 92,859    
Warrants shares, outstanding                 3,796,164           3,796,164          
Conversion of stock, shares                                 205,984      
Conversion of convertible notes value                             226,138 $ 226,138    
Shares, issued for services         7,692         436,533               29,286    
Value, issued for services         $ 50,000           $ 50,000                  
Proceeds from exercise of warrant                   $ 1,494,658         $ 1,494,658        
Number of options                                 753,174 927,373    
Weighted-average grant-date fair value of options granted                             $ 3.20          
Compensation expense related to stock options                 $ 116,410     $ 51,536     $ 475,465 $ 290,876        
Unrecognized compensation expense                 $ 936,000           $ 936,000   $ 1,803      
Weighted-average period                             2 years 1 month 6 days          
Weighted average period term                             4 months 24 days          
Tradeable Warrants [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Exercise price $ 7.80       $ 7.80                              
Sale of stock, description         Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share                              
Non-Tradeable Warrants [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Exercise price 8.125       $ 8.125                              
Sale of stock, description         non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.                              
IPO [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Reverse stock split   completed a 1-for-7 reverse split of our common stock.                                    
Warrant shares     276,289     276,289                            
Conversion of stock, shares     276,289   331,166                              
Conversion of convertible notes value     $ 25,000,000                                  
Additional shares issued         1,297,318                              
Issue price per share $ 6.50       $ 6.50                              
Gross proceeds         $ 8,400,000                              
Equity Option [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Number of options forfeitures                           399,354            
Share based compensation granted                                   29,286    
Original life                                   10 years    
Award period                                   48 months    
Warrants shares vested                                   1,310    
Share-based payment arrangement, expensed and capitalized, amount                                 2,010 $ 157    
Share-based payment arrangement, expensed and capitalized, amount                                 $ 16,601      
Option vested shares                                 16,661 1,310    
Option vested expired shares                                 66,524    
Weighted average remaining contractual term                                 7 years 29 days 7 years 4 months 17 days    
Fair value of warrants                                 $ 6,951 $ 4,941    
Series A Convertible Preferred Stock [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Preferred stock, shares authorized                 5,500,000           5,500,000   5,500,000      
Preferred stock, par or stated value per share                 $ 0.00001           $ 0.00001   $ 0.00001      
Preferred stock, shares issued                 73,449           73,449   73,449      
Series A Preferred Stock [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Preferred stock, shares authorized                                 5,500,000 5,500,000    
Preferred stock, par or stated value per share                                 $ 0.00001 $ 0.00001    
Preferred stock, shares issued                                 73,449 0    
Preferred stock value       $ 315,000                                
Note Holder [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Conversion of convertible securities, shares                                 205,984      
Exchange Agreement [Member] | Series A Preferred Stock [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Conversion of convertible securities, shares                                 734,429      
Exchange Agreement [Member] | Investor [Member] | Series A Convertible Preferred Stock [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Conversion of convertible securities, shares       73,449                                
Prior Agreements And New Agreements [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Shares cancelled                                 112,225      
Twenty Twenty Two Equity Incentive Plan [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Award period           10 years                            
Award authorized under the plan     900,000     900,000     461,500           461,500          
Increased payment award, percentage           15.00%                            
Common Stock [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Conversion of convertible securities, shares                     331,166   205,984       205,984      
Conversion of convertibe notes value                     $ 3   $ 2       $ 2      
Shares cancelled                                 112,225      
Number of shares issued                     1,297,318                  
Shares issued value                   $ 4                  
Shares cancelled                         112,225              
Shares, issued for services                     7,692                  
Value, issued for services                     $ 1                  
Number of options                             507,717 484,525 56,242 486,571    
Common Stock [Member] | IPO [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Reverse stock split         completed a 1-for-7 reverse split of our common stock.                              
Common Stock [Member] | Exchange Agreement [Member] | Investor [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Conversion of convertible securities, shares       734,492                                
Common Stock [Member] | License Agreement [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Number of shares issued                                 38,879      
Shares issued value                                 $ 189,828      
Warrant [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Warrants shares vested                             22,939   174,105 0    
Weighted average remaining contractual term                                 7 years 1 month 17 days 7 years 8 months 23 days    
Fair value of warrants                                 $ 324,283 $ 149,688    
Share based compensation granted                             3,195,906 56,623 123,660 431,659    
Contractual life and vesting period, description                             The warrants have an original life of ten years and vest immediately and over 12 months.   The warrants have an original life of four to ten years and vest immediately and over 12 months. The warrants have an original life of ten years and vest at different rates over as much as 36 months.    
Intrinsic value                             $ 35,712   $ 337,269      
Warrant shares                                 51,941 138,929    
Warrants reclassified with intrinsic value                                 $ 11,097      
Warrant shares, forfeited                                 42,057   99,000  
Fair value of warrants             $ 11,097           $ 11,097         $ 28,683    
Warrant shares forfeiture             200,000                   298,088    
Warrant shares             50,735           50,735              
Exercise price                                     $ 1  
Warrants shares, outstanding                                 752,945 927,516    
Vested shares                                 696,932 617,492   479,940
Intrinsic value                                 $ 337,263 $ 22,208    
Warrant exercised                   436,533                
Number of options                             3,796,164 5,270,617        
Warrant shares, forfeited                                 $ 1,883      
Compensation expense                 $ 5,050     $ 51,086     $ 35,712 $ 289,317        
Warrant [Member] | IPO [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Additional shares issued 276,452                                      
Issue price per share $ 4.27       $ 4.27                              
Weighted average period term 5 years                                      
Warrant [Member] | Underwriters [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Additional shares issued 18,000                                      
Issue price per share $ 8.125       8.125                              
Weighted average period term 4 years                                      
Warrant [Member] | Advisors [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Share based compensation granted                                   200,000    
Contractual life and vesting period, description                                   The warrants have an original life of five years and vest 30 days before the intended IPO    
Fair value of warrants                                   $ 12,462    
Warrant [Member] | Convertible Bridge Debt Agreements [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Warrant shares                                   92,859    
Fair value of warrants                                   $ 12,980    
Warrants and rights outstanding term                                   5 years    
Warrant [Member] | New Agreements [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Warrant shares                                     115,185  
Fair value of warrants                                     $ 15,412  
Exercise price                                     $ 2.50  
Warrant One [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Warrant shares, forfeited                                     195,000  
Warrant One [Member] | New Agreements [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Warrant shares                                     225,000  
Fair value of warrants                                     $ 64,978  
Exercise price                                     $ 2.50  
Tradable Warrant [Member] | IPO [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Additional shares issued 1,297,318                                      
Issue price per share $ 7.80       7.80                              
Weighted average period term 5 years                                      
Tradable Warrant [Member] | Over-Allotment Option [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Additional shares issued 153,409                                      
Issue price per share $ 7.80       7.80                              
Weighted average period term 5 years                                      
Non Tradable Warrant [Member] | IPO [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Additional shares issued 1,297,318                                      
Issue price per share $ 8.125       8.125                              
Weighted average period term 5 years                                      
Non Tradable Warrant [Member] | Over-Allotment Option [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Additional shares issued 153,409                                      
Issue price per share $ 8.125       $ 8.125                              
Weighted average period term 5 years                                      
Unvested Warrants [Member]                                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                                        
Unrecognized compensation expense                             6,556          
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Deferred Taxes (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 924,000 $ 339,000
Valuation allowance (924,000) (339,000)
Net non-current deferred tax asset
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Details Narrative)
Dec. 31, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Operating loss carry forward $ 4,399,055
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Material Agreements (Details Narrative) - USD ($)
1 Months Ended
May 31, 2023
Feb. 28, 2023
Oct. 13, 2022
Jul. 08, 2022
Feb. 22, 2022
Feb. 07, 2018
Oct. 31, 2021
Sep. 30, 2023
Dec. 31, 2022
Jan. 14, 2022
Dec. 31, 2021
Dec. 13, 2021
Nov. 19, 2021
Jun. 15, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Accrued royalty expenses               $ 0 $ 0          
Fianance raised               213,290   $ 10,000 $ 5,000 $ 34,000
2023 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments       $ 60,000                    
JHU - APL Technology License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Warrant percent             5.00%              
Royalty percent             8.00%              
Percentage of sublicense             50.00%              
Maintenance fee           $ 1,500 $ 1,500              
JHU - APL Technology License Agreement [Member] | 2022 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments             20,000              
JHU - APL Technology License Agreement [Member] | 2023 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments             80,000              
JHU - APL Technology License Agreement [Member] | 2024 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments             $ 300,000              
New License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments $ 275,000                          
Common stock issued       279,159                    
Accrued royalty expenses                 30,000          
New License Agreement [Member] | Maximum [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Percentage of sublicense       50.00%                    
New License Agreement [Member] | Minimum [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Sublicense fee based on revenue       25.00%                    
New License Agreement [Member] | Internally Development Drug Projects [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty percent       3.00%                    
New License Agreement [Member] | Other Parties [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty percent       8.00%                    
New License Agreement [Member] | 2022 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments 60,000     $ 30,000                    
New License Agreement [Member] | 2023 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments 75,000     80,000                    
Accrued royalty expenses               45,000            
New License Agreement [Member] | 2024 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments       $ 300,000                    
New License Agreement [Member] | 2025 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments 75,000                          
New License Agreement [Member] | 2026 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments 75,000                          
New License Agreement [Member] | 2027 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments $ 50,000                          
George Washington University - Beta2-spectrin siRNA License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty percent                   3.00%        
Licence initiation fee                   $ 20,000        
Johns Hopkins University - Mebendazole License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty percent         3.50%                  
Accrued royalty expenses               7,500 242,671          
Upfront licence fee         $ 250,000                  
Annual minimum royalty payment         250,000                  
License fee initial payment   $ 200,000     50,000                  
Fianance raised         10,000,000                  
Johns Hopkins University - Mebendazole License Agreement [Member] | 2023 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments         5,000                  
Johns Hopkins University - Mebendazole License Agreement [Member] | 2024 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments         10,000                  
Johns Hopkins University - Mebendazole License Agreement [Member] | 2025 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments         20,000                  
Johns Hopkins University - Mebendazole License Agreement [Member] | 2026 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments         30,000                  
Johns Hopkins University - Mebendazole License Agreement [Member] | 2027 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments         $ 50,000                  
Johns Hopkins University - Prodrug License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty percent     4.00%                      
Upfront licence fee     $ 100,000                      
Annual minimum royalty payment     150,000                      
Johns Hopkins University - Prodrug License Agreement [Member] | 2027 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments     5,000                      
Johns Hopkins University - Prodrug License Agreement [Member] | 2028 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments     10,000                      
Johns Hopkins University - Prodrug License Agreement [Member] | 2029 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments     20,000                      
Johns Hopkins University - Prodrug License Agreement [Member] | 2030 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments     30,000                      
Johns Hopkins University - Prodrug License Agreement [Member] | 2031 [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Royalty payments     $ 50,000                      
License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Accrued expense               $ 0 $ 133,238          
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 13, 2023
Feb. 14, 2023
Feb. 13, 2023
Nov. 30, 2022
Feb. 28, 2023
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]                    
Reverse stock split                 1-for-7 reverse stock split  
Converted common shares                 205,984  
Warrants exercised                 92,859 92,859
Conversion of convertible note payable             $ 226,138 $ 226,138
Gross proceeds           $ 1,494,658 $ 1,494,658    
Tradeable Warrants [Member]                    
Subsequent Event [Line Items]                    
Sale of stock, description         Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share          
Exercise price         $ 7.80          
Non-Tradeable Warrants [Member]                    
Subsequent Event [Line Items]                    
Sale of stock, description         non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.          
Exercise price         $ 8.125          
IPO [Member]                    
Subsequent Event [Line Items]                    
Additional shares issued         1,297,318          
Issue price per share         $ 6.50          
Gross proceeds         $ 8,400,000          
Reverse stock split     completed a 1-for-7 reverse split of our common stock.              
Converted common shares       276,289 331,166          
Warrants exercised       276,289            
Conversion of convertible note payable       $ 25,000,000            
Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Warrants exercised 436,533                  
Gross proceeds $ 1,495,000                  
Subsequent Event [Member] | Tradeable Warrants [Member]                    
Subsequent Event [Line Items]                    
Sale of stock, description   Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share                
Exercise price   $ 7.80                
Subsequent Event [Member] | Non-Tradeable Warrants [Member]                    
Subsequent Event [Line Items]                    
Sale of stock, description   one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125                
Exercise price   $ 8.125                
Subsequent Event [Member] | IPO [Member]                    
Subsequent Event [Line Items]                    
Additional shares issued   1,297,318                
Issue price per share   $ 6.50                
Gross proceeds   $ 8,400,000                
Reverse stock split   the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock                
Converted common shares   55,787                
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 322 313 1 true 79 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://bullfrogai.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://bullfrogai.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://bullfrogai.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://bullfrogai.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit Sheet http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit Condensed Consolidated Statements of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://bullfrogai.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Nature of Business Sheet http://bullfrogai.com/role/OrganizationAndNatureOfBusiness Organization and Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://bullfrogai.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://bullfrogai.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://bullfrogai.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://bullfrogai.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Notes Payable Related Party Notes http://bullfrogai.com/role/NotesPayableRelatedParty Notes Payable Related Party Notes 12 false false R13.htm 00000013 - Disclosure - Convertible Notes Payable Notes http://bullfrogai.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Convertible Notes Payable Related Party Notes http://bullfrogai.com/role/ConvertibleNotesPayableRelatedParty Convertible Notes Payable Related Party Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Sheet http://bullfrogai.com/role/RelatedParty Related Party Notes 15 false false R16.htm 00000016 - Disclosure - Stockholder???s Equity Sheet http://bullfrogai.com/role/StockholdersEquity Stockholder???s Equity Notes 16 false false R17.htm 00000017 - Disclosure - Income Taxes Sheet http://bullfrogai.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 00000018 - Disclosure - Material Agreements Sheet http://bullfrogai.com/role/MaterialAgreements Material Agreements Notes 18 false false R19.htm 00000019 - Disclosure - Commitments and Contingencies Sheet http://bullfrogai.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://bullfrogai.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://bullfrogai.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Convertible Notes Payable (Tables) Notes http://bullfrogai.com/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://bullfrogai.com/role/ConvertibleNotesPayable 22 false false R23.htm 00000023 - Disclosure - Stockholder???s Equity (Tables) Sheet http://bullfrogai.com/role/StockholdersEquityTables Stockholder???s Equity (Tables) Tables http://bullfrogai.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - Income Taxes (Tables) Sheet http://bullfrogai.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://bullfrogai.com/role/IncomeTaxes 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Details Narrative) Sheet http://bullfrogai.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://bullfrogai.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative) Sheet http://bullfrogai.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative Accounts Payable and Accrued Expenses (Details Narrative) Details http://bullfrogai.com/role/AccountsPayableAndAccruedExpenses 27 false false R28.htm 00000028 - Disclosure - Notes Payable (Details Narrative) Notes http://bullfrogai.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://bullfrogai.com/role/NotesPayable 28 false false R29.htm 00000029 - Disclosure - Notes Payable Related Party (Details Narrative) Notes http://bullfrogai.com/role/NotesPayableRelatedPartyDetailsNarrative Notes Payable Related Party (Details Narrative) Details http://bullfrogai.com/role/NotesPayableRelatedParty 29 false false R30.htm 00000030 - Disclosure - Schedule of Convertible Debt (Details) Sheet http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails Schedule of Convertible Debt (Details) Details 30 false false R31.htm 00000031 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://bullfrogai.com/role/ConvertibleNotesPayableTables 31 false false R32.htm 00000032 - Disclosure - Convertible Notes Payable Related Party (Details Narrative) Notes http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative Convertible Notes Payable Related Party (Details Narrative) Details http://bullfrogai.com/role/ConvertibleNotesPayableRelatedParty 32 false false R33.htm 00000033 - Disclosure - Related Party (Details Narrative) Sheet http://bullfrogai.com/role/RelatedPartyDetailsNarrative Related Party (Details Narrative) Details http://bullfrogai.com/role/RelatedParty 33 false false R34.htm 00000034 - Disclosure - Schedule of Stock Options Activity (Details) Sheet http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails Schedule of Stock Options Activity (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Vested and Outstanding Options (Details) Sheet http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails Schedule of Vested and Outstanding Options (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Black Scholes Option Pricing Model (Details) Sheet http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails Schedule of Black Scholes Option Pricing Model (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Stock Warrant Activity (Details) Sheet http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails Schedule of Stock Warrant Activity (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Vested And Outstanding Warrants (Details) Sheet http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails Schedule of Vested And Outstanding Warrants (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Outstanding Warrants (Details) Sheet http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails Schedule of Outstanding Warrants (Details) Details 39 false false R40.htm 00000040 - Disclosure - Stockholder???s Equity (Details Narrative) Sheet http://bullfrogai.com/role/StockholdersEquityDetailsNarrative Stockholder???s Equity (Details Narrative) Details http://bullfrogai.com/role/StockholdersEquityTables 40 false false R41.htm 00000041 - Disclosure - Schedule of Deferred Taxes (Details) Sheet http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails Schedule of Deferred Taxes (Details) Details 41 false false R42.htm 00000042 - Disclosure - Income Taxes (Details Narrative) Sheet http://bullfrogai.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://bullfrogai.com/role/IncomeTaxesTables 42 false false R43.htm 00000043 - Disclosure - Material Agreements (Details Narrative) Sheet http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative Material Agreements (Details Narrative) Details http://bullfrogai.com/role/MaterialAgreements 43 false false R44.htm 00000044 - Disclosure - Subsequent Events (Details Narrative) Sheet http://bullfrogai.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://bullfrogai.com/role/SubsequentEvents 44 false false All Reports Book All Reports bfrg-20230930.xsd bfrg-20230930_cal.xml bfrg-20230930_def.xml bfrg-20230930_lab.xml bfrg-20230930_pre.xml forms-1.htm forms-1_001.jpg forms-1_002.jpg forms-1_003.jpg forms-1_004.jpg forms-1_005.jpg forms-1_006.jpg forms-1_007.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "forms-1.htm": { "nsprefix": "BFRG", "nsuri": "http://bullfrogai.com/20230930", "dts": { "schema": { "local": [ "bfrg-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "bfrg-20230930_cal.xml" ] }, "definitionLink": { "local": [ "bfrg-20230930_def.xml" ] }, "labelLink": { "local": [ "bfrg-20230930_lab.xml" ] }, "presentationLink": { "local": [ "bfrg-20230930_pre.xml" ] }, "inline": { "local": [ "forms-1.htm" ] } }, "keyStandard": 242, "keyCustom": 71, "axisStandard": 18, "axisCustom": 0, "memberStandard": 21, "memberCustom": 58, "hidden": { "total": 252, "http://fasb.org/us-gaap/2023": 189, "http://bullfrogai.com/20230930": 61, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 322, "entityCount": 1, "segmentCount": 79, "elementCount": 524, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1221, "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://bullfrogai.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R2": { "role": "http://bullfrogai.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R3": { "role": "http://bullfrogai.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R4": { "role": "http://bullfrogai.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R5": { "role": "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R6": { "role": "http://bullfrogai.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R7": { "role": "http://bullfrogai.com/role/OrganizationAndNatureOfBusiness", "longName": "00000007 - Disclosure - Organization and Nature of Business", "shortName": "Organization and Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R8": { "role": "http://bullfrogai.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R9": { "role": "http://bullfrogai.com/role/PropertyAndEquipment", "longName": "00000009 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R10": { "role": "http://bullfrogai.com/role/AccountsPayableAndAccruedExpenses", "longName": "00000010 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R11": { "role": "http://bullfrogai.com/role/NotesPayable", "longName": "00000011 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R12": { "role": "http://bullfrogai.com/role/NotesPayableRelatedParty", "longName": "00000012 - Disclosure - Notes Payable Related Party", "shortName": "Notes Payable Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BFRG:NotesPayableRelatedPartyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BFRG:NotesPayableRelatedPartyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R13": { "role": "http://bullfrogai.com/role/ConvertibleNotesPayable", "longName": "00000013 - Disclosure - Convertible Notes Payable", "shortName": "Convertible Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R14": { "role": "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedParty", "longName": "00000014 - Disclosure - Convertible Notes Payable Related Party", "shortName": "Convertible Notes Payable Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BFRG:ConvertibleNotesPayableRelatedPartyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BFRG:ConvertibleNotesPayableRelatedPartyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R15": { "role": "http://bullfrogai.com/role/RelatedParty", "longName": "00000015 - Disclosure - Related Party", "shortName": "Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R16": { "role": "http://bullfrogai.com/role/StockholdersEquity", "longName": "00000016 - Disclosure - Stockholder\u2019s Equity", "shortName": "Stockholder\u2019s Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R17": { "role": "http://bullfrogai.com/role/IncomeTaxes", "longName": "00000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R18": { "role": "http://bullfrogai.com/role/MaterialAgreements", "longName": "00000018 - Disclosure - Material Agreements", "shortName": "Material Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BFRG:LicenseAndRoyaltyAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BFRG:LicenseAndRoyaltyAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R19": { "role": "http://bullfrogai.com/role/CommitmentsAndContingencies", "longName": "00000019 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R20": { "role": "http://bullfrogai.com/role/SubsequentEvents", "longName": "00000020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R21": { "role": "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "BFRG:UseOfEstimatesInPreparationOfFinancialStatementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "BFRG:UseOfEstimatesInPreparationOfFinancialStatementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R22": { "role": "http://bullfrogai.com/role/ConvertibleNotesPayableTables", "longName": "00000022 - Disclosure - Convertible Notes Payable (Tables)", "shortName": "Convertible Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R23": { "role": "http://bullfrogai.com/role/StockholdersEquityTables", "longName": "00000023 - Disclosure - Stockholder\u2019s Equity (Tables)", "shortName": "Stockholder\u2019s Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R24": { "role": "http://bullfrogai.com/role/IncomeTaxesTables", "longName": "00000024 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R25": { "role": "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R26": { "role": "http://bullfrogai.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000026 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2022-01-012022-09-30", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R27": { "role": "http://bullfrogai.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative", "longName": "00000027 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)", "shortName": "Accounts Payable and Accrued Expenses (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R28": { "role": "http://bullfrogai.com/role/NotesPayableDetailsNarrative", "longName": "00000028 - Disclosure - Notes Payable (Details Narrative)", "shortName": "Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RepaymentsOfNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-02-28_us-gaap_ShortTermDebtMember", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R29": { "role": "http://bullfrogai.com/role/NotesPayableRelatedPartyDetailsNarrative", "longName": "00000029 - Disclosure - Notes Payable Related Party (Details Narrative)", "shortName": "Notes Payable Related Party (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2021-12-13", "name": "us-gaap:ShortTermBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "BFRG:NotesPayableRelatedPartyDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-13", "name": "us-gaap:ShortTermDebtPercentageBearingVariableInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "BFRG:NotesPayableRelatedPartyDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R30": { "role": "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails", "longName": "00000030 - Disclosure - Schedule of Convertible Debt (Details)", "shortName": "Schedule of Convertible Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_ConvertibleDebtOneMember_custom_WallachBethMember", "name": "us-gaap:ConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R31": { "role": "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "longName": "00000031 - Disclosure - Convertible Notes Payable (Details Narrative)", "shortName": "Convertible Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2022-01-012022-09-30", "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-02-282023-02-28_custom_ConvertibleBridgeNotesAndWarrantsMember", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R32": { "role": "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "longName": "00000032 - Disclosure - Convertible Notes Payable Related Party (Details Narrative)", "shortName": "Convertible Notes Payable Related Party (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_SimpleAgreementForFutureEquityMember", "name": "BFRG:ConvertibleNotesPayableRelatedParties", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "BFRG:ConvertibleNotesPayableRelatedPartyDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R33": { "role": "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "longName": "00000033 - Disclosure - Related Party (Details Narrative)", "shortName": "Related Party (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R34": { "role": "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "longName": "00000034 - Disclosure - Schedule of Stock Options Activity (Details)", "shortName": "Schedule of Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R35": { "role": "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails", "longName": "00000035 - Disclosure - Schedule of Vested and Outstanding Options (Details)", "shortName": "Schedule of Vested and Outstanding Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "BFRG:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R36": { "role": "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "longName": "00000036 - Disclosure - Schedule of Black Scholes Option Pricing Model (Details)", "shortName": "Schedule of Black Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R37": { "role": "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "longName": "00000037 - Disclosure - Schedule of Stock Warrant Activity (Details)", "shortName": "Schedule of Stock Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "BFRG:ScheduleOfStockWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "BFRG:ScheduleOfStockWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R38": { "role": "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "longName": "00000038 - Disclosure - Schedule of Vested And Outstanding Warrants (Details)", "shortName": "Schedule of Vested And Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "BFRG:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R39": { "role": "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails", "longName": "00000039 - Disclosure - Schedule of Outstanding Warrants (Details)", "shortName": "Schedule of Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_ExercisePriceMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R40": { "role": "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "longName": "00000040 - Disclosure - Stockholder\u2019s Equity (Details Narrative)", "shortName": "Stockholder\u2019s Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-10-05", "name": "BFRG:SharesExchangedForEachConvertiblePreferredStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } }, "R41": { "role": "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails", "longName": "00000041 - Disclosure - Schedule of Deferred Taxes (Details)", "shortName": "Schedule of Deferred Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R42": { "role": "http://bullfrogai.com/role/IncomeTaxesDetailsNarrative", "longName": "00000042 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R43": { "role": "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "longName": "00000043 - Disclosure - Material Agreements (Details Narrative)", "shortName": "Material Agreements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "BFRG:LicenseAndRoyaltyAgreementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "BFRG:LicenseAndRoyaltyAgreementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true, "unique": true } }, "R44": { "role": "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative", "longName": "00000044 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-04-13_us-gaap_SubsequentEventMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r82" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/AccountsPayableAndAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r631" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued consulting fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued royalty expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": [ "r83" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued salaries", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28", "r612" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r50", "r156", "r492" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r168", "r169", "r416", "r417", "r418", "r419", "r420", "r421" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r168", "r169", "r416", "r417", "r418", "r419", "r420", "r421" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r93", "r631", "r756" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r378", "r379", "r380", "r516", "r685", "r686", "r687", "r734", "r759" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Imputed interest", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r65", "r66", "r349" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants issued with convertible notes", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r10", "r51", "r119" ] }, "BFRG_AdjustmentsToAdditionalPaidInReclassificationsOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "AdjustmentsToAdditionalPaidInReclassificationsOfWarrant", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Reclassification of warrant", "documentation": "Adjustments to additional paid in reclassifications of warrant." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r138" ] }, "BFRG_AdvisorsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "AdvisorsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advisors [Member]", "documentation": "Advisors [Member]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r377", "r381" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r161", "r228", "r262", "r265", "r266", "r754" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r5", "r75", "r105", "r313" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r658" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r208" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r399" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r130", "r157", "r182", "r213", "r219", "r223", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r400", "r402", "r415", "r485", "r553", "r631", "r643", "r700", "r701", "r741" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r152", "r164", "r182", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r400", "r402", "r415", "r631", "r700", "r701", "r741" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Non-Current Assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r182", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r400", "r402", "r415", "r700", "r701", "r741" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r658" ] }, "BFRG_AugustTwentyTwentyOneNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "AugustTwentyTwentyOneNoteMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "August 2021 [Member]", "documentation": "August 2021 [Member]" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r657", "r658" ] }, "BFRG_CancellationOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "CancellationOfCommonStock", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cancellation of common stocks", "documentation": "Cancellation of common stock." } } }, "auth_ref": [] }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Project [Axis]", "documentation": "Information by project." } } }, "auth_ref": [ "r127", "r128", "r129" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash balances", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r136", "r486", "r527", "r547", "r631", "r643", "r673" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r37", "r155", "r610" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r108", "r178" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r108" ] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "auth_ref": [ "r689" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r149", "r158", "r159", "r160", "r182", "r202", "r203", "r205", "r207", "r211", "r212", "r259", "r282", "r284", "r285", "r286", "r289", "r290", "r320", "r321", "r323", "r326", "r333", "r415", "r507", "r508", "r509", "r510", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r528", "r539", "r562", "r583", "r600", "r601", "r602", "r603", "r604", "r664", "r680", "r688" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price", "verboseLabel": "Warrant exercise price per share", "terseLabel": "Exercise Price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r334" ] }, "BFRG_ClassOfWarrantOrRightForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ClassOfWarrantOrRightForfeited", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant shares, forfeited", "documentation": "Class of Warrant or Right Forfeited.", "label": "ClassOfWarrantOrRightForfeited" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant shares", "verboseLabel": "Warrants exercised", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants", "verboseLabel": "Number of warrant shares", "terseLabel": "Warrant shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r334" ] }, "BFRG_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant shares, forfeited", "documentation": "Class of warrant or right number of securities called by warrants or rights forfeited." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of Warrants", "verboseLabel": "Warrants shares, outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r61" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r399" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r114" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r685", "r686", "r734", "r755", "r759" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "Common stock, par or stated value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r92" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r92", "r539" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r92" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares, outstanding", "verboseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r92", "r539", "r559", "r759", "r760" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 and 4,021,935 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r92", "r488", "r631" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r85", "r141" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "BFRG_ConversionDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConversionDiscountRate", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion discount rate", "documentation": "Conversion discount rate." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion value", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible securities, shares", "verboseLabel": "Converted common shares", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "BFRG_ConvertibleBridgeDebtAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleBridgeDebtAgreementsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Bridge Debt Agreements [Member]", "documentation": "Convertible Bridge Debt Agreements [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleBridgeNotesAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleBridgeNotesAndWarrantsMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Bridge Notes And Warrants [Member]", "documentation": "Convertible Bridge Notes And Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Price", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r21", "r132", "r753" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible notes", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r89" ] }, "BFRG_ConvertibleDebtEightMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtEightMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Eight [Member]", "documentation": "Convertible Debt Eight [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtFiveMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Five [Member]", "documentation": "Convertible Debt Five [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtFourMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtFourMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Four [Member]", "documentation": "Convertible Debt Four [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r116", "r292", "r293", "r303", "r304", "r305", "r309", "r310", "r311", "r312", "r313", "r621", "r622", "r623", "r624", "r625" ] }, "BFRG_ConvertibleDebtNineMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtNineMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Nine [Member]", "documentation": "Convertible Debt Nine [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtOneMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtOneMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt One [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtSevenMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Seven [Member]", "documentation": "Convertible Debt Seven [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtSixMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtSixMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Six [Member]", "documentation": "Convertible Debt Six [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Convertible Debt", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtTenMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtTenMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Ten [Member]", "documentation": "Convertible Debt Ten [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtThreeMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Three [Member]", "documentation": "Convertible Debt Three [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleDebtTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleDebtTwoMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Two [Member]", "documentation": "Convertible Debt Two [Member]" } } }, "auth_ref": [] }, "BFRG_ConvertibleLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleLoanAgreementMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Loan Agreement [Member]", "documentation": "Convertible Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes payable", "label": "Convertible Notes Payable [Default Label]", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r21", "r132", "r753" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Principal Balance", "verboseLabel": "Principal balance", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r28" ] }, "BFRG_ConvertibleNotesPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleNotesPayableRelatedParties", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable related party", "documentation": "Convertible notes payable related party." } } }, "auth_ref": [] }, "BFRG_ConvertibleNotesPayableRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleNotesPayableRelatedPartiesCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible notes - related party", "documentation": "Convertible notes payable related party current." } } }, "auth_ref": [] }, "BFRG_ConvertibleNotesPayableRelatedPartyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ConvertibleNotesPayableRelatedPartyDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedParty" ], "lang": { "en-us": { "role": { "verboseLabel": "Convertible Notes Payable Related Party", "documentation": "Convertible Notes Payable Related Party Disclosure [Text Block]", "label": "ConvertibleNotesPayableRelatedPartyDisclosureTextBlock" } } }, "auth_ref": [] }, "us-gaap_CostMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostMaintenance", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maintenance fee", "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered." } } }, "auth_ref": [ "r678" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold", "verboseLabel": "Cost of services", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r100", "r469" ] }, "us-gaap_CostOfGoodsAndServicesSoldAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold:" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total cost of goods sold", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r101", "r182", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r415", "r700" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Sales", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r665" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible note payable", "verboseLabel": "Conversion of stock, value", "terseLabel": "Conversion of convertible notes value", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r40", "r42" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of stock, shares", "verboseLabel": "Converted common shares", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r40", "r42" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r115", "r180", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r307", "r314", "r315", "r317" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r21", "r89", "r90", "r131", "r132", "r186", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r424", "r621", "r622", "r623", "r624", "r625", "r681" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r117", "r294" ] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescription", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r21", "r54", "r84", "r89", "r131", "r132" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding balance", "verboseLabel": "Principal balance", "terseLabel": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r76", "r78", "r292", "r424", "r622", "r623" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original issuance discount rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r30", "r76", "r318", "r424" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "verboseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r30", "r293" ] }, "us-gaap_DebtInstrumentIssuanceDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuanceDate1", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Note Date", "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format." } } }, "auth_ref": [ "r22", "r702" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r147", "r621", "r735" ] }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDateRangeEnd1", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maturity date extended", "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r32", "r186", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r424", "r621", "r622", "r623", "r624", "r625", "r681" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt discount", "verboseLabel": "Original Issue Discount", "terseLabel": "Unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r75", "r78", "r703" ] }, "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation expense related to stock options", "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans)." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "verboseLabel": "Unearned revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r674" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net non-current deferred tax asset", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r69", "r733" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/ScheduleOfDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r389" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/PropertyAndEquipmentDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r49" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r529", "r531", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r554", "r555", "r556", "r557", "r571", "r572", "r573", "r574", "r577", "r578", "r579", "r580", "r595", "r596", "r597", "r598", "r633", "r635" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r529", "r531", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r554", "r555", "r556", "r557", "r571", "r572", "r573", "r574", "r577", "r578", "r579", "r580", "r595", "r596", "r597", "r598", "r613", "r633", "r635" ] }, "BFRG_DisclosureConvertibleNotesPayableRelatedPartyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "DisclosureConvertibleNotesPayableRelatedPartyAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Related Party" } } }, "auth_ref": [] }, "BFRG_DisclosureMaterialAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "DisclosureMaterialAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Material Agreements" } } }, "auth_ref": [] }, "BFRG_DisclosureNotesPayableRelatedPartyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "DisclosureNotesPayableRelatedPartyAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable Related Party" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r657" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r655", "r657", "r658" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r656" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r644" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r657" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r657" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r659" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r647" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share attributable to common stockholders basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r192", "r193", "r194", "r195", "r196", "r200", "r202", "r205", "r206", "r207", "r209", "r413", "r414", "r482", "r496", "r616" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NET (LOSS) PER COMMON SHARE:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share attributable to common stockholders diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r192", "r193", "r194", "r195", "r196", "r202", "r205", "r206", "r207", "r209", "r413", "r414", "r482", "r496", "r616" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation related to outstanding stock options", "verboseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r731" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r646" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r650" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r646" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r646" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r663" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r646" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r660" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r658" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r646" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r646" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r646" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r646" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r661" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityTables", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r150", "r168", "r169", "r170", "r187", "r188", "r189", "r191", "r197", "r199", "r210", "r260", "r261", "r335", "r378", "r379", "r380", "r393", "r394", "r404", "r405", "r406", "r407", "r408", "r409", "r412", "r416", "r417", "r418", "r419", "r420", "r421", "r425", "r498", "r499", "r500", "r516", "r583" ] }, "BFRG_ExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ExchangeAgreementMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exchange Agreement [Member]", "documentation": "Exchange Agreement [Member]" } } }, "auth_ref": [] }, "BFRG_ExercisePriceFourMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ExercisePriceFourMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Four [Member]" } } }, "auth_ref": [] }, "BFRG_ExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ExercisePriceMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price [Member]" } } }, "auth_ref": [] }, "BFRG_ExercisePriceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ExercisePriceOneMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price One [Member]" } } }, "auth_ref": [] }, "BFRG_ExercisePriceThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ExercisePriceThreeMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Three [Member]" } } }, "auth_ref": [] }, "BFRG_ExercisePriceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ExercisePriceTwoMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Two [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant expenses", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r5" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7", "r20" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r263", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r316", "r331", "r410", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r495", "r620", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r694", "r695", "r696", "r697" ] }, "BFRG_FullyDilutedEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "FullyDilutedEquity", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fully diluted equity", "documentation": "Fully diluted equity." } } }, "auth_ref": [] }, "BFRG_GainsLossesOnConnversionOfNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "GainsLossesOnConnversionOfNotes", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on conversion of notes", "documentation": "Gains losses on connversion of notes.", "label": "GainsLossesOnConnversionOfNotes" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on conversion of notes", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r52", "r53" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r103", "r564" ] }, "BFRG_GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "George Washington University - Beta2-spectrin siRNA License Agreement [Member]", "documentation": "George Washington University - Beta2-spectrin siRNA License Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r99", "r182", "r213", "r218", "r222", "r224", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r415", "r618", "r700" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r183", "r383", "r386", "r387", "r391", "r395", "r396", "r397", "r398", "r512" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r167", "r384", "r385", "r387", "r388", "r390", "r392", "r506" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "BFRG_IncreaseDecreaseInAccruedExpensesRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "IncreaseDecreaseInAccruedExpensesRelatedParties", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued expenses - related party", "documentation": "Increase decrease in accrued expenses related parties." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r608" ] }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInNotesPayableCurrent", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prncipal balance increase", "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expense", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "BFRG_IncreaseDecreaseInSublicensePercentageBasedOnRevenues": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "IncreaseDecreaseInSublicensePercentageBasedOnRevenues", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sublicense fee based on revenue", "documentation": "Increase decrease in sublicense percentage based on revenues." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r77", "r135", "r171", "r216", "r423", "r568", "r641", "r758" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r174", "r176", "r177" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Interest", "verboseLabel": "Accrued interest", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r83", "r751" ] }, "BFRG_InternallyDevelopmentDrugProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "InternallyDevelopmentDrugProjectsMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Internally Development Drug Projects [Member]", "documentation": "Internally Development Drug Projects [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r137", "r154", "r162", "r273", "r274", "r275", "r468", "r614" ] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestorMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investor [Member]", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r737", "r738" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares issued for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "BFRG_IssuanceOfStockForLicense": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "IssuanceOfStockForLicense", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares issued for license", "documentation": "Issuance of stock for license." } } }, "auth_ref": [] }, "BFRG_JHUAPLTechnologyLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "JHUAPLTechnologyLicenseAgreementMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "JHU - APL Technology License Agreement [Member]", "documentation": "JHU - APL Technology License Agreement [Member]" } } }, "auth_ref": [] }, "BFRG_JohnsHopkinsUniversityMebendazoleLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "JohnsHopkinsUniversityMebendazoleLicenseMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Johns Hopkins University - Mebendazole License Agreement [Member]", "documentation": "Johns Hopkins University - Mebendazole License Agreement [Member]" } } }, "auth_ref": [] }, "BFRG_JohnsHopkinsUniversityProdrugLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "JohnsHopkinsUniversityProdrugLicenseMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Johns Hopkins University - Prodrug License Agreement [Member]", "documentation": "Johns Hopkins University - Prodrug License Agreement [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r182", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r401", "r402", "r403", "r415", "r538", "r617", "r643", "r700", "r741", "r742" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r97", "r133", "r490", "r631", "r682", "r698", "r736" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Deficit" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r153", "r182", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r401", "r402", "r403", "r415", "r631", "r700", "r741", "r742" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "BFRG_LicenceInitiationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "LicenceInitiationFee", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Licence initiation fee", "documentation": "Licence initiation fee." } } }, "auth_ref": [] }, "BFRG_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "LicenseAgreementMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License Agreement [Member]", "documentation": "License Agreement [Member]" } } }, "auth_ref": [] }, "BFRG_LicenseAndRoyaltyAgreementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "LicenseAndRoyaltyAgreementDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/MaterialAgreements" ], "lang": { "en-us": { "role": { "verboseLabel": "Material Agreements", "documentation": "License And Royalty Agreement Disclosure [Text Block]", "label": "LicenseAndRoyaltyAgreementDisclosureTextBlock" } } }, "auth_ref": [] }, "BFRG_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "LoanAgreementMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan Agreement [Member]", "documentation": "Loan Agreement [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "BFRG_LossOnConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "LossOnConversion", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on the conversion", "documentation": "Loss on the conversion." } } }, "auth_ref": [] }, "us-gaap_ManagementFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementFeeExpense", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fees expense", "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment." } } }, "auth_ref": [ "r79", "r564", "r641", "r757" ] }, "BFRG_MarylandTechnologyDevelopmentCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "MarylandTechnologyDevelopmentCorporationMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maryland Technology Development Corporation [Member]", "documentation": "Maryland Technology Development Corporation [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r348", "r467", "r497", "r530", "r531", "r591", "r592", "r593", "r594", "r599", "r606", "r607", "r619", "r626", "r627", "r632", "r702", "r743", "r744", "r745", "r746", "r747", "r748" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r348", "r467", "r497", "r530", "r531", "r591", "r592", "r593", "r594", "r599", "r606", "r607", "r619", "r626", "r627", "r632", "r702", "r743", "r744", "r745", "r746", "r747", "r748" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r175" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r175" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r108", "r109", "r110" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r98", "r110", "r134", "r151", "r165", "r166", "r170", "r182", "r190", "r192", "r193", "r194", "r195", "r198", "r199", "r204", "r213", "r218", "r222", "r224", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r414", "r415", "r494", "r561", "r581", "r582", "r618", "r641", "r700" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impact of Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "BFRG_NewAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NewAgreementMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Agreement [Member]", "documentation": "New Agreement [Member]" } } }, "auth_ref": [] }, "BFRG_NewAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NewAgreementsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Agreements [Member]", "documentation": "New Agreements [Member]" } } }, "auth_ref": [] }, "BFRG_NewLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NewLicenseAgreementMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New License Agreement [Member]", "documentation": "New License Agreement [Member]" } } }, "auth_ref": [] }, "BFRG_NewLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NewLoanAgreementMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Loan Agreement [Member]", "documentation": "New Loan Agreement [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "BFRG_NonTradableWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NonTradableWarrantMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non Tradable Warrant [Member]" } } }, "auth_ref": [] }, "BFRG_NonTradeableWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NonTradeableWarrantsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-Tradeable Warrants [Member]", "documentation": "Non-Tradeable Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental non-cash activity" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense), net" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r683", "r684" ] }, "BFRG_NoteHolderMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NoteHolderMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Note Holder [Member]", "documentation": "Note Holder [Member]" } } }, "auth_ref": [] }, "us-gaap_NotesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAssumed1", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon conversion of notes payable", "documentation": "The fair value of notes assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r21", "r132", "r753" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/NotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable-related party", "verboseLabel": "Short term loan", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r26" ] }, "BFRG_NotesPayableRelatedPartyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "NotesPayableRelatedPartyDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/NotesPayableRelatedParty" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes Payable Related Party", "documentation": "Notes Payable Related Party [Text Block]", "label": "NotesPayableRelatedPartyDisclosureTextBlock" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r213", "r218", "r222", "r224", "r618" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carry forward", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r68" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/OrganizationAndNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r87", "r125", "r503", "r504" ] }, "BFRG_OriginalIssuanceDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "OriginalIssuanceDiscountRate", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Original issuance discount rate", "documentation": "Original issuance discount rate.", "label": "OriginalIssuanceDiscountRate" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued expense", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other (expense) income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r106" ] }, "BFRG_OtherPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "OtherPartiesMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Parties [Member]", "documentation": "Other Parties [Member]" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r657" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForFees", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License fee initial payment", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual minimum royalty payment", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/PropertyAndEquipmentDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payment to acquire equiment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r107" ] }, "BFRG_PayrollAndSalaryRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "PayrollAndSalaryRelatedParties", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Payroll and salary-related party", "documentation": "Payroll and salary-related party." } } }, "auth_ref": [] }, "BFRG_PercentageOfRoyalty": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "PercentageOfRoyalty", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty percent", "documentation": "Percentage of royalty." } } }, "auth_ref": [] }, "BFRG_PercentageOfRoyaltyOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "PercentageOfRoyaltyOnNetSales", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalty percent", "documentation": "Percentage of royalty on net sales.", "label": "PercentageOfRoyaltyOnNetSales" } } }, "auth_ref": [] }, "BFRG_PercentageOfWarrantIssued": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "PercentageOfWarrantIssued", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant percent", "documentation": "Percentage of warrant issued." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r651" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r652" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r633", "r634", "r637", "r638", "r639", "r640", "r755", "r759" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, par or stated value per share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r91", "r320" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r91", "r539" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r91", "r320" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r91", "r539", "r559", "r759", "r760" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding, as of September 30, 2023 and December 31, 2022.", "verboseLabel": "Preferred stock value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r487", "r631" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r163", "r276", "r277", "r611" ] }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "label": "Prepaid Expense", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }, "auth_ref": [ "r81", "r163", "r552", "r750" ] }, "BFRG_PriorAgreementsAndNewAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "PriorAgreementsAndNewAgreementsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prior Agreements And New Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from convertible notes payable", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r35" ] }, "BFRG_ProceedsFromConvertibleNotesPayableRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ProceedsFromConvertibleNotesPayableRelatedParty", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from convertible notes payables-related party", "documentation": "Proceeds from convertible notes payable related party." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock (initial public offering), net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from notes payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ProceedsFromOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherEquity", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from subscription payable", "documentation": "Amount of cash inflow from the issuance of equity classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromOtherShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherShortTermDebt", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds net of payments short term insurance financing", "documentation": "Amount of cash inflow from short-term debt classified as other." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from notes payables - related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "verboseLabel": "Proceeds from exercise of warrant", "terseLabel": "Gross proceeds", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r679" ] }, "us-gaap_ProjectMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProjectMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Planned program of work." } } }, "auth_ref": [ "r80" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r113", "r142", "r145", "r146" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "verboseLabel": "Property and equipment net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r484", "r493", "r631" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r142", "r145", "r491" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r346", "r348", "r372", "r373", "r374", "r443", "r467", "r497", "r530", "r531", "r591", "r592", "r593", "r594", "r599", "r606", "r607", "r619", "r626", "r627", "r632", "r635", "r699", "r702", "r744", "r745", "r746", "r747", "r748" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "auth_ref": [ "r278", "r279", "r280", "r281", "r346", "r348", "r372", "r373", "r374", "r443", "r467", "r497", "r530", "r531", "r591", "r592", "r593", "r594", "r599", "r606", "r607", "r619", "r626", "r627", "r632", "r635", "r699", "r702", "r744", "r745", "r746", "r747", "r748" ] }, "us-gaap_ReceivablesFromStockholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesFromStockholderMember", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Receivables from Stockholder [Member]", "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received." } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r690", "r691", "r692", "r693" ] }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Allowance for Doubtful Accounts", "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized." } } }, "auth_ref": [ "r48" ] }, "BFRG_ReceivablesWithImputedInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ReceivablesWithImputedInterestAmount", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Imputed interest", "documentation": "Receivables with imputed interest amount.", "label": "ReceivablesWithImputedInterestAmount" } } }, "auth_ref": [] }, "BFRG_ReclassificationOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ReclassificationOfWarrant", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification of warrant", "documentation": "Reclassification of warrant.", "label": "ReclassificationOfWarrant" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r347", "r429", "r430", "r533", "r534", "r535", "r536", "r537", "r558", "r560", "r590" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r184", "r185", "r429", "r430", "r431", "r432", "r533", "r534", "r535", "r536", "r537", "r558", "r560", "r590" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r347", "r429", "r430", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r533", "r534", "r535", "r536", "r537", "r558", "r560", "r590", "r740" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/RelatedParty" ], "lang": { "en-us": { "role": { "label": "Related Party", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r426", "r427", "r428", "r430", "r433", "r513", "r514", "r515", "r565", "r566", "r567", "r587", "r589" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r36" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of notes payable", "label": "Repayments in installments", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r36" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of note payable and interest - related party", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r86", "r382", "r749" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r94", "r119", "r489", "r501", "r502", "r511", "r540", "r631" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r150", "r187", "r188", "r189", "r191", "r197", "r199", "r260", "r261", "r378", "r379", "r380", "r393", "r394", "r404", "r406", "r407", "r409", "r412", "r498", "r500", "r516", "r759" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue, net", "verboseLabel": "First service revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r214", "r215", "r217", "r220", "r221", "r225", "r226", "r227", "r344", "r345", "r469" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Contract Services", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r148", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r609" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r563", "r609", "r615" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r172", "r182", "r214", "r215", "r217", "r220", "r221", "r225", "r226", "r227", "r259", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r415", "r483", "r700" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payments", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r102" ] }, "BFRG_SBAPPPLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SBAPPPLoanMember", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SBA PPP Loan [Member]", "documentation": "SBA PPP Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Payroll and salary", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r677" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock value", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, description", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": [ "r9", "r70", "r126" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional shares issued", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issue price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r55", "r121" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://bullfrogai.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Taxes", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r124" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r8", "r56", "r57", "r58", "r59" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Vested and Outstanding Options", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r122" ] }, "BFRG_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingTableTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Vested And Outstanding Warrants", "documentation": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested And Expected To Vest Outstanding [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Options Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r64" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Black Scholes Option Pricing Model", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/NotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r25" ] }, "BFRG_ScheduleOfStockWarrantsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ScheduleOfStockWarrantsActivityTableTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Warrant Activity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding Warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r61" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r645" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r649" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r648" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r653" ] }, "BFRG_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]", "documentation": "Series A Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r675", "r676", "r704" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://bullfrogai.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StatementsOfCashFlows", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-based payment arrangement, expensed and capitalized, amount", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r628" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription": { "xbrltype": "stringItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contractual life and vesting period, description", "documentation": "Share based compensation arrangement by share based payment award non-options contractual life and vesting period description." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercised", "verboseLabel": "Warrant exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Expired", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Warrant shares forfeiture", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted", "verboseLabel": "Share based compensation granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r11", "r12" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award authorized under the plan", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r630" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r368" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r360" ] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanceledIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanceledIntrinsicValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Forfeited / canceled", "documentation": "Share based compensation arrangement by share based payment award options forfeitures and canceled intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Number of Shares, Forfeited / canceled", "verboseLabel": "Number of options forfeitures", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Granted", "verboseLabel": "Share based compensation granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r357" ] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Granted", "documentation": "Share based compensation arrangement by share based payment award options grants in period intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average grant-date fair value of options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at Beginning", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Outstanding at Beginning", "periodEndLabel": "Number of Shares, Outstanding at Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r353", "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-Average Exercise Price, Outstanding at Beginning", "periodEndLabel": "Weighted-Average Exercise Price, Outstanding at Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r353", "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Vested at Ending", "periodStartLabel": "Beginning value, Intrinsic Value of Vested Options", "periodEndLabel": "Intrinsic Value of Vested Options, Intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r369" ] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExercised": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExercised", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Options Exercised", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding exercised." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options Expired", "verboseLabel": "Option vested expired shares", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding expired." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingForfeited", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Options Forfeited", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding forfeited." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options Granted", "verboseLabel": "Option vested shares", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding granted." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExercised", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Options, Exercised", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding intrinsic exercised." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExpired": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExpired", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Options, Expired", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Intrinsic Expired." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicForfeited", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Options, Forfeited", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding intrinsic forfeited." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Options, Granted", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding intrinsic granted." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Vested at Ending", "periodStartLabel": "Beginning value, Options", "periodEndLabel": "Ending value, Options", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Vested at Ending", "periodStartLabel": "Weight Averaged exercise Price, beginning value", "periodEndLabel": "Weight Averaged exercise Price, Ending balance value", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r369" ] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weight Averaged exercise Price, Exercised", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price exercised." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weight Averaged exercise Price, Expired", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price expired." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weight Averaged exercise Price, Forfeited", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price forfeited." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weight Averaged exercise Price, Granted", "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding weighted average exercise price granted." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increased payment award, percentage", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExercised": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExercised", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants, Exercised", "documentation": "Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding exercised." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExpired": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExpired", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants, Expired", "documentation": "Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding expired." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingForfeited", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Forfeited", "documentation": "Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding forfeited." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingGranted": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingGranted", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Granted", "documentation": "Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding granted." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance value", "label": "Vested shares", "documentation": "Share based compensation arrangement by share based payment award warrant vested and expected to vest outstanding number." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExercised", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Warrants, Exercised", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic exercised." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExpired": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExpired", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Warrants, Expired", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic expired." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicForfeited", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Warrants, Forfeited", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic forfeited." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic Value of Vested Warrants, Granted", "verboseLabel": "Intrinsic value", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding intrinsic granted." } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weight Averaged exercise Price, Exercised", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price exercised.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised" } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weight Averaged exercise Price, Expired", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price expired.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired" } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weight Averaged exercise Price, Forfeited", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price forfeited.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited" } } }, "auth_ref": [] }, "BFRG_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted": { "xbrltype": "perShareItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted", "presentation": [ "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weight Averaged exercise Price, Granted", "documentation": "Share based compensation arrangement by share based payment award warrants vested and expected to vest outstanding weighted average exercise price granted.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r358" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Forfeited / canceled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r357" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value of Common Stock on measurement date", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based payment arrangement, expensed and capitalized, amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r376" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic value", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average period term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r629" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r371" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Remaining Contractual Term (Years), Outstanding", "verboseLabel": "Original life", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r122" ] }, "BFRG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average period", "documentation": "Share based compensation arrangement by share based payment award options vested contractual life and vesting period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original life", "verboseLabel": "Weighted-Average Remaining Contractual Term (Years), Vested at Ending", "terseLabel": "Weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r369" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r368" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants shares vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "BFRG_SharesExchangedForEachConvertiblePreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SharesExchangedForEachConvertiblePreferredStock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common stock", "documentation": "Shares exchanged for each convertible preferred stock." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/NotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short term insurance financing", "verboseLabel": "Short term loan", "terseLabel": "Fianance raised", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r88", "r131", "r631", "r752" ] }, "us-gaap_ShortTermDebtInterestRateIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtInterestRateIncrease", "presentation": [ "http://bullfrogai.com/role/NotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/NotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtMember", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Member]", "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtPercentageBearingVariableInterestRate", "presentation": [ "http://bullfrogai.com/role/NotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accruing interest rate", "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r115" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r23" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r111", "r179" ] }, "BFRG_SignificantAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SignificantAccountingPolicyPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies", "documentation": "Significant Accounting Policy [Policy Text Block]" } } }, "auth_ref": [] }, "BFRG_SimpleAgreementForFutureEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SimpleAgreementForFutureEquityMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Simple Agreement for Future Equity [Member]", "documentation": "Simple Agreement for Future Equity [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r654" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r149", "r158", "r159", "r160", "r182", "r202", "r203", "r205", "r207", "r211", "r212", "r259", "r282", "r284", "r285", "r286", "r289", "r290", "r320", "r321", "r323", "r326", "r333", "r415", "r507", "r508", "r509", "r510", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r528", "r539", "r562", "r583", "r600", "r601", "r602", "r603", "r604", "r664", "r680", "r688" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityTables", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r34", "r150", "r168", "r169", "r170", "r187", "r188", "r189", "r191", "r197", "r199", "r210", "r260", "r261", "r335", "r378", "r379", "r380", "r393", "r394", "r404", "r405", "r406", "r407", "r408", "r409", "r412", "r416", "r417", "r418", "r419", "r420", "r421", "r425", "r498", "r499", "r500", "r516", "r583" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r187", "r188", "r189", "r210", "r469", "r505", "r528", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r554", "r555", "r556", "r557", "r558", "r560", "r563", "r564", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r636" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bullfrogai.com/role/BalanceSheetsParenthetical", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r187", "r188", "r189", "r210", "r469", "r505", "r528", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r554", "r555", "r556", "r557", "r558", "r560", "r563", "r564", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r636" ] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity compensation", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r60", "r67" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued for license", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes, shares", "verboseLabel": "Conversion of convertible securities, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r10", "r33", "r54", "r119", "r308" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stocks converted to Series A Preferred stock, shares", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r10", "r54", "r91", "r92", "r119" ] }, "BFRG_StockIssuedDuringPeriodSharesForLicense": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "StockIssuedDuringPeriodSharesForLicense", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Shares issuance for license, shares", "documentation": "Stock issued during period shares for license." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares", "verboseLabel": "Number of shares issued for services", "terseLabel": "Shares, issued for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock (initial public offering), net of issuance cots, shares", "verboseLabel": "Number of shares issued", "terseLabel": "Common stock issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r10", "r91", "r92", "r119", "r507", "r583", "r601" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to warrant exercises, shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity compensation, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r10", "r91", "r92", "r119" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares cancellation, shares", "verboseLabel": "Shares cancelled", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://bullfrogai.com/role/ScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r10", "r91", "r92", "r119", "r358" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes", "verboseLabel": "Conversion of convertibe notes value", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r10", "r34", "r119" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stocks converted to Series A Preferred stock", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r10", "r34", "r119" ] }, "BFRG_StockIssuedDuringPeriodValueForLicense": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "StockIssuedDuringPeriodValueForLicense", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Shares issuance for license", "documentation": "Stock issued during period value for license." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "verboseLabel": "Value, issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock (initial public offering), net of issuance cots", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r91", "r92", "r119", "r516", "r583", "r601", "r642" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to warrant exercises", "verboseLabel": "Shares issued value", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares cancellation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited", "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r19" ] }, "BFRG_StockIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "StockIssuedForServices", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued for services", "documentation": "Stock issued for services.", "label": "StockIssuedForServices" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r635" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares cancellation, shares", "label": "Shares cancelled", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Shares cancellation", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r10" ] }, "BFRG_StockholderEquitySubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "StockholderEquitySubscriptionsReceivable", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Cash from subscription receivables", "documentation": "Stockholder equity subscriptions receivable." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://bullfrogai.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bullfrogai.com/role/BalanceSheets", "http://bullfrogai.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 deficit", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r92", "r95", "r96", "r112", "r541", "r559", "r584", "r585", "r631", "r643", "r682", "r698", "r736", "r759" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://bullfrogai.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://bullfrogai.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholder\u2019s Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r118", "r181", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r411", "r586", "r588", "r605" ] }, "us-gaap_StockholdersEquityNoteStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock split, description", "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements." } } }, "auth_ref": [ "r120" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r120" ] }, "BFRG_SublicensePercentage": { "xbrltype": "percentItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SublicensePercentage", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of sublicense", "documentation": "Percentage of sublicense." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r422", "r435" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r422", "r435" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r422", "r435" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r422", "r435" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r422", "r435" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://bullfrogai.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r434", "r436" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative", "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "BFRG_SubstantialDoubtAboutGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "SubstantialDoubtAboutGoingConcernPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "Substantial Doubt About Going Concern [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r689", "r739" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/RelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "auth_ref": [] }, "BFRG_TradableWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "TradableWarrantMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tradable Warrant [Member]" } } }, "auth_ref": [] }, "BFRG_TradeableWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "TradeableWarrantsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tradeable Warrants [Member]", "documentation": "Tradeable Warrants [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://bullfrogai.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r316", "r331", "r410", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r495", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r694", "r695", "r696", "r697" ] }, "BFRG_TwentyTwentyTwoEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "TwentyTwentyTwoEquityIncentivePlanMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Twenty Twenty Two Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r399" ] }, "BFRG_UnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "UnderwritersMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriters [Member]" } } }, "auth_ref": [] }, "BFRG_UnrecognizedCompensationExpense": { "xbrltype": "sharesItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "UnrecognizedCompensationExpense", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense", "documentation": "Unrecognized compensation expense." } } }, "auth_ref": [] }, "BFRG_UnusualOrInfrequentItemsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "UnusualOrInfrequentItemsPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "COVID-19", "documentation": "Covid 19 [Policy Text Block]" } } }, "auth_ref": [] }, "BFRG_UnvestedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "UnvestedWarrantsMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested Warrants [Member]" } } }, "auth_ref": [] }, "BFRG_UpfrontLicenceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "UpfrontLicenceFee", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Upfront licence fee", "documentation": "Upfront licence fee." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r45", "r46", "r47", "r139", "r140", "r143", "r144" ] }, "BFRG_UseOfEstimatesInPreparationOfFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "UseOfEstimatesInPreparationOfFinancialStatementsPolicyTextBlock", "presentation": [ "http://bullfrogai.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates in the Preparation of Financial Statements", "documentation": "Use of Estimates in the Preparation of Financial Statements [Policy Text Block]" } } }, "auth_ref": [] }, "BFRG_WallachBethMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "WallachBethMember", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ScheduleOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Wallach Beth [Member]", "documentation": "Wallach Beth [Member]" } } }, "auth_ref": [] }, "BFRG_WarrantExpirationPeriod": { "xbrltype": "stringItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "WarrantExpirationPeriod", "presentation": [ "http://bullfrogai.com/role/ScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Expiration Period", "documentation": "Warrant Expiration Period." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://bullfrogai.com/role/ScheduleOfBlackScholesOptionPricingModelDetails", "http://bullfrogai.com/role/ScheduleOfStockWarrantActivityDetails", "http://bullfrogai.com/role/ScheduleOfVestedAndOutstandingWarrantsDetails", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r633", "r634", "r637", "r638", "r639", "r640" ] }, "BFRG_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "WarrantOneMember", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant One [Member]", "documentation": "Warrant One [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://bullfrogai.com/role/ConvertibleNotesPayableDetailsNarrative", "http://bullfrogai.com/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative", "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants term", "verboseLabel": "Warrants and rights outstanding term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r735" ] }, "BFRG_WarrantsIssuedForConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "WarrantsIssuedForConvertibleNotes", "crdr": "credit", "presentation": [ "http://bullfrogai.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants issued with convertible notes", "documentation": "Warrants issued for convertible notes.", "label": "WarrantsIssuedForConvertibleNotes" } } }, "auth_ref": [] }, "BFRG_WarrantsReclassifiedWithIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "WarrantsReclassifiedWithIntrinsicValue", "crdr": "debit", "presentation": [ "http://bullfrogai.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants reclassified with intrinsic value", "documentation": "Warrants reclassified with intrinsic value." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r201", "r207" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r200", "r207" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://bullfrogai.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bullfrogai.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r662" ] }, "BFRG_YearTwentyThirtyMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyThirtyMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2030 [Member]", "documentation": "Year Twenty Thirty [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyThirtyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyThirtyOneMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2031 [Member]", "documentation": "Year Twenty Thirty One [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentyEightMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2028 [Member]", "documentation": "Year Twenty Twenty Eight [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentyFiveMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2025 [Member]", "documentation": "Year Twenty Twenty Five [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentyFourMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2024 [Member]", "documentation": "Year Twenty Twenty Four [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentyNineMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2029 [Member]", "documentation": "Year Twenty Twenty Nine [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentySevenMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2027 [Member]", "documentation": "Year Twenty Twenty Seven [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentySixMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2026 [Member]", "documentation": "Year Twenty Twenty Six [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentyThreeMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2023 [Member]", "documentation": "Year Twenty Twenty Three [Member]" } } }, "auth_ref": [] }, "BFRG_YearTwentyTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://bullfrogai.com/20230930", "localname": "YearTwentyTwentyTwoMember", "presentation": [ "http://bullfrogai.com/role/MaterialAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 [Member]", "documentation": "Year Twenty Twenty Two [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "c(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "932", "SubTopic": "235", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-1B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(a)(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r664": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 74 0001493152-24-004069-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-004069-xbrl.zip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ϡ]>O7%/< M_/2AT'F/$&UW[OAB=+$M3.OSC(3QM*@57S71"LNMLM_?(9\V34,DO%*QR[BN MZX,.[B%5^6J9JN1:KE]3U(;=4T5IPCSHRC";%7B+ E:<(1B1,R^*>/- HA+R M ?8"?%4V09C-I1J*%KEK])S_J>T6L>J_%R K<@EB;/ R);P^Y5)IMZ[G7?<4 MV6T&05#UEL_8Y3RF]MJ.H)?K4,IY U$TYM"J.P-N$;,76GI*:IU=QU2911!: M/!$7*6G*)R02%:<:B)O!C M9TLYZ?^8\ZK3E4A 53-W\V!'5G_-4R&67/Y*J'2[4S7.QUZ[JH$B 57-F!,Q MY^-!SNH#P&IE3_X#L70=% SI@NY-T2UBB-'?+R]T95YTC\C\6***_1*S%ZIJ M0F2@*IOSFK:=M?E_?D=)NCHN"#(#='YE+Y1/JRQ K3+G8-UQ@OV>/T)QG3$\ M1A.IDZV#K^V%EG4B$S!CR9R7ECNCFJY&>X$XP!6(F3F7:UO]K#8_PTDJVW6T M?&,O=$.C)$!]TEQ)?-/@XN41^?3'>\Q^5;'?\E,'-WMCE3#6Q_>= M53 #4@*5KXO\RD[9RM^U-ZA\Y?)EN77;Y'/R XG(0K8\R.;B@SLHFJ=G<6S*8L@9IIKO.RH8&4&%.BE MTS6\T[CK%0*H&<:2QY<$4W.LH%@ISUC4RUFXE7D#4326+=[!B;"2']GK&;WR M7=$^M"N MZX0F 8!*8ZZ@!(^QBQ=$_#!!-R3TT>J/*VM)5(&IS7![J1QJ3(,*85<]7;5; M;9*>>PFSNM79UA^JVRM?TB^/PQ;+FVZ/?,//.ZLT_0L)U+RV+LN.-$\A!6#E MKNDH.ZX]):]:'UO+"U)-WM,3_6QSY^@A75<%61507)_AJI4R!09/LW&[VI<-HAU%=UXC= M>0>UQ)Q;MO+&S<9]HX+/J[CRYHU *QJ,XKP6-.851-U3.&\V*?<4E%[T4WV$(7^:#)!1.BK4!["=6P; M,@J";<-[GI7L[NT/.'V5/D1?5JG/9 M0%K(>["L?Q.R=&XN:1:L-J)>KFN!G#<016..O&&E![Q*B"TW [][+^$\$V3I=?G55ZMZRK(! MM=!LE09MU3&W[NCG?SRGL*SN2'>@F.T(>;6ZNHNX0/4UYO,]+Y]< X10W/$) MPJW@8ZZK86%S\,U MBX7GR3!LKB7W./6B[5IEUSC]!TIOD8^G,3-0\FVBG):P\O7R>=?5L4ZV>I^)HTJ:R V[E55SBO8Y8V5 MGM#0\0EGU:,;04#*],F8"WY7(_UUV-TZ3.E/F@L:_!:3E;VD!AGK)NGE+%#* MO('P5-S??W^WQ3;][(_EWSA_VA@4O:0H#M;;Z8:4'K(HHKQ/O? GRM*[7$!W M_@P%&^\A$GEB._B6U@7%J6M-X@.52!G M&]("W24!_^L_?QO>?+M'_BS&$9XNOH4^.W.LS$ 04M9;K?/8T,FLY<3#;?C3 MO20#:%VCYT8 @>W'O.1)-T 1\P2Z/34C\2NB0D!_>,DLC*:[HX MI:>FXSOF7B=A?!?>7@]+N'SB;@@.2#9MCR-O@/$Q M;[=V&4.82]!JU5T/M]'^!VP4)^^=Q47$$6PSFCL9LI@22Q$3G_"WFNW_R9XK M%\[L,8[;^<9)6(#E8WG?A2R-QK]J/C[XZ(^TMHD%A?^U:V.@)QY!]QQW!+Y--FPS=BSR M"Y;CV4CDE1[C8U/>I.8BKY$-BKSUS5]%D5^'<;,E?-UA?,Q+C;13X-M4@_+^ MU)V\9R%A'D(U65<:CX\_NR#G&L6@C#]W+..1NDIOMA\?.V&4\(@&A=W:)N$? M]!.25@[Y]%_K S[]Q_B>I>"-)I6+;GR?&&T+--UCOQC,-'A:,HH=N[)XBZ(\ M3S>9A8_W^").PW0!.FYX#,H&Z=F7)L5 @)6:/#KWM5D(HY6^N>Z@[M5WEZ?< MWWB$%941;FOUAN.^#;0=9@V6,@()O+7)MGO2MO<8IEY4W&E(TF0T^2U^)/@) M!3<$TYUGNP[0<([I[_[,17&Z*-LL1H3^]$_D2S)$._G8'N^V78H-=+@9K-;& MJ),E)VXU,Q/'ZA*16L6VNE1LBH6U@8\WPTU&(6#T MUBY2P06<*TN"#6U57'EA/FEV'/N:B-/*+41=Y-TL]ZVD7I:T$\E]H\FX;P357@& )*LRE9I>(6+[R(N?6O4K."9*]N4U_J\"KP KB',-.=F MW^5OPK#\Y#5- %2\IGN+$,PL:!\9<]O1H^EW*K(4Q>RQ'X'+;;/A7F(G8K6? ML%0#Y,JI+ZU\M-ENGW'C<6J==U+X(,\U>L[_U/;YHE7_?8:YB01TG^Y!/YA/ MD)>@ERC^);EF/$Q+KQ*+<;:2[QWE 88(S-VV\/W"57:8ID* M47*6$4+I+R55_ .>^"J]]U(-&O,/^EH[N)FX?!^1L7")(.N7UW0OL1(S"WI3 M-%<0@)P"OI@C,4 B\JDR24FJWDN" 5R6N\EA%)^P?.^ MN6CNFE:J;FH@LH:O!+\UJR!TQNYPW\TP25G1[U-,"'YF[W,)CB/UQOL,(<@N M"*,QSTZ>.58:3=]"[R&,PHK9!",J[K?/X*IP#N)<\0/U7)8W>TC0OS)*X<43 M4JX(^Z%6F'-JC*,O,Y38W5 Q4/EN$T'17Z%,+*&$0>F3!XOVC21X-D>]) M0!=7=B4AQQ:%TRL47GMS^F/E_"%= 17ZFMNIQ C@QIQ8N&EUBIWMVYA>?"W= MT:YN1K)=;-7$U,ZE/GSU2AQ=K@/$EH62$O$5.*"UJ=*2*O,!JU$/SA[- M^?W7.&XF&.>('1M.#7=D-!G27DY"TI ;O1P$#0._=8YC&X(]A$*$G;' MG*F5M\K-BF[R5,K19()8&JT@1T-U"%<@;,B0=:>IB@J>H\0G8?[<^\9946G^ M09U=P5&9%3=.7!4 MBN3B7UF8+EC2.DE0_H>[QR@4I.8H='8%4V56( 3UUF=H,G-QG+^.P]:9@MC< M8BM^G:) -$ME75U!3Y$1"#MC-S#.T4.ZIGU%[E6'*^1GI$CJ\Z((!:>+"\^?;;9MN,DV&=H51=#$**0;;:][ M=#_]AW.DN$[\O;,=%!D4B);B:9!IEZ^--? 'P33S*9P$FI)W;MLO(< M\ ?@AX,#X.#@/_[WRRI!3YCD<9;^Y9L/WW[_#<)IF$5Q^O"7;[[<'BYNC\_/ MOT%Y$:11D&0I_LLW:?;-__Y?_^W_0?3__N._'QZBLQ@GT9_0218>GJ?+[,_H M,ECA/Z%/.,4D*#+R9_13D&S87[*S.,$$'6>K=8(+3'\H/_PG],=O/WX(T.&A M1;D_X33*R)>;\Z;,[(K_FW8;:R*_"V"(I-WI3V M_3Q7[YAWZT^^_S#MQEY^.[C]]]_ M^.[_?KZX#1_Q*CB,4]9N(?ZFUF*ER/0^_/CCC]_Q7VM10?+EGB3U-W[XKH;3 ME$Q_C37R'21Y_*>#7_5+RN*97RF#'AF^IOCP0OY6 20KYC^M^E^"$H<,0^]"/[ MT(=_91_ZE^K/%\$]3KY!3)+R0UFO'WME54K?N09[C4F<1:?I--1#;4_PZ=@A MQ185Z.H[K\)=5@3))/!=3>>P+_&T%F_UW+>;LF M[(\7]%\]B/BEH!,8CFJ0K B-!>9?X!-#5793>A;VRDV8-<^(6'8[SZA]WM/S%2YS71?-Z M_>4;&X7OAJ"9ZH+4R ,2&JI?27P79G3R6A>'2=G0I?J29"L['%5#93;2OR3W MS1?*IJ4@%%7IB=%"L@T)\:B>[=;'NF$KB*N$JC _#:>'7VZ_^5^E$FJT#NI_ M(J:(?F:J__4?W[7?IQ3"<98605A\QJM[3"055LBY(I 69LT;J1 ( MNNB0#5E2RZ)*&/U5'_XY08GW#.@ M+L'K'0G2G**C_FE^]-K]16**IA3@@EG3*\8H-U[;.Q7ZUO"VR\%?-U*>1=\D;(^PN?93"8%AD0C@D M$Q=#V1)Q02@SUBTF,5U#7-/2,"$XXN"TYD>KX91/9N@]1JG%X7#*B''(JE(# M+5"C4_-K)FMUOR0/G#;?__C#]YPZ1VLX'=Y MI%4 PRD;E$-^M3J(*1W&*:K4X+#M!H?T7[D8^$Q2R),#/M/)C6W MNU%VE>CO3>EUP##/$JBX;]6H(=9:J*,(B7Y%$*8^CZ,X(*^W08(M-D+5\D[7>";8O?6=2A@, MFTP(A?T$*@5N'_3\^DIK?SJ_NZ2* *M+C>9',%08(AIV/?T=CO4XP??%>9H7 M9,,V)C1F0R;HD@1JH%TVB%)@:*&$-N0'$T2MY$S&0;6%?;2XOKZ^R()4LUDM MR+C;EE; :S>@!P+>NUN'2I@$CA:(RB$F",RJ@%:'N0Y^]DX!-:9AUW,I M5(5![]2O^$Q70O33T1T.'],LR1Y>3_ 33K(U#Q;)R#HC_&Z5VNL86X(SGV1: MU1J/99RZ=W)-QSPD7UT(:DM!G6)0IQPXSA +K+U:+@BA-<$&5T@AZW(BT\+M M3F520>]DLT$G'F(E5)L3YPFCC@YB7.O^[ZOB$1-4/%)GNZ^T4TO8"1AA?O[B M@6 .1VWY3!K.+)T=],:RZ<6]D\L>HTBQ-N:'K]4:M5U'F%WB9PO"R*2Z.*,R98@F]X89"'P1([D$)H%=="M(,_P%DL]_8@%5D1#++>=GUEN1"T M@M[98X/.L/<[Z\5ALU/#/DG);>7%#&1]N"U2N#(_I2?HG1"#\4H H. MO5W.W.?,FA@=65_$$."JB-$(@B3&$)V1&%3!-3&HL+W-Z$E[(X<(64F/5A0F M001\9HHP%<A'2%O=%# M *RD1R,)DQY#>&9Z\",9I_2XC5^LV=&1]44. :Z*&XT@2&H,T1F9015<$P,_ M84V,@D[:&SE$R$IZM*(P"2+@,U.$J3@FR6G\\&AWG"M(^R*)!+**)!U1D"01 M\1E)PE4>>("=F0(5R673MOI7=Z6\Q MD./'&"^;*VQ7RV4<*M*N&*5=D<4"X,TT#MG<-*!XY'O'@. M2&0(/!G(.$T-)8/72P75%?!.$ATJ(1Z)R8!*0W]*/:7L%6.>8>-JK;QL9B'O MDB-&V%V^*(7!<,>$4 Q0"@@^/ IRGG'\E3LQG3L\!Z@L8]=>[NE+^,B^:>'F M*D6=^;D&L(VCJY#SSA4+<$):U$K:F:L[)HL.7?/GM%BMM1D*.Y2EA9J>R]+*@:C_[78A-M9I3#$2> $D_B)WRYN$[/< MQ+DN,9]>Q6VN+3/X?M8MM;QW6HT *6;BJE4@IM>Q7-=X7L]8K6/@KE]LURW5 MYOO,JY.M25)=(M029"#CDAQ2>%UB] 3 D$*&2KS4QV5V?I\O>HKSC&AN!@\E MW-W6DT)K+^?U?O;>MVI,8E;S4LCY;7!V@MRX.F/N@LL5_=T$UU5$?0]R53E'%X M\5\.KW/OOR\ H[<5J%0.@H.;EM""+.77,QYD)2BSFR4 6QCE11RWKEA 4X(*ZJE MG24MNLS2$:3023L\D#%![AS-J$1AL,.(3_+@_*%[DG1SZMP]9^46W3GMI91M MZ5XGNC(:LJ$KN'-S0PUVX'#(Q[ZPP8Q-=CU)X_N7.I+LV-SRX5GX!J_.;JWLT ISZUDSS@_.[NCS"Z6X)(?+_H9=;N5EX]P22,UP9@XC634A)Q4:<]KSV45TGZZ7_U ;U<#" + M3(?U R(X.+/OP=/F1E9)^B&#.B^R7 P@&4PYD0=D<) 1N0]/GP]9+>N)$)I< MR"I!B*0PYD$>TL)%%N0>1'T.9*6H'UIH\A\KY "2PIC[>, )%YF/__.O7Q;7 M%^T;F_;WUVPUG1%F7%4:_MBIP:#3**Q#=E%E=(BH?O=)5<"7XGB2B).@,*;G M:&6:(2=F1@CX,:J*"6] M$\$*WI 1M.\^[GHJ$C#I/5>MN#]&:/Q7C2Q05AB]6-:+KGFA=UQUTMY8H7%? MU:(P.6%T8FD'_L%%6DEK1U4C[#2YI)T[JI2$00<3/&F6R9WYF IZ\*?;KP-2 MQ%ASQBV3SC]A6E7\-<@? MX_2AR-(O:?R$21X7KT>X"#[>KBD($J>W\Z]U__,'M/\K]GZUSC-6WB?\3U. MH^"?M+V,'!];@KLM^DE5:[?J1ZG#H/ DS,+6/2L$5:7T.=LIR3U5AB"(J(+BXG^C5S;LV^CJY+!KY&I MPN#4:+PC_)FJ%/^^C.&=5JVX-U.E>ZE5(PN#5F: $E/U[ZYYH7^:52?MC16: MQUG5HC Y87R>E7;@CPXI\1@3W5.)*DD?5)! E=&@(P:. B(VL?M_^-YU]VLO M7VB$O9% ?05#*0F3"J:+&)0-'^ 1>5G:YJ'?BV.$3KNHVTHB+@WJL;% 5J?$QR'HDD6AZM()0":0U/ )]=F*$ MFHQ%QPQ@63T M4,EX9X8!F'"]@XNB1A;]S*4]<^*">M3G!5X-YR&]J"=N"& 5_&CD(')D",[, M$Z:!N(IKLIQD(7_'ADU_DIKU?W9%"AFHF@C=WT!TO@20\')0)<*=#,<=O* ? MCOC#\DGP(($_^-U5%TMAU7W<^Q%$)\L0";=J:AG$A'QU\PG.0Q+S=%.Z>O3$ MG'>Z!*30]QT96!00@:F9T)'U9-AO\$.<%X3'&[+\1'RO76/&%/*N3;\6]G N MD J#((T-0N5LT55"C98G'BW2=!,D-WB=$1U]^F*N62,#.21+5P841R3 E-0H M95$I[(D1_^\F( 4FR:N1%(*D:UXHH ZI,1 #Q0XY-B5!&G&_'+DC09K'S( 9 M22**.E]N*, *2X^!'"B>*,"IER2-O%^FW#[B)#G.5NL@-1L4F;!KMJ@!#_DB M2H)BC!*>DC-< U4J<&C#=V)95@/+RG;D?9)'@*WC3R,,ED)#A)8L*K?1F9XG M)EUC$F<1=;.)B4."I&OV** .>3,0 \48.38E5TIQQ.7]D^0TC:PHTLCY(<@ MIIP>E1! $-)#K9YQU**N M:&("6_-$)0>"* 9PPM.7I7B/*)YFH/(T^2Q.\.5&$BG!&EQ&:S4P3]#,;<,D(/LLZ O X@)4F *-K2RB E[ M8<0QM4PD2,[3"+_\'_RJK)<@YY83"IA]4@R$ +%"CDQ!BTH8<6E$Q;T0XYK$ MJX"\WL:A8:H0!=U20P6TSXVA%"!R** IV%%)H]OS8Y\SR5WP1SM,P(^NL$^YPG&VH 7P]SB*U MAV+0=N-?"ISFG>(1GS%M?K=<6]^)7%!OWRYQM,1I%'HN*)0DKP"B()\A#II )I)%6IZ)-; MMSC]1 MK>6X^R^S.Q)$=$J\?5W=9XDB^Y14RA4)-!!K'DA$0%!!C4MXH#5#E2@J97UD MI^J!E51G\+LK DAAU5W?^Q%$I\L0"8._U]>>3/[I2_A(06'%A02YF&O3+P,Y M-/]=&1 4T 3%B65**IE?5Q(:*>L![,3\.#-"7@P. $/$)V !ULGX,&;$U!_ MMDP10NW2U7T2/P2*Y(1::=>DT$ >\D,B"HHJ:GQ*F]&HH%;'=49+GN+L/%UF M9,6_?T;_(:FE0LY93DL=S":II4P(!$=TR(2TEF72N8XP8M*N>;&)X@)')9BS M. W2, Z2)CVB;$?;<2, 78_:$8A#().-@@5H3-,Z?!7IH5J MM6HGS N3?LJ235H$A-\E)^H$_(*<6^8H8/89,Q "Q!0Y,@5#&F%42ONYH%UF MCVB<+&;PI"E@].*.KVMK00]N;4ME 7%&"U!UA[O*^='ZQJ66IRN6!29!6,1/ M^"0H@@J;LKXJ<=>7*G6@A[BP5#%!S2EO*6/(,76U'C)- ME/A RGWB& &BF#NF$0%$#QDN3089@FI9+URX705)W3R1[+AZK_*S*NBFDW7)#"[G/$:DH M(*[H\"DX4ZN@4J=.J>N'/"]M0O$RRZ*ZIA)1Q[11@AUP1I"#1!@5.($M"0[9 M?LME5J"[#'W),2H>,>+AK!']>R<3?%F.KY=&PI!=B"B]\C0*B(Q".F'GKXXH M 0MOCPB2((ADA*=^AZ310+6*8]9<40Z3[CJ.@V!OZ2EO.YA57#'(%GS-(Y,\ M"#99@AQRBJOU%]=YO=K%ZPDY]HPE >.<4<"!$>4L%1NM M #^Y\S;W21R>)5F@WF7IR3C.F"?"&R3+:P4 ,4!$I4J1QP41E_32_T=!^BO9 MK(OP]9ID(<8LRBIOK)5I_\U2VRUG1E6ISR8K54 \&X-7P<"V"-0IXZ S8_G< MS&-!XRR;6Q;^>OL8T :\VA0YFT$I,/4NN%;)\?&"104&APP:#4#4LX"I.G#@ MFHBK'J!2&76T/:W/\C8+((Z.7F_P$A-V[^ .OQ1']$._:E88%KJN5V_6U1DN MYHR*($@X%JUJJ9>C;@'HGL6(546@GUDAB)?B^OWRXRPM@I"]&)-G:8H31TP$F1UW]I M^5']X9?;\!%'FP1?+4_P,DXI_7%*_U%<4_#Y29R'299O:)/=!?="A/+$,EPP M:ZOJ,=I-*L [)[=!+<2[5F6P0.FJ%%05@W@YJ%,0-7.LJ'DMW!0^B_5M45[0 M7]B&R? 0;Z2N2_Z.JDZ7MU:*8/@Z!JTP"4NXV:$F^ID5P#?*TXHX(K4& @" M8X@H-JX#K_,D[8XZ#_'&11NR_3O^QB9^"A"T[%L5Q0,@K7>[^%"0;E7MF MJ>N24:.JTV68E2(8QHU!*S"0*J$@C5#(_H%;=>]&_/L<8(S3FQ.*5%D19!?[FY.;V\ M0XO;V].[6_]^T37)UI@4KVS15]"IEDVS:[8E>XG54Y).Q>W,9 ;?GZ#4\F!( M90%2G*Y*%>[NX%K^ *5XWO/".:R4Y5#R:Y5LK!'$64Q )Y_(J-AAO4 #M:+7 M5LX')=1$@-C]VDX'XK5PBGK"@*H*C M&_R$TXW!_*B$'9_>:P /CNLEDF"HHX4G.9#GPHB4TMYY<_N8D>(.D]511DCV MS$*357$S,DFG\4IJJ+VH)%$,#%?4V(0((R:)"BJ*XC3?D(#%2R[+5%ST)%X+N'?T+I4$PQ\M/$DP;BV,4D:G;8ESOR0/G W? M__C#]YP11V1J,2J-5O;.KJF(C81#APB6 MY;)>G/E>E=DMQSROPXP[WM:KL/[9?6<["!)CS)7TQA$#.<"R0D6'J[O%!;HX M7QR=7YS?G9_>>J?!Z#,0**<>X\XY]N!D8_19ANSL(BK/+OQO-E^3:A^!H]0% MN$HE'8<8JJ . @R'8F"XH\8FYL$G[.QK@;H^3:..\O)&[O_X_MOOZ?]]8-X- M>F+%': _'OSQ^^\/Z%]17M[7#3;%8T;B?^+HS^C??CCXPQ]^K'^)66+BB!^P M9>VEW@,4Y.PZTBWM#\QRGJ ?OC] C#E<\@2'U5\_\+]^_-8[B3L7G+4AVH*8 MVS6@'&1_]=>7 4-?WQ37L_%!R4\7/?SWX_L<_'/SK'_[ J?:'@^\_ M?CCX\8<_Z@D[DJ\'=$V0KS'/@9J\^F?O(HIXSK,@N0[BZ#P]#M9Q(;RA:I1V M>F:CA]P[L9&+@F&V'I]P6M-((Q;[?1BG*"P5O-/H!A!^2*\%$1\8V9:TQXFCZK#4BULK]]75.% MU%N]*DTP_!L%5W+;O+_WVVRJ 6-DF25RT6SJ636&J.2/@:H*J)DWU #*. 5, M(].$?5J0C..O+(YA6ZW@FVE]X":6E=*@&=:#:,NNVF/5GY#"\>&$'.%& M!TZKX8EO-JZ;1APBORR=MCZOX'EL0HVT[II2VBNOU(Z:0A0NG[0NFHQ+!U < MM!'/3-BI>*64P2\#_<#$")!V#(/DC[&G!E:XV6XV!-LJI5V2RP"YRRN%*!A* MZ?$-V51*H\[90*W@_V2@NLMK2D8MBKF-N)&#[,?7]&7 <$4!;$B22LQ_Q'4% MY(SV 'NM@D'^&A>/QQMJ#5>8G+Z$R8:90):MB?Z_Z"YXT==\7$D>>#6EJA+J MC2D&&CLG8%<0&$;"OGK0&<:D'S.F,U^P8FL&J.0Q-% 2/!QG>7&U_)1E$0\$ MPN0I#G%^FR6187*S473KA=M6I.^+F[3 &!UKJ*)?GAT:T>?S MV37R M+MEAA-WEBE(8S!QC0CBD4"/?)-#S[['9_0NBRB59S&;(RP^ZQZ MDAFUG$YK=E7H375Z%3!4L\,IS(:E%N=:T-/S3K?;( E(>0'H:_"@W/81Q9S> M@E" [-V!&,B H8P"F!#*%+S2HDJ.Y$QEZY16BIQJU8?8.H]_II^&:U )*PUG M>=/LH#>9TO3BW@EBC]',%6!I' 5?S]8G].QA6WG6L-9B*GCR]7DF.-5PN%(> M]E[0A:.IJEU)+WP1H4H9TXH!Y8P 4'BM@RWC62/4S,E2_XRYS-*L7X.*^X9U MO86>VZ3#EM7HIR V*'F?UL8B%=;]Q2,F*"XC/WY7F:G?PS@B)N&/-CR9@4/S _16>=Y/#$T*!2JI[(9B&(PF7^%,1ISDPA MSJ_2XRQE>=MR:@JOECR?KLT$>"EM&8)5.:EF*PJR69T<6 ML^2QWMX;8M9/:3I5\[E!R:F/9%6!GKNDU0 SGUG!E$]FS2Q636LP)K.Q+ -" ML%'<@D$KHT,^EE;58@ZPIW2)"^-Z;B#CE$0R>#WB= 6 D44"37CC Q[V;G%Y"MO!$Y._H$,@GH.BYM449GO=?70I M #AMJJ(%JU5%0.>U ?>VS+;P4789DS4UZ?I'I]U&O;\XBVZ+@!2Z/14-SF$W M'04)>VC7NTFQ-1J>S8+5P/<[M&TY8CF.*X+4V2]V=";986Q)V-O-?1Z2>,UC M-&YPB.,G2;;SD;K.3BG'5J%OD@L]3RC3O M?SW'Q6-U+C_CZ]).2,V/>K=HKDH?&HE[U1I+7JZ\5Z3M(A9"CE9KYG"CN H] MV@M:,"5W>]K[D+1.>?["'EI>A>6]S]9Z$- M@CD:<>S8V>:;>S7D9JBH]&'>0UXFV]YO"O4^8CFP3VS*P]')AM!%1%DO7AEY M0^A6K&-+$+A<+ +E<>G?=RI7+Y/H\V)[+8TMR MSN5I516X/*X86%R>A-V"RS9[)7"BP=SN8.HZ18X+;#"8@D/<'!YG;?!VYV7T M6QQ22AH+6F,P\%ZT(!C(61 M#6 ]N>[]:!A7C9'#8<='%=I%(%W1)4&>Q\LX+*^77BVK34'9_OGDHIP=9&Q9 MV>9<8V(YWGD\ W@Q5T]?@7'XN=2 8FISU-J@R-BOTB@VEJI0KK-. M@VU!R[GF]ITN_G1G9Q9Z !Q7L1JV"S589V2V2(6S,:K"6%?ZEVU /5IO"/NE M8)'VU:2-\ LF80PA^8S6VY[ RIXB %I**F*]9MH+8HI0YV'F7IC-[G+P2QH7 MV^Z1564 X*V^>E/VP'@!T-FL1:U[:BNO%_4X8G2^Q2SC(%J@P0.I4-DL[FY, MH+.R$ !\-E1PTC[67C!:#WL&2N^%H;[$S_R7*0:ZHPN R/+JV!KD1A$Z;:5H MK3V+W\4L1"5(J(MQG\0A_9TREI9=YN9@XG&M&F8%6.J68W5P=\7?O3#!Y9_/,E*_;C/!($C* ,!J??5L3;-0 '2.:U%;4WV9$917 MNE#YVWW8>3*!E84 8+"A@M;V>>\XK(<]B<1[88SE\6*T!98X5B=4V:I$ #0? M4W5;LVTHSND H(NU^RS'QN.-K:JR-R=QXV(E)W+?LD@ Y!]5^2V#9AW3?^3I MWG9U<7CDI[MYK!C#%.T%G87$)**C--W>.K:N2O_.L5'-N_,Q'JN"7,UJCSD: M2:GAEEPED$GL$E5]TTM5&1._AGJ@":8 .X)AGB\%3$YP\H.'Y!6GJ7G>D:.< MD-YDEXT^+5N(CYPRIB97@MQQOI 9O%?JQK#8S:LERS=QEF3/IA=3]2INO4\S M^/[X564O^IW=6$_#.,&]NWIWV3S4W\VGO*5?F+FQE"D79OH.F &VP\H-AV#G M4RPL@]0?XR>#/.$R_2O[=\C&ZB;G^5* #M3>\T&G+PS?)LX?RYGV!-^K1IV% MGM/WEFVKT7MQV:0$;>_,%O ^O?9T@M=T ,6ZW A]$9>TDH'K,JC[.QA+* $U M)$179$>[6/5)W=62K[SU^U8:86<[54; S=Z44M([!:S@:?:?Z$PUX_[F]F]- M]FO"GP\OD^5U3HJOR'$2Q"M5+,#(,IR^4SFE>KU7+,<4X)VL&G2%JN,%/$_.9C2N3N)\S#;I,4UP:MXLU*M M@\QZ3M>VMM7H+51-2F!LF2U280G9T6.^>$0U452I[L@C:U,KYU_CXK%*Y5D_ M(DP1;>0))^STG/EI8ZK1N&PV2E!6>V,!@\_1>IZ&!%,+>X++_^[LN53Y+PU; M?&,*C*([B/$R![ M8V)MJ5%?!W&D?R38K.:7H_)*Z)G9UX%B*4?B'9*Q$D+5L\$ ^;8(N4.07P>O MDH7R6%UJ483-81NJR^:&WQF#805+US3U$9 M(_T&>GO!0#EF"0F98&WY=A4FJT18V>7\!B?,ME\'1,*R:46XVR^>5KEV%WF< MOG5#?N;_ 33I79["ST_%I#137TIG"@!-\. MR@&+AV!5$@52BGEGG7V,T-9!1E"CO[:+^G+*S"*CRUT=+T?CEB4M-X:00&7M M>?J$\SEB&+4% 6"Q144MV*PIQ?O,OS5T4PQC7)< *C2*KN/J]+WA/S8QP;3B M= 6K]>T,L4BC=@U@C434;37F )<$GE\Q;H$MM>&MDTT&KFP841!/0;,8U9G 9I.(,3H2T( M (LM*FK!9DTIT)T(,W23$[&L2X#E1) LQ#C*SRC$-O"I3/+'8T]4YL;,D$\L!9,/KMD<5G'=:IP6V:$)1Q1=75>!5 M-!W*@V2H J2>G'5:Y\[+(;!XUGG,1W/O1*OABV4*Z"J2#<1!9X::2^=Q)N 7HB*_-#6(=. MW9[-:O*W)=(/7U6[7U=*"3&IQEV0R M@>Z2224+;=/1@%/@5"7<7- $R:BN$=8X:WH57\Q2@5>Q:R@/F6$*K.)S@I5* M3;.:97PSNPX6T;7/EA34J_B:*6THJ),'.6-:(.DY4EYV1*OEBGKH"*=Z(&2.8I82JY5VV[U883Y4P94;/'#J/S#2D3\=4[ MRO!HV,_&9VJ:6MHK\=0)!!6B<*G6PZ>W;_GF/@])O.87_:"X9-8BK4EC "+<,;%W(_X';#^ZW-=A%%^S16)U]Z'G(/WQ;T$7BSL:3 M+NY$-AP.T#U^B-.439EL;<$A>DHB#8P: )-3SU.A$>3 ]*]6M'"3I6BS7B<\ M.W*0U F5S]-E1E8\)XDIV;6MMM,\1N.JU$ML9*<*9D4Z#J^0\ZBC71*5A='1 MJ;XIP'_<7)WIY#J((^J0*-I!D')[NTX*L7^7KB<"AC]R7%)CQC,DL 1KD-+) M9"M\%[RPLS0].T1!Q]C%M[)('7MSD= 4!V141E_=CL9BU/I@[F@(<=@1XW^*I(2G8F0&WE MAAG#,H&@BD[VZFZ3L8^K5#]1NYTN&'Z.!"PX9#UR#D-@=QR7?=QYB%-WU\DD M[&SZ,P)NIC^EI'?B6,$3_?96?FCE_'OPG6<559:J+^+IC5^IQ>G^#L4WTF!S M]BB ^='33A9X&<=5DCZ>-)5 E;U@*KYK[YT*9HCN4NXK*%&_"M '-X(D57) M0LD94:PKT'#&J &*/K9HATRJ]6HN/@K3*T4YKEF=)')7; MZVET3=N3[2F4$VVU(Q$DS9.3ILVEF'-VAS=F7*6@KW[7[NHS7#@=,L^ M0+W2^:%CMWSFSC5?0.TG(#U_NE5;L8<6DBS?$'R'7XJC1)U+8?[/[,VXTS32 M;$-0\HVW,1K5%=,-3#X2+X."JK$Q>+3)XQ3G_J>S*O$T>YV>MD)H\;"J1L'I M$S)&X+VW8Y328$AIA*C(&JM M^JTTP3!Q%%SQ:&VU"L@K,W*=U]V7%%@""GI0\Z1A\^9>U]Q^MN'M%&WS]7 MJRNYM%(\77^0F/Q%K8;C_+8FZ(.$MBIQ.#PS8I0DDBBO5#-:U3J0C.'@N9RZ M9KWG2^SMXN32/*QDIE99LLP96Q080F^'7_FHTG4GC47]RLCI3(_^"W!>HE89D,_OU,-E$I;0_#FEMFD(4*(M, M-HF?@-4&:4='I"T:58H\A949K>WLT'1\E9K34WM5[Y2:AE=+,50IHNLY,NSFMM$ MLW:5Z">;U>MX-ZDC@8JWZSHT0UU%2'LKJLK9[[>,*@$"*2WW94:H@Z>JO=F$ M91S+E),&4S@4__/O'#__VYQR5Y7@G:),\Q/K(2ZOA M)7&+W>&71AP,T7L4SQ;2F32N1J2+3RUDG?ZC$4ZY%"M@%J-'5'IHKP# MS5)#9J]!0MW&^HN6>W C"W!&KDD5:U@V2AO41ML4Y [HMWUFY&RUBHMR\*31 M<<;C\7$:]J*J#.[8R#*<9CZ>4KU>.MLQ!7@WD-N@%G>#FS)XE%RO%*">7@>S MO:]G4O+$5TM_3Z\!D9%C#B0T%/1.MMO-?8[_L:'H3I\L;O*KQ=WF/M:#[B<[ MELN"(94!H'@/K19'I3PDTS6LBW%;3BWODT_Z;3>5,%A&F:\V#BBUH_7$EQQ? M+4_S(EY1'S(_3Z\)7@=$?2.=7ZA\U:XPMB[2V9ICILHWJY MR_-.UADK,>0S M+95=TVW*9<^Z%(\8=4I7Y0OQ;D'/@IC\%"0;W*E_FP:Q:@#%N+?4=6E91U6G M:V6M%+V3> K:(5M;&G8TO//P!M.98(-O<)@]I#$;,GIK/$+/;2R 937Z$0 & M)3"\LT4JGO9S/=11],ZX_ER@J/!0R"67Y "[Q.E+@&&)%)9ITO3.A^I5HN&S M;U96R%+7]?-EUM49OD5E5 3#M3%H9>]J^*<=Z\JT*-W$FSC_]9C@*"[8OY2[ M0AH-M_MN1NC]33>E.!PZ&3%*XG];C9R9M%(%,1WO[*(3+J:#@J4JL/6GU IN M'2D3\+X'I9(&PRPC1.6M^U83$IWN2!"QDSW^9'>-M?U]D239,\M_?I:1DVQS M7RPW29.50+>HG/<3GB@[6^,H2+YU^1"'Q5R5$@92KJ=28U_XXG>WTI MI<6^VEEHM;C;""L]Z'YTE5P6# D- ,6HJE(D>FXIU(REQK=K2R5P>1-<^"DX1Y MBXC?LLSC](&-&TMC9]1RFI_,K@J]/&1Z%3"VSPZGX)BU6M[YU017VSIA*G$O M8>Y63IA<%IKY,N#<983[')%T+!E>N7E47G <8:RLM1W'UHVITB#(SD85C!$; MAU=Z5^SP*,@Q"[EK2_).RM. I-3"YM>8\$>F[,AHU')Z^]6N"KWKL'H5,*2S MPREDA\(%NLCR'%%7#7$][S2[Q,^=)/B97LO=@[ ML@PP5)T(7)BQ5^L@Y M?MK>7%LDK*I\XZ[YM<%O0Y4= HIV%!J:;?!,D5^0\ M79(R%I&_=VX3 FBKZB[4;UQEVI ^.SWO!)P 5MAKN?KI_.3PPX^[>E]S0>UT"5 MBO=YFGJH<7ZU'#Q(8SD[VRJ[G)/'5:@[$]MI>N?B)+A#$G)E-NEVWV7S3L8J M+O",=BB[IL0NE7R-B\?C35[053T9%0)J78B'>-"1%90$AUJ6 (:LDV!+8FNX M)KK=[5O(ZH>Z#'9QM+:[*7MTE=K)VEK5.]NFX16V;H"_K]9),.1S-W$H*\ [S2CU-ZL-W_?D(3AL M%Y/@1YSF\1,N]]G9GA.OJ.H<:%01CA\'&EVYP8M UOI@*#H!M"0*L2X"\3)0 MKQ!4G;_\CI7S>_0S+\K_O6#+BE_$*>:;"-NU7Z<8@)06*CF!UDT9^T;M(? M MZ1/HK$=9)(\Y[!13FQ.05J3;,%T+RN[EEPV:YYM5^;?)EF&;C_@>[=LWD&D$ M3_\"Z%&Y=;5T(^TH">@\3?^2L>>+RY+1-8E#-MX^9Q%.=K7)VM:4U>EKP.Q- M8>>:3BG W5;KE(JUNZUCM+W3=C)DL^M8%3.;ZVBFX=1IL*[PEAZA?S@^AHBO M1I<-.-=8P U?3PU@X0DN!IY@_45(KJ#T=8D:Z!6YB1\>+5(23B_/DX,WK=H* M7VY<8=X'T%PUT(T X+0_P4M,"!WJP0OU0S%/EGP1!_=Q$AE<_H2)ALV'%F-Z?]CE9\0JB,KYI>/T.Y? M;5,),=4@R0N4E\$[B)0E>^KCFFA5_8XW]'^DT@S.E#B6]I2Z[ M//A,)0UO!K# JDHZDN\VHO8:$W:W*WB@+F/U]H]L*T(JYFQ72@.RV2V2R'@? MJP9@0O+=\E=V5S0$D(H3C9%_(1O<;@A?.50.I8X*AW/U7I35&G9AS=D M%RMF3%3F:YZRG4XM4V3R,/;ZUHA5:;#!#7&BC%(*Q;F?HW>.79@2D5PY!L>\P636W#RU"#$457U&B*O"JF,^A/!@:6H#4!K\QI4.FQ6^! M@KE"UZO,A>&BG$K8*;FT@'NTDDK"(90.GD"E(7TN %U18Y$PM7E65+8OXC27 MFP1<+T];YW5I@VB3%#?7Y^2.84;N-K3SE MMB_ )7W&5ZP?8V"K#89ZHR%+'"SN2\65*F!NGBZ7F(6AXRWH*2T#!D,UU;,C MJ:2 />"I&O60JE^$QOTN1YGC$YI6-HMMG5VPKTM]/-6G!VU.U1"SNJW)%JVTE M%TOFHXR0[)F=EVO7RZT8O/UM'4CIHAD5;-&<9('_-)B]%7_KG!SA@-!Z_$3_ MD\V+75?&9NO LB!O>S2C*JK@V( M=%+#%!BDVI,S[U=(E.#-!O:0E=N5_"$= M5,M[-PBUO]"GF\V.AI6FVZ<6K:O2?W71J ;&2-AC59WLG ,]V:DV\4^HU_K! M[M2@K^'QU$8&77-&TQ4'0RPS1MD9-CKQM\B8W1$ -]E8XE7[!!:;YF_A]!U< MQTW /GD9[\%6?PX*=K7K]42]R:E3\&>I9<#5G.M* [73$HA#(M4B*/)GJAGH MTICE<9969@U';3W*8T#EY&FC"],*C$(N>5JI4N:WP=GULP/T%"0 \H(8Z\8O M=.;EHZ$Z?VY,(:X-Q_@*CB)NKP10!F8T;"OFYEQQ1\D,SC9)\GK"[A[CJ+S> M.:B?4LI9*@,UQ":3@2CBG1=Z7$(V*2:(HE*2WT;2)XF%'CD#7ZUK))M5CD[ MRZ005\LVV<1QD"0X.GH=)O=4+;&W+=7IT<<\3=#;$MFN2.^ST[SU4.<<>8:2 MXU5:T=,73,(XQ_R(L?FQJ9W*_YY8EG?*VU;72'130;#I;8E^2.I:#:U!'$@W M+Q.D48F[FY@T.I7]0]%%'%D7L:FID<2R]GR>XX%9R8T"#OZ9W%L2$/7V$%]'?-WG! M>-C.2(H&,.BXM-]6\+N,TRJ L=PV*!5F&TXVC3K>]027_WV>V@>N6>JZ#5(9 M49V^D;-0!$.],6C%+:O^CA4UD?-;!Z$[(^* MNH\LP^GEBRG5ZUW$&%, .02U<$@C*I$)E.M%9CG,56_+M*9QI,UXEZ6P; M7@^UV8"7BWFGAQF;YH 4UC9[?RUY@O.0Q&N-C=+(^XOSD>5BIJQ8#1J!NF=,/>+3Q-M4$A1DT8(61"5>QBR1HUH'338=5&EU'GJ\!I MA"/O]&O-:S5;EX?D^G DDY+[6TZF"HC!S2H-,%2S@JF9+>&$O[4#IA.GW2+E MIS)V1DZK[\_4651+;? TRF"X.!:QAI8PSM+:-*?'64)A9&QU\H0[CP7GU?ZR MXN?.ZB6W2U<[WX?\)+F=NZ'DJ7'G^@J8H;.SJHECK*./.@7PU,_=_WU5/&*" MBL<@17TE*-EZ9VBI"T..WWD_X=;AF;]Q^N[1?.6#&84[J-0NQM_%?.F.M3M= MPDVY&\P?KK@." O^4F_:&!4=[X-95F2P+6;0\L[:T5#E_A;716DW@S(BI3K] MW\1;O#G Z$QP,0]S5<@8J&EQV>3M1BWN1[=;5T,=H= -9&1/9Y:]#B+6;.)] M$]"191*I-N F.[=%A:#9$FD 2;/4^\B"*+@I10MSI^]M*-8@%QF=X])V3U#F_8HRSE86*GC- M(F(HX-UHZ% -.YB)H2RERT^,PD;8NZEHM\E.\!(3@B/V #*FJV_^-&.[>OX: M%X_G:10_Q=$F2,H7D^/T@=^U/@IRMC)ZK5?VUQF=D'$1$ZYYA%.\C(O\Z/4N M+MB7VF*H+/TKK9[\\W8;O'"!^]DPAML>N@UHJ*B]&YF]:RK=.W6U+NHJ]S;I MGBEZU'[W #450+P&A[P*J*X#W^3KUP+5U3A ]Z^(UX1]NBV3Z["?:'74H*!L MRN^\MTU;]BX!N#U+=MVP_06VJZ^#L6#.JRP&H3FT/M:G"KMT"EC\2AFY&I;CWFE304WER3;(ESMN ,$G8)Q8H_2B4/ M/#)40,(GA08T7NEAJOA%&R[?) 6;EI;8W\-/.EM;_OTL([>8/,7AA%E&*&'/ M9ALU?LM9!RTS@O)*V;LI.5VMD^P5XZHVK5O6=:8NV4&RO&^7E65Z'^^\J>Z'3=59+!V]MB+5@HBW M7]4H/Y4MFO*'#4/ZS[N,_:F3FN4K9N?H5(9:VN !W^!5$*?T[\=96I @+.@" MC&5O486H0P+H]EDQ./663.E@T(&Q0>":1)E9,8F7 .X(2&VTV%Q'BN;JM$OI M6.FZ9=[O.#<#NV@F833/^1&G@W)=>N-%0 JM%[^C2JK=_'*!<("Z[T<';.N0 M#D,V;O=^#'[BD7+G:;D>^D2R7.7:[^1+^S0.-4TUYTB4? ;6!+F3NIF'(-<% ML,.KW4KH+C;JJ-1HRIZ$HB"GXV5R1:UWCJ2EP&'[5.AF,C<:_NF\Y9 ^R\@2 MQ\6&[:-5XWI'QD/ZI7V:0#1--><$(OF,FR'U8SFD4OS -DUVZN!)OW2/@TT35/-.= DGWEK TU=13$7.)74#S/ C/&TQG9[ M3E:NLD_3G3)&7O;7=]X?^Z_MDX$[3;WS[ MS*+JPEW+2N6PTFG60(AK0=]CV^)88/S^_\<='5!,0K)/1V9;-/6<9V,38,#9 M]?!6=Z/%: I G1(0*P+][F\X(/GO>U8$AN&8Q^">T_K&:1Z'/ G_[@W\\'M[ MZAW(FVU'_D#_8V_< Y!65@B#?'@@?)&*&G'$Y:'/]KHVRD<=UFSNM,ZC_?Z9#O84=^GG/;+43L,.ON?LCK^+9FOR!>SR8]Y' MHJL:CIA[P1RE;VN<:E/B=;8="6*O)MQ)#3SKG#L*@??![K7:HV?>MQ.%(#07 MOQK@9-%L]VE0HW[&QISW/-7\W?T9X?-5=L3,;C6B 5//8X@,L!W8'=7.? C; M1,R@[U#(WDQ,]F%^,,VGDC;QX2N.A@%JWMA1(\_J+X[$L#^#?C<5'^TS[L(\ M[&CKIM,BBS0ZKL#N?@O'[KM[LY4SIAEGV]*Q^:CWL>NZIB,XAM'Q;4&_+'KCV3;=#](YLQRYV0<88&,#A MTN\FPQ"\A(3PVF:6\.MW./,V"PXGQ\U;X'E;\ZVAV=U.M0HP[VB6U;? B$4Z MI*GUK2\@?6P8[?R2PNC:#\G9W$5 3]6^D3G3YUXS<2],Z3OEJJDYC.0=&%BV M35*9V+=.ZSU;D;]3@F]QNH0JG:A]P+=:G]_W1P'0 5SXU21^KLX=Q[Q\;T) M51C=H+/%*UA_V?N2P$MUA43&93' [WZ9:]E,KEX'JHCB#8U851,['+I#".]E M#"OJ/1S,1@\3^AW/[9P4KT/?"M@;L@8C.L*A@;! ]5YLAGU3C/7I]]V&J/)! MN__\&[('TMS3KK_]7L:V*<]U[=7/=J_4OU_O>=#*<+RAT:MN9A_>_;L;S\J: M3_#P]W_,ZSP7SV; $MH;L@RC.@.(I__N[,>8QACK[>^_/6FN8/GIG,[GWY!= M$!K5X=AOOOU>QO>PPBI_?[9'-OS[^YX'K0S'&QJ]ZF;VX>^_N_&LK/D$?W__ MQ[S.>_%L!BRAO2'+,*HS@/C[[\Y^C&F,L?[^_MN3Z@4D7UNSU_J&U_X CT^.[N='@>JB.(-C5A5$_O9S7]78UA1[TD[^?L] MSO6[DAZ'OA6P-V0-1G0$$(_^G=D,^Z88OWN_SZ^!FEL.P-V]']Y>LJ?1=1<> MH2US._UV;<\]*U7WU-XE34V-,<$K:T6,-YKVFM1[=FGO7=+;JD5&NPRE[;X/ M$I:N=)Y[>_-D#S'FT/*5STH_* #F>=+E7#H+8M*:/TK=59:BVR(+?T7T'RL< MY!O"Z8LB:EAA,&/**&/UY-5IVA)???DJKVM$5Y[RS]E"2TFB8M7UD(N>D;U MY;T=U_JFW-F0EG_V;8YF;5V' [D5>IM#]B1^BB.<1JX';/^[>S]<9C;'JJ2F@K[WY4HBBI9]!KC!,CS;??F]K@?TQZ]O,.R#MC1!YV/TYTVW"P) MFXU?@S4R=UE%Y9!,XB5&OXM3],I3)<,8D[MU)QQN81D [/WTF:7]^KL:Y]H-+?DXW_?-K,LL+4]^ M3_^QH34Z3_.";-BON3+@::Z.&?7IO1C;$QISEE$]XKMO*LWP^'JK$V97H0=O M<23+CUI)3L'=?VW_9US;*@X'XTPY_B .054*(3>?W/-A*$WYX^)[ M;WDHFE+TS):"!^)P[#R[[J[%>Q_=\R$I:< =#\K.%]T,RQ_+89GR4.[=Q-R. MJ:T0,3G7E7F(XY/?(.+%.!R?O8_N^?B4-.#.)\WFBV][VAQ64[)/M(^WW_9A M[\+'(TF[NF\QI=Z*&V\S;5W,?6?[:\!DBK'W*6>Y!3OZV_!O7D]LSNTO5X_\ M,*0=1A\5W_D6H[=QNHNW3L9__ V-U-G?+!G[9>^>FI?J"I<3RV+ /DA6XQN1 M!V:'0_6-/DFV?2//-GS?WZ-D6U?<_DY]_2FP3PK9MX7K=\EF1O:6;(+3E\EF MA>74.9GR^;VQ#!,:U:&3#^<=_)67\ MQ_?&.HQN4*<' &_A19.)U=5M_H-\XVC2ANC.QNH;?<%7JFN@YN4O)-,J("1:(T&;+(-88X@'%-%7%?+.M==U?,5 MFA_SZM=ED/-N!RS 29,A<#%4RL&<7CK^V)BQT5/S/L5(*F$T41T=[_0:"71( MM=*1[LPTOM[^O:9$Q80N$?G[A=HZ##@*P99%]EI.EXD:1;S M$W$/>ZY11SG3/T#K@# W(>=EE&L>1-=J*&?%^+<@64K;)*NOQ5EK^^=CUN M5L]P8?E +C>7(&8YY=OS$C'H\U94.HR*W!I]]9) M7"@J;E9SF@?/LA*]O&,&'>_C?R30(=W*-[!S)G& (IR').99PWQMF'##,]JQ MM5"#9Q7&@!:]B-9 ;^'/[GJPG>?Y!D==+*IVGSBQUVWA RJ$X MN41X_3]3?7;E8+KG!J?^G-2P*W!OF#&R.I;$P"BE$T5N=C1V38@;'&&\PM$5 M.0Z21#8HE%UO5G7@1B8;V/U<UBZN.NR0U'0]O_TCOWR MN^/>L-YZ[N%2VO-I^2S>\8C+S*HMH'DGY-G10;ON!+!EY'?1V8Q?EH!(702+ M#ZC+0+2JJ_UUN'O-6>_ GP4QX4>XL[O?QL_MA3-NV6CS6P+Q6[#6N+NKH/ " M-Q6H@OFR)7KV>^EH\LRL?H=6XGCO_FMP'!Z'=9WS@-%'+J.FIIV)[2)>8CHW M]K;73]KXY5F]RTG?AY^7:(MFW7ZE,N'CWB<"7S661'(VOAD[=.4;-D]E&=4I MDG4P/VS?37R\G$7IVOB<6DZU<\_CVZ+9"\]OGB:? MQ3'<#HIW,:S0T.637B98RCKW'QV.>I;'JUU72=5<6R*L,D*P8U[S9J/%;EB3KI M:*-GJHYB>U.S!=>V'"C:YPSF*]L97^=NCH;1BRHZR*.3F17L6E5VL#ONL3Z.2A;0198'UO6X2=&QB.M@D[7P0?735[ M1?5&K'.CQ1/#=".$'72-M0!,!]Z&L#5BI2?&MH,(5^W>:(-QC#=RWF5Y;/JR M\RR79.5ZS[ WI1FV6 &+A8(Q>'/59/KBUW7?;YM=$9P9LT9L"-$^\'@K]YUD MQ7>[\S7_R1AS68V;$RS>SQ[U.QP#'>'EO 9B[]2?XOFC3QS0Y M+MOEQ(('B$O#@FQUH>V_C\9MGX@)2,(=5>XI.?^E&X-SE =G],]:FVW2]K@Y ME \27.6N[5^=*VM^GMY1VY0'H22<9EH13H^_)U2N1^@1^MZ]IRU "S>1HRAF M/P=)O>M3IB^"Q%;^X,,P':2Z*0;BGE@H!:U@7$\6(KMD 7/A?$&K9DDH.3J MUR0+,8[R,]I/#"&SQNKG4+94!D/% ML8B'W.3Y=R@WRU*\D[(SLCK!?U?+41.P6M.3Q3-516'\5&I@R&>/57 !J29; M"U1)Y_RG6]8ZNN7?J6-[B\D3M>+CD_(*)4!;XTU$+W?M#^I,CTN6B[G2@=6Q M/(YGFWZ5%[ W*S@#?&$_D(F#ZM;YSX'K9]10-"YJJSJ1JI\!]I6+ MINM259AJ\%(#H9.'U[56:,6G.$HEQ%JJ?:>YC;3Q[SA.9FQO>V"Q*1XSPE)] MS#XRE-_9B[1WIF::QU8J/@+'X=U1S>19\()&#&W2"!-4/&*TIH+[.]JH\Q'2 M?P;59S-[W5)_=B#(YHO%F&H\7W]G]DVE=2/) ,">[G MD&(%'K ]OJK(_1VHTF3-@RP;_,>3H,#-!?ZY.V[RCALA[/^@ MWZK>JM0QAW7J&)X[X#"BJFC9"TNO$^+/E%Q@:^MP4CVPIVB]\N)3%#_%T29( M%@D'@2-YJY^6*?.4(00[^)++4;[#INJ'B,S^&3"C=7=UD[QHTF;RJ'(Y(H(3 M_BA4K16XYU(9.!G%G'P8WKZ'VVH/&?DE)8U"/]%,1<]=)IJ!D'E-&5T( M YS;%#4PZMR:!EC(O$]8()O#Z'7.\V;"F)OEX^^+@[D%/O)NMY\;VZ;H;"NH M^W,=>WIR&):;E@OWGWF3K1;G*7\_TAA$2#PKT;[5W5R)@HMK2[,*Z4 M;K5&A[CLGKZ2WK/%\>SKW1TY MV%C)E:=BK.7 %+\(TO8)#W3IX1()TO2&?; MG+P+7A9YCHO\BEK:@"5VO,CR_)BZ,:_4=^'K=,.&DU4)/C831U1-MDEHH>Z= MHM,Q"^_*X@)EM1)*6-ARV%6#1UAV:%!Z']2X/[/(;-O&D6EZ):BZ*EIBBFIN M"/EC2@R/*I441&\H( I>R?1Z'D6RK0Z;A;=@TES]!QY)9D? M4:6SHP5!-WZFVELJP\IEOJI&V-DBP BXM52JT>N_$S-" V"EYXH00NY88@#6J7V ;ID"J5W(ZIA0C ME7-W9*>!V9Z>281@F D-,B',OQ'@=_,:1>\N"3MW_QS$:8%3S3)*D'*:QDX. ML9>YK"_BG1YZ7$-R="30$OOG1&6C]'O:0R&7C) #[!*B+P&&#U)8RBFB/$(! M=KVSO&=QB9_Y3^/OZS::>W5/5T0M.2E896D5 #=//A/%Y%Y'QY_@\K_/4]E$ MQ \ZKM(;_(33C=P_G%B0,_=@JXHV_L.D4KQ;C*VA"_?'&TTVQU0/LU'"DE+- M^Z2S"$-"QTQI_%C:U7(;9Y&RFZ_5GH[JA,]*U>GAZHC*](Y6+?2\4W,"6.$6 M7JF*2#7552=CNWHIYH(1O\[>PC.I8>ER2"[GS-[I8#;F3";DG1(F9,/^KT11 MW,C.X?BJ#M;7M(W3HOJFHNLE0NX.SU4 V^/RH02,'E?!$H[$2SF45-T.89%3 M!2BQ-PH:"Z8P=')1IZFW-&!["1,D@O:E%*>&-.%J" +$X'(DPXNZ112.;/E-)+8\&.7"^;'C!0LKOPH(R1[ MIBM(Q8,R@ABXI; &HO \4!R4.U-_;"C@4[IN+NZ"^T1Y-U\JZC3 M70.V9Y(D.H1!&713]SZ?^"QIJ+.,7G!5ZI/ >UN$?V"* U#&ID MH;)H"-#,)*:!N(J63CL]!ZMS_5>90;5 .G+"$8E>/>)[2'+7T,HRKAK MOAOO\PDFX^,.W12@TYZUZ)4 KRML^Z.I;VNNUO4(ZO3WJ>V M5/PERD)GO*+?XI8]D"24GX):<#'HY[(@U^X: MK^7G@+Q2W-$=#A_3+,D>7D_P$TZR-6N;XXRLL_)"K*)KQZG#ZN!)V,60J+(0 MU):".L6@3CE>^_FX?7'K(@O2Q0/!_"JT7?9J<'JME&8A64O5T8+U.W'1K^TNEX[\O0E?&3I M!DP#32$'JZOT((=]4TL#&5*+Z"G.,Y(K.J#_,ZQVEV(3'RDKA:!,+T:#RONG^9-PL8W2G.>A\^3+>=??F\4[U?;/\%Q MB<<+O>=(#@&*/B:8^BO@U>MNU4W!-VIPSM."Q&D>A_Z624,(L#CDK?[^;5%< M WOC2ZBF WRNI400[W8^ MMS1XBNM[RZL^.H+]M'PM4OPTK59/ 'U0^ M#S8O\;/E+I%2$A;U3##%AS>>@6W]?,)4!7\-\D=*GB)+OZ0QOX-^[=:V'/0S*PGQHKST\AT)(LR2.QEN0BGD M8/6<'N2PCQII&->:_H8#FZ NE)*S>,,$<]@>31Z5H^U\9K#YY MI$/8ME=:6>#](@"UZ1FF!*IOSFA+679-*PJ[9P2<%AW#=&#U"_5T;/NE$07> M+T.<-OU"=?S&<82/.-HD^&HY>4^LGB?-FV(\7Z3:._2(!1:S_#>$L"E9(4)7 MRUY4VK3HM<:SL@U?*S.-(L]>\7# W\8OEB:LD83%,Q-,"P-&54#-*[?LP1W; M7FEE@?>+ -2F9Y@2J+XY9<<,EGW3D87=-R)0B[[A2J#ZYC).;?VQ5A1VSP@X M+3J&Z4#IE\>8L(UC4Y]TQ,#VAXA1VQ=<'%0W7-F,CKXD[,X8PK3HCRO/0X/G M1WO,D@B3TW]L8CHM;N[SD,3E:?<-#G'\-,S!/TH15H^-1"UX[*TZPER?/8S< M%H!(4X*7@_U%]/=-7K 6R.^R113%#%607 =Q=)[2VK'\QO$R#GG[M)F.AQ9RD&1G4O37MC [G:S=VZJG/1G&:G. M2H3^5DK"ZE$3S&&?U?+\ 7.>"'*9$52]*>JE2UH+DW^-B\?SU7I3L.SR!:8- M5BQ6V48R&FV48'74",3"4]*M*GJFNB@NE=G%%*Z- J[N9T0)K]M6C_U4SV/3 M&20)"K9I1(;OW4W1A]6IT\ +8[(J!455,= M?"=5(T_1>!V\,HIV:OPJ=/9(?5B=/0V\D$"D*@6Q9D5A)]]ERA-=KLN2>MW] MZB?*N'U*G4XKMY@\T5E"',!R,5A=I\4H]6BKE"Y\=LPK>2^]4.]A-^B'U!,Z MQ*@!JV]LX2K?#^GTE#"2I!Z"JE)*PN,L$4LOAVY)FC M63_XPU1\^9B]=8AZF:>4A-4C)I@2%[(G;[L.V^J!E_8!L,&0KF9+*=4LM!P^ MZF);A4'.;IT*+")9XY5GZLZ;$=XWO+4;XSU)717^*'JBH@RLCE$#U*>DJU[9 M]C/QF;UBF^C=:<7 ZKZMZJ#+BE^FPZ^*0U5YB!<(*;+W-EZMD_;J$7L%?%-0 M8.46L^JE%@LE6-T\ K&PS."JG;ALYL"6VJA4W\_$.Y4CXB4M^?AO Z.3\XK/ M?RNTSHGZQM.26[?X['ESQG[YO5%\U_EOQA)\+_/;6+?V#A)MC/_V>Z/X[A-F MC"7YGB;$&#%OSIST8NR7WQO%=YV\8KR;XB\YQ>Y;NWS1VP.[RP^_-W+W:NV? MVRF'LZN-X/.4?5!X9+)_CCX0<;;%JP#7"4_H_0Z+J')P8GA!)66UG[!%1U>Q M#Q=QV92R\PS5;5&3%&5J:-$[33@T6D<:"%.,!!J,JA M_]@%\_:KI@O'*,/JQPG(=7O-FH@4%):E^#G@"5ZI7$)GV-L@"E(_:#Z"? MRT_XOOOZ)=WDFR"Y(N?IDN!_;"BV^#\W/ M-DE"JY*PX/[R"%CH.5$$5@DU3QA[DS1^5-']:SN0M MCEC*@\/JLC<_*,RKRS9M;$*/1UIY9XU[?HB; MH[!6\WK'L+TEA"-^2;U^^/"G(-F(BR$[-5A=-@JS\LHAZ6A75_*;-R*?6 %^ M#KT8IN8FV!6Y8=F_&H[B<$/XT=YQP(AV]%K7IA+,U9%\QB"5Z\("V7A\52.[#JR]%]N[2O<9J765H^B467?@4)PF(3)!?QDCV3P$*K MXO3A&I,XBTYPDWE*/'YP^'%8'/)0\_F#VM(L/:Q?' M;."BA>/C)]U.)"*TY M)!2UF'R'H!R1.'K )_B^:!8*JG@S*RU8[!H#6;>34RHCIMTNJ/R^BM'=NE7U MF$0&5O^H 6HWH/VV?.V5*?-A#@5@M;D"G6*:MDYYN86'YR##^^*!AZ^)G'H:^]"#^DM;6#8-+Y+FZ/#\^[LCT5C +!%SQ5*%)0P M&V<5K1G0MSI#ZSK'X^:&!:S?QI&R3> /I[>^,:+K*Z][)5; ?AM:FE;9@\'U MYO=9=/WE=>O%"MAOPTO3*GLPO-[\MHW>''K;R;& ]=O04K;)'@PLG]D1)2\E M7*67N+@-$EDR()TT+!+:0+5Z# )1;J2X8+F!/#V)=+NYK]Z8; &*AD@B!*M' M- CU'9$WBGYR'!2/F%1W:A7Q=*((K*97XA.R&#!!5$EZC6'DCWNF 4N(@9]P MDJU9!4_(YN&:9'^GME:=<])*#U;_C ,MYJBLM5%''3%]5!?@N2^'+WW*; %W M!Z[2&UJ%=&/UV*E%*=#Z>7H5K!X^;4TEB^2O;6CIQ63L2>FR2"]VE-_W#6F= MXR+F+72&Q6E,)@2K#S4(I3><0]8QM2Q:8C^3V)FKPRRR](T&$66:->EVCS*:@$H75!4:<8H:%]+#10,VU.B I M8MA=F;OGS'R7J"<(JTL,*'4WAOA5(:H JCL>"5;=65&+PNX2 :>Y4Y@*I&XY MHZUDURNM).A.$6 :^X1I@.J2^,ERH+22L+MD"-/<)50#4I?Y4Y@*I&XY97OA=MW2$07=+2).8[=P%4C= M;^NBRK3 MNODZ8V/GM44<)"?9YKY8W&>;XE,6IP_'3).DIC<4QA8 K+NGH1?ZNRT&\7(0 M+PCQDE!5%)0G%THRY[1%M%G+Y6*PND^+46YHF3" %.6+S<,F+^Z>:>U>R_^\ M2GE.8\749Y"'U2UV8(47P;@6^OC]QP]^YS]FC%D&?!R=;$B3KJI.H5:E;Q4- MH94:K(X:A5DP>CP7:R>GE876,'5CAN*ZCU8_'JQY$ M].,-RNU!Z,M#IVSH9V]R*-RF<)\*X):_/1MT7<$37>'8&7+0A^E2.L8, A\KVYA>\5+3SZ M)LT-7@5Q6N[[U5FB[S!9R=D. 1G (0&H678W;JK;3Q;9Q.&\YS'RE0Z@5U>M ML"I?U*BW1.BJC"NB,Z_W.C]1]N;,Q\6E,UP[N%=+_K*=T%$&>5@]90=VV%5< M"R5ZKS;YX4,0K']94%!%?KPAA-:[VSE2@5\^_I+<)\[Z MHX>[Z@<]+F'OG4L=H$K.:R-?4D%3.[G>FQGH1!_=Q4CX$I6:R* 6HN37@Q-L^C:AO ]*!8FAQF$UM MT\:>FI;O=S_R5T-S\9EYM=0O?P#3T!IPP_8N?SY BX*NA>\W!;_(4V3LAC ( M=M.%DEV'F'1@C@,]5,W@X*NP4MQ3)\FN\0Y_ ]3H J1AX]8"GIKS.,N+JV4% M0M:F/0% #2O')<8DL9PI2U3)>6KD3X2NN:Y)MHRECDKG9T -+$,EK"B9#"J% M/+7MU1JS (STH8H'D!H&00A0.ZNQ"4DT:DE4B_IN\_,TS%:8;41H6[T5@]CN M$G3JEB^%T>^8^.\]-3_/RX'S0A+>HQ !U.PJ9-+D(RSC527X%O80?_#>"Z-@ M2O1L-EEF;]H:P9%TIA0"/$C%&2#R$3+%2EY,M(E6%>G?,EZ7)V* 1@ MB)BQR6^C'*".K,]-!$6\L?Q077IR-4-Q@,;3'+507$ J2SU O*P#Q/]ZR(M# MU1DLZAS1'K1'8K#X4=9F/H)8E0=IJ,]1#0-%:B,!GB.]6?[TAG?5VVS<"T?3BJ-SC$\1/;1,V_QL7C^6J] M*7C $W>A%RL69RMXJS9* ;I>*SB%IM9V=M2;IBX[YK@=1!'VK6=7@?04+.& MJDQ"^+M:]?J"F7/J4%G-+/KM8$2Z&Y38;7LMUH=5?J0.H[0 MZ=EPKFFC![W[5'#M>Y"5@/P?E(JU.ZFN^6M.,8Q*H+M/A=6R[VIUSZ<@E[@X M#O+':Y(]Q1&.CEZ_Y&P6;O96%V$1/RG'H+TVH*Z< %K8V\$%8F6@NA 61?L[ M5@[MVM^C=F>Z+0M6_YZG5=3NI/Z5:,/O7QWHD?W;%.6_?V]P%;"=LW/7)"A8 MH#DI7E5K0IT\H#ZT@BDN*6JE\G29J_'\]J\^%H$&/I[%:9"&4X>@1!M0]TT M/7((-D7Y'X(,)?O_+ +G*4@8_VZH>2 QN]'!?EBD4?\/'( :9*B&AA@V5(+;1_+/SF4 .V/SUF-73/.T'\JN)?%, P4_H:YN)\DV M0>62 /K7$J!DNU.NX?_0Z8/A$.D#((,OA27/4E)*>4XHXE 2F"(7 M@T)Q SIIFPOB'A-@Y0V83AY+>82040-*G]@#5:3&4FOZ>36%?KC:?.XM\N(\ M3+)\0[ Z6<\(72B]-P6R&%1D78;GI,;;=.ZT8J#T\Y;H-:F2@?=^E3N,.;;E M:YJ+!X)Y (5-IX_2AM+7TT!+GPZS+<63PWA-6#1C\7J=L#QC:<06$_SI04U: MM;&Z@!S-T9"%5TVK NB:GA71W-%:EP%%8)*K=0ZXLA6^"UXL^E,E"ZC_C! E MQW0L0I=J .RV_W PSR._L(P"&Z.[K)@VUVR4-.]_E8:S\RWM*1'7*P-,73,(XQ]>V.BGOSC_V-OFKJ*,SQC;?+V_K[1M# MZ>*TK%>9?><\S0NR*'YZ2&*EB_C2!I:P ;/Q4\G^OZ M*>^S=,59ME)YB/1LI4/;S)^W4KJ5N#393G6.'_&8F>-@'1=!PIX,/4!>TX+4 M(X*%:3'&F_*HZ>0!];@53%4\<7G/A*MYS+2V@S> @,PNEBBE[_\HU3R-GSKC MP5WP4CYIY72VK\.&KE$*\#1+)71>M M-!2K9P=2" /4:4EZIONG"_HO^N?Z3_0_F(-#__+_ U!+ P04 " !91#U8 MJ0B#^ ), D<@4 %0 &)F!5$F[]_]_/-F_G-Z>7E=[,D]:*5%\81^?MW4?S=O__O__D_9NQ_?_M?;][, M+@(2KGZ:G<7^F\MH'?]U=N5MR4^S3R0BU$MC^M?9+UZ8\9_$%T%(Z.PTWCZ$ M)"7L%\6'?YK]\?L/[[W9FS> =G\AT2JF/U]?[MN]3].'Y*>W;Y^>GKZ/XD?O M*::_)=_[\1;6X$WJI5FR;^W=\[OR?T7UOX5!]-M/_(\[+R$SAE>4_/2W M^6]W15LEG^]HN/O&Q[>[[NQ;9K\-%.4K/4F"GY*\>Y]CWTMSVK6?F4E+\'^] MV15[PW_TYOV'-Q_??_^DS3PO="H6\*:0_61#QVR9>TGB_7B M@0]WID]:V-2U;/3M]-Z+-B2YC&[2V/_M/@Y7;.(Y(^O #U*3WD+:L=)_+[F_ M".,G(VA;E8;JV8)NO"CX/:=M'JVNV/1)R6)]DB5!1!)M'X'5!\,QVVX]^K)8 MWP2;*&!4>5$Z]_TXBU*VR"WCD)%'], :M3)4WY MJNH,U:]24A=V[OB/GV&M#/8:/;OR2H+V2FV,NV>D;N=RFK' M+;"^Y97%%&[#9D8\!0PDR9@ZU*?[.+J>K]Z+A]QZ-_?9MX+]U^$*#VAD^)[_ M0A(&%YN/%UF:7VVPU;'L@[$ \+:&E^,D]/S?V#_93Y/BFTO*EOAH\R5>D=!8 M%*/F+.G35ZZW?-?21Y_4C8RC3V4?AE$H26/#2S*$ "/VNW5^,-XQ@UL8'NLS MLB:4DE5^S#!&657;PKG)%%A 57O6&]/.PENP93T:XKV&W]FF07X_ZNZ;9 M7VLP5$4KH/R!!7_[EEK4_?PY@!+3J3)6&EB#[<3 .%Y7O MG\5;+XC$\ N*.8>X1(\JV ND*.$>">V=%P._=&&3XQ>RO3NLBG7$)45UJ._' ML@6\I;I2@5@I8449QD![MZG@'1:#7"\!Q-8&M+K5J(*P2*J1@9VS[Z]X'RY" M;R.9,.I%@-"^1\96*!@6N&U>$U>8BIAH-Z22#T/S@"O4A,),3_3^;1 ME-#P!0)ZJS 0]S\Z@KM$6*P="O6B).!00;!OEP:"_R='P)>)BX3^S3T)0QYV MXD4@W1>5!S+P9T<8D(OL >YS?*,+4-P&BI5@$S\Q4$F6H(CD;$D-(A7;"= M 32T"@,)^-$1 B3"HD)_'JV@P.^+@H]83N'>D!0)]8L@\;VPZ-$%^YG$"*DH M#D4?^X2KE1B5@7\0CX+QKQ2&HH]]Z-5(.S+VIQFEM%XHY]CE7+B@+\ MK?=\N6("YH$5'"\]_M(J4!JP#[$@R5'8X YF]"&NV+1/>; %?3F-5\KI7U,1 MR@SVZ=8 !11^2B'*_W!)WJM8$18'WW0YP85"8D<8^&#&P ' MPN_&,5DE\]BFST(%N+5$YEW5* *%&OMD+)1L;'1Y9RGQY$I=+P'%%ONX*Y)K M9&@_Q_S:YCZ.E$;C=BDHQ-CG5IE\8T_2/+XIDL!3SZ41:6=2'+-)RD*11K[L*F4=&34;_*D+CR]RRZ(40RYJ!P4;^RCI5S& MD<%>4L)))VP[GWNY\0A)NEBO9;.TJCP4?.R3I5YF7!(NDR0CU)0*02TH(=B' M3*C\8T]$Q,_8O/CR_L/=+8_^E4Q#K5)0V+$/F#+Y1H;Y*KZE'D^M7R.L" 4;.SCI$+*D?&N]4.,=*,(%&/LCPOV%S$#DJ)0[+%/I4I)QT8]6P5Y$BO>I8L@\B*?G=H.KQ-( M"-#6@G*!?6*%RH]R,_&5A.%_1?%3=$.\)([(JCA"J"XGI%6@A&"?8D&2H[#Q M2QQF##":^]%297*45E$H^MA'5J6D.*ZKA:?X?ITJ'H%2@2^K >4 ^_P*D1O) MD2\E/)%4\$C.O-0K>ZBB0E8#2@7VZ18B-UJH CUEB]0F5GL)- I"@<<^\BJD M1,'[9NN%8?/A(Q'>C8)0O+&/O0HI4? ^WQ*Z8;/>)QH_I?=E3*X*=TD%*/[8 M9V& U#@\/!\2!!01BDH2!*7!R2C<8$ J+U;NE?VC$#?YRYY40H"J/)0"['.Q M7N:125BD]X16=V!Y9WCW51X?^EI00K /QU#Y<9;D2K8&Y8I<*P>%WHUCL$A& MG%"V["X,_(LP]I3[_5HQ*-1NG'D%$J(@?>)%O]'L(?5?EC3V">$W/\E^# +. M7, &H.RX<1HV0@7'3A%OMW'QW.S-/9,_J2375UHKE/6@++EQ4(9@@+2/2@[Q M=V1U\G+-<_)SQXQ;\IR>L _]IMY6 :I#J<(^6ALC,KH_>)ZNENV^DSB*2"B_ M:1:7A/* ?>16R2F _&]O6]*PUG_;_5;XRUIKQN\$B!]-K[T7\&'V9K:_*\D? M#&!?B!*RXG]+XC!8<>6:E2W-RJ9Z*]':2^YRMB::-K_ ZH[PVD6G&P0# M!1[VR84NQ%8?AF-,@%1>=@SDXO::+?%S?+ ;&W!;W1%JG!AEAD1Y@H+5Q00EK%P1EI M+1$C 5?$@$14=").O>1^'JWX?_C[DX]>R(TH\_34H_0EB#:_>&&F.%X!JX,3 M*5DE2L9!W$4D1_A;4O+@!;L7W>6&]+*\I#CV&F_"CU)B=#YJD@ G- /_>@?P M%TI8P9WUO7@9]G,AM;2'>??2./7"O"0N8VSSZ)NM1J(:V)LT@P5)+C#Z&%K2 M^(&PW2/?Z:1L*N;3\ ,WAUT1Y=2FJ@5D9O@;)RCHS4E.#P$Z3TV9X",&S,?P MUTK=^)").OEY3\<9F*GA+Y[,Y[17P,KGP+L+PB -2,*&??MY>/WJ!&\!R.SP M7J0#G&M-<4*?+"L=!A][577 9U];[!DS("70U;-QZ;&9++T7;JW7;^HEY:%4 M6;-3 +".09*X0PS-V)3>$DO)C:P*E!YKUHDN]*CE1V?HK%QUK\DCB3+]T)&5 MAW)CS3)AS(U:8(2%H7Q8,SH8\Z&0&9V/TSAZ9 ?O@'7MC-RE6DIDY:&L6#,X&+.BEKPO M,7=KNLG1?O?CQWUHG*'J%S<>1MF34!YL69X@/-B+IPC8\AD M7]9G0V;-Y& \=D [L0F;(D#\P8FS9E$8[DSZ"OCK8CP:P%QDX36<8=B=@)%H MN5.QO*^:NW=A82A)UFP-QK0H9$;GHQ+ZHW.$:)6$,F'-K&#,A$Q:=!KFJU7N M^^Z%2R]874:GWD.0"C--[PPDL@I04JS9$XQ)TBE935'%CL)BM.FTI*M% 2&:_2I=T$ 4T/FJ*Q/;GRQH+N4JOW]9$IHGG(-> D3_G;*X8<[>I@GWQZ\5,7W$ENU%E&%;)U M23-J\>:P!TNVDXSV=(G5A]U M*Y.T O:9JCLMCJU)AFFO95)U68VL.35W)P>V%(U_YWUXSW"Q7CP0FCG[ M ^R^^]#D+%[/*HVBJ"'/9;TE^S[I+[>E%; N&/(8.$#&M79)9&.#!OK6!8-8 M4/2)K.S8!1./9^;F??L:I/>G69(R\>CYLQ]F?%SS_ GL_U:WWK.6)+/&L$T/ M4FJ$#'8!RA62E1?ANQ+8E@4S.EY#&,9IG*2+]:]J%\+PS1$&T$,Y0[;,S9!A'&>-[#LKFJ+J*R&;;W0X][<0 )00.?J$XF86"'KY'RU#:* MB\0?Y-:RI:V(G=O-E"\@$NB,W7BA1XM8DJ_>1G7F:I=$3]EF2HI,6$M^1TOO MAPB2OV M/Y_9!A5 8K4P>FZVCCNWML 3IO$JCN*Z8*6.ZO?D@*KHN=[,* :#@3Z!7D8I M85CJM^6M@NCIWN @QVI)NHZ]'XNQ%Y$-7QK[C#[)/N23%T0)GQ](LHA.XXC[ M_B8,WL4ZS\$EV8AH:Z&GA#-F#B06/HW]U\+TGE I.HIE45,//=E(A)PP:;O,-SM/R!,O"7S] MAE13#3W_G!FI(!#0IU!A+PTIH$V+\H&H=B#GG46* M7:>VG'0,W+Z-&T+/FC<(O3J@G',1/[WWH@U)+J-J$KAF1L::T_@?NSB-EY^9 M!=&L^J%_]1[BY*^SW?>P,Z=U2PX-JG[,G=8K=UJ'E);'Y&E6.9E>\K1]KPH% M.HVW#W'$)RA@9B%QM2G2(I8$/2M:HUNZ)$.2XHX1HE*VYE%/+%#%:].%8'1= MHJ%>F6WL)]LPX,/IK#:5@$0=(X*BV!$O7>B02HS.A20=O8X7337L&)8N'(&0 M0.?KFO@D>.0K9<)CVRJ;2WW&1UU-[("6+JQ!\7" N/HK GJZQ.6Q8URZD:22 M'9V:8\[.8\Y.VS3TS]F)MXE&2]II?TL-I&6$W)T#S&*CO/V"GU/0PIL?#XS? MF+'JT13WB3_X+46/>PA\!@%W#"@$RA+H'C2N4+B;["[Q:?"0YY(Y;$$%;.5) M9\'5G3DW21DTD\>1J7&^^N\L2?,;G=M8'IIPY5NF&96>8 M)D%P[@/;C]BR"6>.8$,06H-E$D3FJ\>=EY 5/WR2*,F!OR9L*DJ"E)1I%Y;Y MBL FHW@3Y:UH'ORT_V7L% >#JLT0)*!K6[Z0?>+S&5F=991M1(H.Y[T42ZC9 M4YLVAITLP6S3W0TJ-V@N5JQJUXM=Z,YAU(AFT\:PLRV8T=P-*G2:K8866(LL M %.C"RIP:FSETT+QRD817%9Y<>.&^*RD) 6 6@^AS:)G9N@[X,SP#4 MXN>+&*8B7C"X:P ]G\1P M%-8QF73XNVI/H;&" :JB)ZP89&_EEME+N?IWHZQ6%SU5Q3#[H$F0UMJZ_QP% MZ0!'G;(9]!P4@Q]M:OBXRFI[(]Z-5FD[Z-DJAC^J3(+87!VOR%/^FX[#M%(= M/5/%(,.SA8>K[!5*UYV^5GWTI!3##,/)$)BK6_'CBYCN4J9W&X:"9M 360PR M'*7XN,IJ]1&P/K1*VT'/A#',,)TC:+GR1AD* .Q MZ^P(QS9?=W%"7+0_J"X1NRL/L%7T%!PVKV '4!_K23A5@X+U_S.;_<2)_O8> MAX#*Z)DX#!PHP5A8NM11ZEE71MJUH90@FIZ,Y'%I?>[L[?_K!S@QCAB26OWO MN5 6'N/G$;*IOH?#OPF)#EB-1-VWQ"%R7B(ON;\(XR?)R[5_ZI2$B+4Y*QK% MSC2T%\\HP9"@%IJ7&._+DL:/ 6/XY.5G!OUEM']-8.ZGP6/N5 '(N-^A+>"( MM3Y>%42V'<\Z(H:^2MK--FPM;W1WP*?@,ECSC^&^X9$?A*36U]MXL#%JYVO8 MH7:#J8A-,M UK?;6P?DS[VT6)/?%]'=&[E2/4^JK8@?K6:4N-D4#W_#06UW. M".NS'V@" .JEL(/[1E0"$3R6;!/\(.Y%/BDC\[76"$5Y[&"],0C20.#(;-SH M8?X(8>[YFE0N0!;T-/0"58))PV:PH^Y&'*"= $97"^, K'XQ5M;,62,2#0[$ MFM[=T7P;TS3X/1>HV%J.4#$ZKVQ&F/OY M$I8LO1?ULP" JNCAA!:40(+/I+>$0BEIQB0(O+L@U(00PVJCQR+:T04)2ICJ M(+/XR+J_>Z+]FH1\/EIZ5,)W;@0Q;04]@+$[[YWD=79M/RO5\)H\DD@570RH MBAZA:&$P2_"9],0.O\0:X@K>@2C((2]V#9'KK"CXK\]*A+V,'MGY=QB/#65; M[D1<]O;9 &"&OC:PK>LN=X;_SRR@A G!]#I]689>E,ZC%7 M>-F#J[BSU*_@= C';8CYP('0SL$4Q1RYU[=\7 21%_G#+!_*MMR)*.V]? P MPU\^:.P3LLI?@SE8%*L&OJJZ/&D/9AIOA &Q,DI1LL+[?-G0OT@4)2AXQ2%E01V:A<\927T:% K!$JPL71%*_GR59R2G0&Y8C\2!1CQ M9HQ;00_%[$]=)[D='(O5SL(&8KT&>KREE5$H0@6=MFOR4![O%FL8;?(:Z#&9 M@]&F0V72!]RJ<-6I1+ULJFNA1WU:H5Z&SJ3IKTY)W,FN2*P_4NJA/!GEP/MI/[S:21KV>#$C9PT.8(^>%.^0NHW5,MP5Y^B0S MT :@.F(_.1Q<1PS10=]S[\*2^&,W;!>I .$,)# MB6Z]9VX:U7+2+@NEQ9[S6T]:9.*C,W,51SZ3Y^!T$ZWV!ZP\D1K '07>!)1' M^XGB#+Q03!&R%\I:>[-+]\"9HCR4!GN&.V-,8Y!@/?9)D6[)Z MKQITM6+@!##.,2J6QY'9D5M_#V^)E/?KW C%9,GX-%($/BMX@K< I=">X:XG MA:9@69HG3[D/61B64X/:Y8Y74)2'4F+//ZO//*D% GUX5=(=*X90O124$WLN M5SV'B4AH!T,A*]U4OYW1R%O=Y8&,'^PY6?490&H('.1LEVAIW^>F1YB$/D ] M*)/V?*SZ, D&9F!2QT\!O: ;+RH3[C"(KKPTHV2Q/LF2("*5]*NU9-!_GKV9 M\;P\89RPTNP?U59F7K2:%>WP'-#[EE!6C&K'#HFJ"UF7%2 7ZU(YO/"0PEI_ ME!VH>9S5M%?G#_3?,IT["94A"L-_"3D?]:!JU5CO;=$BV+TA9)S/MEN/OBS6 M-\$FRD_D;)M?9/_@KU?,90.3'\&FFN6-<;>6^$8_'] MN^98W+4S*QO*QV39U&S?%E8:A#SGXTXV+P2L>;R[$Z,A):V M/&34- @N0:8T&H3!H;61\4$Y,F9E [.BA0&-F8=OROJK&!&\!9,&AK3"RKX& M&PR\":,6L$:'*<1MJVP'H"9OGY7$:(N'WL?FT*O4/BY0_9]\J,1X00P?DO)3 M6I[4,CNQ.IED,:B-EA_ HV6,10L@!GC],FIK4%\*_8?AJUK7QMQ8X#KP67/& MZ(7DY)<]_>C]8W/T]A^C Z0^./3ZEGI1PLAE< !,(/J:6,D,D6-65$%-[;&Y"2F MK(0<(V0T;-2UD$<*@!I9I)#K(^4+6QYIX(7S#26%JXIXP+2K\JW47F$;?SBA6Q2W7T0?JHR;,.-PY2>F^K9J1-,DS\R<8?] MH'B7C4G.SH_<'X5$4G^J]RT?CTH+^95RO0VX2\L^,-7C^*%WF/K1\.@[59F4]I+P&]=Y#$AG( M:F!E9JCW!W*4DE=!'CLZ.EIY%S2R.S)"(#[ 2E_@#RWW"[@O\.P/N[_]VS?L M%BS98?Z7SG%3N;Y[WYD6WY^S=ZF1\@P>15CI6Q]73"R^@ MOWAA1BJ]/@3GEMV6JRRP.O@]8W1NS>1RA,3RY3W^3C.;%3FH^B&[MVEKJX)? MB7&%/# HD MKP,DR5I2M@[+D@X ESBZI=Z*6U?S]-D[=__#[^=A&#_Q7"(7,3V+L[MTG87[ MH #-IG'8KP#UP%H6N#YZ,!C(Z)K#4S!$K-D7\-B6UP R:BT?G#&C.N'1V3F- MDW2QOO%,YEY5'2!#UE+%=5@@=0"@ 0S!F\!?!YWAD!3=":=[F^^RMU" M$P8/5USXF-56A!+OCB4&B 7Z\-T[:1@L@+(:4);<,;GHI)_T<#R-MSS'<,.X;8H _38M05EUQQ;4%2U+F5=_CK(D\\(%O8S6M+BWSC/S 2\5 MH;6A/#E@#C*2RRHWW)4@9?OIP MS\\+\+L[23W&^U6(Z0P'72'E*3.-FH&PY M8+3I)J C,^>)EP3)8MV0%CY?0NM#^73'9&.&##J1Y95F^:!W+MC7(+T_S9*4 M[;NIZ74ON!THL>Y8>KHA96N"E3H_ <9@/O,8- "^I\?GRE0T*4G.1*+?YO;\ M?4]K?FRM9"GR&/0_%.T@.:U-.W5#!=4\D4%."^1PKJPVI40.( 2<&$7M2$#5 M &JE/)$'IB*/H&E%J+)Y-]MFN=$FOX'DQAQ*[DF4!(^D,.E]CI/DMIJ,1NBV M:M"*;CRUE-3*L *%JYH)5KTS<9I.-GI)?MCL36FE)3=H[:+0W4BOB%[=5V%% MFI=NQH5:\R['41Y*\!PH6-94>S64:N2L.!\CV:3KW3J+MUX0Z=:.5G$WZ *I M8M,.+1;HL+/"H:5\'^0+V=X1*J>C40S;-5>I3 W@A1*BVSIN_'NRRD*R6.>W M$B=>PN^4#M=,^>9O\5!D;/'3X'&W>X1$@0W0-GZ<2J=5OCDI#H:R\PHSYUJ^ MR6>EDY=#$7;FSA.1/WET50KZ"TD8K-R]Y/F!\*>M;V/^HT66\7?\'6,D:Z(S?(P?BIH94+RQ* M75K%A G@=@(NZ'6PN8=E<^C>I /!70.O3=U =>(>H));3W4!T,KB7,VPAVSR M?RVI]@X*=58ZZ++NL*6\A.S_3>^Y0PNPUT-:"[QFN7 ^BNP 1%L4]9)M=@ M4DGQ3\[971*L K9UXJ'+Y5%/,V_)JS@V1)1SEER*BNT8B91#CZZ\+?MKY2T( MW>0%J>L(33K5:S(&D Q[2KM<+G136:4(=F(1N)XU@W&;8J+/8QJG_/-G/\RX M 9.?F=G_\>.SG*).C6'G>)6> LS"%U1(33K&>F4_S2A'5:X$LO+8=]]@ MHM4"3YI+GC=.L5G,?XM]0PSFJ2H,^CRJ2@AU2!NEL$\!ZV-?[(+9,0,$G;\B M#=&G.%YQP_ -H8^!3Y*;^ "%+ ^3N [V#2E\%&D%QYSQ)-?Q2T)Y5D5OP_9> MY2,CDFMR84GL([">'&G7'1DN\RAE1Y PX[< -\3/:'Z)4NR!R*K8(VT?LK1, MN]W,9S'?\GE ,1L.TSQV(DKX9#DDG.C*T;[VYELIFI#\%S=Q@-XNM)RIW3>5O&>T;<^<649JW3G^9"*B*E*FP<$Y* M;N.YS_I$B;2G"N$,VD ^NX,I;*8L-(8)?4ZM^":=$0:S'^0@L[^')$<[6K%5 M@*;![_G/._ ^W!>P3_I=U6)HC-&51MK#*])E=LMK89L'.H]Y !:3MNU4559E MG:N6PK8F="53)*L3^Z=]#O B:PB?,7R?9B3W#(X2J)M6Z]WB7;O[="1\4U4V M/=NU[=#>JNAELI/?"P$N6LI*:*NNF,Z*YV!I'V:_NXHC7V<=[]XB]EY+3VE[ M.>T%GA,#NII)"#9V6T\H-_((N3)&IYU2J!J]P;9DMX1N]XEU%,8%92TWKO>- M\@JI!7+ Q[+:JY:Q1$"0I+P;U$"4KDF01"!\[TO>H6K7)5'9R5(B$@;= MU;+>*>Y5HG-8DM=P@QFY?BGYJ K2TRM)%LMY,E\NEY]C+Y*Z'.7Q@:UBV'8- MG8[4HALE0J+;) 2/=JKG'FD%-]2\PP0DE0C=@3+W8UL3>K@*#J*-^*'56]:- M1/PKW]5&T+$YN7K(E3-7 M+X7MMJD\6#0?7A#(APYZ?36_C%+"$$ROO93DM\NK@_L'= ^H;@-[]V+$F#DX M#O-YOEX3GK2$]*-4V SVS#D0JPJ(T(F])@_E??%B#9LIY36P+UR,Z-()CLY, M79\N/%_K6":O@>ZPV7T@M05'9V9)F>X$NULOLRL22%UT#TX3MN!@#'P!C7M= M4CXZM_1H^@*[.OE1?752-CC+6QSL(D5B)3KT0R:3XLJ$MV#2 /*Y[22F-'[B M'J6 5A4VZ"Q6!=0&6PH+HQTR!F%* M(?_DMT>'RX+&@T#E7D:X+?KXKI6TJVR&9^VJOEC%6]KOBXYN)4>WDJ-;R=&M M!),:?EFB28HC+OXZB#G(@^Y?TNJ7-A^.K((CU*C43,>)7?^2QM*^B(C2ST1> MW*D;F[;.5-U-=#);2LO>?%;Q*3:!NE+<*;N\$=0MF4>"FA4VTNM:!:?,MV9P MM^4>!_"+.*,F>%?+HX=+=X:[+?5(: >/1MI=+0]$V]K#W#W0;DD]#MHWP;,) MV)7BT"72P36R)?1(6/.L5D9H5RM \79PH10(/@[BY_R5!Q/$:Q6@B#NX5@H$ M'P?QJ\!LSUTM#\7;P<6R+?9(>T&S">76?#IQ<*UL"8U^<=#HH#XUM+ X])H' M>T552V&!DH3XWV_BQ[93R]\O%1B]6JE7($7N* M@:E+),6@H0MZJ(M/2VU8K$B]!#+((L1:F-9[;,O<*J$_:35T Q:3^UG1=.71^!3L*@RDY9]76D&\#AV%B]3)*,9WH^ M\U+R'CI*&Y4F['XO%-^)Y#62F1_DC/WQ?=/KJ.II=,QITM 'O+, Y%1WN++7O+%X^^A%ZTNB7^?12'\>;EC#R2,,Z37)[&]"&F.29* M8XQI(RY;:KH!8ND>8P1KV/#71),VAW%[_F(]9[O$:$/TN7\DQ:.&W*!2J9;-M*:F(EKW,N59ON8;2O(>0&]BA96P M[9H=]5!R3:O Q=*"8$2("@+!_XO#X,OEMP0X7/5[Z;O+"F]1RX\Y1KLN M](HRO;(1_S<=W*M](-=8P=6UT9S63E*2& MF%A:,>;9)DO2VR?6W9?BST64]T3)B+86]'[1"2: &* O'\C7]T[<-1G?WD_O M(OB8"=%6)L2IZ\(7+^5O8;Z<*9/4J.I,V.]#)#SZE,R[6$Q)"4.PG)S(JK() MRQ/1:=P 8"U,RGW#%)C)CU*EL/FSM GWC""K/KK0:&=R7B+F(%G:]EYD8?AR MQI\8)JOB(5K)3E=4T*EP72GLLMX[-'..G*S4WL/6EI*5NO*^_((&FR#RPKUK M5^EW*4F6Q^NHJS@5@:T<01#1)[UVG89>DBS6I=%A0:]YE.)5Q@^^B_7A\?53 M+PS)ZN1E9YPH"RH,F+T;QKX ,#N7#@,C^K0LE./\F9VJ@H0L:>"3_2_WG5?L M:#HVYU3.@$[40R%#)WS7LWFT*KJVR-(D]:)5$&TX G)N]37!E@4G>(0B@4Z9 M$Z$A(^60,-M-V8@-2=F!Y1@94G#NAEVH6VC(]+9F\T*7L M2#K)T:GYXD5>X;=U04CYUHN<%G%I='\.(TI4$J/3<>/E#EMI[/]V&D=)P(#+ M8;PF/@D>R6H15=SKY#P9-@,ET T;3B>,K.:4XCZ2U=M9;?2@)DQIL0# MG;O#P"^GWN(V3'M7KJL'9(.'F[()*(5N6"B, ML7$Y)X;Q8X4?/\#S8R ]7 @0%?R&H5%;V.DS3N.0"1(7X+9#;'S)KZOQ-N"D M&\-]"SFDH@??XL.%!8CPDW\,($MK7A6M]4-^Q8U8'7O#L[6U&!(\_!>57F?, MO&4E4$?:X[W#=(RTGURD_4VP?0C)/L3V(J87&3M@DL*_5!DV!JN*'8\R0!"R M"4;VD]*/GA#!VB7D*TB( "=#5AC;VWF8Q @NQ^E7M_55@4Y>:AM^Y;[#I TW MUJ+1-B,FT*#G JI90C3Y 41EW>#67*,5G V4*V!0:G3[0U%9;"]CN6HIP!][ M\R Q=P1$-/2@2P\5-FL"'!Y65 ML%,2C* / -#0A[@S ;'63(,C$/VM1-%*+'$J;R-)!?1T!F/L^M5H35H3'$_3 M9B^CPDC;"&>RNWV.V.C:ME4"TE1FO#VZH]!1T4[+#&H\J2U[^"4TK X/]ZS H MV#]^;:,E]K!C925%CRK63<7DB-J)$#!5! Y4OA;QQ><^>+B-S]4OL(H$TC6" MK#QR#O173%YPVU7W.CV''&[;6H-]!$]W8^ "$!D,G? BL7XB )0R[T(LA[ M:G:^YH9*"H=3Z^5X&_)CNV6?;Q_"^(60/(_%(L\4H_/.5E3!OE2W.2(:ZJ % M#GV-R'M6V'#/,LHFSB6A0;PJ;+M7Y"G_E6+Q@-9'=@X?_V3>G!B,<)[TIQO=$.MB3JTO!W$\9I'O?)+%+T@]-EZ1=6[-X/E^D9CF7QG![6FO9XTK8*_-7$3K9PSYM_BEDRY:8:E.S=%>$.\\+#\61 M)?5HBGJPZ(O,ISPP[C(JCF"?:)RH3KHV/H9M)AM% 14PXV]!5,?QZFJS"[5= M*32D0UO8]C*8 G0&"9_?GKI[$=,U"7BRP+T"VYLBA!_#MIB-,D4H8#9?I7XL M5JF(;+BW[*17*';6"XI7;T90/^''L,U:HZB? N9O6OTP-^>_?L W&N'LS[GD M@^S0SZ-7HWX-VU8M\1<60OXYYLY./IM!@9&GI M'[(3V/E)AE'.^4II*G3M=C;7=@WT=/=/+2&9&.!.35SOLFQ,#^^'[5W=Y M(C0A.JI'NEE;(![2JFK<$ZC^.7Y[8HDA1T\'%6GFT>J4OQL0DG%.";!/0[4* MZ5ID/""F,L.]DFL.DQ7UF[CI.%[4.6A&-M%2!RXN;$%PU$M0S(1MMP9X#Z Z M.^W;#U-&)K^X&X?MC+3F]^T75%T=O_,8A3TWE-BIV+-7$:SX >D^QD'$>FXW M7 A3MS]7S#<;FGN%CK5)[M$EZ!!P_$K(-F=.9&H_Q$?NY:E(4(JJ#)/\HRI, MLFATQEJ;59K=QTT>PR6=FF0F=Z)YY1/(,>;RN$H>%\FCTG_#1H!I>VT,;@- M&0.6+DOUX.2.?\*PZ2$N"@V^[W8@[[(VX'S&*A,G%] M4\WPV"H(ZIO;D;0. 35Q156E*1D'9?/D)DB^(J/#,7'5VD_J^#HFZHK;L:IX MN$Q4; MB&'MP]%DU4XU;^-K(K!WC@>X.H75Q/4US^6&>OXMO^]X3.O(:$Q0D_DVXIIF$B$T[MZ@)(H/X*;S^ MB+'IN*=]._&ZO2 ZZOVK]5#[=F*!^^-D:1A@1D.;K\17I/*!\"E-RS M41 \L@F;,4L^QTERZ]V%BJG&K!7=M- :#GAS@YE@53N[TW1^;CYJUYG22DMN MT-I%H;N17A&]&I0Z(/$)32NDLW\="&?_^/6:+U#SYT#$(OM]Y=?3IZ8N3R6V M8V2XOQ#).7K7P5T!9,CK>(FQW'7U$ PV'IA?@BC89EL5G(TB:&Z43;A:8 IE ML6-3TJ'J/6M1K1=!\Q/4HRJ2!=]2QZ#)#P7%]H%/87%$^ .RXGEX=\905YO^ M_ R3LQ*4A$-?HUMG,<^JH-NCMXJ[01=(%9L/Q8L%LK("&-#RU>.G[50Z;Y7E M&L7<<#N5*%,#>*&$^+,9MVM S$AF08>V .]ZNA$9?!S,$M3%!G7A!30WI\Z3 M)-L6!JGK(/GM@A)N;R6,(+;.IJ3T@M&I&R;T!'BQT?IH[N M>H =73T9':U3]KIT=&?/_R5F1 0A6^NYR".II^SCV*'4+FJFFJC7J91GP6.P M(M$*027KG\8.NG99(44DN:&.=WI)[TPDM95A$O!-[/CJ(170*BUN:)[=27_< MT<'FZ.#S='!YNA@\PH<;(X7O^->_ [LL'.\^#U> M_&+<(+V2B]\N&^6K."J8WZ5WD(>%0-K'WW6[_N M-J+'?/W^L5B_HSP^=Z)AM*IA^A#0O)EQ-;CVW6_]?MR(GM;H>'-T MO#DZWAP=;XZ.-T>CWQP-G52S[&2/!(2]LD$:?W[BET+C@O6MWPJ]PL2$^%,@ M]MG_^++N:,-BBGD+C]=>Q[=WAUA#+3U-:?[]J=^@C0R7T]ML!Y[G[=.3J5^% MH0$W=:5$>,-WX,Y-_<;,)2Q[[@Q8TW=Q0B:Y*[#V;&:7'DP]/'5TP*8^#=M_ M1KA?7Z8>A8H(W=15$^6MX<&[A_W8\$04N.M[Q-_./L':ZYY=>H#]EK$+6OT* M7CONL,#85L.IOG?L@D:^JB>1AUD['%#7J3R*/!$-[OIN\K>S4[#T(*GY]]'? M7'9!I2?_*G.G4ZA-#9SFN\PNZ.(K>KIYJ*,ELJ).X_'FB>ANM_>=OYV-@1,. METX\]^R"0A]?@_Z&G2Z=> UZ,FYEQ_>BOT6_2R?>BY[,&/D&7Y0V#53^416H M?(Q.[MO;T]!+DL6Z!&]!K[E":F*1577<") #11ZKQ,"/,Q;VKC5C 0R@;Y]B.-"5 MPMCN97V ;LD\"M"LJ(%.UXJCWR'U0KLM^!AX7\09A<-=+0U%VTG=;HMM)X]= M0M/*?H7]Z[!78?_X]9J;%R0;1_;[RJ\=WG\(-XGUWMMY11X"KE2W=QV$JK-E M@.MXB;'<==5*(A<-F.5S7RHX&T70]AA-N%I@"F5!&?_ETU1*5.M%T (R]:B* M9$'/#BJK[R=TOD_*WB>)5S([-(>>P@1F8(&='*'*=[=@IH59N[\N>'A+8 M+G.#N633(RWMY/%4RJ12%)<':,78;S@6:S6Q\X(,-^X$@+CQCB%_;_ ^#AF. M26&)+V]DKGCWT^#QL#&L7O7\\*YUU7-HZ%__Y2\?WO_YK\FL:'!_R3/;MWF\ M[CDFHSTFHSTFHSTFHU7XAAR3T3IQ%75,1NMD,EK6H6T]JYF!-Z=W@NUBT&.2-7=O$*+BOEM%])9Z*[[T MZ!25%Y:4A6:ALN8@"<96*:PE@*_BR 1C>7$HS-8R'H!AUHEL">F?H\?<175G ML5/B+"L,33^%K\QJ<=%7OEO6]F)=<2]6[^4EQ=W8% ZPAY?(9^?6T.3,?>A1 M,H_X&U3>X2=L%$>)Y^?NW[HMC'%#;E"K5-/FT=I41%ON9_Y]?H^ZH23_M,:Y M05(:>X/?4?/J_@Y*)"RM,Y\#GXU\(/RRPOC98OK#KP;"$OJG,5OW:!JPJ?:$ M!JL-.2-WZ;X+ZD4?6!=Z6+"7!Z4_-T8PV=KZDB<@,<*24!KLQ9SWIT$!@270 MES2(Z>&;O-]@&H!UH2N'R^/#""9;9^\G]JF7W9_Q[ME/-JGR&\!EZ$7JXSBX M.M2CQEZ8;W_"3,%"<7:ZY3? B_5EM H>@U7FA7+'1TE1-W;%?0X\/01)3 M];ZL60@O)<$P&(N%1C=9[N]^2_^T_$(1Z(+0KC+]E5PO8\45&]6U,N\2,/BU M5M8-DK2*)_:?K$EBQ]9X0VA DGG%FK#<^3JK'0OR]%3 RM@O,,F5J)9LRP@* M_,FLZ"Z0KITBJBIAOS:DIPDBA2/TG+$^/N:>OI=1DM*,C_[K(-$L-^I:;DQF M ZPX:C$K>H;-'9L,<@=F[; MI 9-7*01VZYK/AQO504HY-9\+ PAUPN/OG34#7AYLELYZ+B[FK%[/(0!HJ$3?J:4".8X]1#(4(?K)6D%?"CC;(2 MFN?ET NG%AB7R#,_TH J8Z=5'Y[,5WV8R24LMNEG&0VB39&#LKKG*[:"E5W$ M#?%9T30@2@?3?NT"U\+Y&#40=EM RJKHK]:,L$C44)JT+K3.7[!4Y5MR#7A3EKLY[L@G\P+;PG=?M!H\-B=@6JXZS9I1":G/P*ZS SY M'[^0)-T?F10>(L-^!:JSSAO +6#OQK:TQT#\)4^ ?)5QK]7%6FN?M/(UL-?9 M%!3,$A=N*%IK])C.02YD!K4YF[A%5Q==K!8_C9-4M\P,] VH6CAO\!X<=\S] MCLHOLL?YIICHYM'J_/F!^.ROMS'_4653F)^ A%X\>^?"<;X/U4MG[>XCX_4- MZVS^>"JBSNZ_CY_U>1(ZV^!K^N?*WEM/%5K 8[J-[8*%/J(_9H6]W;#&>^=A MU/M-;T<&T^$%-+_6MCXD1%^$*O@D+GLL[1T.F)?7M$G>"UU9%CX':\)6EIKA](PD/@T>)*:C7ON^ M3EV :JNS]S'C0^;2O-EE86@-RQSWVWNOQ"*9;S:4;!@CEPR4@!'AYTM&L9)8 M6,O[=@BJPY.XG\%C%%VCA=E']KT_YPD?ZY&67<:0L:)H,RJ1A<#BYXQHV M$,)X1QSUF\[)-?&YA,$Z("O^I$!=W24++K0R_I-5 RR59DC9>G^OGQJ6_FM2 M2^-PS:/GM!R"\J'11E\G=CUDN[2BBR#GN&ZD[H6FF[H MBY34UH0R[*QA%RPI_B(R]&5"*:S^;KJ8 8>^2##^/%37G#7 C@N75=M*7S$ M'A%[6Y$E)\4^/0&GCGS-JMB#PTGOQ<_(77I(M+//DGHX2E8SX2HV5:;M0)7. M6YTW%';!#7VPJG<[M"_I4 MK?(:4")=-_3J,$$G;4ECGY!59J)S9'+"N86ZW./\M#59'= *XQ\>9M6:L@3PY9.%34)URWH)JBX7IZA<;+SZGA6N>\Z74$;J:K@,(LM(T\$/DOSQ@/^Y!Z"SK9M2-0-77>L(S#(+KFGI7[ M4(G41<#6*G@,5ID7SL.\$V0E1HN[@$2)0CNM? RJ@:[;P"TR@:YEY]N','XA MI+3EB#M]Q5T#M"IB>5NZ,;_8.JO+,7%X[A.([C=A,+9X-6TM*$?.6MM!4DJ9^=O;EM3L2[_M?BO\9:TU\IR2:'588&K0 MW&5AR 3>>,'W3(YB(;GQ[\DJX_XTN]/BK?=,DC.2>D%XD"Y(>3OO\O_]\'[V M9G86)'X8)QDE[!^[1F;Q>K9K9I:W,_M#V=*_?8H,OA].%\0TE^H@4.IX_-X;1K:'9H M:;!1)3D6';[?ED(Q:'A=6%4D4\_^E' :AZS?<0%=Q>K $R5=Q4PEQ;^NN.8G MM]Y=J+IPMO MW5!M:?^P(Q9.K]CD8P&1_;[O'5H"F?ZRM$[A@F0S@WX%68\L MZH-0\88%K_H2)([*W;*V%^M*3^?/@4)W),6_,260H% Y."*9C5N2>F+AOA!) MHJ&=R<^T(3<40*G,39.QJ8B'O>N01N/__(^?Y\O/M\2_C^(PWKQ\#GQN$-TO MA%*F>&UH96R+1T>]K!J0S7"R9.&_(D]&_"C*@^_>W*5$BX8E%CX1)C+YZB7W M[-R6QM'/49#G/4E?3MA!YL,-=P^@07037%_-RPXJ6>K1'G1@V7/,[$]C;S@M MT?R?\7V4_$?\\%L0)8<^?2%W[.CL_,5S3;= M&10W@/]0J"WV5(!98LYHI>NYS%E\9*,_(W87N?Z;?FZNY'[OZI-;HY@;&_;1 M3FP-Z2N70,BDG<7<2Q% VZZ@&\0)E4Z&^:[K=DY0_R >O7UB77[9_1DKIRI% M>?"[4+91K6M%=3+22FMI-6A]EY56+]S*&N"\K@XAW99X)*POXHP:05VM $X< MX0[2;7G' IHM+F9 5RI CP[V?+0[(-T2>"2D;X)G(Z KY<$.'@[AW!)W+)C) M(XG,@*[6@$)M;_?> >JVR".!?<[C&8S KM7 ?^'<'&R!R".!?15$9E-UM0+^ MF][F4+<%MH_T?4"YX0B&X):X=\TE" MT\HIG/WK< )G__CUECM)+=:52&^QZ825E11UXQ1NWWPB1Z!R%D8DC@?L7Y,P MQSVY#QYNX_,H#=(7J5E%))"N$62RY1SHN=*)9L"T M-OS:W 6_]HPGEQW=4GSJ/02I%Q8Q6$F:+-8_1P\T?B2K)8T?"&UF/YMO8_:S MWW/A3U[*,B\+RO[VW\37> I9^=BW,NW:Q+!B6D/+<,E[H_-!:A1S@WJ+0ZB= MZ[(JOIV)^C)*"8V\,'PY8\?F,'[@VGE<WY=?7L#:X-G-*M'0:$&E>=M UQ M0-FT7O/90[Y1K?S:C:$RRN:T(G7%D#TR*=)!LNN@(W-8'2\QE@/--YW +!,. MJN!L% %.+,.?@)MPM< 4RH(R;WP)(BVJ]2)@=U$$6$7"6#+55'-CEDEKBGSY MDN5041XY+LY&7$EU^=0B-0)#U_&+%W(#TQ5)^6LHHF6RV5=!'6Q7Z3&IDD+F M8KJX_(4B[H=UD$#"L+@H=ERX;6)5 .%;'MA9Z8L7L%UVI$[@T"J([9)CDS:9 MS(Z05DX/VF13S7+8OCTC4":&!ITQYU MI(8=GQ(O(6>D^.]E)%H?\D1IB^B:NTR(%:,PCG1J"SO"R?:"VPMB]*EB[ON4 MZ78QD04D.97WS7E4Y8VA'G PT7 MS9E5* I^0KA&OUK3@9:4S\XE:E.HF)J4SRZE36N*P3ZE=H>45I@Z+0=)T-.? M"7JF"Z]75'&3F(:BZ;D9R--[:')TWI^2XMC7\UH54Q/BF$,X[UVP"CSZPJ__ M%^O\TD,_CTFJN#E@-#.91!;T!"&5'EUY6_;7RK% .ZD!ZKI#EE(!FXP!),.> MZ"Z7"]WD5BF"/J&!]:Q!14M,]-E,^+Z<)DA%7L6= 0*(ZEJ7\9ZQ?^3^/(6?SV546?M@NRM]*\B>WSH#DF)_!47()5J7 M-/"Y\TW>:1"%C1KHV['.? E%1^=F26.?D%7"8R&Y#GE[1XQPF7M++=9KPMWK M%!>U\":P?;P-V3,&!YW.BKZ=D<2G0?XV=^W0 !IU\LK8^XSN U '"#IYP@7] M_)E0/TA(/GWL?YF4OTW>&V[/]X<;$MP+-'3*<\6\CT,&:7+^SRQ(7[@C M*DU(_HN;AS!0W4Y"*F/O4DW'*QP0=/).XRC/_LWGDZ)[^5:L^'%*5JJQJ:^* M[9YM.@ZA8&#&K@WP .I=>I!T+]QEE*0TX\XAU=VX@G_3=K ]M0V5H1M,D]8, MX3JT/Z,1/Z.%YX\7AF1U\G+N^??ULH8+N5G3V"[D0RSJ7<":V;> [=4^] 33@ 9]KU ]2I:JNMNDJGR@E;70?=E['*=E& SJ)RMWHBQ_ MP_^X\Q+"?O+_ 5!+ P04 " !91#U89D'1'J*1 SBP, "0 &5X,2TQ M+FAT;>R]:7/;6)(N_)T1_ ^X$]T=5 2LLKS5XKH5(6_5GG';?FU7U]RX,7$# M)$$)91!@ Z!D]J]_?'T?__' MHBR:'Z*3VZLF>I-*CG_Y63.O5PQ^_>01+@,^%_[R^:7-X^N$\FV;->'1R?'*#9Z); M\4<,?I8635I=\SX\^N7%BV=O7OT\'IT^C_[^ZL63YR]_?AM'SU\^/O[CMN7Z M9W;C]^7'7W[ZY>63IV]^??/\'6P);,_/;YX^_W]@)_3VIIF559_-T/'J6%4DQRV!&C^D01J_SY-])=/_&3N[D MN_OCT=_7\[HLHK=-E:8-?+9)HY-[)[=O[*3^,ZWJ%#3!XZS9Q-'+_XQN?WOW MY.3&3N>&*X0?G_]T6H]';])5E=9P:I(FNTBC.;Z_7TMW36 M1$U)IQ=.Z[*.4"!F93'/\(%U5,,)A^.+!S8KXO$(/IO5]3JES]5IGNNWU_;, M%W3FLR("6]0?>[1'Y>BW1VHU!@XWEO%&916E8(# C(O^CP>3&X\6\(7+\W(9 M&]Q8_H,N!J9^:-<12.-/Q6K<-4Q2R"\+>J MQE_7L,'+95G ,)IR]CZ._G+[^#;\WTFT2JKH(LEA>U=@#M$@>V1J2>8%?/,: M5N1_0![36PN4GOEX! )=)44SO#"OXJ^YS:3H;D M?+6N9N=)#7,I4ED+F)6=?WMM!AX=\:;8%T1)@^N5?DBK60:O6%79C![_ERO( M44NFUD63Y7"H9^=1 ZH%Q1N'US,>. +Z9EJOQ3K/ W60S%')P8W0X%- 8UQD M\]0M;?>),:V\%8#QZ&IG(I2)G7*P]^;#3G:WJ&_+HX_?\> #@WO.=VU3GH%& M@L-UF8%BPH=M%YI>Z?UD0$AGD3B:8EU M#,LJ5QU>C/R61;9HTK1 6< @U7@T.;G_5W>EF!V-ZC)WVUXN8'_P(>V)\O2[ M(DNZXQN0NBMK"Y!6+R<-2JV3=KC03N@.TZ/2/YH^11"CS8'2 9?D-"O8L&IT M(V&6J)*B&>X&GA7XRW@$^X,RA*^>E1<\_S+865IRTLVUDTMXV@+?Q$>D-:3M MQR3JG)+QZ&K'1+\KTY8Q]$DC7!/AV=.-M?S87*?/GB<7 M*>LW"G;RB.'D7&1Y>@9/G*>PD]G4*_(WZ5E6-^)AO$5_ (4C%E,@FZ&POZ[* M>@4O7OL%,+^:)/C815; 0Z=I7E[RVJ&-(,J"AI?D)I+@9@C&B@CPUN5Z)8^R MB_5%^8-?H(M+,F E%+>T[@LBH01,\:F:'PLX6.5E_<>& M, Y[_E&IM^<_G1QC#+%/KY <>-W!,<)'/QU_JD4X_A8F>(A/_<[#>TX.0+I* M4#WC#B[@-IE[)Z=U03[] .9L<4;7TQ)NKO[8E?PE]&_@%C!B4ZO8X,TJAE?K M??;RL;;Y9'$DYOD11J>?E7B/WSJ))L]@Z-'+\CBZ>_?NK?W+, Z3]CM: >LW(?>^ \% MZ^<#0K*Z9 I4*8T?S=M9OI[3C8S[F6=+,+&J#3I)>IG#;Q/R$B3PU]I:LG%I MHFSVPJ?H5_W;%DW<&\&*+NLF2N$>)_O(/.0(%V^9;,AV 0LB15O@7^M,; $< MQ5R"3LTYV NG>C$<1V^'WVVW)!@'"O3P6&(2=AK$/)WE)/'^@][LDO7=,02S MX&;-.$@* 0C,8'FJ1BO:8$.5Q65.(A+C#B(HT 1*'BT&W&1UK6WTT.Q M?>JFA3HGE'_\9,I8)DE7X/;4$E1VL]?WAH^*V$&KTF2!^=WYVBD('^ (1ZC' M;7@-W53'H[[EU"G"FWGSTCG_+BM4.-H:PBX?>)+UFH,0O"U])[HSV?'HHV8; M&^-Z!I+#0PT"X'U"$?@CSX,(\WB$AX.5/XP&_U%3N&(ZK=*+C'() YK SAQG M'=U[<&W0??B>09'#[[*@#L2I(DKP8RT*8;,C0H6!'2K:7U5OOV_U7 MP-PY1:W2KU*=H&SUN'1!S;5JKL_N\MVY-TGZEP\&,VO\WK.XB #84.MK,UQK MDK7>'KL0!%2WF'$KP%."K MJ]QEK^#L]4^8 CAVSFV/]NOR*&%2_^O6K>A9EN;S'Z+7R5GZ$![PKS4>$?AB M=.N6H(1_?/+\GSH,GM.MIES1O'22MZ9ETY3+'Z('^+MI68$HNM\]RI/9^^CD M^#[,OR[S; Y3>W?ZZ,73Z/'3%R]>GS[!A.?__H_;_T$_OWU]^EA_EI?*\S"B MDJQJ&)S^ZR$X/_@JL-_84-[]A84=_+^UC2%&Q!&M"*!L/O] MH&>_99G__+O9W9_@=7NNEMT:W#(^) ?\Q)_'/\W(*$&]ON_=.6QW)/ HS+N8 M"WS ]XRCR_-L=NYN.8Y96F,2#+-EUC3.B"SU)[RH%E6Y'+!KX3;C@=Z]?3HX M4G$]VJ.-P8S&G T;$_'PM1ADU/ 96VR ]@>VAH>3T!0"S\_:0O1-7"+\-RT@ M_F837<(@/YFIQ(O(;)]+TO,^7_I, MJ@!P,.Y5D\Z+!W,I%/82N:"HF00LZ %>8O*R1CEY@I^8H*?6&T.='TE"SWR= M\N.2_FP_IC\2.]6GQ'^63,XU[^2G%L.##F5@Q-+]SDJ22'MC10ULO> 3#*V(MQD) MSA0IZ^963VC5Q19GESAX.)U[,<%B0X$.HK,*D_CXJRB>$.AT_0O^C\XU#X)[8L"92"<@3W(JT;^$=XR<[!= /%*D@$?-L* MT6]L3;5@,@026M=HN>*6%*+T5$#&(SC2[].F+X;5%9=6R/,?[JMZ %M()CT$ M*F)=*]UFI6"@]7JUHE* !CT#7MX,)'?.RQ/&]L6CZHT\;@G<;CW2X]'0]>%G MTSD.P6E0P8^N0>['H^L1?/ULK&Y+CK$8W>!95H%I#I\&$[R696OY/2@F"J,GHQ ?DM(@V+&@I5VAIM.UD6/,LRY5MT?D MJ>[""NTZWX+K>AWX@N@EX;H0_#)6C"_B0$KTG#>L:L'1KM!Q+@+G>K&NBJP^ M]TE"M:-Z3BF^,EM@\ AF:XXLQY@QL=T" O(&R6MQ1?Q[LQ:(2@V=;R<+ 8T- M7$@BN37=*IKTXJRJRW>U9)&]7)Z0P[B9S-+@Q7(DSO; >3=:L&[Y^ M$0\LPT,D8*Q;^[XH+V$ESM*6RX/!#H(0FW0 +4N5PK\+K[)-QO8+L].^4.-3 MK,_>.Q!-3>LX85(2E=D?)F=PYYLT/> M[*;&'#_?W2J7Z^D,5#ZZ1/ZJXLMU*F$R0[CZH]'XNNO:Y_UT13S M;5_\+ML9A[AC!788S%QC\VDLYNC*!O-X]"O"J1IP?(N>"DJP'&MCIS7= W%,- M1W C.^$8TDL9X<=#7:VG M>39C,VA+@0KA0246(?%!E_"-)B='5XQ#<(K2QR+@R^''?*R!O/ Y9_NV1=L^ M.NH0]04=J !K.:P8A8[TWS5Y@Q(TY5]YP;!/$-]WG\QNGX#L M$PH9CSJQD.UQD.UAD&@P"K)#R*4HN3T%#8#LT@R[@R+1?C$1'H8)BN!_KB\H M$NT=$QF/3FNCW^&S^.BS*EF=T^32O$XOSSG]'X4([T^6)?HS^1;7-:F3SV-. MG!Q9@.6.PV'+,Y=I4BB)@9/_)0+A\:@66.8XC/)@R]L&K%'>K>P$Z/MA=*Z/ MB??BYYWP[V'8Q.RH4\*"3L/*7CB@[(HZX7/AC*ENK-+@A" [%=9+KG 455OIWQ5Q?XU4OYJ@%ZN3+G(.\NP+&[PY"G>"=V&^W_ M;" 8W7L8@VID-B$>'0D1R7+5@#V+E^=@1NGNWQH>$\. MI_I/?W>#1(,ETYLCW5YD91+6 ?3!FF=9;6@-0,)@7MDTE[K_JN>H4Y:.1>OV M_6&,Z!>V!U^F8#T&P7JZ1]PD!^GJ,PN8>JT&N:L769C9W]M3ECK EC7VA+,0 MF^@UEY@-8+SN8RF25-O&] 9.C!@&'2GQ1,,*["UP.E"ZD6ZN(=\ _^[<-R?; M=73RX!X-W%UH _>!-?20Z**8QZ*,;[U/TY4$<'A4%K1S." W8%*3[((#EI[2 MUVE7DPYU:H2R0$*5ZYQ7JUREE0DC\20I_ )&Y7FT M0(RJ,D!)@:W#^6CD).T+S(Q'OQR_/8Y !2$V%^:7S&;IBD8QFY7K0JQX$*QL MA>LV\6O]\^GIZZ"<'QY=H\XG7YCVGH!)I*O+=1.,+2LNRAS3PQ-U+E&;@\)? M%PGHQH8&BTN[[#\H&!8V[&_(!WL9 @CJ6(88+]GM1E@T?/6=^@SN!2W'$(!8ZK7U#)K)3LLL3\_>@F+LRT!H< ML;X"Z12'+A/\G97Z>"O01N:]7^%*5TV,1_M'R0]WU0V8U$2N*M@V(AU)(G]I M/?>BZ6^M/AD.HM ?)UCF_AF/=EY KI((S,7E2@0;C[GH$B)F2>JR(+-MFM09 M*T?#*DC9"5AGBB@72F91.\HR4 -HW/4]&L%Q?AH4;[-1I-=EL/>U7[1K&(Z M(WPWPF1 OZ+)*PDV>E=9!].33%\3[(!]6)4N8: '@RL#ZC:)=X#M;,I/KT([#1!CKD4Y4\P$J3Z(6LHH?742L']#",:2-LP M\MHZ>GOKOXT;8;7\5Z%?13]"ZH#'!A>@>.B:-__"U9KA[^5_3X]>G;.'K]XL5CS7,C MR@B\&[AK*'6-=\DJ*QRH5NX@EVA7)ZO_Q@] _NX:1;=[#YJNO2Y4;\]TT34< M7<[,2@GZQ;BDQ+S9FED0HL:_R;V/F:I^Z## MPZ>J,J^/(SQ;[P+1(.LL$Z\^JCY=7*?A.KD_AS_V6_/'2EHB6H[ZVAKR680%,-'&PY ]&DH M)A$3ULF_K5Z#3W"1<1(1N<.;6N,Z"=;WP*'@@E,F8);?^SF7"_"4,!:&?E1: MU>@!P7\IEH0HI0RV+H%%6A?L'A&T3_PQC/XY=PR]FHH 0U5 $ XHFF68V2* ML+O2'B.< E": M.#-W*TC(CJ)& HT"K0Y>7I7]FW47R&76]R+.-*"H8B6*K19D!IB]UK<;2J2% MY#TJS?&J,5$BJR;[2P.#D6&LL:ZIJ0!]C)"FGH6F+"3*? V+P?3J&)H78>,E M: U,.DZXL>!Y)$Y-=Q[3#W#C<;\>^E#2V'TF*;E(\MH7XHIO+T@:>"8#4]M7 M%Y&B9 OA/CE<.S=A4GCMR+WSK*PN09?=>E&6[U$Z^A(^'@\^'PA0<:*!^'E M[,_*DK(.B)XD_(C<3@MY5R[O^J\#J?F!DQJDGW@,X/"@,H4 X\H]VY# M;[V1N.F3I$F$JB/GRT<_#S+ )8*W-,8ZA\\:+.)VT>QX+X::=>_Z\'[GQ5+M MRHMZ))7K&N#@,T "O@1V&IA?<\&>U>6ZFBF^S;HU3FT@. %,Q8M4Y2@'P>:0^0.MMHE](LM64U&J(>4\'33.Z<7O4ZZ)H)$UKN")G!TL3ZY]WJ=_ M2B3?/" L,ZF8/CH\?+,4#RE9:WINP%.@))(O/9%9D_VHA4OT;K1L"_XWG2,9 MU.&\W(!)33YHB&%:,]'\ N2YR%82*1JN\R?1C7TS)+HA]">F^1&A)NGAXA05 M;KYHX-?X-%314DQ'WCTS5Y?K?![>"P',89:0)J\$3N*J%MGG^;>#'BS-9%S5 MF?8P(YI[Z5G50;)@WBN9H0.%G@X]G(K3Z)6]96H'B;\!DP*)=T%K)'T@=+ * M-^&KVA*?.0(D$&OB)SW++E#;V M<@E!FP:<[(8^$U"=02=S?U(DU\\"I"B^I7_25+ES\OV]VQ:%=A#G/SGEX61Z MQ#T/9IB6H]N:X1_L&N#>2GRS35)*,#!+;M*I?V(N7(PBU6GN,'C!1UK,N&#A MM(I#;6UHIUM>WTL3A]Y8)@W]AEB?%8 RW?SQ(GG]E+(JAKU\L-O! ?<.X(#/ M PZX=P '', !GU4QW$1-=W7;(EBUWPZVZY\Q1?2V28A0IS\"P;B -<4=SL#%_[<4F(##S326$/;KPZ?R6.CG[I@I]%!> M"M.-Y''A]1,7T0_ZU!U1G.02B4\)U(#H9^=$8@'.&AMGP)^F:Q![:JP']O*Z MJKA299I2,A_.9,;1>#E05^H]O;-*HMN).M9]H-WYUQIV@XIT8#+S,AAK@FY% M"N)UI++A^$J?R+#QN)66/W0"1[4=< M:9F$!$,=M" >C](/6%84,7$*E4@E68[K@RPVI7QQ(\$L].(IC M#F*8VMN7# MO#Z:9:B+DCFHS=J%?I&1AEZF8XU]=Q>NQQ%)B4V!56QJMB8&_Q((G NGM:NS MV@5\O(C$G"O8%H99('""Y;6<@N*0;RM<)R0&P0?ZCO/F)_\A&U-W_/>GLAK< MKN>K(\&\Z9-RK++_1#V-HH/ZXE'&FO>I9C>\$#BLP=7%QZ=S2!GAB^1V /M! M<#0!V]I*J=P1?PI?<^"E(& 2.[(MB5OS^^G1],FIS,9U3^^>H!1!1K.4JTB3 M,Z2D#E.B/0BAAEJR"[P&46T8XX/)LQ;Z(4+\E8;_W//Y>$K9MV*_8,;3I'A? MK5?-;(,PL!K+%HL9ZC2POLPU1M@C0<'179@PX1[>+; 465-6M>"5V,6M?=6E M(+40PAN.1D+O*&'+PFO6LF+P&=8G4624,&>$[6N-WP, %^F<3$H*NE*DOO;A M5ARP0J0(,Z9Y9X0>SFD<#EJ4$$C["AN>_UAD746&& M.EWH"$WU)F7KW,?FZ2(M:HT!2T=EN%"K@!!O5JZK1GF5^)(2$F6A)13&N06E M-NB-4ZI$_3IJ9V[ZI#SM)^%XDYE%4@E:%>GFYDKY0+A5(YF=]ML#JB_4C\Y, M0Y6U7B[#Q$. I)3B:OD"MRTN#4^ERT<@/9&U5C!0!=(*I#.)&SF. M9+& T@M.E+,'"?3HEL-\>UJN"R;X)*6'FE\LOA B0GJ%U*X2,,9F/70VDD?: M;O=A%'W U(F)SRF@>(SM%L"8S=)7;@2+.!I:X GQ(7*]I^1=\:+!Y/\LI7VA M("#M8,;=KZ>@",6@G::S=Z0;5E9QQHH/'HXU70X $1@>ZK7SH5K@XNK9&&-8]])HX4RG,;(@@I/HP MF/1=^SLAW0<,L_>UCS9DFYEG\F\.WM$-FY1CV7E91O]4(2:#\V?,A!+F^8EV M&1V$*L!Q<">@[R9B\QG=]&VB!Q>SR)6/R8 Y"VX.DP1[)X$#"6=NA*X/ZD'F M;L"DE"WC,4-E1:Q>EHJ=Q9 >H2$)X4LV&/XJ*,J1;L#4:,ARO$02JK+UE<;# M;35)X9!KGQW,Y5G7908S(=L6OG$7V4,KEQU&$R0=;%O=#_@)>\2X^Z/3P]H' MME.]>,'J>70DZ" M:'++[)KB866.@7GB'8H8S"'PT0!0E&:5;S07YQ:-F/'4 MN.W*0R@'<;!2)!9!]-1RT#D9X?5D[[VL7%38./+PVT?Y&KMOO=](&$+9I*@@ M41;>LKS,X>A4&RUZ+>&?IQIQCU'/'=O;\MGSEV]. _-KH(//:EW-8)N424E[ M'1D/WBRXQ)7ZLUZ3)T=1L*JM#85U\N$K!VVGSS!)]V*-+/@45V'2%K&,*-SQ MM/7P?8XPT8&)<-E8-DQ,;$SAP"?3E,K@^+XQA9!7M..^BOMA.Z;G_@'3\WDP M/?FPC\^-^&'U+[(W=&?HT^*R"199L$W JK93TJKQE5VW M:+EN7+[?6T0R2C!&T"1JHV;A,N1$DI]6D%/BQ\=T-6_@8$LZJ("KL:[1?)OF M4KMF.@GQD,C>0)H$G^Y!=*WAZ6WE-6+% 1 YER84?,<#21003.%C5W4&F/LP@=B$YU1>%3M M20JWS<@>]CUN/%I[8T24XOA;Q)0/XC-DDNDQ_K63N_E3.TOJA1NS3"B?+BE& M[I)/CYKC1,).Q=Z4(9BF#H"DF/2D12A]U?AC0>Z>:;_*O*U1KI0R37*M+;7ACR$RA'K= B M*<9JM5?@ D2%]P<.0>RV?FOWU1"-9=0A/_OA-I>37H"'BR MX/=7L\RW/G8> MJ!/0\:A/_:)S75VTQ14+('!7G-_<68HMH0G:5)1P%6L!-8FJA@7IIN;[H@]< M5]P_^8\Z)P][Z*1]:6D7 :'WPS"O<\ED])X")>3PP$-%A2![M0Z3MEO[7B<' M6MT;-2E/2/4N^9 .](#&+@2^+Z3$U:T=;.\DD'PAJ(\$=5$FK*N/RI3:F&'Z+0V3K-,AN!^7"P*@_)(/\H!9F#CK(E_G %SI&.5C#MFO388&SGB2,[T2'1! M3FN5#J_2>(3MK,FTGDMX[1B-6::, '!4C!N0.%H5T?:?D5*7R=T= MIQ;=*CE1;U5J1:T+V@&:"=E89#S"!PONK+Y:4SJ6(G7R=4>+7PIL2;MPJ/#7 MCN\"@X$8%DJHTKIO)8Z5K'&X]*(15P[2-*.5M8SF62Q-,<\P<\.1A?FM9"$*0)?Y=0?_$!<1#1EB6(.SEX%BQ9' M"!9NNE@R]O\-'%?$&KHH," MP0*/!R&/\[7F!7@UY,0LTI0*2E!1B3.&&PD&V%GJ3.WW&5EWL+X7E-L/FI%P M8@I=Q%J:1A4DQ4DNB:%DKMUT4&*2#_0&_24"$857O,^,ZI4&D;B>)G1YKN*( MF;!9GBB6&P/NR!Y8QT$G!B\<+@';WSZ.^IMZ?E%S-S(F&(C F59!9;PZ43,^M$ODCW/>6SU\LI\Q+T!V(#5QDO>KF?G7^/ M]SI_VM7#V ""?:J$ZP@[J &[\017U^I:7)DB06$N53OBG=4$]W!PPH0U6 M<\5PP9-6.2H=Y(3"_2I #\EH6J'C+<)Z%&.GT"%I<:KQKZ43"61H[8VF72[&J->?*!(=KFGQ[Y%TJH>[_=%GHEAU0F:>_$Z'4S MMG$]C] APSV4X7YPR'!_G@SW@T.&^Y#A/F2X/X['U1#BO7;55S[FB1BLVC,W M8J@_:V)3J(51+G2],")13;-&(>!,W26V)3C766,P_@RA1>,W8;=7'J9Q%&J4 MW>SLI]&3]_Q2E5B'*-MY4",[JJ\5DN? M:!]ZL]!?F Q^F0=+SI4'9/)9>NK=PH]E)KA*&):J9%F,VMZ5XT'EPB*.Y>$' M?C:G,GK*M 2V"?,TS+"#.2Z*:ZA^\J'OF'%KB,H#YGE2;:,MURUY["M] \I-)=<=.NN-?>P=^ % M#+#UL)-SGE5S*:IS!YV;\')9'>Z&(=Q@0 ](.B>W9&2 G"4^ Q:NUCX':Z;Y,=CW@L?5CD"L(L1C&7-,5[AWJA MXI!E1N"4&LU*K%N=(TL-3?NB?)^RL7<](LBBX,Q10N@$0DC?Y+$=@SF12:S' MK$JQG]$K63LY2117(Y8AB/XVFJ60=!#"<3C^H(.!?@,FY:C@B7[M7=;D:3_"A^BXN*4/-CY@0P\_KF R5V3N M)(THN,K* 2^/MAO[5^Y;,MA3F\XW*<1+847.I' =[1YW*8EV<>1?+1 FWGG, M.39#K.X6I&K,=RDF9A70J=GD.G;$9K/U(/TA6*5Y3TUJ9 M_- >M<1)PO#&1@3V56/N(UI'NK7Z&I*A,93-UL1H1&-!;ZH4>/8FVS)CN$R_:*TQ$?$_[\]Q/\_3_S_VT/\_Q#_/\3_/[H]2)-2 MM&K--R5=9%V+2,E&?2Q*/"4.JDB=!EP]V*^&K"-TA8BHD_YA>X'4!,J;IVA8 M8:!)D7;\,_\M*A*:@/M@*SP5V2^U_S8K5QL>46S"9>C?%O;]:+Q4*9>DPRBD M_$2F8L)-O4L4O:'/!<$GPUX@!HBA7=UR>P:4MN"F7Q^;[=6JW-JHV#996&QZ M>,$$UUT#9^L*#+/X;I_QMEZ4PS8Q%9YP+BAU5%T5XF;$0,J*!;KF_!AA1Q)I ML>5("+:DDB_V!;<) V%?T/BM^YM)!2W().CAHFPNOF#'15A/061Y/C2D!1=\ M\+[#\?D'S]*[+914$[O53@0[]V0>LHZ95V07U+HQ:<9P[LNL]FUX1>A\!(U$ M3\-^5" 4LF!M7QIUE,Q0'D9"0^*&TY./W#8/C?]@X51_#)>V$ETG@E33WB!H M"(99G+E>VF[S M>AD&8U3DZVS2_V:43C>ZP+1$2YH.""BCUM M.V%4W[]L+SGIXH\%64:.)'\CJUT'V[N3Y(@NJ7BGF&YUT!X2?UI;' A!N5,> MN 1T'_G=+FNB5.;M/!&B[#'NITBR^6]K>#XG4(0B%6NUX=,I7:$M)G"^>5$/ M%\9;C)GWN^3:WJR@T^$ZB0Y(=B INU+MOT.T+Y0,&?4KW-)!?'K[#G6;H5ZO M0 _*,X'UNJ4['RO/'RG.XY&3YR<[==3U;Z12"ON"7=74=4M-FW(%9%L7?9UR M$'B[2M:8+C\J;=",J%HW61R.HO=FMWO6L)*>V.1+<9A/5MV#G/WRN#"= M;5F@:'P*+W+E.]]K;AC$N0VZ4'Z<=YXCI!N[\HU[&HFA#(Y'G1#J[J27+>IN MTMEY08W$;87''.0N!X4B^ -&C,C-$UZ[=*9]%I)$E:4K-3B2]V@NH]6-50<- MO+>_6Z;DRGG3F5)6>Q(J>X9ZH)R;U6 M+=2^_#-7JVGOC:QK.-T[;PU7\/+:74L+ELZ+I69_2^W_.?:T70:T,:K"M %C M9Y%6>*,P^3#"9S"BB&21A5-^)(5E7IYM_#%JF8].EEP1-N>%.56S[C)]]*(G M#!T&F"*>*UF[+Y1!L<&>9H#):OK4LPTQG[/DNEUCP@D6'@C0A61^/D&"Q2C5WK3=$N\IYZY$R M5K3IQXR;C\_HA5+(:\K"_ 1WC0]O[3F"K3A2;1MZ_/883D"C@8YW+AKVBG9- M\UQP9Z07"8Y#D]T:=?/I<6G-1*D]IJ;L#5*(G;V//6#!0O#MF+8*3:\YATH2 M+B8K^7<4'-0K*=*_XUMMWX:GU+7"E_3?NUIE6WLGAXLGA_-N*-A1O0F* M(P/%PS3 6R2CX5:LT652BY#1AO8[77T^%Z_N,BG6:$J"*J/:Y"[)C("J:H$8 M4;!LAE4Z7-'XZ4)_MHP0I8/3D7*/DGG1TDY8I4S7EG8A5P^.U&*%Q/"IVJPZ M.8X".RTJ0BR!9E7D@* MUV:&=I=$+^V09C$..,Y!"A9Y@AIG)O0&0+Q.9/)[9.9?B>8+T#L>EL.HG=\W M;5 D_1%G0H)RA3C8(2\=?7?(2W^>O/1WA[ST(2]]R$M?.2\MB>FG/LSQ M#_;26E5IF%PJT*9<)!EV\)F2 84^PBSET@]PNAH7'^VA%G:@3% MRN.(_>>LRM#N9T? XOY--#>I,NH7C+V$F!S,P7TC7Z@234$*8&9!/S]J+57V MK:#!#'YLK1XBX"C\^(BVD6>*? [K:JK4AN0=>$!S&':D8G_,^NTU Q2@E]1 MD"$X4.81A($=EP":]/+-P5'ZT)H/TRAH&(S<;(7L$5A"DY&G;;R"RO']I%6M MW!LHQ24'NW< _^,(-Q=1?CGCE?NBRSMXQOHC6[06SF=ZGVY,_!>SXV?N"?JMR]29NL8LWTG%C E!X4 M"Q&Z-TCU/>8S?/0B:9#&=&CJF>$+POYW>:?/4OI2J M)>7/R6RV7JZY;:'XI.,1+BCR[\TV.Y;Y[NT[."2:UI'>/C(!ZI?7BHWZ[;EW M%_E[]+L!#0Y_4:J>3(3;]W##T!$BY^_>/KHU3QP81D+7M,.\]/9]_F4NLDKT M=_,C^H60E M!)#'T=/$9("VCHB3<*;B=3 >+@@B7^A#32?],>$E]E?DO#]0: FF-%FT'55$ M7S!DU-)_GFHP(O!>W/:VMX7C[2Z4IV M_-B\@HLJIQ,4*XD=A0MIC5I"SU(N MJQI\<(%79[?%(&\P;U*Q,4.G>Y&6O.$CS$$4WP>^+;TG2-/EMFR>BFGEOA K MV&0G% /6^!RWR8J\)]&<;@Q ;[JQ[*241N4YSC@SW1;/#FAGEJQKMF_SLO;) MRJ!R^'!9WX!)33[H75U<9%6I8;NV8S6L35RKAMU4QU0N'_O^5?;*94]&6GJB M7!&[9H.^@5")@]VKD6ID@BWKA-I:G"?_!L>G7#.%6/DAFU'%3./*BRZ36D8! MYD;C"4W/TR0G4 5&W1>IE@N#9O(KH4'M2]D7W2'@O,EJQY+4W/"!0FW'P:) MI2(8KO9Y3B%OLV&Z2?0OIB#%(E1.VOC<(:6HDMIY5\31A_J0MM)]BG;10('< MMF-O-K?=TXTRSS'Q:=*72YU<(1/*@6G.HR^(XP5+Q%QO"YE-W4) "17AQF1' MJ7D["L^1#Y3[/ ]'II'7@$(5Z44&,\LW/BA/2]2>"B(!^^))MZF MX%[6!&9$OD/XXM$5AQ%W =SN.G9G;:$5NT&':']MASE7.75[(:*O>NC:*!?7 MT:!U\K8>GQVGIU"(D&UW3!R='?U6@YE0KH61,?R*X*_V/(=6ZPZ;]]94=&?M M8"C<@$F!H2#QU[>O_KOCT[?= $:7,;V[9'01_9,N:WN4?%$(^I?SBZQVUROU M611VC78W RXYM>U/Z>#7E*Y% SQ6K0C'N&$^?YHM]PN@R &=/=0;3QB(UKA^ M)%=SEL(>54%7;7K1VP3#@6E]Z]6'/-UHE]0[M\&[UAXU_2Q"\"APWL_(>S<1 M!XHY"N&.A"Z(*$U?VS!SZ7$[4- =1U"@Y-+ S3GC,PWM#2T,8S/8!(4E52+0R2Q6DO/:@MV[ I%!O M*6=X68#HOTCH).'A8=-<]9?GZ^A4X57L0/CN!XY^*I2=/M?("ZSK.('H3NR? M]#Y-5UK7SXSV9!+Y6)2 WEF*[3?N^S[@>3L,>!*ND=8@=VO MC&?:'0)G8HM)I(E6ZKY,3IJT)^I[-UAKVM"RJ_Y,9/V%J M&5U2B=4)CFJ^A4BH3:D6*KV!#3>L:IHOLR4/5-=A\F3D/CZ.>6[(M7 M]0Z*>@+V5-[L4U1V4$,W8%*DAD0/Z?E]7%;5&L;T6G+3-5_+E"/I$D%%Q5[% MAOA)Q>LZ^B?/_H0GT;9CQV/'=/[) ML]L7W5 @YWT>4X8(883]/S)%]TAH'L MBYHTE8)PL0F+C3MM/$Z7G]0?;0EA@-X,2CSY,F9$L;Y^Z\J*4OPV5(I!(W4& M^0THN99%]>SQZU:^QWFUW!8&\^J^W0[F=M\+O-N#S+.\UO7EIB?DJ-5-M6;U M0ADL(J+'CPR;CUN_"J1/C1H4(J/C.VHRBKD M??3 S(T%#])]P1SYK0 #N-V+\+'HA\>##X:_2A< >"Y'JN'?%TF^=GZ[+*[C MY:)>44EN,E7HL*(KB45!61#"I^V'+7&Y*@=X+A&#B?%'!B2CZRH/5FM9O^+0 MM13KZ3Z 3U-,^1K.QFMUDX(2J,E;V5TPHV!I:&MX.P( MZ $*HTR5L"KCDH@5E37)G4Y7W7Q=,:889LR!C;2H"9O,O2 U"FJ\-QL%X;X@ M:^X$I]_47\ZM441+CL/]*JZM[0C,[P\(S,^#P/S^@, \(# /",RKPGJ$POS5 ML]/'?[29RHRE=%'K)=G!DGV$H4ILK"XZ9'I7X]^HR*J&6TM00=8]E4P,5UO1 M2-3V/&4"T,=H'Y2YOH^>]0YOSW6UB9ZD:(N0G67RAKRN;>\T]">ET;:QG"-O M.(]'FI47]]49QF0,BLE%D3+?P!IO:5QVP3;A MJGX5ML9-G]3DPP=E'H-#XG,+S^#J*B]50) [>;U6>X<(*:6S_0M M:$LS"[.TKJ2$.Y;M>X+F*JO?4RT<^K5SL!?429 A]3-9R>EE'Z?#%:R,5J2" M$.>K[%@S&BP1%Z7%67+&#HX&U$(G0'\+>[)&SH%#)\L;,2F0=0D&/2K+]RP* M;R@F; +2H,A0[T[I$ZU[RX>BN>6AT\1:((PA"^0[0?"XX/"*.LV=T-H/2+\W MDG1^VR0[ MNH0V4O*9<0_L$@L?I288+[OJ#$ZA!#&:\ZIBD+SH66=0S9%/H$MM%. I23_ZISJL MEWNR9P;C(\!,E7LBU0\'X4G^%;*@<"?9:FMJ*4R8M<8P-)D$CB M6III45OE,]\&BS)&VE.7B>"$E]AU["T2K/(C,%."3K 9 3?G D&3*L.RRLZT MQ %I7_O2RAF&&] -,7Z1.WCB*7N33['.AF]D/#)!@0!PY&\>.\W8<%;%K0G[ M56)F(UFGWH$'VF&9;& Y&*'3ME)E=9CW$@PDL;)J1^?"89EGSU^^.3T&]AKL,P+Z 13:4E] M3GSC[@#88!>Q(*)'Y,-1[%6TCBV>3=<>#$ZN,#2[Y\2/>3RZ 8?+8<.-1 M23;6UW!C>?763(A3#WH/@9UFPR_/2X:I80&2/BK\;"RN22$'!CP8;$A/D3]N M-)A@UZ=^,CEMA-6SK!J=E5LWJ>MR)C\Z#DO[0DL;U%RF2,D].;ESA'GGYES: MG2/ L8,!+0RJ>( !'+EQ8#0M&D.%4)O Z[,,JQ<("AJ@(GGQP1I 2.!!I=R M2:%*$?M6NA8[J]8S]!5I,QP@5VCJ*LFZK$>V@4ZVHH*E4)KEMK0Y"G\(#%/< MT .<,0NBB[$O-77'RW6VJ#^<;(BP2,.H\WO.N"L[IX&45 MUCF0IB"4>]JW"3;HV@W*1AF&'4'1(%M!;4@UM+&@)$2W[!7]Y_=O%5>KN8$4 M0\IK[M)Y2%\7:+U0G\D.J4;]*A35=IS/R>T#T.?S 'U.;A^0/@>DSP'I\Q%6 M2V;#8URW@I'.K"XK-JD-Z6HGHDU*66ER7\ M,L<(8+BPP8DNI)+?N78V:]8'!/@J[J&;/BF,RPH*!,RW)'I=91>)E#TII5.K M;,LCN6);S"<6(;W_,J$N;S[MVL=?80JU'''%>"1D%AAT2/"9;C2NOVTOG46F M9X+(K2@D4>\L$,!O_)U9*1P$)GJ-- MGH*YZA<9C.:WV.PJO&6&(_DBZ##GV*"O2IA#M&3-CK,F]'4>SX^C^D5W(U\]?/WURNAV61^U-N+S%D]+G&]M=2!435E]4 MB/ZS;!\XJ[A584CN@\.\)56[6):_@Z-XND9($:A3D#9:+ MW=!M1MQ+,ZH@:*T/ER'[GD)P5--54%/>+6% +->>-<9<9C%4':$<-?CH86%6 MX="%H[)"H5$A@&9L>M58[A0NHDSRC;1_<3)-&]FJ/GHM8PR7W?S=?ME\B,N, MQB,*9W,."BMCZ-/..\06FSCH*DU!F<[G,'G[:5*\MS3P3 4CB6SN@T,:5+[PT$7",1/LM8=E*VK' MJ=2%LKZ(Z>&Y;-CW=0_0!>'),<7A#F'E5M M&,Q GY.^QZE<'+6'V#.HN/,984/J?O28;QWYO$O%$SALUO1-.!P8ZT\86<_ M\!#U?PNUDC2ANM#-$?!+EG*)F]TKIB] F"C;FJ%XN2Q+*.XD%^<<_N#&7FBS MQ)Y9IFZ=XXA)9/P)I;@2'DZM>Z8 L7N["YDX>995IFSP!V2E+ZN, T9ET271 M"$K+.9<%/WKEP0@*T"C"#^O(8EVC'RR<#NC\@FNVQ#9J5-I-5,*^ZEQIA O? M(\V\E8H$I/$Z8BMJ(/5UFJ M)L&%K6C#ZA\H6)HUW?YQOF><5+#R]L%ET7 ;J#9_(4F+N3*T!5?G>W;"K@%/ M]Y9D\X :X@1+2M24%U(<@5#DS!\)Z="P%YY%NR;P1$4K!N41@G,64,(J(8V' M#7"'.DMN-!G*G8EB',D2%+97R]+.KJPJH6,1>I'5ND+,@ /YFZ5XZ(/+",;V M?;8X+$IL4Y59VLZ*89:<.F&;Q:I>']Q:0 M1Q@Q.4\?S:[-(K5R'LJ&UVI,8^?.?QT8IG05XB_49BS:M\B_VF2BK"[:@C9@ MU=>: 7=T&WB8QU79A6-&%GXFHQ=:6>B^Y403\J"@;L"D4$$Y@ )&J-X2D!:U MBMO,MI+:MU'CU964[?35#Z&JRWRN&#[IHEN?)Q4/^3&3-K[%BHT(?&2MT:JS M#[,+$=OI(95VQ/R1MDB#RY=^^4!9\N]3-;)=NJ> M">TM11I0!BY3L>]H$VF/1]27(.9B%.G8*;T*G-7BOF0!B9%\T3Z]7#>JU'$E MI)R#'AW[;J"5:W9\23!+[F A[[*/@.N#$C84J0Q2[@.1<<6C:?\)\RR>']TB M7TW9APY3QAF!V#!HRG-@&/'Z@W5E9W M62\=]? N[NR!,9*Z$K3 L73/2 MS;2^#!HI@?NU(N.'/D7Q_+JF?VLPG@N;A*2K>I_R\_)DFN;ZG64ID?P$>;() MV\15'?2SHTG'\ +&/M(/%*8FL)WCJF<+1UNYFA'.Y8/"M-"Q^(E!*E@Z-:50 M9YV5-$AU;C" 9:/-S\H2OOVD6DN*X7%9+V&&,_; VJ1F3QZW2,TH#(0?>C6; MK5>)-#-[RXSY^#R;#*1T5,!^;_)/[A/OB%+ZK>.+1N9T)LLX%58F'$I"5%N&N4QXF88!ZUA"1[1XLD*GX$+?^J]L]GX* M8C(>O55Z= JFTU+"%V$WN($M36,B?WF<760Y43HV6!?].H7%(6OL!3*@4^R: M(GGGFQH9QPJX\:3LX.VZ /DM4GV>#FI694LVS8.WZO/T8Q3OO[Z<= MU3WWWI.P,35R\OY^V")76W&C)DS/) *3U'7*?*Y%670T,N9#6LNGD%#)F6$1 MF=LP*E'#K.D%'8%9GB:55JY9KCYT7"3UP80 *Z&:YJ>CJ/%/%,_R@19F6G$A MY/;(X%G?<&"&J3>(>=D29=34^\#3W?4+R6DPU# E/WE\%(&>K8D8@WFY7>C_ MU+1@#Y\1.=J#P==0T(Z;>S.]0+18<[>3F<"R/5,VQ_<:"S49CSKY#"(OE']O M?S=,ZTF/3(:I"*I+C ,&V]C0U\:8=,(S&F-&GH;--V08F@^:1#IYEFB\D]X^ MYELJDO']WIT,NPZ!>N$Y?F7&%3/13Z>.7:?5(]U;]J@O-^(&0(O<,W0:AQU[ M5KOR+%5JW'B>EQAI('N6J[WVP<)&(9=P,=Q[9#PRQ?X"FJL<&,1DLGKT ;QD MYP+V=?#NJ?L'*0GR0SZ0JF6<@>PBWF5=N$1K%624VC+6R?/$AN:9 IXB<-,- MVTH]FP9GXNGPF7![WB>ICH26Z&D;IF/EBCJL1W=]!V00\"/96E@8N*Y71(>U M+.>( Z!Y7I3OT_9*7XM\(!0MAB6=?&:HIII(J):K -F-1$TZ.E%<[V MBR-I9:<_YJ1KME^HF63\X]&5)Q!=??R7J4*:TD9K/"JN+"FXBIKY8REPCW0U M\@7ZC.Z#/ES6@(Q8"G@T9B2",YO\[*0=C")F"[DH87J'] 3Z%Q M'!-++5^IL0GBEJXS$B=2_!?,%>P^SHE<&#ZLN/I'ML,>G07":TFC+G$-\A0= M(;B3P6=-T"T4,\IA3^9P+Z'0@>^D(!"QL/P%I%>=NXK:CB!=-VB)8; -P0JN ME5>*)328N]6B.[Z&^/(I-NZ;>CW-TX44"'E5:JE[MW;>"ZX1QK -K*GAOM#/ MM'/O?KI?14CVID^*HS :AE&'"L_N:S@U^O/;9CUWN1T,R=3\"PY@*-;0?YY4 MB_[0D.]J)(EZ$NQE20PR7Y)B(@'/X-@T6,Q6%A)+2,CPD&2#O'(0.8E_F*%" M]?8(FA#@Q]*E1NUIFG)6HN=AT)2L.\GO#Q,^\##P_/AD+E+2A0@DQ*ZUY,Y$ ME+U(0(%[\''WDFBAAMB%IOPD,-)F@#M \(O3)5 MM)E%%SMSG&MRQ@2/TY\E=8(-:0\)!/V2T-FMM:-PK;^R@^GL'Q[']VNE<*:[S MY5=AKNS((-\Y9) _4P;YSB&#?,@@?[H,,ACW/SYWDWW^$UKRGTK?[:/K2"E> M_P3O'8]'K]?5#"XKL-CHIL-;]@D8&B [Y$V_)1S5\1>Y")_60_T9J!?;]E5]!W&[TQWPC MM2U-]!OXNMQMK$3_DR3>O-@CZSS^LERMRAJ>2Q_#*CFWFL$[8<9O9^?@Y\+A M>1YQJ@R.%7K][D6KBO*"&*A"UEX_65[\&9/ 4XD%_>U7WAT$,3)!U5_^+\OJ M/O_[/YC6H^> STL0R MYOP-XCT0=&!,ONNZB&.W%GGJ,_@8:?YL6-%S5,]EF 5ZW/'H[T> M' @M?Q(W%3[M2[5,,5>PQ[Z>KBO#2AO&) +I!ZS<]^T97P7;)U_' 8&DT]]. M6W]34= '.51.>"-Q]@]Q=QSA(C^?8@MX&"B64C G%[6<%9Q7L[FUR!8@+)-[ M]W]\^\OKGYKS'[_!_QY%2(2V"+JD!!![& 2^NTD+ER8-&55:(#">S'CTDC[< M*NSWZ\A_ENWP=V2 QW%EWXO^(]5SG&!L/LY5RE R+:5Q2^NO_;E&%&GI**1T MM2-YWX;I7:SFO#E);M<\_YP\/"%3L0IYY0U8XSNIE9T['L ML;D\<+>[TP8O,R]$G!7NSLY]MH.Z$;3 M#ZO,TWEWGZ SWGT-]Z8HNO/E%BY>#0Z_,DS-:N?=@QOW9Y[09 9NW&O?A;OI MCQJ@QIB;H-R53!YG;#.5!V'U>@P-7QB-)QT&7VA*O/&_9JI:/9G:/ER)Z]NQ ME+9N@<._2JJ$2(.BR?R(;92#@/Z))P2[Q"YD>V^5.MV;T5W^]#[MK;(B)A;# M0V?R"TEV"#LS]%N+HQ8O' M?H"=*QH&AH-&0\(JSMBR'W@-VQQ=U$Y-G9IU-,6;&:O M#>&\2=UE;]%UB]%Y9LE1-#0QX<0A:$)BW OQ9OU*QFZHH:_9*?D/?&ZV8EP M8>XP#^%U8 /H61UXK.QGD*D7>JYME_58H9FONKYE&,M72XO&T"LU@N?0N\>S M8KA[ABW*2D+K%";43ZN/ BJM5'S#@#U(!AV"(K S8P?_UH[%Y&E"'X/;;G)R M%$J9B<"T)EY^C,:*90G<1O'L6OXE!Z-:BQ>[V]IVHEPD,V0L,K"S)RD9Z$B, M]:Z"VZ #QY(/X"K_ZD&\L Z/D3YLCC5JIOKFR:]A2VKP9S>P9\LO_H+>@?*X M>T!Y?":4Q]T#RN. \KBI/ &?PUK'OLK/&S0 A%ZL+"4,9,S6*+1:'1N ;SO$ M9CJ6;9:7A:-05:MIK]N/0CILB@:V"J<(9VFV:IA.$'^QQ$JL[88]?;;7/!74 M=F](<3P*+ "N"L:8\-SFC8ZWK$Y0A*R1NWY+I#?\A^;)9+H&QR5(9=FP[E$X M_X6$F^U,.+GF GM23&7#<)?G):P5.S;^33Z0KCA4*M[M&;QZ;S:=( /I"1;$ MN@1D\7(FS/MV*C"]$5E$DU#PGIG<9-)^R!6CG+N!1E]6S4V\?0ZP=K8Y"/ZI M0EF^>+/E)D]HLNC'+[1!0GW)CHD$NS*&LB,#>%H?J4,;2#"VF+A(;VVP^DQP M"I0 '8^\V1L>!&<[2_PLH$M7 7>ZB12:R8!B\N4*4!T%[/2SK,4>2X$36J]P M-1[\M)X1$_C+3T\_G&=3\!F(&@0A M?[%)UW,8FF,+?3RP1+\.AX\:5F)\@OU5]H3@<-;9AVCR0#H^UB8AR(7UJ(CH M"ZTD]5/WUV[;QH5HL]Y2%R[:QYB]#(@SDRH225'@Q41 #GE0^"I.!$CQ7NY3 MB'PGK1B4PM4==N?&(P]LN!)R:W)R#Q;^7Q%JUUA!EKEVCT&9,@WBHT MI%EQU)<&:2]F886;!E0$<6,4U F\J3)!WMAH#SR*"+]]CE\!4,V*;HL8#6;X![VG+3%LR!C M@#@\..Q7S/RV\+FE14%QX(;L%+@EML<4:WQU>GBCXSK%T4K8IJOH?+/"H!IR MBNPQ\[B=)V],D&Z:LCFF@BOE*:" F*FI/D<*)298HFHO"1>OUDQU3>15'C05 M><9K0T(0*I)4N6^8E2F3I)T8'H9,D0PN9:^$@6W?BS 8V=H/)GHE+O7&45%R M-V%[AW%=,NX %XK/4ZR@'@*+N=,O>N%MP /)#0VB:5G@93?76'7%M-U54_B@ M=CNS6+IFC1UCBUCK@]%QA7I98!,$\R65GS0U=[?<,LQ6A='J][?@]K)'[W@\ M>M**8.XX5YTT5O>R#T*(7/X^&&O$@"AGG'VSU2N&&P\&YI\:W<\E#O>/L6+M M(BV$]?10QO#G%T8J8[#.P4PWT-[R3C^&07[5T/4/7]"*?)E<"EEKFP4'I2VS MSGN*B!'D(@X,49SYO'-/BH^8ZDG)=Y[3SO.-1_?NW)M,CP8)U\ED:D$:)X2+\BS;LEK@E4]6[/_TL5[V,"&I!P7AJ@@YFDZH"=E"QU:W9+P MT%(Y5@3#K?U5U//>]$E-B'KDB?<;Q&J=(@U;87QP_N#'V<5V<78X)# M3VTCDV#=N%A715:?#[2"7S!560;B)*0;'!; J,R*% E!+CGP6I4KXD)P?%?A M0GC(?3@"5(/< 40]@%U/9E#N3 MCT,=24A"O#CQ_^>,SV=2#"^\84<]RD'$K;L_)C)9#"PT?4 =:CV6Y:8G ]&D M^3B%/S8[>\X0(FWXE*FRV<9;$O?;5?+PY^@U5]$S=.=_E16U&@F95Q61'DS4 M$X &DP-39L_9<;E#;>(W!*Y_XM[G&"D]SE!;*CJNDW(E*#[AO+LJ1D9G3J-)3VYFT7UDN EZ=KNNFRH8@5 M:+42B[$'P"Y/'-V[>_N4_O<1+CS\]S&!!:U[,>@6X2G=8P' P%M@OLKI"5:) MTE^RM^E5X):5E1A;=^\RF9WC52*/$+J[3LL_67G;!'!S2OW3KLK'7<\X*@>AF0XFRN]/&+-X0X& MYN@!CC<@4MH ;$Z 5.K! UHE%]QJ(7BO6.3XXKJ,%@FEY0,Z"VX*P>BN$NU> M1P1?:_M""*SP2;[/5A\@FR0SCL**:KJ/:-& M1[;)*87)FFJ=FDZL:#5[GE7L/D2> ^UM*>29[0]804 &D_<\6_=0:52 5>O. MG,7>LV(QS;)JMEYJCY[FG KX,VG9A$L ]EB>)MRJ@A=,-DG;NN*.L%?AAL+) MUQ<('8SAD4Q"UI6KDE![+V,&[HM\$*?C-)I11.I+D0&[<)' M#V1SCE!!)^(]<=L!\5QMI,+%0"H)G0BLP7<-.<;P%*A#6].^GVID"!5I1>E; M)AH2U(WK0F_(=XWFI!"4Y_3=$=,@]Q!\3>'-%V4KO_.2;"-Q6\FN_0WA.@"$ M818;G."WR6]BX93!SB$>N>9&L/.NZE?$<.GV:^)@PONJYJR0H %\]BHJFL]J MJ*,QN)5P=)*$D2H478,*KLUL*^Z/4"#^ .MGQ0[I)!T:5W8@IR+>2X"PKV^> M2:A+Z97UQ*@DQ9V]X?B3G*&OPK^_Z9.:7/2"!JB7C_8ZD0PC'V)*6KFSX]O] M($!7A?5M" 9$.]=$O$P0E!KA2>1N/+*T_T-X,9/?,: M(DCA;F,U9U)M.QW/<'Z.TQ"8,2/4'LP2#P_<*4G2BQ. M?_,H1;,B&3>LLDO!^1@3(.;>XCK!E-NL,-P!]=Q96E#]$#8]DD0!W*T7TO9, M>GCJBX3TG92?@DE!8Z3Y@ELZ?4B$#(5HY+5)X9R B Y\T3/HJ&?,GD=*WG30 M$#=@4MB(,U01=/&T4NEY9^B3"_9?,!N%M5FE@J*H%NP=0)%O45# _Q EU(PQ&=7UJQ.M! M_J]5_GL/ )F*HFLQG6Z]&[2Y1*EOHO,RGPN44L5J5>'%*;D@K. 3#0 L: M=W(_J.\1ODV?_V^S%)![@86/8$_#-0#"6E&E('H9W$:L-M;TA+5TD7(C0+SE MDO4=J!3:]7)!GA#C1Q=OKQDOH0;Y MSJF$ Z+NADZ*VRP'QX5\0/+[2FI*Q]GIK8R]PDQ+W?^*>KU<)N+9M? PV(I2 M,_+4YAL]HF3C+%78LTU?O.-O/L MO,=U=J_L;=<]$5@%+:,IHA>)O4\^==#HB6C9]K'8*_PLPH,A/EX-#M/ M9^_K?C0D?#WUPXK]F @GD]73=57+G=X>I5WF./0%*+;S >1-MX"]#S/^G;Z* ML^OW<5FXQ*7KML#L%M*WO*RY_)\(89<:0*"N=EG1^,WSX$W\G;-?HLD.H0TL M%/RJ 3_CO?,H!Z_I[?M-]'9=7:0;)B@'OV-A \7\47_X3I?H187E^6^UR.D) M.3>U7$KV??8+^N?_3YIM%4DF)/ZORTN&U)XV35D5Z>8H'NHQ!J_U!J R& 06 M8!R8?RS=5)7KFW'3E]!R(V",Q#ZJC>#>PZ"F,?MV;76Z],XR[/>9W>_@E%%V M04XLRS(*%&$\M$I:K0_/3$;,"^,1Y MZGQ0B1U=/?1*-2E:.N;]P)CI8$&ECY=9R5%#T#H_W)R M1'@JN",OIEK/&2H%"]>L*2 @F=PI.%3_=KX?+$RVDJ"2\Y4K3H\PGPX,3:^,4I(&E*H1:!0B!!]*C M0%-OO5040N-)AD&6 M@!S0$UP//7(M):VX,XW5"5$P=56X0N) ?U9 M4G'Z[F SQR/;RYZP3#+";"GC2'F4)_' M$).8N,H67W$C3$(#7HF-6Q"QPE.QJWW M:;KZ6OSYFSXIN ':5T"+0)$4K896KZSPL\;QJH+NP'A@6=5.SP;6$^?7L#\] M"50!!P,)L[[O5D/[5R?8[#=H&]'^:7G FAFWXJYE@!'6QAI0H>G*<4A49(F4.. M^/X3E1"1I52 /&27"H1'Z.)FS$6+U8JS]SU(YU:-)DR!?'UJM@@7<2FI R5M MY!^Y1(!^)K33T-NJ\.;%I Z!6#59-1>O#W_)LA+DB@S(KB=)U+F;?=K'6J=; MEV/;_*.>Z=/67&7^F&3BNE%Z&KWM,EE%NL,12<&90HT3SQ;(OG3!GPJ9,K&% M225Y#-E11U5'QY)C6%QH<5G L\ZSU2YA\#G+D)G-^RZS*IL*$"SG5",<+MY5 MF6DR+?EN%V<^;9JF:EV>R R 69 _-A!#Z^PGG3.9(VXXX5K=DE\SQP4*5VKO@%" M1Q,%J(SFS? Y<;;SQ M#]<-T67V,\7$GJAUSH$6TZ[C4\1HI.\+M4ET>''5M69.) EP>LWH[5%WT\,$ MO"3L.V56W*?OBML0M7;A(M7Z^46PEKP?9]+D#LO.M!,S/M1L%J;VZ,<$IC>O M8R>6((HUD_Z^>?N+%/F3_*/1AE.CS^M*8I/4VM5E!6,MJRMHQ-X+(7C<1/5* MGR3"8;%S"\[O4:OCG4MY(7"BW%!^7*@J:[T.2VJ8B#P?]"^^E#%J0DMI.;NL MW*#WJM]L#9;5#*='55,O=%(D=!1Z?RWCW](/=Q0'M": ?T1![R)G< M,-D^<@[Q8EVIQA9&!?,I8BKFC6WO*YY:H>N$$8AA:,^%$V=UP28]/MC)O7M' M#&P!O8&E"($U,AZ1Z2;.HGA"1)'JJQU#EI9^6V802(W_ W\[^>YV'TVL4;*8 M=+XXLB_LJJ$M[XO;WU7<0DLGK#\IXJ/L":5_W' ^P0/!_7(?H[%3V3 MQR(REZ]/"5/ [=)CZ(7KX?3&X_,L741/F27O@A+0Q'-KU0*>CI/;TUOWZ>Q_ M%:[LCM3T@T-J^C.EIA\<4M.'U/0A-7WEN%:75TYB1DPFA^3JW+S!!99V]2F< M$LR;K!HT4_#90@C&X0:2(F+T8B^?@V@>WV@%:$#;>ZE;D2J'FPGK UP?JUEE>74SDC*!5! M\4R[5[+#':M)>%99HHFPIE M4[#'SP4?(I346#&9<]<)1/HM-6%S7=*8DTU-^1_6?';NIA) M47".OHQK,6-'05P3J=*ZB ^M.ZX1.LP>SLWUAN58G@K9@L;83?' M]^L@.KSIDYI\$ GI(=Z<(H.H8=]4R:%=-O507:VLA5 '$;@!DP(1R%@&=N,= M^X&,5T$G$A1Q"]B1?"7_>=WA/R%MVP#Q^F;+>AKQHPB' MO+1,(W2*MF0?K0A8TVFW)\D1UP,'/=V%W/,RO 05QS;QLU0KGR^GCFR M^"Z27L1/RZ>ZM<1TP<.)+FY)'UWF4A:.,")B(^.?6DS22# DL@*?@U(^)W]U MA>MG55G7_LV.,KD5O-B![?>0QS@Z+R\1]!F+'R,)P0N.E"@>TDVM5>T< M= MKSB8\)+J8NGO0;%:WS9]*]&@X^AEV:#SY7*PDM;BIG,Q)Z"2^06M%=)<9>6Z M!HU%I=6M%8#G]W2 Q@;0UD8?ZE"WE#I[;Y^@C$%2ZZ$P0)/8%W 9,F+UM:.8I0G,IRNG/5 M$ GG4KL]V\]<"DJ7@$+T9#\#C!!H9;2NC*[#0&&HDCY^356'-WU2I+-1:9_V M9M[[0K6$A:Y2 >=0^AXQ%Z5BN:EJG?/(&ZXV-L:(M$ 5^&R?\+=[VOB6D?Q. M04KC<^DLL(-TU?=T.HI28 +C).AJ83_:@2[(=G6^"@G?D;S\]I"\_$S)RV\/ MR+BE'GD;\D2A$RP M+^ZW!D[_A#[Q2A)1B.$ZXGOO:54A^$H>(##LVG[U:?>KF--;5VS04:;#C"W/ MR&W'\#IR -=,4&G(1%JM UV,^ZNXVO[P25U[7^')!Q1GD(LWRO'^&FO9R'T! MT:'"+<1XM1R.9V@MO>7<(:8I"0Z-7OD,RXR\* 70W_;)Z"\P0 QQSCTUF[$LT*\'5N"BYU*K2Z:WL]-H=)FD1*'76605?K[)0D+NRSF%& MGI"GR)[<;F4Y+HP$8@_'DE*2AAX MA'KI M= P:,$:\6\H+A,PT #!1!JB8-''K2^,<%1Q-A0TJ_+6\EDFB2X71-E M"OSE^.VQ0)]=+KC+_<]0_7YYDQVD#O3D-VM;-^5R[QF)A#6)\;45#2F)$1VV M!9S[O]R+[]^^C4PXQT$)HJL &&"U9KP'E=I@PH\C3A2U0%[;GO$$U7J4(16* M;SX(C/%7O2SFMCMF%@C_!D>^9=$:B^C1&\+,YK0G8=&8DHMIJCM<##KIQ>!Q'X_HO!>E"Q7.\B0CWXX//2DB,]H!,1*Q M[')G$7L8Q1P)]U,*[VHRA7]B/3&648!GR:WN'/?2?LL8[5[%=KS' \AS"9<- M-.TUI2USQ"U@V6C"AVE+H.L*@V7'N6_CO68?CT1+,B\8?15+D [FP75WH[]V MT^#'1S_]^/RG!\=HTA4<;'?7BPGA.LEY!;?46:*LJ,]_PMITK MH!5QM G]\BNNP+(?P+JZ&J\DHB?HRR2HC=#S91J>KP+'5,1"V3JEG8?M1>5/ M*546"2 O8VHXL/K5GNI<_;[^33,.8FE1@XW^VBCJRV#VR/">2E3-USQX%!ER MVZF$_/!%G8'/?ZROVW]-P-P'&\#7P?25 M5++&=#/U=T@;""1S97+?+ @4&C8B"J=QI,=T%X-['P.N9BND'RESE+"]QMJE MVX[.E#=H\3<\E0=W!BN,.H+EOEZ4P9A*VY69![.[^[)MTK/I%*%^7#-F(VSC M$5&X<"$;K6>[7W%C:T_5GDVTF8\16WX0]S]6&FGNC1PD;QW=,N?LB*'?T<[8 M]MB]+=!:7<]M;Z6)RTPZ;IGA_=ZO)G*_18_W6?*PR+2];(Y]1=N;D#)AQG>Q M0'LY+SZ9T?E5&IS7?3--/?+#0+E!K?[*)D\=),_!)Y*!!DO[$$YK,L+H(*>2#A'.2U=1. @S XYT .N1.>&^330E(;TK\'$0EI "V(+0+GT]^;0Z;3[[/-R7ECAKZ!#K/4FI!J$ER[08-#;K5H M[;!,U2X &FM'Q-IV0#1/=SPD'_5XUM'&T1"FEH:!6.P$4[L/VPFYI[DB70#T MX; KXN& _XDG-$G1L=48/:'-7C&KWA>_;3L -M\= #:?"6#SW0%@?0X0N&UG2BZ3O"\3'?[AVG3MI!#B5#\9'3%+ZSZ$EK:--SMCZ(^C@]$U^P M5KA,GC:4KD#C#@R8M/AWEL!OSZ]&T?4QNTQ#!L>NX'[!17S+)6_!\<9<=$_WL#&%NX/Q/I(D?+@>YT%S/K M@QA+L%:I? +&#).:W!=ZZ5Z MO8\)+L7YHD5FQ'J9.M9+HB"L,;5SA2SM' M7ZAR0.WP,@!Y.18^_A$)_7;@OK8!RWI@7\. KO$(N?-:;VLU/>\X? CHL%U" MD*Z"\H:3QT>#Z+!H"S@,[NQ/B@Z+B4+'P,)8-P30,)R5<&=(@TSS)Q+Z9/KJ.,BN'GV/N5N)H[S":Q;O;NCUM7=*<2CBCL)O(2MG3IE M?%J6=@V7S*$FY$]N4D_>N])G3BVV@SB[BC)= '.^!NEDAP=^RK&KQ7IE63\E M+X%4J/DF:&@!$OCC(VU@,1X]HC(3:8@PX0K*J-MXS,EK6,LYY1K*:=IT[U^>(.?]887!(@-ICC68272B/"M7 MQG,1Y&I+6W:_KS54XY%\ ^3I($1_\@E-EBVJ.EN4LB/SW((32YF 1^K/RQEQ MK&-^Q8>D:BD.%RQS4O<\FF]M^VRL86V#&Z62X#-'/_^8-2UZ[?G"Z:\=('!P R-@L9Q#]K8=DF Y(LLQXK)2R15D AH M*Z+H/A2WG3V\2Z:I8?PI\O"!S9Q$Q_#QZMLNF:V M'.9#.&SIG]ND3UHFO:F.RPY,% M%MNC^6Y:H'*"23.S=.9]RU0B=J"'K>"OQ"A$J@H[@Y3L2X7V(Y#]F+/]:!>5=*D M.BL\%$G[5"45-19:-]+Y"#.KOFT2=9-"AMENJ5:%F M<":(N'?W]BE] _[QR!,6])-'T#)N75:">VM"Q3'.;:,QD+5V7]*B-E<_%G?6 M_'?7IKG/AJ5IW'^\IWZ/R"1^EU0,@/_"7%J)##[P)G]FELMUH;??I47ON.FW;?@8[=^30C-\]B. MH2:F2V&,_XA2RX$2RWWR@P+>_P)]AD(8CR5:S;X"<6\#M J(1Y:>P#/_A.Y-7# MP])I8**HC2V,2]C8#?\Q'N7)92P$,[GE]6_;&X[<'S:4SZ.TEUI'D:T)0QW)B:9 (@R-0\D)2\6H1N"M0+D"]_V+K$)6A9^A(:M^LZ: M_QU!D7Y_4VY1;'MKPX\N.>_5@R%2 CN[#M% &1TOZZE*#@\#;@4W6I=Y6%NC M$U)7Z9ANNH:EA$5FF#TB'J=LC)BYV'Q\&I MT,6+=GMX5LROP[ES5YIMUG5-SIT=ZU9'SHR0G,N/=>3BW^/)M37&$9%/? YW M[I,8[;_G*FE?#>Q77<_=L-5*WKY04I"[[3+]X^Q6)OJUQFOW9*.0J%W-E_IQ%C@ZGRQ6E7E]_Q3:$97!\T++/T7>,1,G;37TWIJ!*# M,[NP(.N%>'C>*SJ&&U?[F]GN>^W/?_&FXG: @R[JPQQ%PP?X(N DA9\_4X28I=&$F=J M>" M J6_,5=W+9=X$*UWHQU$Z/(P;QF/^#5TV[&S*&TNNAX'M62E^XOKW$QS M4W<%T_4:#)S2>')D)DE.. M!B!XZ@,?!#./G=:-L4FX86WC$8\"ZNANER([@I!AL.AF3*X00YT)[#!;I;^! MU3(3! RWE.1)'D?/"W8#G"TEP45GJTRI[T 3&%V=0<:"$NUVJ.D9HZ:_^K=A MZV)C>^^BR9J:PQ%.P]BR6.+J/1]UJPU/*D MRADBA!.F%R"MTE)*"M LK5-C=>-#'5@V">F)VH=%EL_6K\C)[A(?6>VIT^A,^IXD99-V+@-0/YI];V!+%\ M#N'#+[HA?=!:F+NV"V!4VWG868ZY/)"1><(Q /0"YQ>B/T44CERNH$H5F\:3 MER'647(!IU)7,_/!ILYL*1SERJ+GV8(*GQN6&'K_SL:2FR7G M%;P-QKRY7*C[;?H!?/1:9@O^=,]TVR]Q&W445+!T]U&K#GKD;D*YJ\Q%+@84 M/GFN#DI(R3/*VL&(V#T+!,,1WPL9>YMGK3L!R:5E+?FP"O]V6B$%O05W4/;K!>M^'/1C#AR(N.Z MP@>4O8M4*Q54\90N4$L!%4^ YV_$LBI<0YJ^^ZURE5>,G)08RKQG=U5FL=A? M=-P7[WS?Y F]P[3_H&D:"E_O/:GW7C=;8&JP@[0 !IDQ;=/*#(#-@!8KYA7H M49)#X!RS)@\JZ46(T6DBL*9@*%B#9_1F[0*R@E,(*GXQ?.7W@ L'1;F5F-D> MF)-SQ_P=>"S- ?0K5+DQ'TI\6['<)LEH ;!L>T3K' MNM"H2);I7.+/JCPQOHX5_9?Z(5&C/B(X:%)A'HPRB*WM&%H15,32H^7_;^_* MFM/(KO"[JO0?NB9+22GL".]+,E4((XL)0@J@<5Q3>6A!(W6,:*:[L:WY]3G; MW7I!2*,%F,Y#QI*@^]SMW+-\YSO"SZZQ_\0K@KTM TKKE9AP[";!D3$[!']0FD/:J3'96>8>+)Q=G!:\(T910'YS.*-@T.H&# MQ/+S"8Y\/IG9867;6\2+_NQ**@&,$5&XA)627^$!40.&=D9-"#Y0-U\9LYV= M4?DAPL",I4V?2>:8" A%:;C)^:4"--C"SXW02)]1REV4.FA#!>H/,HF&&?(+ MDI5R15*6.U58MJ)H&93;OF2JF=B8)'^)V?'R<%.-7"WZ#((,XF@6Q0QP2DC3 M62V^R8HK++F)U/" /*;I.\OS'V4W2UG9.K."32@HFPA^P@SK+1)A2S%RO(0 MDN[&LX)/Y/QMR?0XJY*3"4T*?Y)$[M=)^>7:-2\QH^0;FBDM\=&MG+65+Q:- MS[N/X0(W@#I0R=6W (Z!GS#@3-%X38*OB,VFMM0TT7A_P2)Q]C1Y*GU [V%C MP6R0#-J38$RZI]J;\63XB"!WEAM_G48I7*+3(#4=H_,;=$>H+F#'S8<4\51N MS:XM/Y\=G6H.?%W2QF]Q&@CI!&1V G)$W093@*B4@,S+]$*-B^=:9FN(7:'1 M8#S7ARF;I\^L V]!:^94QYLL\UL-M1S&>FFJT1\^3S 5'LC/@0(IV'#B98 K M8BLOA^K(HSDF5!1/Q\[DX0EU$.HYU04;ZF4NY:/L+'$N):)G=C1W_:[9=$P^ MM5+/OI7J>6:XP>9D(Z:1)L$S7%7;6Z5H#S5&'-N4Q5PR0V#)]*^GA;OR<^QKFG%QHCIHBA=JB#6L98(PWHO5%3?E]:!'8N?"/ MHB9NMP:!;&_]'A0(NMI2[G8^#R><7AC'_ARY@Z:$*7/+$KAE; [Y2>5P#/VL M[XQ+2F1VBU,\MC[P=!Y-I$( ZC<)M1H).<&U0,RG>>IZHTP+^W]G%C,QAEW> M!:!NW](H/)S:5[DFS#-OP:O'6F@,Q(:IX=G4B-^-]Q>O0>34*T3.(R%RZA4B MIT+D5(B3$$L<.X.*\JEO1 MEHG?1S")4",N4+_=EPOK-*?_S$>^UQ9&8Z5VIH MIMM8(C>:[]P3RR?=6W[.X>Y?;M+3C)?%3^=JG2Q/@[5 -ZG/(6?B]Z_)QILI MZSP@:EEW@!X^$SL;[Z9AR$QS6]V4H$GSH"3'* _NA(XY)*8F-I80IQ-[0*Q, M$/.6R\'433F$!=J[366$70XAM;&JW4Y1H0FHA7NH-%FZG$@B4[YH21-KR071 M)GZ" 8+8/X_]V8433?/L8%I6M$M=T(]+QPX[9@L+]:6@T3*1V9PL0EQ[:ODO M0E;K*5=Y(;W&\L7"Q0V;.,R=+82S).:86[[((@FX9H.V(L?M&*?Q!,- W["2 MQ]QM3/>%$TQ_)=\,A(+7X 7QFPFH\=LXP?M5Z@WQ( AZQ6*/6+6"BPWD6KHG M^JPW3]W>DHJ(H6&Z8\!FZ0N7V@@TJJG._7+!8':3EB'E9&ZK"] M9D(8LQ2(MB,6>)52Q\ZV%3*Q:^\D8"#CY6LY%FEAL/];D# MS>Z0 9DC.>S%&L[%*C'M-,ND5KH-SB--D_G!.K//K'& MEV2QG*G5]0]Q>81?6S3D\V!*EY=NKE?S9A$F]X:F4+ 6RWPF"PA(GFGX@3%57/P.&+)X] MQ-YAQ4"B05*7LQ@-9YW:XG?;EQ\.<,K6 -VK/O8H4P#6/"J'$3GP,06MM Z3 M:6& 3$/DDT3#+[D&C-+"J:R+4==/1OZO-,/F+=92RW)--$1$OL O8XHUV2#= MS_V66BKZ]]&_!N7B*/8P4"3AY9P*/B[][_1/./E#Z4REA,JUE0R_RT977XJI M>R]3#UD/L(:2?8;*DWEZ$<4A%>60^OP?")V,0@&"$N69[YWYTR_XQTOL:0\?AU%G MQS0*AA-?4M3C '/Z$S+B!,\AKR$K?>?KKG-ZZ2&.XO+3%)-,*$$T3RF101LX M@:.J+_R+""XH29R!$$97H<=!%2BH1XQESW(!%83SC$IK0NOEP M%V*W5=4R6]..1#SZ=(KG]D:.MYNW](,A:%ABO^(3A:61L"\$,!V//9#=O+T[]0> MSK>9S:PQLOQ8UP>H)Q H1E>1.%'@V^J9X-L7,*?#U7]K2G>'T3V/2EG2QV8- M188A"I*2>7MF=5(L\$>SH]CXH/XUV(-G%?;@D; 'SRKL084]J+ '-V.1;!<9 M&ESVOS "L0C5]M;M-J<3[W1=.8%(=>%1)8+@.Q4]26G[E12DFUU$TZ"FDHQL MAT^"]+&3(U52>0D"FG;.,$7TK6Z\XQ#B6X%S8]$4-3,4F+@ 5EU01I2%F4@C MBC)8;LE#'-O/MK=VKG8U\X(D%DDQYZ7V?:4 MO1QS$8'@<6L*:*4%S&$,8EK.)4LOG;;A9LC; 6 MNW^A'TZH(S4BW.=29J\ELZ2AW)94VVQO.5CI,+4Q618<0IGM"?+#2H&R5<]G M9(6GRGD#EQ&,E(GR\V.GE9)*&9GQ"@(X]V8+4D[D0E2G4+Y[3<"W0"GC-M-5 M <.ACV=.#3Q1):SD4=,4^I-*Y:YT&H5S2/6]I]M;?8S!8%-VV5WVNIO$?GO!6,#=Y:..66Y1#[;0NKH'53Z6\J*N YTTI"KVEW_1%0I2 M=)<5J*#8 N*RLVM80DF7MK($A+>T2#N*RLVZ.EFI)XNU>OFYX-1AV<'0]SH#0J7$_PSL M\L\%YLC31=ZY!K%'J)%T$AG("")FSNK!KKI#CBV(ASWP:39\4#UFC)0I# M FFFT"1K5V@'7?:)<*Q8[&_6($P=2FG^QOHI\=["ZXF'U:N_KBDL.Z8/3:C$ MQ/5,1J=JVKO>0Q(_KPY^WB]M8G>@[#FHR6.FC/EO!1-P2P"]Q M8>&,^E/E7W;_,RO(9)>LJ9L!OW"I0V &_9F Y^R:4D MU)_(4.Y:<7CSKAI3O(W-A>QB&3Z!=/[P8C\ S=CT9V&*(V( ZMU(M)S\ 4L\[M+^/R+8 97PJCF'O U$N6O_N7L/4@+M@@(T>F[#"PR_!.)A,8 E(6/CM6WCMP21" MA#9N@L]1_ 7^]=EKI'),W]%3X35>XZEW$(?!B+9)*_GUJ5?3;'1F,O6E@[=# M 5@-C"5%V9@$,;'MJIH7^HOYW&@4$_)A-@M\0VJ5+Q(JL:>L&=W>6G9*X4/! M]+?0A[F"5Q\(&T_3AQTTX7FLX^HVO@;3N19 \&!P:I[7D[1P.NM[>\]?@7EI M36LC3B_ 0S_RXR$:J3BA&Z@IE ID'7$SP,+S"K#P2("%YQ5@H0(LW!]@80G5 ML FZK_X%4V%E34YO/OB"QX9Z%3/ND M*_$5N#KEJL0D0ZMJ]C.L7-K_TSZ\ MQ^0)V>PZD;V-V,[39B%=SO&,0S'B&/JNJ(RZ>4U51K,M?J-FXPE4R MQ;ZF(M/!F;BF;2/K5P*X=".,FE+*#@1LED&QN=[4"] 3#7!:A+SN(!S-P;.( MK\"TY?1[<((I[( *OV)TPPD6%Q'4=8^J^X M]N9"0,MYM\ODR228GL.#I\$Y^#QV ##-%N)F0]P@QM"?,:!G;/>XI$_2=M'< M@^YOY/5##$$*!VQ [!MQF'S)\L3<8OW>@W:HUTP+-H:' 5F@[2 ME..!R?'/>5?YV"_*'W%-$0EE"Z0)$;BD)."B$%@6UJH.IRZ!N="1%(ZDDKV7P9"DG:II@,%9?1R%#:4S48?K[ D#--;Y2AS"TAN"C))>I1 MQ-*ZHH5ZY8;U@58P/U:,!M&!DVU7R0)*1.QO1U3&/ZVXQ)9J+M3 M&LX1Q:QZNN[-)T\NGP14#^#QX&K(9WF]1 IB*PN^8]0VF5SI#'AUT%=\2'+0 M7Z%;C/XI,9A(-;3D.ETK%^Y7D' D74KFF<^J+:\[:&I&J9KJ"!#9.S9W$&S_ MRV?$ 9X=^YW%;Q3^^^7>6VW+%1^2;,O7L"T_4DTVZIV._^V:D RH+R[A%F@< M&[(2N$ ;Y8WKG%^5ZS&SQI^G?%#1^: EZ$A0B/$QOKB(T1;-,W_TK#2HH,']7_ M%F$3K-1&RIA0&]#KSV=H9H#4\QC,JR86<5S96]2N678*Y+>W/F 2#KMJTI>U MZ=X'F6'P4T__W7D<<62!__TU&G(729Q7QDJ1J>#2(' 6S_Z=Q;;^7= D0HN> MF7FR(Y1S]3\)9JBWZ.^ZS]9>FG2C@W$E5OM'ZFP 1_YK, TEISF_?.JU&LU# M[_@ I#AL>C^P'VW+&''SPX[71: M_8'7^L^@!=OUI-4[:@\&K0_>_F>OT_A4\[(/\'JM_DFK.6C_W/):_SYM#SY[ MA\>=#ZU>'Y_K-7NM#^W!<:^_"U8U_(SO..W"GS_UVH-6SSML]5KPZ$\-^#Y^ MX[/7:W\\',"3O:,&/*H!CP71&MZ@UVYT4(J?3GN?O797O1?%P*\U.XWVD;?? MZ(.LIR?'W9K7Z+7[[>Y'[_B4/G3L9!ST&MU^@S[8QR\-6D@W.BWO0[O?[!SW3WLM[Z31_%?C8PL3LC""D]XQC>BTKZ4X:'=AT.8/E6I> M\2&):D8^,M):08PN&4; 61MGKW"AL]3^'V4S-.C$*DY#&A5_2.Z,Q# L,I<, M%H78,A!$BYT*"0L[M&3QJ*UW.':<3H.8Q>]9'V$Q-VK'/.0A4-GXNY/^ M%]CM?7BVGU+)&^6!#RCX2]&2_Z[KN&Y#;/&BPHD\$D[D1843J7 BFTQL<>>W MSHET#T94@/!M@P:?9JL2Z.Z?4M('[)(Y=GR;<:YF-]YQ=1"Q=$,\A)PT3>PUH%][^]C'ZP]4%67]QXB(ZZ M*%4K/]#AM93'\B\H4#,_*%5@5,NRS[O'>0:E9<1J'N,T=__YP[-;S.D][X^? M@_B*)04#>'+E76%M:,T>!RG?E5DQZU:XSPG.7CXK,_Z5W[%W[/#NGW8Z![WC MCRQ;HTWQ'U!0_9K7[C:?.JC*E5NLN]ZL*[LOM>I_B9;;P^S16XMXIQ+N7[U; M*%[&]SK+^E[\R!L-X,7=CB _QZNTLU9T-]VE6.1Q/M FJC;.!FV< 8+M-VWG MB)>__C[6VHC?5.6CVUN^3MR/B/Z">H[[9]'7X,DEU_25\L\MZ-JS:=[SVH@/ M]O.G1J?3:![NMP:'VUO-QDE[T.A0H>^#UR/=\<#4TN1'404W*GOWH7V*^W9[ M-M6RVAS;=R6F\X^S<3;(]EV)^7Q,D_R!,NQK(_TO%NB!2$!2JX *TUP:XK.V M$(A%!MPU2(B7%1+BD9 0+RLD1(6$>"2G;HT46[]YV/IPVFEM;[77>22;C1Q@ M+;$BQNS:V(3W:V.OR\GX1_O'+E'.\G0L^S]BO8@O&:UMG2J:TC4:>U\W&Q7@ M"(*RUWY4)XHL.#.2]3B.&E3P/&O,_.&.Y@")_F]V,KNZ*X"0@*_];OX#GM&[ MC73QL0%;!$[->8S,"&B/1/$[K,]+@P+#X3XBWZ]*_+<[G54K5>?,ZYU$QI\] M=.S^'I:A?O_+8-L3H(;^L=^3D:'%0%6H2;4NJ[0N#1. M,N/=!HU(Y0#6=TPG\[-).-S>.L9F&XC]/J'V*K,@-GOPG??G31R?O2MAB+_\ M[8'0[H\R2MFIZ[M1[0(%(DHF+L[L1MUY\Q?W5[L;,F!L58[T83!F:B D+<:Q M^WOTC1C%LC-1WYB9N V?Y>O*6WTD;_5UY:U6WFKEK=[$6UWK.HZUE1NF_/3' M@S@(MK<^2>'C21Q1P[4YN%VG/Z[UJMP^T/NFNCH?Z>I\4UV=U=5979TWN#I_ M7NNAK*O<='-VHN&7)Z#$P-RYH=&WM76M3(CL3_FZ5_R$OM5I0Q5TN@BQ5*GC6 M*EE.Y^GN7(;*C^;/ MN^KQ4>5'_;(&OY'Z5VG>-N_JU4I*_X9/4X./*U[)"WID-G;B^HTX>B*2*L?] M:]]G0?!X-R^O[NKHNGYWU[BLU6[O__@>24>\OY\:E]?^WX/^6XR;A"N$%NX) M:-E_=8%>J"F[JJOTB>Y[T:Q,I7J/?@?/A$MJ8,M7C]9;9) 45IJU"4V\$!73 MJU*6&:36DO\]DHTL%1DN MPL*7-H3C&+K%LCU:AA%3S<;&4.&C%@'=:T6PZ%\^>G<>S^7PL(&WVL_3SDTD-6*0MO0$5 M2#+4@@F.Z0S?^95/WHYY!\6*4*S^V_5RA<^T@;^ED.IW.H![0D5!T%#V;F8#+H@[VB[E\,1Q,#GXG]L2^!_1OIXV MN6(AO25"+#D&Y^?YY">P?XIE_]3KLD/YIK02J(,I(@PNT^ D<0,=0=3U)R0V MV)$BFHM%\[$WJ\U?:="DU5F^^EN#'3 8I[:)1??-DD$MAG!".!^#LZX@:54S M>;X4XW$,HD*X:FL*N3UXC[P2;E#A[4\&,<$G:8"%-!#"V2\X6^G%WYS[/>ST MAS,:@7,//7L()X1S0)Y]F@2VW*?/66?8E$T5D]G2FK',)**!*P#Y4C&>+_778AQC/ST'F'<$(X!^2\ MW^2#PK;GYSEP69DE>7GO7?E9#DPNG=\6K8R.>NCS&F64GO3NLP[B0VB6'9/% MQF&.&;]3:R!()ALOY3+Q7&F&FQ;J=9NUO08>R,1+F71R69^RT3!ALZS@G:]H MW'Z=N/20D]<;IQ["7+F-N/B'4PS)ZAWSJ7'I0"GD]D\ M==:H]GD!^H911C.Q%4$&3(YK*%'54+RDCFO>N.5NQ]1 RH%,P/J1^@!XM)&\)\D(@"0J MP H9<1M'9:6,>+8CC-CLT@'W3$1M0D+8IZ@'84LP". T;P('P6N3 &/9U%&7 M#!W7;BF^:B,QBMW&:!$B0\6";75#-3[:O00^A6C28\(>)\^J(Y-:KGYTG48C M7,N+*-NJ_3/I,3>*8'D,C04$!&,)(X%B!#=42E(3$SN@B MH'%?!%.%K0 ".H2^=12:*02&H!H(Q*%*NDSI["RNGL>$02NJF:@J?&J9:J-U M,FP]Y=Z;L9"L]P)62-;;."HK)>O-.ZC\%-ZR.$#+JOYF3J= MK!SWPDB])K"D& &=#//YT#J=#7W:7L *?=HV MCLI*?5IA1WS:(^EQ(LB0R5^&2[Y,1=Q&%_A8K8;@X2-WA%XMAE?,Y9,\!Z$Z MME3-PHE/;J-UDX57FP=D/N9,@ .'1SFCY'5 MIXS&*#Q%UG>7%4&5L52"3-D M8,WUP^?6C 3(9-(G&L?($;2HXZ4A+8L:4^YB#B\/-_F_Y.%QZ^<1O;T/XOPG MD4 WE%AF&35PAUQ []=XABJX@5Z\'8!1!G=82%1(N&;?^WVOSZJ*5D*WG&% M]Y_(N;;')$\^,V_^62H8C: CIV,S>ZSIV:,?OD544J +7RUCRDPI;6J-[?#7 MY*345P-5O>\*4E\I]']02P,$% @ 640]6#J+C0!8 P /!0 H !E M>#(S+3$N:'1M[5A=<]HX%'UGAO]PRTSS!!A(LS,%EQG IO'6 0;FCL&6C MUI9<25Z2_OJ]LN.$3;?328>DZ0<*YECV>?!A3]N-NQS=^+@'V5=WQJ77]V)XNG7>P"=[Y[JM6++@>0K^7:PA81A4LZ![6(B.\736T M84,EBULX$(>N[CMN!!F1">,=+?(A8/>;AJW06F1E6VMLSY>+X#!V)R892Z^& M7XM>]E7L$ZW M,8G?*ORD6V9@,A^]9"X1Z#II>Z0E"5\")(E.VS:DO!#(D7! MHTXH4B&'L-\Q38_)T9Z.W!_"S/7]S6HRP]?&JU:O5=97$\>IZ_1WIFNO>=(3DC,A2&6DEPA MH+K4*MV)':SO/\$_F$,6DK3>VBAOZ]KKV('SS8#/>L^/J;FEK K3Q0G)\M$; MF*TFFS:L?'\&-YD(G*<'_,YB08AX63^5=!V3Z7Z_[V8?2)@3U0U%=I2L_,[$ MMS ]%_CW+'B[ A/02Z)^9^,),7VBL'[6!/Q)>$'D585E\++T/R]^J'Q8I;D8 M_[CG!(C\6:<#P+)VE&H)/E(9.I\Z)X_U5H[H# M^X_2[56&J&Z;INC^H-\]0U5*GXS$;GW9H0^[Z].NY_BBP;ICQ#[_M+S=,O^S M$?[[29?2N!QQL]P.0M_J5R^ .OFVA5K4LAR(:1DU*\4>V/]; MYO2O.@XTIX;_ E!+ P04 " !91#U85GEX9&Y2 "Q+@( "0 &5X-"TR M+FAT;>U]^V_;2/+G[P+T/_ &NPOIP'CL/&9WDGR#DVUE8IQC^VQGLH/!8$&) ME,4-16I)RH[VK[]Z]8L/V<[8B>4HP.XD$L6N[JZNKN>G7K\[?W_XIMMY_6XX MV(?_>OCG]?G!^>'PS>L?^;_P[8_R]>O=X_W?O+/SWPZ'__/#)$O+E][.]KST MSN-95'A'T95WFLV"U.U77AE] M+I\$27P!'_U[493Q9/G#F]=OCX_.[5<_F02S.%F^O.[E]&P1_S=B6GYX\[=T M5,Q?O?X17PB3/[D/LO/X8EK>)=&O=]\,/T_C45QV.\^WGK[^N^/#_>&I=_S6.W]W<.;M';]_?WP$(QWO_5_O MY,/IWKO!V=#[.#@]'0 !N[]Y!^=GWF!O;WAR/CC:&WKOX"7';WUO\,OI<'@& M[QBQX/#0^_H&$@>'AX"3?#KL[. [^@ M80Z.O)/3XU\/]H'JP=$^O&'H?>E$7'*[G19Z?:'6]TX.A_N_#)'^=[^=',/0 M>X/SX4U&JGWP%M? .QF>'ASO([7'1["*'X[V80[=SO#@EW?GOWF]G7]L][W] MP6]G\/CAX?''@Z-?:+[#MV^'>^<'OP[A2Q@?AQ["-L#_G?,G\,*SP2%,[>"( M?G ,/SC%7_?VAV\/CF"==H?POKYW?@R+^!L.CK,YQ:4X\GH'_8^#P\/!WKO= MX?D[V)[!R<'YX- [/-RCK3OR@-#AZNS^$<4]QW+WCHR.D M$A;EX\'Y.X<.'W_5.SCHPT]WCX\&WEO83_SV8(_?>#(X/3_B?5Q%"GP-Y'MG M'_;>56FJ4+2U=D=T;24+GN@:O\,)P8,U_.?P=._@;+![.(1C? #[!!SX^[\J M?_[P?H>[89_/UH!^#$=!3L+I\7OBI6NYOMM1[(8WRQ];WJ_'!R SWB*#O'BY MO>V=;+W?\KWA $4'_.+@_="OT]),SEL\?+\-!Z];S^PJ#LLI/KK]UU?>*,O#*'\R MSI(DF!= D/K;#V15O#X_O?T EU%>QN,@4>M59O,?Q$9Y?;[_Q02_V/XKK+G> M2MZ@)_#RE[A!\L]15I;9##ZYR^WY&.1YD);._GAW\>>;S.9L&N11\?+UV8>3 M-SNO?\3_O/[PID'VRY_7/WZP#Q28E_MWOYM?=##E6,9I&.&O63[ M99 L(B^/QE%\&86^]S& NV(\W8W*J;<7S.,R2,@Z@4?CLO""HH!I%]U.9;AW M60)WCC-:7'BP%G&9X&L7\RSU\"=PR\[@-6GH%8O1OZ-Q"5<)?9'$,QBLC+.T M\.#9Z'.4C^,BHD?Q^W&6AC%_/8WR*$Z#";RKVRFB$B=23GTO*.'II5?"8N(K M@&1ZQON=&:'^_W_XWM/MI\]);#YEL5E=1Y$8WE#1@^?*F2<0Z'MQZ@7C,5R\ M*"A 'L+J@6%Z.NAV3A=)Y+W8V=GN7?1[_^CW!GU?B)OG,?P_3)^T]_G6;,OK M(4_\EN6?O+VXY)GT/5FY$ :FC<.5G;T7?6\9!3G\$V[X["I.+^A)1;,2 M7$1S;Q9,<[C442\@ULS7^3C:0#K M,LFSF;>[2!+XRX6'>BFP!% $;'V0CL$P"8#A+X,PZ'9@G>99SB-7B-K+9G/8 M0YL69!X7I3U$MY--/!AZ M!@2=E=GXTY9W#C_5+!6D7_6(T"KL=X*(SF!"NR]/>J(]4U-X7\^8F2WQS##LK\IQGP3 2L9Y9U_WS/89T&,O'519:@G+F("V F(')*$@/I MLQ?-=S;58['RM[S 5X/4(9\M?A4E\HQ(+GA6+1-,3P3=&+@ZY G"5N)9T-*& MQ1 -'NE?#BZB=+R$_^11A*Q$Q_IJ&H^GWAC9@ @MT%* 0P62AR:*IR28SY/E MU[%_'^N-N;WUXFZG IPI9ZG;V4$&W4(]:!^/&E\C_-D!".Z0+Q:7-^10 J<5 MT17*%#Y6-JOR(=.2EWXV#2Z9WV=1D*+X@Y^%S(ETOND-ZI#OO'P42WT_7,/_ MC[1^FTEI 3>83.(D=F_(;@?WMR!]XR3*"[JC4:<*8Y!(9<(",]7_*J=YMKB8 MT@4"W\PRXB=DF2B,@SQ&2D##*?,L*>BGA?HGJ$_>:"F?\2TSYHM''NAV2-T( MA ZZ48H%R"Q1M6"D1<&W HIY^%51YGAK\,M(/WF^_4+?8!&R)UX7J"@.QN6= MR[5OO;&/FUMW8Q TI%M8[$K2J/!%:UN2+LGRBU6;,"I)&V1>([D6YW#[RP5I MA-PX"8"9V("@:P^8Y"4H8Z#N\Z.V4@0"#Y^,4E#N"[R*872@AOX&S.B=YP%J MB-[[(/\4B3P=Q:%1MZHO)/I)1*.*#PS]GT54L!HI7Z01ZG8EO +T GHY3A45 M/-:)W"&1#+[?:R.U4@ZG*PT'2]:. M?W[Y;+O;"5H5?;A_GK_C!!BM-V[D#R&[ MVVE>:=ILF4_#$"#+X)TTAT(SAO-Z%'WT:KUAP@4G9)IH'RGHA7T2X*!P9FB3D4):B H2Q#D*(YP( MF_.L]#?:*61NV(<]2/&>BF Q4#3AMN4!F"=D6:.2S3?'19:%.!!<-"(@6#4O M>*Q9\.^,#(PXY6LM,L)#U"4Y3]FB+$K8.UPFW$*P+N'2 C99H@$=S4OD&*6) MB?'A$X=XDRABST'T&:A%*00C\/'5IM8\B+4(DU]_'_?7_WKRQ'L;@WGWDF[T M)R? L]Z3)V]>[Q_\JH85-^W3%^BFM3ZWAT"WI 00R'&]FP3 -3M;+V#.8,+% MH2$ WO!&_M\:_4=G^&^XX+(RCV'+'P8'_]E1[W1%*-*!Z7#XEZ%RL/ST5TN< MDM^"G3W(NMHODDTF\-;TXJY7]>$KJ7>^ T_5#NS;SDE,;@B#9<%:3ZM'\B'/ MKG']JX(6A=PK> 5HH3 G^.DK4"I('7B)0XF5_\K[%2]E^)H%(D5D+.E;B0O^ M9$E@]5F#$+8BR7;DN!I9EC%:0\*5T'%]ETVPN"$$[$J/))K0+W0 L1Y@=X;[ MXS75.K[RSI=S(&"0!Z-X_,H["F81K_51ABNXX]PVZE?XS1,3O%*!*[Z? MZHL^ KWCTY-1!'HCO'Q.&VG':W_BR3_\-7;64W'MRE6P5^].K^F'+_^^M>9F MC/1% ?IW470[8!S6['0QT9>BZH-8!>T]*!DG]#Y2*(-L2+@:M5&)MD&P**>@MO\779/PNAR.4IRS59 $5^Q=Q[ " M6/T96+6OT($ZS[/+.(Q")-K'#Z;9573)H3_V+XS!@F+G>XS>J!I%QFT^0L=# M-(,18:C1K>GQP@59"K*L8%8L,00XS6:1+*>OOYM&"8@?V-HG_3+'T" MVX'Q2J SFLV3;!E%VM;V,DLOV#A!8E&'5B"+(ABB0NV/["G\ZGRP(/ MMC<"6PCV*0[$W^Q44&JYIB& )^)2M3+L$JR^#':#R10<6! MD#Q+XS$:HV&!%G-:3)#.)=C3L\+KQ>DX69#!A=MS%:-5+ \5?1SNQDP#9G"4 M8U 'C&6<&UK0^,Y%$>$FC>$8P>+G%, 5]\%W8GZM^Z3L .PL+@I@Q 9O-S+< M!U#EX.R=E:#!%;:K&"WSX>/J\HE'C"2%FZ(@)TYAN"A.0:*+4PS M8.GI? 2\,$!DXBLPIX44L,:-%##R,O+/S M\[/G%/,",P%H#7V=S) O$A%+>72Q2.2^!05FMD@N*#6@U+DB&Y99ATEIEN%0 M9V,\EJ*NH**B1PA%@LDU(N%4@@933..Y#SH04(TI'NH1EB&+U/D$Q$L&FA'_ M_M\9B"?O$F:W0&E&*6OP3!*#I9J0=C96RWF-QT]F3'Z[V-D\@[RK:\9\^>/:&RGS_Z&QY9ATEI'C&W MW,VN0G,#/MO<@-\;KRQ&18RI0\N6K*1"/U -B5#R-3IA?(\3V^Q0?9 4F<<> M@XC]4.28L-.95KP:Q.,Q7O#VKK.8.:K;<-MZS IDRO.:1AM[DK7!]F8 M2P,O:$[[V7#".DRJS@F\>\V^ZUK:&&>GD',T$ONM6,TPUV4#*7E"2;4J#>PE M?7STV]G0&\Q@*F.<>4%&'P'UW08F='R5>_)-EHY3=GG'+N/*#\HI+MIDQ3 MOYJKU!,',B40@4&1%Y3>;J\47-!@,5QL5+:;3^KYCJZA^X:G@?SHH*]=-&KS MOS)#J^=\K*5BY@$M+DAKW7-2JA^"F0$ZZK= -^FF52)6:K@PU5?\2JDNV:1Q@: M _/A,J)2*8<DP4P9$W'JVB*S+-3^V6(!FB:1C0*=DD,PD1>S_22AMUI$ MATF6E,?^7DE3S>9)'>;2?)TDTFRR2193^FAKY!?/PY.ZAZ KUWI42F7 M( ? =94>80!3;RM.N*8&Y,:U"9O"CTWAQZ;PXTX+/Z8W+?QPAC]1M?0W+0>! M;6FM!_$VY2#?R_TF[,(&MEV(^ _)T'= M@?GP@87*JRA*;?X!OI3HB@T;L'%CKL6DFMFJQ>!63AO>X 9/C,MC7\,1L^&' M^^6'HC'IT<)@02;@>]BYW312S)6ZW029Q;U[:C D=E: IY,"-KSS8*$N;%21 MIQI51-T:],&CF.>C/.X!F(-'68F.1:UT.M$7KPK0\A3L742N$K"BJVE61$;/ MK0#"H%43@,J01I.8DNGM!RU(HEX!=&BO*A-AO:4-HTE!B.R?[TE 25+#"M21 MXV(*XF:<@*5&UKL%L046![X /U9VCC9?^K[",8HF$XQO*=PUS+8-HXK JJP, M2K;-\XTF-0#Q8EXJGP5P8E4[S=(,_X<:0='_Y_5__^H-* M>)]Q :]O4.IV=K:QC)I!%^8+D"UC73/-@_K70>]58?WJ'!ADIY](9A2'+5FM"B,0N,U7U70@ MW(LY_&Q1H&!6.(<2;]1.T,L +C=T%RFG8*S*S2LR5$ !1,ZR_/;9(>4<%RPX MH82XD3EV!/;9[8 JD$2<%4=IY80^RK!;N APN[#U0%XR.0ACM7[J7X,ENW^O] ML_\'?D[8I)02>.>X= _R5&[ V!V"M[>>WN^RWPG(^/;63HV+[AZ]'X[".I+] M/W=$]#TWW@@*ILWHU"^]7DQF@(+TH!UQ4K)PH=)=VQA>2JHP @ MIL,J,!0W/+?/E?N]IY519#UN/Y3]8@TH32@W\RBE -I$73]< V!":],,!E!7 M4,_&(49:X$XB:,B?MK_/,QN'+*^JAFE%M42(F#A MTW$\AVE7PLRK8\:!1B!6BI.9N38GF4-X90P5M^1SA\4U9X.UC+3>A#UL7F,J M<,$I%%M8+(O6.'I%KC)B<7H%JVEDD$B3+UK-IH/J7.'WT1QB@X_W M)U?O(6)HL7NAAM$F[@6OU;M@7!IW[ASXQAF;P?ELD\'YO69P;HSW M=3+>5QQ_MHSOU'C?W1CO]V>\4ZS.,9M/3#JIW1X#@V84&\!N+RHR\ HUV69U M\MN?I@=Z?!XH65^Y@^;#7<$-"W]S7NG]\ZY$_D;&VS*>PTQ>/:3^I@TNU4^"_(=?>[6!Q6#;LME4]!S@B5XT]I=I5$X06W ME:2L<''4USE3^=6>]8)^[^>^N"RZ'1> QV\*+'/LM@P^1TTP?;R;N//-)A5OT2;NL\=^V7"!?L";TDVDL0\ZBY Q MUF V21B5<&Y95@*B3? 0L[CDD!,G<54J&9R\%P)N!KD4ERI8AH)P80H:*O$H M:00:1M@(&#&RY?-1D)#L5+\F&8HS:N\IJC):\7WR%+[^(_PRS(,KQ+V&AQ%4 M.HSA-F= :Z?UZ,>!VWLT=N&H5"UGP%< ANBPYD-=&/)"JB&3"..@;Y*58,AK MDY7F6%!7ZJ6[/N&(X<*#)*HE=LHSL!VR,1B?VNW74HPK]X-W&3=>?+I2X2IF M=&X-01Y:3(G=>$TBJF_?4[%3]J3WF7,-U7/J*02 ]EE@[",,=EP&0Q1IUPNE4I:AL";O(<1_)4[!X_B8(<2Y_I M.%".@D0LK?"8';C4B^N6+*JUJ8\L07!L#(FY!]9KNQU^K;U?-,D+4 (P[E[U MP%2&1 XP 4ZSZ@[EF$D-FHABX#/,BP_R$ 1;63)41[=S D(N"__,)+V>+BI> MV979TP*SVI$:Y"E)S.IB-"UH4Q:=-!J@LG@4K KA%7D*) \?3FK>.HI@32*K MU)5+?%$YU%FQE3-+L@[^,I>46,7$=E9_@"L/KX+X^%)Q^V'XH MF/_^)/MYPGT&F:"9!8@6-5M*2K4YCOCOUU^ MZ+K"!G;V'8J8,^?!LIJ&BK4!L!'D/TWB_RQBKE@-@UEP(17/E%.$Z03S* V2 M!F&T*YMKP@90# M@AL@)2-_>>H\PQE2TL \GI13-V6"1!"1W[ T([B4:%=!!\D7P+UZ56KOZ';H M)2N$CR2HU!]CV]/D8L 8PC;PW3C&'AS.^C8:<$"D:MB.^ ,53"]U_SAZBSJO M;P=GYYA\=9$',\_I!F*)&VZ44M3JZX4HW+(M;U!P9V"!;>IV+'C1UH/87"M; MJ.<+\_RQ/A\O96E!W"()?+7I%7V#P"IF:-!64JNJ,K?&KP'U,9%"H KS M7G^+;'F52C'I0:E*Q?P: ;B[_)X>MU71LL'B%2H[UWEZ.T]?PEEM1?U05%>+ MT_$'D>W=QES)_W/@R'2T; M1(M+[OT8^M_.)OZ"A)GGFX29NTV8>;Y)F/E>$V;67'K$#2XU_+7VFS'>E8V5#4?VQ#BLHBR8S&!7X\2(U'L3*+0XG*!%+F8P: M.Z6#-0YK=%E2TF(U1)4H105%!I$=R.TDX3[SNN_B?EOW2<7JW)VB<4,=W;Q3 MXC#KB%7M;. VX[EN<#Z+B_IZJ[LAS[W;>=H+^^AT<$WN)@U*UW3J,:YB)0#T M4>&Z2K+<*H;;(]O*Q\F?E\R>R(!16@0*,<+;72R?'*34(P=X$EMQPC[CRY*E M8I(;A&3@#4$8#T9))088,GE'&C3"Q7SXQ MP2B[=#$] CM;@XQ35NNN/UD"PVAY9$+N 6Y[[A7:1K<#AQ6C :,\^U2YCGHX MEY2;B0J8(:U#,%8HC#J,T5?UX)68%+\5U;%)G,^LL(<:!!BHD!A#%27!LFDQ M+@0,5$P"TXG5PUA-)8K0'+BI12Z"E%TWZ*)BNX_JGN8HPRH>N,"S>P,CX]J^ M;TN,N=Y##%>A!U%Y;_.K7LHRPP8)>G.X(,,J MVS)+/=8M/@OU_KZ.\?!JUR IBLR*7$:?$503MD35]3&Q3JGZ;)&4L4"]8'AD M5?R(K7=[E:X"PX+MWMZ8LB92=;WHPZ2WAYQQQ8+5MH(KNP-:N*(E6T$KUV%(ID/>@/KOIMZ\K > 1>Q3K,TPW7LN7@S+B=7XRURL48A M'=UV;[LAJYES)";'"6=&@9<,H&D0.OM>LI@GE*!8(A$>DQ'FW(S1KP>+R-U!&GM;F8P1S^LL.^^?Q(L!F@/"H7%1U=R*P M5AG-YF44.AEU;8*,7D M!96_BD07#WU3;B02MY%$7XIZ&0>:1(UPEE5FB]Y9 M56>K,8?J0@AYF_SEDP6YR)VPG;CGW2.>8VI"*;Y%Z4F$G;>6?91%2 MX! V<*PYZ6J%92ZR^, ./MMQQLJSAX4CQT:6"7W,5(X$1R.RHB"7\91($6 2 MG@:UB5R!$T7W<63K%GAT*&'-TBZ ?VV7)1P&[(G. "2XMH3!*U*:G=/9 HQ# M&CP0%"M@^3&FO"'5'"$?*W0PSMU(PQ_IC?\F?#!*>X #-&ESMCN) 1.C9LGY M4\>]C6,;DD4MN66)[D9DK'OM)/; M/357M(7&R_IW7I)7VR\I!LOZ5I*#[&& M@8W?YFS%8.LR4:ER[VR@@79BD 2:LYVLE M&I41J2&PD.Q<38%>/XEQ 33M;+6*&J QM_A)]8Q8+[$8P$A6M6@.;GMX ZZ@ MNMQ28!"/X<7NIPC^(5YPZSZI2_&2[L&.7>"#Y\%G2=892GL"<2A9&:*-50/ MYX2\*AH7.O^F(>F',ZP-N8&08_( FB?@NQ&A MJVE$+B")&$FPI6Y#HX;V8P?\FB'$L;DNP=68C4-$C MM%$4:]H<:?.AO-C)BE(I'"2+DZ3J&:5.']H8H!8UL,1/0H*\RA",7X"N3 J. MDW]#M3[PVHGDL."43%:ZYR2E=SMWAZW<0C-=07F6@O&U.OZWD?QK,*E+%2#; M2S+%A[M9]JFHUW10\ E=:8S'A.I(@8:PI!DCX'?!!0+HV66\[M51$5>#57Q'6K0=:O=. [\9\&_)@L0/VXISI=6L MZX$COZ]$2^&NT,CF1K(N7;]S&^_I2)03S_$56\(2ZGN7(TKBL!3"E6:M5!55 M&F$(0PSUUSGVJ_1V*BXH+"T5@8_:E@$G8Z"CM#(BBR0:&P9_X;%Z\U% M'ASYE,9JO&*Z1@OU>-\#"H4L6'@DBSW5URX+O[^EQ!ZCN57/*>=\D_LWS5*3 MV]1R0,$DO6[A#9]6EA^^:%I]7?%A2,M1IP05I[!"4PN+..R_!]3R0Z5+K?&( M6VBBKF/>"DUJI[?G^+SU.YS%'>J(&*AIDK=,]6>!]6N/ZZDU];:\28,DN\@6 M6I^T?F4 RB4,<+MU[G:N7>@M$&/8&\\5>[$"(ZU&9'PW\5GQ@TZ&)?:^,@7B3!*KN%D"P=+ MMK2B'&!/T%'"9H"Z=K^Z>K6PKZ#NNBU6LMI/Z.BJ>R7)CQ4C^>#>SMWH.X!M=+\CX7 ML"JO0XL,J]!G\:LTL M+/'+%ZQL@]S[DPL+BLJ?6%ERD% IE03]=:7'#70(O^IZ4/M$JF6:V0%H>".V M$YHLY>J@A![2YL:P%,%XJ;U4SCH[F5HTD$!9V9"$X\ MR1Y.D+*V6C=,O5^A1RJ!DWAPC;2.4TVL8>U M;A0?H>OW1DJ=M:1;G&^(/U.CHVV4TW+44\V;JD>E(A=KQ^T*1W5L\%V)H'2G MGBKQNGWR#3Z$DLRF_8!]$[@=_JW9K_&$M=A]M.E:"2/?MI,-TZ89^B8=HF*7 MUG2OFRFW1:R26Q@D(+ ;#I-K^C8K<&5!P[/5;F4 KA:G3H]*O9+/MW[^^:_8 MSDP2652@BUH]J\DZ'0)LOS_NI:JD\+V?\5U:I#6QASJ=)C_+GK,-Q+]B6YW MPY^QS>S<(3!]Z5DYR=7.T3-*EZ0"Y(A3TN3O-[&%37IMBUAV"@E9A%SWSCBE MKD@4=Y",2%[_VRR_MW+UNYTO7?[5%C%U*FR.,;2O%.;O@RXJ^#89:N<+VB9N M4.<-4FN#1(N[;@VU8Q6#Q!JR13H,P.]_VB$L\J)D*'+LSZ$\2%:AJMO*P&4< MYK"&68_QY!KH" MUNH$LY\V"69W MFV#VTR;!;)-@]F44?O.VU\]TV^L]V&D0L]Y YTT5FP[8#UKV!QQ-9.5N/Z:< M]I ]$V?S)&XNZO0=1!%0'I*HYBJR]$]NY38G!"B.;W/#R2@-G>!?MX-J 3X4 M(K*>,K=0"[#^75 _(JV=HJGF*KZYY>*7//A,_\TJ?+$,154<$*LWUU/3>Z0C ML>,\N,SB4"G*8;88E;X5'E6Q)K'*VXR8J)H8U:Q;:TR5ON#"%8L1KUYQ$ZL2 M%#4*86#*6%ZS''R!@QMGLQ%H1X53UX754N1']ZY ONC?8O!BA@7D M3:-3PZW+/J\'(1V"UIH$1<'E\>*%=*R<;L=U-SF+/ [F,:84,:%5\Q^=%J[7 MLJSG7YJ<.YVJR0:SG:-*O*"=8U$>E)F%+'SEM3MMIN-X,:)ZY^)7D?J!KU9A%4DR<(BCW; M)#*6:A/!#7159*,5>:<6R>0W

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

'CO]( M//VC:.C-EOG@]

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

+EDG'HV2SZSHD>;?&,I.CO!,T(F M$GCP)CR(+TO,:K$17THJM2L0#':(+7'6>_(&M0/_I!2P_ M66G5_T+T]EB/16[#D$G3S\F=%T N @K@[\1\S\@/;\K8$W0.;?4QY.,,QQ0> MV(0\9HH3''7P+,;(57$&?7?IV#&EE43*B*("C*F/'>VB@GR*[.OP5+I]^?GB M%WD I42HA)NDIC!%JV)24V"NYBPV'6XI.,'#C%O26D%-]96.L!KWVNTV24.N+($^U.&C@K5+V/ *EB%':S9.%,V M MEB+?26Y!FR#[=EQX9W4[LR[+Y);F'&&=0'0HVYI35Z5F-:W:+SGI5>G#Q#+$ MUI!^(@GDM-0LG#K]D5>!:/,1Z+-V-YFQB*-DIYM:49ZAB6JJJ MG34_T6Q1[&N!ZZVK>JT!N])/V#2PO/B/8&0L=KD956/J7H*]+YJ.L;YZ_88B M'.C1 (D&LE%7B;PJL6&J5AZWVL0&US;3'8GO@T?]:P[T?NY,"9:A/S;%Y'9 M6OA35][/5._+HC''IF=D+W=;2MWVK[(SF3)8K[7F$W7V=XRH2*\?74C!V=VU M;DJ!+7:+S78847[?.#>&'ZK+Y!GM1EQE;)$>>#+2^K"%(F7+CWKEY#7WU(!, M%]%M&IA2N/2Z#P:T(<[(];/S/@-5 A?X?A]R=J8H3W=NIZO? 6-. 1#7:E<5 M!&)M'38?)HBSB12>D.XP*N^,*V+-]R0+I CBU9^F/35/^SG"BK-MM"1D(HA# M/:< 1@='AV4CB-1X2*CLNJMJ@/@ES-TG,0%+A[-)=7%WI;UDKXR5P"A+,JM& MUQ?/!],U\<]>DXE5 T';WO](>)92XISE_&*OD%6#AK@9?^Q78N-YZ)TRV*&$ MGEZZCS8I.R8L\2Y<5--)I_,'*=?8'',$0($I'-81@MBP7!B).-@8D)0@ZCUF MX&OX8IQNKBG\#BY)ENGK*'WB<$(I:%BTGO?Z0C3(>L<70+? B"UD\>D[N3P= M+B;6O\"/_.:L;>P[):U_^89RK[+%A0*&FL#,_\\,^/]&T%BHQTXJB@N"W:\M M/4!GAZ#GRP;KN;-JW2"&Z29*E5Z!PXPJG)#N<][2Y>@\8TO+_,B)Z:7%GD\F M1*GVCP8@0W'[XXX7@Z&CG.=V3XJ.5&@^?9%<4Z[=5/I#"-_US.9JZ312VO$X M^"'JR;F8RPOTB^2\S7MJE%0>DN*?T*$!)K5%+=$2L\11.I.=.-4=UL,ZE+K5 M7]$!@R$K,A,_J#?C??8^UY[TS3]\D]PG+\Y)T9W2]0?=36UR[6^35K\^$4B4 M7,[]7H].75'*(',]8%2@,0)P'7B-SNH?%;U!5GV8]NJK?X5WEX$75#:_@]F]M/E(?+69+.05$P# !1,>,?_KZ M^PP%&I10 QWD+7F?_X=KX+*$XYC#,P M"?RXD "6(65L>*OO%I=+!O%Y W=#<%:]1]Y*^)%3P."*^+1PVS1Q;T,D9M F M#_H*Z'_G@*&.RW %!OJ?_R:SU7!_VF^!-XX2D@.C'ML:Q6XA[-_*7O\4V3FGMJ-L;&Y>0I3%"U84=& MCK:A1'$7C7!O%[,B3KV=167JS8/EE-DO>5A-CX!5:857176<%SZ$G'^WV\Y0 M+M69Q]F24I)FL>KHG]F#/X63&I%7=7P(6#T$[U*2B*.K"L^:_^6J MJ$_=0\M&!XEH*OD5:15J=*G)@]AX="-@3?NC""8L?2!CO\Z?FO,BT$>(!CO2 MI%Y$L524KNBZ9F/=/@-G0MEGV#_7,?YY$\G2>Z0 KQ[LHD_\850C:XTZ@NJW MYI#?]+U:>][IP#)=@'M>R%JZE4=+PV=\CP+ DP9$N'6GML7;'\.2'S(!HM@= M9! WB;;S3I2Q$]4X#'=+9^LT%GO)G*SZ>>2Y7JN,I@#A^+8L4[AQ-\4\/W)D MZ+Y2-G;];W_[JGN[^AJ3-3$$:1V82Z%0&WVPT#6P$.?"$BW4B46TH6^>IRU9 M@GU[)'TJG?4S!V*(5YF0;)46^;G[DW@"1=:H8;Y#,VTK4B5=#H-_L,P5IW?8 MHD6Z>VUK(_&P+!-$5+MKQH ,UZ'.H:-\GJ!82I/,D&?YUB ;(_:6P/S6!:;Y M0-(^FT!:[71="'],G1U*;CPR2KGR01'3/WZ0)/X7IOB<:L[R2PM9^0M_B-%6 M[7H7?"O9BPO5@J.EHFEF74"W^9P!GY# 2"SF,FEUY[G.++OJC3T&6MO$19]7 MX6Y^-5!+A9]W?LVW@>Y;.&G??QNQ@GOY-N3^@O_=@'<%]*&E"*S"7*Z ?)\\ MGR1+J00=6.9_E(A_)UR]X;;3!.2#1BI7LJZQ43^:SBR%@VQTB:= @\;IUK)O M47M0D@Y.5](S&^FG-]56DSA_UBDO5KOZA$&%L[%X<-ZM:Z\_][#IS?!];SIK MKB_)>(OL.)12!NY/7FK1GZ^WWP@U]$4M\[Y&_H)&HVF_O]<]?P3M8J *)01N M&9L;9)5.*6[4/C8.\)&0O6"H\.L%AR"K5G.G.PX51Z"0XR:^@;Y\\+P*/BD! M[78A5(2%'O \W"ZN?;QI;C!LH]8Q&!CTY2SM25[DS+_E47@^4>(_!"D4=>YM MY98C^ZQT8%CYIQF2L/SB4G6F_"<2#QVR!@ ;OH%ISX]AR75]_G T@).1N?Z# MYKLKVQ=-R^"RK[K8X 2[ECE<1+!1S:U]'M*V<%NWB_:%H(4%K9>63[T[TA\G MSUOY4;+#MAP,,;O#'?5=\R4SJ+&LY73AZ@[QR WI%H !.M(:,!85U K0JB MCW1HQ1&JVBW4!W&MU5^"H#5V9U6@--6PM :U7'_^&L-1A]76G=[N*]]HUW!. M+X\U:CRE*CW;W%XJA=SYZR@YO0J@&U;P+=:W0(ZF4.G)87P[!YR:'X&H'@[> M3,^\PMWSZ=V3]9P?KM$L=G%<@BA*R !?1.=LYXQ2VT+;[&K['7-/5H&)]\^> MY;+T[[)9: =329MF4);93\CI5 M%-160'B>9G7"2V/YUA-\MU0.:[>H]J,D(.0$B=KWD5(T#%BVB![2*)S,O#Y;9+MG:C!*,WX.'$_',[I[%1-7,C%WFY.^,I']E MUO5/:)Q^_2]02P,$% @ 640]6,B&)#.>DNV547$'7+M@X08.[!'<"P:T#! @0 B% XQ(@T$!#@ "-6R"X M)K@[P8*[6_#@+MT$MVZT PWZSPN M/6X!GFJHJJL",# P );_'L#C*D 9@(6)^9_QS[#_#1Q\'!QL;!P"/#Q4))3$A,^;]MCST ,GR,$LQ/6!AL $PR#"PRC,SU] Y"AD;&UC>U'.WNP@_MG#T\OJ+=/Z)>P\*\1D5%)R=^^IZ2FI6<4 M%!85EY26E?^HJV]H;&IN:6WKZQ\8'!K^-3(Z,SLWO["XM+P"@V__V=G=VS\X M1)Y?7%Y=WZ#^WOZ'%P8 "^/_M/];7F3_>&%B8V-AX_V'%P:FUW\6D&'C/!/! M)5=\AV?E2L$F&HQ/J9287]O[A/V%+H+J@]LT 36'&(P3^1]J_\7LOTAKS$^@(MK#%^/&?73NIUH6F0X<5<$( CBV F6WHAHU3+7/M5JJL\U?*^ MY6[4W\QKR_L.-/'=VZ.;#>99 0]A$E3<"L7GMH 2LJYI@@2Z[<\<3,7A>EM; M?VSL6#0K[*I=\TBS/.HS3MHP)P%U:7%2N"@#/'76(]X0K Q$7*P=&G_I@I"%S^F M=F%A=;\MPI&]/+S>L]O]YA%@4\. *H1+'I]M!9)#)TG9!R2O"3G[3PCWJE^K M1\5A)&*V8MW-7WJ'*YL(]^H,OW5UK?BA?MCYQEK_[5M>)U]BRJ"[Z8R__5;V M!5$ GO\)7H;B#ZCH(1G)+X4A6M;O&V?)W> 2;0FLD(@9!=*"@GJ*)4S'G'D% M<2A(,V[4V\4F:>AZ1;/"=]_2J_F;*ETZ5O -HM+SSCW:(L@#K3BXNIX[ [=JCPEG9\PR;S!C19 M#YE]-91UL\'HZT_@"#7F?;:>0**I_:?VKU0/5UC3^=V!W:/R06:A.8+%I8M2PVM'8DJ[3-9TRI"V%Q=7 'X[L[C-C& Y@ MGVYLW\WAO^>O+ASII+HMOLB>^]PBP9[SB M>^'<[_/WRQ=I*:>H4PCP(_")X8$;&"G_M\GQ8[W..;OH*\A$B\ZJFV?^5E96 MS&Z#QR:@*[[XL.W[<(PX[7;<2:-OI!![(_[T4%$EN4CTO88E68[J1J=[(\'\ M\WEKX^2&@M.T#"VC7.*'46#=8/SQ#3P>I0V$68-]AJ.LVE-5ZYOC-5LA4A40 M(Z.=%2804?0>40$UW7H+:$,$;8. OV'UKBYI-=/;=[^/FG1,R^_$('PUPV:E M=D;I+,7D&QHO@_) I/9V<=6W/ SF&M;6-;?$9FS8!XP;X^D%L@YS:'A*#+B\ M.&NF<^;_[2>" /9OD*=G#)EIO#8!I9K]L:].V)+'P; >\UE&PQ(#%N9L9 MHOLITA>A6:9_2VZ3:8<(IF5$Y?PT^JA06M6X!52] TEML1*^;,ZD^7:R#Z1,JUL)C6F(!_42U M?VKEF(_ZF.6F.UP=Q=JT-C,%Z_^"#)*?1>TNO#T0>(/%[J\FKZKBO9/-1!E< MEH?S?UR'2CT>8H"&!?_60@^=A:IJE\_M1[[271->8B0)4_%7SGIA+CT)]NM% MN*8LY'Z\'G!U.7F\R 9PAR*S\H'(YL"B9G 2D6*S'?/\M$!FN",BN>\14$=.,^+J6&8BWH&4PF(M/WR!UM#(&5B8DDY0QL>1NJ"" O/F*)K:[CO4%-&247X40@4KU-'_OF5T$.DSL\ZQ]SE6*J;@F)93 MYX5E8G+4?BTOKUZ?])[@2Z+=5]GTHH_< M0OED70=TU9N:,W[*2 :=4'TDP3K4J__W:/TRU$=:PW3MJ:*1L!'I6SB.K(^+ M0,"[ P7#/-),/U>8F<+0YB"98X9J)%57F)?]!G.W IUF;+(6]0'I>+7HK&UV M3U^X/*FX4/DV*074;=5H5DZVTJ2J.'3Y9=/UK?+@-1V^-0=U3]_H/NJ5ZJ>7 M=D.J.#ZI@\0^=RJ9_=/@E:);__6-?$9^>O"9.]%8JU?E>-F&[O%Z^"AZT'O( ML69>;,DC5NAT:.LUY)3=WH;LUZ_5UZRP;SO:+7_TI=6+,I=(Y5")<"V-N_X% MY3YF=@F?#I^P;S2?C)1=O$65!0=<-7>?$==_J!>QZN&?HCI(J>W0&8KGS5#1 MJ6('$&:Y#9!(7]>(H!P> 8@(:-1>G\P<]>9J-(66567E$\:,B32K"UF,\>DD M[* K#BE8G+RZZTH1WCL52L!_H*N[F.MG@HJM06&I4T#=>V06XSWH,);!Q2/8 MK[NO9M09(6@L>L &4C+T\QF5%ECP<-2FP>3+ER$4UF1D@5_,TP #J5];BXGV MCP 2M @\5FFUKTV./JX@W)09)WNO!>O7_M1N*#LOZ4'> MQQO?W:C\/O8#%J\7?/MI\$_# M]4G]@ICV#_KD_"(<3K(WV?T[M@#+NTB6[WZ_ ]B@UC#M$[-2*-\CP**5_#" MN6V.HVU!:/Z;Q@W!$?4YKL+K(G8.!(")%^/ $XCUN9MHW>10@3;M@+ZSZL?R MZIHI]PK[JRT1D1TWC1C(VE-FI=VFS[E?N18-HXT[YYU+YPTCA18F,E9F3FV5 MZ340I]*6F2"&GY[5BJR@=R6'"SZ#/]8,S58W7ZY%0HJ-GL;_2.+;V#YX@RD7 M!K@J!4G"@1$;-(@@X*KYL]G/34<[:^MLK;=";H$8AN=^QO5M3>'^-*\6.Y2I M^L["38CED[B8NVS:*4G]?N.YS4!.3%GB ^31TBBS'\;@+F%D4QAL0FG?.6I1 MMRN.CLX]=E7]E^F-%!5V#AOJ:^73%&:*F4O6OP-MIZ6[7?)^953!M]XAW2+= M3F=+4]M>T8'V@M8#,@%1#S)-2-+O8)BJ3F*#( M^%1%VUSVCA M40%[9[\[U[AN(*^Z?S:\G!\DEO#'"\P9 Y"GS-4 ),-((R\92&,SSL+%UK5U MYCPT.SD]B)7\'42(M]6Q*S#965]A.6G13:X/0P74Q2])'"_LC!$U [$FVQ_C MD2ZPR;1IDV5'R11Z&_KBE>+%*+:(%^OJYS_8*BL(V;!"!I7)M<<#E3O8X3P= M1K C8G,&W^A7[6$V$HNN:;O!$7\+$[77;:5UY54 3E3$"ZW"-&C)&;21.TG> MA&OQT<)1TZ+QK*F*%^!R/81)9H=1-"N'O[H@2,$GGP"@.3B M$T.Z@5Z=7NT/3CI81RFH[U8U#CE/%@30+SR=/);SE\%NC,]BHXD2!IZ2K%V+ MS_GS]%SFD6+/R]%LM_?#HP4U5BX&?#[?#HB"*1X!CL/8USI^=[LO,6.&"" & MQ^L0",1QOOT9[Q&I,_ED&(Z%U"R=.6_/&*N>PR*2]@"?K'2TN M@C\5 63G40,67P+)5S;$X_5"^#5=*(T/S5\MNMT7.!H6$[/3L7-SO4GA>4G< M($23OXGB+3ZD7VAU@8^(#85,'@@7FVGPGP?,[YI)O_X3%$?U3J\?+I%X\8S'N8<'WYZDH_'E-0N&G#8)R M2_Y9-#]<7G+@EJGSX7O9JH-G9;[68&77AU. LZY/.%Z9$]D:P;+?)U+<#LGA M%8>CA^?M]2BP7(9DG/[7ZYS.#S3'U-9TCP"M&'2J*-F,G'V/[BSKU'E\%S20YI/K?6(O?"3DXZQV(JQCK!7D4\?>.GZJGWV,#OB'YYT MWP'%%)A2M_&BMY)UD:J-WV>Y8](&MD$3V&-$A"--^BLHX5!*^FOA@)!"[7L&HQMNZ]HYU94F? /-^S7DR4+&+ MT>10PIQX!G*E):DYO1>^(94TK))=TA@N_I+,VE/_%\#2-0;C)9-,S=C9VY+3 M2[KB/.S527?5C;E#'JS=L]6]OMNX\CLYA[:'KQZNI4Z,O__: M1'K^_!-PDBL?)TVUQU)'^L^SL2%CLR)F880:FE-&+96PNM/1RP5ZVZOH&%@+QU.%/B3H*T3. M8)4IY[.F)5;JQE^RFTP^V9*DNB^(!C M+N$?Q&D\[&X*9YB1_B;D,%9;P_OA_L\"^'C%JH/U M&?[N#T3(\.QM".8F:#9#D:@X$98NH>7"EUU#5($6BB%(/)07,5F]+\.8TR=^ M;S[;P._N6FZQK7"A* M!V,MA3:/Y!:,[6#X4Q^+(SD(K\K;;/YD<6BDI':V)&.XAZPU[NQ]V+C;T2MR M>@9/QJKNC^EO+;XKQS2ZW@3P(>V&!QHA%'TT"]VD'#HG0E4^*:25C-N.>9ML M*PAU!L5OKGU[7GF]>6CECL:HI2,%9D1CD7TYHXQJUHTV?7!0U$Q='N 3T&N( M!S,P/! 7#434&"(]\PM,U%RX(\6INEM>%^(GAD6RO_Y-@EFF^Y)I[791NQHU MIHCH\+W*=M2>2:WM;(L3N)FLVB,@T#/B$8 \1%G AX\WD=S;-$/1W9$O*C?PVN<;]P7\)%W+WP8?PZ*X MSW/L]41P,H3;L_S6]L1OM1MB,'J8Y/FG%&0DE_PH(#\0#!KSET?K$VB^YG<5 MN7>PE2 %8@3H^/VV<"P+98W?6Z>J+F*4R3BA6 Y#DGUE=(QXV1\>Y./D7>JI>:]_E%<>CD/ M5B[B$1#D)PD3GXS-.U@Q";XY@;QC>;C%XNHXUP[O$HT?NE7XD<.:!)'W,+F+ MO@,W\@Y\7 I:'!86M:5S&,] ^&%>-=\*&FB870_>1EA9H>O%V19X'*PD%@LEN8J"XM1%7)_!# MEN7\JJI3?8W49B*_O+'ED*>ER3>.U44]E\5YF%$\_VU@%PDJ2V#44-X7=3L" M,0/&5LPS7>$C+D(UC5RNML5@5X'F%WS;OK!T?3T;MP$WZ(3+U_[Y0?U8 C*W MS&7!I@5-J@RG'BFI)$^S2>IV%BNSECL%M-!8]^8IZ".]IW*LW\%;>L4#>JB M/P!C=E8'*1DAMDFR].O!V/0PU755=6K1WHZ5XL2X[6VM737X>G'%8XUF09*' M,^1P09%#-Y^.J+(HA+2L,$5#;L*>S?$@9V,&_"&LFO.5W6N](!M6&Q[NF)S< MV /OS?W\0$^\Y):0 MXE&2XZ733];%K+X]G?N\:E4OM6+41Y'FNL;!V=P=9QXZ-3CGMNE^((G'?&WR M6WOQ>PFUQFP)^9]9XNWL)(-^:+(3\[+R\$GO&B *R2#9Y^^S*R[(&:)25B*S M^R3)Y3ZIG4G9_.?T9:N'O-+UIO9LH:) *DA7P+5@6_KC!T >,=%O+6AWR+_$ M1H V15[FT*%\4LT%-5DYYL7';$0.%GA\A#-ZO.M$]B-(/JFS$ER;9G?2!XG* M:6T34_0VL3@O7E4!E>H$?YH>@M1=F+=7W1->G!A\SOXP;#9[L&V@R"0_%6/S:C3X35YYZH M-41;DNP8/AQ+]ZZX_DZ2KBFI^@8KWWDZ;L ID^3Y^;:0ZEU;'/5LZS5S,^Q> M$ M+"TT'4MV@AX!.>X4QT=F15VBOP4? 0M'&4YV77>_AA\FC!8M*#OH[ 8>!'_# M%.++^H#7#G^3K?R8D!1JR)I>PZ M94:.!IKBWCJM@D-JUXYT2>L.J(4"M^$'P4-J9C]$)XZ[X,T"0/NIKQGS!:8'7:PR MW]O_<#1)2+ZH>/KI)2_="-YY34:W@S ^5'-;K_F!%WF?63+#2V M7_QMLJHE%Q'KSBZF/)Z6P@ *Z^/Y6_^21<^//'R!Y8L"@8FT@>/'Z1,;=B1ZM'#75E#FPPC:AYKW3/VGP0_I#F2?Q/\K=B*CV=%X2$^]OA'V4QHGM(QP2/O(-DDG\%^15B!6SW (Y-!F2Z!W<= XE-M0I00%?- M>#*<9=< &5$C3 6]0^+>1T"3Y3UR VK7=POZTN#HSZ]6%Z\]N\72'BYP)9?" M<3ZNS9F6I,Z1Y)@2#U?-2_RQBE9 :O(%47H;U ;)/Y^->9\*IXDH@@/#;Q\! MM2F[@\#KUCQ"&3D/ WSNC1W"P>X=*8O9X2,-D$ MOYXU3KCWAJI.'V^+KID?RNP4J=,'YWPRX;C^)U2"33?[_NS_.XWX-OI0^F*#'VF5E05:4.QG7V/I6B*.N! M<9)U%CV^&BDFX_7>59F[? XO -+X.5H=T;G1LB+&S#6].]]/*?'$ET*[Q8,! MR_E7[S93Q:Y+7""9>'QD(*D'M&$*;_^!-6>!K1\T79+Q]W+_7.[ ,KMJ&COD M^0#MIN?+H=>#?MT_3,%:Q14F12)+6^(=32W8+##HFAN+%&MHUM5NUWNIR=+O M"Z7JNNZ["OP14G%&@@Z45HI3N5[3+!7(D=:WTH/*_N4FX(2&F]2G*WTR(W+! ME $IKM7I5KR.13U-R*?[E@=.I!/'T>+[4K_4 MKQK%6A3W5CN8VNA2JC$Z?VI%O)5%)_FHS=,O@.I*)%7L_:G_-\X)*B'XII\S MPJQH"-]CZKJRVN^(>1F'C5^(H+*+*IC*0>N7H%\CXJK*H0N]8F9XVAUD MCP#G)?#T6/D;,M7-IC(K^G1V4UQ]%E&2G9?RN[F(!VT*<---1GQ\XTG Y*%X MBD1M:]S0AIXE/O^UAP&?XJ^_\0N=U"J"LTRRBTD3_J0]\KK696]308)_-CW80U#[YHP^ M.,5:8# "0-)::>++$!_KIB)^WY#"0E+XK*IA)&%8J#&^76"L5].J]W6\J(=K M,X%-[;3P@_!F[P]4R P$V"=Q+K#B]?7T6U%J92F_._1K00C&:^VW=$.?*@X= M6A@1]AC4XN: GLM2"&6##J;NM J :L /,L-BAE+99N"9:Y@J-A6S]-@H,PI$ M[E"MSOL>V70V9FPHINVJQG;%B-R#,2P4Y]D7Q>2![R)"F78ZO CCTCR(@-D6 M$WZ;I0%SW<0/V'Z<"*;N^(YW))'^"CE-B)6_HMHO*CD&)G7%/]#PQ@Y8RX%: M4-Q#MS0#+D0'#\\0&^4N5?:IR+]-BPLUK1SF#UNAO=B8^*R+KWY>Y6L9?*./ M7EY5NZ 1[8R]N%&GZO4S02Q&RUG!FF?DA.$M'137"087)B8N"H>TM;^"R,D, M'P'^]0V?Z7J9X/[2=S /Q:QY>S!R,=_% MPQ)]$AS/F HJE@U[K>UP&BO5<1KP:U4HK0DB\G!T9 & "KV>ER*:_[/;^=^' M57.:=B_:=4KKBUQ/U#MJ+7>+621">0EH><22#0ZV\B 51P%HW1H?P M'0AL+!SA)[_MJ\5N\=OL),7$DK#H>M,#^$J$)3+GSQ M"\?LY5VZ>%I7_P\CAE637#YM+GN)%Z>DS?:<^A&ZRDRE@,78X:UNC(G"JFCH MHCZTIG)!7L)W7>XO=8JGDL7:3_N0)^RX+XVNQ\Y+2^67&"%^[62,!O2F]7'C MZ2I:;F/64]T?NI>YAK=RXFN,C-#JV6C_3X*E\S:(.W;C_B<@B:,Z^V4;7;I, M3XR_[:!9+&U48B'/G41C/O0['L+!(-Z6]]_%GDAC^@CHX9]"<^:A)7_[O?%8 MDGM7MN; -7SG8"0L7$VM66'%]BI)DQEOS7X>\P1G1)I(RZ\> <+T M,.(OZ>(4F!V]\_3&V[A IQFWA?+7W.+-D^ MOAUWL>+REQBG (8Y3VV;T6\./,D?\2M\;_O^SY_%(,^IG881SD&*R6 M!M^O,\&5QHV=.QV2*9//ITU5Z]C]%;%!=(K4579B_*)FJQT"HAQ&>N7,>;L5 M-1&5-IU1,[+!8N>8>DHQ6];S07T/7!U .&FO,$7#2C!"#K$OX>AKQY5;:OBV MR;."%G3W]O+5MF]=+?_(BLS][%=7A#9<=MUQ.M#9I+452>#@N:$R4%;N^ ?_ MFU6+5DP>S/N7D+0#X&_% T'N'=!/ Q6\?4:$:N[/^*<*NHE-P+F6$L9.@JZ< ML<,9XY,?3)N6,5X:DLAUN0[Z[!WCW '1>B@P0OS83QENIMS;[33'T=GPNVO0 M12ZE5K3L;TS4(.%SP?KFN8Q+P4!8:2R#49>6B6'C7/45"P63G4:4[-[K5ZXK M!9"D)UC..9O0I\,T[6"9I8SCX"&AWD(Y^!Q:[/R3B+T M-.]OG<2R:$=@Y;YT37%-[@<1.C.Y'^_B.9AFF[J]HXJ^K=WES"@PH5)4[F\& M.OT> 8O\LOB/@.NU13J819AQU=X *)I;*"X80PL^/L^HT;^V4G;QG,J-@E:OB!,Z0-S7\GC7,39=1#* N8X1?4( MZ%,LUY1(A8B]UZQ>%PG.$.=V>/'M4%M?GO_@8S^ZZ!.4K>,1L&7B'4AT[/1$ MX!8RL9'A_@AXXVP30SJB H#B]3T"EAPNMN*C3?,A'2[+K MAB\072]J9X"NEG?-T%G44Y3P4*IK\R QOUJ7F?$DM$$V&\**.6U)R"<#$2@N M%E@:$1Q2)N$O2=Y:*(8*7/E2:OJVHA6%JIL09H'YPV08ST151_UZV'&BRM]W M7F01 ':J'O!0NRQX:\;R12+KE0NG;%KZ?R0E"9V1$Y]/][YYT]D0GK>AA\O> MF7WMKPE_$*Q%JM9[U*R#:584NLI=O4NF*%.9EDE,C[H5-1U. M=OW+2=X>8*&&L8C+,MM%E36#DX#SXB+:+^I\P;$SP%0N4AVN3XJ3H+3?#PRH M4LUFQ%"%.YQ!;[;*X_QCYIU*R-8(MEKNF5CBK^Y-:RZ&,WF /Z$+8KCW-\\Y MFC=_J+!$;#\0E3$=VF?,5()-+Y%->N_>$!N84".*X.R."F ^D,F)A7MV+WKX MF^BWMX<:3)_LM(2L<]DN68R[K&-S)(3R_<#E+T)IPZI,^F6:*QDS)"J M3RLW_4!4NE8UU.1]MV4)+?1]2(1^$$ MC)00FON*.H>K=1'B;-G8V*9:/U<0%A.\G3[Z5W.7PYL\C#]'\N8*^!1U?6>P M(.3W8NM7?M?"EJQ+(V^O(Q,W^X-Q@EJZ$,DK/O?UJ#AMB4U\04$Y"&RS<44R M A+;>;716G&$GRS^IXI>A5X],2C8W*PVN/:E%%96D A^OJ?M<=UV;,QZIT>^]+U$S9G@1,,?RY.2!E05;??N>V$^7ZTYD MUGC?1NL1(!=]__LO[6K67LS'GQ[VC358$XX0Q(Q1!ZC4(I+MH;>EPZ)N.:BC M@R9F,'\U\:[CM3RF1\UHZB,@Q!_MVH(L6+* .CC*2I\2U1\MTB0;7=E94Z?\%=03[5\0>J$7(JW'6,8OINJC55_*[$# H+1ZDBL_AS2I;;) M9NO2-_U_0HS4LKGO$N/3XW_BMEX@9?46238)H<(&<_,M-&UY#^.-P]6VS(ZD M-];B+CU=Q(C T)-CU7B2%)?2+]S7WP),3#>.=>C&BU(2D,DC@YZ"WMBB@X3C MT6*MY]-IN'XDGG&HLZB_J8[+#"P\?B[W,7)F=YJ'FO[;@9'G!P82)YFD)/;7 MF)H,+X)3!(ZK!+[L[5F*9 %P/N=B!=KZ:\,$4IJ,K[N+_5Y-5Y%9UR4;SBR9 M&Q94DTL9_AKYZ3HT'6]\JV7B)::+V9V2_^YEWR6!#,9E37(773^LXFR%#?). MCK1H=;ALRDN\J;(IC4>1D#)SY.[\6S) Z'DK=E*/O_AV/)D)2KOO-J7J\Y/P M#2%]GWH1_!_R(Y9 >N0C@'#-LQ:_9SF5.5GXJ_K<_/)75Z9:8Z4\Z& MGZED!+QS@-Y3*=5((%LZ23Y ML4/R3A&?]Q99_@X3!#YO&VVKP;\=Z#U.NO*MI=:I)BHK.)SE];\E^,YW/_>) M64Q'U<.P3KHZ$:J-P&#QL:R..D/5&KM/:/)9D^=+AC<>*^@K\?/-J&[P&0LJ MZERM=AZ&Z SK2#(9)$DG>'.1ME;XYOS-EQ.WHC""Y_@C7!U.8Q+].WKS;S2G M3ZS[)E]4,JLIB2/=UI;VT>;<L\X>HJ M-Z?!;4>T9$!'16K4-T3EB9A%XV2^N%(R;0O&2R,4ZOUA3-Y^I'#"UAK;\Q4M M4E";M+_2NL\@NU=+!"/S:4M .W+_T*U0WC$+V1T*D7,M8"",M&EHB5-IJ>]N M?@28V7WJ*)K.&2=U_D+]/N%UM5<_D$I0X-BEX1% ;V%HS_QL.FHP0(C+T"K[ MK5][FA?SAP1>5@]=.FU^,S7P?C6,,NDE5I)Z/JU,./93;VQ0MIG?A]]793G$ MI.H+&-3W\RF5RTQX[_0K&,#;JEV4:(.$#7#H$VFAEQB-$/HP,:317$& MZS*'#/W4R!T(4"LL\XE8!=VRD^'7OU29G@KZE!BWMD9MPQ%BZYABR>_G(&+[ MZR$5ZY.)F.H]6*YTXMN!!(\ .R 9%-1?[@B?BMX00_H?!QMO>Z!"GB[M6#_S M^]U]/9MQ20S<.OOR.3UVCIZXZ#:%9%T)Q5#QWGJ]O!L(4D] M+ZSK:(1(CE6AY"5_1O-]AO/"PL/0GFGIX7O5 D] M.OGR;K!UC^.260"E]@.5;)B!)/E2L,%O;7EAW)JD;IW$G6"Z]8!D&7UWB%G% M"I0'.K@L!<)!\1VV@7 7DD-C8%1U_H5UYZSN-:&TP$G'8A+=O+$2ME =]=\T MLM YQL45BUI@;VNW[2,@J% )J=IM>1MMIE!3!FFSJ%^B^XZ9]^$3S9_)TR_) M,5<_?$K) MYZ%F3+E]#-K,4,?W[;.-KXM:VI*&-G;^-/FZBB_D[JZ.[&%;+GV0(;+^$*?B M3\(M/P0_OS6R->C,EC?(N-_5^&;-+=XNW[9I5-?1D3%)N.I=G:_O;1FG#V8W MV-'DD0;$?;DZ,05]@3TLHK+A$(<'>_+##9[+"8D1.[4DV9=>'<=Y25U.V:(* MQ^JF-@'472AA^!,/0L=4).=9Q%Z\5E,#&)M\A%?IA%\$1X]M8$D/0RG'&[.= M%,=/?JX!2&;J\()87*":,^=F5*+]+ GBQH#)VBP:&=)OO,ZJ$ M+7E@P[ IJ[->97X(8 MB1A]W1RJRQ$5BM-H_A]"C=[E#@NS2VLKZ[5?)Y+>NP,SQ:(IU2I!%30ZM_9Y'SZ7LB#F2B@$97_4FN)0,1X!=@3'8C=&+L8 M+OS'9$+^A8O+CX#KY5-:&?F!S$\[4>IL)\3- B2B_)'W=1U&P-[XY2C'":#- MS0)-AI-G/(=#>J*0]2?/,@#CLX-#Q[D ?+3=;P59M/QLAPGL;[/B)PE3XU9F MV^P>K/&PX9MON0-/U7"#.*<[L,H&JX5:_2M'',M,VS3+EP_XV.L[DL1Y&7*? MBT5A0G3S@R"%XNMJ-^"Y!D"F"E=OUFQ%%BITNXH=5AKJD4MY=*-I5W@@,>'N MS@OLD\$X5.\+/E0!>,B?--/2UII+!C4DOPWG[(I,JSRA_^NT+7<^JBUW,1'@ MAN:]+_8S0WX QEU?>[IO^"DA+PT\,TARGT@WA=WTO5.'L4?17!!^GC2\JLD+ MM.R4',K%80"AK.!'MKE*DJG"^8?7<3;--&32<8>_LVQ)0.,Z/38T;$$*94B[ M_NXGJ PZ[D4Y8,DA,7WJ14FSMLBG%PFH-86\Q30T-_H;Z>(?,7^8'1('6\E.3L> MT6;WL!QUD4MXM(@T1+]$W$2@N6L&[5>N!NJG8&.]O&%VK_=8Y9R2,>[ZO/CB MB#U8&OS7AT/0=![;L4+P0WEWM: 58YSLAS&6%9LXKAQ[Q57N%!)8>PEIIQ]_ ME:/Q]Y:YTP(D;NU]H5=J1VO+G*U'YPK>F%MFTP@#S@H( -FRM&9YD;[7(-HV MMS\?[6P6GS39DDR8M%CXM8*&^WW=J@E] -]];@ %M'DX '<>C>/H"(LGR:4P M5O:F+G=W:S:NRA75A&XZ.$73$Q+OD_%L6PDT_F'4+%HQ'*T>/),5WH/>LO^-"P1>.WL4;:%%Y M1#\Y8W._T'8ZNPB7^R/#C^D?^]F"-G.@&^=?H*,'?$"QC?):E56TQ@=MC5F@ MNC53X B12!O^IOOKT4+.5ODC.##T@04UC"CL?020==$XF%.W=#T"OAS.GU39 MFA2?'WN J[[$)(E(@>R+B=3H1+;(W=\4GKHL6UPG3G>#2<,]?>8KHUUJ5H89 M92937F]"7!ML:S"VTYRJ5^1QX97KJGA%XMDGL$,P(RX$*4*'7(%8 M$ M_.DC0!6BM7.GLN8-UTZ.""5Y^2P.GYN.U1MZ/$:84C9&I6!R[$V7 @D9!?>5 MB!9$)=>=W;!8KID-.Q(E:[&I$#F8JW- ?D3A:I+[ &07XX\LGL["L<0,%)XU M(^)#]2-:D$0W[U;7#@&,E/4;JK^FT&CFUX\ T#WRCV1;5?.);T'ZE3;QY@8X MY<&__/>)2U%M*(6:5_$0B#T#ADXIY?KGK*[9HTC=:3NWEZQZESQ"RR ME/A)(G&+D9+:+;D#/]9X&Z MC)96#YIJC5=,!ATA!,=Q^$_9V&[YX@"W($+$1'@Q?#,B(T^:W%'3LG0:3XT3?X;M8\-!>_Y[^CTE5>\C9//]=T3W(<,K;."2/DM M<(<1\0,;-"FTY-<7KW_O>(0/B3J[?*?+.>1AY6%?FWE31VU@!-#!3,R8_=K? M'$C3H56,VE9-U6YJ!#OU:[E-KVT8$H+-5J0\S][M/2&0268H$7537?DGK"-R M2)('5_ZIK"/K:D.-YC:S.U+43=M+S^3#F"=J%G U*U//L+PEM%HM,^]T<6XO MLUB4:L/@[+BNPN/ IA.6Y7 MIM0!0I[/2I/LT>8-'R%"6\EA:\.[S=;WRU*_8"O-?NI(Y3X%TO;&QD4YS2+[ M&\F78B(6YL,4KTOS=09L?"_+OQ52>,0J]P8PO6\Y-%Z3 M?,%MC5,F29P+&7GZ" @&R3+%3L5V4:+?-:: JVW:YSPB!)M_J5L(I&WK7P*& MGN.X+(_GL*-VQ,K&!)N_-KR*U<@*%E_+C,1[:.WI#ET0[@@F7W&0C4,N)I'/,Z*3 J? MB>\=+4+-GR#4X*Y?826I1?8/S(L=FA+IG$,90H*05]1W']*G@;ZRK$,]V:)J MQ5Z$KDAA,Z>JYJ]H;J=UN9MDW1;F'=#HR\ MK3Q+$/DA[[G26OJN]C2:TI)&*;T-Q8Q]"P1 M?9V]].-(^-O'VX&:%+B"U @]=I.+=E^K5+.7U$STEH_NWC>[I++B)ZPGM)AX61TK'F: M?1TO_P%-6Q?49A<=_9G>R*E)0V*3/1U\)SCL@M@%/EWE2JQ %0ZYC]&LO$UV MT!T1)#%>+L@(%*#\I$GNO49KO4-U%A^(Y#:%+VK^]N/'V)Z8$V)^<#W;427# M> 0TA;?ZQK()$Z&T^P,D$%5_VF[WKT]3G1D$R\"5.WLQPC<%TM!9E"?E [MY M9]&A0<90IF.@M8R9T?I ?:^<'3^;Z*D!\P"9F1[/^_Y9O7)^%:8E)WD!3I[? M!56TQW&\ ;2'/G7!CS^%NHF98V^& M>%A\C%@S^$2HNO?;>@C0VT6NIG54BG9-G6?5\#/K[2Y>,;9'=6C1GA_9-@.0 MV9ZW;%5-L#+J!&<^]C>A?-:A*X>H\,?WJ*>*=-CT"XTS3I6G0J7-35%TIUGJ MKAP.6!H].#CQNB\![DL@C&T(WTVOS 5T3SGX5#_1&HF;"ACI;#;'&7#<@*;F M'>X3>#R).U)?J+R:$)I]-WMJW5G7'FD7 LWD97L^^E,A30RCL*>X1""S?-T> M,,B@6/Q/Y[X?;B-^:$2^!TU_'A%#E2R@@2X)V):E)+D:J)!E44O.'MT M>I"YQ9^!A)#%_@=.Y-[7;]B:_EKBM%2* #5W A&LU7'U'Q:TO'6H0<0#VJ_" M%;>X!'BG4AAGB_<(P%CIHD4%W]D? @F $.&(,Z*$"=C?K:_]E_P3+ M-<=5C88^X4SKOXU1'Z=Z-\AF/OO2=0%$2=WKT89=:_T$%ZO8)"5@5,Y@*N@-10GTG"*JOJK9]-*0>$_4XS MMRL&$&B&!]:+ZL0EWP?*I3"A*.T. \'5C2.;VJ>>Y;N=HL$6CT"5H_@ MI0/:44E0R2$)=^@YPZJ178B9T RA;SLH!O=OETW,D*KB^B\.RVVVKCMM)FC3 M5BX[;*B0=I_^XGU#3("LC?LM*#]C1RHKE1*15N'.[W3:R):MHBLW+7LK58UW MYPX77_Q70"O5/0(97*Q M6+Y8-P'TX_7V\09]\T+!O'B@8*T HJ^J">=R8QS#ZA=@.PN4B 8BNOO.EI5- MD181)4@^M'S'HK+\@C_'K*$9-_+6O=WD M'B<2\/FN9^!;BC?%Q$.Q>?$R M#_*+I_1FJ@LN-.5&I4EKA;1>B6RX*SO?C@G:2? 8 0'14'?C?TDZ5*5N+F#8 MH[1J[H-^4U?\6#;E.59)@,$0R>RO*?'27(?S7&(_R4XD;KRC=R4T=)C>[+(B M,U9FVTC%WH*;OPN'H'_ZV[G(3!/-5NY7$[;#;=.Y?U=%[H3GN>)?[P:,]1'1 M@1?L?*37:0079Y'&VOUGC+W65MNR]WQGV@VM)K6E%A:J"9I\]_T"MD$)O'_X M;>SP& E^=F/Z8;Y^ 34>0MQ(_EC\=[+9J L-$2PATV#KWTRQ'4'UTEK MR$GEOJU9Y+&[J^MXIZ0 M:3][)2+S5&I(AL*LN^\1$+U!,WLJ!W$2%CJ=0G-XO>A+\8&,_RDJ9PR*3E0)C!9+ BC%QDX@'->(V-.9.;ZTH'BS\NVZ+>#L6!V.K>E*_Y0H*B^I M\B73.;_7() YLZ_)=4HR6.[-AN-?@^OCE!'Y@>PDGIC5/PJC4HQ91!E]J*GM M$B1-I!PWC.5)I7%)2PY;B&9ZR?HUH40P1Z[-C#"(@>J+YH5?Q_>MQ7P4$-99 M'1IPNU#J(1PAIR_JE&K8\:Z5\OQ#L(PB=6"P#[*E=C=(;MA@5N&9GT&7O1QH MRZ,!X?1%&,T^4?VJ!"Z*:WY<4.LF/<#7*XJ[Z[SQI,J/!>7.ON]NL7\[1Z_: M(&2=J38O7G^MR[U\I3A.E-*:>PD497S( M3(>\:@YU$F,TQBG,# E VS=(L; MV=&HQF?]R?H'1-3&W(TH'0SG]]=@<(P^H*MJ)-Q,?K,PQ='O0QE8N FAH\$' MI+(\MSY?5%\"@]V74077Q++&J'1X[ O#-2:Q*H.9V3=I/_>M<==:[3-UVR'/CMW+IWT]S5(FH,J3Q(Q3DNES-2>':(>:\B,DJW[PE M\WWCJISL3QE^_U0YVZ#?1,3$4S4B0Z7JX#1R[9+CJ-L[.$U<(RDV6G;!J<-V MJ^- \,-UM =L@8;:V=0;3!<1+&#T49]6%9#3N'?K\K7!S/K:_[?8(X ]M%A6ZCIJ$@ MEJK(D%KF]W7&W.,Q2#$X@,:?PF+.8PH/FB@N725\UG"O\?HD54+GAX&R6V,@/FI;\Q$03\IR0J> M58<] DC]K&8AD*O$0"OF^&T(9U]G5SDC9$*Q MM8Z[:C3#U85TZ<\,$ZC-GG7P>8X=KB0-+H@)*2:QC0>S2-$RQ\JX%N/@\W/F M'\X4$XAMOR48X6FLR;_?Z?'@&X =S$ MDKT0WQ\HDX&40OTYE\87'B0YSG!^\;FXK![3^_7"T[COA\RLR+!$E$L%-%.K M(_RZ3U[4=TFHJH@D"2[ MY T8J_>.PP%"T%)M%'&U"5JU*VT%^O'!4*R;+*&HTB1NU7&-9'] =>DPCA1! ML!_?U[X.=+=_D$6JYFSVI8)$-E_)U\J\L'[ ,9>_,P0S\V1N643YB5=!XY47 M009UWP5.4C4SF)3@AK4\YRG2C")F0]:X,7#24OW-MU/G#(7Q2,V+U*#INB!3RA%='NGZ#E6 MPT][<_N(;,EG?*T6Z;3AP\S;U=##J>'%MIL(^OX!'Z?) VSRKAR>SJ8KP_I84E'MK9FS%#>" .B?J HIL)JCO'44L2\D=XA5NI_4/:506TX M7[2A0"E>W*%X6]S=R@^W L6MN(3@$B!(<=)0H+A;<"M>W"6A0/$$#?[Z M__[FS;P/NS/[967VGKWG[+T[.Z=YK2\U(<4:54K];D.!]88^!;$0W AQ1#(H ML9PD&<3I1)/,<',56Z/\8GB.]*7Y(7H-*+7MG&H[ $Q:5@);[:AP:QY?7@ M\ ?FGQ JE!1.Q0#:*=EH84J$7P4(]F#ZRRL*JZSX#:&S+49M M/: P#HYP#Y4HI+W3-;)6W6M4RJ.ON]F1NJ$ ,.C@]P/MDA%_3N>9DVJTH >'[1C$ M!N&B%[^[K!XC/!_/XW8K;R9!*L4T6% ^?4:5P M,P^:0'3Y@ IX79I*Y[QJZ]K.QQX[H^NOJ;#7PVPXPAS."G:?@0-305U7*L'V MSX#7M^MW1K&]*K;!0X_B^1I!TS)-X3WDWE+RLHM-1X$2@^1NN$U %:J"CC W M?5O\"V8.,DP5&3]ER27H\#K.K<0VX?%6#+)QHF@/\*':#+ _H$3/Z _P&#HB?H;B")R$2+5<;X0O JNWU>4 MCMWV=;F:R7BTA5E>3<.]Q3V2:J!D,B>$\#7=F8/J-\9CB*TXP20*1_B-POR) MMXGI]CCPK5O9[YW3?.M)T^YP,Y-1@ALM/AR7A+H!9BJL^IM:]6M-0OA\ D8W M]OQ'$%"&V/BEJT*6"MJC+=DV Z+L'V6UH%S[VMBZ> D2&92 :OB5FY1LK=XE MEE.+029[0Y(Y?T=H]]]F'6)+\HP0DCLA43_O>P>&ORRXD=R<7,WBT2H#DW0FDP_X7DA9/[R(]1."[N6JI-+G=X MMZ5!\OEMNO;7%N4!O.27TBZ)@5'521D6I+>9YE&CVG!3>F;!##T-:87E?WM3LQ>O\[*TTL68'>G69G_>"HYFB(0L'! M:G7K0\#FVH@GPWU-8=1%-6_2$(X12:?#7MH0.=KX MWU@1#[*/)2X00GMXP)\YYRL@AQ0UG:X6T(C%O7V9)UV"J67=WN_SRX61S:G_ M9,BZ&;F[BE!' ]D_8OYQ@==_4QS=-@,SD+D['0G?6DW$4P5$?E&B-=7(]0T% MS/OK?>L?:^\+><%ZP \PPB",13M/(4Z>RS_!H-6<=D)0^Q;\Z3:^ MQZN5-N5+J+]UK&-;9UDYPQL(*Z+L2_=+<*5).RH0 9]6FC_9JV]NR[G_L"?K M?'I&SJ:8^F&<.1Y;SX#&@S0ELM8,N3228-+G=K2DO>I(W9U;MA$-':?:-+)B M9+%K266\\-L?5[@%Z[)/\)9)E0W0.8-;IHTZLQQ$?O%,.)8[V B*F.AI[HU: M=]&\2_5;20:(5ITQ&(UN)VA+ZCG^,-E"!;L%^FHEC@FGNZF8H!"=>Y.O;7X[6?;^'1EV=)IR9 MHL;\LS3V1K=2:427@4KD+29&?@@/PC_*E&9$ MN1:N6Y \%KMB-T!']T]>\T6JWY_&YP]WFL8"C"^VDCP['MXO<5F+9NJ\/H@6 MF%]73]XY3W[2^XNW!AP.$@-O$L%=,<%:*B' 3=8<@]C')D.[3Y9X?*-O4^W% MB'Y.U)MY#],^/"BY=*Q$1)[;]JE1 W M W%QU5:$K\'#UU+!@T20Z]_#$5Z/_ZCQ7).ZUO01Q^XTJ'BWO%GAGF&DAU!= M^N0LZJQZ;7U$JC/I$;O\1<+PES*'8))N>G"P4GWH@,9LE1#-G^96V0H&H@]E MZ$M30?ZI*D(':R/J.V3[B'?=J)/R7V+4OE&646Y2U, H*YFW^M"+ZWA4!%PF MO(I',-!%A1NBPNGCX[/T4?%ZU7B(9E3P%P#O=,:CFWN(W.Z0%6-X\?LK M:XH+1LJK-J M _6^YO5C,%M]>/>TV:&V17/H@:J!N8V6-?B)FW(2**Y]5O:0Z7KG>1 +'Q=0 MEP:J+ YLCJ[I64^.7GSG]I5;ZM\<7=DPW/Z#^CH#,<]"48\*'6F1RG*9?&SS M;9U3+'0IP[1?AX4%U.^N]W^+$UPU!>-)/L M YL\'6U T5(BE,7P;R*RC?@22U"9&R_E-J8=O6DOIGOGF8$KV:$Y)FH#E@7Q MXZI2\RTU=USL9HHC,MY,X>2N?,]P18SPP'ZK0J.I.7.R.AQG#"5&3I>ND+X9\W!5%EA0ZX4]]@5V:>VJ?X?:R<<)D/K%^3 M[NP9JCV>I%"NP)\/']KK&Q899!S[ M]#F( E(ZMQI%HX&**#!3JE" 5>[.QR?;^R:CQ9ZS64"KF/RP/_!3O50B1;OH MZ9-9N8'[]EG$TDO.7,H0.VPR(KY.M5)TOU[(,"R&MK3IOU N&7CU!\V9]V>FMFI$JE+4;JPSKWV\ MPCN:L-,;!J(.AWP**$.U(JQ:J%(M@< >Z_T4H+U%[.R&'?WQ;@&5N^V+; F- MLV81[K@*SP?.<=F.S>\M_EI66ZY5@JQRYN,-[J@7]9F+.DC'#A]B.%"9(6"')I-2F< MK87Q<'9X#S6FT5@I7^"^#Y4;=GN=;XD,CH+8=$2TE/F5L4[5V@FO@$4P[#82Q6/OR1>/3% +]O@+T!MS*@3= M.I!3UZ0]3G?!^C-.W6=/$.X+\:"KJ(>+L\.=ABH7PP*DU_JGA86[8M'Y^"=R MQZ/\U[7>"3I' YO8+5%ZBV^DS3;+W/./'WGSNJT)KQKB]T?E\\](:1P&K%U2T\O<*_ZMK4#AC"C_GEY^T//VH\N/ M.F4$12[Z*!I 0MPIHR;7>8,L( ;)!PW (.:>NG9$5\FJ0M%1QAWF5/)Y47/' MLL(+2D.^VP65CC[&KZ%E+D:O;B1P(Y 60]4&^E^? 8/%_<+[FA%)&\!1;9LV M]Z<_YCJ!YG(6O).N!'$[6NBH:]](NK?F*X>KQXW*:U;Y.IW?"MH5_E+^5S\\ M$;R;4WOC@+XHXSB-]W?5U'^S,K!DVF 5J1 MLJ&[FA2WA?:@O$D1)XM2 [G"*CN7\43\NZX;/5HRZM,'WJ^$'G#P_KK]^A;C MJF;KNF#6=BD(S\E'V%V>N\S=[W-'\.K+CV:!-238TF$^_$I63CVQ3_PC?MMT M[P.9#J5$#!>=-_=4?I@=%?=14/CR)]U9K26_NY\]L3 %0-!_/ V+CPQLQ=#3 MSWA91-=WEWI7U*1S;>16Q+ZJ(8,LZ>E;[[.HEIORXG;MJ)-\#^PKW?S'W(A@ MN2*J'8C-S)UIPI7:C+OA.):,3 =^E8P JP973A4[\/*Y"H<1"NN$<&^L97VY&S%RJ) M$BC]Q66_MST='K?<;,&=#]Y3*O>J8%?85L@3"_@;M\9PO7"G-VM>CB]IQNS$ MIQ$,8(L"%F!D2AP0R+%8_81]$$33.&?1?W,!-M"O;TEO[ ]*HR'QA^,L=SC$IIIF%2I&KATQ,C5X4@R>\1J;4KX)H8_]68(VTA)X8?YX3_VT(OZ4OX//_&'1.R<7V-_Q M]F[ \@)[1-*:#$8O\9@HZ>I=LZGVLA1F6,/XA9N'ZU1H M6;LP(30B>1]%L-MWUF;5&1PNTQ < T6O4O*L!M+3-)L)&PI)?; X,2PA/[@I M7"_-C'H#&/PRY6F>*, S^M<&;&K^LFHW(]X50F6.:).6:>&I&Y MF+QA:#?=CY,6 9J_GT\;Z,%WEEXKU^R,K'8K4$P)FRBOXMN]4]_F"!X72BMU MI^=N1M[$5IV<00.? :]VP&)P%;9YP4)*3>_41&8Y.0;4V(AK> M_50DU@E54="$-&$;PB<\I@+U8U^G.4ZQJR.F)%!_S$-X0^W=>S9P&E_&.FD* MO;3NE[$@'"PVQ%(",\(BHEE,Z"R^FREL DF8<(J6TH0O%$TL*9O6H,C M">QCB90$-!_?]!!>)F$; M.0 9\;2/S=G.'PC@B9"F:HK_ED=2K'KW>L-9K:]-W+)4B%1O65D*O%Y.T M)],=[GG=S7!(?1-Z98%2%1S/Z9(Q;\(%&K M>@AE\?GN+>LB::GJ7'E7L!I"F%32K$6/:ZT+XI2>>: M_. 8AF+N*,O J*EE!O"EH";6^ N]U/,3+=F?."\Z&V( $U^HQN LKIVA"LY. MYFB@#U-F6G"1F'S=^@CUU(.,]H;98H:386R_D)U'8)W,!BE:S([1 PD\F$AY MDWZVUGN+JE^RL1RLJ>O*VKX3_R==Z6[1_OYUA';F0\C1/ERF@JB':8\9_$?XC_>E>6U M]6#[T0HC$P[%3(QDSF-+2J/3))G+*4ERS_/T:M=P&2QK1$E"[9$V9S=K^WJO MX ]/.X8S.]V)QKJ1;WS#QZ"/Y2]^8TWS$\--N@@42.#%%5HI]'BM@J5RUEI&ZB#OK@Z#E5U^IFP2>,SM4'B<995I;) MHO7U X)7?2^POY$\ VA?!5-?BB-X7C[\!T4%[]32'G3SS[#-6F7#UPSN?3)J M ZSB.)G8?&RUF5Z":1]&(_:Y-KMJY9$$.7"0,)>\2D_+_#$K5>+>K%ZJ\#/@ MRSNFCL0YU5A5X_^O<.V[&A$>TL.W+W(S,H$_AD?M@9@_!2AL(WE#6BL !/YZ M&;\^!H1IE5BFR#)D^9P@DZX#'BN@0!A#9":"$$(;^L'RY297]Z:9E53#K M)$, E?H)].^N#/@QX.U=Z5A1LGG[$V?:N>J8*"K()GAZM;T'\S S"!V)08^U MY%+2$?IY$G9B#&L5FE?E!]E:+X*_NHV<%6PL&(=("2=?"G*XRTE2 RZ27E0@ M;@:3:/]B[;9T9.,'S02OY$JVAUR3?)@(/BHUFPGB=C!G0F;&>W&89(VA--X\ MS7?[Z5E&.I*M#QHB<)A"!_-$T):7,H,6N@66NFE-P:Z&"(WO_JV)WI_:$'OY M/VY_5NUMH]YU?&>"'^$6M1:3#[9HAK\8DX X0UH#& *G)0RO>0 MB'O[W>/5,R#C5/A&+Z@YMQ@EHXHX&^;"59H%Q7]T]!?:+/,43)R=='=WYW3G M3%,>\6PWW+W-RGN,\&_)QT.L]&?J*& J$U9? 3%" M/I7XF=C4S6IW2;9MVC/D]CZ4H_]>.HV]F*9/:GSXB'+TTEP 5A[Q>S[>*[G) MB )_H\AV>^BNCK1PE+:K71"_QNWAHF2,H0(L3M2@ZNH#5: M!X=>GX\,\),Y5)VUM]SE>M]?97AARXR88+EM$.)'RHJ';$]'4W/ MCS#U7'/*GF*N3P'5%"&IFS*N&_)BI/KW3$ ;.@87A>YC#8\SA_ZXX'?= F8: MED4JA+&:.==B0LD%2N[4)<19*O@9WDJM8AR_0P@Q]/>3NAFD>P2-I^(DQ5UC MN:P<+#ORI!!F'S2-%P^P^#^L(Q>PUZ'[HI9N7WG=KKW>%"4ZTV/A9\Y=&SJ\ M'?EUP1-G00H!VL+:SIJDNG&0&OEGUO5+,+5<$B-3FP\\NKLQ.0F)JK3?^9/! MMT?7)*A\.$^<3%-/3.GB27 #2) .)R" CD"8BSQWWYPSM2AMW/8B4NSV0_DV MSIU)W_7-==U66=A):G\ R2[0@D HQA,#(]33D>U5@D5J.#INV,PK9S??31)$ MT+>=(QXZ,-&I-#4JX8<&^Q UJ+GJ8X>2 "C4),Y.)[%2NF^/<75L'\_MU9%$ M4A79%^.',=094F:P_FE^4P)E5NI A&J0 @X:ZSW69'IZ_NFUN2<>$=1I(6#\ MAA-UT!^PM+&%R 1/]SV ,P=FCJY5W59K(_HXBW\<<+& =K;&':738=D*^>'> MJ"?&!X,9%]"IMX;UX*II:1BZ.UEZZ<3KPO>RX(4Q:(XR%6;@6_1Y*+L[7"M4 MW"[7^46%$T-A+G)T+NTTRUFM:^GH6&>I.8/R2#-Z<]SRVT M16"F5 PT4&E &@NP9E22OSH_+<+">K.MVN9]Q9$NM;%00I$QU^=.ZMG'W^2A MP!2II,.K]V4[E/]5+:=C31#F9(N?+13E,1F1/NKG]0*,,U)I[ 6XBBL<\PBA M]RP!]]5(OYZ&Y7X*#(-3#(Q'U_R98TGN5*'+J?J):$>?4FQY0XXNYD&);J&^ MLJX0;(\_2, 2Z3"8TO ]M(J?<-=<;"<)\V_'S> 1T$R?+$<1Z9,WBC]/3):Z M];%5OL'0EK:X"YK(7Y;R"HLY+!T1!A>NW&9X-5"$&I9I2@F&@'9_"$K<+2D$SX.8G1=R3KR09OU]00QLU"1"Z@?/#FSB6H@E4>J&K5GUFZS(HL MYT0KXU-"BG9X3C05E6GDBT:A6C*P[T@>>Z#\AZ7L ^_RD;#4/2F^&M#)EE?# M=&<0Z:G>*O;8'P*&%-.MJ":&J Z9T,L$>GB@!S!GFMC4X%.,GEXL8!!FPIQ4U91/"R[>GHHHUFRH'>2)]#09N=90?W7BC?_^ M1=R?(3=%YA0?LA>*YU-*4QX>%J6FD/=( 0?/=530K?1"L&N1X=],M3V3D2P= MA^\?J))ED9R1P\T\&"LO])D#^ M3'<^QADWIF=)&W('SWU 7-]V,X)=E6V6SG18E+T5/G%FS*BDUFM">FU&?HW\ M.O6_'T@R ;74$$S4 ;\ M@?ZT95/4XKAFK!@I:>K4PN(H:5B?#I/G&72NFP,2A!B);3JXU" _-Q*J9GI: M^]@U>_H9[(+A_M^-2M;ZRY%OQ(H>HE92BKX/7?SZP[^/Q+H M2YX1::>G'<1 MJ9I4H'EO/[BW^GTM^[$97IT+IRG),1N'P+O. 8-A=?<(;*N6/P^UE29OJ]O$E/8LW**TE; MZO*R1='Z>"<:!9F1'AJ-7DAP,)_R0W-X_)PO((M5Q2HJ"4($IK0-S-9$A98AU)41PKNF> MHY;D4)C:"GASY_*57)YN)EP!P_.7LK+;K.IMAM:&D@XK8.9$8 MN*%>[/J!\M_;!-[GBBCUI"YB_XG_^73A.ED7ZD$:G_>C>^)5])9YR-GX76/A9ZCE?E-28-<,BJHX%J4T]+$_(/23^/JK\;>^1-(SM.ZJC01Y6+6 MWO4-SUZI]Y'MP&N0FE;>V7/EIMI8[58-[D4Y-^9XQ9:#O.MHF9X+QVU#Y?P \ M5Q>5WEH0DCO*'=X3LRH2#I&'I2_OJ- MQOE8S45]FV?\HY-Q6?_92YXDP:1H'V/S6K;\*J%!7M-EKI/+47=:G6*FGYF; MLQ* 09A<=J/!H)Y";GY0SF3=7)/-PHGQ%%!\@P\,47.Z;QDG6O:\->(,E5N)_E MF4:5_ RHC,+_^HG38[C+;J OF+2;%9QFDL"4O34@'ISIRIT36,ZZ6>GH/$'7 M]-<^<,8OE6WXN[+%+M\0%"_V3@"FE__E]&RW?6X6'DQAHDB.A"ID+)Q$:52Q M[)+,C0W:,_"0$D/ZD";7VK^? 4 9PA5P6J\T*3UZMT-\4J43]^+O3>6"RK7F MV#\5!ICJ\:\K]&&1'#M_'O/^E]<(%XD*HCQ MSGHW8:Z_@A$FAA_[:)<>-2 3W3<]"@LF7X]@1SE?Z?!*Q[B]E#DJ>@;,J?Y" MC?YTR*-!%2)&S.<++W@XMW02E]?Z;3N2NVJVF%C,#>O71N[%1*G>4&L<2_1U MOY]]P@93J".>:F%5[2ME,JG_^9'B;JUS5?@UV>0:L M^E\,YV'.05FW*_0N:XDVLM1Y.53*MP9P.4C^U$YC.,/TY-&80S3)_!]U:YL: M3-; 97 6]7K.PPZ&4.=EC>X_%Z^_HL?%I2JA/YJ"V;]35(KS] 8R#]$S=B%; MD[S,)#XB(PN)^QB^ME/K=:3J4-I2NO*2L^YBD%NY1P ^,H<\?CN#!N]PN<@0 MH1IAXBCNL;<:-9G7DPK6U* :P'GU\6! ^O=X:.*G5H"E+-G5BT ^R=\KM_%A(M3O@0_B!0ADID7 PFW+CEWUGZ MU?8FZ(6\+%UD%^R(D,2QT?&NM,HW0V<;RF__CP$AIU]6KZZ6YD)YY:GE\93+ M4X9Y?Q9\!D@ ) R([)&=_>,>1,$F'[6CKP+?7Z@F7S[^<4X;%#CZ M(G-DT%P;+OZRHESEIV'I2)10A1A(5SYK=6)D81Z2^LBB3Z:V\R$P3@UQVO9- MM^BHQ9?[4(Q(^>F_GLC1&!G52U;+(UEZCR6&UQ#J M,^QYTU3!G)Q1QG[]== M*N/NQZU*ZK?9;X"3QMC6VO34)X!E ^B04$ M]_8D;M*@D#"9DT!B_=;N9D_7BK\W&+C5TC 5?-*X*RP\46_29OS^S7^"!(B#L)"Q9 MN8;Y.AO5+M,7'.[?$WU).+G:I,)GU[-C^KFG>>N.84*P%VY9<@.HNE5F,V2#X7_ MP%Q@#!M2=,%?SL7)V#(*=TZTA@U:J;5"=&A^Q$R(!+%TZ"R2.Q-06:,S.'X- M]E;6D_'[<@N$$ZY8CZS>G @YYY$L0I7<63>3[-E*B\W'\_EW.(G53$;E-J\G MSRN'2URQ4GUB[Y=@^3%55UN$U=_%G?W)3E/[A^__2_@0AYU,F"(+H/PUP(P6 MJ4-(^V5:M:Q)\W!2.#N0>H->$92^,(ITQ=6K<,@&VN55U'[RZ.9%*;F60"20 M7%/?EZC+XK))YX-;>'(F.SHZ6BP%WWRW)/'')"K00TO$8NOB&1#_0\^&./U6 M9?Q]S8E\9D/IZ:C \H[Z-P1T17FV";W9[J3C4%AXX-UZA[BN=+29K3C'\3] &8 M/#RMZOA1>=I##J.=<\A*M[TCM_+B(U8!:FWD^HD,:()K8B142[2%?DU'OQ"2 M:NKM:SVHS8-47B?XGHIV(<, Y@^D&+ >H7\+33) *D0\1OS.$&):4__B G-D M:I'_C;G1H7B[1;MMJ61DRQ F3;*Z.5H#SIN[=_THUK-P%?!K]O2DSDT\M+PX M/ &@1_?20VNDAQ+B2-\5Z+<]*6,RWTSXPB%%'HC9-3D_U$S"%&-NDNDL.)Z! M4_!0;"FYE)9M)W@.E1C\I%'+/#CEZ23&300_8CN>;;B0_HTBM&=-ZM?"Q8ZY MJ.$*6K[O./VV:GTW:I;77+P&#E/JFCTKOJAR_1S@N+-N '$I-;2AC0_U-QAD M:)0YX;)'7 RFH>2'GIB^24JQIG3,4=]/M 4H)J3CO>\5>#56]T8$MRXDP&"1 MG@9U@=@?2KWU5TJ$R@0*NWU.THY6)BS\T/?E@3Y1'^> M8T0D=ZJC6GNC->(9H#@'T>6)_MR2XBW&^)I"H#T>O[PTW.8$3U]TOHZ*$=,K M:X>,UH!H79$E8O&3BSPC!L/@IYRH(([?4O+QR*60_$$*\H[A)!_!8#+'\OX1 M[54C*@)<.?%GP+BR!3K'@M9$">_+;N!C1;<8^+T,6G?*#B'^1EE22U>#XV)C M<]=0(?-+\*GL;8'+3S=Y:TR/$L*ZE3J%.J\NS[C0/> M7*$D=*M(/-*[TXUG0"#.]O"G7%$%71\/1[/+[DSIM7#^"3;@MP!)E[IP6PEV M>VZ](+U#1X5_O9 @3YX2I.,JN*,"!:_M9H$Y'RP[1LVJWX<,8O6QX'UF<+JS M,%SH9H" '[.$M(@<_#^Y3Q8)E__1[1$]]<&R5#LO][KSE0&CYRK&NX5?':7-72_8T1J9T( MSGA8).UVXLY?S_544Y'XPJA$+BLRPRVMAF? KQMWM[&+JARB+$M$OE[%!Q4N M$UV-U<5 @Y0;]FO[1*A R[[2P@G$OI07CU.HH&7)J2R9>$]H=4N%A+USH9(A M+INS-:84%4E3B^V4&EHT9Q:O0#K2%@O)*KWC(#G1Z\9[T)Q]\(/1T6/Z536W M78X[UGAUHAXJT_43W-^8)U%)T:GH?K>7U$'M#&?^PO%L'Z4Z_$2GIC7' M/)$I#IIW[2INT30V9)5_GS7"=\8:I![Q&\&=[XU$A^M7"M=5EZ(L3%L;D.;? M"N7>RZR:J;[)@^L],>Z:]'R--V"Q:79!^5[[I/6+\!V)&\2P:1&]Y\?H:"$Y M<&?^WL1K7#\)M2\[S35\!A"YI,.>*.8A/KI$Y:/R. MG@,Q?Y>CRG OMSSJ2?HS"%RB\LDU/AA[BI>C"E%=&_K$$C35VK'8[)SW?J8D M37NQAFG.A?*77EG&!]+AL;4'Z&<;>CYS;=@S8%GK7Q5=AK@98@AC>"T$(KCQ M=S(V.U(7PE62V7!;3L.PI5+;QP@[D*61?HN*083UB0NG! ? ZAWA^*]:H_&H MYU-'6<-_JR:/.C>Z<+.\X&@]7[6\M3*E/F\_^G6_$&3QU\_]ZO&A?&$!UMI43M)<_]N%JY'\$1#.D&Z M"IW?)0SYZ_E,UPB[D37G-?D"[W-[8>["$;K]4_@-+!75=-C)X6YSC+9ITAE;;_ M"P5SRDDW^Y-XQ?ZDRGC[M<[@:YW=JEO!A2R])]+@G_Q_!C@2QM/CQVG%'C)$ MNQFU1C4#N_ $C_AB_VW9;-%YN\.$?8 U>F(!45+5E89)WR8=2H*B/V :T]S) MG+*G$=J>YD0#[[:^J\";2'79JZD9^63""V*GO.@_LT71V,K(43%%RW M,A#NMP(#9=00(^&UY&(9IWNO=>8U7Q+SEMMDE<-\'SGFNX7 1X,]@">*O@*! M58TJE-CGO.#72L3C]$U47_%%!2H<;+WL?72"CAWDA<\!]&%0#;88I.J.8N;0 M)@%U";5TF+@\?F2Q.VG ;W4,\IF2+SX,C9#9U^.A/3+,DD=!8\\ /*A&E2-N M\'8@N2@WYQ_\O;)U#:G\)7=8.;'BJH;(V<>@9 M%O9RY*&(B*$)ZN^\V!K=$;A2%/QAAW'-[L:GEND#X$5X)?LB+ X_."/ M;1GC*F866G,3GLLKZ\H?2_N+.C@NWQ:\E_:3?3?GDJX%U%@U,7,X]M4>L7H[ M P9/GHL$>/4$^$K6PH('>C#^MM1M'@01ST%$79IBJ#D.FB5*;-I46+2;4]U9 MH0$?A7=N8E8I=]B7'TC@?Z%D"&XN^X$[G8,*/UI^H=RAP0AB1:\61_4R3R;N MW@E-$\"5C!"$<8=P%7W'_HND;@'88/"?):>X S$RKX4S9O\#2:[S3][7&;@8 MBO-7W"J^%*LM@))0Q$IJW^N8.VTRF)D8(KB+;86FHC#/1RP=Q712QDGJU:-? MM&S7%WI4%>RD&0V_E\$1&+0"6NV?<(R.GM3:UB\!>T@X/R,B4V!FS*H6!)*; M;R.Y[(?VV-OF= RYU2.M!>,G)7BCW/B%?Z.-TY485/TO(9P.(H;8K"T'6^T= MC;1^EMJK*'= =6?O*6!0Y&T34:?%OW=!+U 8QH38(X^N@Y%79RO%R+98);M1X.=VI4HF.\)&F(4 M!*6< 1N?3Y+3T&G);0!9J^I#, QX:V:5^R,-:"*Q/F :C4$2G)\!9)?3JYZJ MJ'8DH<;\ W,1*G5/0DKN3:?AJ5?N>[@6$T8.NM=;G!%MF.?F%GP&,)LRXB^4_!:0)W6RQF'43Q#HNFELY#-W0#]A0$ZK/!-&*L<;YL!9ZV*4(W!4O4T7#&UJM+"P*COYLT@>I.(I6ERXX=7BDF M)<'MJ::[O_1DZX4!5P #"KAKW!:1R^4 001BSX2CG9+#W-QIT>/5ZWW/$DO$ M*9;L(+<6RW88S+IQHI6KO,*:8YC8?Z63@MHCL[\&;'_R#=DYE(]S:8$RJ*XR M.O)P2@XL.2*1K3/P2B%UOA !Z.OA)GQ;2\E^>,RYCIU_!L#>:>A=3;HW M4ZX?+VCL?/M8U\D.&' =MNP?I00"F M1Z]K4!5._+95]U1,M[9%CD7]652S3$@W1WTW=.[R,>AB,%LE3C9,9>F$H#4"2TEM;O[3#'D?!@'06HO5_!C@O7SP#4CC^O$/2&X2%1O*047:! M)HY7-2K_:56M#'CT]N%>6D6&T@U(X;Y2@2V3W]Q *BY6(!99B_?@C)2);^8* M4)M]HEN7+W>8&P'Y/A96F;"\/_^06D/-OQLY8OH I9Y?%)IF.&@!!50=;F(C M@O*P)H7FM+QTGS FES9MK(>X=IU8[6V'.J-WF"V50O MJ<5(^>LNW\13P\I0K#!P32ETIJ #T?P0Y6GJ0*%C_"+0F%5:-[@W>0FPR;X MT:*BMHB3-( 7;+ @NM- EO;/@"\B. ;TAWMM275;X(Y#$X[_VI!<\Z#=49?L MYL66&1'O#/M4FK?*IVW)B6"A.KJEH5R106%S3"1YNL@@(>%A1FN&@"PSDGK( MWIV&5(+*+CJ"DP;#):F<=FDB._.$$?X,H#\0YE]&Y=TKSSI_3AP3FJO9\7/9 M32!5DUS"*6@4.+TU<(KWFO1'#YI>W.1?8IO)XPCTU/G2OVF\7*YA P2D?^KWN@,D^G?XP"[JI+>VP;VW04S]>Z+'A'7C/SU4#Z[GYJ_S M5TAVA#N1V!"%_V72;[14^A5S4KQVTE&L8*D;AV*D.0 ZFNSW #9$>1Y:LWS) MGK&W47W/ '2(%"+?/$JEO:W'T/N67(-]V*?5PKY;+;<'N2N8 L,ARHA1_2HC MGJR)ZS_.$"U-R/RY";F7]?VUS_*ADY3GTP_=9T!0Y6SO7+42_BLKUDG!9OO* M#.U!2X37@57IOU:0??$L_RGER;K_$B-L*[8#*UJ(;'9R<%6S35$SI;(?Y-*S M_78+$E!H>6;F9SU-MNEOCU4.H9O)_-BV((CM F6N4O>5VHN%"Z9WV8:$X>7M MIDE?99:#C3[P% LP-#C>>3G8\H6%G"N/:6J9$G L]U@SK*69(D?B MO+9P4-W/@'N7-1U/S+PR%C52Q 0%D]B+$$I>+*R:0$\+,?#:-2E2NNNG'%E^ MW -+9J5'MJFCN^][O_/4>S(9'U^^Y4=^:?U_"\I?";Y6Z409(-$'[O9CH!K% M&B4''0U5YP?/ (=,[T4^6ME;V<^=/!/*M-;5KI)L+ZD4\#3>SX%'>(((8=K/ M@,CEQSB*Q+&?^H.[3\.I_8J$*U,<6QXMV:=K 3^"2A57]DJJ&/#!G:I(N1XS M[K_K4N'/ +MV_8@=AY)>"65OK$*L)&U]+P82QSRVUK9\U>[()YJ ;\Z[J2]_ MJ11;-3#>Z/ "!9">QO_7MR6JKEG\"@#I6 ?GV5-:S_]=>/F6"<7M$%([F*,A M'A=;X1KFT_*S( .OI-"Z,?L)&M)XKC>(5MGK&?""S*\9!-17NM,D@Y BA:! MO!@TQT6-(&Z,$1G%WL$E%>U:S#I /1NSI#?W.KN]?!QR_-]AB7,1D@8#3TR/ M(5X@3YUV:#/2(MH6-Y"LJA)8, BW$-:/%4MN'ML33J$+#-+Q^6(1,(J(TD%2 MK.H$8QV(@R(V5LTF7Y953WMM<716.:7\6$CR:FCI75X_#EA<+(1MX4#$%J"2 MK@FP>>]J#SY[L@I'9K74AI0!D@8,_C$WL'ZR=2I',59,;>82N(IEG6VAIFFN M_G" OY:6?9[EML+3T^CF%#*.8-CF3D%0?%JLJ9:4AY%I,Z M416Z=Z6/"7Y)M4''AUKC*?BP;]=\$=I?P[CK63">X^U"C!%!:4@UC0;D'"IH2QGADQ. .6YN,@P2 MDG*953PO31ZG,HA='GGG5G*:_);= =8D"IZ=M#73,$PM[S[2/\"@OZ>9X9A/IG^+U,$_/]+U2HL(17^(U G$ M42G-N]!JE=M3M\;Q0)0XG0S3*=%>U39)2L I>_YY3+0#'S?PBRD>/"):'_8^ M7UR!#6B(G^7G')LD9H3*^GX%.R ;<.JMQH )89@9+G0M,#12GZHS7CNX=G Y M8W=MQS.DR5V^W_90 1!+NL(M^NXM:%&9\O.2?K8_1^!)KSD1 ^ZPHZ;_9DZV M(U5FI_'3VU/J;GWD+TA"?Y+2S\'.XBZEK #>;[Y:JG:$6VR?2(%(GBU6/]>KN F/^EL26J8<7 MOL1_Z3Q$^\0DX?65BKE@4;V$N;]3_LO^AEGBWD6E%#-Y9O^."0&47Q485SMV M9*!2,/+L^"Z\X^N//=]OVF;NC)]6]6S17Y63M5I+:8[$]MAUB>CJ7BO,7@$_ M2INQ#V5[^<>CK["_,55Z!@36,6S43&\O%OXX8B"\/#KAD$L:(&]4$07Q"RN> MY[*!UUBE=3RB4BY/S!8Q]<3=2LE><;#^GLT5U0XMTS#F*))6:T.1;,O@J0/O_['E2[".6S,\A V/WND)XK M<9,]=7%X=^B/ 0'I<7QZ,H^.:*^DP6QM3T[L'L@R=.]X-W='.'V!CB"5^-[1I+>SF1)-TK M-LYI>QCJG6CI+.73>C76<-;:P6]-6U1T,JJ=2RX4G[Z922J=)@?MPJ M5ESQ3#?=>O-2%$0.#EP^^3';')W0!)^DF6AS\ZR?+Z(<8'ZM%O).M,)A/$)% M-U.0[MM^-S?B)G9[L;E=<-E;KN2Q6:'LCJOG.^MYZ6H^?R@(.LWN3D7CQT*W MX"\E#Q>.@E<1)#>[8E MI=\M>$G)]XHOQ16V(:43O,%I*^ HQI3BG?J?:5CE:%-,4O=&VX/( NU^K=,F6]/<@X!GS0>6!4Y8 M"["$VNGV3!QSX[Z@!Y+7ZST)&;A7?-"< 0EASVF*AQUU[$?V:UD#77-R<,,M M/*W(J&RX2PW#(J?E],^@# ';,N\>V!V1Z+U,8L:.EX7LUQEI[FV[=3/? M5E].2RSX[)^].SF/;$:^F'6E!+>L/CW!N4R/*(C'5ML-:UCQY$R_OZ_76\U_ M2[ERHZ1Z"[UGB!ZOZU[#)[ /\&=@'5QIX7C7>^],Q^VW=:I4JV'%C+)GCPXB MQ*?&O><2%D)B4$?,+U)DFRWVLK8K)Q,*4;K:Q8PK_K%%$\-*?4R#LB,'MI.B MX[MQDM10N=L@[>R (ZGWJ $K$X:C@K9L(85,23+UL)GZ$*5P5*K%:U3G\!W+ M,X#0N9G+8(C:>4^T1C#.DRFFVXB'5S/>F#O@5H(QUC16NP@1SB]Q9$JF2SX&L97Q_1^Z'#Q& M+Z4X,VE,>'MU!^&,HV(N2?4F&K/2HEOFRZB]$XA(Y=;*8\2#9*KIZD9@5NHT MO:TE;?OTW:_B7SOXO4+;>>):F \BB\WY+X'XU4"K3?*G861PQ)6?[B>U(+WJ MFC^L8;=OCNW0$B=+DSV 20B+DW<[^:NX6O5U_Z:::V6!@_U"I<8AB#YC;PCG M.T4JF8ZQQM906Y%U5H*_:^(.R@RQ!;O::T4<_4/[]5X(/OZ: M:;3!85;!1S]!W_!ZNT M)R*X;W<<6/<^BW<&,T0I'2B@X,_85GR[>L=J 'VM&?'#L,J+PP]H:+)G@J5J MW5R7/\;PW9H=A9*C1Y.P)D@Y!F !%28&J9E G"+IEQ#N@O;"QP\D+ M)^NXTDG<;CP?. 7"?UH+]Z5Z_-6,JSD3Q)HY5FBRKFT%9\/FWQU'422LF%;8V.\!7!3 MXER7 /3[B/;XZ?,659 IZU/3T;O"8EMSC[,X.>%[,!>($S*-CP G'2H@4L2]^S+OC/1%Q;K!:>DJO0E MB[7L^2X^N\K7F2\91,Q: ZO#)R*YH+V2L#'?,-*UPP< ,40LCJ6BYL;Q%"XD M@(7>6W.$%T@X'D[)GC)XBHP6(<0*F,'^H\CS1-9!( X,26$*V5A5:- MFEV4C^!RM+;#9*(BR_!.6D2-Z]+-]N#I4Z.E>Q:P/8SGD5_:[ OXL'A =>3Z]::P]\$JZSX=@C[0=ND<]VFZ M M8+_ -L-KTY7(VUM-/ADM'9VEMSC4_U+$AV=6!_D_CY HV^.:?@Y/6B5KP;B7 M'$F>(MSM!R6LN5!;&;[U2!T&ER6!@(! 0;R:IR7GGR6?S(LY]NO'1>.?4G]I M26@_-LCC<4UU^7<(2;\5Q:JA:4O1T'NJ*>_+@8J;0O'(&",C\%"():!@B8F&EC0STA;8VL#]+W>/< MR/CWA/ DG]0(8T08[BLG-!I&90TTJ^G6J]HPU<+G;5()_?$3M:["Q,9\0^+[PBG@\ M]M&)L5*Y]CCG(%+6!&$3([V?#M>2,"_R"Q5X]4V"8A MVGBL3P9LZ\-,L:3XV0$#X2F,0WYA+R.66'\K63L],3W5_=(]3]!],_BZ@S!P=@4LO MJB_]-/G*,%EH&S/CAB8K]M6]YJ1^@2LP:RPR0I;.VU+4?9(I ^_R_CD\L3K. MBQ*VT]%17%/SVW<.9EA2B]R&Z3Q3++'$->];2E3>K-I0^":(Y, M&H%^\8XNLSQZW>I,(W-UN- G0"%E#$_Q$2N5N_Y4Z',+-2>!#!@#:6825^U4 MU?JZ)0P](&))F"P97/X%$*IK%FA=8.'21X+5K %K;RMWH9:A10D_7<[$%:C) M3QG7$Z RW]LO$+P5>W$<5-C"%X>O7F]#MP%"$$7WBI,?F&*+HY(%/V+3='TS M:\8"7AC'BPX/U3ONVZ?.^A5B]R0(!K_1&WIOYN]0G9JS7-K"?YP<-6. M$0VLQCBI-%-A=,.9S5 [>MQ)<[FH7][%!-O[H)2X[;I ]@-M3 SND.U/Q@VTU2]7?)7^LK M,]Y4T_2K/^M[4@->ZM*YO(9?6DFDE[G0W41L@AG[W>NM)!507\!U&F^)[Q= M\O]*S^]KE1X S7S]#P!'4$0;"TU6?V=?$L0/"4Q(TIY@G'K"N/J\<#)CG!3!)RY6B'")!V\\%4;Y)? M!8WMOA@8T2'\8TE&EF\34QY=@AK@[*&LN3P%_WJ2X_OIRI9Y_MF1Q+P/$EMNVMS<;NO'_'N M+10X>)SUK*'AC!SI5K"O-^10WW,2YZ6UC^F.9 5V'KGL;9\DBE..=?2#\X&3 MW8JEAY20-VCNI.JCSIA*LH8/LDH-%F\GXJ_&6B_XO?EB7*S," 9&-B*O?P07 M/(7HHD:CSE3*BJK[Q0E8N0OI_FJJ$L@_1= MN<_?08W0%O16FBH'@!]OAP?;/H-#OL/),\/EGFS-J&)J44MC6A_0SCG#40:C M;EY,GZM?. P87$@S?Z=1>*FKB&QW5T"6Y18^ )PQQ",W\QO@M#FY'U-E6<&U MQBN[G&.?<8]>C3"_H;=KA]3PA6EAY,26:%MS#N+$B9/DU[@B!!C5[,M-U1C" M<=V5'!W[[Z48JL"W_=:4*.BGM:L)=U$$MO-]@5OC$C+IN84+NLT7FG0(/_7[ M$,#'XA,!D*?&]!5C[=$V(ROR#&#B87F1I9IZ ?W_.DM7VI7'3>M-J^$P)"*( MP^&_2@[ U0:>"!'?3\F+HLXC?7LD=3'U-> YH(."\WQ+N7.-!Q'>'CF.V:+: MZXT+?@,9=JN'WAD MQ'2RV*$>=%L2EO0_")<)43;+GQS*9VA('":M$8ZF8E&/?P'=]I>"D_FD;RS/ M%#0U>X7.9TG7PY*XQ^^9G,U#R\48'N6GF4#FJT[3SHX)2(GEF0IQO/$4?FJ3 M H).^P:%R+&R7.S]6-A3,S9\2Y[:=MGA\\QH#>Q6>P+8B$1JRB43]_Q=) MNHRG]/)^V.@YAC)70\]TYKS&!3 M[8K$&6(1"4+V*6%#=O#@=[QKSC46^KW=W?&#<[_>-?"GO_,L^BZUUDVE3;03 MKOT(HH-6O@K T*'3D7[UR;**Q4 &SJ"DZNWC+ F&;YZKEANJZ<\R%D8"I._R MAC*<5[XQUUY2_C%CX> ;0G+Q+Z57DIDX=/T1KBKGE.-^84T1+G 93W;6G!3YENR"9"%^A).M3OQKZ&JPX(C;%P$MV M[4O)/6XQ%^OU;+T<1M(),4,%UM3JPYC5MD64)2^:VQ!_GPPI7[?[*C%.<)[. MGW3Y=OS;TZF 6:S:4C?7!7A]*&WM39[?%(GX7ASKEB_>-!1MK'=W:8V_8;D> MT=@;T_F7QP:ZQ;'@+9X2:][<< W5:&EKT+D]Y--X *0L!O8Y]>&XZJL(-A76 MQ^TGIC6"XY%6:OB)5+0?'0W^X':%D,/,G>*:5UI(V>_7#7]DG5FN3C2.A-&( ME[0S?,KGJ+P??@ 0M)"^8W['BK=VN/:=BJBP;]8I9]#9@?#Y;)'? $%/BE:# MA(3QU0@26,\MS)KGO?X=0N*83*#3%]2A N#>+.[H>PI10%TGGCE93E-461R':^_X%.BM:*)1YN/J$0&:;#"B1FNV>C\>WS3]!XL7) M1AM@JTJ-&YI=_S4,7E1 V:V")&49@K>%^T[>^<"V.&,W73-O'%1VH3H&235J M3SCM(DP_M5@LF*C<"D 4,(ME,\76$(U?W:(@4*GI<+FI6%N:9HB31^KC_GA. M@A>;$4GG73Y.A.&/ &"A$9WD?!Z,$)I'$U4PG/)()>*?Q<+8(]WB*](9;MYF\]'OOT Z"U2$H:4L:@>V)G&[0!=9 M$/2L&-( -#ALM&V6,(S)Q:N:!-KP:X#^2DCTR4W)Z3O_(*$4[#.*!,V"_[)$ M3LTT_T&KM"4\DW_]/WA,T^ Y$]28=AV"6+G3J&&Y6.B6964)MSLL0&WF*6$2 MI+=J7;P+?:A(<%58Y@Y2HJ+D/D_LY'6?<5PE%.&.A1,7Q%H+9JWRM$(? &_" M69?"I7M*XR:94_RI4DW MFJ R\!E)F_Z)Z.@+CEY,O.2)Y6B2_"-,\$!K0.CS]%&&Q8QX6_'ZV+]\2:HS MG @]BK'&3)[PJMTT50)GO*5>+O">/ O8_-R8P?&J ZP0X/3]J.&9H)"3U"H5 MX/7X\6CT,TZTS=SGW<&C9&^^8R&,L71^K1-+$3(LIM4_E"S:W&5GEN>BA:]9NA.-75N@[9Q.:V57$&N(XW"A MX. ='&LW9OM;2$8[<_4*0PAG?%$GID#E/(>)( Y(U$(&'XHS!L<]N3MZ[O^D M7&X>WZG'LY<9)30(BO+/)YG%6GQW#GT^OT-E[FK-CKI;W])>]D":"J9^P$42 M4'DDNFT ')\A>_\UHD:AB#BNIMD_+4DQ1J>G]@/7^$^FT==1!B/61(N^F@$6 MQ FQ34 ?AFB)ZR?*0VRCUPY&LD&ZA%,^F*:!? E4?9(;5J'>6A-Y1VS9L2@K M4W5T$S(U-=4RV9\\0! Z>O@8KI4?LQC033+T5AG M>O,-,X$N#?Q+G(@/$$CAYU"3 >NO1NNVWC^"= MS:FU'C5EMR_B'>C3)%VM! ##%J+O [ Z1J$_Q.Z)Z6+(ZE&022 M56&B_,E?Q%O+3^R]W>6"W8=$)UW9:3K).%->$\;>OW8-E>KL0IU'B)%3\&?6 M-9Q(#UH,UI=S<,-3B;APRKSZ>6+O+WW"O?01?E,R.BVHK!C;CE_-75KZA#\6 MD*U=RA4U7MU4&GZ=.GF;V1+TF5P)WL(V%! B#%)6!8TD)]\>+<'8#TFW)#(H MN63I3;F4KD\!N%_RM%"1"Z]D/7*TK9DF#C(YE$AQO6=%TZ82)"#CL"K?1UV" M.HN:DHGNIUXEBWIPJ"^[L0%NV8T NP=>W^=_'VPCOLW3%:89U*1D!FAQ#* MD[\#H_@OF_-+)U73(? M';RCI;2OV1*Q/I;HY!I.+@ &<..^X?H:T7N%GTQ-\.'U&/75+/G8K1.2H ]M M K>)^KL=MY23\LE/2_Y%YH[9C_GH.47PSXD$+P8ZV\9PU7>?.0$>NWC6.NB4 M':L'P' *^12H9MOE6MJ]-^VZTJOHB/T*QT_6+94S+2Y[T$@SO?NEL5WJKQ0% M3!**8!E!WM_W;%T-Y(38M!/#%'?-8K5$K8\EP]]UY$_XK3X>MY5XV^BU4.W7 MA^* WR,23U+WI@PL*!IF(M3G_;9U::*?HUBIL$%_B--#+])L M(:4Y,L6GGC 6;*DE??*[^?[ 9R^,PFR\XM"D=391D_,M[VVRUWT(<.B,LO!S M241R^2,=?(8[=5#T X"XKL6&<+CLT)SQZ*8LLS/IS^RVW'CX>:(TP>V[T\$. MM[R#M78M P1H"$0).$!P=5K7!$BFJ?FV3?*L0L94OM?'E;Q(3H?,?3XN)0*$ M T^PLLA$-?S;()K*R_E*I[*CDK\L\M,B6V)7]#628KP#9EM+SAC)_C6W&VAL M+6?LQQ>6,GVVCX(=)+."W@U9*/JI_Y&PL11WX4PTV; M"L8$-:WP-,S!99L8"=4*T<@D*LXY%%\J8-+_MTPIRO1NG%_K6OO)JS.@A6HC M2@W:RXHI/M#ZU:WPJ*P)<=<6Q'_=9NU?1-EZJ^MGM?/J /!JS9/U@-6_-R!! ME$F-UDGO9Y6*$J6Q9FV63SD/4K8O!N-$^>67?I[K>IN'48C8/VIY^OMY\Z6" M*G#=Y !#:4R3$TUWSNGXW&^J.6)-QF#U .8TF +8/^,Q$5=&W-]ZFT6(U\XV MO6L^0Z]T3F^TO4,OI]8[&4VBXKN+9N.4*9CKZJ8H0%U*US,XL+:@7X'0^0'P M!&(46(;E7P*5]\W7E6L%*W9'V[:\9*R(XFQ+OB78_"WRC]]3=!@L^?L$/D/A MK("*QY3#I(?+LF,XLX:NK#D7&(C]M&KW9DCTE7G5%9U>?"?MV'@L_C-43.$J M!P4:T1)"_C=F[I\G60ROX&E[ ,K,0/H)F1;LKC0;QM& M<)F?Y/DA<@-^F&@Q*KB7KR652);8L]=[..3].VU]:C-D%GE+TMJ%YX/JNOH_;ZQQ&\[+L^<\ZY_X$;UHO MZ5WY=_:DS6F]'8-U)R-Y=/O3IG\'S@#R^2[Z-&*"-_4?NQLV[RU[S(\=U+>$ ME-^*FHY*POBZNCZ53#+'I/IYVR_M.2,_1^W8V>2&>1+*,ER]GH2^LF3]-CNX MY_<-H0>D/5O> &J*04"#F)\>(%7A2J5IT7?+%_(9&$E$ 3UP*<@IH=D&=TL' MF3LDMQ#Z,L'02GYIE3M3;:7UTB)5.F^CP]B?F5D5L/< !;$*32?1\E*T.DN MB.F0N;B[7FR0$ZC/6S5KA%^,G?4Z:$1>?WY$F+3*WF.@B9KN@F^38M04Y[M? M-6%R+M]#QUIGL2YA;A/%XJ1>TF[$3.]@'E*[WU[8#UN$18>RST(D:W20%D(T M-I8V%KS'-U'Y'/-<\0B#5!:/]&O/RFDZ.3(+?@UY.RP6(H=X ,2$TLZ'TDT* MG _UT6'ZD$Q$F09&HMQ@UI/EXW56-;;UC,--_A V!E$MF6F#MP M X6=,Q]NL:$7NQM).726W-UWE7WN M"3J$$,D%,1OR%6NU'0%_VJ:Y-:+3L\Q7<,)L,2IU8MY6HZ TXPZ;E5&D6FRW M(XI<9;8XQ'M9 _4GS<6$9TB"2'QW[N76^_2Q?XFI;(BG:Q1E7,OP]PY M)!@^13P8)'YSY%/:9-XS>'3Q=BQ 3%C#A3YZ?'2&N/*#O/OB(H0!LXFZ[)<> MODY%W,Z0 P-:)?1<4]5"/O"??X\7J/:C=/FLOA=J[(B33.=+$S-YKVYENQG*S8 M;BGO6;/&\"*!\ACRK?HIH!IX+L3_ KZ^KIZ&JX>-76A2F!CX M0F.0&"$:_S?EOUA<'VN80@?NTE]\#NHI=Y&:%Y ;^0"2@M[.A=)DW4IAI5 / M@*$' !0E_TE@\^ J/3>W>A(3Y3/)]D^BD8Q:<+,HV+[/_*_G8$\B$U"9_#&2 M>3^SYJH18U(>74YB6*_'%;!OCW$:"**+K+F?*CJB#7JO=AZ22:,:YN]1$S+. MW2&4PNLF2\S202\@&%EI=CS$NI'L2/4 V.5.ZZ'\SER=CHGT*[8&B\+\I:?+ MG>SMN:(^;XY[\59$ M0RO$&:GENK(ZEGZ6&K+2BN!@5G]#W.8XRC%S3X_IL\$4NQV2%:/F>P@JT(Z? MEC'UXT.(10WC"FT(C^#QJ9LVYTHR^=[,#/9RSV/M"U=/I"VW_)+F0$H31E_^ M./K)5K^<:,Q7Q&?)^''4V5TP(DF,4C-Z%E/'5#QUF8T4_ !B2 M"^%$A@ZI+:.;;K^F&:]B,'CP^OC\E_/NXG+2( KPD*E)S%SP28=#I$J3+OZU M<#^]ZG=5F-M'.0>_KR9"/ -ZI;O:;/E^J6D[ MXZ5AHE%M0PHT8JFEF.KW]\OS3>FNRU0C2?B.)PV?7[_SB:"2-#J++$@0[-I>^?EWWSUD11 M39%Y[>5&V$D557!?4(L]&JIA$,,+KM8/[UP]=$2&$ZP.'_1:_FFI#K3>.R#4J)MJ[<<4Y\0[&-V-N)5:O=> M([N^KN6<_/GV'^S1WTO6WZ*WIM:ABS;D?RU.G=Y!WZ%IH;Z96<5CDJOE9%TE M::]@&6/X-)SPY';Q/VM_:H1-S5<8+H<^T)33?83^IZLBY^+XO1?_>V7F,+,W M,@U^(@*<4$!\[Q9B[H%=KA_["X^6D'IQ]K:9ZCLSGN%_V&AR!#.1GJ21TQQ? ML*4^^?Q8E@*8'XDXA[J#D+U0I?F2[ICEW\(_!9:]WQ#@VR?3 4B"G@ N1C&S MI9!W34V_ZB!"S*BE9M._"186)_T-FK<596X3%4K\H:XIXAHRJ3^Z<3W];&)# MB6;Y0>*D3OVT:R%U"=]9>:7VWMS[>@X(K4I04+/^J5AT^.!MUDC]L:=X!Z$3 M57>ZWY8U%&2A*%YL*AOV49>TT][-%"^:WIKP6JVP1LY'<0["5^>B-#JPYG=S M#&1)#7C%=Y#@"3!Z/ &!Z4TZ)/)>PW4)1;:9:ILS%WA:4/TQ2T!@B#YC03.U MYHZ(DF/VJ]C*Y.?\=KOZHZ__>?I8Y5>C1?C"\ Y9GL_]MM!-MY&(*S?7?-%& M=LW+(,SQV1] SN,B:XNKS?<.%--+UYE\Q/IF/D^P*'G+\16 Y36*P\:VR) D MS#?(\"E$< XDOTYZ:>4:9#47Z%ZRK>W8D.3])"HJD7NSQ$/^['4AFMNJ!C6&E-R*X>1 MUPK5(5K!:L[R/P!VSFZUVX'$7> 'P,'WSVZIIF2_HW"6G6G.<[2S7(I=4*8K MYD..3KA1\5OX3V)+?N"5ZLCR>3&J'MD^V@AI_9OLFM9:X$P(B5^ V[4LM,]#. MT]X4('*38]C]U29!-)+XL-8OACE*OY[JEO ->.]V7F,288*W_/4'7P3:"?8? M>#(.R5.U)ABAN7':,S^$CI86,6EX#V%B]S[8?&V_K;XD>Q;Z6@VM9IHR>,_: ME35PH?X^H#._II)IE<0(\4/*^2"++9(]Z^U_D(N2 PV&4LW+TI6,EKD8;SNU M&8O(B-*FN5AD9:K)=B<&\L/27' *X"# &EC%H\XQW\K"JF_M)KG%G[# O]^6 MA(R2VK.ACD;-+4W'F%KHG75&] XKW5'ODU][B^)2S';&E&HD+ZR!<:8(]CA" M(0X6W)1=4@!/HJQ=.9A')=U@(4>'_U4,(YBB^UI4DHA$72J0'@7 >N*([]P+ M_/(0'SO]B$[.HJU%UE.#YIOKR0A,(M5;^'K]QQ^9&R4Z[G.<4ZOLG ?(4Z/J MBBI<^U#9F#$5VGJ&5PWSLOU7-_SXWCB'\S\> &8O'@!^GH69M:A3;G1,:256 M*9/VL_7;)7,207_W'ZH3XV/_M(:2=G?.'O>\%,MI>JI1+7J@0(85QS@5*D3Y M!6_C;F@A-NW?64RVG[=H)AGQ[[[H5V9ZD\Z-[_%S3YW1^Y67]3;7KCP%ZL8" MZ%V?V$OC*AP)JM:X3[OQU8J(\PP4&9AW>P $OI(\.%],>8Q9.)G#2B\4_9)5 MJ=MG;VI+ZLK6B.J&9K3V;KI ?.7N&<_YL:' A#E>Y/%=),Z3%#JL-XJUCJ#W_>!Z-)%*;I#7, M@!,0CJT%KDT:B$T%)#1R4SE)03^"KU9UFEVTE76DO@,Z2E T@A MG -8']FYVAKKVP:9W2;]4!=^M6O1KI".70I_VSVB'5+-?O.(=4R7#CJC(+JE M*U>G6;'.?*+*PT[5<-V+$NE =AS-Y&'L7EAM/*J8$_H(^_:7(H@$Z[Z<:B+C MCE6VIL*HP:R9YFQ%-[@**,8\N:PC=)Z:!&B:KEV8? M?.AX48JS\YF1)::GJS^,3I:C&H@&Y@MW+H"P^M [EI?\&LWS(F3VK?$2H6IL M$SL_0;KR>I?0W[>W%!@^>,'P/MJ_ 7FJ.0(=BB-K^+[JRJ9;JC:^387JM7_Q M7&7"*7AW[;.7P:]O)G>7ES7<<_-5_^I;7_?&.*8>'3S8>1U%]V8>J^)"NAU; MAY@CS]\G3'YF<7U!\_GEX"#GP3+-B?_2C7;]=X$:3:<*EUS\#USK8BIO^NEW M*1--H!!5C!$\A-QZ7CPX^_S/IL36,P%WWR3&:9?R[J\^7Z#\4#?AR8SU1%J> M3Y;?MDG@BR"]4 9EP7J9&N_6TAJ72B<[,C@]04!XK>DT730YJ\0 T1( M$(@EA6Q8I*Y!H,1\S;2F/6XOD-TQ OU9 AXAFOBT ^AZ"2=/V5>59UL6@EC@ MSAP,V=G7B?FGPB%5[B#V[/>$/->-/S@/XO>P&N@P&$/2,I;-A&%@OEGF:U@C MJ XDQIECU5_5D]=D.G&LH3]Q$:AHO^NY05*MN% &S\L5K2CG]4Z2,FM>O-/) MQ6H\]JJ:6"LKHCD]S2-/2[ F5-FK%/"V!;0JCMZ+)X M(9(U+>9O^D=+]GIM5&;/ 2E-:^IEK\.V+_*5OV7QY!0A9Z#W1"B">KF_VU%_ MG]O;[W?,?US66LIF5XWGN27_A/%GQC\DAT:EPUI>5%*N)"BGK<)+O MJ#JBHQ*8.$HHKEV.GK3]*.SN?*%))EK0^YB-UN :N.\MVT27555@7CWS\X^\ M9,Q%8JAA58T[R.7GGQ-[\AW00 BC$9IFI*/6.<32O M_A%'6UORZ]UH$QEZ_%1%?6F&8WG:PVT*(?%-B4F-'M3Y8,'IBT=_\TM+S<5F MP3%L(G/$SWE62[)810N?+_NK/1LU@-O\-]CG_Y)CU'[_9=R.DH9%EUJ$B/RK M_;->=CQ#]RW?V "!3#4I5_=*0QV9A;LG.-8'K,Z]RR!G@/YPLAL MGEYLK&^N._@\W[@W!*M^T-#]R7<\TRI[<-5R]U5>##,R*X151':Q,AP&:62> MG*;A_UAOMQ5:'7)_4^C3W"3,41M8T-_' /&Y*Q5OPS@1)M;*"L&G1#94JK)] MJ]79&UMUOK"K[573<9*0/2G(3DT.K4L8F<,*+PA\Q-R6;P,9ACO%%Y/;\-2\ M2AXEIN3S>1I^A]M^*^G8^[+#!C% 9QEB[)'J$!-:J&1BBY;JN5'[PI_;CO.2 MUD:1C4SGLT7';^_;T$Z=,]OGF*U7T(;SC'(G6N8._?@HB%K"*W[L&*CCLWLL[A&>F8"#]AQ=. M7GBE7@6$OJ80&82 _L4!C($@GN.;M55=:?>+&-D7T5'O'.R%O:L2,HZG(BK4 M-% '5[%]"WY:'$,L$@LM4XSP#%:Z<^U+&"9DJD16R^I$"=E&JU!8(FQG,$(:ZLY.!!"4W](:\W:N2SN4L?3 MB_K9BNK- ^*G%J]1YU'0V+%-BM*X#P\!/FF%$#JAS; *B&WREMYRT(Z[MI;$ M:GOBP$>[ZN?LG:J>GZM+5"D-ZT1O?YX*7&:=$J%DKESF[-/?H_*[Q63R MZ-Z[FQ@O_#YS[$DV7?4"X2B(?'7T;N=@?#-^S)=UE]PK"Y[76!8G)[=P19M; M!5+HV#T B#B$YY&MZMB^ING8H@RS]V_?=2DUGGU0MCWTXEX:&1V>6>=#M@V1 MQ[5=6=.B::VW5'\8;%I2,=>CWF[0%$:3M!K FPT6HOH7:,+ADRDG9-LP MB,3F.$MW!=.)E&&L_O;]I<=L5-)W1Q,'QT1"(_U]67?[O/8Z420H&H+?RSWK M+LO-"7W3W$+I*DFAPW^Y]8XQ4X#-B'^H\JW1,SB3SY0%C3(Y5F/EAJ0->OD> M^0#0*WKYK[1\N^%WJ!AZ-%Z6#QX("2S#)._HH7I;+TTWCA@RBTAS!YYGFK8) M1.>^Y(TW88NV[2?_"FS"$.Z0DT \T;VIB!#V$_UYL6!6,DOB=5*Q_]BU(U.R M+8DUI)?3D6T\XE)82LKH$%( *Z#M9D:P/L%HK_>SD)FQT[H[(:>>&H0+U%7> MMB9+73_?<-+C;$^7==0@Q&.T06D?B0EA+$B9$R7C:M6*;7(/VAV%Z;6&V]L, M^Z?A1==/%_*%;?A@*__4V(=-!@RO=PCFDX\.G1+'&_YI@>=_OIB@"]'[L]]V MRXQENK P6&P.'J")$N*PL@0&N/Z %38U_>3\[7W MLR^7!'M''4$!%:["(<7*Y-_"B1XC=OZEII"13VB%Z%6;U=66;)OF1GH(PM.V MIU747G:\.WO27\DA-81+]DJ1YG)7H6&SY>]_RJT#=YSS^]Y6GM7^_NVN4D/[ M_JK *5G34$0AE0VB[9^7.SH1^[I^#QLI"T.^U"YS3ZG5=KEM[7.ZV[IW*OD; MOP*6-@TT)_<+845ZR=-BE&]?6+IF^DN+/566N[%H%@UITD^FN_S5_>+C!TJK M6=,J45RO_GHMC ^*#WX>"WE9E4*@$1: V%1R:NJUT/J(&O;B= +R>4#ROO]E MC99!L/XN1SP H&U+UYUE)?^IVW$OK_@&A<':U]^>[3O[4^9VPU'5M6R?52U683 M-^=A32%TP4\R7.]'CR\S*ON:0N1/\FUVSJ%+"K@0O! D.;YK+_OL7]-ZW^%+ M5I.N/A.] !([AF>.L,J&54AWN"*;[:6I24&S2;18>UD[&BPOCO9X[__T6/L( MWR<_<'/JM,5]3/^-(-8C"I68+,E-,TYH47W78IC@^D1:KOBU[$MXF@\4%>V=4W[Q5#^?^V;ZWL7!B\(HV_> MQCG,YYCSZ_!@O%4"?VQJ;&X))&ER6Y=D@#0G7*W4>8I,;[..=>!U@GL['EPC(V[_1OM2"_U95A0>"(H)F.Q23O:BW[.3++!;!"* MG,8$%W1W$B ?C8WS@#P *3# L MJ";1O=G,>DY.^C"E1WRX/F?DM:KJOY+'&RG=,+S1DQ/D>#6+LL2H2P1LF8$@3S*N M^?N/V2\)ZE)W1T?12R6B#X MICULAKI$;Z[YL*SALSLQ:4V ?E/L! F"6=4LNUH>^ MK![]EM-([7W(>6TLV4E2S&E$TJ@4K0Y()'/&(QB%EV;%-^>&41R&474' M(Q("$884=:4,-?(V9Q-??!U)GGSV&E&L"5'67(0(<8^%N?PKM/7_QU":GP7> M\.]7<5LNW< R8_P*CVH#JYV71-?6U'HM:ET-I-F8FI,=/Q2FIVD3:(@GE9C- M[*B80DB_FV,X!A,];VY<9@<"_ O^[%%:LN?/JY?7&9&3OF&QJ80XHI=2Q$<* M$/7,*U@M-/Z[VKL4(#PA>U/9-[ LV3:5!Y*:1HA3/28O=2@OWK/ CI9,[I;! M-3O.\K+8398:V!*W#N8W(1#T @GB&4F FZ5AVC#UB^PE670,BA9BB&AR1 MHR7N<*1-[SEMG@^G%BPR$J*OTUV^J5[/QSEQ[&@:H%JJ[;\Y0PP5<>W@IOE5;335%G9\H-B5$G1) M3C'Z ""6&8T<^D[4+8SX1W5B.K;)?+K*6-C,T5FXSI<<>/&)*6<$O9]2"Q&= M.UT?Z.5=R#5:$*0:>C\K7G)7 N2?)A.Q>,K.'N-OQXU;!/]3S4+6CF8=M"$? M*G/=>MJQ5&+L4M=23SXMN-O9[M-IMA=]I?XL.SUZ.QD ?W+#<3QYSYP#BNKE M:$7UK#>!=0RRZR(#GO/\]F$)[?\=S)H-@_V9"'MRL$#9YK36?;\SO/4(TU2\ M=2CBVCI?"PMV:NBP!P80'3.IL9FH&>-$VK.%JP0&)"NX$,D_.EKC3D#F5@CY M&=2NNHQ7I#U>\#UR>'G5$ F+?<7)C.4>O'890&PS!,NG7/)&):R M)G=?RI+G5'I\:;UAOFEESI]Y0F452,K>6-+TJ2-1*T4QPI,TR.T; #@-<6&- MA!!Q?ZWL@];6^YUOF1]>24@<+OMTG0E^C@PGG-[[!G_QD3/<&?=+ :/.54@M M+)2QKQW81U) ::'RM+KY/+N_^4V'/;>#7A?]0>*EC3S6$T4>WN<:\F%$B.EP M6>_8OU-YTLG+J5J\.0@8[?(QMB_UDG63QH<]\U&H:?]D0;DL!]R,^]?\/54N M,POPJC68J_E'VW!/1J[[ T E*86_D/W,/@GF20UX"=&$YQ&JS'J W&7%2RPW ME!VON#2G?@Q=^0RHA=1&#\C%27'TN*NV6(JK&$=]<^BLI<_1-W9*QN++4V!8 MRU>PHBB;J"RM)<=?V[ XP"&XLF77[I=&R:?6_W><]A,9:$6E-C]9!T'9TUY M!;Z%^9N_EWZ_%',\ *)URO)?6DG632JT)R.T^D?H_6*_\\2*7!/=FN)8>;S% M%$''Y^)P,'G./4K5 N?5C8JW'IY! \8/$>E^P[^F2L8GPJA;D M6CWIH)G=MOJI]V1#UCZA%,\3I309AGW?;6@02T&EF:N[0];-5(WU.]?E?DU_ MD_Q&RC1/]1E+*FF&HVKAZ/^WC&Q_G$\YVU)KH;UPWCQIT:.F]1$H4UE"RM7A MYO%BL^G3-^-A:D#XA\SX%SBBJHB3*=WEM LM.ETMJ0A74G>V5OM/\?-WIMO:QH.-^WBVM>VR6L:*XW]J2*/3C&H$:)PM M/D:^!6-SJQ0Z^0!@..]SKJW>9[D5K"0T5L#P G#!I?&/GXIH)>1(R?NT)QK9M)HSVE!.5^]SX7#:>7))G M]X(9?P(% RPX*_5+7ZA:HKVN,^YW>+\LODWGQ'@A@5][R3!ARN@'0+A0/;RQ M(7[D!@C$"7RXJ :^]^_DU92[I;?? M7B03;MID<;7_[RR1! TD%@BV1G^?0H(%,E_XKAJ-6W/'\7M>^ (*>?;XMN70 M/[/!?&T8G[+F%:SX]4ZBNZ'N*P!S. VJX/?RK3:XR7QA#]V6_ #XX1M"")LC M>GL3\OUBHU'E]GLLZ#-^M'\'B^GG,Z?-".#I# FF20T=FLY26NSJWUG[)8^[ M^8MZX0V3K_QH#B ; WHGF=D6MMH:!FPQ8.[^WP&G"(V<$>,SO=^\UU^H0UZN M1PO^C@=<6@4/WA1$B"?T/<7(KY_J;2KDU8 ]1&A VJ\\!"YA 0 _)OX>1E(H MTUDE/(P$HH0Z:T'6$[GTK4EV#I>L6ZYR(I>G0>(,;_U2GWUH)Z4G#/(V(3V6 M*WOO?O+/I !<,A"4&5>G@^PCJ+$W_4)^2LJB=G':XLOD':3F24@L%-;YCYX7 M)P$11H210=)%;\E)'!BW96X1RTDX=GQ-UYW?;?KH'!4/S\C0I-+$I:=09(LT M8Q'$X!4>TDKG'4 ADH&5+7=)O5\KS-:/N1R#31_S_JH9*'8A +"=CC&]DO,7 M^CXG"[3G29$5K59#@"B/B@J[Q^C.O"OL=EFC1W$ M8*;E7G2(6G7-](P#G?NMUS>Y^!]JZ,GJ%^3L<[/]!B^\I-\8 Q<2N%C3H3*[ MJL#QQ!8]P8/[H^\;6T0L'P#%C$!J?F,QD:*?;T<4M].'<,)7!7MS-=$[KDM; MU/-^S*'S^F 3_67K7;,C!'O*^',N\/K/"0_"<56FNSUXRK<"Y#E4GBOT5^?, MT'J@GP+]R1.J6\TEM_.B6Z:U'.ZC#Z:.L#!'%<['NR(%J:WP2^L&M/)P'Y78 M.7'KIQTM36V4LFL2J-3TF(4E2CQCZ/T D]S"Z!US!G%>+H$2ME'X-8!9/I>L M %F/>W3/A4Z)._W#3*LJVS9\]V)9Z.R.V+"GW<'K/] MQA2K46U>_":+5G>RQOJ%+HW)-,X5 $"_ 1AM^7C"(H\&C>RE:Z),8NI_0X3_ M@_OCG*7J(+&##M[ B-7TGR'?]ZS?%'[J,(R\?('/HX-N&Q%PU1+N=N0JB!'@ M$3ZALV8,-Q_PG!PRLY@>+O59T!!IC!XP8FQJ6Y&E0RT//@#(_AS^[A8M,CUL M/>Y2F/V L^+WK^!<^#Q-@R=GO[F +,F(+BNS; /1"\ MX\*\K_\D=_11'-Y3HNYKF6/JJ\"Y2/*X']P)RG3GLJ/,S(6)HR3 _ !U&O#) M&R;).-_M)R>]./._$2BNW@ROJO':%8O33-K[B8X(OL1&?N"E6/'&+MN.G :> M[,%0<%B4M\L5"LN!L:O71!+Q(_,16 7QI7002;3BJMQN&GL:F>IC_YVB>B]I MMZ5.2.=,BDWP&$P M!DZ?<=DU=@U)*!R<>ZY:#PA(>C.^WEW.LS<DW^?B,+Z\'B#=B3@[3860$NIO >AFRU#XE M:)5R0SU;KVOD#__S7LV-0W)Y:Z7TI/Y/\?\L3^(:>UF_<&0O[AZLJ]7VD+K, MY5E<\!7DVS">-Z] 3+S*CFBSKJ2YXD2&@15;C$M*)CP3WYH"?WRZK_V$YW*4 MFGZI6HEF-,Q!YZ\9M8:S9KX*3Y/35@FY13?!IT83>U^;'^5SHK\LA_(LN1?Y MIJBA8)YKHZ"^<=VJ:[L]HL0?B>IC)3ZV)E/H^ZG_P%P+_T0BC.KO2?O$NU,7 M.BC\J=)X(&EY)N(LW%C(A_BE0$12EUSU$9A.#J%0NSSBU+SI;*BY>EM;K2 ( M/5Y=IC$N2K/UQL;_'P]G&14%]\7K0?!%Z4[I4BGI;FD! >E4&J1KD($AI!ND M6UIBJ*$9ND6ZAIP!07H&!49BN/[7NO=^V&N=C^?#7OOW/&>O=6HKG@MN6:C] MK+*N(D3T.L@ZE/QH]_XVGAO_MN?%^+BGZPV^-5IOM-LF>F4.4S60]W,TH]IY M;C4J?=;\,-UL./]]1ZKRVUP[@#N)AG=BRA=CIR@%QSXB%^, LC5@R["!N8WK MKGK1C1[QZUGXEMC86A9MFD?\N'8$V'?_O? 8KMAE=,RM$'!%!5BN%^]KO6$Q M.&>V8;,V+6/N$!!) 1W+$EK?VZUT0_S+:\1)MC!$T/EPMH;G9$'/_@&@DA_7 M$NO]GT5X]\&(,O^[S/I0^*6\Z'V>NYB[A/[BQP/4^V5^@:QE+$_OXFC^3VFI M"X_7ADC>U8$-4)LQ'@2/X<90"942(\^&";\SV26<%AS+*P]<<<[ZJ!8N.@N8 M_>LH,:A5-:5N^8; #O LS4HO1DR0$CL#X[1Y?/1IT9I]]OU<.G+TLE7&B2:\ MO. ^W9!_4(2-3*;$>)PMFO01S!LSO5OHIHFQ*IVIPK0,^+@$DH\*_%G7 :P> MI4T(GC->-_,^#=N,&!]ZYFUC$3DV^]TK;?2]P_13WLI0=[44.>!<4;:+0KYL MA#O#F"JLLZTI9VNTF?RJAN/)O 2()* !B,L3QINQ+,^^YM*NATX<]>>B.[XUMFS_NXJ M/L#C7PHH5'=&2O4>3+?Y7':1Z-Z@93-I)Q7 MGJ5CYF=WM.Z(UI\3V(';2@I^5;G X17^?]V. M@E-2%!P? *0AF3!6,WA=*$'+[)#N%&SHC6-2Z@AK4QJ8N&>\K,OG.UJ M_1NHY Q?Iã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Ǻ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Ð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forms-1_htm.xml IDEA: XBRL DOCUMENT 0001829247 2023-01-01 2023-09-30 0001829247 dei:BusinessContactMember 2023-01-01 2023-09-30 0001829247 2022-12-31 0001829247 2021-12-31 0001829247 us-gaap:NonrelatedPartyMember 2022-12-31 0001829247 us-gaap:NonrelatedPartyMember 2021-12-31 0001829247 us-gaap:RelatedPartyMember 2022-12-31 0001829247 us-gaap:RelatedPartyMember 2021-12-31 0001829247 2023-09-30 0001829247 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2023-09-30 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2022-12-31 0001829247 2022-01-01 2022-12-31 0001829247 2021-01-01 2021-12-31 0001829247 2023-07-01 2023-09-30 0001829247 2022-07-01 2022-09-30 0001829247 2022-01-01 2022-09-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001829247 us-gaap:CommonStockMember 2020-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2020-12-31 0001829247 us-gaap:RetainedEarningsMember 2020-12-31 0001829247 2020-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001829247 us-gaap:CommonStockMember 2021-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2021-12-31 0001829247 us-gaap:RetainedEarningsMember 2021-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001829247 us-gaap:CommonStockMember 2022-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001829247 us-gaap:RetainedEarningsMember 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001829247 us-gaap:CommonStockMember 2023-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001829247 us-gaap:RetainedEarningsMember 2023-03-31 0001829247 2023-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001829247 us-gaap:CommonStockMember 2023-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001829247 us-gaap:RetainedEarningsMember 2023-06-30 0001829247 2023-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001829247 us-gaap:CommonStockMember 2022-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001829247 us-gaap:RetainedEarningsMember 2022-03-31 0001829247 2022-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001829247 us-gaap:CommonStockMember 2022-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001829247 us-gaap:RetainedEarningsMember 2022-06-30 0001829247 2022-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001829247 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2021-01-01 2021-12-31 0001829247 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001829247 us-gaap:ReceivablesFromStockholderMember 2022-01-01 2022-12-31 0001829247 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001829247 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001829247 2023-01-01 2023-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001829247 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001829247 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001829247 2023-04-01 2023-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001829247 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001829247 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001829247 2022-01-01 2022-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001829247 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001829247 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001829247 2022-04-01 2022-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001829247 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001829247 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001829247 us-gaap:ReceivablesFromStockholderMember 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001829247 us-gaap:RetainedEarningsMember 2023-09-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001829247 us-gaap:CommonStockMember 2022-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001829247 us-gaap:RetainedEarningsMember 2022-09-30 0001829247 2022-09-30 0001829247 us-gaap:IPOMember 2023-02-13 2023-02-13 0001829247 BFRG:SBAPPPLoanMember 2020-05-05 0001829247 us-gaap:ShortTermDebtMember 2023-01-31 0001829247 us-gaap:ShortTermDebtMember 2023-02-28 0001829247 us-gaap:ShortTermDebtMember 2023-02-01 2023-02-28 0001829247 us-gaap:ShortTermDebtMember 2023-09-30 0001829247 2021-06-15 0001829247 2021-06-14 2021-06-15 0001829247 2021-11-19 0001829247 2021-11-18 2021-11-19 0001829247 2021-12-13 0001829247 2021-12-12 2021-12-13 0001829247 2021-12-01 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:MarylandTechnologyDevelopmentCorporationMember 2020-03-27 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:MarylandTechnologyDevelopmentCorporationMember 2020-03-27 2020-03-27 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:MarylandTechnologyDevelopmentCorporationMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-09 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-09 2021-08-09 0001829247 BFRG:ConvertibleLoanAgreementMember 2022-12-31 0001829247 BFRG:NewAgreementMember 2022-05-31 0001829247 BFRG:NewAgreementMember 2022-12-31 0001829247 BFRG:NewAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:LoanAgreementMember 2021-12-20 0001829247 BFRG:LoanAgreementMember 2021-12-20 2021-12-20 0001829247 BFRG:LoanAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:LoanAgreementMember 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-12-20 0001829247 BFRG:LoanAgreementMember 2022-04-01 2022-04-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-04-28 2022-04-28 0001829247 BFRG:WallachBethMember 2022-04-28 2022-04-28 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-09-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-09-01 2022-09-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember 2022-09-01 2022-09-30 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-30 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-01 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-01-01 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:AugustTwentyTwentyOneNoteMember BFRG:ConvertibleLoanAgreementMember 2022-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2022-05-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-12-20 2021-12-20 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember BFRG:WallachBethMember 2022-10-01 2022-12-31 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember 2023-02-28 2023-02-28 0001829247 BFRG:ConvertibleDebtOneMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtOneMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtTwoMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtTwoMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtThreeMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtThreeMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtFourMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtFourMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtFiveMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtFiveMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtSixMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtSixMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtSevenMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtSevenMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtEightMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtEightMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtNineMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtNineMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleDebtTenMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:ConvertibleDebtTenMember BFRG:WallachBethMember 2022-01-01 2022-12-31 0001829247 us-gaap:ConvertibleDebtMember BFRG:WallachBethMember 2022-12-31 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2021-07-08 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2022-12-31 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2021-12-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-19 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-18 2021-08-19 0001829247 BFRG:NewLoanAgreementMember 2022-05-31 0001829247 BFRG:NewLoanAgreementMember 2022-12-31 0001829247 BFRG:NewLoanAgreementMember 2022-01-01 2022-12-31 0001829247 us-gaap:RelatedPartyMember BFRG:SimpleAgreementForFutureEquityMember 2021-07-08 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2023-02-28 2023-02-28 0001829247 BFRG:ConvertibleLoanAgreementMember 2023-02-28 2023-02-28 0001829247 BFRG:ConvertibleLoanAgreementMember 2023-02-28 0001829247 srt:ChiefFinancialOfficerMember 2021-01-01 2021-12-31 0001829247 srt:ChiefFinancialOfficerMember 2023-01-01 2023-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001829247 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001829247 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001829247 us-gaap:InvestorMember us-gaap:CommonStockMember BFRG:ExchangeAgreementMember 2022-10-04 2022-10-05 0001829247 us-gaap:InvestorMember BFRG:SeriesAConvertiblePreferredStockMember BFRG:ExchangeAgreementMember 2022-10-04 2022-10-05 0001829247 us-gaap:SeriesAPreferredStockMember 2022-10-05 0001829247 2020-06-01 2020-06-30 0001829247 BFRG:NoteHolderMember 2022-01-01 2022-12-31 0001829247 us-gaap:CommonStockMember BFRG:LicenseAgreementMember 2022-01-01 2022-12-31 0001829247 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001829247 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001829247 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2022-12-31 0001829247 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 BFRG:AdvisorsMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 BFRG:AdvisorsMember us-gaap:WarrantMember 2021-12-31 0001829247 us-gaap:WarrantMember 2022-06-01 2022-06-30 0001829247 us-gaap:WarrantMember 2021-12-31 0001829247 us-gaap:WarrantMember BFRG:ConvertibleBridgeDebtAgreementsMember 2021-12-31 0001829247 us-gaap:WarrantMember 2022-06-30 0001829247 us-gaap:WarrantMember 2022-05-31 0001829247 us-gaap:WarrantMember BFRG:NewAgreementsMember 2022-05-31 0001829247 BFRG:WarrantOneMember 2022-05-31 0001829247 BFRG:WarrantOneMember BFRG:NewAgreementsMember 2022-05-31 0001829247 2022-10-05 0001829247 us-gaap:SeriesAPreferredStockMember BFRG:ExchangeAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:PriorAgreementsAndNewAgreementsMember 2022-01-01 2022-12-31 0001829247 us-gaap:IPOMember 2023-02-01 2023-02-28 0001829247 us-gaap:IPOMember 2023-02-28 0001829247 BFRG:TradeableWarrantsMember 2023-02-01 2023-02-28 0001829247 BFRG:TradeableWarrantsMember 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember 2023-02-01 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember 2023-02-28 0001829247 us-gaap:CommonStockMember us-gaap:IPOMember 2023-02-01 2023-02-28 0001829247 2023-02-01 2023-02-28 0001829247 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001829247 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001829247 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2022-11-01 2022-11-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2022-11-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2023-09-30 0001829247 us-gaap:WarrantMember us-gaap:IPOMember 2023-02-28 2023-02-28 0001829247 us-gaap:WarrantMember us-gaap:IPOMember 2023-02-28 0001829247 us-gaap:WarrantMember BFRG:UnderwritersMember 2023-02-28 2023-02-28 0001829247 us-gaap:WarrantMember BFRG:UnderwritersMember 2023-02-28 0001829247 BFRG:TradableWarrantMember us-gaap:IPOMember 2023-02-28 2023-02-28 0001829247 BFRG:TradableWarrantMember us-gaap:IPOMember 2023-02-28 0001829247 BFRG:NonTradableWarrantMember us-gaap:IPOMember 2023-02-28 2023-02-28 0001829247 BFRG:NonTradableWarrantMember us-gaap:IPOMember 2023-02-28 0001829247 BFRG:TradableWarrantMember us-gaap:OverAllotmentOptionMember 2023-02-28 2023-02-28 0001829247 BFRG:TradableWarrantMember us-gaap:OverAllotmentOptionMember 2023-02-28 0001829247 BFRG:NonTradableWarrantMember us-gaap:OverAllotmentOptionMember 2023-02-28 2023-02-28 0001829247 BFRG:NonTradableWarrantMember us-gaap:OverAllotmentOptionMember 2023-02-28 0001829247 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001829247 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001829247 BFRG:UnvestedWarrantsMember 2023-01-01 2023-09-30 0001829247 srt:MinimumMember 2022-01-01 2022-12-31 0001829247 srt:MaximumMember 2022-01-01 2022-12-31 0001829247 srt:MinimumMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 srt:MaximumMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 srt:MinimumMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember 2023-01-01 2023-09-30 0001829247 us-gaap:WarrantMember 2020-12-31 0001829247 BFRG:ExercisePriceMember 2023-09-30 0001829247 BFRG:ExercisePriceMember 2023-01-01 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceOneMember 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceOneMember 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceOneMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceOneMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceOneMember 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceTwoMember 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceTwoMember 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceTwoMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceTwoMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceTwoMember 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceThreeMember 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceThreeMember 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceThreeMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceThreeMember 2023-01-01 2023-09-30 0001829247 BFRG:ExercisePriceThreeMember 2023-09-30 0001829247 BFRG:ExercisePriceFourMember 2023-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceFourMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceFourMember 2023-01-01 2023-09-30 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2018-02-05 2018-02-07 0001829247 BFRG:YearTwentyTwentyTwoMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:YearTwentyTwentyFourMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:OtherPartiesMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 BFRG:InternallyDevelopmentDrugProjectsMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 srt:MaximumMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 srt:MinimumMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 BFRG:YearTwentyTwentyTwoMember BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:YearTwentyTwentyFourMember BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember 2022-12-31 0001829247 BFRG:GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember 2022-01-14 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentyFourMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentyFiveMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentySixMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentySevenMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-12-31 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-13 0001829247 BFRG:YearTwentyTwentySevenMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyTwentyEightMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyTwentyNineMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyThirtyMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyThirtyOneMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:LicenseAgreementMember 2022-12-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:YearTwentyTwentyThreeMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyFiveMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentySixMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentySevenMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyTwoMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:NewLicenseAgreementMember 2023-09-30 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2023-02-28 2023-02-28 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2023-09-30 0001829247 BFRG:LicenseAgreementMember 2023-09-30 0001829247 us-gaap:SubsequentEventMember us-gaap:IPOMember 2023-02-14 2023-02-14 0001829247 us-gaap:SubsequentEventMember us-gaap:IPOMember 2023-02-14 0001829247 BFRG:TradeableWarrantsMember us-gaap:SubsequentEventMember 2023-02-14 2023-02-14 0001829247 BFRG:TradeableWarrantsMember us-gaap:SubsequentEventMember 2023-02-14 0001829247 BFRG:NonTradeableWarrantsMember us-gaap:SubsequentEventMember 2023-02-14 2023-02-14 0001829247 BFRG:NonTradeableWarrantsMember us-gaap:SubsequentEventMember 2023-02-14 0001829247 us-gaap:IPOMember 2022-11-30 2022-11-30 0001829247 us-gaap:IPOMember 2022-11-30 0001829247 us-gaap:SubsequentEventMember 2023-04-13 0001829247 us-gaap:SubsequentEventMember 2023-04-05 2023-04-13 iso4217:USD shares iso4217:USD shares pure false 0001829247 S-1 BULLFROG AI HOLDINGS, INC. NV 84-4786155 325 Ellington Blvd. Unit 317 Gaithersburg MD 20878 (240) 658-6710 Vininder Singh 325 Unit 317 Gaithersburg MD 20878 (240) 658-6710 Non-accelerated Filer true true false 57670 10014 15000 72670 10014 7699 7699 80369 10014 543993 68594 416072 68557 566916 285666 32000 10000 49000 0 12962 1323890 284038 0 1584 254850 253266 3137721 1019121 3137721 1019121 0.00001 0.00001 5500000 5500000 73449 73449 0 0 1 0.00001 0.00001 100000000 100000000 4021935 4021935 4622789 4622789 40 46 0.00001 0.00001 100000000 100000000 4021935 4021935 4622789 4622789 40 46 1341662 587415 -4399055 -1596568 -3057352 -1009107 -3057352 -1009107 80369 10014 10000 10000 800 800 9200 609270 25000 1307882 327329 98250 449599 203033 2465001 555362 -2455801 -555362 347145 40395 459 9917 -346686 -30478 -2802487 -585840 -0.70 -0.70 -14 -14 4009852 4009852 4116336 4116336 3603422 36 470274 -100 -1010728 -540518 100 100 13661 13661 4539 4539 9385 9385 1019367 10 89556 89566 -585840 -585840 4622789 46 587415 -1596568 -1009107 4622789 46 587415 -1596568 -1009107 9221 9221 340152 340152 205984 2 226136 226138 -11097 -11097 112225 -1 1 39879 189828 189828 73449 1 -734492 -7 6 -2802487 -2802487 73449 1 4021935 40 1341662 -4399055 -3057352 73449 1 4021935 40 1341662 -4399055 -3057352 -2802487 -585840 9917 1045 189828 340152 98951 214429 12665 -9221 -4539 15000 475399 -25853 373273 27384 281250 85666 22000 10000 -910890 -382405 8744 -8744 1016290 298900 49000 88400 100 967290 387400 47656 4995 10014 5019 57670 10014 5757 11097 226138 8 189828 340152 20 13661 <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zCwKOXfHIaQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span>ORGANIZATION AND NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_829_zGI9cVRMyHa9" style="display: none">Organization and Nature of Business</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bullfrog AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for an a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&amp;D and clinical trial settings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zuFEkDKOC6ib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2–<span>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82B_zPFiduDmaNje" style="display: none">Summary of Significant Accounting Policies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"> </span></span></p> <p id="xdx_84F_ecustom--UseOfEstimatesInPreparationOfFinancialStatementsPolicyTextBlock_z8wUMbEazBo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_865_zc3U0Jps2Deg">Use of Estimates in the Preparation of Financial Statements</span></span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zujhSp1Euucj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_z5cnQLmzsVjb">Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zcMzQAvTjkS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zX84OvcRS4xk">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had <span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_doxL_c20210101__20211231_zZEMUxgjCas9" title="First service revenue::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0576">no</span></span> revenue. In Q4 2022 the Company recognized its first service revenues in the amount of $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zzibZo0RZ5be" title="First service revenue">10,000</span> related to the achievement of a contract milestone under a contract with a Pharmaceutical company. In compliance with the agreement, we have met the following milestones – receipt of data for analysis; data conversion and staging for ingestion. For the years-ended December 31, 2022 and 2021, our balance sheet reflects customer down payment received in early 2022 and late 2021 as unearned revenue in the amount of $<span id="xdx_903_eus-gaap--DeferredRevenueCurrent_iI_c20221231_z2aPmZZvb0Gf" title="Unearned revenue">32,000</span> and $<span id="xdx_90E_eus-gaap--DeferredRevenueCurrent_iI_c20211231_zU2sNkLJ25M9" title="Unearned revenue">10,000</span>, respectively. This unearned revenue represents payments received from a leading rare disease non-profit organization under a contract with a single deliverable. As is more fully discussed below, we are of the opinion that none of our contracts for products contain significant financing components that require revenue adjustment under FASB ASC Topic 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is recognized based on the following five step model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification of the contract with a customer</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification of the performance obligations in the contract</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step describes how distinct performance obligations in the contract must be handled</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Determination of the transaction price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation of the transaction price to the performance obligations in the contract</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognition of revenue when, or as, the Company satisfies a performance obligation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Services</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Collaborative Arrangements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition of Rights to Certain Drugs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zYObEEAGQtQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_865_z9HjrNDn7Z81">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeO1muIOdhs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_86D_zDzPcs4TMAvf">Cash</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $<span id="xdx_902_eus-gaap--Cash_iI_c20221231_z7PxYa7lFVI5" title="Cash balances">57,670</span> and $<span id="xdx_90E_eus-gaap--Cash_iI_c20211231_zttsYIUqc7Vl" title="Cash balances">10,014</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zXbTSJxUIS08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_86C_zck0c8zsrJBb">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_zOpPVydN4rGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_865_zZrEQiq6yag9">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zsRfHFePUvr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_86C_zDqMK9zbBqz1">Allowance for Doubtful Accounts</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zVyrC7zRZK4b" title="Allowance for doubtful accounts"><span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zDdyyk8LjIkk" title="Allowance for doubtful accounts">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zmw9IjrgkSf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zHBdNYEBh6p7">Inventories</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have inventory and does not plan to have inventory in the near future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zf8kv2BHUoAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zkB33FZ30UUh">Cost of Sales</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $<span id="xdx_907_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_z311j2lDHhxh" title="Cost of services">800</span> as cost of goods sold which represents the <span id="xdx_908_ecustom--PercentageOfRoyalty_iI_pid_dp_uPure_c20221231_z1SlKvnXltV8" title="Royalty percent">8%</span> royalty on the $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zWbVKfJYJ2Af" title="First service revenue">10,000</span> in service revenue in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z67x7gYD0Fw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_863_zWIEn2yZCLU7">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_znxTJWyglgm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_866_zxFlHTA2Zg5i">Advertising</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company follows the policy of charging the costs of advertising to expense as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zB1oGWwmDrgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zMKNChpsbtkf">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z27GldZVGwol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zQf0T5zFTWe8">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z2TlibJlOElh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zMfZm9dj8mSg">Net Loss per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zGDbGXAnHiqe" title="Number of warrants">927,373</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zqnkDCufnjXi" title="Number of warrants">753,174</span> warrants (post reverse stock split) were not included in the calculation of net loss per share, respectively. In addition, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQtyQVXmuqN6" title="Number of options">486,571</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBsyyis6dKO8" title="Number of options">56,242</span> options for common shares (post reverse stock split) were not included in the calculation of net loss per share, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQHQKMrxMnHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zDXxGThuo378">Recent Accounting Pronouncements</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All staff are working remotely; therefore, the Company does not currently have a lease or rent office space. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--UnusualOrInfrequentItemsPolicyTextBlock_z8GgWSPwE6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zlfdsDC7O541">COVID-19 </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_zIaFpFylxmlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zISBq2SsWrFg">Going Concern</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.</span></p> <p id="xdx_85E_zPJY2coh5OCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_84F_ecustom--UseOfEstimatesInPreparationOfFinancialStatementsPolicyTextBlock_z8wUMbEazBo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_865_zc3U0Jps2Deg">Use of Estimates in the Preparation of Financial Statements</span></span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zujhSp1Euucj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_z5cnQLmzsVjb">Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zcMzQAvTjkS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zX84OvcRS4xk">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We have adopted FASB ASC Topic 606 for our reporting period as of the year-ended December 31, 2019. As of December 31, 2021, we have had <span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_doxL_c20210101__20211231_zZEMUxgjCas9" title="First service revenue::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0576">no</span></span> revenue. In Q4 2022 the Company recognized its first service revenues in the amount of $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zzibZo0RZ5be" title="First service revenue">10,000</span> related to the achievement of a contract milestone under a contract with a Pharmaceutical company. In compliance with the agreement, we have met the following milestones – receipt of data for analysis; data conversion and staging for ingestion. For the years-ended December 31, 2022 and 2021, our balance sheet reflects customer down payment received in early 2022 and late 2021 as unearned revenue in the amount of $<span id="xdx_903_eus-gaap--DeferredRevenueCurrent_iI_c20221231_z2aPmZZvb0Gf" title="Unearned revenue">32,000</span> and $<span id="xdx_90E_eus-gaap--DeferredRevenueCurrent_iI_c20211231_zU2sNkLJ25M9" title="Unearned revenue">10,000</span>, respectively. This unearned revenue represents payments received from a leading rare disease non-profit organization under a contract with a single deliverable. As is more fully discussed below, we are of the opinion that none of our contracts for products contain significant financing components that require revenue adjustment under FASB ASC Topic 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is recognized based on the following five step model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification of the contract with a customer</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification of the performance obligations in the contract</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step describes how distinct performance obligations in the contract must be handled</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Determination of the transaction price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation of the transaction price to the performance obligations in the contract</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognition of revenue when, or as, the Company satisfies a performance obligation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Services</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Collaborative Arrangements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also intends to enter collaborative arrangements with pharmaceutical companies who have drugs that have failed late Phase 2 or Phase 3 trials. These arrangements could take several forms including true partnerships where BullFrog contributes data analysis using the bfLEAP™ platform with the partner contributing the drug candidate and other resources needed to continue development towards commercialization with BullFrog receiving an equity or royalty right in the commercialized product. In other arrangements the Company may earn cash payments based on achieving certain milestones as determined under each specific arrangement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition of Rights to Certain Drugs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In certain circumstances, we may also acquire rights to drugs that are in early-stage clinical trials, use our technology to sponsor and support a successful later stage precision medicine trial, and divest the asset. The same process may apply to the discovery of new drugs. In these instances, divestiture may be in the form of an outright sale of all rights or possibly a license to develop and commercialize enhanced development candidates. License agreements could include developmental and commercial milestones in addition to royalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000 32000 10000 <p id="xdx_847_eus-gaap--UseOfEstimates_zYObEEAGQtQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_865_z9HjrNDn7Z81">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeO1muIOdhs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_86D_zDzPcs4TMAvf">Cash</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2022 and 2021, cash balances were $<span id="xdx_902_eus-gaap--Cash_iI_c20221231_z7PxYa7lFVI5" title="Cash balances">57,670</span> and $<span id="xdx_90E_eus-gaap--Cash_iI_c20211231_zttsYIUqc7Vl" title="Cash balances">10,014</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 57670 10014 <p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zXbTSJxUIS08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_86C_zck0c8zsrJBb">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_zOpPVydN4rGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_865_zZrEQiq6yag9">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zsRfHFePUvr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_86C_zDqMK9zbBqz1">Allowance for Doubtful Accounts</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivables are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, allowance for doubtful accounts was $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zVyrC7zRZK4b" title="Allowance for doubtful accounts"><span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zDdyyk8LjIkk" title="Allowance for doubtful accounts">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zmw9IjrgkSf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zHBdNYEBh6p7">Inventories</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have inventory and does not plan to have inventory in the near future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zf8kv2BHUoAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zkB33FZ30UUh">Cost of Sales</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. We recognized $<span id="xdx_907_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_z311j2lDHhxh" title="Cost of services">800</span> as cost of goods sold which represents the <span id="xdx_908_ecustom--PercentageOfRoyalty_iI_pid_dp_uPure_c20221231_z1SlKvnXltV8" title="Royalty percent">8%</span> royalty on the $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zWbVKfJYJ2Af" title="First service revenue">10,000</span> in service revenue in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 800 0.08 10000 <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z67x7gYD0Fw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_863_zWIEn2yZCLU7">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_znxTJWyglgm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_866_zxFlHTA2Zg5i">Advertising</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company follows the policy of charging the costs of advertising to expense as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zB1oGWwmDrgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zMKNChpsbtkf">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021, the Company has not recorded any unrecognized tax benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z27GldZVGwol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zQf0T5zFTWe8">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z2TlibJlOElh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zMfZm9dj8mSg">Net Loss per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We compute net loss per share in accordance with ASC 260, Earning per Share. We report both basic and diluted loss per share. Loss earnings per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of warrants, stock options or any other type of convertible securities. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the contingently convertible notes and related dilutive shares are not included in the dilutive shares calculation upon the Initial Public Offering (IPO). Diluted loss per share is calculated based on the weighted average number of shares of common stock outstanding and the dilutive effect of stock options, warrants and other types of convertible securities are included in the calculation. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2021 and December 31, 2022, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zGDbGXAnHiqe" title="Number of warrants">927,373</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zqnkDCufnjXi" title="Number of warrants">753,174</span> warrants (post reverse stock split) were not included in the calculation of net loss per share, respectively. In addition, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQtyQVXmuqN6" title="Number of options">486,571</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBsyyis6dKO8" title="Number of options">56,242</span> options for common shares (post reverse stock split) were not included in the calculation of net loss per share, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 927373 753174 486571 56242 <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQHQKMrxMnHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zDXxGThuo378">Recent Accounting Pronouncements</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We adopted this standard using a modified retrospective approach since inception of the company. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced as of the inception of the company; initial direct costs for leases that commenced as of inception of the company; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company elected the package of practical expedients permitted under ASC 842 allowing it to account for its prior operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or (iii) the accounting for indirect costs as defined in ASC 842.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All staff are working remotely; therefore, the Company does not currently have a lease or rent office space. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Consistent with ASC 842-20-50-4, the Company’s financial statements for the years ended December 31, 2022 and 2021, do not have a monthly rent obligation. The Company had no cash flows arising from a lease, no finance lease cost, short term lease cost, or variable lease costs. The Company does not produce any sublease income or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is part of the FASB’s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this update did not have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company elected early adoption, effective January 1, 2021. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update did not have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--UnusualOrInfrequentItemsPolicyTextBlock_z8GgWSPwE6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zlfdsDC7O541">COVID-19 </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the World Health Organization declared the global emergence of the COVID-19 pandemic. The impact of COVID-19 on the Company’s business is currently unknown. The Company will continue to monitor guidance and orders issued by federal, state, and local authorities with respect to COVID-19. As a result, the Company may take actions that alter its business operations as may be required by such guidance and orders or take other steps that the Company determines are in the best interest of its employees, customers, partners, suppliers and stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of the Company’s common stock, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 could negatively impact capital expenditures and overall economic activity in the impacted regions or depending on the severity, globally, which could impact the demand for the Company’s products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is unknown whether and how the Company may be impacted if the COVID-19 pandemic persists for an extended period of time or if there are increases in its breadth or in its severity, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. The COVID-19 pandemic poses a risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_zIaFpFylxmlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zISBq2SsWrFg">Going Concern</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has had negative cash flows from operations and operated at a net loss since inception. In the prior year our auditors included a paragraph in their opinion regarding the substantial doubt that existed of our ability to continue as a going concern. As noted in note 14 we completed our initial public offering subsequent to year end. We believe that the funds raised and notes that were converted from debt to equity now provides enough liquidity to alleviate the substantial doubt. There can be no assurance that we will not need additional funding in the future.</span></p> <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z0w1JgzDvGB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 3 – <span>PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zuMIiMDryESa" style="display: none">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="display: none"> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company acquired $<span id="xdx_90A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220101__20221231_zFSlUSOavgu4" title="Payment to acquire equiment">8,744</span> of equipment and has accumulated depreciation of $<span id="xdx_907_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20221231_zLPmdmOdNCa5" title="Accumulated depreciation">1,045</span>, for a net of $<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zYIM7g0wCZAk" title="Property and equipment net">7,699</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense totaled $<span id="xdx_90B_eus-gaap--Depreciation_c20220101__20221231_zEuA9ljrXW16" title="Depreciation expense">1,045</span>, and $<span id="xdx_900_eus-gaap--Depreciation_dxL_c20210101__20211231_zm82ohDaB32b" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0646">0</span></span> in the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 8744 1045 7699 1045 <p id="xdx_80A_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zACdWkr7O2Gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 4 – <span>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zwFNiF71v84a" style="display: none">Accounts Payable and Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="display: none"> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2022 and 2021, the Company had accounts payable and accrued expenses totaling $<span id="xdx_902_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231_zBAynUteuqcj" title="Accounts payable and accrued expenses">1,526,981</span> and $<span id="xdx_90E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20211231_ztPPT5tqnkT1" title="Accounts payable and accrued expenses">422,817</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1526981 422817 <p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zYh8SG0QhRbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 5 –<span>NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span></span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span><span id="xdx_82F_z0xbHy1BLLF5" style="display: none">Notes Payable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 5, 2020 the Company received an SBA PPP loan in the amount of $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20200505__us-gaap--DebtInstrumentAxis__custom--SBAPPPLoanMember_zfwKOQ204pj6" title="Notes payable">9,917</span>, at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200505__us-gaap--DebtInstrumentAxis__custom--SBAPPPLoanMember_z4N6hWG3GQl8" title="Interest rate">1%</span> interest. The loan was forgiven on March 15, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 9917 0.01 <p id="xdx_80B_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_z618uOOQhube" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 6 –<span>NOTES PAYABLE RELATED PARTY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82E_zxveDpQpPkKa" style="display: none">Notes Payable Related Party</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 15, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $<span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_c20210615_zN3jrQV8LUX6" title="Short term loan">34,000</span>, with a one-year maturity date, accruing interest at <span id="xdx_90B_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_iI_dp_uPure_c20210615_zVNJ5J7rKKQd" title="Accruing interest rate">5%</span> and imputing an additional <span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20210614__20210615_ziQYncfxoVie" title="Interest rate">1%</span> interest. The full amount of the loan and interest was repaid in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On November 19, 2021, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_c20211119_z9cJEq6P4hM9" title="Short term loan">5,000</span>, with a one-year maturity date, accruing interest at <span id="xdx_90D_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_iI_dp_uPure_c20211119_z1wMCiOMZrIb" title="Accruing interest rate">5%</span> and imputing an additional <span id="xdx_904_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20211118__20211119_zTiLzHahJm0e" title="Interest rate">1%</span> interest. The full amount of the loan and interest was repaid in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 13, 2021, the company entered into an unsecured short term loan agreement with a related party for an aggregate principal balance of $<span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20211213_zkugrcVy6eK2" title="Short term loan">10,000</span>, with a one-year maturity date, accruing interest at <span id="xdx_902_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_iI_dp_uPure_c20211213_zDOdlcs6yLP6" title="Accruing interest rate">5%</span> and imputing an additional <span id="xdx_901_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20211212__20211213_z1fHbT0ctTNe" title="Interest rate">1%</span> interest. The full amount of the loan and interest was repaid in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 34000 0.05 0.01 5000 0.05 0.01 10000 0.05 0.01 <p id="xdx_800_eus-gaap--ShortTermDebtTextBlock_zQiCjd0MVnu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 7 – <span>CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_821_zVo0sUyFU7d7" style="display: none">Convertible Notes Payable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On March 27, 2020, the company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zFQvEQoTeoqi" title="Prncipal balance">200,000</span> at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zWdu0icQpl0c" title="Interest rate">6%</span> interest. The maturity date of the loan was <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20200327__20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zPNwcMngAjkj" title="Maturity date">September 27, 2021</span>. During the year ended December 31, 2022, the full amount of the loan and interest totaling $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20221231__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zaZnZ6cRuHQ4" title="Conversion of stock,value">226,138</span> was converted into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z0FcYlWn0P79" title="Conversion of stock, shares">205,984</span> shares of common stock (post reverse stock split) of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest divided by $<span id="xdx_90D_ecustom--FullyDilutedEquity_iI_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z5q3ZpKNGERd" title="Fully diluted equity">5,000,000</span> times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion, being within the terms of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 9, 2021, the company entered into a convertible loan agreement with an unrelated party to loan up to $<span id="xdx_903_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zFQQxVoFZbQ" title="Prncipal balance">195,000</span> at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zoCehZd3aN1c" title="Interest">9%</span> interest, with a principal balance of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zTPK3iGa6Sg1" title="Prncipal balance">72,000</span>, as of December 31, 2021. This loan included an original issuance discount of <span id="xdx_906_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20210809__20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zcXdM4oVsjzh" title="Original issuance discount rate">5%</span>, and included <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z2pdjxgzFue7" title="Number of warrants">195,000</span> Warrants at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z2ETdtXY89oj" title="Exercise price">1</span>, exercisable for <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zhPOewfbOFm1" title="Warrants term">5</span> years from the issue date on the face of the Warrant. The noteholder has the right to convert the principal and interest into common shares of the Company. The maturity date of the loan was <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20210809__20210809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zTgyE3lcGWv8" title="Maturity date">February 9, 2022</span>. During the year ended December 31, 2022, another $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zGTm0KyqFOPd" title="Prncipal balance">123,000</span> principal with an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zoARqEPHRav8" title="Issuance discount">6,150</span> original issuance discount, was loaned to the Company. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and entered into a new agreement for <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_zY6B3sp1Nksg" title="Number of warrants">225,000</span> warrants with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_zIap3p8ChXx3" title="Exercise price">2.50</span>. As of December 31, 2022, the loan was outstanding with a principal balance of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_zpAi0Q2LnRu6" title="Prncipal balance">195,000</span>, accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_zepwWWljcg7e" title="Accrued interest">35,078</span>, amortization of debt discount of $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_z2omX47BTr0i" title="Amortization of debt discount">8,393</span>, and unamortized debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_z2WYEdlHNOGa" title="Unamortized debt discount">0</span>. The warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and new warrants in accordance with the new terms were issued. We assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants. During the year ended December 31, 2022 the Company recorded an expense of $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewAgreementMember_zxyO6fQA2Lwb" title="Warrant expenses">64,978</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 20, 2021, the company entered into a loan agreement with an unrelated party, with a principal balance of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zx2TiV8zsEl5" title="Principal balance">25,000</span> at <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zYfBVMYT1RAi" title="Interest rate">6%</span> interest. The maturity date of the loan was <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zC4n8oeh0pMc" title="Maturity date">December 19, 2022</span>. During the year ended December 31, 2022, the note principal was increased by $<span id="xdx_90B_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zk14B6fIx5Ai" title="Prncipal balance increase">2,778</span> representing a <span id="xdx_90C_ecustom--OriginalIssuanceDiscountRate_dp_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZVnh3gpgyac" title="Original issuance discount rate">10%</span> original issue discount pursuant to the enhanced terms mentioned below. As of December 31, 2022, the loan remained outstanding had accrued interest of $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zpWB7MTDxBv" title="Accrued interest">2,301</span>. The loan was converted to common stock in February 2023 in connection with the Company IPO. Initially, the loan was estimated to be issued with <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211220__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zGMLeRVDo0D" title="Number of warrants">355,114</span> warrants. Subsequent to the entry into the December 20, 2021 the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $<span id="xdx_905_eus-gaap--ProceedsFromNotesPayable_pn6n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zRaqSEKFh3De" title="Proceeds from notes payable">1</span>M in face value of convertible bridge notes, as described in footnote 13. Pursuant to the enhanced terms, the warrants will not be issued until the note converts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. As discussed in Footnote 2, a significant component of the Company’s plan to secure capital is the intention of the Company to seek to be listed on a national exchange through an initial public offering (“IPO”) of its common stock. WallachBeth was engaged in this regard and on April 28, 2022, the Company received net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zzmyXWA9ZWh5" title="Proceeds from notes payable">775,000</span> from the sale of Convertible Bridge Notes and Warrants to several institutional investors as well as several individual accredited investors. In connection with the April 28th note sale, the Company paid approximately $<span id="xdx_908_eus-gaap--ManagementFeeExpense_c20220428__20220428__dei--LegalEntityAxis__custom--WallachBethMember_zsAFgaAGz0O5" title="Expenses">91,560</span> in fees and expenses. In addition to the money received on April 28th, the Company also received $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zUaVFPcAhSva" title="Sale of stock value">100,000</span> from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company sold one additional bridge note to an unrelated party, with a principal balance of $<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zhQINOKNcCD9" title="Convertible notes payable">27,779</span>. The Convertible Bridge Notes were issued with a <span id="xdx_900_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_z8Mz9IRR54F5" title="Original issuance discount rate">10%</span> original issue discount and are convertible at the IPO at a <span id="xdx_902_ecustom--ConversionDiscountRate_dp_uPure_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zgYxVDHlFaof" title="Conversion discount rate">20%</span> discount to the IPO price. <span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember_z2TUYKS7rMO4" title="Debt description">The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price.</span> The Convertible Bridge Notes maturity date was <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_ziYQ8ChHfgR4" title="Maturity date">October 31, 2022</span>. The Company has amended the Convertible Bridge Notes to extend the maturity date until <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_z1hii6MzyYSd" title="Maturity date extended">December 31, 2022</span>. The Company has filed an S-1 Registration Statement and conducted an IPO in February 2023. All of the Convertible Bridge Notes and accrued interest through November, 30, 2022 were converted at the IPO. Pursuant to further amendments to the notes, the maturity date was extended, interest accrued after November 30, 2022 though conversion will be paid to the holders in cash and the conversion right was revised to be equal to a $<span id="xdx_90A_eus-gaap--ConversionOfStockAmountIssued1_pn6n6_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zE5LEYWQFGu9" title="Conversion value">25</span> million dollar Company valuation, or $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zBYIOMHPv9J8" title="Exercise price">4.27</span>, which was also established as the warrant exercise price. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2022, the table below reflects the balances of the Convertible Bridge Notes sold pursuant April 11, 2022 agreement with WallachBeth. All notes are mandatorily converted at the IPO at the conversion ratio noted above and the purchasers will also be issued a warrant for each share of common stock issued upon conversion with an exercise price set by the exchange ratio. Due to the IPO price not yet being probable at year end, no current accounting for these warrants has been journalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ConvertibleDebtTableTextBlock_zPRdW6poxJJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none"><span id="xdx_8B5_z9b2C9AKa7be">Schedule of Convertible Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center">Note Date</td> <td> </td> <td colspan="2" id="xdx_484_eus-gaap--ConvertibleDebt_iI_zRFSGp8OVv64" style="text-align: center"><span id="xdx_91D_eus-gaap--ConvertibleDebt_z6EDrizrodLh">Purchase Price</span></td><td> </td><td> </td> <td colspan="2" id="xdx_48D_eus-gaap--ConvertibleNotesPayableCurrent_iI_zBta8ZsDh8F4" style="text-align: center"><span id="xdx_912_eus-gaap--ConvertibleNotesPayableCurrent_zVYIoV3Yzpj3">Principal Balance</span></td><td> </td><td> </td> <td colspan="2" id="xdx_488_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_ziXzpRzrWtGf" style="text-align: center"><span id="xdx_916_eus-gaap--DebtInstrumentUnamortizedDiscount_zNVMs3idlLad">Original Issue Discount</span></td><td> </td><td> </td> <td colspan="2" id="xdx_48A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_z27WqNNqdukb" style="text-align: center"><span id="xdx_914_eus-gaap--InterestPayableCurrentAndNoncurrent_zmueEHXCLduf">Accrued Interest</span></td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">Note</td> <td> </td> <td colspan="2" style="text-align: center">Purchase</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Principal</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Original Issue</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accrued</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Balance</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Discount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember__dei--LegalEntityAxis__custom--WallachBethMember_zZL1WJ8buffl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left"><span id="xdx_908_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember__dei--LegalEntityAxis__custom--WallachBethMember_zt7uWlGg582i" title="Note Date">4/28/2022</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">277,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,083</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember__dei--LegalEntityAxis__custom--WallachBethMember_zo0QtrxHFjRf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember__dei--LegalEntityAxis__custom--WallachBethMember_z2jw7SsxDby2" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">277,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,083</td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtThreeMember__dei--LegalEntityAxis__custom--WallachBethMember_zi2mzmZI0kG9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtThreeMember__dei--LegalEntityAxis__custom--WallachBethMember_z9OoN4Vw2Ci6" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">277,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,083</td><td style="text-align: left"> </td></tr> <tr id="xdx_41C_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFourMember__dei--LegalEntityAxis__custom--WallachBethMember_zBbpUgqwX675" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFourMember__dei--LegalEntityAxis__custom--WallachBethMember_z1p0Tced8xKb" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,708</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFiveMember__dei--LegalEntityAxis__custom--WallachBethMember_zyEMJsqyISQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFiveMember__dei--LegalEntityAxis__custom--WallachBethMember_zRJYQXTglxo2" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">28,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,913</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSixMember__dei--LegalEntityAxis__custom--WallachBethMember_zO0FLHqZXsD6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSixMember__dei--LegalEntityAxis__custom--WallachBethMember_zfzM0RWVNUA7" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">28,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,913</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSevenMember__dei--LegalEntityAxis__custom--WallachBethMember_zvSH7hfd48h6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSevenMember__dei--LegalEntityAxis__custom--WallachBethMember_znHFIqJn9Rz1" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,392</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtEightMember__dei--LegalEntityAxis__custom--WallachBethMember_zDtlHwSalqA6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_904_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtEightMember__dei--LegalEntityAxis__custom--WallachBethMember_fKg_____znPgC0rQD36f" title="Note Date">12/20/2021</span>*</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,301</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtNineMember__dei--LegalEntityAxis__custom--WallachBethMember_zzYn1echNUvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtNineMember__dei--LegalEntityAxis__custom--WallachBethMember_fKg_____zhEuANqSrfGj" title="Note Date">4/13/2022</span>*</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">111,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,111</td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTenMember__dei--LegalEntityAxis__custom--WallachBethMember_znDuuPV8UfZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_909_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTenMember__dei--LegalEntityAxis__custom--WallachBethMember_zhwSRBxWTLR1" title="Note Date">9/9/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,088</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_417_20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__dei--LegalEntityAxis__custom--WallachBethMember_z8fWDBO59u12" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Total</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,016,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,128,889</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112,889</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,675</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span id="xdx_F08_zgMosSH86ur6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td><span id="xdx_F12_zOdkb9Ffqjsh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes sold by Company prior to the April 28, 2022 closing</span></td></tr> </table> <p id="xdx_8A0_zOfvLg8POPV8" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. The Company specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, if the equity securities underlying the conversion option are not readily convertible to cash, and the conversion option requires gross physical settlement of the underlying shares, the embedded conversion option may not meet the net settlement criterion, and therefore would not meet the definition of a derivative. Considering that the Common shares of the Company were not publicly traded as of December 31, 2022, the convertible options are not considered to be readily convertible to cash. In addition, the beneficial conversion feature was eliminated under ASU 2020-06. Therefore, no derivative liabilities will be triggered from these convertible notes. All conversions are contingent upon an effective IPO, which had not yet been considered probable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 200000 0.06 2021-09-27 226138 205984 5000000 195000 0.09 72000 0.05 195000 1 P5Y 2022-02-09 123000 6150 225000 2.50 195000 35078 8393 0 64978 25000 0.06 2022-12-19 2778 0.10 2301 355114 1000000 775000 91560 100000 27779 0.10 0.20 The purchasers will also be issued a warrant for each share of common stock issued upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to complete the IPO before October 22, 2022, 90% of the IPO price. 2022-10-31 2022-12-31 25000000 4.27 <p id="xdx_894_eus-gaap--ConvertibleDebtTableTextBlock_zPRdW6poxJJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none"><span id="xdx_8B5_z9b2C9AKa7be">Schedule of Convertible Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center">Note Date</td> <td> </td> <td colspan="2" id="xdx_484_eus-gaap--ConvertibleDebt_iI_zRFSGp8OVv64" style="text-align: center"><span id="xdx_91D_eus-gaap--ConvertibleDebt_z6EDrizrodLh">Purchase Price</span></td><td> </td><td> </td> <td colspan="2" id="xdx_48D_eus-gaap--ConvertibleNotesPayableCurrent_iI_zBta8ZsDh8F4" style="text-align: center"><span id="xdx_912_eus-gaap--ConvertibleNotesPayableCurrent_zVYIoV3Yzpj3">Principal Balance</span></td><td> </td><td> </td> <td colspan="2" id="xdx_488_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_ziXzpRzrWtGf" style="text-align: center"><span id="xdx_916_eus-gaap--DebtInstrumentUnamortizedDiscount_zNVMs3idlLad">Original Issue Discount</span></td><td> </td><td> </td> <td colspan="2" id="xdx_48A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_z27WqNNqdukb" style="text-align: center"><span id="xdx_914_eus-gaap--InterestPayableCurrentAndNoncurrent_zmueEHXCLduf">Accrued Interest</span></td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">Note</td> <td> </td> <td colspan="2" style="text-align: center">Purchase</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Principal</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Original Issue</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accrued</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Balance</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Discount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember__dei--LegalEntityAxis__custom--WallachBethMember_zZL1WJ8buffl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left"><span id="xdx_908_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember__dei--LegalEntityAxis__custom--WallachBethMember_zt7uWlGg582i" title="Note Date">4/28/2022</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">277,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,083</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember__dei--LegalEntityAxis__custom--WallachBethMember_zo0QtrxHFjRf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember__dei--LegalEntityAxis__custom--WallachBethMember_z2jw7SsxDby2" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">277,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,083</td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtThreeMember__dei--LegalEntityAxis__custom--WallachBethMember_zi2mzmZI0kG9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtThreeMember__dei--LegalEntityAxis__custom--WallachBethMember_z9OoN4Vw2Ci6" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">277,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,083</td><td style="text-align: left"> </td></tr> <tr id="xdx_41C_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFourMember__dei--LegalEntityAxis__custom--WallachBethMember_zBbpUgqwX675" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFourMember__dei--LegalEntityAxis__custom--WallachBethMember_z1p0Tced8xKb" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,708</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFiveMember__dei--LegalEntityAxis__custom--WallachBethMember_zyEMJsqyISQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFiveMember__dei--LegalEntityAxis__custom--WallachBethMember_zRJYQXTglxo2" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">28,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,913</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSixMember__dei--LegalEntityAxis__custom--WallachBethMember_zO0FLHqZXsD6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSixMember__dei--LegalEntityAxis__custom--WallachBethMember_zfzM0RWVNUA7" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">28,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,913</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSevenMember__dei--LegalEntityAxis__custom--WallachBethMember_zvSH7hfd48h6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtSevenMember__dei--LegalEntityAxis__custom--WallachBethMember_znHFIqJn9Rz1" title="Note Date">4/28/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,392</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtEightMember__dei--LegalEntityAxis__custom--WallachBethMember_zDtlHwSalqA6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_904_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtEightMember__dei--LegalEntityAxis__custom--WallachBethMember_fKg_____znPgC0rQD36f" title="Note Date">12/20/2021</span>*</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,301</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtNineMember__dei--LegalEntityAxis__custom--WallachBethMember_zzYn1echNUvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtNineMember__dei--LegalEntityAxis__custom--WallachBethMember_fKg_____zhEuANqSrfGj" title="Note Date">4/13/2022</span>*</td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">111,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,111</td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTenMember__dei--LegalEntityAxis__custom--WallachBethMember_znDuuPV8UfZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_909_eus-gaap--DebtInstrumentIssuanceDate1_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTenMember__dei--LegalEntityAxis__custom--WallachBethMember_zhwSRBxWTLR1" title="Note Date">9/9/2022</span></td> <td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,088</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_417_20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__dei--LegalEntityAxis__custom--WallachBethMember_z8fWDBO59u12" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Total</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,016,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,128,889</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112,889</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,675</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span id="xdx_F08_zgMosSH86ur6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td><span id="xdx_F12_zOdkb9Ffqjsh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes sold by Company prior to the April 28, 2022 closing</span></td></tr> </table> 2022-04-28 250000 277778 27778 17083 2022-04-28 250000 277778 27778 17083 2022-04-28 250000 277778 27778 17083 2022-04-28 25000 27778 2778 1708 2022-04-28 28000 31111 3111 1913 2022-04-28 28000 31111 3111 1913 2022-04-28 35000 38889 3889 2392 2021-12-20 25000 27778 2778 2301 2022-04-13 100000 111111 11111 7111 2022-09-09 25000 27778 2778 1088 1016000 1128889 112889 69675 <p id="xdx_801_ecustom--ConvertibleNotesPayableRelatedPartyDisclosureTextBlock_zEO2yGRtxbo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 8 – <span>CONVERTIBLE NOTES PAYABLE RELATED PARTY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_825_zfdUacR8so59" style="display: none">Convertible Notes Payable Related Party</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On July 8, 2021, the company entered into a Simple Agreement for Future Equity (SAFE), with a related party, with an amount of $<span id="xdx_90E_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20210708__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zwvyI4Hjvitb">150,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">, with <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210708__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zWZRaiXdFxh">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">% interest. Under the SAFE agreement, </span><span style="font: normal 10pt Times New Roman, Times, Serif">if there is an Equity Financing before the termination of this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE</span><span style="font: normal 10pt Times New Roman, Times, Serif">, on the initial closing of such Equity Financing, this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE </span><span style="font: normal 10pt Times New Roman, Times, Serif">will automatically convert into the number of shares of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE </span><span style="font: normal 10pt Times New Roman, Times, Serif">Preferred Stock equal to the Purchase Amount divided by the Conversion Price, which means either: (1) the Safe Price (the price per share equal to the Post-Money Valuation Cap divided by the Company </span>Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation results in a greater number of shares of Safe Preferred Stock</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">If there is a Liquidity Event before the termination of this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE</span><span style="font: normal 10pt Times New Roman, Times, Serif">, this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE</span> <span style="font: normal 10pt Times New Roman, Times, Serif">will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds, due and payable to the Investor immediately prior to, or concurrent with, the consummation of such Liquidity Event, equal to the greater of (i) the Purchase Amount (the “Cash-Out Amount”) or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the “Conversion Amount”). If any of the Company’s securityholders are given a choice as to the form and amount of Proceeds to be received in a Liquidity Event, the Investor will be given the same choice, provided that the Investor may not choose to receive a form of consideration that the Investor would be ineligible to receive as a result of the Investor’s failure to satisfy any requirement or limitation generally applicable to the Company’s securityholders, or under any applicable laws.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">This </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE</span> <span style="font: normal 10pt Times New Roman, Times, Serif">will automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SAFE</span><span style="font: normal 10pt Times New Roman, Times, Serif">) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this SAFE under agreement; or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">As of December 31, 2022 and 2021, the $<span id="xdx_900_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zvRCvQCaYTzh" title="Convertible notes payable related party"><span id="xdx_902_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zO4G5wnozcr3" title="Convertible notes payable related party">150,000</span></span> received from SAFE was recorded at</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_z7sgN1hMmHf2" title="Interest rate"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211231__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zwansTfCXGq4" title="Interest rate">6</span></span>% imputed interest. The maturity date of the loan is defined by the SAFE agreement as discussed above. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 19, 2021, the company entered into a convertible loan agreement with a related party, with a principal balance of $<span id="xdx_90D_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z1qXhsPX5T12" title="Convertible notes payable related party">99,900</span> at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zLLCm0ajtD3e" title="Interest rate">9</span>% interest. The noteholder has the right to convert the principal and interest into common shares of the Company. This loan included an original issuance discount of <span id="xdx_90A_ecustom--OriginalIssuanceDiscountRate_pid_dp_uPure_c20210818__20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zYMGxo7S17O3" title="Original issuance discount rate">5</span>% and included <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zUMEdFmpAU0c" title="Number of warrant shares">99,900</span> Warrants at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_ztsBdHgTOoje" title="Warrant exercise price per share">1</span>, exercisable for <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zvEKGYwN8jrl" title="Warrants term">5</span> years from the issue date on the face of the Warrant. The maturity date of the loan was <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210818__20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z5Dfs3uRZ49c" title="Debt instrument, maturity date">February 19, 2022</span>. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and entered into a new agreement for <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_zjVQ0n1O76j" title="Number of warrant shares">115,185</span> warrants with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_zt0L9nZL3XTb" title="Warrant exercise price per share">2.50</span>. As of December 31, 2022, the $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_zMvAXufbouO5" title="Principal amount">99,900</span> principal and the $<span id="xdx_909_eus-gaap--RepaymentsOfConvertibleDebt_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_zHaYW5aaXl31" title="Repayments of debt">4,950</span> overpayment of the note remained outstanding and had accrued interest of $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp2d_c20221231__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_zglVTzgO1n51" title="Accrued interest">12,463.53</span>. The warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and new warrants in accordance with the new terms were issued. We assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The SAFE and the convertible loan agreement with accrued interest converted to common stock at the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company specified that an entity should adopt ASU 2020-06 as of the beginning of its annual fiscal year. After adoption of ASU 2020-06, no derivative liabilities will be triggered from these convertible notes. See Note 7 for details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 150000 0 150000 150000 0.06 0.06 99900 0.09 0.05 99900 1 P5Y 2022-02-19 115185 2.50 99900 4950 12463.53 <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zooPqCePHGzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 9 –<span>RELATED PARTY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_825_zrTupIhB3xgf" style="display: none">Related Party</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During the year-ended December 31, 2021, there were <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zwX3Rc4nu4B4" title="Number of shares issued">57,143</span> shares of common stock (post reverse stock split) issued to CFO Dane Saglio, for services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2022 and 2021, the accrued salary for related parties was $<span id="xdx_907_eus-gaap--AccruedSalariesCurrent_iI_c20221231_zE5Z2v1E7k14" title="Accrued salaries, current">566,916</span> and $<span id="xdx_906_eus-gaap--AccruedSalariesCurrent_iI_c20211231_zzek6mtsHHp7" title="Accrued salaries">285,666</span>, respectively. The increase reflects salaries accrued for employees, but not paid in the year ended December 31, 2022. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2022, the Company accrued consulting fees to related parties of $<span id="xdx_90D_eus-gaap--AccruedProfessionalFeesCurrent_iI_c20221231_zgjhg8fXdfia" title="Accrued consulting fees">90,000</span> for services provided to the Company. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During the year ended December 31, 2021, the Company issued options totaling <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231_zmCBk5GxpZNb" title="Number of shares issued for services">29,286</span> shares of common stock (post reverse stock split) to related party for services rendered. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The options have an original life of ten years and vest at different rates over as much as 24 months. During the year ended December 31, 2022, the Company did not issue any options and recognized $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231_zTbZvqbdeSfe" title="Stock-based compensation related to outstanding stock options">1,803</span> of stock-based compensation related to outstanding stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 57143 566916 285666 90000 29286 1803 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zV4w6p0bg05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 10– <span>SHAREHOLDER’S DEFICT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_824_zC0XwXjOqUC3" style="display: none">Stockholder’s Equity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>Preferred Stock</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zL1ekl3S3hwi" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock authorized at a par value of $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zCNaIUPcJuad" title="Preferred stock, par or stated value per share">0.00001</span>. As of December 31, 2021, there were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zjgRKpHwIMUj" title="Preferred stock, shares issued">no</span> preferred shares issued. On October 5, 2022, the Company entered into an exchange agreement with the Investor whereby all of his common stock, <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_ziEdrzEhUzr5" title="Conversion of convertible securities, shares">734,492</span> shares of commons stock (post reverse stock split), were exchanged into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfrqGFZK6rBg" title="Conversion of convertible securities, shares">73,449</span> shares of Series A Convertible Preferred Stock (post reverse stock split). Per the agreement the exchange was based on a 1 Series A Convertible Preferred Stock for each <span id="xdx_900_ecustom--SharesExchangedForEachConvertiblePreferredStock_iI_c20221231_zBgMSOKTEer5" title="Number of common stock">10</span> shares of common stock. Each holder of Series A Preferred Stock may, from time to time, convert any or all of such holder’s shares of Series A Preferred Stock into fully paid and nonassessable shares of Common Stock in an amount equal to ten shares of common stock for each one share of Series A Preferred Stock surrendered. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. T<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he Company evaluated the terms of the exchange and determined there would be no significant change in fair value and therefore no accounting entry recorded as a result of the exchange. The value of the Series A Preferred Stock was determined to be $<span id="xdx_90E_eus-gaap--PreferredStockValue_iI_c20221005__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyvUZ1eTJvw1" title="Preferred stock value">315,000</span> which is the Investor’s basis in the common stock that was exchanged.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June of 2020, <span id="xdx_905_eus-gaap--StockholdersEquityNoteStockSplit_c20200601__20200630_z1Ts3SjyAl76" title="Stock split, description">BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock</span>. Share amounts in our financial statements for December 31, 2022 and 2021, have been adjusted to reflect this forward share split and shares exchange. All of our operations are currently conducted through BullFrog AI Holdings, Inc. BullFrog AI, Inc., is a wholly owned subsidiary, has the sole purpose of housing and protecting all of the organization’s intellectual property. BullFrog AI Management, LLC is a wholly owned subsidiary that handles all HR and payroll activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_z9EqArPehpe9" title="Common stock, shares authorized">100,000,000</span> shares of common stock authorized at a par value of $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zsB7RnH1qbSk" title="Common stock, par or stated value per share">0.00001</span>. During year ended December 31, 2022, <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zojP2jr6nzPi" title="Conversion of convertible securities, shares">734,492</span> shares of common stock (post reverse stock split) were exchanged for preferred shares as noted above, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NoteHolderMember_z1jHxTZIb44j" title="Conversion of convertible securities, shares">205,984</span> shares of common stock (post reverse stock split) were issued for conversion of principal and interest of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20221231_zPAXAqvKjm1j" title="Conversion of convertibe notes value">226,138</span> by a noteholder, <span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvShZyaaf87i" title="Shares cancelled">112,225</span></span> shares of common stock (post reverse stock split) were canceled as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zN4DxKAmkgCd" title="Number of shares issued">38,879</span> shares of common stock (post reverse stock split) were issued under a license agreement and valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueOther_c20220101__20221231_zPvTaiQ2CaIj" title="Shares issued for license">189,828</span>, see Note 12 for further discussion. As of December 31, 2022 and 2021, there are <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zJbKFCJcCaO8" title="Common stock, shares outstanding">4,021,935</span> and <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zExra8DFWQ83" title="Common stock, shares outstanding">4,622,789</span>, shares of common stock (post reverse stock split) outstanding, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board of Directors and stockholders approved an amendment to our Certificate of Incorporation to effect a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zqHOVoFiPog2" title="Reverse stock split">1-for-7 reverse stock split</span> of our common stock in connection with the offering, subsequent to the year ended December 31, 2022. As a result of the reverse stock split, every 7 shares of our outstanding common stock will be combined and reclassified into one share of our common stock. Unless otherwise noted, the share and per share information in this Form 10-K filing reflects, other than in our historical financial statements and the notes thereto, a proposed reverse stock split of the outstanding common stock of the Company at an assumed 1-for-7 ratio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the first quarter of 2022, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDVIjPSk2Dvg" title="Number of options forfeitures">399,354</span> shares of options <span style="background-color: white">(post reverse stock split)</span> were forfeited due to the termination of employment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company granted a total of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zl9OGyzngcH5" title="Share based compensation granted">29,286</span> shares of options (post reverse stock split) to employees of the Company for services rendered. The options have an original life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dc_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1WdSSVINdz6" title="Original life">ten years</span> and vest at different rates over as much as <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1RERdmxakRc" title="Share-based compensation arrangement by share-based payment award, award vesting period">48 months</span>. During the years ended December 31, 2021, the Company vested <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA5Usgx5wnG5" title="Share-based payment award, options, vested, number of shares">1,310</span> of these options (post reverse stock split) and recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ1YCscPFvvj" title="Share-based payment arrangement, expensed and capitalized, amount">157</span> of stock-based compensation related to outstanding stock options. During the year ended December 31, 2022, <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWRIp9CXon83" title="Share-based payment arrangement, expensed and capitalized, amount">16,601</span> shares of these options (post reverse stock split) were vested and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1VnlNKhMvX2" title="Share-based payment arrangement, expensed and capitalized, amount">2,010</span> stock-based compensation was recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zzOPvk052i5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zJ7iLB3KA8kb" style="display: none">Schedule of Stock Options Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; padding-bottom: 1.5pt">Granted and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z6xGc9M8twr5" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Granted and outstanding, Beginning">884,821</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_z1omev8Buzmk" style="text-align: right" title="Granted">29,286</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_ztExLGxo43db" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_zG9xXUC305Kj" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zxcuIyHrXdG7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired">(445,536</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zX0yQLKPRWV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Granted and outstanding, Beginning">468,571</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted during 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zCdrpC55rGjj" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z9uMfXX0LBp5" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zpKBXcoc1lWa" style="text-align: right" title="Forfeited">(399,354</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zIfZYMRrfMuh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zcWBqBLZKhC3" style="border-bottom: Black 2.5pt double; text-align: right" title="Granted and outstanding, Ending">69,217</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zwYj2K0PAlWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zBxUgwXE8J5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z6spQ3GVbsk7" style="display: none">Schedule of Vested and Outstanding Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic Value of Vested Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weight Averaged exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-bottom: 1.5pt">Vested and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20210101__20211231_zBgxiQ11iDRi" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Beginning value, Options">104,795</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zQP3ShwiVUWd" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Beginning value, Intrinsic Value of Vested Options">12,706</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zBztT2nU6lv7" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Weight Averaged exercise Price, beginning value">3.36</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted and vested during 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted_c20210101__20211231_zl870ZpqYjql" style="text-align: right" title="Options Granted">1,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20210101__20211231_zAApzZQe7cS3" style="text-align: right" title="Intrinsic Value of Vested Options, Granted">157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_iI_c20210101__20211231_zH9tXDk5Y4A2" style="text-align: right" title="Weight Averaged exercise Price, Granted">2.66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExercised_c20210101__20211231_zr93ewU3Kqej" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20210101__20211231_zJwY11gI35n1" style="text-align: right" title="Intrinsic Value of Vested Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20210101__20211231_z8Va5vN3eTy8" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingForfeited_c20210101__20211231_zVplcF6eNG94" style="text-align: right" title="Options Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0987">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20210101__20211231_zUqE57S6Y0ed" style="text-align: right" title="Intrinsic Value of Vested Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20210101__20211231_zXEEQX5acHb2" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired_c20210101__20211231_z5j3T8jL70xh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Expired">(66,524</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20210101__20211231_z79uHhFrYaT7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Options, Expired">(7,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20210101__20211231_z1gkC4RD7CCc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired">(3.36</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220101__20221231_zpEURxVmamGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning value, Options">39,581</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220101__20221231_zckAIYRcYuqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning value, Intrinsic Value of Vested Options">4,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zU67cp7yG4M4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, beginning value">3.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted and vested during  2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted_c20220101__20221231_zsiAVZpCTT5g" style="text-align: right" title="Options Granted">16,661</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20220101__20221231_zw6g11WUOfBd" style="text-align: right" title="Intrinsic Value of Vested Options, Granted">2,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_c20220101__20221231_zJEVjNUan7d1" style="text-align: right" title="Weight Averaged exercise Price, Granted">2.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExercised_c20220101__20221231_zPv7hmu5Ga1j" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20220101__20221231_zbBnHfCDJwm1" style="text-align: right" title="Intrinsic Value of Vested Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20220101__20221231_zVhUZAg3LKtj" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingForfeited_c20220101__20221231_zt0Db2xFiqDa" style="text-align: right" title="Options Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20220101__20221231_z357WMWDY3n9" style="text-align: right" title="Intrinsic Value of Vested Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20220101__20221231_zkLVMKHhuzs6" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired_c20220101__20221231_zFSPf3VUg73" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20220101__20221231_zn6ajNQnRwFb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20220101__20221231_z0mKsL7I3tT4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20220101__20221231_zuO49zOwqCq" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending value, Options">56,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zaOlL43yRAM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value of Vested Options, Intrinsic value">6,951</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zYKWRoO9Dv1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, Ending balance value">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zxbqCXPVxYXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, <span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBUZl625cg85" title="Option vested shares">16,661</span> and <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrL8C15JhrX7" title="Option vested shares">1,310</span> options (post reverse stock split) vested, respectively, <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired_dxL_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxSac7NpI3Oi" title="Option vested expired shares::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1039">0</span></span> and <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCSxqHYxjkZd" title="Option vested expired shares">66,524</span> (post reverse stock split) options expired and the outstanding stock options have a weighted average remaining life of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcVUKINokgS3" title="Share based compensation weighted average remaining contractual term">7.08</span> and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziFhNyXttyN5" title="Share based compensation weighted average remaining contractual term">7.38</span> years, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the fair value of options vested and outstanding was $ <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLThhkmPqcPj" title="Fair value of options vested and outstanding">6,951</span> and $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoTsRRk60P7k" title="Fair value of options vested and outstanding">4,941</span>, respectively. The aggregate fair value of the options measured during the year ended December 31, 2022 and 2021 was calculated using the Black-Scholes option pricing model based on the following assumption:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zoCFtdpNibV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zEK0SqtvEOF8" style="display: none">Schedule of Black Scholes Option Pricing Model</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20221231_zSm1uNV1TsX9" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">4.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20211231_zFoV09jtmcQ2" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">0.308</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_z5nWRtyRbcd6" title="Risk free interest rate, minimum">0.79</span>% to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_z6G3ZRclbaJl" title="Risk free interest rate, maximum">3.01</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zVEFBcYqgz3f" title="Risk free interest rate, minimum">1.26</span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_zhyc83F2slQb" title="Risk free interest rate, maximum">1.33</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20221231_zAGBUOU2nC0g" title="Volatility">89</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20211231_zvYQhUHKJKmj" title="Volatility">93</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231_zHoqiT7klgv7" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20210101__20211231_zHCVTgntPxY1" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zGep45OVfyGb" title="Expected Term">4</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zkUM8f96fR8f" title="Expected Term">10</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zRAozZWnKT2j" title="Expected Term">10</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zRGjG7zqSnb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company does not expect to pay a dividend in the foreseeable future.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">During the year ended December 31, 2022, the Company granted a total of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIpBfqJq1DWd" title="Share based compensation granted">123,660</span> warrants <span style="background-color: white">(post reverse stock split)</span>. <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAPRe02ZJMRd" title="Contractual life and vesting period, description">The warrants have an original life of four to ten years and vest immediately and over 12 months.</span> During the year ended December 31, 2022, <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYWsxs9l2t1g" title="Warrants shares vested">174,105</span> shares of warrants <span style="background-color: white">(post reverse stock split)</span> were vested and amended with an intrinsic value of $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRTYCdOF9Lif" title="Intrinsic Value">337,269</span>, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvAMJFVTEBdj" title="Warrant shares">51,941</span> shares of warrants (post reverse stock split) were reclassified with an intrinsic value of $<span id="xdx_900_ecustom--WarrantsReclassifiedWithIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDEg3u4B3eUd" title="Warrants reclassified with intrinsic value">11,097</span>, and <span id="xdx_90A_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zURzFi81hRh4" title="Warrant shares, forfeited">42,057</span> shares of warrants (post reverse stock split) with an intrinsic value of $1,883 were forfeited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company granted a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDDg8S5f9py7" title="Share based compensation granted">431,659</span> warrants <span style="background-color: white">(post reverse stock split)</span>. Of this amount <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zU9m2yGH8WKf" title="Share based compensation granted">200,000</span> warrants <span style="background-color: white">(post reverse stock split)</span>, with a fair value of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_z88jpjMc3wG4" title="Fair value of warrants">12,462</span>, were granted to advisors related to the Company’s IPO objective. <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zr7Tekv4Wb24" title="Contractual life and vesting period, description">The warrants have an original life of five years and vest 30 days before the intended IPO</span>. During the year ended December 31, 2021, <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaGayjuhpavf" title="Warrants shares vested">0</span> shares of these warrants were vested. As of June 30, 2022, the warrants for <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220601__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbKrWSexw4Lk" title="Warrant shares forfeiture">200,000</span> shares <span style="background-color: white">(post reverse stock split)</span> were <span style="background-color: white">cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. </span>In 2021, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOMOGTuX0KIk" title="Warrant shares">138,929</span> warrants <span style="background-color: white">(post reverse stock split)</span>, with a fair value of $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVO00bZKn8Ag" title="Fair value of warrants">28,683</span>, were issued for services rendered. <span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqZWe9oIRWa7" title="Contractual life and vesting period, description">The warrants have an original life of ten years and vest at different rates over as much as 36 months.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_z7O9SatbqWYd" title="Warrant shares">92,859</span> warrants <span style="background-color: white">(post reverse stock split)</span> with a fair value of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_ziV2uTNSFg1b" title="Fair value of warrants">12,980</span>, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zt5LfSmBIWu9" title="Warrant term">five years</span>. During the period ending June 30, 2022, the Company determined that <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKeFchcgDMBa" title="Warrant shares">50,735</span> warrants <span style="background-color: white">(post reverse stock split)</span>, with a fair value of $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZLsqYISug4g" title="Fair value warrants">11,097</span>, should not have been issued as further described in footnote 8. The fair value was reclassified to Additional Paid in Capital. <span style="background-color: white">As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous <span id="xdx_90D_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziQckulllRkf" title="Class of warrant forfeiture">99,000</span> warrants (post reverse stock split) and entered into a new agreement for <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zov3pnlU3Fwl" title="Warrant shares">115,185</span> (post reverse stock split) and the exercise price increased to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zldJOhXYgTWb" title="Warrant exercise price per share">2.50</span> from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIMFmBPTPfNd" title="Warrant exercise price per share">1</span>,</span> with a fair value of $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zIDHbeFp8yCg">15,412</span><span style="background-color: white">. As discussed in Note 8 in May 2022, the Company and the note holders agreed to cancel and void the previous <span id="xdx_905_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_z2DkpldtEkm2" title="Class of warrant forfeiture">195,000</span> (post reverse stock split) warrants and entered into a new agreement for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zXbnetWu8bo2" title="Warrant shares">225,000</span> warrants (post reverse stock split) with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zZVl609WzqI7" title="Warrant exercise price per share">2.50</span>,</span> with a fair value of $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_z8XDHAJpCX7g">64,978</span><span style="background-color: white">. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zz6RDfrhpcGh" title="Warrant shares">92,859</span> warrants (post reverse stock split) discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and these individuals were or will be issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p id="xdx_892_ecustom--ScheduleOfStockWarrantsActivityTableTextBlock_zCpycs4U7XCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zdg3AkvXm0A1" style="display: none">Schedule of Stock Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; padding-bottom: 1.5pt">Granted and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztpU5a0D7Hv4" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Beginning balance">495,714</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7jjLxsUn8k" style="text-align: right" title="Granted">431,659</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt2YqybiwT99" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv53i7mGbJlb" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxiEGaPU6RI4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1149">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxHwCAqn1g15" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">927,373</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted during 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3thbXjUnPL6" style="text-align: right" title="Granted">123,660</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0PgA6ii7Jkd" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTXh33azbDv3" style="text-align: right" title="Forfeited">(298,088</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z16WqcJw36lg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpkEek29y94e" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">752,945</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zkOGjjCcJH24" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingTableTextBlock_z4gpX3Ku1rW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zxPgtFMGESKf" style="display: none">Schedule of Vested And Outstanding Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic Value of Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weight Averaged exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-bottom: 1.5pt">Vested and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw7JNzMFvU17" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Beginning balance">479,940</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVXsCkfU2Onc" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Intrinsic Value of Vested Warrants, beginning balance">127,480</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zox3whGhjyEj" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Weight Averaged exercise Price, beginning value">0.98</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted and Vested 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zavN0JClRDSg" style="text-align: right" title="Warrants Granted">137,552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpAzjuoQjnVd" style="text-align: right" title="Intrinsic Value of Vested Warrants, Granted">22,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkAXbElKKyxk" style="text-align: right" title="Weight Averaged exercise Price, Granted">3.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSuBOeoAfRLk" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYpEuG6Zb333" style="text-align: right" title="Intrinsic Value of Vested Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5D28lsYTPd" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingForfeited_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hPSQcuSo9e" style="text-align: right" title="Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1183">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDH7V6ayTGL1" style="text-align: right" title="Intrinsic Value of Vested Warrants, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgQgJJrmA1U" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExpired_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjNJMA8jHMrj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKcOqQXwDuEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFrl9TRcB0Jd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyAJQ5KJp0u6" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">617,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znsJIoBbyF0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value of Vested Warrants, beginning balance">149,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvpqSGBLnpS5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, beginning value">2.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted and Vested 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRKTqtgfZVK2" style="text-align: right" title="Warrants Granted">174,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zK6I3axr4R9j" style="text-align: right" title="Intrinsic Value of Vested Warrants, Granted">337,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0v1AUjUXyi7" style="text-align: right" title="Weight Averaged exercise Price, Granted">3.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1LW11XrNGEf" style="text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjclv64TTq6" style="text-align: right" title="Intrinsic Value of Vested Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6528Lvdxyq5" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYS1914aJpGg" style="text-align: right" title="Warrants Forfeited">(94,665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2v8qx91Ws1f" style="text-align: right" title="Intrinsic Value of Vested Warrants, Forfeited">(12,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZ8pR6YYp5" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExpired_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1jBy3O0aJb8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV6EyYNSjk03" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNu9Mqkzmni" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcxNHSHh1Nha" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance value">696,932</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwrO8oWKSmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value of Vested Warrants, ending balance">473,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMo7R55Wjzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, Ending balance value">1.96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zOE98gtfJjD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXKtoJOl3aWd" title="Warrants shares, outstanding">752,945</span> warrants <span style="background-color: white">(post reverse stock split)</span> are outstanding, and <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPo8oo8wQpyj" title="Vested shares">696,932</span> warrants <span style="background-color: white">(post reverse stock split)</span> vested, and the vested stock warrants have a weighted average remaining life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwJAsRHo52Oa" title="Weighted average remaining contractual term">7.13</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022, the aggregate fair value of warrants vested was $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFIurK5oLo6c" title="Fair value of warrants">324,283</span>. The aggregate fair value of the warrants measured during the year ended December 31, 2022 was calculated using the Black-Scholes option pricing model and recorded as stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2021, <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCaAmmWGL7J3" title="Warrants shares, outstanding">927,516</span> warrants (post reverse stock split) are outstanding, <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPFc1wyGAtfj" title="Vested shares">617,492</span> warrants (post reverse stock split) are vested with an intrinsic value of $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWlKd6IZ9l77" title="Intrinsic value">22,208</span>, and the vested stock warrants have a weighted average remaining life of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTuQdM77xPwg" title="Weighted average remaining contractual term">7.73</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the aggregate fair value of warrants vested was $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMpdtz0ScrKl" title="Fair value of warrants">149,688</span>. The aggregate fair value of the warrants measured during the year-ended December 31, 2021 was calculated using the Black-Scholes option pricing model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of warrants related to the Convertible Bridge Notes discussed Note 7 is not yet determinable, given some of the terms discussed in Note 8 have not been completed. Therefore, the warrants to be issued are not accounted for in our warrants outstanding. <span style="background-color: white">Due to the IPO price not being completed at December 31, 2022, no current accounting for these warrants has been journalized.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white"> </span></span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt8jsiISkTWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5AZci8qn511" style="display: none">Schedule of Black Scholes Option Pricing Model</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBgC7EqquBd3" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">4.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQL2WFhP1rm5" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">0.308</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYCelkSSiDj9" title="Risk free interest rate, minimum">1.86</span>% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJUMX8yZdb2d" title="Risk free interest rate, maximum">1.97</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2s3UxIl13i" title="Risk free interest rate, minimum">0.78</span>% to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQb1owUk4364" title="Risk free interest rate, maximum">1.63</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zchnWH1EOtY5" title="Volatility">89</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpfXWgSJCnmi" title="Volatility">93</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zju3QMSs52hb" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXQsskWDRUAl" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJyAFy8p38O8" title="Expected Term">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEl7Fu875Fgj" title="Expected Term">5</span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztkt0myFX9Va" title="Expected Term">10</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_ze19xFsjOZfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances for all 2022 grant date stock prices.</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zdv1my5Na7I1" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides details over the Company’s outstanding warrants as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zxlPsVDHkqce" style="display: none">Schedule of Outstanding Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Expiration</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: center">$</td><td style="width: 30%; text-align: center"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_z8tDQkIEPdE7" title="Exercise Price">0.0007</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zTSWNAkmOyk2" title="Expiration Period">2030</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zCYTdyvBKZO6" title="Number of Warrants">274,286</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_ziycEWrUbgKe" title="Exercise Price">2.10</span> - $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zte1DpNN77a5" title="Exercise Price">2.66</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zUpvrtRqqb93" title="Expiration Period">2026</span> - <span id="xdx_902_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zFfWXnYzSds4" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_z29tU4JoWJDb" title="Number of Warrants">460,445</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zO4Gj0DAWHfd" title="Exercise Price">3.36</span> - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zuQLwNMfd6cl" title="Exercise Price">4.27</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_z1R77ZNVEFx6" title="Expiration Period">2028</span> - <span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zqdAdL0pdgzk" title="Expiration Period">2029</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zlaYwJTj4hP2" title="Number of Warrants">115,277</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_ztc4S2UhzKfa" title="Exercise Price">6.51</span> - $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zVLu06D8Ijq5" title="Exercise Price">7.80</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zotuvMVvnBek" title="Expiration Period">2026</span> - <span id="xdx_909_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zH2FC3Ucqvob" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_zz6R6zkyUMN4" title="Number of Warrants">1,484,929</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zaOMXFjBIpQk" title="Exercise Price">8.125</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_z2iVihAUw35e" title="Expiration Period">2027</span> - <span id="xdx_900_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zccWF3B0Ccuh" title="Expiration Period">2028</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zxa9OggChFI1" title="Number of Warrants">1,461,227</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930_zoUfDGpHwOck" title="Number of Warrants">3,796,164</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 10000000 0.00001 0 734492 73449 10 315000 BullFrog AI Holdings, Inc. acquired BullFrog AI, Inc. via a 1:1 share exchange. Immediately prior to the share exchange, each authorized common share of BullFrog AI, Inc. was split into 25 shares of common stock 100000000 0.00001 734492 205984 226138 112225 38879 189828 4021935 4622789 1-for-7 reverse stock split 399354 29286 P10Y P48M 1310 157 16601 2010 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zzOPvk052i5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the stock options (post reverse stock split) activity for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zJ7iLB3KA8kb" style="display: none">Schedule of Stock Options Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; padding-bottom: 1.5pt">Granted and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z6xGc9M8twr5" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Granted and outstanding, Beginning">884,821</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_z1omev8Buzmk" style="text-align: right" title="Granted">29,286</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_ztExLGxo43db" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_zG9xXUC305Kj" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zxcuIyHrXdG7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired">(445,536</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zX0yQLKPRWV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Granted and outstanding, Beginning">468,571</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted during 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zCdrpC55rGjj" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z9uMfXX0LBp5" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zpKBXcoc1lWa" style="text-align: right" title="Forfeited">(399,354</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zIfZYMRrfMuh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zcWBqBLZKhC3" style="border-bottom: Black 2.5pt double; text-align: right" title="Granted and outstanding, Ending">69,217</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 884821 29286 445536 468571 399354 69217 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zBxUgwXE8J5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z6spQ3GVbsk7" style="display: none">Schedule of Vested and Outstanding Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic Value of Vested Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weight Averaged exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-bottom: 1.5pt">Vested and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20210101__20211231_zBgxiQ11iDRi" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Beginning value, Options">104,795</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zQP3ShwiVUWd" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Beginning value, Intrinsic Value of Vested Options">12,706</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zBztT2nU6lv7" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Weight Averaged exercise Price, beginning value">3.36</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted and vested during 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted_c20210101__20211231_zl870ZpqYjql" style="text-align: right" title="Options Granted">1,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20210101__20211231_zAApzZQe7cS3" style="text-align: right" title="Intrinsic Value of Vested Options, Granted">157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_iI_c20210101__20211231_zH9tXDk5Y4A2" style="text-align: right" title="Weight Averaged exercise Price, Granted">2.66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExercised_c20210101__20211231_zr93ewU3Kqej" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20210101__20211231_zJwY11gI35n1" style="text-align: right" title="Intrinsic Value of Vested Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20210101__20211231_z8Va5vN3eTy8" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingForfeited_c20210101__20211231_zVplcF6eNG94" style="text-align: right" title="Options Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0987">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20210101__20211231_zUqE57S6Y0ed" style="text-align: right" title="Intrinsic Value of Vested Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20210101__20211231_zXEEQX5acHb2" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired_c20210101__20211231_z5j3T8jL70xh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Expired">(66,524</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20210101__20211231_z79uHhFrYaT7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Options, Expired">(7,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20210101__20211231_z1gkC4RD7CCc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired">(3.36</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220101__20221231_zpEURxVmamGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning value, Options">39,581</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220101__20221231_zckAIYRcYuqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning value, Intrinsic Value of Vested Options">4,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zU67cp7yG4M4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, beginning value">3.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted and vested during  2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingGranted_c20220101__20221231_zsiAVZpCTT5g" style="text-align: right" title="Options Granted">16,661</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20220101__20221231_zw6g11WUOfBd" style="text-align: right" title="Intrinsic Value of Vested Options, Granted">2,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_c20220101__20221231_zJEVjNUan7d1" style="text-align: right" title="Weight Averaged exercise Price, Granted">2.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExercised_c20220101__20221231_zPv7hmu5Ga1j" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20220101__20221231_zbBnHfCDJwm1" style="text-align: right" title="Intrinsic Value of Vested Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20220101__20221231_zVhUZAg3LKtj" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingForfeited_c20220101__20221231_zt0Db2xFiqDa" style="text-align: right" title="Options Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20220101__20221231_z357WMWDY3n9" style="text-align: right" title="Intrinsic Value of Vested Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20220101__20221231_zkLVMKHhuzs6" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingExpired_c20220101__20221231_zFSPf3VUg73" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20220101__20221231_zn6ajNQnRwFb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20220101__20221231_z0mKsL7I3tT4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20220101__20221231_zuO49zOwqCq" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending value, Options">56,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zaOlL43yRAM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value of Vested Options, Intrinsic value">6,951</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zYKWRoO9Dv1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, Ending balance value">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 104795 12706 3.36 1310 157 2.66 -66524 -7922 -3.36 39581 4941 3.36 16661 2010 2.73 56242 6951 3.15 16661 1310 66524 P7Y29D P7Y4M17D 6951 4941 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zoCFtdpNibV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zEK0SqtvEOF8" style="display: none">Schedule of Black Scholes Option Pricing Model</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20221231_zSm1uNV1TsX9" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">4.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20211231_zFoV09jtmcQ2" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">0.308</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_z5nWRtyRbcd6" title="Risk free interest rate, minimum">0.79</span>% to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_z6G3ZRclbaJl" title="Risk free interest rate, maximum">3.01</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zVEFBcYqgz3f" title="Risk free interest rate, minimum">1.26</span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_zhyc83F2slQb" title="Risk free interest rate, maximum">1.33</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20221231_zAGBUOU2nC0g" title="Volatility">89</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20211231_zvYQhUHKJKmj" title="Volatility">93</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231_zHoqiT7klgv7" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20210101__20211231_zHCVTgntPxY1" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zGep45OVfyGb" title="Expected Term">4</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zkUM8f96fR8f" title="Expected Term">10</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zRAozZWnKT2j" title="Expected Term">10</span></td><td style="text-align: left"> </td></tr> </table> 4.76 0.308 0.0079 0.0301 0.0126 0.0133 0.89 0.93 0 0 P4Y P10Y P10Y 123660 The warrants have an original life of four to ten years and vest immediately and over 12 months. 174105 337269 51941 11097 42057 431659 200000 12462 The warrants have an original life of five years and vest 30 days before the intended IPO 0 200000 138929 28683 The warrants have an original life of ten years and vest at different rates over as much as 36 months. 92859 12980 P5Y 50735 11097 99000 115185 2.50 1 15412 195000 225000 2.50 64978 92859 <p id="xdx_892_ecustom--ScheduleOfStockWarrantsActivityTableTextBlock_zCpycs4U7XCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the warrant activity (post reverse stock split) for the year ended December 31, 2022 and 2021,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zdg3AkvXm0A1" style="display: none">Schedule of Stock Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; padding-bottom: 1.5pt">Granted and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztpU5a0D7Hv4" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Beginning balance">495,714</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG7jjLxsUn8k" style="text-align: right" title="Granted">431,659</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt2YqybiwT99" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv53i7mGbJlb" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxiEGaPU6RI4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1149">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxHwCAqn1g15" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">927,373</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted during 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3thbXjUnPL6" style="text-align: right" title="Granted">123,660</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0PgA6ii7Jkd" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTXh33azbDv3" style="text-align: right" title="Forfeited">(298,088</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Expired during 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z16WqcJw36lg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Granted and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpkEek29y94e" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">752,945</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 495714 431659 927373 123660 298088 752945 <p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingTableTextBlock_z4gpX3Ku1rW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zxPgtFMGESKf" style="display: none">Schedule of Vested And Outstanding Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic Value of Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weight Averaged exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-bottom: 1.5pt">Vested and outstanding, December 31, 2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw7JNzMFvU17" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Beginning balance">479,940</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVXsCkfU2Onc" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Intrinsic Value of Vested Warrants, beginning balance">127,480</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zox3whGhjyEj" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Weight Averaged exercise Price, beginning value">0.98</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted and Vested 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zavN0JClRDSg" style="text-align: right" title="Warrants Granted">137,552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpAzjuoQjnVd" style="text-align: right" title="Intrinsic Value of Vested Warrants, Granted">22,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkAXbElKKyxk" style="text-align: right" title="Weight Averaged exercise Price, Granted">3.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSuBOeoAfRLk" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYpEuG6Zb333" style="text-align: right" title="Intrinsic Value of Vested Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5D28lsYTPd" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingForfeited_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hPSQcuSo9e" style="text-align: right" title="Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1183">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDH7V6ayTGL1" style="text-align: right" title="Intrinsic Value of Vested Warrants, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgQgJJrmA1U" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExpired_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjNJMA8jHMrj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKcOqQXwDuEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFrl9TRcB0Jd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyAJQ5KJp0u6" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">617,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znsJIoBbyF0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value of Vested Warrants, beginning balance">149,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvpqSGBLnpS5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, beginning value">2.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Granted and Vested 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRKTqtgfZVK2" style="text-align: right" title="Warrants Granted">174,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zK6I3axr4R9j" style="text-align: right" title="Intrinsic Value of Vested Warrants, Granted">337,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0v1AUjUXyi7" style="text-align: right" title="Weight Averaged exercise Price, Granted">3.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1LW11XrNGEf" style="text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjclv64TTq6" style="text-align: right" title="Intrinsic Value of Vested Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6528Lvdxyq5" style="text-align: right" title="Weight Averaged exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYS1914aJpGg" style="text-align: right" title="Warrants Forfeited">(94,665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2v8qx91Ws1f" style="text-align: right" title="Intrinsic Value of Vested Warrants, Forfeited">(12,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZ8pR6YYp5" style="text-align: right" title="Weight Averaged exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingExpired_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1jBy3O0aJb8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingIntrinsicExpired_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV6EyYNSjk03" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value of Vested Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceExpired_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNu9Mqkzmni" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weight Averaged exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Vested and outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcxNHSHh1Nha" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance value">696,932</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwrO8oWKSmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value of Vested Warrants, ending balance">473,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMo7R55Wjzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weight Averaged exercise Price, Ending balance value">1.96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 479940 127480 0.98 137552 22208 3.15 617492 149688 2.80 174105 337263 3.15 -94665 -12980 696932 473971 1.96 752945 696932 P7Y1M17D 324283 927516 617492 22208 P7Y8M23D 149688 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt8jsiISkTWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5AZci8qn511" style="display: none">Schedule of Black Scholes Option Pricing Model</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBgC7EqquBd3" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">4.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQL2WFhP1rm5" style="width: 18%; text-align: right" title="Fair Value of Common Stock on measurement date">0.308</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYCelkSSiDj9" title="Risk free interest rate, minimum">1.86</span>% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJUMX8yZdb2d" title="Risk free interest rate, maximum">1.97</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2s3UxIl13i" title="Risk free interest rate, minimum">0.78</span>% to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQb1owUk4364" title="Risk free interest rate, maximum">1.63</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zchnWH1EOtY5" title="Volatility">89</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpfXWgSJCnmi" title="Volatility">93</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zju3QMSs52hb" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXQsskWDRUAl" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJyAFy8p38O8" title="Expected Term">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEl7Fu875Fgj" title="Expected Term">5</span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztkt0myFX9Va" title="Expected Term">10</span> years</span></td><td style="text-align: left"> </td></tr> </table> 4.76 0.308 0.0186 0.0197 0.0078 0.0163 0.89 0.93 0 0 P10Y P5Y P10Y <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zdv1my5Na7I1" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides details over the Company’s outstanding warrants as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zxlPsVDHkqce" style="display: none">Schedule of Outstanding Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Expiration</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: center">$</td><td style="width: 30%; text-align: center"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_z8tDQkIEPdE7" title="Exercise Price">0.0007</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zTSWNAkmOyk2" title="Expiration Period">2030</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zCYTdyvBKZO6" title="Number of Warrants">274,286</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_ziycEWrUbgKe" title="Exercise Price">2.10</span> - $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zte1DpNN77a5" title="Exercise Price">2.66</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zUpvrtRqqb93" title="Expiration Period">2026</span> - <span id="xdx_902_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zFfWXnYzSds4" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_z29tU4JoWJDb" title="Number of Warrants">460,445</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zO4Gj0DAWHfd" title="Exercise Price">3.36</span> - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zuQLwNMfd6cl" title="Exercise Price">4.27</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_z1R77ZNVEFx6" title="Expiration Period">2028</span> - <span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zqdAdL0pdgzk" title="Expiration Period">2029</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zlaYwJTj4hP2" title="Number of Warrants">115,277</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_ztc4S2UhzKfa" title="Exercise Price">6.51</span> - $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zVLu06D8Ijq5" title="Exercise Price">7.80</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zotuvMVvnBek" title="Expiration Period">2026</span> - <span id="xdx_909_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zH2FC3Ucqvob" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_zz6R6zkyUMN4" title="Number of Warrants">1,484,929</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zaOMXFjBIpQk" title="Exercise Price">8.125</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_z2iVihAUw35e" title="Expiration Period">2027</span> - <span id="xdx_900_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zccWF3B0Ccuh" title="Expiration Period">2028</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zxa9OggChFI1" title="Number of Warrants">1,461,227</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930_zoUfDGpHwOck" title="Number of Warrants">3,796,164</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 0.0007 2030 274286 2.10 2.66 2026 2032 460445 3.36 4.27 2028 2029 115277 6.51 7.80 2026 2032 1484929 8.125 2027 2028 1461227 3796164 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zoEPcvmqVUwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span>INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_822_zprH9x5jGUnk" style="display: none">Income Taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20221231_z9kwARFXb643" title="Operating loss carry forward">4,399,055</span>, that do not expire, that may be used to offset future taxable income, but could be limited under Section 382. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax position that meets the more likely than not threshold is then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. <span style="background-color: white">We file income tax returns in the U.S. and in the state of California and Utah with varying statutes of limitations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zbeCRKSG5OLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zWTWZtemVgii" style="display: none">Schedule of Deferred Taxes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zIWcgtwxzGV5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_zGep3aayFEbf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-Current deferred tax asset:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz4ui_zOIcPmfDgxu" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">924,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">339,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4ui_zKJlnSYWuOS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(924,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(339,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4ui_zgg1JQQAa063" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net non-current deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z5Vvd98S2qj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> 4399055 <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zbeCRKSG5OLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s deferred taxes as of December 31, 2022 and 2021 consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zWTWZtemVgii" style="display: none">Schedule of Deferred Taxes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zIWcgtwxzGV5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_zGep3aayFEbf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-Current deferred tax asset:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz4ui_zOIcPmfDgxu" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">924,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">339,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4ui_zKJlnSYWuOS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(924,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(339,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4ui_zgg1JQQAa063" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net non-current deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 924000 339000 924000 339000 <p id="xdx_806_ecustom--LicenseAndRoyaltyAgreementDisclosureTextBlock_zlqjHwYdw9n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 12 – <span>MATERIAL AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_825_zrJGiAHEBkC1" style="display: none">Material Agreements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JHU-APL Technology License</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, 1 new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an Amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five (<span id="xdx_90C_ecustom--PercentageOfWarrantIssued_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zFc8ZhUwdTT" title="Warrant percent">5%</span>) percent of the then fully diluted equity base of the Company, which shall be diluted following the closing of this offering. Under the terms of the License Agreement, JHU will be entitled to eight (<span id="xdx_905_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_z1k1mFAbZp43" title="Royalty percent">8%</span>) percent royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty (<span id="xdx_90D_ecustom--SublicensePercentage_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_z00iPszcg6Gl" title="Percentage of sublicense">50%</span>) percent of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $<span id="xdx_90D_eus-gaap--CostMaintenance_c20180205__20180207__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zFzbY3HHRugb" title="Maintenance fee">1,500</span>. Minimum annual royalty payments are $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zZbBDAoE3Yp9" title="Royalty payments for 2022">20,000</span> for 2022, $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zKYBkrO7sdA2" title="Royalty payments for 2023">80,000</span> for 2023, and $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zqEUfe8wwucc" title="Royalty payments for 2024">300,000</span> for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31<sup>st</sup> of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breech, the Company shall have 60 days to cure the material breech. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember_zMVrzKLIDAE7" title="Common stock issued">279,159</span> shares of common stock. (see note 10) Under the terms of the new License Agreement, JHU will be entitled to eight (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--OtherPartiesMember_zwUVhvvodNv7" title="Royalty percent">8%</span>) percent of net sales for the services provided by the Company to other parties and <span id="xdx_907_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--InternallyDevelopmentDrugProjectsMember_z7EiT3sRErRg" title="Royalty percent">3%</span> for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at <span id="xdx_90C_ecustom--SublicensePercentage_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zT8TLlePb3eb">50%</span> and reduce to <span id="xdx_905_ecustom--IncreaseDecreaseInSublicensePercentageBasedOnRevenues_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zqnyMF3Izqhg" title="Sublicense fee based on revenue">25%</span> based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zzSSJqs3CO63" title="Royalty payments for 2022">30,000</span> for 2022, $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zpnLRKsY1nVb" title="Royalty payments for 2023">80,000</span> for 2023, and $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zHH6g4T0TYj" title="Royalty payments for 2024">300,000</span> for 2024 and beyond. As of December 31, 2022, we have accrued, $<span id="xdx_90D_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember_z87veCwx4hI3" title="Accrued minimum royalty payment">30,000</span> of the 2022 minimum annual royalty payments. See Note 10 for details on common shares and warrants issued related to this agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Washington University - Beta2-spectrin siRNA License</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In consideration of the rights granted to the Company under the License Agreement GWU received a $<span id="xdx_903_ecustom--LicenceInitiationFee_iI_c20220114__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_zq3CoGvn5VQc" title="Licence initiation fee">20,000</span> License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (<span id="xdx_908_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220114__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_z8Ny6GRW0amd" title="Royalty percent">3%</span>) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of December 31, 2022, there has been no accrual for royalties, since we have not begun revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johns Hopkins University – Mebendazole License</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to mebendazole at any dose during the trial. 41.7% of patients who received mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $<span id="xdx_909_ecustom--UpfrontLicenceFee_iI_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zoKNYyaqmyR6" title="Upfront licence fee">250,000</span>. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three- and one-half percent (<span id="xdx_90A_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zIOmiV44vQwe" title="Royalty percent">3.5%</span>) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zpLnzyJXO2x8" title="Royalty payments for 2023">5,000</span> for 2023, $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_z93lkmaQuNck" title="Royalty payments for 2024">10,000</span> for 2024, $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFiveMember_z9d1pNT0igZc" title="Royalty payments for 2025">20,000</span> for 2025, $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySixMember_zKkYPaP25dd3" title="Royalty payments for 2026">30,000</span> for 2026 and $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zk1VvcEwBdUl" title="Royalty payments for 2027">50,000</span> for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zGBcJ7zcYpZk" title="Annual minimum royalty payment">250,000</span>. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement JHU will receive a staggered Upfront License Fee of $<span id="xdx_90E_ecustom--UpfrontLicenceFee_iI_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zxQdDMgstuHe" title="Upfront licence fee">250,000</span>. The initial payment for $<span id="xdx_908_eus-gaap--PaymentsForFees_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zRIfLIRYDwcg" title="Licence fee initial payment">50,000</span> was paid and the remaining balance is deferred until the earlier of; we complete the IPO, raise $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn6n6_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zBVLlazNJRZc" title="Fianance raised">10</span> million in financing or until 9 months from the effective date of the license. As of December 31, 2022, the balance of accrued expense related to this license agreement was $<span id="xdx_903_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zksdiBdq46T9" title="Accrued royalty exoenses">242,671</span>. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johns Hopkins University – Prodrug License</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $<span id="xdx_907_ecustom--UpfrontLicenceFee_iI_c20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_zXt19L4y5xxi">100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (<span id="xdx_907_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_zCwnIwBUfS82">4.0%</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zHznVJ9wDcdb">5,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for 2027, $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyEightMember_zLEmU6yHHwK3">10,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for 2028, $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyNineMember_zFxBDPccDXOf">20,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for 2029, $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyThirtyMember_zYz6xEKRysk2">30,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for 2030 and $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyThirtyOneMember_zRMk8Co1XrW9">50,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $<span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_zIyC4EJlSBX2">150,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of December 31, 2022, the balance of accrued expense related to this license agreement was $<span id="xdx_90F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zjOjaEdv1Jl5" title="Accrued expense">133,238</span>. The Company assessed whether the license should be capitalized and determined that the licensed program is early stage and therefore the Company expensed the license fee and will expense development costs until commercial viability is likely. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.05 0.08 0.50 1500 20000 80000 300000 279159 0.08 0.03 0.50 0.25 30000 80000 300000 30000 20000 0.03 250000 0.035 5000 10000 20000 30000 50000 250000 250000 50000 10000000 242671 100000 0.040 5000 10000 20000 30000 50000 150000 133238 <p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zdph85xB2ef5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 13 – <span>COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82B_ztcPL7WjzGee" style="display: none">Commitments and Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief sought or expected to be sought.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zRnk0q7Wq0h9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 14 – <span>SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82E_zWdW2juEWnxh" style="display: none">Subsequent Events</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 14, 2023 the Company conducted its initial public offering of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230214__20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCf6xMmsq3Fj" title="Additional shares issued">1,297,318</span> units (each, a “Unit,” collectively, the “Units”) at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvjGUO1qQcI4" title="Issue price per share">6.50</span> per unit for a total of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230214__20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zWYfwoKaPfY6" title="Gross proceeds">8.4</span> million of gross proceeds to the Company. <span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20230214__20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zDhU34OS9TA1" title="Sale of stock, description">Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zSufPxUzOl77" title="Exercise price of warrant">7.80</span> per share</span>, and <span id="xdx_901_eus-gaap--SaleOfStockDescriptionOfTransaction_c20230214__20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_z8yOa7HjpqCh" title="Sale of stock, description">one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_zGbuSONY0D43" title="Exercise price of warrant">8.125</span></span>. The offering closed on February 16, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the offering, <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20230214__20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMfb8ITGa0u7" title="Reverse stock split">the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock</span>. Also, in connection with the IPO a SAFE and convertible loan agreement held by a related party converted into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230214__20230214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEbTgLHzilwb" title="Converted common shares">55,787</span> shares of post reverse common stock. Additionally, all outstanding Convertible Bridge Notes and accrued interest through November 30, 2022 were converted into <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20221130__20221130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zsGDngGFLtik" title="Converted common shares">276,289</span> shares common stock and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20221130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zztNxPAeDhRi" title="Number of warrant">276,289</span> warrants to purchase common stock were issued to the Convertible Bridge Note holders at conversion. The Bridge Note conversions and the warrant exercise pricing was determined using a <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20221130__20221130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXIARZTViyqf" title="Conversion value">$25</span> million dollar company valuation immediately before the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between April 5 and April 13, 2023, the holders of warrants exercised <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230413__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXFJFIXOOYE1" title="Warrants exercised">436,533</span> warrants for common shares at various exercise prices and the Company received proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20230405__20230413__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeRgxGH5ynGl" title="Gross proceeds">1,495,000</span>.</span></p> 1297318 6.50 8400000 Each Unit consists of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share 7.80 one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125 8.125 the Company common shares were subject to a 1-7 reverse stock split - 1 share of new common for 7 shares then outstanding common stock 55787 276289 276289 25000000 436533 1495000 3856037 57670 352433 15000 4208470 72670 6406 7699 4214876 80369 110503 543993 122257 982988 32000 213290 1323890 254850 446050 3137721 0.00001 0.00001 5500000 5500000 73449 73449 73449 73449 1 1 0.00001 0.00001 100000000 100000000 6094644 6094644 4021935 4021935 61 40 12226742 1341662 -8457978 -4399055 3768826 -3057352 4214876 80369 65000 65000 65000 65000 5200 5200 5200 5200 59800 59800 380015 39421 1023619 448375 983929 601131 3067940 1424383 1363944 640552 4091559 1872758 -1304144 -640552 -4031759 -1872758 5758 124159 76880 234668 92959 56924 18 142675 457 51166 -124141 -27164 -234211 -1252978 -764693 -4058923 -2106969 -0.21 -0.21 -0.16 -0.16 -0.72 -0.72 -0.45 -0.45 6094644 6094644 4752959 4752959 5667997 5667997 4669952 4669952 73449 1 4021935 40 1341662 -4399055 -3057352 127450 127450 1297318 13 7293638 7293651 7692 1 49999 50000 331166 3 1535612 1535615 -1325547 -1325547 73449 1 5658111 57 10348361 -5724602 4623817 262267 262267 436533 4 1494654 1494658 -1480398 -1480398 73449 1 6094644 61 12105282 -7205000 4900344 121460 121460 -1252978 -1252978 73449 1 6094644 61 12226742 -8457978 3768826 4622789 46 587415 -1596568 -1009107 2360 2360 30017 30017 -11097 -11097 -566359 -566359 4622789 46 608695 -2162927 -1554186 2361 2361 209323 209323 205984 2 226136 226138 112225 -1 1 -775917 -775917 4716548 47 1046516 -2938844 -1892281 4716548 47 1046516 -2938844 -1892281 2250 2250 51536 51536 39879 189828 189828 -764693 -764693 4756427 47 1290130 -3703537 -2413360 4756427 47 1290130 -3703537 -2413360 -4058923 -2106969 1293 604 511177 290876 189828 50000 -92959 20000 174998 -6971 337433 15000 -433490 51946 -796865 409502 104000 -32000 22000 -4983282 -871244 8744 -8744 7293651 1494658 961190 100000 319950 49000 213290 8781649 912190 3798367 32202 57670 10014 3856037 42216 93916 4399 11097 1535615 226138 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOa3v09woCFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zNnExKDw2Pdj">Organization and Nature of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC. which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through Bullfrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in-house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&amp;D and clinical trial settings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Going Concern</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). We believe that the funds raised and notes that were converted from debt to equity in connection with the IPO now provide enough liquidity to fund operations beyond 9 months from the date of this filing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z2znDKQg3Lv" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zqlq0NiCQjR3">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z3yXICqa0ZSh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zU9T0n6livI6">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 13, 2023, we <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230213__20230213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6mogtoycxmb" title="Reverse stock split">completed a 1-for-7 reverse split of our common stock.</span> Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zdeu2eM5YXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zJVVaalwSSdi">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue based on the following five step model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Identification of the contract with a customer</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Identification of the performance obligations in the contract</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step describes how distinct performance obligations in the contract must be handled.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Determination of the transaction price</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Allocation of the transaction price to the performance obligations in the contract</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recognition of revenue when, or as, the Company satisfies a performance obligation</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBGTLns6xpL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span><span id="xdx_863_zy7UHuUhCPu8">Contract Services</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--SignificantAccountingPolicyPolicyTextBlock_zExxfIHd33C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zo4PxziXGY0b">Significant Accounting Policies</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwOPJgiKHAG6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zGQJOtohPkGg">Impact of Recently Issued Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.</span></p> <p id="xdx_857_z8pD4qY1ZJce" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z3yXICqa0ZSh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zU9T0n6livI6">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 25, 2023. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in the 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results for the nine months ended September 30, 2023 are not necessarily indicative of the operating results expected for the year ending December 31, 2023 or any other future period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 13, 2023, we <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230213__20230213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6mogtoycxmb" title="Reverse stock split">completed a 1-for-7 reverse split of our common stock.</span> Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> completed a 1-for-7 reverse split of our common stock. <p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zdeu2eM5YXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zJVVaalwSSdi">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue based on the following five step model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Identification of the contract with a customer</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Identification of the performance obligations in the contract</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step describes how distinct performance obligations in the contract must be handled.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Determination of the transaction price</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Allocation of the transaction price to the performance obligations in the contract</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recognition of revenue when, or as, the Company satisfies a performance obligation</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBGTLns6xpL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span><span id="xdx_863_zy7UHuUhCPu8">Contract Services</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report is complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--SignificantAccountingPolicyPolicyTextBlock_zExxfIHd33C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zo4PxziXGY0b">Significant Accounting Policies</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwOPJgiKHAG6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zGQJOtohPkGg">Impact of Recently Issued Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.</span></p> <p id="xdx_804_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zl5cMti2Bs39" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zWwl7zUKyWt2">Notes Payable Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At various times in 2021, the Company entered into unsecured short term loan agreements with a related party for an aggregate principal balance of $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20211231_zwyDAHzaV8U" title="Short term loan">49,000</span>, each with a one-year maturity date, accruing interest at <span id="xdx_908_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_iI_dp_uPure_c20211231_zTCtZkIdlM87" title="Accruing interest rate">5</span>% and imputing an additional <span id="xdx_908_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20211201__20211231_z9nKzoibWT8h" title="Interest rate">1</span>% interest. The full amount of the loans and interest was repaid in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 49000 0.05 0.01 <p id="xdx_807_eus-gaap--ShortTermDebtTextBlock_zu5ZbRVczEyd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Convertible Notes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_82F_zdzuLpL89797" style="display: none">Convertible Notes Payable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">March 2020 Note</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2020, the Company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zv8dRQ6KJz55" title="Principal balance">200,000</span> at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zEaSzRRvcRZg" title="Interest rate">6</span>% interest. The maturity date of the loan was <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20200327__20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z0TQJIfEnGpk" title="Principal balance">September 27, 2021</span>. During the year ended December 31, 2022, the full amount of the loan and interest totaling $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20221231__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zyWLfEr8bVC1" title="Conversion of stock, value">226,138</span> was converted into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z3sB1WpDghjd" title="Conversion of stock, shares">205,984</span> shares of common stock of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest, divided by $<span id="xdx_90D_ecustom--FullyDilutedEquity_iI_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zdFJVPTeenWe" title="Fully diluted equity">5,000,000</span>, times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion being within the terms of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">August 2021 Note</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $<span id="xdx_905_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zJcgVZvW2fB5" title="Principal balance">195,000</span> with a <span id="xdx_907_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20210830__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zyvEBsG5b9Y9" title="Original issuance discount rate">5</span>% original issue discount and a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zHxviRtahqhb" title="Interest rate">9</span>% interest rate. The loan provided for a maturity date of <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zhOYGcQKg07e" title="Maturity Date">February 9, 2022</span>. We borrowed $<span id="xdx_90C_eus-gaap--ProceedsFromNotesPayable_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zmgGsSM8BJSh" title="Proceeds from notes payable">72,000</span> and $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_znyY9Zxnmmj3" title="Proceeds from notes payable">123,000</span> of principal in the years ended December 31, 2021 and 2022, respectively. The noteholder had the right to convert the principal and interest into common shares of the Company at the IPO at a <span id="xdx_900_ecustom--ConversionDiscountRate_dp_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zptW5kInjDqa" title="Conversion discount rate">20</span>% discount to the IPO price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As December 31, 2022, the loan was outstanding with a principal balance of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneNoteMember_zgYiOaOV8Xx3" title="Principal balance">195,000</span> and accrued interest of $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zpVNqHExFxjf" title="Accrued interest">35,078</span>. The loan was paid in its entirety in February 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the convertible loan agreement, the Company also issued <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zwwljT8NDTV6" title="Number of warrants">195,000</span> Warrants with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zZxtWvCg1JEe" title="Exercise price">1.00</span> exercisable for <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z5d6IsfONNc9" title="Warrants term">five years</span> from issuance. In May 2022, the Company and the note holder agreed to cancel and void the warrants and enter into a new agreement for <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zOVVxZWdvw3d" title="Number of warrants">225,000</span> warrants with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220531__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z8RNj9Joy2Kj" title="Exercise price">2.50</span>. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">December 2021 Note</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 20, 2021, the Company entered into a loan agreement with an unrelated party. The loan provided for a <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zacKdB3Ea8zl" title="Maturity date">December 19, 2022</span> maturity, a <span id="xdx_903_ecustom--OriginalIssuanceDiscountRate_dp_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zgZFolDtyvM6" title="Original issuance discount rate">10</span>% original issue discount and a <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zqADxEtk4fv4" title="Interest rate">6</span>% interest rate. The Company received $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z1JrR0icSJ4g" title="Proceeds from notes payable">25,000</span> of proceeds from this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The note was automatically convertible into shares of common stock at a discount to the IPO price or based on the valuation of the Company, whichever was more favorable to the holder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initially, the loan was estimated to be issued with <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211220__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zWyWz9Pd7g49" title="Number of warrants">355,114</span> warrants. Subsequent to the closing of the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $<span id="xdx_905_eus-gaap--ProceedsFromNotesPayable_pn6n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zRfzTz8af4wg" title="Proceeds from notes payable">1</span> million in face value of convertible bridge notes. Pursuant to the enhanced terms, the warrants were issued concurrently with the conversion of the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with the closing of the Company’s IPO, the note converted according to its terms into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zKihB944ISC2" title="Conversion of stock, shares">6,939</span> shares of common stock. No gain or loss was recognized on the conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Convertible Bridge Notes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. On April 28, 2022, the Company received approximately $<span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_z6oOILGONuf" title="Proceeds from notes payable">775,000</span> of proceeds, net of approximately $<span id="xdx_905_eus-gaap--ManagementFeeExpense_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zPWykc9gKKBi" title="Fees expense">91,000</span> of fees and a <span id="xdx_903_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zazEOsISgdd" title="Original issuance discount rate">10</span>% original issue discount from the sale of Convertible Bridge Notes and Warrants to several institutional investors and several individual accredited investors. In addition, the Company also received $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zmhRXb3V1YDh" title="Sale of stock value">100,000</span> from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company received an additional $<span id="xdx_908_eus-gaap--ProceedsFromNotesPayable_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zyCJhVwlJsD9" title="Proceeds from notes payable">25,000</span> of proceeds, net of a <span id="xdx_900_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zNrOxbU33x82" title="Original issuance discount rate">10</span>% original issue discount from the sale of an additional Convertible Bridge Note and Warrant to an unrelated party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Convertible Bridge Notes were initially convertible at the IPO at a <span id="xdx_902_ecustom--ConversionDiscountRate_dp_uPure_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zkr81W7nSJm5" title="Conversion discount rate">20</span>% discount to the IPO price. The Convertible Bridge Notes provided for an original maturity date of October 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Convertible Bridge Notes, the purchasers were also entitled to conditional warrants to be issued upon completion of the Company’s IPO. <span id="xdx_903_eus-gaap--DebtInstrumentDescription_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_z5SGEOTIsAJi" title="Debt description">The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the fourth quarter of 2022, the Company amended the Convertible Bridge Notes to (a) extend the maturity date until December 31, 2022, (b) provide that the conversion right would include interest through November 30, 2022, with interest accruing beyond that date being paid in cash and (c) revise the conversion price to be $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zhYDIKOFCeKf" title="Conversion price">4.27</span> based on a $<span id="xdx_907_eus-gaap--ConversionOfStockAmountIssued1_pn6n6_c20221001__20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zmEhAidOGLM3" title="Conversion value">25</span> million Company valuation. Additionally, the exercise price of the warrants was revised to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__dei--LegalEntityAxis__custom--WallachBethMember_zp7FhA7nlRuc" title="Exercise price">4.27</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230228__20230228__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember_zWzIG8F85gXg" title="Conversion of stock, shares">269,513</span> shares of common stock. No gain or loss was recognized on the conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 200000 0.06 2021-09-27 226138 205984 5000000 195000 0.05 0.09 2022-02-09 72000 123000 0.20 195000 35078 195000 1.00 P5Y 225000 2.50 2022-12-19 0.10 0.06 25000 355114 1000000 6939 775000 91000 0.10 100000 25000 0.10 0.20 The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price. 4.27 25000000 4.27 269513 <p id="xdx_801_ecustom--ConvertibleNotesPayableRelatedPartyDisclosureTextBlock_z8ocfnE3YLk8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Convertible Notes – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_820_zsWA8y7y8Ovf" style="display: none">Convertible Notes Payable Related Party</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">SAFE Agreement</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, at a purchase price of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20210708__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zLJfiJndxrWd" title="Notes payable">150,000</span>. The SAFE provided for no interest and terminated after conversion upon completion of the Company’s IPO. The SAFE provided for automatic conversion into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, defined as either: (1) the SAFE Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate), whichever calculation results in a greater number of shares of SAFE Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the SAFE terminated and converted into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zy8DTW8W4yYe" title="Conversion of stock, shares">32,967</span> shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $<span id="xdx_905_ecustom--LossOnConversion_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_z9RqfD2Ummh5" title="Loss on the conversion">63,626</span> loss on the conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the $<span id="xdx_908_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zm4JiWLurZhd" title="Convertible notes payable related party">150,000</span> received from the SAFE was recorded at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_z6mCW6QLQXp5" title="Interest rate">6</span>% imputed interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">August 2021 Note</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2021, the Company entered into a convertible loan agreement with a related party, with a principal balance of $<span id="xdx_90D_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zUSah29oFwS" title="Convertible notes payable related party">99,900</span>, an original issuance discount of <span id="xdx_90A_ecustom--OriginalIssuanceDiscountRate_pid_dp_uPure_c20210818__20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zpCNQHSm2ege" title="Original issuance discount rate">5</span>% and a <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zg6FXtQpGG83" title="Interest rate">9</span>% interest rate. The loan provided for a maturity date of <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20210818__20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zVPIHF7mJ7W" title="Maturity date">February 19, 2022</span>. The noteholder had the right to convert the principal and interest into common shares of the Company at a conversion price based on a discount to the IPO price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the related party elected to convert the convertible loan into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zTgnNZqFQ153" title="Conversion of stock, shares">21,747</span> shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $<span id="xdx_906_ecustom--LossOnConversion_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_z8lSQ2qNWC18" title="Loss on the conversion">29,333</span> loss on the conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the convertible loan agreement, the Company also issued <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zBUSnFNfOQl" title="Number of warrant shares">99,000</span> Warrants with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zMCvkr73yG4e" title="Warrant exercise price per share">1.00</span> exercisable for five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and enter into a new agreement for <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_z514kfjAQml4" title="Number of warrant shares">115,185</span> warrants with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember_zns4ylbuup8f" title="Warrant exercise price per share">2.50</span>. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 150000 32967 63626 150000 0.06 99900 0.05 0.09 2022-02-19 21747 29333 99000 1.00 115185 2.50 <p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zwh6sFu8A3i6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zUUAIuRZZCg8">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023 the Company entered into a short-term note payable with a principal balance of $<span id="xdx_908_eus-gaap--NotesPayable_iI_c20230131__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_z7mVl0W1FPfa" title="Notes payable">100,000</span>, an original discount of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230131__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zXjcLUSyx8Nf" title="Original issuance discount rate">20</span>% and a <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230131__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zua5sp8BSGE" title="Interest rate">9</span>% interest rate. The note was paid in its entirety in February 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $<span id="xdx_90A_eus-gaap--NotesPayable_iI_c20230228__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zeQCvS1Sxms4" title="Notes payable">697,534</span> of the premium, repayments in 10 equal monthly installments of $<span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_c20230201__20230228__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zrLiwbWQYi06" title="Repayments in installments">71,485</span> each through December 2023 and accrued interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230228__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zYg4vIfaJdQ7" title="Accrued interest">6.5</span>%. The balance outstanding at September 30, 2023 was $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zvAhDDwOf3Cd" title="Outstanding balance">213,290</span>. The related balance of the premium of $<span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20230930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermDebtMember_zYBmMCJB9Rgb" title="Prepaid expenses">307,735</span> is included in prepaid expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 100000 0.20 0.09 697534 71485 0.065 213290 307735 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdu3U3g1nVH9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zr3qEI1TBeY1">Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zQZpWIlXM1Cf" title="Stock option services">75,000</span> stock options to its Chief Financial Officer for services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlfkqT9bLgih" title="Number of shares issued for services">29,286</span> common stock options to related parties for services rendered. The options have an original life of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6oaPQhjFllc" title="Original life">10</span> years and vest over different periods for up to 24 months. During the three months ended September 30, 2023 and 2022, the Company recognized $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrzC0CL8q9Hc" title="Stock-based compensation">430</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzasgBMLqOq6" title="Stock-based compensation">450</span>, respectively, of stock-based compensation related to these options. During the nine months ended September 30, 2023 and 2022, the Company recognized $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcMX0tNMV4Ob" title="Stock-based compensation">1,290</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbDsIlNq7nr2" title="Stock-based compensation">1,350</span>, respectively, of stock-based compensation related to these options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 75000 29286 P10Y 430 450 1290 1350 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUsdKmf9xN4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zDSLxRi1TdZ5">Stockholder’s Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred Stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930_zspS79ZmAvhl" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock authorized at a par value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930_z4tKCcBbiNM2" title="Preferred stock, par or stated value per share">0.00001</span> with <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXya8gKC0lz8" title="Preferred stock, shares authorized">5,500,000</span> being designated as Series A Convertible Preferred Stock. On October 5, 2022, the Company entered into an exchange agreement with an Investor providing for the exchange of <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zRoz4FfzTa86" title="Conversion of convertible securities, shares">734,492</span> shares of commons stock into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zETMjkdKfnG9" title="Conversion of convertible securities, shares">73,449</span> shares of Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock is convertible at any time into <span id="xdx_90B_ecustom--SharesExchangedForEachConvertiblePreferredStock_iI_c20221005_zuBX6ybvHWhd" title="Number of common stock">10</span> shares of the Company’s common stock. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than 4.99% of the Company’s outstanding common stock at such time. The Company evaluated the terms of the exchange and determined there was no significant change in fair value and therefore the Series A Preferred Stock was valued at $<span id="xdx_90E_eus-gaap--PreferredStockValue_iI_c20221005__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zw7xhlyZYI06" title="Preferred stock value">315,000</span> which is the Investor’s basis in the common stock that was exchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common Stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_z3PFT2SRLop2" title="Common stock, shares authorized">100,000,000</span> shares of common stock authorized at a par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zprmKUyd5gWk" title="Common stock, par or stated value per share">0.00001</span>. During the year ended December 31, 2022, the Company:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchanged <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z1cH8u3Zvzoa" title="Conversion of convertible securities, shares">734,429</span> shares of common stock for shares of Series A Convertible Preferred stock as noted above,</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231_z7nhPjpq9r" title="Conversion of convertible notes shares">205,984</span> shares of common stock pursuant to a conversion of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20221231_zEEUG3NLuGP8" title="Conversion of convertible notes value">226,138</span> worth of convertible notes principal and interest,</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PriorAgreementsAndNewAgreementsMember_zaU8wmZtRebc" title="Shares cancelled">112,225</span> shares of common stock as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zYQoQl3zWnN4" title="Number of shares issued">38,879</span> shares of common stock pursuant to a license agreement valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueOther_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zTp1Wy7Lqqgh" title="Shares issued value">189,828</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the Company completed its IPO for the sale of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxgWwFvGTl5g" title="Sale of shares">1,297,318</span> units (each, a “Unit,” collectively, the “Units”) at a price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zJArfeDSzJOb" title="Issue price per share">6.50</span> per Unit for a total of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zP8u5p4vjmfi" title="Gross proceeds">8.4</span> million of gross proceeds. <span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20230201__20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zMckUtDji8xk" title="Sale of stock, description">Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zHlE7rA7LqQ" title="Exercise price of warrant">7.80</span> per share</span>, and one <span id="xdx_90B_eus-gaap--SaleOfStockDescriptionOfTransaction_c20230201__20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_zRH40cLdJhAa" title="Sale of stock, description">non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_zOxSxNYwAJlh" title="Exercise price of warrant">8.125</span>.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the completion of its IPO, the Company issued an aggregate of <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1k8uzD75Qw3" title="Conversion of stock, shares">331,166</span> shares of common stock upon the conversion of certain outstanding convertible debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the IPO, in February 2023, the Company <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs1pmTMwXjbg" title="Reverse stock split">completed a 1-for-7 reverse split of our common stock.</span> Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230201__20230228_zC2wx7bQ4wyk" title="Shares, issued for services">7,692</span> shares of common stock for consulting services and recognized $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230201__20230228_zQNg08KdWGZk" title="Value, issued for services">50,000</span> of compensation expense related to these shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the second quarter of 2023, we issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230401__20230630_zCQ5BI5s5tDa" title="Shares, issued for services">436,533</span> shares of common stock following the exercise of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSCZNkPn1IRd" title="Warrant exercised">436,533</span> warrants for proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20230401__20230630_ziMSsbGeNR5b" title="Proceeds from exercise of warrant">1,494,658</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of September 30, 2023, <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2EkCnepTOql" title="Number of warrants">3,796,164</span> warrants and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuNm6snQqso2" title="Number of options">507,717</span> options for common shares were excluded in the calculation of net loss per share. As of September 30, 2022, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPq4mnpAh1Y7" title="Number of warrants">5,270,617</span> warrants and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL2tpCZu30yf" title="Number of options">484,525</span> options for common shares were excluded in the calculation of net loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">2022 Equity Incentive Plan</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2022, the Company’s Board of Directors adopted, and its shareholders approved the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20221101__20221130__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zmVtEYW5E5vi" title="Award period">10</span> years and any exercise prices shall not be less than 100% of the fair market value of one share of common stock on the grant date. The Plan authorizes an initial maximum number of shares underlying awards of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20221130__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zFZ2EkpEDxwc" title="Award authorized under the plan">900,000</span> with an automatic annual <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_c20221101__20221130__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zRM2916WtMk4" title="Increased payment award, percentage">15</span>% increase beginning in 2024. As of September 30, 2023, there were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zbBxm38RyYtf" title="Award authorized under the plan">461,500</span> awards authorized but unissued available under the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock Options</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsZQF5d32bN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the stock option activity for the nine months ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zyCjIhBqEZPj" style="display: none">Schedule of Stock Options Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Shares</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zSFDydM8Non4" style="width: 10%; text-align: right" title="Number of Shares, Outstanding at Beginning">69,217</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930_zemlQiBFoX55" style="width: 10%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zuM6MpDVvWL" style="width: 10%; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">7.08</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20230930_zmjiFjYURB83" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">117,669</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_zkgrjoN3xvag" style="text-align: right" title="Number of Shares, Granted">438,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_ztreohmsyMf3" style="text-align: right" title="Weighted-Average Exercise Price, Granted">4.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_c20230101__20230930_zmGMSFv8k3F4" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zp8ilNvudlj4" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2297">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930_zT76GXMP5Vrj" style="text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2299">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20230101__20230930_zo7wXZ7NiSw4" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230930_ziHOuxN3fEp5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited / canceled"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930_z4inNABsuzbg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanceledIntrinsicValue_c20230101__20230930_zVg3AMBm4PFh" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Forfeited / canceled"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zqeDoT04RX8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Outstanding at Ending">507,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930_zjr5RO6kAnV7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">4.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zxSdi4XogpLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">9.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230930_z012NHObYBh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">102,441</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230930_z2whqnce56pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Vested at Ending">215,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20230930_zxIX59rCl5Rl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">3.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zlWJOwT9EkR3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20230930_z57Siqgkk16b" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">52,644</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zWrENsu1D60i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zty9Cen68jy6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zoSSoyJKGhsf" style="display: none">Schedule of Black Scholes Option Pricing Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 18%; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930_zfxX6W6ilmL" title="Expected dividend yield">0%</span></td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20230930_zBJFMC2hQJg5" title="Expected volatility, minimum">87</span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20230930_zUptfMHiAnRa" title="Expected volatility, maximum">92%</span></span></td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20230930_zYh3BSgVddzb" title="Risk-free interest rate, minimum">3.4</span>%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20230930_zdQwdEo8m9Sd" title="Risk-free interest rate, maximum">4.1</span></span>%</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in  years)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zCu2UCZ8iwll" title="Expected life (in years)">5.0</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zmMwRJx4u5Zd" title="Expected life (in years)">6.0</span></span></td><td style="text-align: left"></td></tr> </table> <p id="xdx_8A6_zMu3N1aU78jh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2023 was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930_zgKEl6UOw9v8" title="Weighted-average grant-date fair value of options granted">3.20</span>. No options were issued in the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No options were exercised in any of the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and nine months ended September 30, 2023, the Company recognized $<span id="xdx_90F_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_c20230701__20230930_z59aeCV37Ob2" title="Compensation expense related to stock options">116,410</span> and $<span id="xdx_907_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_c20230101__20230930_z8U218McAUGc" title="Compensation expense related to stock options">475,465</span>, respectively of compensation expense related to stock options. During the three and nine months ended September 30, 2022, the Company recognized $<span id="xdx_904_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_c20220701__20220930_zXx3NLz7FbFc" title="Compensation expense related to stock options">51,536</span> and $<span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_c20220101__20220930_zlTBhbympFH9" title="Compensation expense related to stock options">290,876</span> of compensation expense, respectively related to stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the total unrecognized compensation expense related to unvested stock options, was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230930_zRY9HPdKuft1" title="Unrecognized compensation expense">936,000</span>, which the Company expects to recognize over a weighted-average period of approximately <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230930_zzFx2NMGgz26" title="Weighted-average period">2.1</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023 and 2022, the Company granted a total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLLcwKuSY9Cd" title="Share based compensation granted">3,195,906</span> and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUpml7WFtpUh" title="Share based compensation granted">56,623</span> warrants, respectively. <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsJ4Utg4Rd57" title="Contractual life and vesting period, description">The warrants have an original life of ten years and vest immediately and over 12 months.</span> During the nine months ended September 30, 2023, warrants to purchase <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjSyquuTcsJ1" title="Warrants shares vested">22,939</span> shares vested and had a fair value of $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhaQi5IEPdek" title="Intrinsic value">35,712</span>. During the year ended December 31, 2022, <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zosessTNWjdj" title="Warrants shares vested">174,105</span> shares of warrants were vested and amended with a fair value of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvmMnvZZCN36" title="Intrinsic value">337,269</span>, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpXdXObt5rSh" title="Warrant shares">51,941</span> shares of warrants were reclassified with a fair value of $<span id="xdx_900_ecustom--WarrantsReclassifiedWithIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8CnsSsWaJ18" title="Warrants reclassified with intrinsic value">11,097</span>, and <span id="xdx_90A_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7i1VgVVnXP" title="Warrant shares, forfeited">42,057</span> shares of warrants with a fair value of $<span id="xdx_908_ecustom--ClassOfWarrantOrRightForfeited_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSCqSXdIftNk" title="Warrant shares, forfeited">1,883</span> were forfeited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company granted a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zb4FinRJvHnh" title="Share based compensation granted">431,659</span> warrants. Of this amount, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_z7UQxYX2OJl5" title="Share based compensation granted">200,000</span> warrants, with a fair value of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zYNvYzMFyEB" title="Fair value of warrants">12,462</span>, were granted to advisors related to the Company’s IPO objective. The warrants have an original life of five years and vest 30 days before the intended IPO. During the year ended December 31, 2021, <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zstgz6ZIf0If" title="Warrants shares vested">0</span> shares of these warrants were vested. As of June 30, 2022, the warrants for <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220601__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znkleVircxp8" title="Warrant shares forfeiture">200,000</span> shares were cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss due to cancellation. In 2021, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN9ouP0cPmG4" title="Warrant shares">138,929</span> warrants, with a fair value of $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0w7kAHpb8g2" title="Fair value of warrants">28,683</span>, were issued for services rendered. <span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionContractualLifeAndVestingPeriodDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8xUAEVyZAS4" title="Contractual life and vesting period, description">The warrants have an original life of ten years and vest at different rates over as much as 36 months.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zq9MtO6MWhe4">92,859</span> warrants with a fair value of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zxeuQGRGQnRf">12,980</span>, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zfQAtgUVoewj" title="Warrants and rights outstanding term">five years</span>. During the period ending June 30, 2022, the Company determined that <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaqhyHbcWQsd">50,735</span> warrants, with a fair value of $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqTpYAYuQHWk">11,097</span>, should not have been issued. The fair value was reclassified to Additional Paid in Capital. In May 2022, the Company and the note holders agreed to cancel and void the previous <span id="xdx_90D_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl3W741vNL6">99,000</span> warrants and entered into a new agreement for <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zBnDSdXxio0k">115,185</span> warrants and the exercise price increased to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zOKWWHPKuYz6">2.50</span> from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEAoFfxkT1w4">1</span>, with a fair value of $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zKZXKI9kUK48">15,412</span>. In May 2022, the Company and the note holders agreed to cancel and void the previous <span id="xdx_905_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zmfyqHqvixak">195,000</span> warrants and entered into a new agreement for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_z2N4yvhqRJGg">225,000</span> warrants with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zP2NUPzfaTG5">2.50</span>, with a fair value of $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zukcJW9DFUQa">64,978</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211231_z0DgcWT1X455" title="Warrant shares">92,859</span> warrants discussed above were initially discounted against the notes, subsequent to year end December 31, 2021, they were deemed voided and these individuals were issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company issued the following warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, in connection with the completion of the initial public offering, the Company issued <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7hrqdGqmUV7" title="Additional shares issued">276,452</span> contingent warrants to certain debt holders with an exercise price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9zZvCfBISZ3" title="Issue price per share">4.27</span> and an expiration date <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5irOSXOjAoh" title="Expiration term">5</span> years from issuance.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, in connection with the completion of the initial public offering, the Company issued <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmYC8BIVUYna" title="Additional shares issued">18,000</span> contingent warrants as fees to the Company’s underwriters with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvVLuppEjjfj" title="Issue price per share">8.125</span> and an expiration date <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNEhrv6I2BD1">4</span> years from issuance.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the sale of units in the Company’s initial public offering the Company issued <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zdDHjdSvJyOg" title="Additional shares issued">1,297,318</span> tradable warrants with an exercise price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zBCuZyaWvuPl" title="Issue price per share">7.80</span> and an expiration date <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_z3ieyvaT8KIi" title="Expiration term">5</span> years from issuance. Also, as part of the sale of units in the Company’s initial public offering, the Company issued <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zhvoy0QyU5H2" title="Additional shares issued">1,297,318</span> non-tradable warrants with an exercise price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zF5tHPVsR0g9" title="Issue price per share">8.125</span> and an expiration date <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zIh44owQjRj6" title="Expiration term">5</span> years from issuance.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, as part of the Company’s initial public offering, the Company issued <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zHfxC9nBsdsc" title="Additional shares issued">153,409</span> tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zvMTOnCJb0v9" title="Issue price per share">7.80</span> and an expiration date <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zBUIW8Mbwkvf" title="Expiration term">5</span> years from issuance. Also in February 2023, as part of the Company’s initial public offering the Company issued <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_z7M2NEsjSwYa" title="Additional shares issued">153,409</span> non-tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_z5KZzORwJMkf" title="Issue price per share">8.125</span> and an expiration date <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230228__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zjqRwm9msfHj" title="Expiration term">5</span> years from issuance.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and nine months ended September 30, 2023, the Company recognized $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9KleNaHNUA3" title="Compensation expense">5,050</span> and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znvFkU46SCui" title="Compensation expense">35,712</span>, respectively of compensation expense related to certain warrants. During the three and nine months ended September 30, 2022, the Company recognized $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvwhBu0nFyde" title="Compensation expense">51,086</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLCBVa1vU1z4" title="Compensation expense">289,317</span> of compensation expense related to certain warrants. As of September 30, 2023, the total unrecognized compensation expense related to unvested warrants was $<span id="xdx_90C_ecustom--UnrecognizedCompensationExpense_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--UnvestedWarrantsMember_zl0rSgah5RLj" title="Unrecognized compensation expense">6,556</span>, which the Company expects to recognize over a weighted-average period of approximately <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230101__20230930_zcHRPt8QCaEg" title="Weighted average period term">0.4</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zALaAfkXOdB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides details over the Company’s outstanding warrants as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zNmMwX37BUYh" style="display: none">Schedule of Outstanding Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Expiration</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: center">$</td><td style="width: 30%; text-align: center"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_z7pOkJbaG0Fj" title="Exercise Price">0.0007</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center"><span id="xdx_908_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zb1R4vZjJw07" title="Expiration Period">2030</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zRw5XsYaAcje" title="Number of Warrants">274,286</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zGfDMtBJYiz8" title="Exercise Price">2.10</span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zRXltDDLKWy4" title="Exercise Price">2.66</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zKzmKDMiHwJ6" title="Expiration Period">2026</span> - <span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zNYSEdjLG39j" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_zccgPDBWfszd" title="Number of Warrants">460,445</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_znb2LwHpEGK5" title="Exercise Price">3.36</span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zwmeaW8UzICd" title="Exercise Price">4.27</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zrZ2bA1aT4R7" title="Expiration Period">2028</span> - <span id="xdx_90D_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zUTmG3Rn1wEf" title="Expiration Period">2029</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zIbHZDo4gNc5" title="Number of Warrants">115,277</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zoPVLqaknkRe" title="Exercise Price">6.51</span> - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_ztFNGGWKV6l4" title="Exercise Price">7.80</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zxZrY7bL3Lvj" title="Expiration Period">2026</span> - <span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zFllc9V8kw6e" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_zgSDLetDCVp6" title="Number of Warrants">1,484,929</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zMBR3G36F1zj" title="Exercise Price">8.125</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90D_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zXNLY6dyhRni" title="Expiration Period">2027</span> - <span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_z0ZKYSHrTPq5" title="Expiration Period">2028</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_z2szCtkv42G2" title="Number of Warrants">1,461,227</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930_z5yrV0m2l35f" title="Number of Warrants">3,796,164</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zjVNvWWaPy63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 0.00001 5500000 734492 73449 10 315000 100000000 0.00001 734429 205984 226138 112225 38879 189828 1297318 6.50 8400000 Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share 7.80 non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125. 8.125 331166 completed a 1-for-7 reverse split of our common stock. 7692 50000 436533 436533 1494658 3796164 507717 5270617 484525 P10Y 900000 0.15 461500 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsZQF5d32bN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the stock option activity for the nine months ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zyCjIhBqEZPj" style="display: none">Schedule of Stock Options Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Shares</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zSFDydM8Non4" style="width: 10%; text-align: right" title="Number of Shares, Outstanding at Beginning">69,217</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930_zemlQiBFoX55" style="width: 10%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zuM6MpDVvWL" style="width: 10%; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">7.08</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20230930_zmjiFjYURB83" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">117,669</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_zkgrjoN3xvag" style="text-align: right" title="Number of Shares, Granted">438,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_ztreohmsyMf3" style="text-align: right" title="Weighted-Average Exercise Price, Granted">4.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_c20230101__20230930_zmGMSFv8k3F4" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2295">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zp8ilNvudlj4" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2297">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930_zT76GXMP5Vrj" style="text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2299">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20230101__20230930_zo7wXZ7NiSw4" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230930_ziHOuxN3fEp5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited / canceled"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930_z4inNABsuzbg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanceledIntrinsicValue_c20230101__20230930_zVg3AMBm4PFh" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Forfeited / canceled"><span style="-sec-ix-hidden: xdx2ixbrl2307">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zqeDoT04RX8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Outstanding at Ending">507,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930_zjr5RO6kAnV7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">4.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zxSdi4XogpLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">9.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230930_z012NHObYBh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">102,441</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230930_z2whqnce56pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Vested at Ending">215,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20230930_zxIX59rCl5Rl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">3.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zlWJOwT9EkR3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20230930_z57Siqgkk16b" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">52,644</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 69217 3.06 P7Y29D 117669 438500 4.41 507717 4.23 P9Y2M1D 102441 215623 3.97 P8Y7M20D 52644 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zty9Cen68jy6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of options granted in the nine months ended September 30, 2023 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zoSSoyJKGhsf" style="display: none">Schedule of Black Scholes Option Pricing Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 18%; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930_zfxX6W6ilmL" title="Expected dividend yield">0%</span></td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20230930_zBJFMC2hQJg5" title="Expected volatility, minimum">87</span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20230930_zUptfMHiAnRa" title="Expected volatility, maximum">92%</span></span></td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20230930_zYh3BSgVddzb" title="Risk-free interest rate, minimum">3.4</span>%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20230930_zdQwdEo8m9Sd" title="Risk-free interest rate, maximum">4.1</span></span>%</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in  years)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zCu2UCZ8iwll" title="Expected life (in years)">5.0</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zmMwRJx4u5Zd" title="Expected life (in years)">6.0</span></span></td><td style="text-align: left"></td></tr> </table> 0 0.87 0.92 0.034 0.041 P5Y P6Y 3.20 116410 475465 51536 290876 936000 P2Y1M6D 3195906 56623 The warrants have an original life of ten years and vest immediately and over 12 months. 22939 35712 174105 337269 51941 11097 42057 1883 431659 200000 12462 0 200000 138929 28683 The warrants have an original life of ten years and vest at different rates over as much as 36 months. 92859 12980 P5Y 50735 11097 99000 115185 2.50 1 15412 195000 225000 2.50 64978 92859 276452 4.27 P5Y 18000 8.125 P4Y 1297318 7.80 P5Y 1297318 8.125 P5Y 153409 7.80 P5Y 153409 8.125 P5Y 5050 35712 51086 289317 6556 P0Y4M24D <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zALaAfkXOdB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides details over the Company’s outstanding warrants as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zNmMwX37BUYh" style="display: none">Schedule of Outstanding Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Expiration</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Number of Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: center">$</td><td style="width: 30%; text-align: center"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_z7pOkJbaG0Fj" title="Exercise Price">0.0007</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center"><span id="xdx_908_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zb1R4vZjJw07" title="Expiration Period">2030</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zRw5XsYaAcje" title="Number of Warrants">274,286</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zGfDMtBJYiz8" title="Exercise Price">2.10</span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zRXltDDLKWy4" title="Exercise Price">2.66</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zKzmKDMiHwJ6" title="Expiration Period">2026</span> - <span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zNYSEdjLG39j" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_zccgPDBWfszd" title="Number of Warrants">460,445</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_znb2LwHpEGK5" title="Exercise Price">3.36</span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zwmeaW8UzICd" title="Exercise Price">4.27</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zrZ2bA1aT4R7" title="Expiration Period">2028</span> - <span id="xdx_90D_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zUTmG3Rn1wEf" title="Expiration Period">2029</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zIbHZDo4gNc5" title="Number of Warrants">115,277</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zoPVLqaknkRe" title="Exercise Price">6.51</span> - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_ztFNGGWKV6l4" title="Exercise Price">7.80</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zxZrY7bL3Lvj" title="Expiration Period">2026</span> - <span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zFllc9V8kw6e" title="Expiration Period">2032</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_zgSDLetDCVp6" title="Number of Warrants">1,484,929</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zMBR3G36F1zj" title="Exercise Price">8.125</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90D_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zXNLY6dyhRni" title="Expiration Period">2027</span> - <span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_z0ZKYSHrTPq5" title="Expiration Period">2028</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_z2szCtkv42G2" title="Number of Warrants">1,461,227</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930_z5yrV0m2l35f" title="Number of Warrants">3,796,164</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.0007 2030 274286 2.10 2.66 2026 2032 460445 3.36 4.27 2028 2029 115277 6.51 7.80 2026 2032 1484929 8.125 2027 2028 1461227 3796164 <p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zlGhR5RfrSVi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_z17O51b0rr57">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not recorded any tax provision or benefit for the three and nine months ended September 30, 2023 and 2022. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefits from deductible temporary differences, net operating loss carryforwards and research and development credits are not more-likely-than-not to be realized at September 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_804_ecustom--LicenseAndRoyaltyAgreementDisclosureTextBlock_ztpskSZguxnj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_z9VT6aGV4v06">Material Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">JHU-APL Technology License</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five percent (<span id="xdx_90D_ecustom--PercentageOfWarrantIssued_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zyZL7tKUR0d8" title="Warrant percent">5</span>%) of the then fully diluted equity base of the Company, which shall be diluted following the closing of the IPO. Under the terms of the License Agreement, JHU will be entitled to eight percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zK2LP4sqdHBg" title="Royalty percent">8</span>%) royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty percent (<span id="xdx_90D_ecustom--SublicensePercentage_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zea8V1hKKnGb" title="Percentage of sublicense">50</span>%) of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $<span id="xdx_904_eus-gaap--CostMaintenance_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_z4Vrs7DCUvyk" title="Maintenance fee">1,500</span>. Minimum annual royalty payments are $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zaavWBO8uXTl" title="Royalty payments for 2022">20,000</span> for 2022, $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zRkFbB5rfBC9" title="Royalty payments for 2023">80,000</span> for 2023, and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zOi4URPO48I3" title="Royalty payments for 2024">300,000</span> for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breach, the Company shall have 60 days to cure the material breach. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights, and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember_zdMwxCzelb4d" title="Common stock issued">279,159</span> shares of common stock. Under the terms of the new License Agreement, JHU will be entitled to eight percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--OtherPartiesMember_zl0cDqjhMePe" title="Royalty percent">8</span>%) of net sales for the services provided by the Company to other parties and three percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--InternallyDevelopmentDrugProjectsMember_zBeY9B84E1d2" title="Royalty percent">3</span>%) for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at <span id="xdx_90C_ecustom--SublicensePercentage_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zEjsRX1Ofn87">50</span>% and reduce to <span id="xdx_905_ecustom--IncreaseDecreaseInSublicensePercentageBasedOnRevenues_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z4FoJqFK1wj7" title="Sublicense fee based on revenue">25</span>% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zOGfdh20JTV6" title="Royalty payments">30,000</span> for 2022, $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_z67Lx9HO34lc" title="Royalty payments">60,000</span> for 2023, and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zPKNpJ5JmJMi" title="Royalty payments">300,000</span> for 2024 and beyond.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember_zDrrnPhGTRBh" title="Royalty payments">275,000</span>. The first of these payments for $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zaAUDO2OrDRc" title="Royalty payments">75,000</span> was due in July 2023 followed by payments of $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFiveMember_zi7BuOlWys2k" title="Royalty payments">75,000</span>, $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySixMember_zju1gpfgxuR9" title="Royalty payments">75,000</span> and $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_ziOKSEBP1Yv8" title="Royalty payments">50,000</span> in years 2025, 2026 and 2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zbqMYTaS6uwd" title="Royalty payments">60,000</span>, all other financial terms remain the same. As of September 30, 2023, we have accrued $<span id="xdx_90C_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_znMNMm7lENzk" title="Accrued royalty payments">45,000</span> of the 2023 minimum annual royalty payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">George Washington University - Beta2-spectrin siRNA License</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In consideration of the rights granted to the Company under the License Agreement the Company paid GWU a $<span id="xdx_90F_ecustom--LicenceInitiationFee_iI_c20220114__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_zqCbP4Dwnxv8" title="Licence initiation fee">20,000</span> License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220114__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_z5gGZBflE6Q8" title="Royalty percent">3</span>%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, there has been <span id="xdx_90D_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_do_c20230930_z0YrZ9PrYxM7" title="Accrued royalty payments"><span id="xdx_90D_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_do_c20221231_znjoVWASAjS2" title="Accrued royalty payments">no</span></span> accrual for royalties since we have not begun to generate applicable revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Johns Hopkins University – Mebendazole License</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $<span id="xdx_901_ecustom--UpfrontLicenceFee_iI_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zsLAYJNQios4" title="Upfront license fee">250,000</span>. The initial payment for $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zwcPGEwS7N1f" title="License fee initial payment">50,000</span> was paid and the remaining balance of $<span id="xdx_908_eus-gaap--PaymentsForFees_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zIw58OQco6fc" title="License fee initial payment">200,000</span> was paid after the Company completed its IPO. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three and one-half percent (<span id="xdx_907_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zfn5qaG2OYla" title="Royalty percent">3.5</span>%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zp6cJTjEds98" title="Royalty payments">5,000</span> for 2023, $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zsPPpYIX1pv8" title="Royalty payments">10,000</span> for 2024, $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFiveMember_zW3CWlEYUF6a" title="Royalty payments">20,000</span> for 2025, $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySixMember_z40pBN9itX54" title="Royalty payments">30,000</span> for 2026 and $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zBrFqJz5UjH5" title="Royalty payments">50,000</span> for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zNliPbdhh6og" title="Annual minimum royalty payment">250,000</span>. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, the balance of accrued expense related to this license agreement was $<span id="xdx_903_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zqpRzzLtxZc" title="Accrued royalty expenses">7,500</span> and $<span id="xdx_907_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zOUsm1vAv1Gc" title="Accrued royalty expenses">242,671</span>, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Johns Hopkins University – Prodrug License</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $<span id="xdx_904_ecustom--UpfrontLicenceFee_iI_c20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_z5tti0EFxSD5" title="Upfront licence fee">100,000</span>. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (<span id="xdx_907_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_zs8q9bi2Iio3">4.0</span>%) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zgO2qCPOoW2k" title="Royalty payments">5,000 </span>for 2027, $<span id="xdx_90E_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyEightMember_zRu0NDkkYvWc" title="Royalty payments">10,000</span> for 2028, $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyNineMember_zJlgA4tmjAV8" title="Royalty payments">20,000</span> for 2029, $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyThirtyMember_zg0g139gDhK1" title="Royalty payments">30,000</span> for 2030 and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyThirtyOneMember_zPAyhPKxsxqc" title="Royalty payments">50,000</span> for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_zQWJnxH5M4Ff" title="Annual minimum royalty payment">150,000</span>. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of September 30, 2023 and December 31, 2022, the balance of accrued expense related to this license agreement was $<span id="xdx_90B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrpG720IXKe7" title="Accrued expense">0</span> and $<span id="xdx_90A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zZbcdbiNP7wc" title="Accrued expense">133,238</span>, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely.</span></p> 0.05 0.08 0.50 1500 20000 80000 300000 279159 0.08 0.03 0.50 0.25 30000 60000 300000 275000 75000 75000 75000 50000 60000 45000 20000 0.03 0 0 250000 50000 200000 0.035 5000 10000 20000 30000 50000 250000 7500 242671 100000 0.040 5000 10000 20000 30000 50000 150000 0 133238 Notes sold by Company prior to the April 28, 2022 closing